,id,ticker,title,category,content,date,provider,url,article_id
196665,418181,MYL,Mylan Issues Nationwide Recall for Contaminated Ulcer Medication,news,"Mylan  NASDAQ MYL  announced today that its American based business issued a voluntary nationwide recall for its ulcer medication after discovering trace amounts of carcinogens in some of its old batches  Three different lots of nizatidine capsules  including both the 150mg and 300mg dose variants  were found to contain small amounts of N Nitrosodimethylamine  NDMA   and the company has since issued a voluntary recall for all capsules suspected to be contaminated  
NDMA is a known carcinogen  a type of substance that causes cancer in living tissues  NDMA is especially harmful to the liver  with high levels of exposure to the compound causing internal bleeding  liver damage  cancer  and death  Mylan s stock is up slightly since its opening price today 

The contaminated batches in question were distributed across the country between June 2017 and August 2018  Mylan hasn t heard of any adverse reactions from these contaminated batches so far 
Previous contamination problems
Nizatidine is used primarily as a treatment for stomach ulcers  but also can be prescribed for heartburn as well as gastroesophageal reflux disease  GERD   which occurs when acid from the stomach flows back into the esophagus 
It turns out that nizatidine has a history of having elevated NDMA levels  The Food and Drug Administration issued a report in November that found that nizatidine exceeded acceptable concentrations of NDMA for human ingestion  While overall levels were relatively low  equivalent to eating a smoked or grilled piece of meat  the FDA deemed that it still surpasses acceptable limits for daily consumption and that Mylan should recall any batches of nizatidine that it finds to have excessive levels of contaminants  
The FDA recommends patients consider alternative pharmaceutical medications that haven t been shown to have impurities  such as Pepcid  Tagamet  and Nexium ",2020-01-08,The Motley Fool,https://invst.ly/pfk-k,2055370
196666,418182,MYL,Here s Why Mylan Fell 26 6  in 2019,news,"What happened
Shares of Mylan  NASDAQ MYL  fell over 26  last year  according to data provided by S P Global Market Intelligence  The generic drug manufacturer struggled to overcome its negative association in the national discussion related to drug pricing practices and became embroiled in an industrywide price fixing lawsuit brought by 44 state attorneys general  
The performance of the pharma stock looks even worse when considering that the S P 500 delivered a 28 8  gain in 2019  Can plans to combine with Upjohn  the generic drug division of Pfizer  NYSE PFE   provide relief to shareholders in 2020 

So what
Most of the stock s terrible performance last year can be traced back to the day  May 7  Mylan reported first quarter 2019 operating results  The update made it clear that the business was still struggling to overcome severe headwinds facing generic drugs in the United States  which are being pressured by unsustainable levels of competition  manufacturing missteps  and changing distribution models  
The barrage of bad news continued a week later when 44 state attorneys general alleged that generic drug manufacturers from Teva Pharmaceuticals to Lannett Company to Mylan engaged in a far reaching price fixing scheme covering dozens of drug products  
In the final days of July  investors finally had something to look forward to  Mylan and Pfizer s Upjohn division agreed to combine operations  The idea is that bigger is better when it comes to successfully navigating the headwinds of the generic drug industry  The combined company  which will be called Viatris  is expected to generate pro forma revenue of at least  19 billion in 2020  
Now what
For Mylan  the merger with Upjohn is also a rebranding effort  which could help given all of the negative news swirling around the company s current name  Whether it will be enough to respond to difficult market conditions for generic drug manufacturers or allow the combined company to more easily access Chinese markets  and whether that pays off as expected  remains to be seen ",2020-01-10,The Motley Fool,https://invst.ly/pgijh,2057092
196667,418183,MYL,Is Mylan Stock a Buy ,news,"Shareholders of drugmaker Mylan  NASDAQ MYL  are off to a good start this year  with an 8 4  gain after last year s 27  loss  The market may be thinking of the company s planned combination with Pfizer s Upjohn business  which focuses on off patent branded drugs and generics  The deal is expected to close around the middle of this year and is a bright spot among challenges that haven t gone away 

Mylan  a company best known for generic drugs  watched its stock slide last year after it was named along with other generic drug manufacturers in a case alleging price fixing  The lawsuit  brought by more than 40 state attorneys general  describes an industrywide conspiracy to fix prices of generic drugs  Rather than one quick blow to the stock price  this could be a drawn out process that weighs on the shares periodically as the case unfolds 
Climate for generics
The climate for generic drug pricing in the U S  is another headwind that isn t about to go away  According to an AARP Public Policy Institute report  generic drug prices have generally declined over the past 15 years  In 2017  the retail prices of 390 common generic prescription drugs fell by 9 3  from the previous year  the data showed  And the average annual cost for one generic used on a chronic basis was  365 in 2017  down considerably from  751 in 2013  A new initiative by California  meant to lower healthcare costs for residents  could lead to further pressure on generic drug prices  Gov  Gavin Newsom is proposing that California create its own generic drug label and negotiate with manufacturers to provide the medications  If the state follows through on this plan  it would be another door leading to lower prices 
In addition to the generic drug climate  earnings haven t been much of an incentive to buy shares of Mylan  Though Mylan beat analysts  earnings per share expectations in the third quarter  sales of  2 96 billion missed some analysts  forecasts for  3 01 billion  The company also narrowed its full year total revenue outlook to the range of  11 50 billion to  12 billion  The highest end of the range was  12 5 billion  according to Mylan s earlier prediction 
Upjohn and Mylan
Against this backdrop  the combination with Upjohn and Mylan s launch of a biosimilar to rival Roche s Herceptin are two positive elements 
Mylan launched Ogivri  a biosimilar of trastuzumab to treat breast cancer and gastric cancer  in December  Biosimilars are biological drug products that are similar to another biological drug that has already been approved  Roche s Herceptin is a drug that brought in about  7 billion in sales in 2018  Ogrivi is a positive addition to Mylan s portfolio  but its importance shouldn t be overestimated  as it isn t the only biosimilar rivaling Herceptin  It is set to face competition from at least four others  including Kanjinti  a Herceptin biosimilar from Amgen and Allergan that was approved last year 
Returning capital to investors
In the Upjohn transaction  each Mylan share will be converted into a share of the new company  which will be called Viatris  and Mylan shareholders will hold 43   Shareholders of Pfizer will own 57  of the business  Pro forma 2020 revenues for the combined company are expected to be between  19 billion and  20 billion  Pro forma 2020 adjusted EBITDA  earnings before interest  taxes  depreciation  and amortization  is expected to be in the range of  7 5 billion to  8 billion  With a focus on returning capital to shareholders  the plan is to start with a dividend of about 25  of free cash flow beginning the first full quarter after the deal closes 
All of this sounds favorable  but investors should keep in mind Upjohn s latest earnings results  Third quarter revenue fell 26  operationally as generic competitors for nerve pain drug Lyrica entered the U S  market  and excluding the Lyrica impact  operational revenue fell 6   Though Upjohn predicted growth in China  the picture in the U S  remains lackluster 
Is Mylan a buy 
For investors specifically seeking to invest in a generic drug maker  Mylan is a better prospect than competitor Teva  the main drugmaker cited in the price fixing lawsuit noted above  Mylan s combination with Upjohn may bring investors dividends and a chance at better growth  That said  companies with a strong position in generics    considering the environment for generics in the U S     are not the best place to be these days  Mylan isn t a buy right now  but if you re interested in investing in healthcare  you might want to keep an eye on Viatris  first couple of quarters to see if this new company can make it past the headwinds blowing in the direction of generic drug makers ",2020-01-25,The Motley Fool,https://invst.ly/pmpty,2067703
196668,418184,MYL,Pfizer s Q4 Earnings Fall More Than Expected,news,"Investing com     Pfizer    NYSE PFE  said it expects underlying revenue growth of around 8  this year as it carves out another of its main divisions into a separate company  
The company said that after folding its Upjohn unit into pharma rival Mylan  NASDAQ MYL   it expects operational growth of around 8   However  earnings per share  adjusted for foreign exchange swings  are expected to fall by around 3 3  to a range around  2 89 
The Upjohn deal is Pfizer s second big corporate action in a year  after spinning off its consumer health unit into a joint venture with GlaxoSmithKline last year 

 Pfizer   NYSE PFE  ended 2019 on a comparatively weak note  It said adjusted diluted earnings per share fell 13  on the year in the fourth quarter to 55c  on a 9  drop in revenue to  12 69 billion 
Analysts polled by Investing com anticipated EPS of  0 58 on revenue of  12 61 billion  
 

Analysts are expecting EPS of  0 72 and revenue of  11 7 billion in the upcoming quarter 

 Pfizer   NYSE PFE  stock is currently 10  below the record high it set last July  amid fears about the loss of patent protection for key drugs in the coming years 
 The biggest challenge that Pfizer is facing over the next few years is how to make up for the pending loss of patent protection   said Investing com analyst Haris Anwar   Some of its top revenue generating products    Xeljanz  Ibrance  Xtandi  Eliquis and Tafamidis    all are losing patent protection from 2025 to 2029 
To mitigate the impact of revenue loss  Pfizer is trying to reorganize its business  spending heavily in developing new drugs and buying companies whose success is uncertain 
 In the short run  the company s revenue growth is dependent on its more established prescription drugs and cancer drugs that now make up more of Pfizer s revenue than any other segment    Anwar added 
Pfizer follows other major Healthcare sector earnings this monthOn January 22  J J reported fourth quarter EPS of  1 88 on revenue of  20 75B  compared with a forecasts for EPS of  1 87 on revenue of  20 8B 
Abbott Labs earnings matched analysts  expectations on January 22  with fourth quarter EPS of  0 95 on revenue of  8 31B  Investing com analysts anticipated EPS of  0 95 on revenue of  8 263M
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2020-01-28,Investing.com,https://www.investing.com/news/stock-market-news/pfizers-q4-earnings-fall-more-than-expected-2069198,2069198
196669,418185,MYL,Pfizer profit misses as breast cancer drug sales fall short of estimates,news," Reuters     Pfizer  Inc  N PFE  posted a quarterly profit on Tuesday that came in below Wall Street estimates  as sales of breast cancer drug Ibrance fell short of expectations  Under Albert Bourla  who took the helm at the start of last year  Pfizer has streamlined operations and announced plans to separate its off patent branded drugs business  Upjohn  and combine it with generic drugmaker Mylan NV  O MYL   The company said it expects 2020 adjusted earnings per share to be in the range  2 82 to  2 92  Excluding Upjohn unit  it expects full year adjusted earnings in the range  2 25 to  2 35 per share  Sales of breast cancer drug Ibrance rose 13 2  to  1 28 billion in the fourth quarter  but missed the consensus estimate of  1 35 billion  according to IBES data from Refinitiv  Revenue fell 9  to  12 69 billion  partly hurt by intense competition for its pain treatment Lyrica that lost patent protection last year  Excluding items  it earned 55 cents per share  missing the average analyst estimate of 58 cents per share  
Net loss attributable to Pfizer narrowed to  337 million  or 6 cents per share  in the quarter  from  394 million  or 7 cents per share  a year earlier ",2020-01-28,Reuters,https://www.investing.com/news/stock-market-news/pfizer-posts-9-fall-in-fourthquarter-revenue-2069206,2069206
196670,418186,MYL,Biogen Sees Huge Bounce on MS Drug Patent Ruling,news,"By Kim Khan 
Investing com   Biotech Biogen  NASDAQ BIIB  soared in afternoon trading Wednesday following a report of a favorable patent ruling on a best selling multiple sclerosis drug 
The U S  Patent Trial and Appeal Board ruled to uphold Biogen s patent for MS treatment Tecfidera  Bloomberg reported 
Mylan  NASDAQ MYL  had challenged the patent and Biogen  would have lost eight years of exclusivity on the drug if the ruling had gone against it 
Biogen  shares jumped 20   Mylan  was up 2 3  
Tecfidera accounted for about 30  of Biogen s sales in 2019 
Even with today s jump  Biogen  shares are up just 1 5  in the past 52 weeks ",2020-02-05,Investing.com,https://www.investing.com/news/stock-market-news/biogen-sees-huge-bounce-on-ms-drug-patent-ruling-2077127,2077127
196677,418193,MYL,New tuberculosis treatment for developing countries to cost  1 040,news,"By Manojna Maddipatla and Manas Mishra
 Reuters    A newly approved three drug treatment for tuberculosis will be available in 150 countries including India and South Africa  priced at  1 040 for a complete regimen  more than twice the cost proposed in the past by advocacy groups for other treatments 
The United Nations backed Stop TB Partnership said on Monday that BPaL would be obtainable in eligible countries through the Global Drug Facility  GDF   a global provider of TB medicines created in 2001 to negotiate lower prices for treatments 
Tuberculosis was responsible for 1 5 million deaths in 2018 
BPaL is an oral treatment which promises a shorter  more convenient option to existing TB treatment options  which use a cocktail of antibiotic drugs over a period of up to two years 
The new cocktail  which will treat extensively drug resistant strains of the illness  consists of drug developer TB Alliance s newly approved medicine pretomanid  in combination with linezolid and Johnson   Johnson s  N JNJ  bedaquiline 
Pretomanid  which will be available at  364 per treatment course  is only the third new medicine for drug resistant tuberculosis to be approved in about 40 years  after J J s bedaquiline and Otsuka Pharmaceutical Co Ltd s delamanid 
Advocacy groups have long criticized the cost for bedaquiline and delamanid  Not for profit M decins Sans Fronti res  MSF  has waged a running battle in public with J J over its  400 price tag for a six month course for bedaquiline 
MSF has argued that bedaquiline could be produced and sold at a profit for 25 cents per day  and that the price of treatments for drug resistant TB should be no higher than  500 for a complete treatment course 
Leena Menghaney  the South Asia head for MSF s Access Campaign  said it was a cause of concern that pretomanid was priced just below the price of bedaquiline 
But Stop TB Partnership says costs of other regimens for extremely drug resistant TB range from  2 000 to  8 000 for courses of at least 20 months 
TB Alliance in April granted a license to U S  drugmaker Mylan NV  O MYL  to manufacture and sell pretomanid as part of certain regimens in high income markets  as well as a non exclusive license for low income and middle income countries  where most tuberculosis cases occur 
Stop TB Partnership said it would start supplying the regimen following World Health Organization s guidance on using the drug  Mylan  however  said it will also sell the drug directly to countries 
Prices in low income countries would be in line with the price offered through GDF  but would be decided on a case by case basis where the drug is not supplied through GDF  it said 
The drug will be available in bottles of 26 tablets  with a six month treatment requiring seven bottles 
India based Macleods Pharmaceuticals Ltd has also been granted a non exclusive license to make pretomanid as part of the BPaL regimen  TB Alliance said on Monday 
The generic drugs maker will market the treatment in about 140 countries with high tuberculosis rates ",2019-10-28,Reuters,https://www.investing.com/news/stock-market-news/new-tuberculosis-treatment-for-developing-countries-to-cost-1040-2005945,2005945
196678,418194,MYL,Pfizer raises 2019 forecast as sales of cancer drug  heart medicine surge,news,By Tamara Mathias and Aakash B  Reuters     Pfizer  Inc  N PFE  posted third quarter profit well above analysts  estimates on higher sales of cancer drug Ibrance and new heart medicine Vyndaqel  encouraging the largest U S  drugmaker to lift its earnings forecast for the year  Shares of the company rose 3 4  on Tuesday as the results suggested that Chief Executive Officer Albert Bourla s efforts to slim down the sprawling drugmaker were paying off  Pfizer announced in July it would separate its off patent branded drugs business and combine it with generic drugmaker Mylan NV  O MYL   allowing it to focus on its more profitable drugs  Bourla said on Tuesday Pfizer would become a  smaller  science based company  following the Mylan deal  which is expected to close next year  Pfizer raised its 2019 adjusted earnings per share forecast to between  2 94 and  3 00 from a prior estimate of between  2 76 and  2 86  Analysts on average were expecting  2 82 per share  according to Refinitiv IBES  Although sales of Ibrance rose to  1 28 billion and those of rheumatoid arthritis drug Xeljanz jumped nearly 39  to  599 million  analysts called out Vyndaqel as the biggest surprise in the quarter  Vyndaqel  chemically known as tafamidis  was approved in May and brought in revenue of  156 million  nearly double the consensus estimate of  82 million   Priced at  225 000 per year  Vyndaqel s high cost has faced criticism  with experts affiliated with Boston based Institute for Clinical and Economic Review  ICER  warning that it could be among the most costly cardiovascular treatments ever sold   Importantly  Ibrance is back to strong growth after a period of slowing      and  the Vyndaqel number in particular is impressive   UBS analyst Navin Jacob said  The company also said sales of its patented medicines benefited from demand in emerging markets  which contribute about a quarter of total sales  Net income attributable to Pfizer s shareholders rose nearly 87  to  7 68 billion  or  1 36 per share  as the company recognized a gain of  8 1 billion after closing its consumer health joint venture with Britain s GlaxoSmithKline Plc  L GSK   Excluding special items  Pfizer earned 75 cents per share  easily beating the average estimate of 62 cents  Investor sentiment on Pfizer has been poor since it announced the deal with Mylan  making the third quarter beat a relief  Jacob said  Including Tuesday s gains  Pfizer shares had lost about 11  of their value since the deal with Mylan was announced  Total revenue fell about 5  to  12 68 billion as sales of pain treatment Lyrica  which recently lost patent protection in the United States  more than halved to  527 million ,2019-10-29,Reuters,https://www.investing.com/news/stock-market-news/pfizer-raises-2019-profit-forecast-shares-rise-2006405,2006405
196679,418195,MYL,Mylan third quarter profit rises 7  on new drug launches,news," Reuters    Mylan NV  O MYL  reported a 7 4  rise in third quarter profit on Tuesday  as the generic drugmaker benefited from new product launches 
The company  which in July said it would merge with  Pfizer  Inc s  N PFE  off patent branded drugs unit  said net earnings rose to  189 8 million  or 37 cents per share  in the quarter ended Sept 30 from  176 7 million  or 34 cents per share  a year earlier 
Total revenue rose to  2 96 billion from  2 86 billion ",2019-11-05,Reuters,https://www.investing.com/news/stock-market-news/mylan-thirdquarter-profit-rises-7-on-new-drug-launches-2012181,2012181
196689,418205,MYL,Mylan stock boost follows long share struggles for company  generics industry,news,By Lewis Krauskopf NEW YORK  Reuters    Shares of Mylan NV  O MYL  surged on Monday after the generic drugmaker agreed to combine with  Pfizer  Inc s  N PFE  off patent branded drugs business  But in the bigger picture  the surge is lost in a bleaker landscape for Mylan s stock price and the broader generic drug industry since 2015  Mylan shares have been in decline for the past four years  after topping  76 in April 2015  according to Refinitiv data  On Monday  the shares closed at  20 78  a more than 70  decline from that 2015 peak  This year alone  Mylan shares had lost one third of their value through Friday  before news broke of the Pfizer tie up  Graphic  Mylan share price    Mylan is far from alone when it comes to share price swoons for generic drugmakers  which broadly have seen severe declines over the past several years    You have seen very challenging valuations for these companies and I think Pfizer sees that as an opportunity   said Kevin Kedra  an analyst with G  Research   Mylan is essentially issuing them stock at a depressed level   U S  traded shares of Israel based Teva Pharmaceutical  NYSE TEVA  Industries  TA TEVA  have tumbled nearly 90  since peaking four years ago  Teva sought to buy Mylan in the summer of 2015  but Mylan successfully resisted Teva s unsolicited bid  Shares of other makers of generic drugs  such as  Perrigo Co  Plc  N PRGO   Amneal Pharmaceuticals Inc  N AMRX  and Endo International Plc  O ENDP   have also skidded  Graphic  Generic drug stock    Their struggles since the start of 2015 contrasts with a climb of more than 45  for the overall S P 500  SPX  as well as with a more modest 11  gain for the NYSE Arca Pharmaceutical index of U S  and European drug stocks  DRG    Graphic  Generic drug stocks versus market    While the companies each have their specific issues  a main culprit afflicting the industry broadly has been pricing pressure in the United States  partly due to buyers having gained more negotiating power  analysts said  Generic drug revenue in North America has declined about 50  in roughly the past four years  predominantly driven by pricing declines  according to Soo Romanoff  an analyst at Morningstar  Earnings for many generic drug companies have stagnated or struggled as their share prices have fallen over the past four years  Graphic  Sickly generic drugmaker profits    Many companies have also faced regulatory and legal uncertainty  analysts said  including lawsuits related to the U S  opioid abuse epidemic and to alleged price fixing for generic drugs  At the same time  high leverage also hurt the outlook for the companies  including from debt related to acquisitions as the sector consolidated   It kind of created this storm where they couldn t issue equity to reduce their leverage   Kedra said   All of a sudden  these companies were in declining businesses with high leverage and Wall Street is breathing down their neck  ,2019-07-29,Reuters,https://www.investing.com/news/stock-market-news/mylan-stock-boost-follows-long-share-struggles-for-company-generics-industry-1938250,1938250
196690,418206,MYL,Mylan deal puts future of its beleaguered EpiPen in spotlight,news,"By Carl O Donnell and Tamara Mathias
 Reuters    Mylan NV s  O MYL  planned merger with  Pfizer  Inc s  N PFE  off patent branded drugs business may have boosted its share price on Monday  but one of its most pressing problems remains  shortages of its flagship EpiPen emergency allergy treatment 
For the past year  Mylan has been struggling to address an ongoing EpiPen shortage that could potentially worsen as thousands of school children with allergies need to restock EpiPen supplies ahead of the school year 
Now  the planned tie up will bring together two businesses that have long collaborated on making EpiPens  For years  Pfizer has manufactured EpiPen on Mylan s behalf through its Meridian Medical Technologies unit 
It was not yet clear if the combination will help ease the shortages by simplifying the company s complex manufacturing processes 
Although Meridian will not be merged with Mylan as part of the transaction announced on Monday  the companies were in talks to transfer Meridian to the newly created generics business  a Pfizer spokeswoman said 
The discussions are still ongoing and there is no guarantee that a deal will be reached  but the parties are aiming to reach a final decision before the close of the larger Pfizer Mylan deal in 2020  Pfizer said 
 We ve had some conversations with Mylan about that potentially transferring to Mylan as a supplement to the existing transaction  but nothing has been finalized to date yet   Frank D Amelio  Pfizer s chief financial officer told Reuters 
If the company is transferred to the new Mylan Pfizer spinoff  it could potentially help streamline a fix to the manufacturing issues that have led to shortages 
 Over the long term  having all EpiPen operations under one unified company would reduce complexity   said Ashtyn Evans  an Edward Jones analyst 
Meridian  which produces all EpiPens sold globally at a single plant near St  Louis  has been hit by a series of manufacturing problems since at least 2018 that resulted in shortages in the United States and elsewhere  The company said in early July it anticipates further supply shortages over the coming months 
Canada s national health agency said earlier this month it continued to experience EpiPen shortages as well 
Mylan  a generic drugmaker that came under fire from mothers and politicians over steep EpiPen price hikes  has been facing new competition for its emergency allergy treatment 
Teva Pharmaceuticals Industries  TA TEVA  has launched its own EpiPen generic  and other companies including  Novartis  AG  S NOVN   Kaleo Inc and Amneal Pharmaceuticals Inc  N AMRX  also are in the market with rival products ",2019-07-29,Reuters,https://www.investing.com/news/stock-market-news/mylan-deal-puts-future-of-its-beleaguered-epipen-in-spotlight-1938260,1938260
196691,418207,MYL,Mylan reaches  30 million settlement in SEC s EpiPen probe,news," Reuters    Mylan NV  O MYL  has reached a tentative agreement to pay  30 million to resolve a probe by the U S  Securities and Exchange Commission related to its emergency allergy shot EpiPen  which became the center of a firestorm over price increases 
The drugmaker in a regulatory filing on Monday disclosed that it had reached an agreement in principle with the SEC s enforcement staff to resolve the investigation that dated back to 2016  Mylan said it will neither admit nor deny wrongdoing as part of the accord  The EpiPen  which Mylan acquired in 2007  is a handheld device that treats life threatening allergic reactions by automatically injecting a dose of epinephrine 
Mylan came under fire in 2016 after raising the price of a pair of EpiPens to  600  from  100 in 2008  enraging consumers and putting it in the center of the ongoing U S  debate over the high cost of prescription medicines 
In 2017  the drugmaker finalized a  465 million settlement resolving U S  Justice Department claims it overcharged the government for EpiPen 
The deal resolved claims that Mylan avoided higher rebates to state Medicaid programs by misclassifying EpiPen as a generic product  even though it was marketed and priced as a brand name product 
In 2016  Mylan revealed the SEC had launched its own investigation related to EpiPen and sought copies of its communications with the U S  Centers for Medicare and Medicaid Services and documents related to the Medicaid rebate program 
Mylan said the settlement with the SEC is subject to approval by the agency s commissioners 
Separately on Monday  Mylan confirmed that it would merge with  Pfizer  Inc s  N PFE  off patent branded drugs unit  a move that will help it diversify its business as it continues to be pressured by falling prices of generic drugs in the United States 
Shares of generic drugmakers have suffered over the past several years and  this year alone  Mylan shares had lost one third of their value through Friday  before news broke of the Pfizer tie up 
The companies are also in talks to transfer a Pfizer manufacturing unit that makes EpiPen to the newly created business  although it remains unclear whether this will address an ongoing shortage of the product ",2019-07-30,Reuters,https://www.investing.com/news/stock-market-news/mylan-reaches-30-million-settlement-in-secs-epipen-probe-1939125,1939125
196692,418208,MYL,Denmark s Novo Nordisk files lawsuit against Mylan over patent,news,"COPENHAGEN  Reuters     Novo Nordisk   CO NOVOb  said on Thursday it has filed litigation in a Delaware district court against Mylan  O MYL  aimed at blocking its attempt to market a generic version of the Danish insulin maker s drug Victoza 
 We can confirm that Novo Nordisk has filed a lawsuit against Mylan for patent infringement of Victoza   the company said in an e mail 
The news was first reported by Bloomberg ",2019-08-22,Reuters,https://www.investing.com/news/stock-market-news/denmarks-novo-nordisk-files-lawsuit-against-mylan-over-patent-1960926,1960926
196693,418209,MYL,Pfizer veteran Ian Read to retire as executive chairman,news," Reuters     Pfizer  Inc  N PFE  said on Friday Ian Read will retire as executive chairman at the end of this year  after a four decade association with the largest U S  drugmaker that included eight years as chief executive officer 
Company veteran Albert Bourla  who succeeded Read  will assume the additional role of chairman 
Read  66  helped Pfizer weather patent expirations of several blockbusters  including cholesterol drug Lipitor  through dealmaking  expansion in emerging markets and cost cuts 
The drugmaker has since eschewed large  transformative deals because of confidence in the strength of its pipeline 
In July  Pfizer announced plans to spin off its off patent branded drugs business and combine it with generic drugmaker Mylan NV  O MYL   a move that will help the company focus on its innovative drugs that generate more profit 
Separately  the drugmaker reported positive data from a late stage study testing its experimental atopic dermatitis treatment  abrocitinib 
The company s shares gained 0 6  at  36 in premarket trading ",2019-09-27,Reuters,https://www.investing.com/news/stock-market-news/pfizer-veteran-ian-read-to-retire-as-executive-chairman-1987799,1987799
196694,418210,MYL,U S  SEC sues Mylan for concealing possible loss tied to EpiPen,news," Reuters    The U S  Securities and Exchange Commission on Friday sued Mylan NV  O MYL   accusing it of failing to timely disclose a possible loss related to a Department of Justice probe into whether the company overcharged Medicaid by hundreds of millions of dollars for sales of the EpiPen Auto Injector 
In a complaint filed with the federal court in Washington  D C   the SEC accused Mylan of misclassifying EpiPen  which is used to treat severe allergic reactions  as a  generic  or  non innovator  drug ",2019-09-27,Reuters,https://www.investing.com/news/stock-market-news/us-sec-sues-mylan-for-concealing-possible-loss-tied-to-epipen-1987867,1987867
196702,418218,MYL,Pfizer in talks to merge off patent drugs business with Mylan,news," Reuters     Pfizer  Inc  N PFE  is in talks to merge its off patent drugs business with Mylan NV  O MYL  in a stock deal  according to a source familiar with the matter   Mylan shareholders would receive a little more than 40  of the newly formed entity  with Pfizer shareholders receiving the remainder  the person said  adding that Pfizer would also get about  12 billion in proceeds from a new sale of debt  Separation of Pfizer s off patent business would be a tax free spin off  the person added  Last year  Pfizer said it was planning to reorganize into three units  separating its consumer healthcare business  The restructuring will allow the company to evaluate its businesses better and could result in selling or spinning off its off patent drugs  Wall Street analysts earlier said  The Wall Street Journal first reported about the talks between the companies on Saturday  
Pfizer and Mylan did not immediately respond to requests for comment ",2019-07-27,Reuters,https://www.investing.com/news/stock-market-news/pfizer-in-talks-to-merge-offpatent-drugs-business-with-mylan-1936780,1936780
196703,418219,MYL,Pfizer posts 30  rise in quarterly profit,news," Reuters     Pfizer  Inc  N PFE  on Monday reported a 30  rise in quarterly profit  helped by demand for its branded treatments such as Ibrance  Eliquis and Xeljanz 
Pfizer  which was scheduled to report its second quarter earnings on Tuesday  also said it would combine Upjohn  its off patent drugs business  with Mylan NV  O MYL  
Pfizer said net income rose to  5 05 billion  or 89 cents per share  in the second quarter  from  3 87 billion  or 65 cents per share  a year earlier 




Revenue fell 1 5  to  13 26 billion ",2019-07-29,Reuters,https://www.investing.com/news/stock-market-news/pfizer-posts-30-rise-in-quarterly-profit-1937387,1937387
196720,418236,MYL,Novartis buys dry eye drug from Takeda for up to  5 3 billion,news,"By Takashi Umekawa and John Miller TOKYO ZURICH  Reuters    Novartis is buying dry eye drug Xiidra from Takeda Pharmaceutical Co for up to  5 3 billion as the Swiss drugmaker refreshes its ophthalmic medicines portfolio with a potential blockbuster  The deal  announced early on Thursday  calls for  3 4 billion up front and milestone payments up to  1 9 billion  Novartis said  The acquisition from Takeda  which is jettisoning the medicine to reduce debt  adds to several big Novartis transactions over the last year as the Basel based company both beefs up its portfolio and sheds non core assets to focus on prescription drugs  It is also the latest Japanese European deal in the pharmaceutical sector following British drugmaker Astrazeneca s  6 9 billion agreement in January to work with Daiichi Sankyo on an experimental breast cancer drug   Expected to close after July  the transaction includes 400 Takeda employees  which analysts from Bank Vontobel in Zurich said gives Novartis a marketing team to sell not only Xiidra but another prospective eye drug entrant  RTH258 for macular degeneration  now awaiting regulatory approval   Despite generic competition   we think that Xiidra is sufficiently differentiated   Vontobel analyst Stefan Schneider said   The market  is  big enough for it to reach blockbuster status  justifying the price   Xiidra  with  400 million in 2018 sales and approval in markets including the United States  Canada and Australia  competes with Allergan s older Restasis   Generics maker Teva has a generic version of Restasis in Canada and is planning a launch in the United States  as is Mylan  NASDAQ MYL   pending resolution of legal disputes  Xiidra has yet to get European regulatory approval    Following closing  we will explore the opportunity for the other territories acquired   a Novartis spokesman told Reuters  BLOCKBUSTER BOUND  For Takeda  this is its first divestment since its leveraged takeover of Shire in January  part of a flurry of multibillion dollar pharmaceutical deals as drugmakers seek to buy other companies to combat expiring patents on their blockbuster medicines and renew their drug pipelines   Japan s biggest drugmaker aims to dispose of  10 billion worth of assets to cut debt  and also said it is selling TachoSil  a surgical patch for bleeding control  to Johnson   Johnson s Ethicon for  400 million   We are working to strategically simplify and optimize our portfolio  while also rapidly deleveraging   Takeda CEO Christophe Weber said in a statement  For roughly 34 million U S  dry eye sufferers  tears fail to adequately lubricate their eyes  and the condition can become painful  potentially leading to eye damage  Novartis said  Xiidra  which treats signs and symptoms of dry eye by controlling inflammation  won U S  regulatory approval in 2016 under Shire s watch and was considered then its most important new medicine   We look forward to leveraging our well established commercial infrastructure to bring this medicine to more patients   said Paul Hudson  who heads Novartis s drugs business  adding the company sees Xiidra  well positioned for blockbuster potential  topping  1 billion annual sales  Novartis just shed its eyecare division Alcon into a separate publicly listed company in a  30 billion shareholder spin off  but only after moving Alcon s prescription eye drugs into Novartis s main pharmaceuticals business  
Novartis shares were down 0 7 percent at 0812 GMT  Takeda shares closed up 0 2 percent in Tokyo ",2019-05-09,Reuters,https://www.investing.com/news/stock-market-news/takeda-sells-dry-eye-drug-to-novartis-to-help-cut-debt-1861985,1861985
196731,418247,MYL,U S  charges pummel drugmaker Indivior  hurt Reckitt,news,"By Justin George Varghese and Martinne Geller  Reuters    Indivior Plc lost three quarters of its stock market value on Wednesday and former parent Reckitt Benckiser also fell after the U S  Justice Department accused the British drugmaker of illegally boosting prescriptions for its blockbuster opioid addiction treatment  An indictment  filed in federal court in Abingdon  Virginia  alleged Indivior made billions of dollars by deceiving doctors and healthcare benefit programs into believing the film version of its Suboxone treatment was safer and less susceptible to abuse than similar drugs  Shares in the company crashed as much as 80 percent  wiping out 620 million pounds in market value  and touching their lowest since listing in 2014  They were down 74 percent at 27 04 pence at 1230 GMT   Shares in Reckitt Benckiser  from which Indivior was spun out  slumped 5 percent to the bottom of London s blue chip FTSE 100 index  erasing many of the gains made in 2019 after three tough years  Reckitt wasn t charged but the indictment said the illegal marketing began before the spin off    This indictment is not against RB Group Plc or any other group company and we currently have no additional or new information in respect of this matter  apart from what has been publicly issued by the Department of Justice and Indivior Plc   Reckitt responded in a brief statement on Wednesday  It referred investors back to a previous statement that it was recognizing a provision of  400 million relating to the issue  but that its final cost could be substantially higher   TOUGH TIMES Indivior had prospered as U S  officials stepped up efforts to combat an opioid epidemic that President Donald Trump has declared a public health emergency  U S  sales account for 80 percent of last year s  1 billion in revenue   Shares  however  had already been hurt by expectations of a slump in Suboxone sales with the arrival of new generic competition this year and the company has struggled to convince analysts and financial investors that it has an adequate replacement   The company is scheduled to be arraigned in court on May 6 and plans to plead not guilty at that hearing  according to a spokesman   This also comes at a bad time for Reckitt  which was just starting to regain investor confidence after a series of one off problems including a safety scandal in South Korea  a failed product launch  a cyber attack and a manufacturing glitch   Its chief executive Rakesh Kapoor  who oversaw several acquisitions and divestitures with the aim of turning Reckitt into a global consumer healthcare company  will retire this year  even though a major undertaking   splitting Reckitt into two business units   is unfinished  POTENTIAL PUNISHMENT In an indictment which charged Indivior and its subsidiary Indivior Inc with conspiracy  health care fraud  mail fraud and wire fraud  the government said it would seek to have it forfeit at least  3 billion   An adverse verdict may have a material adverse effect on the company and its financial position and outlook   Indivior said  The potential penalty is triple last year s annual revenue  The company had net cash of  681 million at the end of the year   Indivior said in a statement it was  extremely disappointed  by the department s decision to charge it  and added it would vigorously contest it   The headline potential penalties are severe but a settlement is also still possible   Jefferies analysts said in a note   Indivior has spent the last two years fighting multiple legal battles and patent disputes in the United States with companies including Dr Reddy s  Teva and Mylan  NASDAQ MYL  to block them from launching generics   RECKITT FEARS Reckitt spun off its pharmaceuticals business into Indivior in 2014  as the shrinking unit battled competition from cheaper generic rivals  The spin off  and the 2017 sale of Reckitt s food unit  let Reckitt focus on expanding its consumer health business  which targets ageing populations and those interested in health and wellness in the West and rising incomes in developing markets   In addition to concern about Reckitt s direct liability from the charges  investors on Wednesday worried about a possible spillover effect on Reckitt s infant formula business   The company had previously flagged implications including  potential criminal indictment of the group or employees  with reputational impact  distraction and potential debarment which could theoretically extend  to its infant formula business   The business  which sells Enfamil formula  derives a portion of its sales from government contracts in the U S  supplying a program to support low income parents   
However  Reckitt said on Wednesday any risk to the infant formula business was theoretical and seen as  highly unlikely and only a remote possibility  ",2019-04-10,Reuters,https://www.investing.com/news/stock-market-news/indivior-shares-tank-after-us-indictment-for-illegal-marketing-1832103,1832103
196732,418248,MYL,Mylan Earnings Beat  Revenue Misses In Q1,news,"Investing com   Mylan  NASDAQ MYL  reported first quarter earnings  that Beat analysts  expectations on Tuesday and revenue that fell short of forecasts 
The firm reported earnings per share of  0 82 on revenue of  2 5B  Analysts polled by Investing com expected EPS of  0 79 on revenue of  2 7B  That compared to EPS of  0 96 on revenue of  2 65B in the same period a year earlier  The company had reported EPS of  1 3 on revenue of  3 08B in the previous quarter 
Mylan shares lost 2 69  to trade at  27 50 in pre market trade following the report 
Mylan follows other major Healthcare sector earnings this month
 On April 16  J J reported first quarter EPS of  2 1 on revenue of  20 02B  compared to forecasts of EPS of  2 04 on revenue of  19 61B 
Pfizer earnings Beat analysts  expectations on April 30  with first quarter EPS of  0 85 on revenue of  13 12B  Investing com analysts expected EPS of  0 75 on revenue of  12 99B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-05-07,Investing.com,https://www.investing.com/news/stock-market-news/mylan-earnings-beat-revenue-misses-in-q1-1858910,1858910
196733,418249,MYL,Mylan reports quarterly loss due to plant restructuring expenses,news," Reuters    Drugmaker Mylan  NASDAQ MYL  NV reported quarterly loss on Tuesday  hurt by restructuring related expenses at its Morgantown manufacturing plant in West Virginia  The company reported a net loss of  25 million  or 5 cents per share  in the first quarter ended March 31  compared with profit of  87 1 million  or 17 cents per share  a year earlier  
Total revenue fell to  2 50 billion from  2 68 billion ",2019-05-07,Reuters,https://www.investing.com/news/stock-market-news/mylan-reports-quarterly-loss-due-to-plant-restructuring-expenses-1858936,1858936
196734,418250,MYL,StockBeat  Mylan Slumps on Revenue Miss  Strategic Review No Show,news,"Mylan  NASDAQ MYL  slumped on Tuesday after delivering mixed quarterly results and failing to provide an update on its long running strategic review 
Mylan reported first quarter earnings of  0 82 a share  beating estimates from Investing com for earnings of  0 79  but revenue of  2 5 billion missed estimates of  2 7 billion  sending the shares down more than 18   Because of the stock price slump  Mylan shares are now down nearly 16  for the year and are off 46  from their 52 week high 
The company also revealed that attorneys general from several states intend to file a complaint against the drug maker alleging anticompetitive practices concerning some of its generic drugs 
But it s not the first time Mylan has ended up on the wrong side of antitrust laws 
The drugmaker is facing a class action suit over its EpiPen allergy treatment as plaintiffs claim the rebate program  blocked Sanofi  PA SASY  from accessing a significant portion of the market for epinephrine autoinjectors   U S  District Judge J  Paul Oetken ruled late last year 
There was more drama to come as the company  during the post earnings call  said that conclusions from its strategic view should be available in the  near term   after previously announcing last quarter that the review was in the final stages 
That seemingly has sparked speculation among investors that the company is still undecided on the best way forward amid falling sales of generic drugs in North America and slowing sales of its EpiPen 
Analysts have touted three possible options available to drug maker  including a classic restructuring  a leverage buyout or an acquisition or merger 
Sales in North America fell 6  to  922 9 million in the first quarter  primarily driven by changes in the competitive environment and the impact of the Morgantown plant remediation activities   Mylan said 
Yet  there are some on Wall Street who continue to back the drug maker 
 While Q1 sales growth was well below our expectation  we still think 2019 revenue can increase about 5  vs  2018 on strong ramps of generic Advair  biosimilar Neulasta and several other new launches in 2H 2019   said CFRA  the independent research provider 
 We continue to think shares are an attractive value with the low end of 2019  free cash flow  guidance representing a 16  yield on current market cap  and FCF growth expected over the long term  
Mylan reaffirmed a full year adjusted free cash flow range of  1 9 billion to  2 3 billion ",2019-05-07,Investing.com,https://www.investing.com/news/forex-news/stockbeat-mylan-slumps-as-strategic-review-noshow-revenue-miss-1859318,1859318
196753,418269,MYL,Revance on recent regulatory progress and provides anticipated 2019 milestones,news,In December of 2018  Revance Therapeutics  RVNC  0 2   completed its pre Biologics Licensing       Application meeting with the FDA for its submission of       DaxibotulinumtoxinA for Injection  RT002  in the treatment of glabellar       lines In February of 2018  announced a collaboration and license       agreement with Mylan  NASDAQ MYL  N V  on a biosimilar to BOTOX   In 2019  we will have an extensive and active clinical pipeline   a       total of six programs for RT002 injectable that address over half of the       current  4B global neuromodulation market   said Dan Browne  President and CEO at Revance RVNC is  0 24   to  20 34 JPM19Now read ,2019-01-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/revance-on-recent-regulatory-progress-and-provides-anticipated-2019-milestones-1739438,1739438
196754,418270,MYL,Teva expects sales injection from U S  EpiPen market,news,"By Tova Cohen TEL AVIV  Reuters    Teva Pharmaceutical Industries  NYSE TEVA  expects its generic version of Mylan s EpiPen to claim about 25 percent of the U S  market by the end of the year  CEO Kare Schultz said on Tuesday  as the company closes in on a return to growth in 2020  Wall Street has viewed the EpiPen rival as a welcome profit booster for Teva as it contends with declining U S  margins for its older generic medicines  competition for multiple sclerosis treatment Copaxone and costly acquisitions   When the device s approval was announced last year analysts suggested it could add  250 million to Teva s annual revenue and 4 6 cents per share in earnings  providing a welcome lift for a company that has fired thousands of employees and worked to reduce its debt load to  27 billion from  35 billion  Mylan  NASDAQ MYL  also produces a generic version of its life saving EpiPen allergy treatment  which like Teva s product is priced at about  300  The U S  market for EpiPen is worth roughly  750 million a year  When asked how much of that market Teva expects to hold by the end of this year  Schultz said   It s difficult to say exactly  but the simple answer would be 25 percent roughly   Israel based Teva  the world s largest generic drugmaker  is already selling its product for adults and plans to start supply of a junior version for young children in 3 4 months  the Danish born CEO told reporters  Many of the largest U S  pharmacies and drug distributors do not yet have Teva s version of EpiPen  five months after it was approved for sale in the United States  pharmacy chains and a group that tracks drug shortages told Reuters last month  Mylan s EpiPen has also been in short supply because of manufacturing problems at the lone  Pfizer   NYSE PFE  plant that makes the auto injectors  Teva received U S  approval for its copy of EpiPen in August after several years of delay  but Schultz said additional  validations  were required by the U S  Food   Drug Administration  which it has now done   While any pharmacy can call and buy Teva s product  the company does not have enough supply for all the wholesellers and pharmacies  he said   We will be filling up the supply chain more and more over the coming months   Schultz said  Schultz estimates that Teva should approach a 50 percent market share by the end of 2020  Last week  Teva shares dropped sharply after it published a 2019 outlook that disappointed the market   Its shares were down 0 7 percent at midday in Tel Aviv  
 The fact is  we have a tough situation where revenues are going downhill   Schultz said on Tuesday   People forgot that a little bit so we had to remind them  ",2019-02-19,Reuters,https://www.investing.com/news/stock-market-news/teva-pharm-expects-about-25-percent-of-epipen-market-by-year-end-1783047,1783047
196755,418271,MYL,Mylan Earnings miss  Revenue beats In Q4,news,"Investing com   Mylan  NASDAQ MYL  reported fourth quarter earnings  that missed analysts  expectations on Tuesday and revenue that topped forecasts 
The firm reported earnings per share of  1 3 on revenue of  3 08B  Analysts polled by Investing com forecast EPS of  1 35 on revenue of  3 07B  That compared to EPS of  1 43 on revenue of  3 24B in the same period a year earlier  The company had reported EPS of  1 25 on revenue of  2 83B in the previous quarter 
Mylan shares lost 6 89  to trade at  28 51 in after hours trade following the report 
Mylan follows other major Healthcare sector earnings this month
 On January 29  Pfizer reported fourth quarter EPS of  0 64 on revenue of  13 98B  compared to forecasts of EPS of  0 63 on revenue of  13 9B 
Roche Holding ADR earnings beat analyst s expectations on January 31  with fourth quarter EPS of  18 14 on revenue of  14 88B  Investing com analysts expected EPS of  1 04 on revenue of  14 88B
Stay up to date on all of the upcoming earnings reports by visiting Investing com s earnings calendar",2019-02-26,Investing.com,https://www.investing.com/news/stock-market-news/mylan-earnings-miss-revenue-beats-in-q4-1791436,1791436
196756,418272,MYL,Mylan shares sink as bleak profit outlook sparks growth concerns,news," Reuters    Mylan  NASDAQ MYL  NV shares slid 10 percent on Wednesday after the generic drug maker predicted poor 2019 earnings that led some Wall Street analysts to wonder if its finances would worsen further  Mylan said on Tuesday its lower than expected profit outlook was due to rising costs related to marketing and research and development  It added that product launches should offset revenue declines for existing products this year as prices of generic drugs remain under pressure due to increased competition   Even with the approvals and launches of Copaxone  Neulasta and Advair these approvals are only providing some relief  but are not altering the systemic problems inherent with the generic model   Cowen   Co analyst Ken Cacciatore said in a report to clients  Mylan this month launched its generic version of GlaxoSmithKline s blockbuster asthma treatment Advair at a price 70 percent lower than the branded medicine  Five brokerages cut their 12 month targets on Mylan s share price  and analysts at Cowen   Co were the most negative with a  25 target  a third lower than the median Wall Street price target   Clearly spending roughly  15 billion on product and company acquisitions and having flat cash generation over 4 5 years should be alarming   Cacciatore said  Generic drug prices in the United States have been declining as regulators approve more cheaper  copycat drugs  spurring competition and weighing on the profits of generic drug makers like Mylan and Teva Pharmaceutical Industries  NYSE TEVA  Ltd  Additionally  manufacturing troubles at Mylan s Morgantown plant in West Virginia is hurting profits  The market would have to see evidence that the company s increased investments in 2019 are translating to higher revenue before Mylan s stock price recovers  said JPMorgan  NYSE JPM  analyst Chriss Schott  A  lack of earnings visibility makes it hard to tell if Mylan is still built to last   Cantor Fitzgerald analysts said  Eleven of 16 Wall Street analysts covering Mylan have positive ratings  while five have neutral or  hold  ratings  according to IBES data from Refinitiv  
Mylan shares were last down 9 5 percent at  27 72 in early trade  The stock has fallen nearly 27 percent over the past 12 months ",2019-02-27,Reuters,https://www.investing.com/news/stock-market-news/mylan-shares-sink-as-bleak-profit-outlook-sparks-growth-concerns-1792419,1792419
196776,418292,MYL,FDA OKs Theravance and Mylan s COPD med revefenacin,news,The FDA approves YUPELRI  revefenacin  for the treatment of patients with moderate to very severe chronic obstructive pulmonary disease  COPD   The FDA s action date was Tuesday  November 13  The long acting muscarinic antagonist was co developed by Theravance Biopharma  TBPH  6 2   and Mylan N V   MYL  0 9    Previously  Theravance Bio s revefenacin shows treatment effect in late stage COPD studies  Sept  17  Now read ,2018-11-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-oks-theravance-and-mylans-copd-med-revefenacin-1682529,1682529
196777,418293,MYL,Galectin Therapeutics misses by  0 01,news,"Galectin Therapeutics  NASDAQ GALT   Q3 GAAP EPS of   0 07 misses by  0 01 
Cash and cash equivalents of  10 14M
Press Release
Now read ",2018-11-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/galectin-therapeutics-misses-by-001-1685897,1685897
196783,418299,MYL,Class action suit against Mylan and Pfizer to proceed,news,A Kansas district court judge has dismissed motions by Mylan  MYL  0 6     Pfizer   PFE  0 8   and others to dismiss class action complaints accusing them of RICO Act violations  specifically  their activities aimed at monopolizing the market for emergency allergy med EpiPen  epinephrine  Substantially all claims can proceed Now read ,2018-08-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/class-action-suit-against-mylan-and-pfizer-to-proceed-1580671,1580671
196784,418300,MYL,FDA extends EpiPen expiry date to combat shortage,news," Reuters    The U S  Food and Drug Administration on Tuesday extended the expiration date of specific lots of Mylan  NASDAQ MYL  NV s EpiPen allergy injectors by four months to mitigate the shortage of the life saving treatment  The decision  comes at a time when the shortage has come under focus at the start of back to school season  and applies to specific lots of 0 3 milligram EpiPen products  after the regulator reviewed data provided by Mylan  Earlier this month  Mylan issued a warning that the devices may not always be available  The shortage has largely been due to ongoing manufacturing issues at a  Pfizer   NYSE PFE  plant which supplies EpiPens  EpiPen autoinjectors allow the patient or a caretaker to administer a dose of epinephrine in case of a severe allergic reaction  such as to bee stings or exposure to peanuts   
Last week  the FDA approved Teva Pharmaceuticals  generic version of Mylan s drug ",2018-08-21,Reuters,https://www.investing.com/news/stock-market-news/fda-extends-epipen-expiry-date-to-combat-shortage-1581926,1581926
196785,418301,MYL,FDA investigation into NDMA impurity in valsartan continuing  changes in manufacturing process suspected,news,In a statement  the FDA says its investigation into an impurity in valsartan  used to treat high blood pressure and heart failure  appears to point to changes in the manufacturing process at bulk manufacturer Zhejiang Huahai Pharmaceutical in China  Further testing is in process to confirm this The impurity  called NDMA  is a probable carcinogen at low doses  although the agency says its scientists have estimated a miniscule theoretical risk to patients  Specifically  if 8 000 users consumed the highest dose of the tainted valsartan  320 mg  for four years  the estimated time the NDMA containing product has been on the U S  market  there could be one additional case of cancer over the lifetimes of the 8 000 patients Four companies have voluntarily recalled valsartan products  including Teva Pharmaceutical Industries  TEVA  0 4    13 other ingredient manufacturers who supply more than 20 drug firms with product have been contacted and testing will be done to determine the presence of NDMA in their respective ingredients Selected tickers   PRGO  1 8   MYL  0 5  Previously  Teva recalls certain lots of valsartan and valsartan hydrochlorothiazide tablets due to impurities  July 16 Now read ,2018-08-30,Seeking Alpha,https://www.investing.com/news/stock-market-news/fda-investigation-into-ndma-impurity-in-valsartan-continuing-changes-in-manufacturing-process-suspected-1593175,1593175
196786,418302,MYL,Agile Therapeutics up 62  on development path for Twirla,news,Nano cap Agile Therapeutics  AGRX  62 4   is up on a healthy 15x surge in volume on the heels of its announcement that the FDA has provided a path forward for contraceptive patch Twirla  levonorgestrel ethinyl estradiol transdermal system  The agency s Office of New Drugs has suggested a wear study to assess if Twirla has similar adhesion performance to Mylan s  MYL  5 2   Xulane  norelgestromin and ethinyl estradiol transdermal system   a generic version of Ortho s Evra  If successful  the study should be sufficient to support Twirla s adhesion claim The FDA will still need to review the efficacy data  however  if and when Agile resubmits its marketing application  An advisory committee meeting and review is also expected Shares collapsed in May on the news that the FDA would require bioadhesion and bioequivalence studies to support a marketing application Previously  Agile Therapeutics down 76  on additional work needed for U S  approval of Twirla  May 18 Now read ,2018-10-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/agile-therapeutics-up-62-on-development-path-for-twirla-1637255,1637255
196794,418310,MYL,Another antibiotic crisis  fragile supply leads to shortages,news,"By Ben Hirschler LONDON  Reuters    Shortages of some life saving antibiotics are putting growing numbers of patients at risk and fuelling the evolution of  superbugs  that do not respond to modern medicines  according to a new report on Thursday  The non profit Access to Medicine Foundation  AMF  said there was an emerging crisis in the global anti infectives market as fragile drug supply chains   reliant on just a few big suppliers   come close to collapse  The result is shortages of products like piperacillin tazobactam  an antibiotic combination used intravenously in intensive care  which has been in tight supply since a 2016 explosion at a Chinese pharmaceutical ingredients factory  Another antibiotic  benzathine penicillin G  BPG   faces shortages in at least 39 countries  including Germany and Brazil  BPG is a key drug for preventing transmission of syphilis from mother to child and the shortage frustrated Brazil s efforts to bring a disease outbreak under control between 2012 and 2015  BPG is also used to fight rheumatic heart disease  In absence of the right drugs  patients may take less effective or poor quality medicines that increase the risk of antimicrobial resistance developing   Things are getting worse because the market is not fixing the problem  despite the expansion in the need for such specialist antibiotics   said AMF Executive Director Jayasree Iyer  Global demand for antibiotics has grown by two thirds since 2000  driven by population growth and the need for medicines to fight infectious diseases in low  and middle income countries  Most antibiotics are cheap  off patent generic medicines  which is good for affordability  But that also means they have very low profit margins   particularly compared to modern drugs for diseases like cancer   offering manufacturers little incentive to invest in new production facilities  The rise in shortages has gone hand in hand with a wave of consolidation among the companies making generic drugs   which range from global pharmaceutical giants to smaller firms in countries such as India   reducing the number of suppliers making individual product lines  Sporadic drug shortages are not unique to antibiotics  Recently  for example  there has been a worldwide shortage of Mylan s  O MYL  market leading EpiPen emergency allergy device   But antibiotic shortages can have especially dire consequences  since doctors have to resort to sub optimal treatments that are less efficient at killing specific pathogens  leading to the rise of resistant bacteria or so called superbugs  
An estimated 70 percent of bacteria are already resistant to at least one antibiotic that is commonly used to treat them  making the evolution of such superbugs one of the biggest threats facing medicine today ",2018-05-31,Reuters,https://www.investing.com/news/world-news/another-antibiotic-crisis-fragile-supply-leads-to-shortages-1469724,1469724
196800,418316,MYL,Mylan reaffirms 2018 guidance,news,At its Investor Day today  Mylan N V   MYL  0 2   reiterated its previously announced outlook for 2018 Revenues   11 75B   13 25B  non GAAP EPS   5 20   5 60 Previously  Mylan Q4 top line off 1   earnings down 42   shares up 1  after hours  Feb  28 Now read ,2018-04-11,Seeking Alpha,https://www.investing.com/news/stock-market-news/mylan-reaffirms-2018-guidance-1390071,1390071
196801,418317,MYL,EpiPen shortages seen in Canada  UK but U S  supply intact,news,"By Bill Berkrot NEW YORK  Reuters    Mylan  NASDAQ MYL  N V  s emergency allergy antidote EpiPen is in short supply in Canada and Britain  but remains available in the United States  the treatment s manufacturer said on Friday  EpiPens deliver potentially lifesaving doses of the generic drug epinephrine  via an automatic injector that a patient or caregiver can administer in the event of severe allergic reaction    We are shipping product  Currently there is no shortage in the U S    said Steve Danehy  a spokesman for  Pfizer  Inc  NYSE PFE   which produces the global supply of EpiPens for Mylan out of a single facility near St  Louis  Missouri  Mylan is in charge of managing allocation of the EpiPen supply  Danehy said in an email to Reuters  It was not immediately clear why Canada and the UK would be subject to a shortage at this time  A Mylan spokeswoman was not available for comment   Mylan s EpiPen sales practices in the United States sparked public outrage in 2016 as consumers saw the price for a pack of two auto injectors rise sixfold to  600 in less than a decade  making the devices unaffordable for a growing number of families   Since then  the company has launched a generic version of EpiPen for half the price  though the U S  market is still the most lucrative   Meridian Medical Technologies Inc  the unit of Pfizer that manufactures EpiPens  has been hit by a series of manufacturing problems  In March 2017  Mylan recalled tens of thousands of devices after complaints that some had failed to activate   In September  Meridian received a warning letter from the U S  Food and Drug Administration  The FDA said Meridian had failed to thoroughly investigate product failures  including EpiPen products that were associated with patient deaths and severe illnesses  It said the company failed to take corrective actions until FDA s inspection  At the time  Mylan said it did not anticipate any impact on EpiPen supply based on the warning letter   But on Thursday  Pfizer Canada said it was  experiencing supply constraints  for EpiPens used by both adults and children  due to delays at the manufacturing facility   as well as problems in sourcing a component for the device from an outside supplier  There are no alternatives on the market in Canada  federal health officials there said  They advised patients and caregivers to use expired EpiPens in an emergency if they have nothing else on hand  and then call 911    Pfizer understands and regrets the challenges that these ongoing supply constraints pose to patients and the healthcare community   the company said in a statement on its website  On Friday  the UK website for EpiPen notified consumers of  intermittent supply constraints  for the adult injector  It said the next shipment to EpiPen s distributor in the country was expected toward the end of April   
Mylan s revenue from EpiPen dropped sharply over the last year due to increased competition  the launch of its own cheaper generic and higher rebates that it has had to pay to as a result of a settlement for overcharging the U S  government ",2018-04-13,Reuters,https://www.investing.com/news/stock-market-news/epipen-shortages-seen-in-canada-uk-but-us-supply-intact-1394813,1394813
196802,418318,MYL,Mylan cuts 15 percent of workforce at West Virginia plant,news, Reuters    Generic drugmaker Mylan NV  O MYL  on Friday announced layoffs of about 15 percent of its workforce at a pharmaceutical manufacturing plant in Morgantown  West Virginia  The company  which had faced intense criticism and political scrutiny over price hikes for its life saving EpiPen emergency allergy treatment  said the Morgantown plant  needed to be rightsized to be less complex  for continued operations  The layoffs involved more than 400 employees represented by a United Steel Workers local union  reported WAJR  a Morgantown radio station  Mylan said the affected employees were primarily in operations  It said it continues to employ about 3 000 people in West Virginia   We remain committed to a U S  manufacturing base and plan to continue making the majority of the medicines we supply to the U S in the U S    Mylan said in a statement   Generic drugmakers have seen profits shrink due to intensifying pricing pressure on the low cost pharmaceuticals  Mylan s bottom line has also been hit by its decision to sell a generic EpiPen for about half the price of the branded product in response to public outrage in 2016  Consumers saw the price for a pack of two auto injectors rise sixfold to  600 in less than a decade  making them unaffordable for a growing number of families  The Morgantown plant is not involved in EpiPen production  EpiPens are manufactured for Mylan by  Pfizer  Inc  N PFE  at a plant in St  Louis  which has experienced production problems that have led to shortages in some international markets  including Canada and Britain ,2018-04-20,Reuters,https://www.investing.com/news/stock-market-news/mylan-cuts-15-percent-of-workforce-at-west-virginia-plant-1406277,1406277
196806,418322,MYL,Should Value Investors Buy Mylan  MYL  Stock ,opinion,"Here at Zacks  we focus on our proven ranking system  which places an emphasis on earnings estimates and estimate revisions  to find winning stocks  But we also understand that investors develop their own strategies  so we are constantly looking at the latest trends in value  growth  and momentum to find strong companies for our readers 
Of these  perhaps no stock market trend is more popular than value investing  which is a strategy that has proven to be successful in all sorts of market environments  Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large 
On top of the Zacks Rank  investors can also look at our innovative Style Scores system to find stocks with specific traits  For example  value investors will want to focus on the  Value  category  Stocks with high Zacks Ranks and  A  grades for Value will be some of the highest quality value stocks on the market today 
Mylan  NASDAQ MYL  is a stock many investors are watching right now  MYL is currently sporting a Zacks Rank of  2  Buy   as well as a Value grade of A  The stock has a Forward P E ratio of 4 92  This compares to its industry s average Forward P E of 9 20  Over the past 52 weeks  MYL s Forward P E has been as high as 6 47 and as low as 3 83  with a median of 4 45 
MYL is also sporting a PEG ratio of 1 13  This metric is used similarly to the famous P E ratio  but the PEG ratio also takes into account the stock s expected earnings growth rate  MYL s industry currently sports an average PEG of 1 14  Over the last 12 months  MYL s PEG has been as high as 1 19 and as low as 0 78  with a median of 0 96 
We should also highlight that MYL has a P B ratio of 1  The P B is a method of comparing a stock s market value to its book value  which is defined as total assets minus total liabilities  This stock s P B looks solid versus its industry s average P B of 1 32  Within the past 52 weeks  MYL s P B has been as high as 1 36 and as low as 0 73  with a median of 0 87 
Value investors also use the P S ratio  The P S ratio is is calculated as price divided by sales  This is a popular metric because sales are harder to manipulate on an income statement  so they are often considered a better performance indicator  MYL has a P S ratio of 0 99  This compares to its industry s average P S of 2 95 
These figures are just a handful of the metrics value investors tend to look at  but they help show that Mylan is likely being undervalued right now  Considering this  as well as the strength of its earnings outlook  MYL feels like a great value stock at the moment ",2020-01-26,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-buy-mylan-myl-stock-200501916,200501916
196807,418323,MYL,Top Ranked Value Stocks To Buy For January 27th,opinion,Here are four stocks with buy rank and strong value characteristics for investors to consider today  January 27th American Equity Investment Life Holding Company  AEL   This company that provides life insurance products and services carries a Zacks Rank  1  Strong Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 39 1  over the last 90 days American Equity Investment Life Holding Company Price and Consensus   American Equity Investment Life Holding has a price to earnings ratio  P E  of 6 74  compared with 13 10 for the industry  The company possesses a  of A American Equity Investment Life Holding Company PE Ratio  TTM    CURO Group Holdings Corp   CURO  This is a diversified consumer finance company  which provides consumer finance to a range of underbanked consumers has a Zacks Rank  1  and seen the Zacks Consensus Estimate for its current year earnings rising 1 8  over the last 90 days CURO Group Holdings Corp  Price and Consensus   CURO Group Holdings has a price to earnings ratio  P E  of 3 45  compared with 7 60 for the industry  The company possesses a Value Score of B CURO Group Holdings Corp  PE Ratio  TTM    Mylan  NASDAQ MYL  N V   MYL   This company that develops  licenses  manufactures  markets  and distributes generic  branded generic  brand name  and over the counter pharmaceutical products has a Zacks Rank  1  and seen the Zacks Consensus Estimate for its current year earnings rising 1 2  over the last 90 days Mylan N V  Price and Consensus   Mylan has a price to earnings ratio  P E  4 87  compared with 16 70 for the industry  The company possesses a Value Score of A Mylan N V  PE Ratio  TTM    ViacomCBS Inc   VIAC   This is a media and entertainment  that creates content and experiences for audiences has a Zacks Rank  2  Buy   and seen the Zacks Consensus Estimate for its current year earnings rising 5 8  over the last 90 days ViacomCBS Price and Consensus   ViacomCBS has a price to earnings ratio  P E  of 5 82  compared with 14 40 for the industry  The company possesses a Value Score of A ViacomCBS PE Ratio  TTM    See Learn more about the Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2019  while the S P 500 gained and impressive  53 6   five of our strategies returned  65 8    97 1    118 0    175 7  and even  186 7  This outperformance has not just been a recent phenomenon  From 2000   2019  while the S P averaged  6 0  per year  our top strategies averaged up to  54 7  per year ,2020-01-27,Zacks Investment Research,https://www.investing.com/analysis/top-ranked-value-stocks-to-buy-for-january-27th-200501933,200501933
196808,418324,MYL,Pfizer  PFE  Lags Q4 Earnings   Sales Estimates  Stock Down,opinion,Pfizer  Inc    NYSE PFE   reported fourth quarter 2019 adjusted earnings per share of 55 cents  which missed the Zacks Consensus Estimate of 57 cents  Earnings declined 13  year over year due to lower revenues and higher costs The pharma heavyweight recorded revenues of  12 69 billion  which also missed the Zacks Consensus Estimate of  12 70 billion  Revenues declined 9  from the year ago quarter on a reported basis  On an operational basis  excluding the 1  negative impact of currency  revenues declined 8  year over year as higher sales of some key brands in Pfizer s Biopharmaceuticals group was offset by revenue decline in the Upjohn segment  The segment was hurt mainly by the loss of Lyrica exclusivity in July 2019 in the United States Importantly  excluding the spin off of the Consumer Healthcare  CHC  unit  fourth quarter revenues declined 1  operationally  We remind investors that in August last year Pfizer merged its CHC unit with Glaxo s   NYSE GSK   Consumer unit to form a new joint venture  JV   Pfizer owns a stake of 32  in the JV and Glaxo owns the remaining 68   In the fourth quarter  Pfizer did not record any revenues from the Consumer Healthcare unit  Instead  it recorded its share of profits generated by the Consumer Healthcare JV International revenues declined 4  to  7 2 billion  On an operational basis  international sales declined 2  in the quarter  U S  revenues declined 15  to  5 49 billion Adjusted selling  informational and administrative  SI A  expenses rose 4   operationally  in the quarter to  4 07 billion  Adjusted R D expenses rose 4  to  2 53 billion Segment DiscussionPfizer reports under two business units   Pfizer Biopharmaceuticals Group and Upjohn In July 2019  Pfizer announced a definitive agreement to spin off its Upjohn unit and combine it with generic drugmaker Mylan   NASDAQ MYL   in a Reverse Morris Trust transaction for the creation of a generic pharmaceutical company called Viatris  The transaction is expected to close by mid 2020 Pfizer Biopharma sales grew 7  on a reported basis  up 9  an operational basis  from the year ago period to  10 53 billion  Higher sales of brands like Eliquis  Ibrance  Inlyta and Xeljanz and higher biosimilars revenues drove this segment s sales growth  Weaker sales of Prevnar 13 Prevenar 13 in the United States and Enbrel internationally offset the increase Within the Biopharma group  Oncology revenues increased 26   on an operational basis  to  2 47 billion  Vaccine revenues rose 7  to  1 71 billion  Internal Medicine rose 2  to  2 37 billion  The Inflammation   Immunology franchise declined 2  to  1 25 billion  The portfolio of Rare Disease rose 25  to  686 million  The newly added Hospital sub segment s sales rose 3  to  2 06 billion  The Hospital segment comprises Pfizer s global portfolio of sterile injectable and anti infective medicines Pfizer s Upjohn group s sales declined 32   both on a reported and operational basis to  2 16 billion mainly due to U S  loss of exclusivity of Lyrica Performance of Key DrugsIbrance revenues rose 15  year over year to  1 28 billion on continued strong uptake in international markets and consistent growth in the United States  However  Ibrance revenues fell short of the Zacks Consensus Estimate of  1 36 billion Xeljanz sales rose 11  to  607 million driven mainly by growth in international markets Inlyta revenues increased 72  to  161 million  driven mainly by 249  growth in the United States  U S  sales gained from increased uptake resulting from recent FDA approvals for the combination of Inlyta plus Pfizer s Bavencio and Inlyta plus Merck s   NYSE MRK   PD L1 inhibitor Keytruda in first line treatment of advanced renal cell carcinoma patients Global Prevnar 13 Prevenar 13 revenues rose 6  to  1 58 billion  Prevnar 13 revenues declined 7  in the United States  Prevenar 13 revenues rose 18  in international markets Enbrel revenues declined 18  to  414 million in key European markets due to continued biosimilar competition  Pfizer has exclusive rights to Amgen s  AMGN  blockbuster RA drug  Enbrel  outside the United States and Canada Eliquis alliance revenues and direct sales rose 22  to  1 1 billion  Xalkori sales rose 39  to  145 million  Xtandi recorded alliance revenues of  244 million in the quarter  up 29  year over year  Sutent sales declined 10  to  231 million  Chantix sales declined 4  to  282 million in the quarter Total biosimilar revenues were  279 million  up 35  year over year In the Upjohn segment  sales of key drug Lyrica declined 68  to  433 million due to multi source generic erosion  Viagra sales declined 5  to  119 million due to generic competition 2019 ResultsFull year 2019 sales declined 4  to  51 75 billion  missing the Zacks Consensus Estimate of  51 81 billion  However  sales were within the guided range of  51 2 billion to  52 2 billionAdjusted earnings for 2019 of  2 95 per share were below the Zacks Consensus Estimate of  2 96  Earnings however rose 1  year over year  Earnings were within the guided range of  2 94  3 00 2020 Guidance The company issued its financial guidance for 2020 for the present Pfizer as well as for the  New Pfizer   after the Upjohn divesture  Revenues are expected in the range of  48 5 billion to  50 5 billion  the midpoint of which indicates a decline from 2019 levels due to lost revenue contribution from CHC unit Adjusted earnings per share are expected in the range of  2 82  2 92  The respective Zacks Consensus Estimate for sales and earnings is pegged at  45 82 billion and  2 62 per share  The above guidance includes full year contribution from Upjohn The  New Pfizer  is expected to record revenues in the range of  40 7 billion to  42 3 billion  the midpoint of which indicates 8  volume driven operational growth compared to 2019 Biopharma revenues  Adjusted EPS guidance for the  New Pfizer  is in the range of  2 25  2 35 Research and development expense for present Pfizer is expected in the range of  8 1   8 5 billion while SI A spending is projected in the range of  12 0  13 0 billion   Adjusted tax rate is expected to be approximately 15  in 2020 Our TakePfizer s fourth quarter 2019 performance was weak as it missed estimates for both earnings and sales  Pfizer s shares declined around 2  in pre market trading  Pfizer s shares have declined 1 6  in the past year against an increase of 16 1  for the    Nonetheless  we believe the Consumer Healthcare joint venture with Glaxo  the Array acquisition  July 2019  and the pending merger of Upjohn unit with Mylan  if successful  will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines  The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff goes away  Pfizer expects strong growth of key brands like Ibrance  Xeljanz and Eliquis to continue to drive sales  In addition  new brands such as Vyndaqel Vyndamax  Braftovi  Mektovi and oncology biosimilars should bring in additional sales However  Lyrica generic erosion  currency headwinds and pricing pressure will remain near term top line headwinds Pfizer currently sports a Zacks Rank  1  Strong Buy   You can see  5 Stocks Set to DoubleEach was hand picked by a Zacks expert as the  1 favorite stock to gain  100  or more in 2020  Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth Most of the stocks in this report are flying under Wall Street radar  which provides a great opportunity to get in on the ground floor ,2020-01-27,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-lags-q4-earnings--sales-estimates-stock-down-200502243,200502243
196809,418325,MYL,Glaxo  GSK  Lags Q4 Earnings   Revenue Estimates  Stock Down,opinion,"GlaxoSmithKline plc   NYSE GSK   reported fourth quarter 2019 adjusted earnings of 64 cents per American depositary share  which missed the Zacks Consensus Estimate of 68 cents  Adjusted earnings were down 21  reportedly and 16  at constant exchange rate   CER    year over year Shares of Glaxo were down almost 4 4  on Feb 5  following the earnings release  However  the stock has gained 11  in the past year compared with the  s 12 6  increase  Quarterly revenues rose 9  on a reported basis and 11  at CER to  11 46 billion   8 9 billion   driven by strong performance across Vaccines and Consumer Healthcare segments  However  the top line missed the Zacks Consensus Estimate of  11 77 billion                                                          Glaxo reports financial figures under three segments  Pharmaceuticals  Vaccines and Consumer Healthcare Full Year ResultsThe company s adjusted earnings per ADS were  3 22  for the full year  up 1  at CER  Full year revenues rose 8  at CER to approximately  43 9 billion All growth rates mentioned below are on a year over year basis and at CER Respiratory Drugs Drive Pharmaceuticals Segment Sales         Pharmaceuticals sales were down 4  at CER as Respiratory segment growth was offset by sales decline at Established Pharmaceuticals segment  Sales in the United States were down 6   Sales in European markets were down 3  at CER while it remained flat in international markets Respiratory sales were up 9  at CER mainly driven by increase in sales of Trelegy Ellipta and Nucala across European and international markets  Nucala sales were up 28  at CER during the quarter  Sales of Nucala grew 24  and 32  in the United States and Europe  respectively  In the International markets  sales of Nucala increased 36   Trelegy Ellipta sales more than doubled year over year driven by an increase in market share in the United States  Relvar Breo Ellipta registered a decline of 19  in sales during the fourth quarter driven by steep decline in U S  sales  Sales of Relvar Breo Ellipta decreased 41  in the United States due to impact of Advair generic and competitive pricing pressure  The launch of generic versions of Glaxo key respiratory drug  Advair  has created significant pricing pressure in inhaled corticosteroid   ICS   long acting beta agonist   LABA   market in the United States  The pricing pressure is expected to continue in 2020  However  sales of Relvar Breo Ellipta increased 6  and 14  in European and international markets  respectively HIV sales remained flat year over year at CER as growth in sales of Juluca and Dovato was completely offset by decline in sales of Tivicay  Sales of dolutegravir franchise were up 2   while sales from remaining drugs  comprising 4  of HIV portfolio  declined 30  at CER  The company expects sales of HIV segment to remain flat in 2020 as well The dolutegravir franchise comprises two three drug regimens   Triumeq and Tivicay   and two two drug regimens   Juluca and Dovato  Dovato was launched in the United States in April followed by launch in Europe in the third quarter of 2019  The growth in sales of Juluca and Dovato in the fourth quarter was partially offset by decline in sales of Triumeq and Tivicay due to transition of patients from three drug regimens to two drug regimens Sales of the dolutegravir franchise were up 2  in the U S  market as transition to the new two drug portfolio was offset by a net price benefit  Sales of this franchise were down 1  in Europe as strong volume growth was more than offset by price erosion and couple of other factors  In international markets  sales were up 11  at CER mainly driven by Tivicay  Please note that Glaxo markets Juluca in collaboration with J J   NYSE JNJ   Sales of Established Pharmaceuticals declined 14  due to lower sales of Advair  partially offset by strong uptake of authorized generic version of Ventolin  Advair lost 64  of sales year over year in the United States while Seretide sales were down 18  in Europe due to generic competition  Sales of Ventolin were up 8  during the quarter We remind investors that Mylan   NASDAQ MYL   launched the first generic version of Advair  Wixela Inhub  in the United States in February Immuno inflammation drugs like Benlysta rose 24  in the quarter  with U S  sales growing 25   The company is planning to file regulatory application for label expansion of Benlysta in lupus nephritis in the first half of 2020 Oncology sales were  66 million  comprising sales of PARP inhibitor  Zejula  which was acquired from TESARO in 2019  compared with  64 million in the third quarter   During the quarter  the company submitted regulatory application for label expansion of Zejula as first line maintenance treatment for ovarian cancer patients Consumer Healthcare Sales Up Sales in the Consumer Healthcare segment increased 37  at CER  primarily driven by Pfizer s  PFE  legacy brands  Glaxo formed a new joint venture   JV   with Pfizer   NYSE PFE   in August 2019 to create the world s largest Consumer Healthcare business  Fourth quarter sales of this segment include the first full quarter of legacy Pfizer brand sales  arising after the creation of the JV  Sales of Wellness  Oral health and Skin health categories increased 31   7  and 32   respectively  in the quarter  Nutrition sales more than doubled in the fourth quarter On a pro forma basis  sales in the Consumer Health segment were flat at CER The company may revise the category structure for this segment s report from the first quarter of 2020 Vaccines Segment Growth Continues Sales from the Vaccines segment were impressive  up 21  at CER  primarily driven by strong growth of new shingles vaccine  Shingrix and impressive performance of meningitis vaccines  partially offset by decline in sales of influenza vaccines  Shingrix sales more than doubled to  532 million in the reported quarter  driven by strong uptake in the United States Although growth trend of Bexsero slowed down this quarter with sales increasing 5   sales of another meningitis vaccine  Menveo were up 57  due to higher demand in international markets  However  sales of influenza vaccine Fluarix and Established vaccines were down 26  and 3   respectively  year over year Operating Expenses UpSelling  general and administration  SG A  costs increased 23   11  on pro forma basis  year over year to  2 8 billion  The rise in SG A costs was driven by increased commercial activities to support launches and costs related to the acquisition of TESARO  partly offset by cost saving initiatives and benefits of restructuring in Pharmaceuticals segment Research and development  R D  expenses were up 16   13  on pro forma basis  to  1 16 billion  reflecting increased investments to support progress of clinical studies  especially those on Zejula  Glaxo has 39 new medicines  including 15 vaccines  in different development stages 2020 Guidance Glaxo provided guidance for adjusted earnings in 2020  It currently expects adjusted EPS to decline 1  to 4  at CER  year over year  in 2020 Key DevelopmentsGlaxo initiated a two year program to split itself into two standalone companies  The new Glaxo will be a biopharma company focusing on developing new treatments  The Consumer Healthcare segment will become a separate company The separation program is expected to generate  800 million in annual savings by 2022 and cost  2 4 billion Our TakeGlaxo missed on earnings and sales in the fourth quarter  Sales of the company s established drugs continued to decline  However  the company s new products from every segment performed well in the reported quarter  especially Shingrix  However  the company stated on its earnings release that it has limited opportunity for further growth in supply capacity for Shingrix  which may impact sales in the future quarters  Meanwhile  it expects new drug launches to boost sales of Pharmaceuticals unit in 2020 The company boosted its oncology portfolio with the acquisition of TESARO and a collaboration agreement with Germany based Merck KgaA in 2019  These transactions along with restructuring initiatives in the Consumer Health segment should help the company to offset slowdown in sales of legacy drugs  However  loss of Advair sales due to generic competition and competitive pricing will continue to hamper revenues GlaxoSmithKline plc Price  Consensus and EPS Surprise
    Zacks RankGlaxo currently carries a Zacks Rank  3  Hold   You can see  More Stock News  This Is Bigger than the iPhone It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ",2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/glaxo-gsk-lags-q4-earnings--revenue-estimates-stock-down-200505253,200505253
196810,418326,MYL,Biogen Soars On Patent Win For MS Drug Tecfidera Over Mylan,opinion,"Shares of Biogen Inc    NASDAQ BIIB   rallied 17 5  on Wednesday after the Patent Trial and Appeal Board  PTAB  of the U S  Patent And Trademark Office  USPTO  gave a favorable ruling to the company over a patent dispute with Mylan   NASDAQ MYL   for its best selling multiple sclerosis  MS  drug  Tecfidera 
Mylan in an inter partes review  IPR  was challenging Biogen s  514 patent  which covers the treatment of multiple sclerosis with 480mg dose of dimethyl fumarate  DMF   the active ingredient of Tecfidera  The patent provides market exclusivity in the United States until 2028 
Per the statement from the PTAB  generic drugmaker Mylan failed to demonstrate that some claims were not patentable 
Though Mylan announced its intention to appeal against this decision  the favorable ruling raises hopes for Biogen s chances of maintaining Tecfidera s exclusivity until 2028  Tecfidera constituted 39  of the company s total product revenues in 2019 
The news removes a short term overhang from the company  Biogen also faces a generic litigation in a court case related to the same patent  The favorable ruling increases the chances of winning the court case 
Shares of Biogen have increased 7 8  in the past year versus the  decrease of 0 1  

Notably  in 2017  Biogen strengthened its patent position for Tecfidera through a settlement and licensing agreement with Danish biotech Forward Pharma A S regarding the same patent  Per the settlement  Biogen agreed to pay  1 25 billion for buying the license to Forward Pharma s intellectual property covering DMF 
Meanwhile  last week  Biogen delivered better than expected fourth quarter 2019 results  The company beat on both earnings and sales in the reported quarter 
Revenue growth in the quarter was principally driven by higher sales of its key MS drugs  continued global growth of its spinal muscular atrophy  SMA  drug Spinraza and expansion of its biosimilar business 
Notably  Tecfidera has been one of the top revenue drivers for Biogen over the years  The drug generated sales worth  4 4 billion in 2019  reflecting an increase of 4  year over year 
Zacks Rank   Stocks to Consider
Biogen currently carries a Zacks Rank  3  Hold   Better ranked stocks in the biotech sector include Xenon Pharmaceuticals Inc    NASDAQ XENE   and Kala Pharmaceuticals  Inc    NASDAQ KALA    both sporting a Zacks Rank  1  Strong Buy   You can see  
Xenon Pharmaceuticals  loss per share estimates have narrowed 12 04  for 2020 over the past 60 days  The stock has soared 85 7   in the past year 
Kala Pharmaceuticals  loss per share estimates have narrowed 0 9  for 2020 over the past 60 days 
More Stock News  This Is Bigger than the iPhone 
It could become the mother of all technological revolutions  Apple  NASDAQ AAPL  sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years  creating a  1 7 trillion market Zacks has just released a Special Report that spotlights this fast emerging phenomenon and 6 tickers for taking advantage of it  If you don t buy now  you may kick yourself in 2020 ",2020-02-05,Zacks Investment Research,https://www.investing.com/analysis/biogen-soars-on-patent-win-for-ms-drug-tecfidera-over-mylan-200505277,200505277
196811,418327,MYL,What s In Store For Acorda  ACOR  This Earnings Season ,opinion,Acorda Therapeutics  Inc    NASDAQ ACOR   is scheduled to report fourth quarter 2019 and full year results on Feb 13  before the market opens Acorda boasts an excellent earnings surprise history  surpassing expectations in each of the trailing four quarters  the average being 68 80   In the last reported quarter  the company delivered a positive surprise of 9 80  Shares of Acorda have plummeted 86 5  in the past year  underperforming the  decrease of 1  Factors to ConsiderAcorda s Parkinson s disease  PD  drug Inbrija was launched in the United States last February and was off to a strong start ever since  Sale of the drug has been rising with a solid sequential increase as was reported in the third quarter of 2019  a trend that most likely continued in the soon to be reported quarter as well Meanwhile  in September 2019  Inbrija was granted a marketing authorization by the European Commission  EC   Even though it is less likely to have contributed to the to be reported quarter s sales  this should boost Inbrija s sales in the future quarters On Jan 15  the company released preliminary results of Inbrija sales for 2019  which totaled  15 3 million Notably  Acorda s lead multiple sclerosis  MS  drug Ampyra is facing generic competition in the United States  During the first nine months of 2019  sales of Ampyra tanked significantly year over year due to generic launches  This sales erosion is likely to have hurt the company s fourth quarter top line as well In September 2018  Ampyra lost its exclusivity as generics like Mylan s   NASDAQ MYL   authorized generic version entered the market For 2019  Ampyra s preliminary sales were reported to be  162 6 million  For the full year  Acorda generated preliminary total revenues worth approximately  188 million including  178 million of net product revenues 2020 GuidanceLast month  in addition to preliminary results for 2019  Acorda issued financial guidance for 2020 The company expects total product net revenues in the range of  120  150 million for the full year while total revenues are projected in the band of  130  160 million Inbrija net revenues for the full year are predicted in the bracket of  35  40 million For 2020  the company envisions Ampyra net revenues within  85  110 million  Operating expenses for the period are forecast within  170  180 million  lowered from the previous range of  180 190 million Earnings WhispersOur proven model does not conclusively predict an earnings beat for Acorda this season  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of a positive surprise  But this is not the case here  You can uncover the best stocks to buy or sell before they re reported with our Earnings ESP  Acorda has an Earnings ESP of  5 35  Zacks Rank  Acorda carries a Zacks Rank  3  which increases the predictive power of ESP  However  its negative ESP leaves surprise prediction inconclusive Acorda Therapeutics  Inc  Price and EPS Surprise   Stocks That Warrant a LookHere are a few healthcare stocks worth considering as our model shows that these have the right mix of elements to beat estimates this time around Vericel Corporation   NASDAQ VCEL   has an Earnings ESP of  11 29  and a Zacks Rank of 1  You can see  Karyopharm Therapeutics Inc    NASDAQ KPTI   has an Earnings ESP of  3 05  and a Zacks Rank of 3  The company is scheduled to release earnings results on Feb 13 The Hottest Tech Mega Trend of AllLast year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2020-02-09,Zacks Investment Research,https://www.investing.com/analysis/whats-in-store-for-acorda-acor-this-earnings-season-200506135,200506135
196817,418333,MYL,Mylan director Wendy Cameron to retire from board,news," Reuters    Mylan NV  O MYL  said on Monday non executive director Wendy Cameron  who had been under investor pressure to step down  will retire 
Cameron used to head Mylan s compensation committee when director Robert Coury came under fire for his near  100 million pay package last year  at a time of growing backlash from U S  consumers over the price of the company s life saving allergy treatment EpiPen 
More than a third of the investors voting at the generic drugmaker s annual meeting last year cast votes against Coury  while over half voted against Cameron 
The company said it had nominated Pauline van der Meer Mohr for election to its board ",2018-02-26,Reuters,https://www.investing.com/news/stock-market-news/mylan-director-wendy-cameron-to-retire-from-board-1311432,1311432
196818,418334,MYL,Mylan to launch two new HIV meds in U S ,news,Mylan N V   NASDAQ MYL  announces that it will launch two new HIV medications in the U S Symfi Lo  efavirenz  lamivudine and tenofovir disoproxil fumarate or TDF  will launch in the coming weeks and Cimduo  lamivudine and TDF  next quarter The company says both will be offered at significant discounts from currently available alternatives Now read ,2018-03-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/mylan-to-launch-two-new-hiv-meds-in-us-1322119,1322119
196819,418335,MYL,Benitec launches mid stage study of BB 401 in HNSCC  shares up 4 ,news,Thinly traded nano cap  Benitec Biopharma   BNTC  4 2   commences an Australia and Russia based Phase 2 clinical trial evaluating BB 401 in patients with head and neck squamous cell carcinoma  HNSCC  The open label 30 subject study will assess the safety  tolerability and efficacy of BB 401 administered via intratumoral injection According to ClinicalTrials gov  the estimated primary completion date is April 2019 BB 401 is a recombinant DNA construct that produces an antisense RNA specific to Epidermal Growth Factor Receptor  EGFR   More than 90  of HNSCC lesions overexpress EGFR  BB 401 is designed to inhibit the expression of EGFR which will control cancer progression Now read ,2018-03-05,Seeking Alpha,https://www.investing.com/news/stock-market-news/benitec-launches-midstage-study-of-bb401-in-hnscc-shares-up-4-1325419,1325419
196820,418336,MYL,Mylan and Biocon receive approvals from the EC and TGA Australia for insulin glargine biosimilar,news,Mylan N V   NASDAQ MYL  and Biocon Ltd   OTC BCNQY  announces that their co developed biosimilar insulin glargine Semglee has received marketing authorization approval from the European Commission  EC  following the positive recommendation by the advisory group CHMP Semglee is the first biosimilar from Biocon and Mylan s joint portfolio to be approved in Europe  Additionally  the Therapeutic Goods Administration  TGA   Australia has also approved Semglee for diabetes patients in Australia  Product launch is expected to begin later this year in Australia and in H2 2018 in Europe  Now read ,2018-03-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/mylan-and-biocon-receive-approvals-from-the-ec-and-tga-australia-for-insulin-glargine-biosimilar-1366810,1366810
196829,418345,MYL,Pfizer  PFE  Sees A Difficult 2019  Can It Rebound In 2020 ,opinion,Pfizer Inc    NYSE PFE   is one of the biggest drugmakers in the world  boasting a diversified portfolio of drugs and a strong pipeline However  the year 2019 has not been a smooth sail for the company  The stock has declined 9 8  so far this year against the  rally of 11 6  Challenges of 2019During the period  Pfizer faced a major setback when one of its key drugs Lyrica lost exclusivity in the United States in July  LOEs  loss of exclusivity  are expected to hurt current year sales by  2 1 billion Other products like Chantix and Sutent will lose exclusivity in the United States in the next couple of years  Pfizer saw incremental business development activity in 2019  The company merged its Consumer Healthcare unit with GlaxoSmithKline   NYSE GSK   to establish a joint venture  JV   While the former owns 32  stake in the JV  the latter holds the remaining 68   In July  Pfizer bought Array BioPharma for  48 per share in cash for a total enterprise value of approximately  11 4 billion in a bid to strengthen its cancer portfolio Importantly  in July  Pfizer announced a definitive agreement to spin off its Upjohn unit and combine it with the generic drugmaker Mylan   NASDAQ MYL   in a Reverse Morris Trust transaction to create a generic pharmaceutical company  which will be called Viatris  This downside is probably because the drugs divested were key cash flow generators for Pfizer and funded its R D efforts  The divestiture of Upjohn will significantly lower Pfizer s cash resources The transaction is expected to close in mid 2020 Moreover  Pfizer s sterile injectables portfolio is seeing lower revenues since the last few quarters due to continued legacy Hospira product shortages in the United States  Though some recovery was seen in the third quarter of 2019  we would like to wait for more sustainable improvement Moreover  unfavorable changes in recommendation guidelines for Prevnar 13 and negative FDA updates on Xeljanz U S  label may dent sales of these key drugs in the future quarters In July  Xeljanz s prescribing information in the United States was updated by the FDA to include two additional boxed warnings as well as changes to the indication and dosing for ulcerative colitis following review of a post marketing study Meanwhile  due to some unfavorable revisions in Advisory Committee on Immunization Practices   ACIP  pneumococcal vaccination guidelines for Prevnar 13 in adults across the United States  Pfizer expects some decline in demand for Prevnar  which can weaken its sales in the future quarters Can the Scenario be Better in 2020 Despite the aforementioned headwinds  not everything went wrong for Pfizer in 2019 as it has its own share of strengths too Notably  the company had a strong third quarter  surprising investors  as it beat on both earnings and sales while raising its guidance for the bottom line The company secured FDA approval for four new cancer medicines last year  which can boost its oncology sales in future years  Biosimilar versions of Roche s   OTC RHHBY   cancer drugs Herceptin  Trazimera   Avastin  Zirabev  and Rituxan  Ruxience  and AbbVie s Humira  Abrilada  were approved by the FDA in 2019  which can contribute to sales next year  once launched The company also flaunts a solid pipeline and looks well positioned to deliver several innovative medicines in the next five years  These new breakthroughs bode well for the long term  Pfizer expects approximately 25 30 drug approvals through 2022 including the nod for 15 products with blockbuster prospects  The recent acquisitions and licensing deals strengthened its product portfolio Strikingly  the Consumer Healthcare joint venture with Glaxo  the Array acquisition and the pending merger of Upjohn unit with Mylan  if successful  will make Pfizer a smaller entity with a prolific portfolio of innovative drugs and vaccines  The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff will also go away  Meanwhile  the company anticipates consistent growth of its key brands like Ibrance and Eliquis as well as biosimilars to aid sales in 2020 Though Pfizer s stock has declined in 2019  we expect the same to recover in 2020 Moreover  the company currently carries a Zacks Rank  2  Buy   Its earnings estimates have moved 2 8  north for 2020 over the past 60 days  You can see  Pfizer Inc  Price   Zacks Top 10 Stocks for 2020In addition to the stocks discussed above  would you like to know about our 10 top tickers for the entirety of 2020 These 10 are painstakingly hand picked from over 4 000 companies covered by the Zacks Rank  They are our primary picks to buy and hold ,2019-12-26,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-sees-a-difficult-2019-can-it-rebound-in-2020-200495098,200495098
196830,418346,MYL,Is Mylan  MYL  Doomed To Witness A Terrible 2020 Too ,opinion,"The year 2019 has not been a smooth one for Mylan N  V    NASDAQ MYL   due to challenging business conditions in North America and pricing pressure  Year to date  shares of this Zacks Rank  3  Hold  company have lost 28 6  against the  s growth of 8 3   Let us look at some of the challenges  which plagued the company this year  and whether or not it holds any promise going into the next 

 
A Close Introspection
Generic maker Mylan has not seen the best of 2019 for a few reasons  The company s North America segment witnessed lower sales of existing products due to changes in the competitive environment  including the loss of exclusivity on tadalafil 
It also faced legal issues  The U S  Securities and Exchange Commission  SEC  announced charges against the company in connection with its EpiPen product probe  The SEC charged Mylan for accounting and disclosure failures relating to a Department of Justice  DOJ  probe into whether the company overcharged Medicaid by hundreds of millions of dollars for its largest product  EpiPen  The SEC stated that investors were kept in the dark about EpiPen misclassification and the potential loss the company faced as a result of the pending investigation into the misclassification  Consequently  Mylan has agreed to pay  30 million as charges for the same  Moreover  the complaint alleges that Mylan produced documents and other information to DOJ  including potential damage calculations and offers for settlement  The allegations of misclassification and resultant charges further added to Mylan s woes  
Moreover  rival Teva Pharmaceutical   NYSE TEVA   has already won FDA approval for the first generic version of Mylan s EpiPen and EpiPen Jr  which  in turn  will unfavorably impact sales further 
Earlier  there were allegations against Mylan and Teva for inflating the prices of generic drugs  Both companies were also accused of obstructing a probe on the same by a few lawmakers 
Can the Stock Stage a Comeback in 2020 
In July  Mylan announced a merger agreement with Upjohn  Pfizer s   NYSE PFE   off patent branded and generic established medicines business  includes Lipitor  Celebrex and Viagra   to create a new global pharmaceutical company   Per the agreement  which is structured as an all stock  Reverse Morris Trust transaction  each Mylan share would be converted into one share of the new company  Mylan had previously undertaken a strategic review of its business due to challenging business conditions in North America and pricing pressure  The decision to merge with Upjohn comes as a result of this review 
Pfizer s shareholders would own 57  of the combined entity  while Mylan s shareholders would own the remaining 43   The transaction has been unanimously approved by the boards of both companies 
The new company will be named Viatris upon the closing of the merger  which is expected in mid 2020  Viatris will boast a diverse portfolio across many geographies and focus on key therapeutic areas 
This merger looks encouraging for the company  The transaction will allow the new company to meaningfully expand the geographic reach of Mylan s existing broad product portfolio and future pipeline   including significant investments in complex generics and biosimilars   into new growth markets where Upjohn has existing sales infrastructure and local market expertise 
Thus  with this merger  Mylan could see a brighter 2020 
The company also launched a few key products in 2019 
Mylan and partner Biocon Ltd  launched Ogivri  trastuzumab dkst   a biosimilar to Roche Holding  SIX ROG  AG s   OTC RHHBY   blockbuster breast cancer drug Herceptin  in the United States 
These new launches along with the company s key products  including Yupelri  Copaxone  Fulphila and Wixela Inhub  are likely to help revive  growth 
Mylan is a Zacks Rank  3  Hold  stock  currently  You can see  Mylan N V  Price
    Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above  would you like to know about our 10 top tickers for the entirety of 2020  These 10 are painstakingly hand picked from over 4 000 companies covered by the Zacks Rank  They are our primary picks to buy and hold ",2019-12-26,Zacks Investment Research,https://www.investing.com/analysis/is-mylan-myl-doomed-to-witness-a-terrible-2020-too-200495145,200495145
196831,418347,MYL,Is Mylan  MYL  A Great Value Stock Right Now ,opinion,"The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks  Nevertheless  we know that our readers all have their own perspectives  so we are always looking at the latest trends in value  growth  and momentum to find strong picks 
Looking at the history of these trends  perhaps none is more beloved than value investing  This strategy simply looks to identify companies that are being undervalued by the broader market  Value investors use a variety of methods  including tried and true valuation metrics  to find these stocks 
In addition to the Zacks Rank  investors looking for stocks with specific traits can utilize our Style Scores system  Of course  value investors will be most interested in the system s  Value  category  Stocks with  A  grades for Value and high Zacks Ranks are among the best value stocks available at any given moment 
One company value investors might notice is Mylan  NASDAQ MYL   MYL is currently sporting a Zacks Rank of  2  Buy   as well as a Value grade of A  The stock holds a P E ratio of 4 74  while its industry has an average P E of 9 21  Over the last 12 months  MYL s Forward P E has been as high as 6 47 and as low as 3 83  with a median of 4 45 
Investors should also note that MYL holds a PEG ratio of 1 10  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  MYL s industry currently sports an average PEG of 1 14  Within the past year  MYL s PEG has been as high as 1 19 and as low as 0 78  with a median of 0 95 
Another valuation metric that we should highlight is MYL s P B ratio of 0 96  The P B ratio is used to compare a stock s market value with its book value  which is defined as total assets minus total liabilities  This stock s P B looks attractive against its industry s average P B of 1 32  MYL s P B has been as high as 1 36 and as low as 0 73  with a median of 0 87  over the past year 
These are only a few of the key metrics included in Mylan s strong Value grade  but they help show that the stock is likely undervalued right now  When factoring in the strength of its earnings outlook  MYL looks like an impressive value stock at the moment ",2020-01-09,Zacks Investment Research,https://www.investing.com/analysis/is-mylan-myl-a-great-value-stock-right-now-200498040,200498040
196832,418348,MYL,Pfizer  PFE  Q4 Earnings Coming Up  What s In The Cards ,opinion,"Pfizer  Inc    NYSE PFE   will report its fourth quarter 2019 results on Jan 28  before market open  In the last reported quarter  the company delivered a positive earnings surprise of 19 05  This pharma giant s earnings surpassed expectations in each of the last four quarters  with the average positive surprise being 8 73  Pfizer Inc  Price and EPS Surprise
    Pfizer s shares have declined 4 7  in the past year against an increase of 14 7  for the  Factors at PlayHigher sales of Pfizer s key brands  Eliquis  Xeljanz  Inlyta  Ibrance in the Biopharma segment  biosimilars and strong emerging market sales are likely to have made up for lower sales in the Upjohn group  Within the Biopharma group  the Zacks Consensus Estimate for oncology and vaccine products is  2 58 billion and  1 67 billion  respectively  The Zacks Consensus Estimate for the Upjohn group is  2 13 billion However  sales of some key drugs like Prevnar 13 Prevenar 13 and Enbrel declined in the past two quarters  It remains to be seen if sales of these drugs have improved this time around  In the Upjohn segment  sales of key drug Lyrica are likely to have declined due to multi source generic competition that began in July 2019  Viagra sales are likely to have declined due to generic competition that began in December 2017 Meanwhile  Pfizer s sterile injectables portfolio showed a recovery in the third quarter as Pfizer s manufacturing recovery efforts started taking shape  The portfolio had been seeing lower revenues since the last few quarters due to persistent legacy Hospira product shortages in the United States  It remains to be seen if the improved sales continued in the fourth quarter Importantly  in July 2019  Pfizer announced a definitive agreement stating that it will spin off its Upjohn unit and combine it with generic drugmaker Mylan   NASDAQ MYL   in a Reverse Morris Trust transaction to create a generic pharmaceutical company to be called Viatris  An update is expected on the conference call What Our Model IndicatesOur proven model does not conclusively predict an earnings beat for Pfizer this time around  The combination of a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  increases the odds of an earnings beat  But that s not the case here Earnings ESP  Its Earnings ESP is  1 02   The Zacks Consensus Estimate stands at 57 cents per share  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Pfizer carries a Zacks Rank  1 Stocks to Consider Here are some large drug biotech stocks that have the right combination of elements to beat on earnings in their upcoming release Merck   NYSE MRK   has an Earnings ESP of  1 05  and a Zacks Rank  3  The company is scheduled to release results on Feb 5  You can see  AstraZeneca   NYSE AZN   has an Earnings ESP of  3 31  and a Zacks Rank  3  The company is scheduled to release results on Feb 14 The Hottest Tech Mega Trend of All                 Last year  it generated  24 billion in global revenues  By 2020  it s predicted to blast through the roof to  77 6 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ",2020-01-22,Zacks Investment Research,https://www.investing.com/analysis/pfizer-pfe-q4-earnings-coming-up-whats-in-the-cards-200501000,200501000
196834,418350,MYL,Israel stocks higher at close of trade  TA 35 up 0 97 ,news,"Investing com   Israel stocks were higher after the close on Thursday  as gains in the Biomed  Technology and Insurance sectors led shares higher 
At the close in Tel Aviv  the TA 35 gained 0 97  
The best performers of the session on the TA 35 were Teva Pharmaceutical Industries Ltd  TA TEVA   which rose 7 50  or 504 points to trade at 7227 at the close  Meanwhile   Israel Corp   TA ILCO  added 7 00  or 4320 points to end at 66000 and Mylan NV  TA MYL  was up 3 87  or 580 points to 15580 in late trade 
The worst performers of the session were  Azrieli Group  Ltd  TA AZRG   which fell 1 52  or 290 points to trade at 18820 at the close   Isramco  Negev 2 LP  TA ISRAp  declined 1 33  or 0 6 points to end at 44 4 and Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ  was down 1 30  or 6 8 points to 516 2 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 256 to 136 and 30 ended unchanged 
Crude oil for February delivery was up 1 34  or 0 85 to  64 42 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March rose 0 81  or 0 56 to hit  69 76 a barrel  while the February Gold Futures contract rose 0 15  or 2 00 to trade at  1321 30 a troy ounce 
USD ILS was down 0 19  to 3 4201  while EUR ILS rose 0 59  to 4 1189 
The US Dollar Index Futures was down 0 52  at 91 63 ",2018-01-11,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-097-1092857,1092857
196835,418351,MYL,Israel stocks higher at close of trade  TA 35 up 0 28 ,news,"Investing com   Israel stocks were higher after the close on Thursday  as gains in the Insurance  Financials and Banking sectors led shares higher 
At the close in Tel Aviv  the TA 35 added 0 28  to hit a new 52 week high 
The best performers of the session on the TA 35 were  Bazan  Oil Refineries Ltd  TA ORL   which rose 3 11  or 4 8 points to trade at 159 0 at the close  Meanwhile   Cellcom Israel  Ltd  TA CEL  added 2 40  or 78 points to end at 3325 and  Big  Shopping Centers Ltd  TA BIG  was up 2 34  or 550 points to 24060 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 1 87  or 300 points to trade at 15740 at the close   OPKO Health Inc   TA OPK  declined 1 06  or 18 points to end at 1679 and Nice Ltd  TA NICE  was down 0 95  or 300 points to 31270 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 205 to 205 and 23 ended unchanged 
Crude oil for March delivery was up 0 43  or 0 28 to  65 89 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March rose 0 38  or 0 27 to hit  70 80 a barrel  while the February Gold Futures contract unchanged 0 00  or 0 00 to trade at  1356 30 a troy ounce 
USD ILS was down 0 83  to 3 3824  while EUR ILS fell 0 18  to 4 2248 
The US Dollar Index Futures was down 0 61  at 88 48 ",2018-01-25,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-028-1151677,1151677
196836,418352,MYL,Israel stocks higher at close of trade  TA 35 up 0 72 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Communication  Biomed and Insurance sectors led shares higher 
At the close in Tel Aviv  the TA 35 gained 0 72  to hit a new 52 week high 
The best performers of the session on the TA 35 were Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ   which rose 4 52  or 25 3 points to trade at 585 3 at the close  Meanwhile   Sodastream International Ltd   TA SODA  added 3 65  or 950 0 points to end at 26950 0 and Shufersal  TA SAE  was up 2 65  or 64 points to 2475 in late trade 
The worst performers of the session were  OPKO Health Inc   TA OPK   which fell 1 97  or 33 points to trade at 1646 at the close  Leumi  TA LUMI  declined 1 12  or 24 points to end at 2113 and Mylan NV  TA MYL  was down 0 89  or 140 points to 15600 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 266 to 132 and 37 ended unchanged 
Shares in Sodastream International Ltd  TA SODA  rose to all time highs  gaining 3 65  or 950 0 to 26950 0  Shares in Shufersal  TA SAE  rose to 5 year highs  rising 2 65  or 64 to 2475  
Crude oil for March delivery was up 1 08  or 0 71 to  66 22 a barrel  Elsewhere in commodities trading  Brent oil for delivery in April unchanged 0 00  or 0 00 to hit  70 15 a barrel  while the February Gold Futures contract fell 1 06  or 14 50 to trade at  1348 40 a troy ounce 
USD ILS was down 0 11  to 3 3904  while EUR ILS rose 0 19  to 4 2148 
The US Dollar Index Futures was down 0 36  at 88 87 ",2018-01-28,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-072-1162084,1162084
196837,418353,MYL,Israel stocks lower at close of trade  TA 35 down 0 71 ,news,"Investing com   Israel stocks were lower after the close on Tuesday  as losses in the Biomed  Insurance and Technology sectors led shares lower 
At the close in Tel Aviv  the TA 35 lost 0 71  
The best performers of the session on the TA 35 were  Elbit Systems  Ltd  TA ESLT   which rose 3 05  or 1510 points to trade at 51010 at the close  Meanwhile   Frutarom  Industries Ltd  TA FRUT  added 2 36  or 810 points to end at 35110 and Partner  TA PTNR  was up 1 45  or 28 points to 1963 in late trade 
The worst performers of the session were Teva Pharmaceutical Industries Ltd  TA TEVA   which fell 4 85  or 355 points to trade at 6970 at the close  Mylan NV  TA MYL  declined 4 50  or 710 points to end at 15060 and  OPKO Health Inc   TA OPK  was down 4 15  or 68 points to 1572 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 282 to 132 and 18 ended unchanged 
Shares in Frutarom Industries Ltd  TA FRUT  rose to all time highs  up 2 36  or 810 to 35110  
Crude oil for March delivery was down 2 14  or 1 40 to  64 16 a barrel  Elsewhere in commodities trading  Brent oil for delivery in April fell 1 69  or 1 17 to hit  68 03 a barrel  while the February Gold Futures contract rose 0 03  or 0 40 to trade at  1340 70 a troy ounce 
USD ILS was up 0 62  to 3 4207  while EUR ILS rose 0 89  to 4 2456 
The US Dollar Index Futures was down 0 22  at 88 97 ",2018-01-30,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-071-1171305,1171305
196838,418354,MYL,Israel stocks higher at close of trade  TA 35 up 0 56 ,news,"Investing com   Israel stocks were higher after the close on Wednesday  as gains in the Banking  Financials and Oil   Gas sectors led shares higher 
At the close in Tel Aviv  the TA 35 gained 0 56  
The best performers of the session on the TA 35 were  Azrieli Group  Ltd  TA AZRG   which rose 4 02  or 720 points to trade at 18630 at the close  Meanwhile  First  International  Bank of Israel Ltd  TA FTIN  added 1 85  or 140 points to end at 7720 and Teva Pharmaceutical Industries Ltd  TA TEVA  was up 1 62  or 113 points to 7083 in late trade 
The worst performers of the session were Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ   which fell 2 35  or 13 6 points to trade at 564 5 at the close  Mylan NV  TA MYL  declined 1 66  or 250 points to end at 14810 and  OPKO Health Inc   TA OPK  was down 1 34  or 21 points to 1551 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 220 to 174 and 25 ended unchanged 
Shares in First International Bank of Israel Ltd  TA FTIN  rose to all time highs  gaining 1 85  or 140 to 7720  
Crude oil for March delivery was down 0 85  or 0 55 to  63 95 a barrel  Elsewhere in commodities trading  Brent oil for delivery in April fell 0 73  or 0 50 to hit  68 02 a barrel  while the February Gold Futures contract rose 0 46  or 6 10 to trade at  1341 50 a troy ounce 
USD ILS was down 0 22  to 3 4100  while EUR ILS rose 0 20  to 4 2476 
The US Dollar Index Futures was down 0 34  at 88 72 ",2018-01-31,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-056-1177040,1177040
196839,418355,MYL,Mylan launches generic Sustiva in U S ,news,Mylan N V   NASDAQ MYL  announces the U S  commercial launch of Efavirenz Tablets USP  600 mg  its generic version of Bristol Myers Squibb s  NYSE BMY  HIV 1 med Sustiva Per IQVIA  the U S  market is   113M Now read ,2018-02-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/mylan-launches-generic-sustiva-in-us-1182021,1182021
196840,418356,MYL,Opioid makers paid millions to advocacy groups  U S  Senate report,news,"By Nate Raymond  Reuters    Five opioid manufacturers including OxyContin maker Purdue Pharma LP have paid more than  10 million to advocacy groups and doctors tied to them  many of whom amplified industry messages supporting the use of the painkillers  a U S  Senate report said on Monday  The report  released by Democratic Senator Claire McCaskill  said groups who received the donations aligned themselves with industry goals and may have played a role in an epidemic that in 2016 led to 42 000 opioid overdose deaths  The report released by McCaskill  the U S  Senate Homeland Security and Governmental Affairs Committee s ranking Democrat  said the groups issued guidance promoting opioids for chronic pain and lobbied against laws to curb their use   These financial relationships were insidious  lacked transparency  and are one of many factors that have resulted in arguably the most deadly drug epidemic in American history   McCaskill  of Missouri  said in a statement  Purdue Pharma  which on Saturday announced it would stop promoting opioids to doctors  was the biggest donor  giving  4 15 million to 12 groups from 2012 to 2017  the report said  The groups include patient advocacy organizations and medical professional societies  One recipient was the Academy of Integrative Pain Management  AIPM   which partnered with another group to lobby state legislatures on opioid related issues and fight efforts to restrict opioid prescribing  the report said  Purdue said in a statement that it supported organizations interested in helping patients receive appropriate care  AIPM Executive Director Bob Twillman said that financial contributions had not influenced its positions  The report said Insys Therapeutics Inc  which markets the fentanyl based cancer pain drug Subsys  gave  3 15 million to U S  Pain Foundation and others  ranking No  2 in donations to the 14 groups examined  Federal prosecutors have accused several former Insys executives and employees  including billionaire Insys founder John Kapoor  of engaging in a scheme to pay kickbacks to doctors to prescribe Subsys  Kapoor has pleaded not guilty  U S  Pain Foundation said the  2 5 million Insys donated in 2017 was for a fund to help cancer patients pay for pain drugs  and that the money did not influence its values  Insys said it strives to follow regulations  The report said the groups also received  1 07 million from Depomed Inc   465 142 from Johnson   Johnson  NYSE JNJ  and  20 250 from Mylan  NASDAQ MYL  NV  Doctors affiliated with the organizations received  1 6 million  the report said  
Depomed said its contributions amounted to on average just about  20 000 a year for nine groups and said it believed it acted responsibly in marketing its drugs  J J said it co operated with McCaskill  Mylan emphasized its small opioid marketshare ",2018-02-12,Reuters,https://www.investing.com/news/stock-market-news/opioid-makers-paid-millions-to-advocacy-groups-us-senate-report-1234357,1234357
196846,418362,MYL,Mylan  MYL  Launches Herceptin Biosimilar Ogivri In The US,opinion,Mylan N V     NASDAQ MYL   and partner Biocon Ltd  announced the launch of Ogivri  trastuzumab dkst   a biosimilar of Roche s   OTC RHHBY   blockbuster breast cancer drug  Herceptin  trastuzumab   in the United States This was the first biosimilar approved by the FDA and was unanimously recommended by the agency s Oncologic Drugs Advisory Committee  ODAC  Ogivri is approved for all indications of the branded drug  including the treatment of HER2 overexpressing breast cancer and metastatic stomach cancer  gastric or gastroesophageal junction adenocarcinoma   It is available in a 420 mg multi dose vial and a 150 mg single dose vial for patient dosing and treatment flexibility However  the biosimilar also contains a Boxed Warning for cardiomyopathy  infusion reactions  pulmonary toxicity and embryo fetal toxicity like Herceptin The FDA approval of Ogivri was based on robust data  which showed that the drug is highly similar to Herceptin with no clinically meaningful differences between the biosimilar and the branded drug in terms of safety  purity and potency  Notably  the long term results of the landmark HERITAGE study  including the overall survival data at 36 months  were presented at this year s American Society of Clinical Oncology  ASCO  Annual Meeting Meanwhile  the FDA recently approved two supplemental Biologics License Applications  expanding the manufacturing capability for Ogivri and Fulphila  biosimilar to Neulasta   which is Mylan and Biocon s first biosimilar in the United States Ogivri is the second biosimilar from the Mylan and Biocon partnership to be launched in the United States  Mylan has exclusive commercialization rights to the product in the United States  Canada  Japan  Australia  New Zealand  and the European Union and European Free Trade Association countries  Biocon has co exclusive commercialization rights with Mylan for the product in the rest of the world Mylan and Biocon launched the world s first biosimilar  trastuzumab  in India in 2014 Mylan s stock has lost 31 9  year to date against the  s growth of 3 6  Meanwhile  the company s decision to merge with Upjohn  Pfizer s   NYSE PFE   off patent branded and generic established medicines business  is encouraging  given the challenges faced by the generic business However  competition is stiffening for EpiPen as rival Teva Pharmaceutical   NYSE TEVA   won FDA approval for the first generic version of Mylan s EpiPen and EpiPen Jr  which in turn will unfavorably impact sales Zacks RankMylan currently carries a Zacks Rank  3  Hold   You can see  7 Best Stocks for the Next 30 DaysJust released  Experts distill 7 elite stocks from the current list of 220 Zacks Rank  1 Strong Buys  They deem these tickers  Most Likely for Early Price Pops  Since 1988  the full list has beaten the market more than 2X over with an average gain of  24 6  per year  So be sure to give these hand picked 7 your immediate attention ,2019-12-02,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-launches-herceptin-biosimilar-ogivri-in-the-us-200489567,200489567
196847,418363,MYL,Why Is Mylan  MYL  Up 10  Since Last Earnings Report ,opinion,"A month has gone by since the last earnings report for Mylan  NASDAQ MYL   Shares have added about 10  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Mylan due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Mylan s Q3 Earnings Beat Estimates  Revenues MissMylan reported adjusted earnings of  1 17 per share in the third quarter of 2019  which beat the Zacks Consensus Estimate of  1 14 but declined from  1 25 reported in the year ago quarter However  third quarter revenues of  2 96 billion missed the Zacks Consensus Estimate of  3 03 billion  Revenues increased 3  reportedly and 6  at constant exchange rate   CER   from the prior year quarter Quarter in DetailThe company posts results in three segments on a geographic basis   North America  Europe and Rest of World North America segment s net sales came in at  1 09 billion  up 8  year over year  The growth was driven by higher sales of new products  especially Wixela Inhub and Yupleri  This was partially offset by lower sales of existing products due to lower volumes as well as lower pricing and changes in the competitive environment  including loss of exclusivity on tadalafil Net sales in the Europe segment were  1 05 billion  up less than 1  on the back of higher sales of new products including Hulio  and higher volumes of existing products  However  it was partially offset by unfavorable impact of foreign currency translation and lower pricing on existing products  Net sales in the segment were up 6  at CER Rest of World segment net sales of  793 7 million were up 3   driven by new product sales and higher volumes of existing products  This was partially offset by lower pricing on existing products and unfavorable impact of foreign currency translation  Net sales were up 4  at CER Adjusted gross margin of 53  declined from 55  in the year ago quarter 2019 GuidanceThe company updated its guidance for 2019  Revenues are projected between  11 5 billion and  12 billion compared with the previously expected range of  11 5 billion    12 5 billion The company anticipates adjusted EPS around  4 20  4 40  previously  3 80  4 80   
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in estimates review 
VGM Scores
Currently  Mylan has a subpar Growth Score of D  however its Momentum Score is doing a lot better with a B  Charting a somewhat similar path  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of B  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  Notably  Mylan has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-04,Zacks Investment Research,https://www.investing.com/analysis/why-is-mylan-myl-up-10-since-last-earnings-report-200490339,200490339
196848,418364,MYL,Theravance Bio  TBPH  Up 25 6  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Theravance Biopharma  TBPH   Shares have added about 25 6  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Theravance Bio due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Theravance Q3 Loss In Line  Revenues Lag EstimatesTheravance Biopharma incurred a loss of  1 05 per share in third quarter 2019  in line with the Zacks Consensus Estimate  Meanwhile  the figure is narrower than the year ago quarter s loss of  1 10 Total revenues of  12 4 million in the quarter missed the Zacks Consensus Estimate of  13 million  Revenues decreased 3 1  year over year  mainly due to lack of product sales following the divesture of its only marketed drug Vibativ last November  Total revenues in the third quarter comprised collaboration revenues of  8 8 million and  3 6 million received from Mylan  NASDAQ MYL  Quarterly DetailsResearch   development expenses were  52 million  down 1 3  from the year ago quarter  primarily owing to lower employee related expenses linked with the reduction in sales force Selling  general   administrative expenses escalated 16 9  to  25 6 million due to higher external expenses and higher share based compensation As of Sep 30  2019  Theravance had cash  cash equivalents  marketable securities and restricted cash of  352 9 million compared to  396 1 million as of Jun 30  2019 2019 OutlookFor 2019  Theravance anticipates operating loss excluding non cash share based compensation to be in the range of  200  210 million  narrowed from the previous guidance of  210  230 million 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates have trended downward during the past month  The consensus estimate has shifted 8 4  due to these changes 
VGM Scores
Currently  Theravance Bio has a subpar Growth Score of D  however its Momentum Score is doing a lot better with a B  However  the stock was allocated a grade of F on the value side  putting it in the lowest quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions looks promising  Notably  Theravance Bio has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-12-04,Zacks Investment Research,https://www.investing.com/analysis/theravance-bio-tbph-up-256-since-last-earnings-report-can-it-continue-200490322,200490322
196849,418365,MYL,Israel stocks higher at close of trade  TA 35 up 1 06 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Oil   Gas  Banking and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 35 rose 1 06  to hit a new 6 months high 
The best performers of the session on the TA 35 were Mylan NV  TA MYL   which rose 5 49  or 700 points to trade at 13460 at the close  Meanwhile  Delek Drilling LP  TA DEDRp  added 4 52  or 47 points to end at 1086 and  Delek Group   TA DLEKG  was up 4 24  or 2360 points to 58000 in late trade 
The worst performers of the session were  Ormat Technologies   TA ORA   which fell 2 64  or 610 points to trade at 22490 at the close  Alony Hetz Properties and Investments Ltd  TA ALHE  declined 2 20  or 82 points to end at 3650 and  Bazan  Oil Refineries Ltd  TA ORL  was down 2 02  or 3 6 points to 174 2 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 197 to 190 and 27 ended unchanged 
Crude oil for January delivery was up 1 57  or 0 90 to  58 30 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February rose 1 58  or 0 99 to hit  63 62 a barrel  while the December Gold Futures contract rose 0 51  or 6 50 to trade at  1279 70 a troy ounce 
USD ILS was down 0 30  to 3 4848  while EUR ILS fell 0 36  to 4 1458 
The US Dollar Index Futures was down 0 17  at 92 81 ",2017-12-03,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-106-945816,945816
196850,418366,MYL,Israel stocks higher at close of trade  TA 35 up 0 60 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Insurance  Technology and Communication sectors led shares higher 
At the close in Tel Aviv  the TA 35 added 0 60  
The best performers of the session on the TA 35 were Teva Pharmaceutical Industries Ltd  TA TEVA   which rose 7 55  or 393 points to trade at 5600 at the close  Meanwhile  Mylan NV  TA MYL  added 5 95  or 760 points to end at 13530 and Perrigo  TA PRGO  was up 4 63  or 1330 points to 30050 in late trade 
The worst performers of the session were Delek Drilling LP  TA DEDRp   which fell 3 25  or 33 points to trade at 983 at the close   Elbit Systems  Ltd  TA ESLT  declined 2 82  or 1340 points to end at 46120 and  Sodastream International Ltd   TA SODA  was down 1 82  or 450 0 points to 24210 0 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 200 to 195 and 26 ended unchanged 
Crude oil for January delivery was up 1 15  or 0 65 to  57 34 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February rose 1 82  or 1 13 to hit  63 33 a barrel  while the February Gold Futures contract fell 0 22  or 2 80 to trade at  1250 30 a troy ounce 
USD ILS was up 0 23  to 3 5248  while EUR ILS rose 0 27  to 4 1500 
The US Dollar Index Futures was up 0 10  at 93 84 ",2017-12-10,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-060-974681,974681
196851,418367,MYL,Israel stocks higher at close of trade  TA 35 up 0 19 ,news,"Investing com   Israel stocks were higher after the close on Tuesday  as gains in the Real Estate  Oil   Gas and Biomed sectors led shares higher 
At the close in Tel Aviv  the TA 35 gained 0 19  
The best performers of the session on the TA 35 were Mylan NV  TA MYL   which rose 2 69  or 370 points to trade at 14120 at the close  Meanwhile   Delek Group   TA DLEKG  added 2 38  or 1220 points to end at 52450 and  Frutarom  Industries Ltd  TA FRUT  was up 1 92  or 590 points to 31320 in late trade 
The worst performers of the session were  Bazan  Oil Refineries Ltd  TA ORL   which fell 2 13  or 3 6 points to trade at 165 6 at the close   OPKO Health Inc   TA OPK  declined 1 96  or 36 points to end at 1801 and  Cellcom Israel  Ltd  TA CEL  was down 1 53  or 54 points to 3478 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 225 to 168 and 29 ended unchanged 
Shares in Frutarom Industries Ltd  TA FRUT  rose to all time highs  rising 1 92  or 590 to 31320  
Crude oil for January delivery was down 0 45  or 0 26 to  57 73 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February fell 0 32  or 0 21 to hit  64 48 a barrel  while the February Gold Futures contract fell 0 55  or 6 80 to trade at  1240 10 a troy ounce 
USD ILS was up 0 54  to 3 5494  while EUR ILS rose 0 18  to 4 1627 
The US Dollar Index Futures was up 0 21  at 94 14 ",2017-12-12,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-019-982926,982926
196852,418368,MYL,Israel stocks higher at close of trade  TA 35 up 0 24 ,news,"Investing com   Israel stocks were higher after the close on Thursday  as gains in the Biomed  Technology and Real Estate sectors led shares higher 
At the close in Tel Aviv  the TA 35 rose 0 24  
The best performers of the session on the TA 35 were Teva Pharmaceutical Industries Ltd  TA TEVA   which rose 13 48  or 753 points to trade at 6340 at the close  Meanwhile  Mylan NV  TA MYL  added 3 80  or 530 points to end at 14470 and  Bazan  Oil Refineries Ltd  TA ORL  was up 2 48  or 4 1 points to 169 6 in late trade 
The worst performers of the session were  OPKO Health Inc   TA OPK   which fell 4 13  or 75 points to trade at 1742 at the close   Elbit Systems  Ltd  TA ESLT  declined 3 15  or 1510 points to end at 46490 and  Frutarom  Industries Ltd  TA FRUT  was down 2 33  or 730 points to 30640 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 229 to 156 and 30 ended unchanged 
Crude oil for January delivery was down 0 23  or 0 13 to  56 47 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February rose 0 40  or 0 25 to hit  62 69 a barrel  while the February Gold Futures contract rose 0 58  or 7 20 to trade at  1255 80 a troy ounce 
USD ILS was up 0 11  to 3 5282  while EUR ILS fell 0 26  to 4 1567 
The US Dollar Index Futures was up 0 30  at 93 68 ",2017-12-14,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-024-992666,992666
196853,418369,MYL,Israel stocks higher at close of trade  TA 35 up 0 30 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Banking  Communication and Technology sectors led shares higher 
At the close in Tel Aviv  the TA 35 added 0 30  
The best performers of the session on the TA 35 were Partner  TA PTNR   which rose 1 64  or 34 points to trade at 2107 at the close  Meanwhile  Tower Semiconductor Ltd  TA TSEM  added 1 62  or 190 points to end at 11900 and  Amot Investments  Ltd  TA AMOT  was up 1 16  or 23 points to 2010 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 1 87  or 270 points to trade at 14200 at the close   Bazan  Oil Refineries Ltd  TA ORL  declined 1 30  or 2 2 points to end at 167 4 and  Ormat Technologies   TA ORA  was down 1 23  or 270 points to 21630 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 182 to 170 and 43 ended unchanged 
Crude oil for February delivery was unchanged 0 00  or 0 00 to  57 33 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February fell 0 13  or 0 08 to hit  63 23 a barrel  while the February Gold Futures contract rose 0 06  or 0 80 to trade at  1257 90 a troy ounce 
USD ILS was down 0 20  to 3 5136  while EUR ILS fell 0 44  to 4 1286 
The US Dollar Index Futures was unchanged 0 00  at 93 46 ",2017-12-17,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-030-1001290,1001290
196854,418370,MYL,Israel stocks higher at close of trade  TA 35 up 0 07 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Biomed  Technology and Insurance sectors led shares higher 
At the close in Tel Aviv  the TA 35 added 0 07  to hit a new 52 week high 
The best performers of the session on the TA 35 were Harel  TA HARL   which rose 2 28  or 61 points to trade at 2737 at the close  Meanwhile  Mylan NV  TA MYL  added 2 23  or 330 points to end at 15150 and  Delek Group   TA DLEKG  was up 2 17  or 1310 points to 61700 in late trade 
The worst performers of the session were Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ   which fell 1 55  or 8 6 points to trade at 545 0 at the close  Teva Pharmaceutical Industries Ltd  TA TEVA  declined 1 15  or 76 points to end at 6520 and  OPKO Health Inc   TA OPK  was down 1 14  or 20 points to 1728 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 255 to 148 and 33 ended unchanged 
Shares in Harel  TA HARL  rose to 5 year highs  gaining 2 28  or 61 to 2737  
Crude oil for February delivery was down 0 73  or 0 45 to  61 56 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March fell 0 51  or 0 35 to hit  67 72 a barrel  while the February Gold Futures contract fell 0 11  or 1 40 to trade at  1320 20 a troy ounce 
USD ILS was down 0 60  to 3 4318  while EUR ILS fell 0 84  to 4 1316 
The US Dollar Index Futures was up 0 16  at 91 75 ",2018-01-07,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-007-1072376,1072376
196855,418371,MYL,Israel stocks lower at close of trade  TA 35 down 0 44 ,news,"Investing com   Israel stocks were lower after the close on Monday  as losses in the Communication  Real Estate and Biomed sectors led shares lower 
At the close in Tel Aviv  the TA 35 lost 0 44  
The best performers of the session on the TA 35 were Mylan NV  TA MYL   which rose 1 78  or 270 points to trade at 15420 at the close  Meanwhile  Teva Pharmaceutical Industries Ltd  TA TEVA  added 1 53  or 100 points to end at 6620 and  Isramco  Negev 2 LP  TA ISRAp  was up 1 11  or 0 5 points to 45 4 in late trade 
The worst performers of the session were Perrigo  TA PRGO   which fell 3 36  or 1060 points to trade at 30490 at the close  Melisron  TA MLSR  declined 2 53  or 410 points to end at 15810 and  OPKO Health Inc   TA OPK  was down 2 08  or 36 points to 1692 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 227 to 169 and 30 ended unchanged 
Shares in Melisron  TA MLSR  fell to 52 week lows  falling 2 53  or 410 to 15810  
Crude oil for February delivery was up 0 23  or 0 14 to  61 58 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March rose 0 12  or 0 08 to hit  67 70 a barrel  while the February Gold Futures contract fell 0 16  or 2 10 to trade at  1320 20 a troy ounce 
USD ILS was up 0 41  to 3 4458  while EUR ILS fell 0 11  to 4 1272 
The US Dollar Index Futures was up 0 28  at 92 01 ",2018-01-08,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-044-1076366,1076366
196856,418372,MYL,Israel stocks lower at close of trade  TA 35 down 0 79 ,news,"Investing com   Israel stocks were lower after the close on Wednesday  as losses in the Communication  Technology and Oil   Gas sectors led shares lower 
At the close in Tel Aviv  the TA 35 fell 0 79  
The best performers of the session on the TA 35 were  Israel Corp   TA ILCO   which rose 3 63  or 2160 points to trade at 61680 at the close  Meanwhile   Azrieli Group  Ltd  TA AZRG  added 1 81  or 340 points to end at 19110 and  Amot Investments  Ltd  TA AMOT  was up 1 33  or 28 points to 2128 in late trade 
The worst performers of the session were Tower Semiconductor Ltd  TA TSEM   which fell 3 16  or 390 points to trade at 11940 at the close  Mylan NV  TA MYL  declined 2 72  or 420 points to end at 15000 and Harel  TA HARL  was down 2 33  or 65 points to 2719 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 293 to 114 and 16 ended unchanged 
Crude oil for February delivery was up 0 51  or 0 32 to  63 28 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March rose 0 22  or 0 15 to hit  68 97 a barrel  while the February Gold Futures contract rose 0 47  or 6 20 to trade at  1319 90 a troy ounce 
USD ILS was down 0 51  to 3 4249  while EUR ILS fell 0 13  to 4 1039 
The US Dollar Index Futures was down 0 39  at 91 87 ",2018-01-10,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-079-1087687,1087687
196858,418374,MYL,Glaxo  GSK  Beats Q3 Earnings Estimates  Raises  19 EPS View,opinion,"GlaxoSmithKline plc   NYSE GSK   reported third quarter 2019 adjusted earnings of 95 cents per American depositary share  which beat the Zacks Consensus Estimate of 83 cents  Adjusted earnings were up 9  reportedly and 1  at constant exchange rate   CER    year over year Shares of Glaxo were up almost 2 4  on Oct 30  The stock has gained 19 4  so far this year compared with the  s 2 5  increase Quarterly revenues rose 16  reportedly and 11  at CER to  11 56 billion   9 4 billion   driven by strong performance across all segments  The top line beat the Zacks Consensus Estimate of  11 34 billion                                                           All growth rates mentioned below are on a year over year basis and at CER Glaxo reports financial figures under three segments  Pharmaceuticals  Vaccines and Consumer Healthcare Pharmaceuticals Recovers  Respiratory Drugs Sales Strong    After a weak performance in the second quarter  the Pharmaceuticals division registered 3  increase in revenues at CER  However  sales in the United States were down 2   The downside was due to lower sales of Established Pharmaceuticals  partially offset by strong growth of Respiratory segment  Sales in European and international markets were up 9  and 10   respectively Respiratory sales were up 19  at CER mainly driven by increase in sales of Trelegy Ellipta and Nucala across European and international markets  Nucala sales were up 33  at CER during the quarter  Sales of Nucala grew 29  and 39  in the United States and Europe  respectively  In the International markets  sales of Nucala increased 56   Trelegy Ellipta sales more than doubled year over year driven by an increase in market share in the United States In September  Nucala s label expansion application to include severe eosinophilic asthma patients aged six to eleven was approved by the FDA  Glaxo stated that Nucala continues to be the leader in terms of total sales in the asthma biologics market across major markets worldwide Relvar Breo Ellipta registered a decline of 8  in sales during the third quarter  Sales of Relvar Breo Ellipta decreased 32  in the United States due to impact of Advair generic and competitive pricing pressure  The launch of generic versions of Glaxo key respiratory drug  Advair  is  has created significant pricing pressure in inhaled corticosteroid   ICS   long acting beta agonist   LABA   market in the United States  However  sales of Relvar Breo Ellipta increased 19  and 22  in European and international markets  respectively HIV sales remained flat year over year at CER as growth in the dolutegravir franchise was completely offset by decline in sales of remaining drugs in the HIV portfolio  The dolutegravir franchise comprises two three drug regimens   Triumeq and Tivicay   and two two drug regimens   Juluca and Dovato  Dovato was launched in the United States in April followed by launch in Europe in the third quarter of 2019  The growth in sales of Juluca and Dovato was more than offset by decline in sales of Triumeq and Tivicay due to transition of patients from three drug regimens to two drug regimens Sales of the dolutegravir franchise were flat in the U S  market as transition to the new two drug portfolio was offset by a net price benefit  However  sales of this franchise were up 3  in Europe and 9  in international markets  mainly driven by Tivicay in Europe and Triumeq in international markets  Please note that Glaxo markets Juluca in collaboration with J J   NYSE JNJ   Sales of Established Pharmaceuticals declined 5  due to lower sales of Advair  partially offset by strong uptake of authorized generic version of Ventolin  Advair lost 64  of sales year over year in the United States while Seretide sales were down 9  in Europe due to generic competition  Glaxo moved Advair to its Established Pharmaceuticals portfolio starting first quarter of 2019  Sales of Ventolin were up 27  during the quarter We remind investors that Mylan   NASDAQ MYL   launched the first generic version of Advair  Wixela Inhub  in the United States in February  The steep decline in sales of Advair is expected to continue in the fourth quarter Immuno inflammation drugs like Benlysta rose 35  in the quarter  In April  Benlysta s label was expanded to include children with lupus aged five years or older in the United States  Earlier this week  the drug was approved in Europe for a similar indication Oncology sales were  64 million  comprising sales of PARP inhibitor  Zejula  which was acquired from TESARO this year  compared to  57 million in the second quarter Consumer Healthcare Sales UpSales in the Consumer Healthcare segment increased 25  at CER primarily driven by Pfizer s   NYSE PFE   legacy brands  Glaxo has formed a new joint venture   JV   with Pfizer to create the world s largest Consumer Healthcare business  Third quarter sales of this segment include nine weeks of legacy Pfizer brand sales  arising after the creation of the JV  Sales of Wellness  Oral health and Skin health categories increased 22   10  and 9   respectively  in the quarter  Nutrition sales more than doubled in the third quarter On a pro forma basis  sales in the Consumer Health segment were up 3  at CER on the back of strong performance in Oral health  Pro forma growth was negatively impacted by approximately one percentage point due to divestments and the phasing out of low margin contract manufacturing Vaccines Segment Growth Continues Sales from the Vaccines segment were impressive  up 15  at CER  primarily driven by strong growth of new shingles vaccine  Shingrix and impressive performance of meningitis vaccine  Bexsero  Shingrix sales were up 76  to  535 million in the reported quarter  driven by strong uptake in the United States Although growth trend of Bexsero continued this quarter with sales increasing 19  on the back of strong demand across all markets  sales of another meningitis vaccine  Menveo fell 1  due to lower demand in international markets  Sales of influenza vaccine Fluarix were up 15  on the back of market share gain and reversal of provisions made for prior year returns  Sales of Established vaccines declined 1  year over year Operating Expenses UpSelling  general and administration  SG A  costs increased 16  year over year to  2 8 billion  The rise in SG A costs was driven by increased commercial activities to support launches and costs related to the acquisition of TESARO  partly offset by cost saving initiatives and benefits of restructuring in Pharmaceuticals segment Research and development  R D  expenses were up 18  to  1 16 billion  reflecting increased investments to support progress of clinical studies  especially those on Zejula  Glaxo has 41 new medicines  including 17 vaccines  in different development stages 2019 Guidance Glaxo raised its guidance for adjusted earnings in 2019  It currently expects earnings to remain flat year over year at CER  indicating an improvement over previous expectation of a decline of 3 5  at CER in 2019  The new guidance reflects improvement in operating performance  lower expected effective tax rate and increased investment in R D Our TakeGlaxo beat on earnings and sales in the third quarter  The company s new products from every segment performed well in the reported quarter  especially Shingrix  This prompted the company to raise its expectation for 2019 earnings We are encouraged by Glaxo s restructuring initiatives to focus on strengthening its pharmaceutical portfolio  The company boosted its oncology portfolio with the acquisition of TESARO in January and a collaboration agreement with Germany based Merck KgaA  in February  Following these two transactions  the company has 16 oncology pipeline candidates including in house candidates These transactions along with restructuring initiatives related to the Consumer Health segment will help the company to offset slowdown in legacy businesses  However  loss of Advair sales due to generic competition and competitive pricing will continue to hamper revenues GlaxoSmithKline plc Price  Consensus and EPS Surprise
    Zacks RankGlaxo currently carries a Zacks Rank  2  Buy   You can see  Free  Zacks  Single Best Stock Set to DoubleToday you are invited to download our just released Special Report that reveals 5 stocks with the most potential to gain  100  or more in 2020  From those 5  Zacks Director of Research  Sheraz Mian hand picks one to have the most explosive upside of all This pioneering tech ticker had soared to all time highs and then subsided to a price that is irresistible  Now a pending acquisition could super charge the company s drive past competitors in the development of true Artificial Intelligence  The earlier you get in to this stock  the greater your potential gain ",2019-10-30,Zacks Investment Research,https://www.investing.com/analysis/glaxo-gsk-beats-q3-earnings-estimates-raises-19-eps-view-200480980,200480980
196859,418375,MYL,Mylan  MYL  Q3 Earnings Surpass Estimates,opinion,"Mylan  NASDAQ MYL  came out with quarterly earnings of  1 17 per share  beating the Zacks Consensus Estimate of  1 14 per share  This compares to earnings of  1 25 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 2 63   A quarter ago  it was expected that this generic drugmaker would post earnings of  0 95 per share when it actually produced earnings of  1 03  delivering a surprise of 8 42  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Mylan  which belongs to the Zacks Medical   Generic Drugs industry  posted revenues of  2 96 billion for the quarter ended September 2019  missing the Zacks Consensus Estimate by 2 39   This compares to year ago revenues of  2 86 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Mylan shares have lost about 28  since the beginning of the year versus the S P 500 s gain of 22 8  
What s Next for Mylan 
While Mylan has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Mylan was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 29 on  3 27 billion in revenues for the coming quarter and  4 26 on  11 66 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Generic Drugs is currently in the top 24  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-11-04,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-q3-earnings-surpass-estimates-200482198,200482198
196860,418376,MYL,Theravance  TBPH  Q3 Loss In Line  Revenues Lag Estimates,opinion,Theravance Biopharma  Inc    NASDAQ TBPH   incurred a loss of  1 05 per share in third quarter 2019  in line with the Zacks Consensus Estimate  Meanwhile  the figure is narrower than the year ago quarter s loss of  1 10 However  total revenues of  12 4 million in the quarter missed the Zacks Consensus Estimate of  13 million  Revenues also decreased 3 1  year over year  mainly due to lack of product sales following the divesture of its only marketed drug Vibativ to Cumberland Pharmaceuticals last November  Total revenues in the third quarter comprised collaboration revenues of  8 8 million and  3 6 million received from Mylan   NASDAQ MYL   Theravance has collaboration with Mylan for the development and commercialization of Yupelri  revefenacin   which was approved by the FDA last November  The drug is used for maintenance treatment of adults with chronic obstructive pulmonary disease  COPD  Per the press release  Yupelri witnessed strong customer acceptance and brand performance across key market metrics in the third quarter Shares of Theravance have lost 33 1  in the year so far versus the  growth of 4 3  Quarter in DetailResearch   development expenses were  52 million  down 1 3  from the year ago quarter  primarily owing to lower employee related expenses linked with the reduction in sales force Selling  general   administrative expenses escalated 16 9  to  25 6 million due to higher external expenses and higher share based compensation As of Sep 30  2019  Theravance had cash  cash equivalents  marketable securities and restricted cash of  352 9 million compared to  396 1 million as of Jun 30  2019 Product   Pipeline UpdatesNotably  Theravance has an economic interest in royalties earned from GlaxoSmithKline   NYSE GSK   on triple combination COPD treatment Trelegy Ellipta s global sales  In the third quarter  Glaxo recorded sales of  172 8 million from Trelegy Ellipta  Theravance is eligible to receive 5 5 8 5   tiered  of the product s worldwide net sales The company also has a collaboration agreement with Johnson   Johnson s   NYSE JNJ   subsidiary Janssen to develop its JAK inhibitor TD 1473 for the treatment of inflammatory intestinal diseases  A phase II study on TD 1473 for treating Crohn s disease and a phase IIb III study for ulcerative colitis are ongoing  Data from the phase IIb portion of the ulcerative colitis and phase II Crohn s disease studies are expected in late 2020 Theravance is evaluating ampreloxetine  TD 9855  in a phase III program for treating patients with symptomatic neurogenic orthostatic hypotension  nOH  The company is developing inhaled  lung selective pan Janus kinase  JAK  inhibitor TD 8236 in a phase I study for the treatment of inflammatory lung diseases with minimal systemic exposure  In September 2019  Theravance announced  from a phase I study on TD 8236  having evaluated it in single ascending doses  up to 4500 mcg  and multiple ascending doses  up to 4000 mcg  Theravance is also developing its gut selective irreversible JAK3 inhibitor TD 5202 in a phase I study for addressing inflammatory intestinal diseases 2019 OutlookFor 2019  Theravance anticipates operating loss excluding non cash share based compensation to be in the range of  200  210 million  narrowed from the previous guidance of  210  230 million Theravance Biopharma  Inc  Price  Consensus and EPS Surprise   Zacks RankTheravance currently carries a Zacks Rank  3  Hold   You can see  Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 5  per year These 7 were selected because of their superior potential for immediate breakout ,2019-11-05,Zacks Investment Research,https://www.investing.com/analysis/theravance-tbph-q3-loss-in-line-revenues-lag-estimates-200482974,200482974
196861,418377,MYL,Israel stocks lower at close of trade  TA 35 down 0 28 ,news,"Investing com   Israel stocks were lower after the close on Tuesday  as losses in the Biomed  Banking and Real Estate sectors led shares lower 
At the close in Tel Aviv  the TA 35 fell 0 28  
The best performers of the session on the TA 35 were Mylan NV  TA MYL   which rose 3 56  or 450 points to trade at 13100 at the close  Meanwhile   Isramco  Negev 2 LP  TA ISRAp  added 2 37  or 1 1 points to end at 47 5 and  OPKO Health Inc   TA OPK  was up 1 47  or 34 points to 2346 in late trade 
The worst performers of the session were Teva Pharmaceutical Industries Ltd  TA TEVA   which fell 3 60  or 155 points to trade at 4155 at the close   Frutarom  Industries Ltd  TA FRUT  declined 2 96  or 860 points to end at 28240 and  Sodastream International Ltd   TA SODA  was down 1 72  or 390 0 points to 22260 0 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 211 to 194 and 12 ended unchanged 
Crude oil for December delivery was down 0 14  or 0 08 to  57 27 a barrel  Elsewhere in commodities trading  Brent oil for delivery in January fell 0 44  or 0 28 to hit  63 99 a barrel  while the December Gold Futures contract fell 0 55  or 7 02 to trade at  1274 58 a troy ounce 
USD ILS was up 0 33  to 3 5180  while EUR ILS rose 0 02  to 4 0710 
The US Dollar Index Futures was up 0 37  at 94 97 ",2017-11-07,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-028-839561,839561
196862,418378,MYL,Israel stocks lower at close of trade  TA 35 down 0 30 ,news,"Investing com   Israel stocks were lower after the close on Wednesday  as losses in the Biomed  Technology and Communication sectors led shares lower 
At the close in Tel Aviv  the TA 35 declined 0 30  to hit a new 1 month low 
The best performers of the session on the TA 35 were Tower Semiconductor Ltd  TA TSEM   which rose 4 50  or 510 points to trade at 11850 at the close  Meanwhile   Delek Group   TA DLEKG  added 3 24  or 1750 points to end at 55800 and  Frutarom  Industries Ltd  TA FRUT  was up 2 44  or 690 points to 28930 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 2 75  or 360 points to trade at 12740 at the close   OPKO Health Inc   TA OPK  declined 2 43  or 57 points to end at 2289 and Teva Pharmaceutical Industries Ltd  TA TEVA  was down 2 29  or 95 points to 4060 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 217 to 180 and 14 ended unchanged 
Crude oil for December delivery was down 0 84  or 0 48 to  56 72 a barrel  Elsewhere in commodities trading  Brent oil for delivery in January fell 0 49  or 0 31 to hit  63 38 a barrel  while the December Gold Futures contract rose 0 68  or 8 65 to trade at  1284 45 a troy ounce 
USD ILS was down 0 13  to 3 5116  while EUR ILS fell 0 13  to 4 0677 
The US Dollar Index Futures was up 0 04  at 94 85 ",2017-11-08,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-030-840427,840427
196863,418379,MYL,Israel stocks lower at close of trade  TA 35 down 0 13 ,news,"Investing com   Israel stocks were lower after the close on Thursday  as losses in the Biomed  Banking and Technology sectors led shares lower 
At the close in Tel Aviv  the TA 35 declined 0 13  to hit a new 1 month low 
The best performers of the session on the TA 35 were Perrigo  TA PRGO   which rose 13 92  or 3920 points to trade at 32090 at the close  Meanwhile  Mylan NV  TA MYL  added 3 38  or 430 points to end at 13170 and Teva Pharmaceutical Industries Ltd  TA TEVA  was up 1 87  or 76 points to 4136 in late trade 
The worst performers of the session were  OPKO Health Inc   TA OPK   which fell 15 60  or 357 points to trade at 1932 at the close   Israel Corp   TA ILCO  declined 5 14  or 3410 points to end at 62910 and  ICL  Israel Chemicals Ltd  TA ICL  was down 3 69  or 55 points to 1434 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 296 to 108 and 9 ended unchanged 
Shares in OPKO Health Inc  TA OPK  fell to all time lows  falling 15 60  or 357 to 1932  
Crude oil for December delivery was up 1 06  or 0 60 to  57 41 a barrel  Elsewhere in commodities trading  Brent oil for delivery in January rose 0 95  or 0 60 to hit  64 09 a barrel  while the December Gold Futures contract fell 0 02  or 0 30 to trade at  1283 40 a troy ounce 
USD ILS was up 0 28  to 3 5208  while EUR ILS rose 0 58  to 4 0948 
The US Dollar Index Futures was down 0 22  at 94 56 ",2017-11-09,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-013-841319,841319
196864,418380,MYL,Israel stocks higher at close of trade  TA 35 up 0 18 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Oil   Gas  Biomed and Technology sectors led shares higher 
At the close in Tel Aviv  the TA 35 rose 0 18  
The best performers of the session on the TA 35 were Delek Drilling LP  TA DEDRp   which rose 1 88  or 18 points to trade at 975 at the close  Meanwhile  Israel Discount Bank Ltd  TA DSCT  added 1 76  or 16 5 points to end at 953 0 and Mylan NV  TA MYL  was up 1 67  or 220 points to 13390 in late trade 
The worst performers of the session were Perrigo  TA PRGO   which fell 2 96  or 950 points to trade at 31140 at the close  Melisron  TA MLSR  declined 0 78  or 140 points to end at 17810 and  ICL  Israel Chemicals Ltd  TA ICL  was down 0 70  or 10 points to 1424 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 300 to 99 and 15 ended unchanged 
Shares in Israel Discount Bank Ltd  TA DSCT  rose to 5 year highs  rising 1 76  or 16 5 to 953 0  Shares in ICL Israel Chemicals Ltd  TA ICL  fell to 52 week lows  down 0 70  or 10 to 1424  
Crude oil for December delivery was down 0 51  or 0 29 to  56 88 a barrel  Elsewhere in commodities trading  Brent oil for delivery in January fell 0 41  or 0 26 to hit  63 67 a barrel  while the December Gold Futures contract fell 0 96  or 12 37 to trade at  1275 13 a troy ounce 
USD ILS was up 0 69  to 3 5492  while EUR ILS rose 0 93  to 4 1420 
The US Dollar Index Futures was down 0 13  at 94 30 ",2017-11-12,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-018-845371,845371
196865,418381,MYL,Theravance submits U S  marketing application for COPD med revefenacin,news,Theravance Biopharma  TBPH  3 1   and development commercialization partner Mylan N V   MYL  1 2   announce the filing of a New Drug Application  NDA  in the U S  seeking approval for revefenacin  TD 4208  for the once daily treatment of chronic obstructive pulmonary disease  COPD  The companies are collaborating on the development of the long acting nebulized bronchodilator  Theravance is leading U S  development while Mylan is responsible for ex U S  development and commercialization  Theravance is eligible to receive up to  220M in development  and sales related milestones and double digit royalties on ex U S  sales  Theravance retains global rights to revefenacin delivered through other dosage forms  e g   metered dose inhaler or dry powder inhaler  as well as the rights to nebulized revefenacin in China Now read ,2017-11-13,Seeking Alpha,https://www.investing.com/news/stock-market-news/theravance-submits-us-marketing-application-for-copd-med-revefenacin-849721,849721
196866,418382,MYL,Israel stocks lower at close of trade  TA 35 down 0 29 ,news,"Investing com   Israel stocks were lower after the close on Monday  as losses in the Insurance  Banking and Financials sectors led shares lower 
At the close in Tel Aviv  the TA 35 lost 0 29  
The best performers of the session on the TA 35 were Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ   which rose 4 78  or 23 5 points to trade at 515 5 at the close  Meanwhile  Teva Pharmaceutical Industries Ltd  TA TEVA  added 3 64  or 177 points to end at 5042 and Delek Drilling LP  TA DEDRp  was up 2 06  or 20 points to 1015 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 2 88  or 380 points to trade at 12820 at the close   Big  Shopping Centers Ltd  TA BIG  declined 2 39  or 600 points to end at 24500 and Poalim  TA POLI  was down 2 38  or 57 points to 2343 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 220 to 158 and 32 ended unchanged 
Crude oil for January delivery was down 1 98  or 1 17 to  57 78 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February rose 0 06  or 0 04 to hit  63 51 a barrel  while the December Gold Futures contract rose 0 54  or 6 96 to trade at  1294 26 a troy ounce 
USD ILS was down 0 30  to 3 5002  while EUR ILS fell 0 38  to 4 1730 
The US Dollar Index Futures was down 0 03  at 92 69 ",2017-11-27,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-029-915900,915900
196867,418383,MYL,Israel stocks higher at close of trade  TA 35 up 0 42 ,news,"Investing com   Israel stocks were higher after the close on Thursday  as gains in the Oil   Gas  Insurance and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 35 added 0 42  to hit a new 3 months high 
The best performers of the session on the TA 35 were Tower Semiconductor Ltd  TA TSEM   which rose 7 17  or 850 points to trade at 12700 at the close  Meanwhile   Delek Group   TA DLEKG  added 4 12  or 2200 points to end at 55640 and Delek Drilling LP  TA DEDRp  was up 2 87  or 29 points to 1039 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 2 45  or 320 points to trade at 12760 at the close   Elbit Systems  Ltd  TA ESLT  declined 1 88  or 930 points to end at 48420 and Teva Pharmaceutical Industries Ltd  TA TEVA  was down 1 24  or 65 points to 5166 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 216 to 173 and 36 ended unchanged 
Shares in Tower Semiconductor Ltd  TA TSEM  rose to 5 year highs  rising 7 17  or 850 to 12700  
Crude oil for January delivery was up 0 14  or 0 08 to  57 38 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February rose 0 32  or 0 20 to hit  62 73 a barrel  while the December Gold Futures contract fell 0 27  or 3 45 to trade at  1278 65 a troy ounce 
USD ILS was down 0 28  to 3 4941  while EUR ILS rose 0 33  to 4 1645 
The US Dollar Index Futures was down 0 45  at 92 80 ",2017-11-30,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-042-934729,934729
196870,418386,MYL,Theravance Pipeline Strong  Dependence On Yupelri A Concern,opinion,Theravance Biopharma  Inc    NASDAQ TBPH   is a biopharmaceutical company focused on developing treatments targeting various therapeutic areas such as infectious  respiratory  gastrointestinal  cardiovascular  renal  inflammation and immunology diseases The company received a huge boost when the FDA approved Yupelri  a long acting muscarinic antagonist  LAMA   as a once daily  nebulized treatment of chronic obstructive pulmonary disease  COPD  last November Theravance has a collaboration deal with Mylan   NASDAQ MYL   for the development and commercialization of Yupelri  Both companies formally launched Yupelri in early 2019 and the product is witnessing a strong uptake ever since Mylan and Theravance are sharing US profits and losses reported in connection with the commercialization of Yupelri  While Mylan gets 65  of the profits  Theravance is entitled to receive 35   The product has witnessed strong customer acceptance and brand performance across the key market metrics Notably  in November 2018  Theravance completed the sale of its only marketed drug Vibativ to Cumberland Pharmaceuticals Meanwhile  Theravance has an economic interest in GlaxoSmithKline s   NYSE GSK   COPD drug Trelegy Ellipta and earns royalties on its sales This apart  Theravance has a promising pipeline portfolio  which is progressing well  Last month  the company announced promising outcomes from a phase I study on its inhaled  lung selective pan Janus kinase  JAK  inhibitor TD 8236  The candidate is being developed for the treatment of inflammatory lung diseases with minimal systemic exposure Theravance also has a collaboration agreement with Johnson   Johnson s   NYSE JNJ   subsidiary Janssen to develop its JAK inhibitor TD 1473 for treating inflammatory intestinal diseases  A phase II study on TD 1473 to treat Crohn s disease and a phase IIb III study for ulcerative colitis are ongoing  The company plans to report data from both these studies on TD 1473 by late 2020 Theravance is also evaluating TD 9855 in a phase III study for treating patients with symptomatic neurogenic orthostatic hypotension  nOH  Successful development and subsequent approval of these candidates will be a huge boost to the company given their potential to offer transformational value to patients and healthcare providers However  with the potential sale of Vibativ  Theravance is now solely dependent on profit sharing revenues from Mylan for Yupelri and collaboration revenues from J J for funding its pipeline development  Any agreement termination regarding these in the future might be a massive setback for the company Just Released  Zacks  7 Best Stocks for TodayExperts extracted 7 stocks from the list of 220 Zacks Rank  1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of  24 6  per year These 7 were selected because of their superior potential for immediate breakout ,2019-10-06,Zacks Investment Research,https://www.investing.com/analysis/theravance-pipeline-strong-dependence-on-yupelri-a-concern-200471183,200471183
196871,418387,MYL,Why The Earnings Surprise Streak Could Continue For Mylan  MYL ,opinion,"Have you been searching for a stock that might be well positioned to maintain its earnings beat streak in its upcoming report  It is worth considering Mylan  NASDAQ MYL   which belongs to the Zacks Medical   Generic Drugs industry 
When looking at the last two reports  this generic drugmaker has recorded a strong streak of surpassing earnings estimates  The company has topped estimates by 6 11   on average  in the last two quarters 
For the most recent quarter  Mylan was expected to post earnings of  0 95 per share  but it reported  1 03 per share instead  representing a surprise of 8 42   For the previous quarter  the consensus estimate was  0 79 per share  while it actually produced  0 82 per share  a surprise of 3 80  
Price and EPS Surprise

For Mylan  estimates have been trending higher  thanks in part to this earnings surprise history  And when you look at the stock s positive Zacks Earnings ESP  Expected Surprise Prediction   it s a great indicator of a future earnings beat  especially when combined with its solid Zacks Rank 
Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank  3  Hold  or better produce a positive surprise nearly 70  of the time  In other words  if you have 10 stocks with this combination  the number of stocks that beat the consensus estimate could be as high as seven 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Mylan currently has an Earnings ESP of  1 88   which suggests that analysts have recently become bullish on the company s earnings prospects  This positive Earnings ESP when combined with the stock s Zacks Rank  3  Hold  indicates that another beat is possibly around the corner 
Investors should note  however  that a negative Earnings ESP reading is not indicative of an earnings miss  but a negative value does reduce the predictive power of this metric 
Many companies end up beating the consensus EPS estimate  but that may not be the sole basis for their stocks moving higher  On the other hand  some stocks may hold their ground even if they end up missing the consensus estimate 
Because of this  it s really important to check a company s Earnings ESP ahead of its quarterly release to increase the odds of success  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported ",2019-10-09,Zacks Investment Research,https://www.investing.com/analysis/why-the-earnings-surprise-streak-could-continue-for-mylan-myl-200472321,200472321
196872,418388,MYL,Mylan  MYL  Expected To Beat Earnings Estimates  Should You Buy ,opinion,"Mylan  NASDAQ MYL  is expected to deliver a year over year decline in earnings on higher revenues when it reports results for the quarter ended September 2019  This widely known consensus outlook gives a good sense of the company s earnings picture  but how the actual results compare to these estimates is a powerful factor that could impact its near term stock price 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on November 5  On the other hand  if they miss  the stock may move lower 
While management s discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations  it s worth having a handicapping insight into the odds of a positive EPS surprise 
Zacks Consensus Estimate
This generic drugmaker is expected to post quarterly earnings of  1 14 per share in its upcoming report  which represents a year over year change of  8 8  
Revenues are expected to be  3 03 billion  up 6  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 0 61  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  Our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction     has this insight at its core 
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Mylan 
For Mylan  the Most Accurate Estimate is higher than the Zacks Consensus Estimate  suggesting that analysts have recently become bullish on the company s earnings prospects  This has resulted in an Earnings ESP of  0 70  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination indicates that Mylan will most likely beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Mylan would post earnings of  0 95 per share when it actually produced earnings of  1 03  delivering a surprise of  8 42  
Over the last four quarters  the company has beaten consensus EPS estimates three times 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Mylan appears a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-10-28,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-expected-to-beat-earnings-estimates-should-you-buy-200479542,200479542
196876,418392,MYL,Israel stocks higher at close of trade  TA 35 up 0 33 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Oil   Gas  Real Estate and Communication sectors led shares higher 
At the close in Tel Aviv  the TA 35 gained 0 33  
The best performers of the session on the TA 35 were  Frutarom  Industries Ltd  TA FRUT   which rose 3 58  or 1000 points to trade at 28950 at the close  Meanwhile  Nice Ltd  TA NICE  added 2 28  or 650 points to end at 29210 and Delek Drilling LP  TA DEDRp  was up 2 22  or 21 points to 975 in late trade 
The worst performers of the session were Teva Pharmaceutical Industries Ltd  TA TEVA   which fell 2 62  or 127 points to trade at 4727 at the close  Mylan NV  TA MYL  declined 1 89  or 260 points to end at 13470 and Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ  was down 0 78  or 4 1 points to 524 4 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 264 to 133 and 16 ended unchanged 
Shares in Teva Pharmaceutical Industries Ltd  TA TEVA  fell to 5 year lows  down 2 62  or 127 to 4727  Shares in Nice Ltd  TA NICE  rose to all time highs  up 2 28  or 650 to 29210  
Crude oil for December delivery was up 2 91  or 1 53 to  54 17 a barrel  Elsewhere in commodities trading  Brent oil for delivery in January unchanged 0 00  or 0 00 to hit  60 13 a barrel  while the December Gold Futures contract rose 0 51  or 6 46 to trade at  1276 06 a troy ounce 
USD ILS was up 0 20  to 3 5355  while EUR ILS fell 0 05  to 4 1028 
The US Dollar Index Futures was up 0 18  at 94 72 ",2017-10-29,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-033-759789,759789
196877,418393,MYL,Israel stocks lower at close of trade  TA 35 down 0 20 ,news,"Investing com   Israel stocks were lower after the close on Tuesday  as losses in the Biomed  Technology and Real Estate sectors led shares lower 
At the close in Tel Aviv  the TA 35 lost 0 20  
The best performers of the session on the TA 35 were Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ   which rose 3 26  or 16 6 points to trade at 525 8 at the close  Meanwhile  Delek Drilling LP  TA DEDRp  added 3 17  or 32 points to end at 1040 and  Isramco  Negev 2 LP  TA ISRAp  was up 2 66  or 1 3 points to 50 1 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 7 50  or 1020 points to trade at 12580 at the close  Perrigo  TA PRGO  declined 3 80  or 1120 points to end at 28360 and  OPKO Health Inc   TA OPK  was down 2 06  or 50 points to 2374 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 219 to 184 and 21 ended unchanged 
Crude oil for December delivery was up 0 07  or 0 04 to  54 19 a barrel  Elsewhere in commodities trading  Brent oil for delivery in January rose 0 10  or 0 06 to hit  60 65 a barrel  while the December Gold Futures contract fell 0 58  or 7 39 to trade at  1270 31 a troy ounce 
USD ILS was down 0 16  to 3 5199  while EUR ILS fell 0 23  to 4 0989 
The US Dollar Index Futures was up 0 08  at 94 46 ",2017-10-31,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-020-761121,761121
196878,418394,MYL,U S  states move to expand generic drug price fixing lawsuit,news,"By Karen Freifeld WASHINGTON  Reuters    A large group of U S  state attorneys general on Tuesday moved to expand a lawsuit alleging price fixing of generic drugs to 18 companies and 15 medicines on Tuesday  including Novartis AG s generic unit Sandoz and India based Sun Pharmaceutical Industries Ltd  The lawsuit  brought by the attorneys general of 45 states and the District of Columbia  also targeted two individual executives  including Rajiv Malik  president and executive director of Mylan  NASDAQ MYL  Pharmaceuticals Inc  Shares of Mylan  also named as a defendant  fell more than 6 percent after the news  to  35 91  Mylan said in a statement it had found no evidence of price fixing by the company or any of its employees  and vowed to defend itself vigorously   Mylan has deep faith in the integrity of its president  Rajiv Malik  and stands behind him fully   it said  In addition to Malik  the states are seeking to sue Satish Mehta  chief executive officer and managing director of Emcure  The states claim that the drugmakers and executives conspired to fix prices and split up the market for generic drugs  which are intended to deliver lower prices to consumers   It is our belief that price fixing is systematic  it is pervasive  and that a culture of collusion exists in the industry   Connecticut Attorney General George Jepsen  who is leading the case  said at a news conference in Hartford  The original complaint  filed in December  targeted Emcure Pharmaceuticals  unit Heritage Pharmaceuticals Inc  Aurobindo Pharma USA Inc  Citron Pharma LLC  Mayne Pharma USA Inc  Mylan and Teva Pharmaceuticals USA Inc  The states are now seeking to file a new complaint that would add Sandoz  Sun  Endo International PLC s unit Par Pharmaceutical  Dr  Reddy s Laboratories  Apotex Corp  Glenmark Generics Ltd  Lannett Company Inc  Alkem Laboratories Ltd s unit Ascend Laboratories and Cadila Healthcare Ltd s unit Zydus Pharmaceuticals Inc  The news hurt shares of companies named in the expanded suit that are traded in the United States  pulling Lannett down as much as 7 percent  Shares of Endo pared nearly 8 percent off a more than 12 percent gain on the day  which followed the company s earlier estimate it would earn more than expected  Teva spokeswoman Denise Bradley said the company denied the allegations  The other companies did not immediately respond to requests for comment  The expansion of the suit requires the court s permission  The original lawsuit centered on just two medicines  a delayed release version of a common antibiotic  doxycycline hyclate  and glyburide  an older drug used to treat diabetes  The amended complaint would expand the number of drugs to include glipizide metformin and glyburide metformin  which are among the most commonly used diabetes treatments  Others include  acetazolamide  which is used to treat glaucoma and epilepsy  the antibiotic doxycycline monohydrate  the blood pressure medicine fosinopril  the anti anxiety medicine meprobamate  and the calcium channel blocking agent nimodipine  The U S  Department of Justice is conducting a parallel criminal investigation  On Friday  the department asked the Pennsylvania court presiding over the lawsuit to put the lawsuit s discovery process on hold  saying it could interfere with the criminal probe  
Connecticut Assistant Attorney General Joseph Nielsen said Tuesday that the states would likely oppose that request  which could slow the lawsuit ",2017-10-31,Reuters,https://www.investing.com/news/stock-market-news/exclusive-us-states-to-expand-generic-drug-pricefixing-suit--sources-761067,761067
196879,418395,MYL,Israel stocks higher at close of trade  TA 35 up 0 30 ,news,"Investing com   Israel stocks were higher after the close on Wednesday  as gains in the Communication  Real Estate and Insurance sectors led shares higher 
At the close in Tel Aviv  the TA 35 rose 0 30  
The best performers of the session on the TA 35 were Mylan NV  TA MYL   which rose 3 97  or 500 points to trade at 13080 at the close  Meanwhile  Perrigo  TA PRGO  added 2 89  or 820 points to end at 29180 and  Sodastream International Ltd   TA SODA  was up 2 65  or 600 0 points to 23210 0 in late trade 
The worst performers of the session were Delek Drilling LP  TA DEDRp   which fell 2 31  or 24 points to trade at 1016 at the close   Isramco  Negev 2 LP  TA ISRAp  declined 1 60  or 0 8 points to end at 49 3 and  OPKO Health Inc   TA OPK  was down 1 56  or 37 points to 2337 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 209 to 204 and 13 ended unchanged 
Crude oil for December delivery was down 0 13  or 0 07 to  54 31 a barrel  Elsewhere in commodities trading  Brent oil for delivery in January fell 0 26  or 0 16 to hit  60 78 a barrel  while the December Gold Futures contract rose 0 54  or 6 88 to trade at  1277 38 a troy ounce 
USD ILS was down 0 20  to 3 5144  while EUR ILS fell 0 40  to 4 0833 
The US Dollar Index Futures was up 0 25  at 94 69 ",2017-11-01,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-030-761901,761901
196880,418396,MYL,Israel stocks lower at close of trade  TA 35 down 1 06 ,news,"Investing com   Israel stocks were lower after the close on Thursday  as losses in the Oil   Gas  Biomed and Technology sectors led shares lower 
At the close in Tel Aviv  the TA 35 lost 1 06  to hit a new 1 month low 
The best performers of the session on the TA 35 were Israel Discount Bank Ltd  TA DSCT   which rose 2 19  or 20 3 points to trade at 946 0 at the close  Meanwhile   Mizrahi Tefahot   TA MZTF  added 1 81  or 115 points to end at 6475 and First  International  Bank of Israel Ltd  TA FTIN  was up 1 78  or 120 points to 6865 in late trade 
The worst performers of the session were Teva Pharmaceutical Industries Ltd  TA TEVA   which fell 13 65  or 670 points to trade at 4238 at the close  Mylan NV  TA MYL  declined 5 73  or 750 points to end at 12330 and  Sodastream International Ltd   TA SODA  was down 3 83  or 890 0 points to 22320 0 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 265 to 144 and 7 ended unchanged 
Shares in Israel Discount Bank Ltd  TA DSCT  rose to 5 year highs  gaining 2 19  or 20 3 to 946 0  Shares in Teva Pharmaceutical Industries Ltd  TA TEVA  fell to 5 year lows  losing 13 65  or 670 to 4238  Shares in First International Bank of Israel Ltd  TA FTIN  rose to 5 year highs  up 1 78  or 120 to 6865  
Crude oil for December delivery was unchanged 0 00  or 0 00 to  54 30 a barrel  Elsewhere in commodities trading  Brent oil for delivery in January fell 0 12  or 0 07 to hit  60 42 a barrel  while the December Gold Futures contract rose 0 17  or 2 12 to trade at  1279 42 a troy ounce 
USD ILS was down 0 21  to 3 5044  while EUR ILS rose 0 19  to 4 0889 
The US Dollar Index Futures was down 0 18  at 94 53 ",2017-11-02,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-106-762892,762892
196881,418397,MYL,Israel stocks higher at close of trade  TA 35 up 0 18 ,news,"Investing com   Israel stocks were higher after the close on Monday  as gains in the Oil   Gas  Real Estate and Communication sectors led shares higher 
At the close in Tel Aviv  the TA 35 rose 0 18  
The best performers of the session on the TA 35 were Teva Pharmaceutical Industries Ltd  TA TEVA   which rose 7 05  or 284 points to trade at 4310 at the close  Meanwhile  Mylan NV  TA MYL  added 2 02  or 250 points to end at 12650 and Delek Drilling LP  TA DEDRp  was up 1 95  or 19 points to 974 in late trade 
The worst performers of the session were Harel  TA HARL   which fell 2 92  or 70 points to trade at 2325 at the close   Azrieli Group  Ltd  TA AZRG  declined 1 95  or 390 points to end at 19590 and Melisron  TA MLSR  was down 1 94  or 360 points to 18240 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 224 to 187 and 8 ended unchanged 
Crude oil for December delivery was up 0 93  or 0 52 to  56 16 a barrel  Elsewhere in commodities trading  Brent oil for delivery in January rose 1 45  or 0 90 to hit  62 97 a barrel  while the December Gold Futures contract rose 0 32  or 4 11 to trade at  1273 31 a troy ounce 
USD ILS was up 0 06  to 3 5105  while EUR ILS fell 0 11  to 4 0667 
The US Dollar Index Futures was up 0 08  at 94 91 ",2017-11-06,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-018-770033,770033
196887,418403,MYL,Mylan  MYL  Down 12 9  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Mylan  NASDAQ MYL   Shares have lost about 12 9  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Mylan due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Mylan Beats on Q2 Earnings  Inks Deal with Pfizer  NYSE PFE Mylan reported adjusted earnings of  1 03 per share in the second quarter of 2019  which beat the Zacks Consensus Estimate of 95 cents but declined from  1 07 in the year ago quarter Second quarter revenues of  2 85 billion easily beat the Zacks Consensus Estimate of  2 82 billion and was up 2  from the prior year quarter Quarter in DetailThe company posts results in three segments on a geographic basis   North America  Europe and Rest of World North America segment s net sales came in at  1 023 billion  up 2  year over year  driven by new product sales  partially offset by lower volumes of existing products  New product sales were primarily driven by sales of Fulphila  biosimilar to Neulasta  and Wixela Inhub  the generic of GlaxoSmithKline s Advair Diskus Net sales in the Europe segment were  989 6 million  down by a million due to unfavorable impact of foreign currency translation and lesser extent pricing  The unfavorable impact of foreign currency translation was offset by new product sales  including Hulio and the TOBI Podhaler  and higher volumes of existing products  Rest of World segment s net sales of  805 2 million were up 5  primarily driven by products sold in China and new product sales in Australia and emerging markets Adjusted gross margin expanded to 54  from 53  in the year ago quarter 2019 GuidanceThe company reaffirmed its guidance for 2019  Revenues are projected between  11 5 billion and  12 5 billion  The company anticipates adjusted EPS of  3 80  4 80  It targets to repay  1 1 billion of debt by the end of the year Deal with PfizerConcurrent with the quarterly results  Mylan announced a merger agreement with Upjohn  Pfizer s off patent branded and generic established medicines business  includes Lipitor  Celebrex and Viagra   to create a new global pharmaceutical company   Per the agreement  which is structured as an all stock  Reverse Morris Trust transaction  each Mylan share would be converted into one share of the new company Pfizer s shareholders would own 57  of the combined entity  while Mylan s shareholders would own the remaining 43   The transaction has been unanimously approved by the boards of both the companies The resultant will boast a diverse portfolio across many geographies and focus on key therapeutic areas  The new company is expected to generate revenues of  19  20 billion for 2020  The combined entity will be renamed and rebranded  and led by Mylan s current chairman Robert J  Coury  who will serve as the executive chairman of the new company  
How Have Estimates Been Moving Since Then 
It turns out  estimates revision have trended downward during the past month 
VGM Scores
At this time  Mylan has an average Growth Score of C  though it is lagging a bit on the Momentum Score front with a D  However  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Mylan has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-08-27,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-down-129-since-last-earnings-report-can-it-rebound-200459357,200459357
196888,418404,MYL,Forget Pfizer  Add These Big Drugmakers To Your Portfolio,opinion,"Pfizer   NYSE PFE    one of the biggest drugmakers in the world  is witnessing tough times in 2019  The company s stock has declined 19 7  this year so far   Pfizer has a Zacks Rank  5  Strong Sell   Its earnings estimates have declined 1 7  for 2019 and 11 5  for 2020 over the past 30 days Pfizer lost exclusivity for its key drug Lyrica in the United States in July  Loss of exclusivity  LOE  of Lyrica and some other drugs is Pfizer s main cause of concern in 2019  LOEs are expected to hurt 2019 sales by  2 6 billion In July  along with the earnings  Pfizer lowered its previously issued sales and earnings guidance for 2019 to reflect the formation of the Consumer Healthcare joint venture with Glaxo   NYSE GSK   and the Array BioPharma acquisition Pfizer merged its Consumer Healthcare unit with Glaxo s unit to form a new joint venture  JV   Pfizer owns 32  stake in the JV  In July  Pfizer bought Array BioPharma for  48 per share in cash for a total enterprise value of approximately  11 4 billion in a bid to strengthen its cancer portfolio Other than this business development activity  incremental negative impact of foreign exchange and unfavorable product developments in case of Prevnar  vaccine  and Xeljanz  autoimmune diseases  also resulted in the guidance cut In July  Xeljanz s prescribing information in the United States was updated by the FDA to include two additional boxed warnings as well as changes to the indication and dosing for ulcerative colitis indication  following review of a post marketing study   Pfizer stated on the second quarter call that the label update may have some negative impact on prescribing and hurt sales in the future quarters Meanwhile  due to some unfavorable revisions in Advisory Committee on Immunization Practices   ACIP  pneumococcal vaccination guidelines for Prevnar 13 in adults in the United States  Pfizer expects some decline in demand for Prevnar  which can hurt sales in the future quarters Meanwhile  Pfizer s sterile injectables portfolio is seeing lower revenues since the past few quarters due to continued legacy Hospira product shortages in the United States  Pfizer is facing supply shortages for sterile injectable products mainly due to capacity constraints and technical issues Importantly  in July  Pfizer announced a definitive agreement to spin off its Upjohn unit and combine it with generic drugmaker Mylan   NASDAQ MYL   in a Reverse Morris Trust transaction to create a new generic pharmaceutical company  Upjohn is Pfizer s global  off patent branded and generic established medicines business  The news did not go down well with investors and Pfizer s stock declined after the announcement  probably because the drugs being divested were key cash flow generators for Pfizer and funded its R D efforts  The divestiture of Upjohn will significantly lower Pfizer s cash resources even though it might boost growth and also take away the Lyrica LOE cliff How is the Large Cap Pharma Industry Performing The Zacks industry  comprising some of the biggest drugmakers in the world  has declined 2 1  in 2019 so far  probably due to poor performance of big names like Pfizer  Bristol Myers and Lilly  However  the industry features in the top 11  of the 256 Zacks ranked industries and there are many attractive investment options in the space We believe that new product sales ramp up as a result of rising demand  driven by growth in ageing population  successful innovation and product line extensions in important therapeutic areas  strong clinical study results  and frequent FDA approvals  26 new drugs approved so far in 2019  have helped the big drug giants to do well this year despite broader macro issues or the industry s own challenges  The industry is likely to perform well even if the global economy slows in the remainder of the year  as is widely expected  This is because it is a defensive sector  which is almost insulated from broader macroeconomic factors  Also  the spate of pharma M A deal announcements this year so far has provided impetus to drug stocks Meanwhile  most big pharma companies are resorting to restructuring activities  which is increasing their financial capacity  The funds can be used to re stock pipelines with promising new drug candidates bought from smaller innovative drug biotech companies However  the sector faces its share of headwinds like government scrutiny of high drug prices  pricing and competitive pressure  generic competition for blockbuster treatments  slowdown in sales of some of the most high profile older drugs and most importantly major pipeline setbacks Nonetheless  we believe pipeline success  cost cutting  share buybacks  product launches  increased M A and collaboration activity and appropriate utilization of cash should keep the sector afloat through the rest of this year In this scenario  investing in stocks with a large market cap is a prudent move  given the fact that they control a large portion of the industry Here we have highlighted three bigshot drugmakers  which may prove to be good buys  All these stocks carry a Zacks Rank  1  Strong Buy  or  2  Buy   have outperformed the industry this year and witnessed positive estimate revisions in the past 60 days You can see  A chart showing the share price movement of the three stocks and the Large Cap Pharmaceuticals industry this year so far is given below   3 Stocks to BuyMerck   NYSE MRK  Shares of Merck have risen 13 2  this year so far  Earnings estimates for 2019 and 2020 have risen 3 2  and 1 3   respectively over the past 60 days  Merck has a Zacks Rank  2 A significant part of Merck s outperformance this year so far has been driven by strong performance of its PD 1 inhibitor  Keytruda and positive regulatory updates related to it  Keytruda is continuously growing and expanding into new indications and markets globally  The drug generated sales of almost  5 billion in the first half of 2019  reflecting a massive 56 6  surge year over year The Keytruda development program is also progressing well with Merck spending billions for research and development of this medicine to secure more approvals in earlier lines of treatment  Undoubtedly  Keytruda has strong future growth prospects based on increased utilization  approval for new indications and expectation of additional approvals worldwide  In addition to Keytruda  Merck s other new products  Lynparza  and Bridion are contributing meaningfully to its top line Merck gained FDA approval for its new combination antibacterial injection  Recarbrio  a fixed combination of relebactam with imipenem cilastatin  and a new indication   two types of pneumonia infections   for its antibacterial medicine  Zerbaxa  It also gained several label expansion approvals for PARP inhibitor Lynparza  for which it has partnership with AstraZeneca   NYSE AZN   Merck has also been on a strong footing in terms of collaborations and M A activity  Meanwhile  Merck s animal health and vaccine products are also performing strongly and remain core growth drivers Roche   OTC RHHBY  Roche s earnings estimates have increased 3 7  for 2019 and 5 3  for 2020 over the past 60 days  The company s shares have increased 10 4  this year so far  Roche is a  1 Ranked stock Roche has gained regulatory approvals for label expansions of its PD L1 inhibitor  Tecentriq  leukemia drug  Venclexta  rheumatoid arthritis drug  MabThera and hemophilia drug  Hemlibra this year  These approvals have expanded the eligible patient population for these drugs  mainly Tecentriq  which can drive sales of Roche higher in the future quarters  Earlier this month  Roche gained FDA approval for personalized medicine Rozlytrek  entrectinib  for the treatment of adults with ROS1 positive  metastatic non small cell lung cancer Moreover  the pending acquisition of Spark will enable Roche to gain a foothold in the promising gene therapy space as it faces stiff competition from biosimilars of key drugs such as Avastin  Rituxan and Herceptin  Meanwhile  the company continues to progress with its pipeline  It is looking to restructure the portfolio beyond oncology into multiple sclerosis and hemophilia  among othersNovartis   NYSE NVS  Novartis  earnings estimates have increased 2 8  for 2019 and 3 1  for 2020 over the past 60 days  Novartis stock has returned 3 7  so far in 2019  Novartis has a Zacks Rank of 2 Novartis has a strong oncology portfolio of drugs like Afinitor  Exjade  Jakavi  Zykadia  Tasigna  Promacta and Jadenu  Solid performance of new drugs like Cosentyx  Entresto and Lutathera has boosted results in recent times  The strong uptake of biosimilars boosted performance of the generic division  Sandoz  and offset the weakness in generics  New launches like Zolgensma and Piqray should further bolster performance in the second half of the year  Novartis has restructured the business to focus on becoming a core drug focused company  The company earlier spun off its eye care unit  Alcon  into a new company in order to grow as a medicines company solely Large Cap Pharmaceuticals Industry 5YR   Return
  
Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ",2019-08-28,Zacks Investment Research,https://www.investing.com/analysis/forget-pfizer-add-these-big-drugmakers-to-your-portfolio-200459960,200459960
196889,418405,MYL,Momenta  MNTA  Up 10  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Momenta Pharmaceuticals  MNTA   Shares have added about 10  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Momenta due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Momenta Q2 Loss Wider Than Expected  Revenues MissThe company reported a loss of  1 16 per share in the quarter  wider than the Zacks Consensus Estimate of a loss of 42 cents and the year ago quarter s loss of 91 cents Revenues in the quarter came in at  5 2 million  which declined from  13 0 million in the year ago quarter and missed the Zacks Consensus Estimate of  9 million Quarter in DetailMomenta s top line comprises product revenues of  3 3 million from Sandoz s sales of Glatopa  a generic version of Copaxone  20 mg   which decreased from  11 8 million in the year ago quarter due to increasing competition from Mylan s entry into the Copaxone market Research and development revenues came in at  1 8 million compared with  1 3 million in the year ago quarter Research and development expenses came in at  32 1 million  up from  31 3 million in the year ago quarter  due to lower personnel costs General and administrative expenses were  46 6 million  up 107  year over year due to  21 0 million paid to Amphastar in June 2019 Pipeline UpdateMomenta s novel auto immune portfolio includes M230  a Selective Immunomodulator of Fc receptors  SIF3   Nipocalimab  M281   an anti FcRn monoclonal antibody  and M254  a hypersialylated immunoglobulin designed as a high potency alternative for intravenous immunoglobulin  IVIg  Momenta recently commenced an adaptive phase II III clinical study of nipocalimab in warm autoimmune hemolyticannemia  wAIHA   The FDA accepted its Investigational New Drug  IND  application for the same and granted it Fast Track designation  Clinical sites are currently being activated and patient recruitment is underway  Momenta expects to report top line data from this study by the end of 2021  Vivacity MG  the phase II study of nipocalimab in generalized myasthenia gravis  gMG   continues to open sites and enroll patients  The top line data is expected in the second or third quarter of 2020 Unity  the phase II study of nipocalimab in hemolytic disease of the fetus and newborn  HDFN   continues to open sites and enroll patients  Top line data is expected in 2021  The candidate has been granted Fast Track designation by the FDA for this indication In January 2019  Momenta announced that the first subject was dosed in the phase I II clinical trial of M254 in immune thrombocytopenia  ITP   The multi part study has completed Part A  which evaluated M254 in a single ascending dose  SAD  cohort of healthy volunteers  and has advanced into Part B  which will evaluate M254 in a SAD cohort of ITP patients  Parts C and D include a randomized cross over study comparing M254 to IVIg and a multiple ascending dose  MAD  study of M254  respectively  Enrollment for this trial is ongoing and preliminary data is expected in the first half of 2020 The phase I trial on M230 in healthy volunteers to evaluate the safety and tolerability is ongoing  Momenta s partner  CSL  expects to complete the phase I study by the end of 2019 Momenta has ceased active development of M923  a fully owned proposed biosimilar to AbbVie s Humira  due to changes in the market opportunity associated with the drug s patent litigation settlements  Meanwhile  M710  which is a proposed biosimilar to Regeneron s Eylea  is being developed in collaboration with Mylan  NASDAQ MYL  2019 GuidanceMomenta expects 2019 expenses to be  45  55 million    
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  22 13  due to these changes 
VGM Scores
Currently  Momenta has a poor Growth Score of F  a grade with the same score on the momentum front  Following the exact same course  the stock was allocated a grade of F on the value side  putting it in the bottom 20  quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  It s no surprise Momenta has a Zacks Rank  5  Strong Sell   We expect a below average return from the stock in the next few months ",2019-08-31,Zacks Investment Research,https://www.investing.com/analysis/momenta-mnta-up-10-since-last-earnings-report-can-it-continue-200460652,200460652
196890,418406,MYL,Acorda  ACOR  Down More Than 60  In 3 Months  Here s Why,opinion,Shares of Acorda Therapeutics  Inc    NASDAQ ACOR   have declined sharply in the past three months  The stock has plunged 65 1   significantly wider than the  decrease of 3 5  Acorda s lead multiple sclerosis  MS  drug Ampyra is facing generic competition in the United States  Notably  during the first half of 2019  sales of Ampyra tanked significantly year over year due to generic launches  Last September  Ampyra lost its exclusivity as generics entered the market including Mylan s   NASDAQ MYL   authorized generic version However  Ampyra s sales were higher than the company s internal projections in the second quarter because sales erosion due to generic launches was less severe  Meanwhile  the company still believes that Ampyra sales will see a sharp fall moving ahead Acorda is heavily dependent on Ampyra to draw major part of its revenues and losing out on the same in the upcoming quarters will thus be a major blow to the company s top line Meanwhile  Acorda s Parkinson disease  PD  drug Inbrija  launched in February this year  generated sales of  3 million in the second quarter  reflecting a significant sequential increase  The company believes that Inbrija sales will pick up in the future quarters  having received an encouraging feedback from doctors as well as patients since its launch Notably  last December  the FDA approved Inbrija  Following this nod  the product became the first and the only approved inhaled levodopa for treating OFF periods in patients suffering Parkinson s and receiving a carbidopa   levodopa regimen In July 2019  the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  rendered a positive opinion recommending the approval of Inbrija in Europe  A final decision is expected by this year end We would like to remind investors that the successful commercialization of Inbrija is imperative to Acorda s long term growth  especially as generic competition looms large on Ampyra  Although Inbrija is off to a promising start  it still remains to be seen if the product can deliver the desired results and be a worthy replacement for Ampyra in the long run Notably  more than 3 50 000 people in the United States are suffering OFF periods related to Parkinson s disease  Acorda estimates Inbrija s market opportunity to be more than  800 million in the United States Although Inbrija is pretty new to the market  the drug s successful commercialization along with its sales uptick should help the stock recover in the days ahead Acorda Therapeutics  Inc  Price   Zacks Rank   Other Stocks to ConsiderAcorda currently sports a Zacks Rank  1  Strong Buy   Other top ranked stocks in the healthcare sector include Emmaus Life Sciences  Inc    NASDAQ EMMA   and NuCana PLC   NASDAQ NCNA    both sporting the same solid Zacks Rank as Acorda  You can see  Emmaus Life s loss per share estimates have been narrowed 17 8  for 2019 and 26 4  for 2020 over the past 60 days NuCana s loss per share estimates have been narrowed 17 5  for 2019 and 16  for 2020 over the past 60 days Legalizing THIS Could Be Even Bigger than MarijuanaAmericans spend an estimated  150 billion in this industry every year  more than twice as much as theyspend on marijuana Now that 8 states have fully legalized it  with several more states following close behind   Zacks hasidentified 5 stocks that could soar in response to the powerful demand  One industry insider describedthe future as  mind blowing    and early investors can still get in ahead of the surge ,2019-09-02,Zacks Investment Research,https://www.investing.com/analysis/acorda-acor-down-more-than-60-in-3-months-heres-why-200461097,200461097
196897,418413,MYL,Premarket analyst action   healthcare,news,Gilead Sciences  NASDAQ GILD  resumed with Hold rating and  93  12  upside  price target by Jefferies  Shares are up a fraction premarket Intercept Pharmaceuticals  NASDAQ ICPT  downgraded to Market Perform by JMP Securities  Shares down 2  premarket on light volume Verex Imaging  NASDAQ VREX  downgraded to Underweight with a  33  5  downside risk  price target by JPMorgan  NYSE JPM  Mylan N V   NASDAQ MYL  price target raised to  45  38  upside  from  42 by BTIG Research after FDA OK of generic Copaxone 40 mg  Shares are up 16  premarket on robust volume RedHill Biopharma  NASDAQ RDHL  price target raised to  36  283  upside  from  33 by H C  Wainwright based on data from Phase 2 study of Bekinda in IBS D  Shares up 3  premarket on light volume Now read ,2017-10-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-analyst-action--healthcare-536713,536713
196898,418414,MYL,Premarket Losers as of 9 05 am,news,CLSN  31  MNTA  23  on FDA s approval of Mylan  NASDAQ MYL  s 40 mg version of Copaxone SBBP  17  on announcing proposed public offering of ordinary shares ECYT  15  TEVA  12   on FDA s approval of Mylan s 40 mg version of Copaxone ODP  10  on buying Compucom for about  1B ANTH  8  RIGL  6  on launching  40M stock offering MBI  7  on president Trump wiping out Puerto Rico debt ETRM  5   Now read ,2017-10-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/premarket-losers-as-of-905-am-536706,536706
196899,418415,MYL,Cowen bearish on Teva after FDA nod for Mylan s generic Copaxone,news,Cowen s Ken Cacciatore says investors should avoid Teva Pharmaceutical Industries  TEVA  14   citing a  painful nightmare scenario  on the heels of the FDA s OK of Mylan s  MYL  19 7   generic version of top seller Copaxone He has cut his price target to  18 from  30  although shares are currently exchanging hands at   16  adding that  deep value  investors may jump on board if shares dip to the  10   13 range Best case scenario has TEVA maintaining   3 5B in cash flow next year Source  BloombergNow read ,2017-10-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/cowen-bearish-on-teva-after-fda-nod-for-mylans-generic-copaxone-536770,536770
196900,418416,MYL,Healthcare   Top 5 Gainers   Losers as of 11 00 am,news,Gainers  MYL  20   NLNK  16   CTMX  16   SNSS  14   MNKD  13  Losers  CLSN  23   SBBP  18   MNTA  18   TEVA  14   KOOL  10  Now read ,2017-10-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/healthcare--top-5-gainers--losers-as-of-1100-am-536797,536797
196901,418417,MYL,Israel stocks lower at close of trade  TA 35 down 0 29 ,news,"Investing com   Israel stocks were lower after the close on Wednesday  as losses in the Oil   Gas  Communication and Biomed sectors led shares lower 
At the close in Tel Aviv  the TA 35 fell 0 29  
The best performers of the session on the TA 35 were Harel  TA HARL   which rose 2 68  or 65 points to trade at 2487 at the close  Meanwhile   Bazan  Oil Refineries Ltd  TA ORL  added 1 73  or 3 1 points to end at 182 3 and Mylan NV  TA MYL  was up 1 41  or 190 points to 13670 in late trade 
The worst performers of the session were  Delek Group   TA DLEKG   which fell 5 39  or 3270 points to trade at 57350 at the close  Teva Pharmaceutical Industries Ltd  TA TEVA  declined 4 11  or 209 points to end at 4870 and Delek Drilling LP  TA DEDRp  was down 3 52  or 35 points to 960 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 237 to 168 and 13 ended unchanged 
Shares in Harel  TA HARL  rose to 5 year highs  up 2 68  or 65 to 2487  Shares in Delek Group  TA DLEKG  fell to 5 year lows  down 5 39  or 3270 to 57350  Shares in Teva Pharmaceutical Industries Ltd  TA TEVA  fell to 5 year lows  down 4 11  or 209 to 4870  Shares in Delek Drilling LP  TA DEDRp  fell to 5 year lows  losing 3 52  or 35 to 960  
Crude oil for December delivery was down 0 65  or 0 34 to  52 13 a barrel  Elsewhere in commodities trading  Brent oil for delivery in December fell 0 15  or 0 09 to hit  58 24 a barrel  while the December Gold Futures contract rose 0 01  or 0 11 to trade at  1278 41 a troy ounce 
USD ILS was up 0 06  to 3 5071  while EUR ILS rose 0 40  to 4 1421 
The US Dollar Index Futures was down 0 33  at 93 52 ",2017-10-25,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-029-547552,547552
196909,418425,MYL,Theravance  TBPH  Q2 Loss Narrower  Revenues Beat Estimates,opinion,"Theravance Biopharma  Inc    NASDAQ TBPH   incurred a loss of 72 cents per share in second quarter 2019  narrower than the Zacks Consensus Estimate of a loss of  1 22 but wider than the year ago quarter s loss of 76 cents 
Total revenues of  26 2 million in the quarter exceeded the Zacks Consensus Estimate of  14 million  Revenues also increased 11 5  year over year  The increase was mainly due to licensing revenues of  18 5 million received from Mylan as an upfront payment related to the expansion of their present development and commercialization agreement for Yupelri to include China and certain adjacent territories 
In November 2018  Theravance completed the sale of its only marketed drug  Vibativ  to Cumberland Pharmaceuticals  As a result  the company was not able to generate any revenues from product sales in the second quarter of 2019  Collaboration revenues were  7 7 million in the quarter 
Shares of Theravance have lost 18 5  in the year so far versus the  growth of 7 8  

 
Research   development expenses were  46 4 million  down 4 5  from the year ago quarter  primarily due to lower employee related expenses and a decrease in share based compensation 
Selling  general   administrative expenses declined 11 2  to  22 2 million due to lower Vibativ related external expenses and lower share based compensation 
Product   Pipeline Updates
Theravance has collaborated with Mylan   NASDAQ MYL   for the development and commercialization of Yupelri  revefenacin  as the maintenance treatment for adults with chronic obstructive pulmonary disease  COPD   which was approved by the FDA last November 
The company stated that  in the second quarter  Yupelri witnessed strong customer acceptance and brand performance across key market metrics 
Notably  Theravance has an economic interest in royalties earned from GlaxoSmithKline   NYSE GSK   on triple combination COPD treatment Trelegy Ellipta s global sales  In the second quarter of 2019  Glaxo recorded sales of 151 4 millionfrom Trelegy Ellipta  Theravance is eligible to receive 5 5 8 5   tiered  of the product s worldwide net sales 
The company also has a collaboration agreement with Johnson   Johnson s   NYSE JNJ   subsidiary  Janssen  to develop its JAK inhibitor  TD 1473  for the treatment of inflammatory intestinal diseases  A phase II study on TD 1473 for treating Crohn s disease and a phase IIb III study for ulcerative colitis are ongoing 
Theravance is evaluating ampreloxetine  TD 9855  in a phase III program for treating patients with symptomatic neurogenic orthostatic hypotension  nOH  
The company is also developing inhaled  lung selective pan Janus kinase  JAK  inhibitor  TD 8236  in a phase I study for the treatment of various serious respiratory diseases  The company plans to provide the biomarker data of TD 8236 in the third quarter of 2019 after evaluating healthy volunteers and asthma patients 
2019 Outlook
For 2019  Theravance anticipates operating loss excluding non cash share based compensation to be  210  230 million  unchanged from the previous guidance Theravance Biopharma  Inc  Price  Consensus and EPS Surprise

   
 
Zacks Rank
Theravance currently carries a Zacks Rank  4  Sell   You can see  
Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/theravance-tbph-q2-loss-narrower-revenues-beat-estimates-200449489,200449489
196910,418426,MYL,Acorda  ACOR  Q2 Earnings And Revenues Surpass Estimates,opinion,Acorda Therapeutics  Inc    NASDAQ ACOR   reported second quarter 2019 loss per share of 55 cents  narrower than the Zacks Consensus Estimate of a loss of  1 06  However  the figure came in against the year ago earnings of  1 40 Meanwhile  the company generated total revenues of  50 1 million in the second quarter  comprehensively beating the Zacks Consensus Estimate of  26 2 million  However  sales tumbled 67 3  year over year due to lower sales of multiple sclerosis  MS  drug Ampyra Shares of Acorda have plunged 61  so far this year  outperforming the  decrease of 0 4  Quarter in DetailInbrija generated sales of  3 million in the reported quarter  reflecting a significant sequential increase Notably  last December  the FDA approved Acorda s Parkinson s disease  PD  drug Inbrija  Following this nod  the product became the first and the only approved inhaled levodopa for treating OFF periods in patients suffering Parkinson s and receiving a carbidopa   levodopa regimen  Inbrija was launched in February this year Last month  the European Medicines Agency s  EMA  Committee for Medicinal Products for Human Use  CHMP  rendered a positive opinion recommending the approval of Inbrija in Europe  A final decision is expected by the end of 2019 The company believes that Inbrija sales will pick up in the future quarters  having received an encouraging feedback  both from doctors and patients since its launch  An approximately 4 500 prescription request forms for Inbrija were received through July 2019 Although majority of Acorda s net product revenues were drawn from the company s MS drug Ampyra  which raked in sales of  44 2 million in the quarter  the sales figure nonetheless suffered a huge 70 6  slump year over year due to generic competition  However  sales improved 10 2  sequentially  On a positive note  Ampyra sales were higher than the company s internal projections in the second quarter because sales erosion due to generic launches was less severe Last September  Ampyra lost its exclusivity as generics entered the market including Mylan s   NASDAQ MYL   authorized generic version  Consequently  Acorda believes that Ampyra sales will see a sharp decline in the quarters ahead in 2019 Meanwhile  royalty revenues were  2 8 million in the quarter  almost in line with the year ago reported figure Acorda s research and development  R D  expenses  excluding share based compensation expenses  were  18 2 million  down 25 4  year over year Selling  general and administrative  SG A  expenses  excluding share based compensation expenses  were  46 7 million  up 15  year over year Acorda had  296 9 million cash  cash equivalents and investments as of Jun 30  2019 compared with  343 3 million as of Mar 31  2019 We would like to remind investors that the successful commercialization of Inbrija is imperative for long term growth at Acorda  especially as generic competition looms large on Ampyra  Although Inbrija is off to a promising start  it still remains to be seen if the product can deliver the desired results and be a worthy replacement for Ampyra in the long run Notably  more than 350 000 people in the United States are suffering OFF periods related to Parkinson s disease  Acorda estimates Inbrija s market opportunity to be more than  800 million in the United States 2019 GuidanceAcorda expects Ampyra revenues to exceed  140 million for the full year  Previously  the company decided not to provide any outlook for Ampyra due to its waning revenues  induced by the entrance of generics The company expects full year R D and SG A expenses  excluding share based compensation  in the band of  70  80 million and  200  210 million  respectively Acorda Therapeutics  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Other Stocks to ConsiderAcorda currently sports a Zacks Rank  1  Strong Buy   Other top ranked stocks from the healthcare sector include Merus N V    NASDAQ MRUS   and Repligen Corporation   NASDAQ RGEN    both carrying a Zacks Rank of 1  You can see  Merus  loss per share estimates have been narrowed 9 1  for 2019 and 9 2  for 2020 over the past 60 days  The stock has rallied 15 2  so far this year Repligen s earnings estimates have been revised 4 3  upward for 2019 and 3 6  for 2020 over the past 60 days  The stock has soared 81 1  year to date Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-08-01,Zacks Investment Research,https://www.investing.com/analysis/acorda-acor-q2-earnings-and-revenues-surpass-estimates-200450099,200450099
196911,418427,MYL,Momenta  MNTA  Q2 Loss Wider Than Expected  Revenues Miss,opinion,Shares of Momenta Pharmaceuticals Inc    NASDAQ MNTA   gained 1 8  on Aug 2 even though the company reported a wider than expected loss and missed revenue estimates in the second quarter Momenta s stock has gained 5 9  in the year so far  against the  decline of 1 7   The company reported a loss of  1 16 per share in the quarter  wider than the Zacks Consensus Estimate of a loss of 42 cents and the year ago quarter s loss of 91 cents Revenues in the quarter came in at  5 2 million  which declined from  13 0 million in the year ago quarter and missed the Zacks Consensus Estimate of  9 million Quarter in DetailMomenta s top line comprises product revenues of  3 3 million from Sandoz s sales of Glatopa  a generic version of Copaxone  20 mg   which decreased from  11 8 million in the year ago quarter due to increasing competition from Mylan s   NASDAQ MYL   entry into the Copaxone market Research and development revenues came in at  1 8 million compared with  1 3 million in the year ago quarter Research and development expenses came in at  32 1 million  up from  31 3 million in the year ago quarter  due to lower personnel costs General and administrative expenses were  46 6 million  up 107  year over year due to  21 0 million paid to Amphastar in June 2019 Pipeline UpdateMomenta s novel auto immune portfolio includes M230  a Selective Immunomodulator of Fc receptors  SIF3   Nipocalimab  M281   an anti FcRn monoclonal antibody  and M254  a hypersialylated immunoglobulin designed as a high potency alternative for intravenous immunoglobulin  IVIg  Momenta recently commenced an adaptive phase II III clinical study of nipocalimab in warm autoimmune hemolyticannemia  wAIHA   The FDA accepted its Investigational New Drug  IND  application for the same and granted it Fast Track designation  Clinical sites are currently being activated and patient recruitment is underway  Momenta expects to report top line data from this study by the end of 2021  Vivacity MG  the phase II study of nipocalimab in generalized myasthenia gravis  gMG   continues to open sites and enroll patients  The top line data is expected in the second or third quarter of 2020 Unity  the phase II study of nipocalimab in hemolytic disease of the fetus and newborn  HDFN   continues to open sites and enroll patients  Top line data is expected in 2021  The candidate has been granted Fast Track designation by the FDA for this indication In January 2019  Momenta announced that the first subject was dosed in the phase I II clinical trial of M254 in immune thrombocytopenia  ITP   The multi part study has completed Part A  which evaluated M254 in a single ascending dose  SAD  cohort of healthy volunteers  and has advanced into Part B  which will evaluate M254 in a SAD cohort of ITP patients  Parts C and D include a randomized cross over study comparing M254 to IVIg and a multiple ascending dose  MAD  study of M254  respectively  Enrollment for this trial is ongoing and preliminary data is expected in the first half of 2020 The phase I trial on M230 in healthy volunteers to evaluate the safety and tolerability is ongoing  Momenta s partner  CSL  expects to complete the phase I study by the end of 2019 Momenta has ceased development of M923  a fully owned proposed biosimilar to AbbVie s   NYSE ABBV   Humira  due to changes in the market opportunity associated with the drug s patent litigation settlements  Meanwhile  M710  which is a proposed biosimilar to Regeneron s   NASDAQ REGN   Eylea  is being developed in collaboration with Mylan 2019 GuidanceMomenta expects 2019 expenses to be  45  55 million Our TakeThe company s second quarter results were dismal  The generic business has been adversely impacted by competition  Momenta has decided to focus on the discovery and development of novel drugs to treat rare  immune mediated disorders  The generic business is no longer a key area for the company  The company has narrowed its focus on its biosimilars portfolio Hence  Momenta is now focussing on its novel drugs portfolio  We expect investors to focus on further updates from the drug candidates in development as the year progress Zacks RankMomenta currently carries a Zacks Rank  3  Hold   You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ,2019-08-04,Zacks Investment Research,https://www.investing.com/analysis/momenta-mnta-q2-loss-wider-than-expected-revenues-miss-200450892,200450892
196912,418428,MYL,Should Value Investors Pick Mylan N V   MYL  Stock ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Mylan N V    NASDAQ MYL   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Mylan N V  has a trailing twelve months PE ratio of 4 48  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 compares in at about 17 75  If we focus on the stock s long term PE trend  the current level puts Mylan N V   current PE ratio slightly below its midpoint  which is 8 76  over the past five years Further  the stock s PE compares favorably with the Zacks Medical sector s trailing twelve months PE ratio  which stands at 19 98  At the very least  this indicates that the stock is relatively undervalued right now  compared to its peers We should also point out that Mylan N V  has a forward PE ratio  price relative to this year s earnings  of just 4 45  so it is fair to say that a slightly more value oriented path may be ahead for Mylan N V   stock in the near term too   P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Mylan N V  has a P S ratio of about 0 90  This is significantly lower than the S P 500 average  which comes in at 3 15 right now  Also  as we can see in the chart below  this is somewhat below the highs for this stock in particular over the past few years If anything  this suggests some level of undervalued trading at least compared to historical norms    Broad Value OutlookIn aggregate  Mylan N V  currently has a Value Style Score of A  putting it into the top 20  of all stocks we cover from this look  This makes MYL a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  the P CF ratio  another great indicator of value  comes in at 2 20  which is slightly better than the industry average of 3 78  Clearly  MYL is a solid choice on the value front from multiple angles What About the Stock Overall Though Mylan N V  might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth grade of C and a Momentum score of A  This gives MYL a VGM score or its overarching fundamental grade of A   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter has seen two estimates go higher in the past sixty days and three lower  while the full year estimate has seen three upward and four downward revisions in the same time period This has had a noticeable impact on the consensus estimate  as the current quarter consensus estimate has fallen 1 7  in the past two months  while the full year estimate has inched up 0 5   You can see the consensus estimate trend and recent price action for the stock in the chart below Mylan N V  Price and Consensus    This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineMylan N V  is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  Moreover  a strong industry rank  top 26  out of more than 250 industries  further supports the growth potential of the stock  However  with a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past one year  the sector has clearly underperformed the broader market  as you can see below So  value investors might want to wait for estimates  analyst sentiment and industry trend to turn favorable in this name first  but once that happens  this stock could be a compelling pick Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-08-13,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-pick-mylan-nv-myl-stock-200455103,200455103
196913,418429,MYL,Company News For Aug 15  2019,opinion,Wayfair Inc  s   NYSE W   shares plummeted 10 4  after the company decided to offer  750 million of new debtMylan N V    NASDAQ MYL   tumbled 8 5  after two U S  lawmakers want more proof from the compny over alleged drug pricing probeMacy s Inc  s   NYSE M   shares plunged 13 2  after the company reported second quarter 2019 adjusted earnings per share of  0 28  missing the Zacks Consensus Estimate of  0 45Shares of CAE Inc    TSX CAE   declined 5  after posting first quarter fiscal 2019 adjusted earnings per share of  0 18  lagging the Zacks Consensus Estimate of  0 20,2019-08-14,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-aug-15-2019-200455481,200455481
196917,418433,MYL,Israel stocks lower at close of trade  TA 35 down 0 36 ,news,"Investing com   Israel stocks were lower after the close on Tuesday  as losses in the Communication  Technology and Biomed sectors led shares lower 
At the close in Tel Aviv  the TA 35 declined 0 36  
The best performers of the session on the TA 35 were  Isramco  Negev 2 LP  TA ISRAp   which rose 2 02  or 1 0 points to trade at 50 6 at the close  Meanwhile   Israel Corp   TA ILCO  added 1 56  or 1090 points to end at 71040 and Harel  TA HARL  was up 1 43  or 30 points to 2128 in late trade 
The worst performers of the session were Teva Pharmaceutical Industries Ltd  TA TEVA   which fell 2 89  or 181 points to trade at 6080 at the close   Frutarom  Industries Ltd  TA FRUT  declined 2 68  or 800 points to end at 29000 and Mylan NV  TA MYL  was down 2 04  or 230 points to 11060 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 244 to 164 and 14 ended unchanged 
Crude oil for November delivery was down 0 42  or 0 21 to  50 14 a barrel  Elsewhere in commodities trading  Brent oil for delivery in November fell 0 45  or 0 25 to hit  55 23 a barrel  while the December Gold Futures contract rose 0 22  or 2 91 to trade at  1313 71 a troy ounce 
USD ILS was down 0 40  to 3 5123  while EUR ILS fell 0 17  to 4 2078 
The US Dollar Index Futures was down 0 16  at 91 66 ",2017-09-19,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-036-530499,530499
196918,418434,MYL,Exclusive  Africa to get state of art HIV drugs for  75 a year,news,"By Kate Kelland and Ben Hirschler LONDON  Reuters    Makers of generic AIDS drugs will start churning out millions of pills for Africa containing a state of the art medicine widely used in rich countries  after securing a multi million dollar guarantee that caps prices at just  75 per patient a year   Global health experts hope the deal will help address two looming problems in the HIV epidemic   the rising threat of resistance developing to standard AIDS drugs  and the need for more investment in manufacturing capacity   Bill Gates  charitable foundation will guarantee minimum sales volumes of the new combination pills using dolutegravir  a so called integrase inhibitor that avoids the drug resistance that often develops with older treatments   In return the drugmakers  India based Mylan Laboratories  O MYL  and  Aurobindo Pharma   NS ARBN   will agree the maximum price of about  75 per patient for a year s supply   less than the list price for one day s supply of a dolutegravir combination in the United States  The agreement  which will make the treatment available to 92 poor countries  starting in Africa  will be formally announced during the United Nations General Assembly in New York on Thursday   We need to make that guarantee because  of  the fixed costs of everybody gearing up to make high volume   Gates told Reuters in a telephone interview   That just wasn t going to happen unless we put forward a very substantial volume guarantee   The Bill   Melinda Gates Foundation s pledge is a central plank of a new partnership   the largest of its kind in global health   that also includes the governments of South Africa and Kenya  the Clinton Health Access Initiative  and American  British and U N  agencies   Under the deal  Mylan and Aurobindo will ramp up availability of a new fixed dose combination of tenofovir disoproxil fumarate  lamivudine and dolutegravir  TLD    Health ministries and other public sector purchasers will be able to buy TLD from next year at the capped price  The agreement could potentially save them more than  1 billion in drug bills over the next six years  the partners estimate   As well as improving treatment  the drug combination should also reduce the need for more expensive second  and third line drugs   TREATMENT AND RESISTANCE  Around 37 million people around the world are infected with HIV  according to the United Nations AIDS agency UNAIDS  Just over half of them   about 19 5 million patients   get antiretroviral therapy medicines to keep their disease in check  That represents remarkable progress in the past 20 years  driven by the availability of a first wave of cheap generic drugs from Indian companies  But rising levels of drug resistance are now a growing concern  while low prices have cut the incentive for investment in generic drug making capacity  In six out of 11 countries surveyed recently in Africa  Asia and Latin America  researchers found that more than 10 percent of HIV patients starting antiretroviral drugs had a strain of HIV resistant to the most widely used medicines  Once the 10 percent threshold is reached  best practice calls for switching to different drug regimens  Dolutegravir is already being used on a limited basis as a single drug in Kenya  Nigeria  and Uganda  The drug was originally developed by ViiV Healthcare  the HIV business majority owned by GlaxoSmithKline  L GSK   ViiV has offered licensing deals to generic companies to sell low cost versions of the medicine in poor countries  Clinical trials have shown that treatment regimens including dolutegravir work faster  have fewer side effects and demonstrate greater potency against drug resistance than standard HIV drugs used in Africa and other poor countries  The TLD combination pill developed by Mylan and Aurobindo has already received tentative approval from the U S  Food and Drug Administration under the President s Emergency Plan for AIDS Relief program  In Western markets  makers of patented AIDS drugs  such as GSK and arch rival Gilead Sciences  O GILD   notch up billions of dollars of highly profitable sales each year   But the picture is very different for low price generic companies in India  which have very low margins   The market is always on the edge where these guys don t make enough money to stay in the business   said Gates  With the HIV positive population still growing   there were an estimated 1 8 million new cases of infection in 2016   the number of patients needing treatment is steadily increasing   Industry experts like Johnson   Johnson  N JNJ  Chief Scientific Officer Paul Stoffels question the feasibility of maintaining lifelong treatment for a patient population that could reach 50 million  
 The people who are infected today will need therapy for the next 30 to 50 years  so the science of treatment has to evolve and the science of prevention has to evolve as well to stop the pool of patients growing   he told Reuters in a recent interview ",2017-09-21,Reuters,https://www.investing.com/news/stock-market-news/exclusive-africa-to-get-stateofart-hiv-drugs-for-75-a-year-531350,531350
196919,418435,MYL,Expanded use of Roche s Gazyvaro OK d in Europe,news,The European Commission approves Roche s  OTCQX RHHBY  Gazyvaro  obinutuzumab   in combination with chemo  followed by Gazyvaro maintenance in responding patients  for treatment naive patients with advanced follicular lymphoma The approval was based on results from the GALLIUM study that showed superior progression free survival over standard of care MabThera  rituximab  based treatment This is the third approved indication for Gazyvaro in the EU  In 2014  it was approved for chronic lymphocytic leukemia  in combination with chlorambucil  and in June 2016 for follicular lymphoma  in combination with fludarabine  Now read ,2017-09-22,Seeking Alpha,https://www.investing.com/news/stock-market-news/expanded-use-of-roches-gazyvaro-okd-in-europe-531814,531814
196920,418436,MYL,Israel stocks higher at close of trade  TA 35 up 0 05 ,news,"Investing com   Israel stocks were higher after the close on Monday  as gains in the Biomed  Technology and Banking sectors led shares higher 
At the close in Tel Aviv  the TA 35 rose 0 05  
The best performers of the session on the TA 35 were Mylan NV  TA MYL   which rose 2 48  or 270 points to trade at 11150 at the close  Meanwhile   Sodastream International Ltd   TA SODA  added 2 28  or 470 0 points to end at 21100 0 and Teva Pharmaceutical Industries Ltd  TA TEVA  was up 1 69  or 101 points to 6091 in late trade 
The worst performers of the session were Alony Hetz Properties and Investments Ltd  TA ALHE   which fell 2 37  or 92 points to trade at 3794 at the close   Airport City  Ltd  TA ARPT  declined 2 35  or 107 points to end at 4452 and Partner  TA PTNR  was down 1 95  or 38 points to 1908 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 217 to 190 and 14 ended unchanged 
Crude oil for November delivery was up 1 32  or 0 67 to  51 33 a barrel  Elsewhere in commodities trading  Brent oil for delivery in December rose 1 86  or 1 05 to hit  57 47 a barrel  while the December Gold Futures contract rose 0 42  or 5 49 to trade at  1302 99 a troy ounce 
USD ILS was up 0 53  to 3 5123  while EUR ILS fell 0 23  to 4 1662 
The US Dollar Index Futures was up 0 42  at 92 34 ",2017-09-25,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-005-532476,532476
196921,418437,MYL,Stocks   U S  Futures Mixed Ahead of Employment Data  Yellen speech  ,news,"Investing com   U S  futures were mixed on Wednesday as investors wait for economic indicators that a December rate hike could be on the horizon 
The S P 500 futures fell half a point or 0 02  as of 5 52 AM ET  10 52 GMT  while Dow futures were up one point or 0 01   Tech heavy Nasdaq 100 futures was down four points or 0 07  
The medical sector was the biggest winner in pre market trades  Health care IT firm Medical Transcription Billing Corp  NASDAQ MTBC  jumped 26 26  while pharmaceutical company Mylan  NASDAQ MYL  increased 16 20  after it announced the FDA had approved a new drug used for the treatment of patients with relapsing forms of multiple sclerosis  Biopharmaceutical company  Synergy Pharmaceuticals Inc   NASDAQ SGYP  was up 6 8  
The U S  arm of Spanish bank Santander  MC SAN  was among the biggest losers before the start of the bell  falling 2 65  as the Catalan vote for independence continues to rattle Spanish banks  The region is expected to declare its independence in the next few days 
Pharmaceutical company  Momenta Pharmaceuticals  Inc  NASDAQ MNTA  also decreased 25 43  
In economic news  the ISM non manufacturing PMI  is expected to increase to 55 5 in September from 55 3 in August  due at 10AM ET  14 00GMT   The ADP nonfarm employment  for September is expected to decrease from 237 000 to 125 000 and is out at 8 15AM ET  12 15GMT   Both are seen as a precursor to Friday s jobs report 
Investors will also be listening in to Federal Reserve Chair Janet Yellen for any news on whether the Fed will increase the benchmark rate in December  Yellen is due to deliver a speech at a community banking conference hosted by the Federal Reserve Bank of St  Louis at 3 15PM ET  19 15GMT  
European stocks continued to drag on Wednesday  Spain sIBEX 35 set for its worst day in 14 months with a 2 47  fall as Spanish banks took a heavy hit  The Euro Stoxx 50 was down 0 28  while German s DAX increased 0 05  after being closed on Tuesday  France s CAC 40 was also down 0 30  
Gold futures increased 0 21  while crude oil continued to fall 0 36   The US dollar index future  which measures the greenback against a basket of six major currencies  decreased to 93 15 ",2017-10-04,Investing.com,https://www.investing.com/news/stock-market-news/us-futures-mixed-ahead-of-employment-data-yellen-speech-536582,536582
196922,418438,MYL,Mylan surges as its generic of Teva s Copaxone gets FDA nod,news," Reuters    Shares of Mylan  NASDAQ MYL  NV jumped about 17 percent in premarket trading on Wednesday after the U S  Food and Drug Administration approved the drugmaker s copycat version of Teva Pharmaceutical Industries  NYSE TEVA  Ltd s blockbuster multiple sclerosis drug  U S  listed shares of Israel based Teva were down 9 7 percent at  17 premarket on Wednesday  Mylan s shares were trading at  38 and was top gainer among S P 500 components trading before the opening bell  The drug  Copaxone  generated sales of  1 02 billion in the second quarter of this year  according to Teva s latest financial report  
The FDA on Monday said it would introduce a slew of measures to speed up bringing to market generic versions of complex drugs in an attempt to address the rising cost of pharmaceuticals in the United States ",2017-10-04,Reuters,https://www.investing.com/news/stock-market-news/mylan-surges-as-its-generic-of-tevas-copaxone-gets-fda-nod-536594,536594
196926,418442,MYL,Acorda  ACOR  To Post Q2 Earnings  What s In The Cards ,opinion,Acorda Therapeutics  Inc    NASDAQ ACOR   is scheduled to report second quarter 2019 results on Aug 1  after the market closes Acorda has an excellent earnings surprise history  surpassing expectations in each of the trailing four quarters  the average being 79 32   In the last reported quarter  the company delivered a positive surprise of 42 27  Shares of Acorda have plunged 56 2  so far this year against the  rise of 0 3  Let s see how things are shaping up for this announcement Factors to ConsiderLast December  the FDA approved Acorda s Parkinson s disease  PD  drug Inbrija  Following this nod  the product became the first and the only approved inhaled levodopa for the treatment of OFF periods in patients suffering Parkinson s and receiving a carbidopa   levodopa regimen  The drug was launched in February this year and registered its first sales in the last reported quarter  It is also under review in Europe with a decision expected before 2019 end In the first quarter of 2019  Inbrija generated sales of  1 3 million  Acorda believes that Inbrija sales will pick up in the future quarters as well  having received an encouraging feedback both from doctors and patients since its launch  An approximately 2 000 prescription request forms for Inbrija were received through April 2019  We expect this positive trend to get reflected in the upcoming quarterly results However  Acorda s key multiple sclerosis drug Ampyra is facing a generic competition  which is significantly hurting the company s top line  Notably  in the first quarter of 2019  sales of Ampyra tanked 61  year over year and 37 5  sequentially due to generic launches Mylan   NASDAQ MYL   launched its authorized generic version of Ampyra last September after the U S  Court of Appeals invalidated four patents of Ampyra  Acorda believes that Ampyra sales will see a sharp decline in the future quarters during 2019  We expect management to provide an update on the same during the upcoming earnings call Although Inbrija is off to a promising start  it still remains to be seen if the product can deliver the desired results and be a worthy replacement for Ampyra in the long run  Acorda estimates Inbrija s market opportunity to be more than  800 million in the United States Earnings WhispersOur proven model does not conclusively show that Acorda is likely to beat estimates this quarter to be reported  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat on earnings  But that is not the case here as you will see below Earnings ESP  Acordahas an Earnings ESP of  9 01   representing the percentage difference between the Most Accurate Estimate of a loss of  1 15 and the Zacks Consensus Estimate of a loss of  1 06  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Acorda sports a Zacks Rank of 1  which increases the predictive power of ESP  However  its negative ESP in the combination leaves surprise prediction inconclusive We caution against the Sell rated stocks   4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions Acorda Therapeutics  Inc  Price and EPS Surprise   Stocks That Warrant a LookHere are some biotech stocks worth considering as our model shows that these have the right mix of elements to beat on earnings this reporting cycle Gilead Sciences  Inc    NASDAQ GILD   is scheduled to release second quarter results on Jul 30  after the market closes  The company has an Earnings ESP of  3 20  and a Zacks Rank  2  You can see  Regeneron Pharmaceuticals  Inc    NASDAQ REGN   has a Zacks Rank  3 and an Earnings ESP of  6 25   The company is scheduled to release second quarter results on Aug 6  before the market opens This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ,2019-07-24,Zacks Investment Research,https://www.investing.com/analysis/acorda-acor-to-post-q2-earnings-whats-in-the-cards-200444880,200444880
196927,418443,MYL,Mylan  MYL  Q2 Earnings And Revenues Top Estimates,opinion,"Mylan  NASDAQ MYL  came out with quarterly earnings of  1 03 per share  beating the Zacks Consensus Estimate of  0 95 per share  This compares to earnings of  1 07 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 8 42   A quarter ago  it was expected that this generic drugmaker would post earnings of  0 79 per share when it actually produced earnings of  0 82  delivering a surprise of 3 80  
Over the last four quarters  the company has surpassed consensus EPS estimates three times 
Mylan  which belongs to the Zacks Medical   Generic Drugs industry  posted revenues of  2 85 billion for the quarter ended June 2019  surpassing the Zacks Consensus Estimate by 0 97   This compares to year ago revenues of  2 81 billion  The company has topped consensus revenue estimates just once over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Mylan shares have lost about 32 6  since the beginning of the year versus the S P 500 s gain of 20 7  
What s Next for Mylan 
While Mylan has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Mylan was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 17 on  3 06 billion in revenues for the coming quarter and  4 25 on  11 65 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Generic Drugs is currently in the top 27  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-07-29,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-q2-earnings-and-revenues-top-estimates-200446287,200446287
196928,418444,MYL,Company News For Jul 30  2019,opinion,Mylan N V  s   NASDAQ MYL   shares gained 12 6  as the company reported second quarter earnings of  1 03 per share surpassing the Zacks Consensus Estimate of 95 cents Sanofi   NASDAQ SNY   shares rose 1 6  after the company reported second quarter earnings of 74 cents per American depositary share beating the Zacks Consensus Estimate of 67 cents Shares of Cooper Tire   Rubber Company   NYSE CTB   fell 9 6  as the company reported Q2 earnings of  0 18 per share  missing the Zacks Consensus Estimate of  0 51 Shares of Mercury General Corporation   NYSE MCY   declined 6 2  after the company reported second quarter earnings of  0 74 per share  missing the Zacks Consensus Estimate of  0 91 ,2019-07-29,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-jul-30-2019-200447492,200447492
196929,418445,MYL,Israel stocks higher at close of trade  TA 35 up 0 88 ,news,"Investing com   Israel stocks were higher after the close on Tuesday  as gains in the Banking  Communication and Oil   Gas sectors led shares higher 
At the close in Tel Aviv  the TA 35 gained 0 88  
The best performers of the session on the TA 35 were  Gazit Globe  Ltd  TA GZT   which rose 4 80  or 161 points to trade at 3512 at the close  Meanwhile   Cellcom Israel  Ltd  TA CEL  added 3 00  or 91 points to end at 3123 and Nice Ltd  TA NICE  was up 2 69  or 730 points to 27900 in late trade 
The worst performers of the session were Harel  TA HARL   which fell 1 00  or 21 points to trade at 2070 at the close  Mylan NV  TA MYL  declined 1 00  or 110 points to end at 10940 and Delek Drilling LP  TA DEDRp  was down 0 78  or 10 points to 1267 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 217 to 186 and 12 ended unchanged 
Shares in Mylan NV  TA MYL  fell to all time lows  losing 1 00  or 110 to 10940  
Crude oil for October delivery was up 0 88  or 0 42 to  47 95 a barrel  Elsewhere in commodities trading  Brent oil for delivery in October rose 0 97  or 0 50 to hit  52 16 a barrel  while the December Gold Futures contract fell 0 40  or 5 22 to trade at  1291 48 a troy ounce 
USD ILS was up 0 07  to 3 6207  while EUR ILS fell 0 40  to 4 2562 
The US Dollar Index Futures was up 0 44  at 93 41 ",2017-08-22,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-088-521109,521109
196930,418446,MYL,Israel stocks higher at close of trade  TA 35 up 0 72 ,news,"Investing com   Israel stocks were higher after the close on Thursday  as gains in the Biomed  Communication and Technology sectors led shares higher 
At the close in Tel Aviv  the TA 35 gained 0 72  
The best performers of the session on the TA 35 were Mylan NV  TA MYL   which rose 4 17  or 450 points to trade at 11250 at the close  Meanwhile   Delek Group   TA DLEKG  added 4 10  or 2710 points to end at 68760 and Teva Pharmaceutical Industries Ltd  TA TEVA  was up 4 01  or 224 points to 5808 in late trade 
The worst performers of the session were Paz Oil  TA PZOL   which fell 1 50  or 870 points to trade at 57020 at the close   Big  Shopping Centers Ltd  TA BIG  declined 1 33  or 340 points to end at 25260 and  Frutarom  Industries Ltd  TA FRUT  was down 1 22  or 340 points to 27520 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 255 to 150 and 9 ended unchanged 
Crude oil for October delivery was up 2 70  or 1 24 to  47 20 a barrel  Elsewhere in commodities trading  Brent oil for delivery in November rose 2 96  or 1 50 to hit  52 23 a barrel  while the December Gold Futures contract rose 0 61  or 8 08 to trade at  1322 18 a troy ounce 
USD ILS was down 0 14  to 3 5872  while EUR ILS fell 0 15  to 4 2626 
The US Dollar Index Futures was down 0 03  at 92 81 ",2017-08-31,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-072-524368,524368
196931,418447,MYL,Israel stocks higher at close of trade  TA 35 up 0 07 ,news,"Investing com   Israel stocks were higher after the close on Wednesday  as gains in the Communication  Banking and Real Estate sectors led shares higher 
At the close in Tel Aviv  the TA 35 added 0 07  
The best performers of the session on the TA 35 were Partner  TA PTNR   which rose 2 51  or 47 points to trade at 1922 at the close  Meanwhile   Israel Corp   TA ILCO  added 1 83  or 1270 points to end at 70700 and Mylan NV  TA MYL  was up 1 59  or 180 points to 11480 in late trade 
The worst performers of the session were Teva Pharmaceutical Industries Ltd  TA TEVA   which fell 2 64  or 149 points to trade at 5501 at the close  Nice Ltd  TA NICE  declined 1 28  or 360 points to end at 27670 and  Sodastream International Ltd   TA SODA  was down 1 26  or 270 0 points to 21110 0 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 228 to 179 and 8 ended unchanged 
Shares in Teva Pharmaceutical Industries Ltd  TA TEVA  fell to 5 year lows  down 2 64  or 149 to 5501  
Crude oil for October delivery was up 0 99  or 0 48 to  49 14 a barrel  Elsewhere in commodities trading  Brent oil for delivery in November rose 1 20  or 0 64 to hit  54 02 a barrel  while the December Gold Futures contract rose 0 01  or 0 10 to trade at  1344 60 a troy ounce 
USD ILS was down 0 60  to 3 5504  while EUR ILS fell 0 39  to 4 2386 
The US Dollar Index Futures was down 0 27  at 92 03 ",2017-09-06,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-007-526043,526043
196932,418448,MYL,Israel stocks higher at close of trade  TA 35 up 0 61 ,news,"Investing com   Israel stocks were higher after the close on Tuesday  as gains in the Biomed  Technology and Real Estate sectors led shares higher 
At the close in Tel Aviv  the TA 35 added 0 61  to hit a new 1 month high 
The best performers of the session on the TA 35 were Teva Pharmaceutical Industries Ltd  TA TEVA   which rose 6 99  or 444 points to trade at 6799 at the close  Meanwhile  Perrigo  TA PRGO  added 6 77  or 1990 points to end at 31370 and Mylan NV  TA MYL  was up 2 17  or 250 points to 11790 in late trade 
The worst performers of the session were Delek Drilling LP  TA DEDRp   which fell 3 95  or 42 points to trade at 1020 at the close   Cellcom Israel  Ltd  TA CEL  declined 2 77  or 94 points to end at 3304 and  Delek Group   TA DLEKG  was down 2 31  or 1510 points to 63820 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 222 to 177 and 16 ended unchanged 
Shares in Delek Drilling LP  TA DEDRp  fell to 52 week lows  down 3 95  or 42 to 1020  Shares in Delek Group  TA DLEKG  fell to 52 week lows  falling 2 31  or 1510 to 63820  
Crude oil for October delivery was up 0 15  or 0 07 to  48 14 a barrel  Elsewhere in commodities trading  Brent oil for delivery in November rose 0 65  or 0 35 to hit  54 19 a barrel  while the December Gold Futures contract fell 0 29  or 3 94 to trade at  1331 76 a troy ounce 
USD ILS was up 0 41  to 3 5369  while EUR ILS rose 0 44  to 4 2280 
The US Dollar Index Futures was down 0 01  at 91 91 ",2017-09-12,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-061-527918,527918
196933,418449,MYL,Israel stocks lower at close of trade  TA 35 down 0 03 ,news,"Investing com   Israel stocks were lower after the close on Sunday  as losses in the Oil   Gas  Communication and Banking sectors led shares lower 
At the close in Tel Aviv  the TA 35 declined 0 03  
The best performers of the session on the TA 35 were  Azrieli Group  Ltd  TA AZRG   which rose 2 34  or 460 points to trade at 20100 at the close  Meanwhile   Elbit Systems  Ltd  TA ESLT  added 2 05  or 990 points to end at 49170 and  Frutarom  Industries Ltd  TA FRUT  was up 1 57  or 450 points to 29190 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 3 73  or 440 points to trade at 11350 at the close  Teva Pharmaceutical Industries Ltd  TA TEVA  declined 3 14  or 209 points to end at 6441 and Perrigo  TA PRGO  was down 1 69  or 530 points to 30840 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 237 to 157 and 18 ended unchanged 
Shares in Frutarom Industries Ltd  TA FRUT  rose to all time highs  gaining 1 57  or 450 to 29190  
Crude oil for November delivery was unchanged 0 00  or 0 00 to  50 44 a barrel  Elsewhere in commodities trading  Brent oil for delivery in November rose 0 07  or 0 04 to hit  55 51 a barrel  while the December Gold Futures contract fell 0 29  or 3 88 to trade at  1325 42 a troy ounce 
USD ILS was up 0 01  to 3 5208  while EUR ILS rose 0 20  to 4 2084 
The US Dollar Index Futures was unchanged 0 00  at 91 65 ",2017-09-17,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-003-529719,529719
196939,418455,MYL,Acorda  ACOR  Down 11 3  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Acorda Therapeutics  ACOR   Shares have lost about 11 3  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Acorda due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Acorda Earnings and Revenues Beat Estimates in Q1Acorda reported first quarter 2019 loss per share of 56 cents  narrower than the Zacks Consensus Estimate of a loss of 97 cents  However  the figure came in against the year ago earnings of 14 cents Acorda generated total revenues of  44 1 million in the first quarter  comprehensively beating the Zacks Consensus Estimate of  36 6 million  However  sales tumbled a massive 58 4  year over year due to lower sales of Ampyra Quarter in DetailInbrija was launched in February this year and generated sales of  1 3 million in the first quarter of 2019  An approximately 2 000 prescription request forms for Inbrija were received through April 2019 Notably  majority of Acorda s net product revenues were drawn from Ampyra  which raked in sales of  40 1 million in the quarter  Sales of Ampyra tanked 61  year over year and 37 5  sequentially due to generic competition  Last September  Ampyra lost its exclusivity and generics entered the market including Mylan  NASDAQ MYL  s authorized generic version Acorda believes that Ampyra sales will see a sharp decline in the quarters ahead in 2019 Meanwhile  royalty revenues decreased 12 5  to  2 8 million in the quarter Acorda s research and development  R D  expenses  excluding share based compensation expenses  were  15 3 million  reflecting a deterioration of 47 1  year over year Selling  general and administrative  SG A  expenses  excluding share based compensation expenses  were  49 9 million  representing a 15  year over year rise Acorda had  343 3 million cash  cash equivalents and investments as of March 31  2019 compared with  445 6 as of Dec 31  2018 2019 GuidanceThe company no longer provides any outlook for Ampyra due to its waning revenues  induced by the entry of generics The company expects full year R D and SG A expenses  excluding share based compensation  in the band of  70  80 million and  200  210 million  respectively 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
At this time  Acorda has a poor Growth Score of F  however its Momentum Score is doing a lot better with a C  However  the stock was allocated a grade of F on the value side  putting it in the bottom 20  quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  Notably  Acorda has a Zacks Rank  1  Strong Buy   We expect an above average return from the stock in the next few months ",2019-05-31,Zacks Investment Research,https://www.investing.com/analysis/acorda-acor-down-113-since-last-earnings-report-can-it-rebound-200427417,200427417
196940,418456,MYL,Mylan  MYL  Down 18 8  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Mylan  NASDAQ MYL   Shares have lost about 18 8  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Mylan due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  Mylan Q1 Earnings Beat Estimates  Revenues MissMylan reported adjusted earnings of 82 cents per share in the first quarter of 2019  which beat the Zacks Consensus Estimate of 79 cents but declined from 96 cents in the year ago quarter However  first quarter revenues of  2 50 billion missed the Zacks Consensus Estimate of  2 69 billion and declined 7  from the prior year quarter Quarter in DetailThe company posts results in three segments on a geographic basis   North America  Europe and Rest of World North America segment s net sales came in at  922 9 million  down 6  year over year  This decline is primarily attributable to lower volumes of existing products due to changes in the competitive environment and remediation activities at the Morgantown plant  Pricing also declined from the year ago quarter Net sales in the Europe segment were  895 3 million  down 14  due to unfavorable impact of foreign currency translation  lower volumes of existing products driven by the timing of purchases of the company s products by customers and temporary business disruptions due to the adoption of serialization across Europe  and pricing Rest of World segment s net sales of  642 4 million were up 3   driven by new product sales and higher volumes of existing products Adjusted gross margin of 54  increased from 53  in the year ago quarter 2019 GuidanceThe company reaffirmed its guidance for 2019  Revenues are projected between  11 5 billion and  12 5 billion The company anticipates adjusted EPS around  3 80  4 80 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  5 49  due to these changes 
VGM Scores
At this time  Mylan has a poor Growth Score of F  a grade with the same score on the momentum front  However  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions indicates a downward shift  Notably  Mylan has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-06-05,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-down-188-since-last-earnings-report-can-it-rebound-200429100,200429100
196941,418457,MYL,Stock Exchange  Brilliant Trading Or Is The Market Just Up ,opinion,"The Stock Exchange is all about trading  Each week  we do the following 
Discuss an important issue for traders 
Highlight several technical trading methods  including current ideas 
Feature advice from top traders and writers  and
Provide a few  minority  reactions from fundamental analysts 
We also have some fun  We welcome comments  links and ideas to help us improve this resource for traders  If you have some ideas  please join in 
Review  Do You Evaluate Your Trading Mistakes 
Our previous Stock Exchange asked the question  Do You Evaluate Your Trading Mistakes  We reminded traders that it is important to evaluate your past trading mistakes  and to do so objectively  Specifically  leave your emotions and excuses at the door  Rather  try to learn from your mistakes  and improve systematically 
This Week  Brilliant Trading Or Is The Market Just Up 
It s easy to feel smart when the overall market is up  But just because your account balance is getting fatter  does that mean you are a brilliant trader  or is their something else going on 
Some investors point out that the market goes up over time  whereas others are deathly afraid of market volatility so they cluster their nest egg in cash or highly rated investment grade bonds  regardless of the disgusting low interest rates  
Others offer trading strategies that have lower correlations with the overall market so they can can earn strong returns over time that also offer some important diversification benefits versus straight stock market investment strategies 
On the other hand  perhaps you do deserve some credit for being brave enough to be in the market thereby benefiting your nest egg with a higher balance  And then of course there are those who only brag about the their successes when the market is up  but  crickets  when the market is down 

A classic 60 40 mix of stocks and bonds works for some  and you can cater those percentages up or down based on your preferences  And you can also mix in a trading strategy that offers long term return potential with less  stock market risk   or  beta risk   depending on who you re talking to  
Model Performance
We are sharing the performance of our proprietary trading models  as our readers have requested 

For more information about our models  and their specific trading processes   click through at the bottom of this post for more information  readers are additionally invited to write to main at newarc dot com for our free  brief description of how we created the Stock Exchange models  
Expert Picks From The Models
Note  This week s Stock Exchange report is being moderated by Blue Harbinger  a source for independent investment ideas 
Holmes  I bought shares of Ollie s Bargain Outlet Holdings  OLLI  on 6 14  You can see the chart below 

Blue Harbinger  I know you re a  dip buyer  Holmes  and I can see the dip in the chart 
Holmes  Yep  that s correct  I use a mean reversion approach to identify stocks that have moved  abnormally  far from their recent price history  And Ollie s did  and I also identified the additional conditions necessary for me to purchase  Sometimes market conditions may impact my trades  but since these mean reversion stocks are often at a low recent price point  they are generally less impacted by market  beta  as you say  Besides  beta is a longer term horizon metric anyway  and I typically hold for around only 6 weeks 
BH  Interesting  but with the market up so much in the last few years  I think a premium high end store could be a better idea than something called  bargain outlet   but alas you are the dip buyer  By the way  Ollie s other brands are called  Ollie s Bargain Outlet  Good Stuff Cheap  Ollie s Army  Real Brands Real Cheap   Real Brands  Real Bargains  Sarasota Breeze  Steelton Tools  American Way  and Commonwealth Classics names   Anyway  here is a look at the FastGraph 

Road Runner  I recently bought some shares of Planet Fitness  PLNT  on 6 12  I like to purchase stocks in the lower end of a rising channel and then hold them for about 4 weeks  What do you think about that 

BH  Well I think Planet Fitness is probably getting some good rent concessions because every time I hear about a struggling shopping mall REIT  management is always talking about renting the former space of bankrupt retailers to fitness franchises  Here is a look at the Fast Graph 

RR  The Fast Graph and fundamental data are nice  but as we ve discussed previously  I look for a certain type of situation  some call it a pattern  others may call it a setup  etc   where the probability of a particular action is not a matter of chance  50 50  but has been historically noted to result in a greater tendency towards a particular outcome   Trending in a channel  is one such situation  An equity will often  cycle  between the upper and lower bounds of that channel for substantial periods of time  My model design attempts to take advantage of this property by identifying stocks trending in an upwards channel and waiting until the stock price drifts to the lower bound  making it a candidate for purchase  These types of situations have a relatively high probability of positive outcome with a reasonable profit potential  Planet Fitness can be seen to be in this type of a situation  This is a short term trade that has traditionally shown profitability when the right conditions have been met  One way or another  I ll be out of it shortly   usually after about 4 weeks 
BH  Thanks for that explanation  And how about you  Athena   do you have any trades to share this week 
Athena  I bought shares of Tableau Software  DATA   How do you feel about that 

BH  I think that is a powerful growth stock that you ought too hold for many months  Here is a look at the Fast Graph 

Athena  Well  for your information  I look for stocks having strong positive trends and then select only those with the very strongest trends   king of the hill    constantly replacing the ones with weaker trends  It should not surprise anyone that I bought Tableau  A quick look at the chart makes the strength of the trend fairly obvious  And I generally continue to hold my positions until either the strength of the trend abates or a stock with an even higher trend strength comes along  I don t have a set  holding period  for a position  I will exit only when either a stronger stock comes along or if market conditions dictate a strong potential for loss   capital preservation remains the key driver in all situations 
BH  Thanks Athena  that is interesting stuff and a nice trade idea  And how about you  Felix   anything to share this week 
Felix  No trades  but I do have a ranking to share  This week  I ran the stocks of the Nasdaq 100 through my technical trading model  and my top 20 are ranked in the following list 

BH  Mylan  NASDAQ MYL   Felix  Really  That s a pharmaceuticals company  and together with its subsidiaries  it develops  licenses  manufactures  markets  and distributes generic  branded generic  brand name  and over the counter  OTC  pharmaceutical products in North America  Europe  and internationally  I suppose that s in the healthcare sector  which is down this year   and it seems like long term demographics eventually need to drive the sector higher  Thanks for sharing that list 
Oscar  This week I ran the stocks of our comprehensive and diverse ETF universe through my model  and my top 20 are ranked below 

BH  I swear  Oscar you ve had that Invesco Solar ETF  TAN  ranked at the top of your list for a while now  But I suppose it is up over 50  year to date  Thank you for sharing 
Conclusion 
The S P 500  SPY  NYSE SPY   is up over 17  this year  so it s easy to feel like a genius if you ve just been holding stocks  But how were you feeling during Q4 of 2018 when the market was down sharply  Less of a genius  Many traders focus on alpha  but beta can be a far bigger driver of performance if you re not careful  Choose your beta wisely  And on the other hand  if you are a long term investor beware of beta disguised as alpha  Just because the market is up  that doesn t mean you are a trading genius ",2019-06-20,Jeff Miller,https://www.investing.com/analysis/stock-exchange-brilliant-trading-or-is-the-market-just-up-200433118,200433118
196943,418459,MYL,Israel stocks lower at close of trade  TA 35 down 1 14 ,news,"Investing com   Israel stocks were lower after the close on Wednesday  as losses in the Banking  Technology and Financials sectors led shares lower 
At the close in Tel Aviv  the TA 35 lost 1 14  to hit a new 3 years low 
The best performers of the session on the TA 35 were Tower Semiconductor Ltd  TA TSEM   which rose 1 80  or 166 points to trade at 9377 at the close  Meanwhile   OPKO Health Inc   TA OPK  added 1 29  or 29 points to end at 2280 and Mylan NV  TA MYL  was up 1 12  or 130 points to 11740 in late trade 
The worst performers of the session were Perrigo  TA PRGO   which fell 4 35  or 1060 points to trade at 23300 at the close   Delek Group   TA DLEKG  declined 2 88  or 1980 points to end at 66700 and Delek Drilling LP  TA DEDRp  was down 2 78  or 36 points to 1260 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 302 to 94 and 9 ended unchanged 
Shares in Perrigo  TA PRGO  fell to 5 year lows  down 4 35  or 1060 to 23300  Shares in Delek Group  TA DLEKG  fell to 52 week lows  down 2 88  or 1980 to 66700  Shares in Mylan NV  TA MYL  rose to all time lows  gaining 1 12  or 130 to 11740  
Crude oil for September delivery was up 0 26  or 0 13 to  49 30 a barrel  Elsewhere in commodities trading  Brent oil for delivery in October rose 0 46  or 0 24 to hit  52 38 a barrel  while the December Gold Futures contract rose 1 16  or 14 63 to trade at  1277 23 a troy ounce 
USD ILS was down 0 31  to 3 5964  while EUR ILS fell 0 43  to 4 2215 
The US Dollar Index Futures was up 0 06  at 93 54 ",2017-08-09,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-114-516562,516562
196944,418460,MYL,Israel stocks lower at close of trade  TA 35 down 0 97 ,news,"Investing com   Israel stocks were lower after the close on Thursday  as losses in the Banking  Financials and Communication sectors led shares lower 
At the close in Tel Aviv  the TA 35 fell 0 97  to hit a new 3 years low 
The best performers of the session on the TA 35 were Perrigo  TA PRGO   which rose 21 59  or 5030 points to trade at 28330 at the close  Meanwhile  Mylan NV  TA MYL  fell 0 85  or 100 points to end at 11640 and  Amot Investments  Ltd  TA AMOT  was down 1 11  or 21 points to 1877 in late trade 
The worst performers of the session were Teva Pharmaceutical Industries Ltd  TA TEVA   which fell 4 40  or 289 points to trade at 6278 at the close  Tower Semiconductor Ltd  TA TSEM  declined 4 02  or 377 points to end at 9000 and  Cellcom Israel  Ltd  TA CEL  was down 3 91  or 130 points to 3198 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 289 to 107 and 14 ended unchanged 
Shares in Teva Pharmaceutical Industries Ltd  TA TEVA  fell to 5 year lows  losing 4 40  or 289 to 6278  
Crude oil for September delivery was down 0 28  or 0 14 to  49 42 a barrel  Elsewhere in commodities trading  Brent oil for delivery in October rose 0 08  or 0 04 to hit  52 74 a barrel  while the December Gold Futures contract rose 0 92  or 11 72 to trade at  1291 02 a troy ounce 
USD ILS was down 0 33  to 3 5827  while EUR ILS fell 0 49  to 4 2098 
The US Dollar Index Futures was down 0 01  at 93 40 ",2017-08-10,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-097-517164,517164
196945,418461,MYL,Israel stocks higher at close of trade  TA 35 up 0 18 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Banking  Financials and Communication sectors led shares higher 
At the close in Tel Aviv  the TA 35 rose 0 18  
The best performers of the session on the TA 35 were  Delek Group   TA DLEKG   which rose 2 84  or 1850 points to trade at 66950 at the close  Meanwhile   Frutarom  Industries Ltd  TA FRUT  added 2 72  or 660 points to end at 24960 and  Elbit Systems  Ltd  TA ESLT  was up 1 94  or 880 points to 46130 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 4 30  or 500 points to trade at 11140 at the close  Perrigo  TA PRGO  declined 1 94  or 550 points to end at 27780 and  Amot Investments  Ltd  TA AMOT  was down 1 39  or 26 points to 1851 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 230 to 172 and 9 ended unchanged 
Shares in Mylan NV  TA MYL  fell to all time lows  down 4 30  or 500 to 11140  
Crude oil for September delivery was up 0 37  or 0 18 to  48 77 a barrel  Elsewhere in commodities trading  Brent oil for delivery in October rose 0 17  or 0 09 to hit  51 99 a barrel  while the December Gold Futures contract rose 0 38  or 4 90 to trade at  1295 00 a troy ounce 
USD ILS was down 0 08  to 3 5840  while EUR ILS rose 0 41  to 4 2400 
The US Dollar Index Futures was down 0 33  at 92 99 ",2017-08-13,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-018-517971,517971
196946,418462,MYL,Galectin Therapeutics net loss improves in Q2,news,Galectin Therapeutics  GALT  Q2 results  Revenues   0  R D Expense   3 4M   19 0    SG A   1 1M   15 4    Operating Loss    4 5M    18 2    Net Loss    4 8M    17 2    Loss Per Share    0 14    30 0    Quick Assets   9 1M   40 9   No guidance given Now read ,2017-08-14,Seeking Alpha,https://www.investing.com/news/stock-market-news/galectin-therapeutics-net-loss-improves-in-q2-518189,518189
196947,418463,MYL,Israel stocks higher at close of trade  TA 35 up 1 66 ,news,"Investing com   Israel stocks were higher after the close on Monday  as gains in the Banking  Oil   Gas and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 35 gained 1 66  
The best performers of the session on the TA 35 were Tower Semiconductor Ltd  TA TSEM   which rose 4 46  or 399 points to trade at 9350 at the close  Meanwhile  Delek Drilling LP  TA DEDRp  added 3 73  or 46 points to end at 1280 and  Azrieli Group  Ltd  TA AZRG  was up 3 71  or 730 points to 20420 in late trade 
The worst performers of the session were Teva Pharmaceutical Industries Ltd  TA TEVA   which fell 1 93  or 122 points to trade at 6200 at the close  Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ  declined 1 46  or 7 4 points to end at 500 5 and Mylan NV  TA MYL  was down 0 72  or 80 points to 11060 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 281 to 127 and 4 ended unchanged 
Shares in Teva Pharmaceutical Industries Ltd  TA TEVA  fell to 5 year lows  down 1 93  or 122 to 6200  Shares in Mylan NV  TA MYL  fell to all time lows  falling 0 72  or 80 to 11060  
Crude oil for September delivery was up 0 41  or 0 20 to  49 02 a barrel  Elsewhere in commodities trading  Brent oil for delivery in October rose 0 27  or 0 14 to hit  52 24 a barrel  while the December Gold Futures contract fell 0 28  or 3 62 to trade at  1290 38 a troy ounce 
USD ILS was down 0 06  to 3 5820  while EUR ILS fell 0 44  to 4 2212 
The US Dollar Index Futures was up 0 27  at 93 24 ",2017-08-14,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade-ta-35-up-166-518261,518261
196948,418464,MYL,Mylan  U S  finalize  465 million EpiPen settlement,news,"By Nate Raymond BOSTON  Reuters    Mylan NV  O MYL  has finalized a  465 million settlement with the U S  Justice Department  resolving claims it overcharged the government for its EpiPen emergency allergy treatment  which became the center of a firestorm over price increases  The U S  Attorney s Office in Massachusetts revealed the accord on Thursday  10 months after Mylan said it reached a deal resolving claims it misclassified the EpiPen as a generic rather than a branded product to reduce the rebates it pays to the Medicaid healthcare program for the poor   Taxpayers rightly expect companies like Mylan that receive payments from taxpayer funded programs to scrupulously follow the rules   Acting U S  Attorney William Weinreb said in a statement  Under the deal  Mylan did not admit wrongdoing  It will reclassify EpiPen and pay the rebate applicable to its new classification as of April 1  2017   Bringing closure to this matter is the right course of action for Mylan and our stakeholders to allow us to move forward   Mylan Chief Executive Heather Bresch said in a statement  The deal followed a False Claims Act whistleblower lawsuit filed by French rival Sanofi SA  PA SASY  in 2016  two years after it first raised the matter with authorities  Weinreb s office said  Sanofi  which formerly marketed a rival product called Auvi Q  will receive nearly  38 8 million as a reward from the government  Sanofi in a statement called pursuing the matter  the right thing to do   It has a separate antitrust lawsuit pending alleging Mylan engaged in illegal conduct to squelch competition to EpiPen  Mylan shares rose 2 10 percent to  31 11 on the Nasdaq   The EpiPen  which Mylan acquired in 2007  is a handheld device that treats life threatening allergic reactions by automatically injecting a dose of epinephrine  Mylan came under fire last year after raising the price of a pair of EpiPens to  600  from  100 in 2008  enraging consumers and putting it in the center of the ongoing U S  debate over the high cost of prescription medicines  Mylan has since offered its own generic version for about  300   The settlement resolved claims that Mylan avoided higher rebates to state Medicaid programs by misclassifying EpiPen as a generic product  even through it was marketed and priced as a brand name product  Some congressional members previously criticized the  465 million settlement as too small  
A U S  Department of Health and Human Services  Office of Inspector General analysis released in May found the U S  government may have overpaid for EpiPens by up to  1 27 billion between 2006 and 2016 ",2017-08-17,Reuters,https://www.investing.com/news/stock-market-news/mylan-us-finalize-465-million-epipen-settlement-519727,519727
196955,418471,MYL,Theravance  TBPH  Q1 Loss Widens  Revenues Miss Estimates,opinion,Theravance Biopharma  Inc    NASDAQ TBPH   incurred a loss of  1 32 per share in first quarter 2019  wider than the Zacks Consensus Estimate of a loss of  1 18 as well as the year ago loss of  1 22 Total revenues of  5 3 million in the quarter significantly missed the Zacks Consensus Estimate of  16 45 million  Moreover  revenues dropped 36 1  year over year due to no product sales in the quarter Last November  Theravance completed the sale of its only marketed drug  Vibativ  to Cumberland Pharmaceuticals  As a result  the company was not able to generate any revenues from product sales in the first quarter of 2019 The entire revenues comprised collaboration revenues from partner Johnson   Johnson   NYSE JNJ   for the joint development of the company s pan Janus kinase inhibitor  TD 1473  to treat inflammatory intestinal diseases  Collaboration revenues were  4 6 million in the year earlier quarter Shares of Theravance have lost 4 5  in the year so far versus the  rally of 10 6  Research and development expenses were  53 8 million  up 12 8  from the year ago quarter  primarily due to higher costs to support key programs and higher employee related expenses Selling  general   administrative expenses inched up 2  to  25 2 million due to increased collaboration expenses related to the launch activities of Yupelri Product and Pipeline UpdatesTheravance has collaborated with Mylan   NASDAQ MYL   for the development and commercialization of Yupelri  revefenacin  pertaining to the maintenance treatment of adults with chronic obstructive pulmonary disease  COPD   which was approved by the FDA last November On first quarter conference call  management stated that Theravance and Mylan formally launched the sales and marketing efforts of Yupelri in early 2019  These include physicians  pharmacists  respiratory therapists and other health care prescribers Notably  Theravance has an economic interest in royalties earned from GlaxoSmithKline   NYSE GSK   on Trelegy Ellipta s global sales  Trelegy Ellipta  a triple combination therapy of inhaled corticosteroid  ICS  LAMA LABA  fluticasone furoate umeclidinium vilanterol  FF UMEC VI    was approved in September 2017 as a maintenance treatment for COPD patients  who are not adequately treated by a combination of ICS and LABA In the first quarter of 2019  Glaxo recorded sales of  112 7 million for Trelegy Ellipta  Theravance is eligible to receive 5 5 8 5   tiered  of the product s worldwide net sales The company is currently enrolling patients in the phase II study on TD 1473 for treating Crohn s disease and in the phase IIb III study for ulcerative colitis Theravance is evaluating ampreloxetine  TD 9855  in a phase III program for treating patients with symptomatic neurogenic orthostatic hypotension  nOH   The company plans to present 5 month data from the completed phase II investigation for the given patient population at a medical meeting in June 2019 Theravance is also developing inhaled  lung selective pan Janus kinase  JAK  inhibitor  TD 8236  in a phase I study to assess its potential for the treatment of various serious respiratory diseases  The company plans to provide the biomarker data of TD 8236 in the third quarter of 2019 after evaluating healthy volunteers and asthma patients 2019 OutlookFor 2019  Theravance anticipates operating loss excluding non cash share based compensation to be  210  230 million  unchanged from the previously issued guidance Theravance Biopharma  Inc  Price  Consensus and EPS Surprise   Zacks RankTheravance currently carries a Zacks Rank  4  Sell  You can see  Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-05-07,Zacks Investment Research,https://www.investing.com/analysis/theravance-tbph-q1-loss-widens-revenues-miss-estimates-200418984,200418984
196956,418472,MYL,After Mylan Lost A Quarter Of Its Value  Look For A Bounce,opinion,"Summary 
Mylan  NASDAQ MYL  sank 24  on Tuesday after the company posted earnings that beat Wall Street expectations for earnings but missed on revenue 
As this move is coming toward the end of its current market cycle  we expect a small bounce  but expect this to be followed by more downside risk 

The company reported earnings per share of  0 82 and total revenue of  2 5 billion  compared to analyst estimates of  0 79 and  2 7 billion  Management also reaffirmed its guidance  which is in line with expectations 
Facing an array of problems  CEO Heather Bresch had announced a strategic review on which   There is a tremendous amount of work being done   However  she was unable to give an update or a specific date on which she would provide the results  This did not assuage investor concerns 
Our approach to stock analysis focuses on market cycles  It is clear to us that MYL is towards the end the declining phase of its current cycle  This stock followed our analysis well  as you can see from the cycle patterns on the chart above  Our view is that a bottom is soon due  but that the subsequent bounce will likely be temporary given the MYL s negative momentum 
For more from Slim  or to learn about cycle analysis  check out the askSlim Market Week show every Friday on our YouTube channel ",2019-05-08,Steve Miller,https://www.investing.com/analysis/after-mylan-lost-a-quarter-of-its-value-look-for-a-bounce-200418962,200418962
196957,418473,MYL,Generic Drugmakers Face Antitrust Suit Alleging Price Fixing,opinion,"Shares of Teva Pharmaceutical Industries Limited   NYSE TEVA   fell almost 15  on May 13 following media reports of an antitrust lawsuit filed by 44 states against the company and several other generic drugmakers for allegedly artificially inflating prices of generic drugs  in some cases exceeding 1000   Other companies named in the 510 page lawsuit were Mylan   NASDAQ MYL    Sandoz  the generic arm of Novartis    NYSE NVS      Dr  Reddy s Laboratories and a subsidiary of Pfizer   NYSE PFE   among others  While shares of Mylan were down 10   Novartis  stock declined around 2   Dr Reddy s was down more than 4  and Pfizer declined slightly The group of 44 states was led by Connecticut attorney general William Tong  The lawsuit  filed in Connecticut federal court  alleged that these drugmakers conspired during lunches  dinners  golf outings and other social events  to inflate the prices of more than 100 generic drugs  The lawsuit alleges that these companies perpetrated a multi billion fraud on Americans by manipulating prices of generic drugs  which are supposedly cheaper  copycat  versions of the branded drugs  The generic drugmakers allegedly  systematically  divided the market so that they do not compete with one another and at the same time can charge high prices  If the allegations are true  the companies will be slapped with huge damages and penalties   Teva alone allegedly increased prices of more than 100 generic drugs Teva denied the charges saying that these were just allegations and that the company has not engaged in any conduct that will result in civil criminal liability The lawsuit comes amid attempts by both President Trump and Congress to keep prices of drug prices low and ensure affordability of high cost drugs  Trump has  time and again  criticized pharmaceutical companies for steep pricing of medicines  Industry players have been reeling under pressure for quite some time now as they fear that Trump s pharma plan could dent their profits Though the industry has been constantly warned by Trump to keep prices of drugs affordable  it is probably not doing anything about it  On his part  the President can take several steps in this direction  He can push for faster generic approval  which he is already doing  He can also ask for discounted rebates to be disclosed  put limitations on promotions advertisements of the drugs and mandate Medicare to negotiate drug prices with manufacturers It is high time drug companies take steps to provide relief to consumers by keeping cost of medicines affordable  Until then  the drug pricing controversy will remain an overhang on the space Teva  Mylan and Dr Reddy s carry a Zacks Rank  3  Hold   You can see  Medical   Generic Drugs Industry 5YR   Return
 Today s Best Stocks from Zacks Would you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-05-13,Zacks Investment Research,https://www.investing.com/analysis/generic-drugmakers-face-antitrust-suit-alleging-price-fixing-200421265,200421265
196958,418474,MYL,The Zacks Analyst Blog Highlights  Teva  Mylan  Novartis And Pfizer,opinion,For Immediate ReleaseChicago  IL  May 15  2019   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Teva Pharmaceutical Industries Ltd    NYSE TEVA    Mylan   NASDAQ MYL    Novartis   NYSE NVS   and Pfizer   NYSE PFE   Here are highlights from Tuesday s Analyst Blog Generic Drugmakers Face Antitrust Suit Alleging Price FixingShares of Teva Pharmaceutical Industries Ltd  fell almost 15  on May 13 following media reports of an antitrust lawsuit filed by 44 states against the company and several other generic drugmakers for allegedly artificially inflating prices of generic drugs  in some cases exceeding 1000   Other companies named in the 510 page lawsuit were Mylan  Sandoz  the generic arm of Novartis   Dr  Reddy s Laboratories and a subsidiary of Pfizer among others  While shares of Mylan were down 10   Novartis  stock declined around 2   Dr Reddy s was down more than 4  and Pfizer declined slightly The group of 44 states was led by Connecticut attorney general William Tong  The lawsuit  filed in Connecticut federal court  alleged that these drugmakers conspired during lunches  dinners  golf outings and other social events  to inflate the prices of more than 100 generic drugs  The lawsuit alleges that these companies perpetrated a multi billion fraud on Americans by manipulating prices of generic drugs  which are supposedly cheaper  copycat  versions of the branded drugs  The generic drugmakers allegedly  systematically  divided the market so that they do not compete with one another and at the same time can charge high prices  If the allegations are true  the companies will be slapped with huge damages and penalties   Teva alone allegedly increased prices of more than 100 generic drugs Teva denied the charges saying that these were just allegations and that the company has not engaged in any conduct that will result in civil criminal liability The lawsuit comes amid attempts by both President Trump and Congress to keep prices of drug prices low and ensure affordability of high cost drugs  Trump has  time and again  criticized pharmaceutical companies for steep pricing of medicines  Industry players have been reeling under pressure for quite some time now as they fear that Trump s pharma plan could dent their profits Though the industry has been constantly warned by Trump to keep prices of drugs affordable  it is probably not doing anything about it  On his part  the President can take several steps in this direction  He can push for faster generic approval  which he is already doing  He can also ask for discounted rebates to be disclosed  put limitations on promotions advertisements of the drugs and mandate Medicare to negotiate drug prices with manufacturers It is high time drug companies take steps to provide relief to consumers by keeping cost of medicines affordable  Until then  the drug pricing controversy will remain an overhang on the space Teva  Mylan and Dr Reddy s carry a Zacks Rank  3  Hold   You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here Medical   Generic Drugs Industry 5YR   ReturnToday s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year See their latest picks free   Media ContactZacks Investment Research800 767 3771 ext  9339 Past performance is no guarantee of future results  Inherent in any investment is the potential for loss  This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ,2019-05-14,Zacks Investment Research,https://www.investing.com/analysis/the-zacks-analyst-blog-highlights-teva-mylan-novartis-and-pfizer-200421648,200421648
196959,418475,MYL,I See Technical Upside In This Pharmaceutical Play,opinion,"Shares of Mylan  NASDAQ MYL  have collapsed in the last two weeks  falling from over  28 share to under  20  That drop is a continuation of the down trend that started when the stock was trading at  48 share in early 2018  While nasty and ugly  pro traders are starting to take interest after Mylan put in a strong bottoming tail on Wednesday 
Here s The Trade
Bottoming tails are bullish reversal signals  which mean there is likely a near term pop in the stock  Based on the technical charts  Mylan has upside back to  26 before running into major resistance  Pro traders are moving into the stock  looking for this pop ",2019-05-16,Gareth Soloway,https://www.investing.com/analysis/i-see-technical-upside-in-this-pharmaceutical-play-200422234,200422234
196960,418476,MYL,Israel stocks lower at close of trade  TA 35 down 0 27 ,news,"Investing com   Israel stocks were lower after the close on Tuesday  as losses in the Oil   Gas  Communication and Insurance sectors led shares lower 
At the close in Tel Aviv  the TA 35 declined 0 27  
The best performers of the session on the TA 35 were  Sodastream International Ltd   TA SODA   which rose 2 83  or 550 0 points to trade at 20010 0 at the close  Meanwhile  Paz Oil  TA PZOL  added 1 33  or 780 points to end at 59500 and Alony Hetz Properties and Investments Ltd  TA ALHE  was up 1 18  or 42 points to 3597 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 2 58  or 360 points to trade at 13590 at the close  Perrigo  TA PRGO  declined 2 53  or 670 points to end at 25860 and  Delek Group   TA DLEKG  was down 2 14  or 1640 points to 75100 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 239 to 150 and 22 ended unchanged 
Crude oil for August delivery was up 1 02  or 0 47 to  46 49 a barrel  Elsewhere in commodities trading  Brent oil for delivery in September rose 1 09  or 0 53 to hit  48 95 a barrel  while the August Gold Futures contract rose 0 59  or 7 32 to trade at  1241 02 a troy ounce 
USD ILS was down 0 33  to 3 5674  while EUR ILS rose 0 60  to 4 1320 
The US Dollar Index Futures was down 0 65  at 94 30 ",2017-07-18,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-35-down-0.27-506862,506862
196961,418477,MYL,Israel stocks higher at close of trade  TA 35 up 0 18 ,news,"Investing com   Israel stocks were higher after the close on Thursday  as gains in the Insurance  Financials and Biomed sectors led shares higher 
At the close in Tel Aviv  the TA 35 added 0 18  
The best performers of the session on the TA 35 were Mylan NV  TA MYL   which rose 3 31  or 450 points to trade at 14050 at the close  Meanwhile  Perrigo  TA PRGO  added 2 35  or 610 points to end at 26530 and Teva Pharmaceutical Industries Ltd  TA TEVA  was up 2 11  or 240 points to 11590 in late trade 
The worst performers of the session were  Azrieli Group  Ltd  TA AZRG   which fell 2 15  or 430 points to trade at 19570 at the close   Airport City  Ltd  TA ARPT  declined 2 06  or 100 points to end at 4757 and Alony Hetz Properties and Investments Ltd  TA ALHE  was down 1 48  or 53 points to 3520 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 203 to 198 and 22 ended unchanged 
Crude oil for September delivery was up 0 27  or 0 13 to  47 45 a barrel  Elsewhere in commodities trading  Brent oil for delivery in September rose 0 40  or 0 20 to hit  49 90 a barrel  while the August Gold Futures contract rose 0 27  or 3 34 to trade at  1245 34 a troy ounce 
USD ILS was down 0 40  to 3 5543  while EUR ILS rose 0 62  to 4 1354 
The US Dollar Index Futures was down 0 64  at 94 03 ",2017-07-20,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.18-507937,507937
196962,418478,MYL,Express Scripts goes with Mylan s EpiPen on 2018 formulary,news,Pharmacy benefit manager Express Scripts  ESRX  0 3   will include only Mylan s  MYL  1   EpiPen auto injector in its 2018 formulary  On the outside looking in are rivals Impax Laboratories  IPXL  0 5   and privately held Kal o Now read ,2017-08-01,Seeking Alpha,https://www.investing.com/news/stock-market-news/express-scripts-goes-with-mylans-epipen-on-2018-formulary-512914,512914
196963,418479,MYL,Israel stocks lower at close of trade  TA 35 down 0 55 ,news,"Investing com   Israel stocks were lower after the close on Wednesday  as losses in the Biomed  Technology and Communication sectors led shares lower 
At the close in Tel Aviv  the TA 35 declined 0 55  
The best performers of the session on the TA 35 were  Airport City  Ltd  TA ARPT   which rose 3 11  or 146 points to trade at 4839 at the close  Meanwhile   Ormat Technologies   TA ORA  added 1 79  or 380 points to end at 21640 and Poalim  TA POLI  was up 1 30  or 32 points to 2499 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 3 72  or 520 points to trade at 13470 at the close  Teva Pharmaceutical Industries Ltd  TA TEVA  declined 3 39  or 390 points to end at 11130 and  Sodastream International Ltd   TA SODA  was down 2 39  or 480 0 points to 19600 0 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 240 to 164 and 10 ended unchanged 
Crude oil for September delivery was up 0 02  or 0 01 to  49 17 a barrel  Elsewhere in commodities trading  Brent oil for delivery in October rose 0 17  or 0 09 to hit  51 87 a barrel  while the August Gold Futures contract fell 0 23  or 2 91 to trade at  1269 69 a troy ounce 
USD ILS was up 0 50  to 3 5792  while EUR ILS rose 1 00  to 4 2459 
The US Dollar Index Futures was down 0 30  at 92 64 ",2017-08-02,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade-ta-35-down-055-513546,513546
196964,418480,MYL,Mylan down 4  premarket in sympathy with Teva  Q2 earnings August 9,news,Mylan N V   NASDAQ MYL  is joined at the hip with Teva  Shares are down 4  premarket on robust volume  matching Teva s decline  Q2 earnings are on tap for Wednesday  August 9 before the open Previously  Teva s travails bearish for Mylan   RBC  Aug  4 Now read ,2017-08-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/mylan-down-4-premarket-in-sympathy-with-teva-q2-earnings-august-9-515318,515318
196965,418481,MYL,CVS Health s dull third quarter forecast overshadows profit beat,news,"By Sruthi Ramakrishnan  Reuters    CVS Health Corp  NYSE CVS  forecast current quarter profit below Wall Street estimates and said it has been ordered to cooperate with investigations into possible false claims submitted to a government healthcare program and drug pricing  Shares of the company  which also reported its fourth straight decline in quarterly comparable sales  fell 1 4 percent to  78 03   The No 2 U S  drug store chain  however  reported quarterly profit above Wall Street estimates on strength in its pharmacy benefits management business  PBM   which helped to more than offset a 2 6 percent drop in same store sales    Retail side of the business is struggling even if PBM was better than expected and actually pretty strong for what was expected   Jeremy Bryan  portfolio manager at Gradient Investments  CVS Health forecast current quarter adjusted profit of  1 47 to  1 50 per share  below the average analyst estimate of  1 63  according to Thomson Reuters I B E S  LEGAL ISSUES The company said the attorney general for the Southern District of New York has sought information on possible false claims submitted in connection with reimbursements for Medicare Part D prescription drugs    Minnesota s attorney general has also sought information from it regarding a probe into pricing of insulin and epinephrine drugs  CVS Health said   Sanofi  PA SASY  SA  Eli Lilly and Co and  Novo Nordisk   CO NOVOb  were named in a proposed class action lawsuit  which alleged the firms simultaneously hiked insulin prices by over 150 percent in the past five years  Mylan  NASDAQ MYL  NV  the maker of emergency epinephrine injectors EpiPen  is facing investigations after it doubled the cost of its syringes used to treat severe allergic reactions  On Monday  a class action lawsuit was filed against CVS Health  which alleged the company colluded with third party PBMs to raise generic drug prices   The allegations against us made in this proposed class action suit are built on a false premise and are completely without merit   CVS Health spokesman Michael DeAngelis said in a statement on Tuesday  Net income attributable to drug store chain rose about 19 percent to  1 1 billion  or  1 07 per share  in the second quarter ended June 30   Excluding items  the company earned a profit of  1 33 per share  beating the average analyst estimate of  1 31  
Net revenue rose 4 5 percent to  45 69 billion  beating expectations of  45 37 billion ",2017-08-08,Reuters,https://www.investing.com/news/stock-market-news/cvs-healths-dull-thirdquarter-forecast-overshadows-profit-beat-516042,516042
196975,418491,MYL,Earnings Preview  Mylan  MYL  Q1 Earnings Expected To Decline,opinion,"The market expects Mylan  NASDAQ MYL  to deliver a year over year decline in earnings on higher revenues when it reports results for the quarter ended March 2019  This widely known consensus outlook is important in assessing the company s earnings picture  but a powerful factor that might influence its near term stock price is how the actual results compare to these estimates 
The stock might move higher if these key numbers top expectations in the upcoming earnings report  which is expected to be released on May 7  On the other hand  if they miss  the stock may move lower 
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management s discussion of business conditions on the earnings call  it s worth handicapping the probability of a positive EPS surprise 
Zacks Consensus Estimate
This generic drugmaker is expected to post quarterly earnings of  0 79 per share in its upcoming report  which represents a year over year change of  17 7  
Revenues are expected to be  2 69 billion  up 0 3  from the year ago quarter 
Estimate Revisions Trend
The consensus EPS estimate for the quarter has been revised 3 31  lower over the last 30 days to the current level  This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period 
Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts 
Price  Consensus and EPS Surprise

Earnings Whisper
Estimate revisions ahead of a company s earnings release offer clues to the business conditions for the period whose results are coming out  This insight is at the core of our proprietary surprise prediction model    the Zacks Earnings ESP  Expected Surprise Prediction  
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter  the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate  The idea here is that analysts revising their estimates right before an earnings release have the latest information  which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier 
Thus  a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate  However  the model s predictive power is significant for positive ESP readings only 
A positive Earnings ESP is a strong predictor of an earnings beat  particularly when combined with a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold   Our research shows that stocks with this combination produce a positive surprise nearly 70  of the time  and a solid Zacks Rank actually increases the predictive power of Earnings ESP 
Please note that a negative Earnings ESP reading is not indicative of an earnings miss  Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and or Zacks Rank of 4  Sell  or 5  Strong Sell  
How Have the Numbers Shaped Up for Mylan 
For Mylan  the Most Accurate Estimate is lower than the Zacks Consensus Estimate  suggesting that analysts have recently become bearish on the company s earnings prospects  This has resulted in an Earnings ESP of  4 75  
On the other hand  the stock currently carries a Zacks Rank of  3 
So  this combination makes it difficult to conclusively predict that Mylan will beat the consensus EPS estimate 
Does Earnings Surprise History Hold Any Clue 
While calculating estimates for a company s future earnings  analysts often consider to what extent it has been able to match past consensus estimates  So  it s worth taking a look at the surprise history for gauging its influence on the upcoming number 
For the last reported quarter  it was expected that Mylan would post earnings of  1 33 per share when it actually produced earnings of  1 30  delivering a surprise of  2 26  
Over the last four quarters  the company has beaten consensus EPS estimates just once 
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower  Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors  Similarly  unforeseen catalysts help a number of stocks gain despite an earnings miss 
That said  betting on stocks that are expected to beat earnings expectations does increase the odds of success  This is why it s worth checking a company s Earnings ESP and Zacks Rank ahead of its quarterly release  Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they ve reported 
Mylan doesn t appear a compelling earnings beat candidate  However  investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release ",2019-04-29,Zacks Investment Research,https://www.investing.com/analysis/earnings-preview-mylan-myl-q1-earnings-expected-to-decline-200413104,200413104
196976,418492,MYL,Glaxo  GSK  Beats On Q1 Earnings   Sales  Shingrix Impresses,opinion,"GlaxoSmithKline plc   NYSE GSK   reported adjusted earnings of 79 cents per American depositary share   ADS   for the first quarter of 2019  which beat the Zacks Consensus Estimate of 66 cents  Earnings were up 18  year over year at constant exchange rate   CER   Shares of Glaxo were down almost 1 8  on May 1 despite the strong results  The stock has gained 5 8  so far this year against the  s 0 1  decrease Quarterly revenues rose 5  at CER to  10 1 billion   7 7 billion   driven by growth in all the three business segments  especially strong performance at the Vaccines segment  The top line beat the Zacks Consensus Estimate of  9 86 billion                                                          All growth rates mentioned below are on a year over year basis and at CER Quarterly HighlightsGlaxo reports financial figures under three segments  Pharmaceuticals  Vaccines and Consumer Healthcare The Pharmaceuticals division registered 2  increase in revenues at CER  Sales in the United States were up 1   The upside was driven by HIV drugs and new respiratory disease drugs  Nucala and Trelegy  Glaxo has stated that Nucala continues to be the leader in terms of total sales in the asthma biologics market Sales of Established Pharmaceuticals declined 6  due to lower sales of Advair  partly offset by launch of authorized generic version of Advair and Ventolin Glaxo moved Advair to its Established Pharmaceuticals portfolio starting this quarter  The launch of Mylan s   NASDAQ MYL   generic version of Advair   Wixela Inhub   the first Advair generic in the United States  in February resulted in 27  decline in Advair sales  The steep decline in sales of Advair is expected to continue in 2019 HIV sales increased 4  at CER on the back of 7  growth in combined sales of Triumeq  Tivicay and Juluca  which partly ofset lower sales of other drugs in the portfolio  While U S  sales were up 3   international sales increased 29  at CER  However  sales of dolutegravir products fell 2  in Europe  The company held 26 5  of the HIV vaccine market in the United States during the first quarter  Sales of other HIV drugs tumbled 35  at CER due to severe generic competition and transition to new regimens Notably  the company s latest product from the HIV portfolio is Juluca  dolutegravir   rilpivirine   the first two drug regimen  once daily  single pill for HIV  The drug was approved in the United States in November 2017  Please note that rilpivirine is marketed by Janssen  a subsidiary of J J   NYSE JNJ    as Eudrant  Juluca generated sales of  70 million  reflecting sequential growth of 12 9   In April  Glaxo s another single tablet  two drug regimen  Dovato  dolutegravir   lamivudine   was approved in the United States for newly diagnosed patients with HIV 1 Respiratory sales were up 25  at CER  The sales increase from the Ellipta portfolio and Nucala across all regions drove the growth  Sales of new respiratory drugs grew 19  and 33  in the United States and Europe  respectively  In the International markets  sales of new respiratory drugs increased 30  Immuno inflammation drugs like Benlysta rose 15  in the quarter under discussion  In April  Benlysta s label was expanded to include children with lupus aged five years or older Oncology sales were  43 million  driven by the recently added PARP inhibitor  Zejula  with acquisition of TESARO Sales in the Consumer Healthcare segment increased 1  at CER as growth in Oral health and Nutrition was partly offset by decline in the Wellness and Skin health category  International markets drove sales of the segment higher  However  the company is facing increased competition in Europe Divestment of Horlicks and MaxiNutrition along with other smaller brands in the United Kingdom unfavorably impacted overall sales by a percentage point Late last year  Glaxo announced a joint venture with Pfizer   NYSE PFE   to create the world s largest Consumer Healthcare business  The deal is expected to close in the second half of 2019 Sales from the Vaccines segment were impressive  up 20  at CER  primarily driven by strong growth of new shingles vaccine  Shingrix and impressive performance of influenza products  Meningitis vaccines Bexsero and Menveo returned to growth during the quarter as evident from sales increase of 14  and 11   respectively  Shingrix sales more than doubled to  357 million in the reported quarter driven by market expansion in new patient population  Sales were up more than 60  sequentially Selling  general and administration  SG A  costs increased 4  year over year to  2 4 billion due to increased commercial activities to support launches and costs related to the acquisition of TESARO Research and development  R D  expenses were up 6  to 971 million  reflecting developmental activities following acquisition of TESARO and increased investments to support progress of clinical studies  especially oncology  This increase was partly offset by lower clinical activity related to HIV products 2019 ViewGlaxo still expects its earnings to decline 5 9  at CER in 2019  including the impact of Advair generic and costs related to the acquisition of TESARO  The guidance assumes the closure of the joint venture with Pfizer for Consumer Healthcare business and divestment of certain nutrition brands in India Bangladesh in 2019Our TakeGlaxo had stated on its fourth quarter earnings call that the company will be back on growth track in 2019  The company started 2019 on a strong note with significant earnings growth  New products from every segment performed encouragingly  especially Shingrix We are encouraged by Glaxo s restructuring initiatives to focus on strengthening its pharmaceutical portfolio  The company boosted its oncology portfolio with the acquisition of TESARO in January and a collaboration agreement with Germany based Merck KgaA  announced in February  Following these two transactions  the company has 16 oncology pipeline candidates including in house candidates These transactions along with restructuring initiatives related to the Consumer Health segment will help the company to get rid of slowing businesses GlaxoSmithKline plc Price  Consensus and EPS Surprise
    Zacks RankGlaxo currently carries a Zacks Rank  3  Hold   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/glaxo-gsk-beats-on-q1-earnings--sales-shingrix-impresses-200415590,200415590
196977,418493,MYL,Acorda  ACOR  Earnings And Revenues Beat Estimates In Q1,opinion,Acorda Therapeutics  Inc    NASDAQ ACOR   reported first quarter 2019 loss per share of 56 cents  narrower than the Zacks Consensus Estimate of a loss of 97 cents  However  the figure came in against the year ago earnings of 14 cents Acorda generated total revenues of  44 1 million in the first quarter  comprehensively beating the Zacks Consensus Estimate of  36 6 million  However  sales tumbled a massive 58 4  year over year due to lower sales of Ampyra Shares of Acorda were up almost 2  in pre market trading  probably owing to better than expected earnings result  However  the stock has plunged 35 5  so far this year versus the  increase of 4  Quarter in DetailLast December  the FDA approved Acorda s Parkinson s disease  PD  drug Inbrija  Following this nod  the product became the first and the only approved inhaled levodopa for treating OFF periods in patients suffering Parkinson s and receiving a carbidopa   levodopa regimen  Inbrija was launched in February this year  It is also under review in Europe with a decision expected before the end of 2019 The medicine generated sales of  1 3 million in the reported quarter  The company believes that it will pick up sales in the future quarters  having received an encouraging feedback  both from doctors and patients since its launch  An approximately 2 000 prescription request forms for Inbrija were received through April 2019 Notably  majority of Acorda s net product revenues were drawn from the company s multiple sclerosis  MS  drug  Ampyra  which raked in sales of  40 1 million in the quarter under review  Sales of Ampyra tanked 61  year over year and 37 5  sequentially due to generic competition  Last September  Ampyra lost its exclusivity and generics entered the market including Mylan s   NASDAQ MYL   authorized generic version Acorda believes that Ampyra sales will see a sharp decline in the quarters ahead in 2019 Successful commercialization of Inbrija is imperative for long term growth at Acorda  especially as generic competition looms large on Ampyra  Although Inbrija is off to a positive start  it still remains to be seen if the product can deliver the desired results and be a perfect replacement for Ampyra in the long run Meanwhile  royalty revenues decreased 12 5  to  2 8 million in the quarter Acorda s research and development  R D  expenses  excluding share based compensation expenses  were  15 3 million  reflecting a deterioration of 47 1  year over year Selling  general and administrative  SG A  expenses  excluding share based compensation expenses  were  49 9 million  representing a 15  year over year rise Acorda had  343 3 million cash  cash equivalents and investments as of March 31  2019 compared with  445 6 as of Dec 31  2018 2019 GuidanceThe company no longer provides any outlook for Ampyra due to its waning revenues  induced by the entrance of generics The company expects full year R D and SG A expenses  excluding share based compensation  in the band of  70  80 million and  200  210 million  respectively Acorda Therapeutics  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Stocks to ConsiderAcorda currently carries a Zacks Rank  4  Sell  Better ranked stocks from the healthcare sector include Merus N V    NASDAQ MRUS   and PDL BioPharma  Inc    NASDAQ PDLI    both sporting a Zacks Rank  1  Strong Buy   You can see  Merus  loss per share estimates have been narrowed 28  for 2019 and 30 7  for 2020 over the past 60 days  The stock has rallied 11 9  year to date PDL BioPharma s earnings estimates have been revised 100  upward for 2019 and 30  for 2020 over the past 60 days  The stock has gained 10 3  year to date Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ,2019-05-01,Zacks Investment Research,https://www.investing.com/analysis/acorda-acor-earnings-and-revenues-beat-estimates-in-q1-200415708,200415708
196978,418494,MYL,Mylan  MYL  Surpasses Q1 Earnings Estimates,opinion,"Mylan  NASDAQ MYL  came out with quarterly earnings of  0 82 per share  beating the Zacks Consensus Estimate of  0 79 per share  This compares to earnings of  0 96 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 3 80   A quarter ago  it was expected that this generic drugmaker would post earnings of  1 33 per share when it actually produced earnings of  1 30  delivering a surprise of  2 26  
Over the last four quarters  the company has surpassed consensus EPS estimates two times 
Mylan  which belongs to the Zacks Medical   Generic Drugs industry  posted revenues of  2 50 billion for the quarter ended March 2019  missing the Zacks Consensus Estimate by 7 32   This compares to year ago revenues of  2 68 billion  The company has not been able to beat consensus revenue estimates over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Mylan shares have added about 3 1  since the beginning of the year versus the S P 500 s gain of 17  
What s Next for Mylan 
While Mylan has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Mylan was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 02 on  2 92 billion in revenues for the coming quarter and  4 38 on  11 98 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Generic Drugs is currently in the bottom 33  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2019-05-06,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-surpasses-q1-earnings-estimates-200418191,200418191
196979,418495,MYL,Israel stocks lower at close of trade  TA 35 down 0 23 ,news,"Investing com   Israel stocks were lower after the close on Tuesday  as losses in the Oil   Gas  Communication and Real Estate sectors led shares lower 
At the close in Tel Aviv  the TA 35 fell 0 23  
The best performers of the session on the TA 35 were  OPKO Health Inc   TA OPK   which rose 3 76  or 87 points to trade at 2400 at the close  Meanwhile  Mylan NV  TA MYL  added 1 22  or 160 points to end at 13240 and Perrigo  TA PRGO  was up 0 93  or 240 points to 26100 in late trade 
The worst performers of the session were Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ   which fell 4 80  or 31 1 points to trade at 616 9 at the close   Cellcom Israel  Ltd  TA CEL  declined 2 17  or 73 points to end at 3284 and Partner  TA PTNR  was down 1 69  or 32 points to 1866 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 243 to 154 and 103 ended unchanged 
Crude oil for August delivery was down 3 11  or 1 38 to  43 05 a barrel  Elsewhere in commodities trading  Brent oil for delivery in August fell 2 84  or 1 33 to hit  45 58 a barrel  while the August Gold Futures contract fell 0 19  or 2 37 to trade at  1244 33 a troy ounce 
USD ILS was up 0 69  to 3 5510  while EUR ILS rose 0 48  to 3 9505 
The US Dollar Index Futures was up 0 26  at 97 48 ",2017-06-20,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-35-down-0.23-497313,497313
196980,418496,MYL,Israel stocks higher at close of trade  TA 35 up 0 22 ,news,"Investing com   Israel stocks were higher after the close on Wednesday  as gains in the Biomed  Real Estate and Banking sectors led shares higher 
At the close in Tel Aviv  the TA 35 gained 0 22  
The best performers of the session on the TA 35 were Mylan NV  TA MYL   which rose 2 11  or 280 points to trade at 13520 at the close  Meanwhile   Azrieli Group  Ltd  TA AZRG  added 1 55  or 300 points to end at 19600 and  Bazan  Oil Refineries Ltd  TA ORL  was up 1 53  or 2 4 points to 159 0 in late trade 
The worst performers of the session were  Frutarom  Industries Ltd  TA FRUT   which fell 1 70  or 410 points to trade at 23670 at the close  Tower Semiconductor Ltd  TA TSEM  declined 1 59  or 137 points to end at 8470 and  Strauss Group   TA STRS  was down 0 93  or 64 points to 6830 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 244 to 157 and 99 ended unchanged 
Crude oil for August delivery was up 0 57  or 0 25 to  43 76 a barrel  Elsewhere in commodities trading  Brent oil for delivery in August rose 0 35  or 0 16 to hit  46 18 a barrel  while the August Gold Futures contract rose 0 24  or 3 02 to trade at  1246 52 a troy ounce 
USD ILS was up 0 03  to 3 5431  while EUR ILS rose 0 13  to 3 9487 
The US Dollar Index Futures was down 0 05  at 97 35 ",2017-06-21,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.22-497797,497797
196981,418497,MYL,Mylan shareholders re elect board  vote against executive pay,news,"AMSTERDAM  Reuters    Mylan  NASDAQ MYL  NV shareholders re elected the generic drugmaker s board at its annual meeting on Thursday  despite a shareholder campaign to vote down most of the directors in the wake of a scandal related to its high prices for emergency allergy treatment EpiPen   Shareholders voted against a measure to approve the company s executive compensation  The shareholder campaign against Mylan s board picked up steam after Chairman Robert Coury s nearly  100 million pay package was disclosed earlier this year  
The company did not disclose the vote totals for the directors ",2017-06-22,Reuters,"https://www.investing.com/news/stock-market-news/mylan-shareholders-re-elect-board,-vote-against-executive-pay-498255",498255
196982,418498,MYL,Israel stocks lower at close of trade  TA 35 down 0 08 ,news,"Investing com   Israel stocks were lower after the close on Thursday  as losses in the Biomed  Communication and Real Estate sectors led shares lower 
At the close in Tel Aviv  the TA 35 fell 0 08  
The best performers of the session on the TA 35 were Tower Semiconductor Ltd  TA TSEM   which rose 2 80  or 237 points to trade at 8707 at the close  Meanwhile  Mylan NV  TA MYL  added 1 26  or 170 points to end at 13690 and Delek Drilling LP  TA DEDRp  was up 1 05  or 14 points to 1342 in late trade 
The worst performers of the session were Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ   which fell 2 08  or 12 8 points to trade at 602 7 at the close   Bazan  Oil Refineries Ltd  TA ORL  declined 1 45  or 2 3 points to end at 156 7 and  Israel Corp   TA ILCO  was down 1 05  or 770 points to 72700 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 255 to 147 and 98 ended unchanged 
Crude oil for August delivery was up 1 39  or 0 59 to  43 12 a barrel  Elsewhere in commodities trading  Brent oil for delivery in August rose 1 72  or 0 77 to hit  45 59 a barrel  while the August Gold Futures contract rose 0 50  or 6 20 to trade at  1252 00 a troy ounce 
USD ILS was up 0 36  to 3 5521  while EUR ILS rose 0 23  to 3 9621 
The US Dollar Index Futures was up 0 02  at 97 24 ",2017-06-22,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-35-down-0.08-498288,498288
196983,418499,MYL,Investors call on Mylan chairman  director to step down,news,"By Michael Erman NEW YORK  Reuters    An investor group led by New York City s comptroller called for Mylan NV s  O MYL  Chairman Robert Coury and Director Wendy Cameron to step down  as part of a campaign against the firm s executive pay packages and high prices for an allergy treatment  More than a third of the investors voting at the generic drugmaker s annual meeting last week cast votes against Coury  while over half voted against Cameron   who heads Mylan s compensation committee  a letter reviewed by Reuters shows   We believe Mylan s independent directors must act swiftly   or risk further erosion in shareowner confidence and value   the investors wrote in the letter to Mylan s independent directors    Mylan s share price is already down nearly 50 percent since its April 2015 peak and the company remains under legal  regulatory and public scrutiny for its EpiPen pricing practices   they added in the letter  Mylan could not be immediately reached for comment  The company has been grappling with a growing backlash from U S  consumers over the price of its life saving allergy treatment EpiPen after it shot up to more than  600 for a two pack of the device from less than  100 in 2007   nL2N1HB1KX  While the sharp price spike spurred congressional  Justice Department and other government investigations  the shareholder campaign against Mylan s board picked up steam after Chairman Coury s nearly  100 million pay package was disclosed earlier this year   nL1N1J41AU  The investor group  including New York City and State pension funds and the California teachers pension fund  have asked for Coury to forfeit most of the pay he received last year  It also urged Mylan to hire an independent chairman and reconstitute its board with a majority of independent directors  The investors agitating against Mylan s board had a steep threshold to cross as more than two thirds of the shares voted  as well as more than half of Mylan s outstanding shares  would have needed to be cast against the directors for them to lose   Neil Dimick and Mark Parrish  directors on the company s compensation committee  had just under 50 percent of the shares voted cast against their re election   Investors also cast more than a quarter of the shares voted against Chief Executive Heather Bresch   Mylan announced the vote totals from the meeting in a filing with regulators on Wednesday  The company had previously only said that all its directors had been re elected   More than 80 percent of the company s shares voted were cast against the company s 2016 executive pay packages  That vote was a non binding  advisory measure  New York City comptroller Scott Stringer  who oversees the city s pensions and is one of the leaders of the campaign against the drugmaker s board  said the board needed to act swiftly to restore investor confidence  
 This board s oversight failures have hurt investors  consumers and American taxpayers  We need to see change   Stringer said in a statement ",2017-06-29,Reuters,https://www.investing.com/news/stock-market-news/more-than-a-third-of-mylan-investors-voted-against-chairman-500329,500329
196984,418500,MYL,Israel stocks lower at close of trade  TA 35 down 0 17 ,news,"Investing com   Israel stocks were lower after the close on Wednesday  as losses in the Biomed  Real Estate and Technology sectors led shares lower 
At the close in Tel Aviv  the TA 35 fell 0 17  
The best performers of the session on the TA 35 were  Isramco  Negev 2 LP  TA ISRAp   which rose 1 68  or 0 9 points to trade at 54 4 at the close  Meanwhile  Delek Drilling LP  TA DEDRp  added 1 07  or 15 points to end at 1411 and  Elbit Systems  Ltd  TA ESLT  was up 0 87  or 380 points to 43880 in late trade 
The worst performers of the session were Teva Pharmaceutical Industries Ltd  TA TEVA   which fell 1 71  or 200 points to trade at 11520 at the close  Mylan NV  TA MYL  declined 1 03  or 140 points to end at 13450 and  Azrieli Group  Ltd  TA AZRG  was down 0 96  or 190 points to 19510 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 197 to 190 and 20 ended unchanged 
Crude oil for August delivery was down 3 76  or 1 77 to  45 30 a barrel  Elsewhere in commodities trading  Brent oil for delivery in September fell 3 29  or 1 63 to hit  47 98 a barrel  while the August Gold Futures contract rose 0 14  or 1 71 to trade at  1220 91 a troy ounce 
USD ILS was down 0 03  to 3 5143  while EUR ILS fell 0 21  to 3 9815 
The US Dollar Index Futures was up 0 15  at 96 13 ",2017-07-05,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-35-down-0.17-502296,502296
196985,418501,MYL,Israel stocks higher at close of trade  TA 35 up 0 27 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Real Estate  Biomed and Technology sectors led shares higher 
At the close in Tel Aviv  the TA 35 added 0 27  to hit a new 3 months high 
The best performers of the session on the TA 35 were  Sodastream International Ltd   TA SODA   which rose 3 44  or 640 0 points to trade at 19220 0 at the close  Meanwhile  Tower Semiconductor Ltd  TA TSEM  added 3 13  or 283 points to end at 9325 and Mylan NV  TA MYL  was up 2 03  or 280 points to 14050 in late trade 
The worst performers of the session were Teva Pharmaceutical Industries Ltd  TA TEVA   which fell 3 15  or 370 points to trade at 11390 at the close  Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ  declined 1 13  or 6 4 points to end at 558 0 and Paz Oil  TA PZOL  was down 0 34  or 200 points to 58850 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 247 to 160 and 20 ended unchanged 
Shares in Tower Semiconductor Ltd  TA TSEM  rose to 5 year highs  gaining 3 13  or 283 to 9325  Shares in Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ  fell to 3 years lows  falling 1 13  or 6 4 to 558 0  
Crude oil for August delivery was up 1 00  or 0 46 to  46 54 a barrel  Elsewhere in commodities trading  Brent oil for delivery in September rose 1 30  or 0 63 to hit  49 05 a barrel  while the August Gold Futures contract rose 0 95  or 11 58 to trade at  1228 88 a troy ounce 
USD ILS was up 0 53  to 3 5554  while EUR ILS rose 1 12  to 4 0766 
The US Dollar Index Futures was down 0 69  at 94 90 ",2017-07-16,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.27-506088,506088
196989,418505,MYL,Insys Plunges On Auditor s Concern About Insufficient Funds,opinion,"Insys Therapeutics  Inc    NASDAQ INSY   announced in its 10 K filing with Securities Exchange Commission that the company s auditor has raised concerns about its ability to continue operations  Shares of the company plunged more than 25  on Mar 13 following the filing However  shares of Insys have increased 21 4  so far this year compared with the  s rally of 11 9  In fact  the auditor stated that the company may not be able to meet its ongoing legal expenses and obligations and continue its operations due to uncertainty around the generation of sufficient funds  The company has been incurring losses over the years and also has a negative operating cash flow  The company ended 2018 with  104 1 million in cash  cash equivalents  and short term investments  However  it spent  228 million in 2018  A higher cash burn rate made the scenario worse Insys spent more than  50 million in legal expenses in 2018  almost equivalent to its research and development  R D  expenses  The company spent a huge amount on legal defense of criminal charges on former executives  The executives allegedly bribed doctors to increase sales of the company s opioid painkiller  Subsys Moreover  with the progress of pipeline candidates in the later stage of development  R D expenses are set to increase further  Two candidates   Cannabidiol oral solution and Buprenorphine sublingual spray   are being evaluated in phase III studies  The company is also planning to file a new drug application for Naloxone nasal spray in the second quarter of 2019  An early stage candidate   epinephrine nasal spray   showed similar PK profile with Mylan s   NASDAQ MYL   EpiPen as well as Par Pharmaceuticals   a subsidiary of Endo   NASDAQ ENDP    Adrenalin  epinephrine injection  in treating anaphylaxis  Insufficiency of funds can disrupt development of one or all its pipeline candidates Insys is reviewing strategic alternatives and has hired advisors to address issues such as high legal costs  legal settlement obligations and negative cash flow In November 2018  the company provided a few strategic alternatives  which it may choose to avoid closure or bankruptcy  The company may raise capital through borrowing or sale of its common stock  It may also enter strategic licensing deals and partnerships or joint ventures  Insys is also looking to sell Subsys and focus on developing dronabinol and cannabidiol candidates  The company stated on its fourth quarter earnings call that it has been actively negotiating deals to sell the drug The company currently has two marketed drugs   Subsys and Syndros  While Subsys was launched in 2012  Syndros is available since mid 2017  The company earns the majority of its product revenues from the sales of Subsys  However  demand for Subsys fell in 2018  pulling the company s top line down by almost 42  year over year  Moreover  Teva Pharma s   NYSE TEVA   abbreviated NDA seeking approval generic version of Subsys is under review Although Syndros  a dronabinol  is unlikely to face any setback due to the current legal scenario  the drug generates minimal sales  If there is no significant increase in demand of the drug  Insys will lose a major chunk of its revenues if it divests Subsys Investors can expect a detailed update on the situation when the company reports first quarter earnings Insys Therapeutics  Inc  Price
    Zacks RankInsys currently carries a Zacks Rank  4  Sell  You can see  Today s Best Stocks from ZacksWould you like to see the updated picks from our best market beating strategies  From 2017 through 2018  while the S P 500 gained  15 8   five of our screens returned  38 0    61 3    61 6    68 1   and  98 3  This outperformance has not just been a recent phenomenon  From 2000   2018  while the S P averaged  4 8  per year  our top strategies averaged up to  56 2  per year ",2019-03-13,Zacks Investment Research,https://www.investing.com/analysis/insys-plunges-on-auditors-concern-about-insufficient-funds-200397840,200397840
196990,418506,MYL,Acorda  ACOR  Down 6  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for Acorda Therapeutics  ACOR   Shares have lost about 6  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Acorda due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important drivers  Acorda Q4 Earnings and Revenues Surpass EstimatesAcorda announced fourth quarter 2018 earnings per share of 45 cents  significantly beating the Zacks Consensus Estimate of a loss of 60 cents  However  the figure declined from the year ago earnings of 61 cents Acorda generated total revenues of  69 1 million in the fourth quarter  comprehensively outshining the Zacks Consensus Estimate of  41 million  However  sales tumbled a massive 63 3  year over year Quarter in DetailMajority of Acorda s net product revenues were drawn from the company s key multiple sclerosis  MS  drug Ampyra  which raked in sales of  64 2 million in the reported quarter  Sales of Ampyra plunged 61 6  year over year and 53 4  sequentially due to generic launches including Mylan  NASDAQ MYL  s authorized generic version Also  on fourth quarter conference call  the company stated that Ampyra sales will see a steady decline in the quarters ahead in 2019 Notably  in the quarter under consideration  royalty revenues plummeted 82 6  to  2 8 million from the year ago figure of  16 1 million Acorda s research and development  R D  expenses  excluding share based compensation expenses  were  25 9 million  reflecting a decrease of 21 2  year over year Selling  general and administrative  SG A  expenses  excluding share based compensation expenses  were  33 million  representing a 3 2  year over year dip 2019 GuidanceThe company will no longer provide any outlook for Ampyra due to declining revenues  resulting from the entrance of generics The company expects full year R D and SG A expenses  excluding share based compensation  for 2019 in the band of  70  80 million and  200  210 million  respectively 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates ",2019-03-15,Zacks Investment Research,https://www.investing.com/analysis/acorda-acor-down-6-since-last-earnings-report-can-it-rebound-200398390,200398390
196991,418507,MYL,Glaxo Presents Encouraging Data On Endometrial Cancer Drug,opinion,GlaxoSmithKline plc   NYSE GSK   presented data from the phase I II GARNET study on oncology candidate  dostarlimab at the 2019 Society for Gynecologic Oncology  SGO  Annual Meeting on Women s Cancer in Honolulu  Hawaii The study evaluated dostarlimab  formerly TSR 042   an investigational humanized anti programmed death  PD  1 monoclonal antibody  in women with recurrent or advanced endometrial cancer who progressed on or after a platinum based regimen We note that endometrial cancer is the most common gynaecologic malignancy in the United States  with limited treatment options for women whose disease progresses on or after first line therapy  Endometrial cancer can be classified as microsatellite stable  MSS 75   or microsatellite instability high  MSI H 25   The study analysed 125 patients  including 41 MSI H  33    79 MSS  63   and 5 patients with an unknown MSI status  4    Dostarlimab was dosed at 500 mg once every 3 weeks for 4 doses  followed by 1000 mg once every 6 weeks until disease progression The results from the study showed clinically meaningful and durable response rates of dostarlimab in this patient population  regardless of microsatellite instability status  Moreover  the safety findings indicate that dostarlimab is well tolerated  with a safety profile consistent with that of an anti PD therapy Glaxo plans to further analyse the data from the GARNET study  using the RECIST 1 1 criteria to support regulatory filing for the drug  The company expects to submit a Biologics License Application  BLA  for dostarlimab for the treatment of endometrial cancer at the end of 2019 At the time of data cutoff  treatment was still ongoing in 84  of responders  Among these responders  89   33 of 37  have been on treatment for more than six months and 49   18 of 37  for more than a year The GARNET study is evaluating dostarlimab as monotherapy in patients with advanced solid tumors  The trial included a weight based dose escalation study  Part 1  and a fixed dose safety study  Part 2A   both of which have been completed  Results of these studies were used to determine the recommended phase II dose  Part 2B of the study includes four expansion cohorts   MSI H endometrial cancer  MSI H non endometrial cancer  MSS endometrial cancer and non small cell lung cancer  NSCLC  In 2018  the FDA granted Breakthrough Therapy designation to Eisai s orally available kinase inhibitor in combination with Merck s   NYSE MRK   anti PD 1 therapy  Keytruda  pembrolizumab  for the potential treatment of patients with advanced and or MSI H proficient mismatch repair  pMMR  endometrial carcinoma who have progressed following at least one prior systemic therapy Meanwhile  dostarlimab was added to GlaxoSmithKline s pipeline  following the Tesaro acquisition in January 2019   The acquisition of Tesaro added ovarian cancer drug  Zejula to Glaxo s portfolio  which will strengthen the latter s position in the oncology market We note that stiff competition  genericization and pricing pressure on key drugs are hurting Glaxo s top line  The FDA recently approved Mylan s   NASDAQ MYL   generic version of Glaxo s top selling drug  Advair  which will adversely affect the drug s sales  The company has undertaken restructuring initiatives to strengthen its business  It has also formed a joint venture with Pfizer   NYSE PFE   to create a premier global consumer healthcare company Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-03-19,Zacks Investment Research,https://www.investing.com/analysis/glaxo-presents-encouraging-data-on-endometrial-cancer-drug-200399515,200399515
196992,418508,MYL,Momenta  MNTA  Down 6 8  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Momenta Pharmaceuticals  MNTA   Shares have lost about 6 8  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Momenta due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Momenta Q4 Loss Narrower Than Expected  Revenues BeatThe company reported loss per share of 7 cents in the quarter  excluding restructuring charges   narrower than the Zacks Consensus Estimate of 46 cents and the year ago loss of 18 cents Revenues in the quarter came in at  42 8 million  which declined from  64 6 million in the year ago quarter but beat the Zacks Consensus Estimate of  21 1 million Quarter in DetailMomenta s top line comprises product revenues of  10 8 million earned from Sandoz s sales of Glatopa  a generic version of Copaxone  20 mg   compared with  13 4 million in the year ago quarter due to increasing competition from Mylan s entry into the Copaxone market Research and development revenues came in at  32 1 million compared with  51 2 million in the year ago quarter Research and development expenses decreased to  28 7 million from  36 1 million in the year ago quarter  due to decrease in spending on biosimilars program  As a result of its strategic review  results announced in October 2018   Momenta concluded to advance two late stage biosimilar assets   M923  which is its wholly owned proposed biosimilar to Humira  and M710  which is a proposed biosimilar to Regeneron s Eylea being developed in collaboration with Mylan  NASDAQ MYL   The company decided to exit participation in the development of its five other biosimilar programs  including M834  a proposed biosimilar to Orencia General and administrative expenses were  21 5 million  up 36 1  year over year due to increased legal costs and depreciation Pipeline UpdateMomenta entered into a settlement agreement with AbbVie  NYSE ABBV  in November 2018  providing worldwide rights to launch M923  Under the terms of the agreements and subject to approval by health regulatory authorities  Momenta may launch M923 worldwide based on agreed to launch dates  including in the United States in November 2023  In August 2018  Mylan initiated a clinical trial in patients with diabetic macular edema to compare safety  efficacy and immunogenicity of M710 with Eylea Momenta s novel auto immune portfolio includes M230  a Selective Immunomodulator of Fc receptors  SIF3   M281  an anti FcRn monoclonal antibody  and M254 Momenta initiated two phase II proof of concept clinical trials on M281  one in generalized myasthenia gravis  gMG  and the other in hemolytic disease of the fetus and newborn  HDFN   with top line results anticipated in 2020 and 2021  respectively   Momenta also plans to initiate a third study of M281 in an additional autoimmune indication in 2019 In January 2019  Momenta announced that the first subject was dosed in the phase I II clinical trial of M254 in immune thrombocytopenia   ITP   The multi part study will first enroll healthy volunteers  and includes single and multiple dose studies  and a randomized cross over study comparing M254 to IVIg  Preliminary clinical data is expected in 2020 The phase I trial on M230 in healthy volunteers to evaluate the safety and tolerability of the candidate is ongoing  Momenta s partner  CSL expects to complete the phase I study by the end of 2019 2018 ResultsMomenta generated revenues of  75 6 million in 2018  significantly down from  138 8 million in 2017 2019 GuidanceMomenta expects 2019 expenses to be  45  55 million   The company completed a  230 million equity financing in December and ended the year with a cash balance of  449 million  
How Have Estimates Been Moving Since Then 
Fresh estimates followed an upward path over the past two months  The consensus estimate has shifted 22 22  due to these changes 
VGM Scores
At this time  Momenta has a poor Growth Score of F  however its Momentum Score is doing a lot better with a B  However  the stock was allocated a grade of D on the value side  putting it in the bottom 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Momenta has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-03-23,Zacks Investment Research,https://www.investing.com/analysis/momenta-mnta-down-68-since-last-earnings-report-can-it-rebound-200400509,200400509
196993,418509,MYL,Mylan  MYL  Up 8 6  Since Last Earnings Report  Can It Continue ,opinion,"A month has gone by since the last earnings report for Mylan  NASDAQ MYL   Shares have added about 8 6  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is Mylan due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Mylan Q4 Earnings   Revenues Miss EstimatesMylan reported lower than expected results for the fourth quarter and issued a tepid 2019 guidance Adjusted earnings of  1 30 per share missed the Zacks Consensus Estimate of  1 33 and declined from  1 43 in the year ago quarter However  fourth quarter revenues of  3 08 billion missed the Zacks Consensus Estimate of  3 12 billion and declined 4 9  from the prior year quarter Quarter in DetailThe company posts results in three segments on a geographic basis  namely North America  Europe and Rest of World North America segment s net sales came in at  1 10 billion  down 16   This decline was primarily attributable to lower volumes on existing products due to actions associated with the restructuring and remediation activities at the Morgantown plant  the timing of purchases of products by customers and the impact of the implementation of new accounting standards The FDA completed an inspection at Mylan s plant in Morgantown  WV  in 2018 and made observations through a Form 483  Thereafter  Mylan submitted a comprehensive response to the FDA  During the second quarter of 2018  Mylan started a restructuring and remediation program to reduce complexity at the Morgantown manufacturing facility  which led to the discontinuation and transfer of a number of products to other manufacturing sites  a reduction in workforce and extensive remediation activities These actions have led to a temporary disruption in supply of certain products  In the fourth quarter  the company received a warning letter related to the previously disclosed observations Net sales in the Europe segment were  1 09 billion  up  15 8 million  which was primarily driven by new product sales and higher volumes on existing products Rest of World segment s net sales of  851 4 million were up 4   driven by new products Adjusted gross margin of 54 6  was slightly down from 55 5  in the year ago quarter 2018 ResultsEarnings per share of  4 58 were up from  4 56 in 2017 but missed the Zacks Consensus Estimate of  4 63  Revenues were  11 43 billion  down 4  from 2017 and missed the Zacks Consensus Estimate of  11 46 billion 2019 GuidanceRevenues are projected between  11 5 billion and  12 5 billion  with a midpoint of  12 billion that is above the Zacks Consensus Estimate of  11 89 billion The company anticipates adjusted EPS around  3 80  4 80  lower than the Zacks Consensus Estimate of  4 99  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  The consensus estimate has shifted  18 92  due to these changes 
VGM Scores
At this time  Mylan has a nice Growth Score of B  though it is lagging a bit on the Momentum Score front with a C  Charting a somewhat similar path  the stock was allocated a grade of B on the value side  putting it in the top 40  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of this revision indicates a downward shift  It s no surprise Mylan has a Zacks Rank  5  Strong Sell   We expect a below average return from the stock in the next few months ",2019-03-27,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-up-86-since-last-earnings-report-can-it-continue-200401829,200401829
196994,418510,MYL,United Therapeutics  UTHR  Down 7 2  Since Last Earnings Report  Can It Rebound ,opinion,"A month has gone by since the last earnings report for United Therapeutics  UTHR   Shares have lost about 7 2  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is United Therapeutics due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  United Therapeutics Q4 Earnings   Sales Beat EstimatesUnited Therapeutics reported adjusted earnings of  3 34 per share for the fourth quarter of 2018  which beat the Zacks Consensus Estimate of  2 54  However  earnings declined 14 1  year over year Adjusted earnings excluded the impact of share based compensation expenses  impairment charge related to investment in a privately held company  one time license fee and some other items  Including these items  reported earnings came in at  1 48 per share compared with 43 cents in the year ago quarter Revenues for the reported quarter were  381 4 million  beating the Zacks Consensus Estimate of  357 7 million  Revenues  however  fell 17 9  year over year owing to loss of exclusivity for Adcirca The Quarter in DetailUnited Therapeutics markets four products for the treatment of PAH   Remodulin  Tyvaso  Adcirca and Orenitram Adcirca sales were  41 7 million  down 65  year over year as generic competition resulted in lower volumes in the quarter  Adcirca experienced loss of exclusivity in May this year and a generic formulation was launched by Mylan  NASDAQ MYL  in August 2018 and by Dr Reddy s in February 2019  A higher allowance for product returns offset the price increase by Lilly and also hurt Adcirca s sales Orenitram sales amounted to  49 6 million in the reported quarter  up 3 3  year over year due to an increase in the number of patients being treated with the drug and price hikes  Remodulin sales were  159 1 million  down 11 7  year over year owing to lower sales in international markets  which offset higher U S  sales  Tyvaso sales totaled  106 9 million  up 15 7  year Unituxin s  for the treatment of pediatric patients with high risk neuroblastoma  sales of  24 1 million were down 3 2  year over year Research and development  R D  expenses escalated 52 9  to  139 9 million mainly on account of up front payment of  45 0 million made to MannKind related to the acquisition of the latter s phase III ready investigational drug device combination product  Treprostinil Technosphere in October General and administrative  G A  expense rose 13  to  58 1 million due to higher consulting fees while sales and marketing  S M  expense declined 4 0  to 16 9 million 2018 ResultsFull year 2018 sales declined 5 7  to  1 63 billion  slightly beating the Zacks Consensus Estimate of  1 60 billion Adjusted earnings for 2018 were  15 36 per share  which surpassed the Zacks Consensus Estimate of  15 14  However  earnings declined 7  year over year 
How Have Estimates Been Moving Since Then 
It turns out  fresh estimates flatlined during the past month  The consensus estimate has shifted 10  due to these changes 
VGM Scores
At this time  United Therapeutics has a poor Growth Score of F  however its Momentum Score is doing a lot better with a B  Charting a somewhat similar path  the stock was allocated a grade of C on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of D  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
United Therapeutics has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2019-03-28,Zacks Investment Research,https://www.investing.com/analysis/united-therapeutics-uthr-down-72-since-last-earnings-report-can-it-rebound-200402236,200402236
196995,418511,MYL,Careful With Mylan,opinion,"Mylan  NASDAQ MYL  is currently downtrending and trading within a descending triangle having it s base on the  26 mark  This short term support was tested effectively ending December and then in late February and it appears it s headed towards that price again 

However  since the price is getting more and more closer to the angle closing the triangle  it might not be such a good idea to test this support again  Now  the stock might bounce once it hits it  but it doesn t seem to have much space on the upside 
Other technical tools like MACD and Ichimoku Cloud  also show bearish signs weighing on the pharmaceutical company 

Ichimoku Cloud is pretty effective cause it anticipates the stock s movement in a 26 term  this case days   time period  When the price is trading in this case below the cloud and below it s base line  red line   you have a bearish scenario  And lastly  RSI shows it still has room for a further decrease without entering yet in oversold territory 
In conclusion  the juice ain t worth the squeeze going long on  26 but rather wait till it breaks this mark downwards to open shorts ",2019-04-04,Felipe Potes,https://www.investing.com/analysis/careful-with-mylan-200404022,200404022
196996,418512,MYL,Acorda To Gain From Inbrija Sales And Neurological Pipeline,opinion,On Apr 10  we issued an updated research report on Acorda Therapeutics  Inc    NASDAQ ACOR   Acorda received a huge boost when the FDA approved its Parkinson s disease  PD  drug  Inbrija  levodopa inhalation powder   late last December  Following this nod  the product became the first and the only approved inhaled levodopa for treating OFF periods in patients suffering Parkinson s and receiving a carbidopa   levodopa regimen In February this year  Inbrija was officially launched in the United States  The drug is also under review in the EU with a decision expected anytime soon Notably  more than 350 000 people in the United States are suffering OFF periods related to Parkinson s disease  Inbrija will help address the large unmet medical need for those afflicted with the ailment  Acorda estimates Inbrija s market opportunity to exceed  800 million in the United States Shares of Acorda have lost 17 9  in the year so far against the increase of 9 8   As Inbrija was launched during the first quarter of 2019  Acorda is yet to generate substantial revenues from the drug  Till now  majority of Acorda s net product revenues came from the company s key multiple sclerosis  MS  drug  Ampyra  However  sales of the medicine have been declining sharply year over year due to stiff competition from Mylan s   NASDAQ MYL   unveiled authorized generic version Notably  on fourth quarter 2018 conference call  the company stated that Ampyra sales will see a persistent decline in the quarters ahead this year As a result  Inbrija s successful commercialization is crucial for long term growth at Acorda  especially as generic rivalry looms large on Ampyra  It remains to be seen if Inbrija can deliver the desired results and be a perfect replacement for Ampyra Apart from these two drugs  Acorda has a pipeline of novel neurological therapies  addressing a wide range of disorders  The company is evaluating two phase II candidates   SYN120 and BTT1023   for the treatment of PD dementia and primary sclerosing cholangitis  respectively Another early stage candidate  CVT 427   an inhaled zolmitriptan  is being evaluated for the treatment of acute migraine  using Acorda s ARCUS drug delivery technology Approval of these candidates provides long term growth opportunities for the company  given the lucrative market that is being targeted Acorda Therapeutics  Inc  Price and Consensus   Zacks Rank   Stocks to ConsiderAcorda currently carries a Zacks Rank  3  Hold   Better ranked stocks in the healthcare sector include Kamada Ltd    NASDAQ KMDA   and PDL BioPharma  Inc    NASDAQ PDLI    both sporting a Zacks Rank  1  Strong Buy   You can see  Kamada s earnings estimates have moved 34 3  north for 2019 and 5  for 2020 over the past 60 days  The stock has rallied 19  so far this year PDL BioPharma s earnings estimates have been revised 100  upward for 2019 and 30  for 2020 over the past 60 days  The stock has surged 32 7  year to date Breakout Biotech Stocks with Triple Digit Profit PotentialThe biotech sector is projected to surge beyond  775 billion by 2024 as scientists develop treatments for thousands of diseases  They re also finding ways to edit the human genome to literally erase our vulnerability to these diseases Zacks has just released Century of Biology  7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance  Our recent biotech recommendations have produced gains of  98    119  and  164  in as little as 1 month  The stocks in this report could perform even better ,2019-04-10,Zacks Investment Research,https://www.investing.com/analysis/acorda-to-gain-from-inbrija-sales-and-neurological-pipeline-200406003,200406003
196997,418513,MYL,Israel stocks higher at close of trade  TA 35 up 0 47 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Banking  Technology and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 35 rose 0 47  
The best performers of the session on the TA 35 were  OPKO Health Inc   TA OPK   which rose 8 13  or 175 points to trade at 2328 at the close  Meanwhile  First  International  Bank of Israel Ltd  TA FTIN  added 2 64  or 164 points to end at 6367 and  Frutarom  Industries Ltd  TA FRUT  was up 1 99  or 450 points to 23120 in late trade 
The worst performers of the session were Perrigo  TA PRGO   which fell 3 05  or 810 points to trade at 25750 at the close  Mylan NV  TA MYL  declined 1 65  or 230 points to end at 13750 and Partner  TA PTNR  was down 1 08  or 21 points to 1916 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 234 to 164 and 105 ended unchanged 
Shares in First International Bank of Israel Ltd  TA FTIN  rose to 5 year highs  up 2 64  or 164 to 6367  
Crude oil for July delivery was down 1 20  or 0 58 to  47 78 a barrel  Elsewhere in commodities trading  Brent oil for delivery in August fell 1 19  or 0 60 to hit  50 03 a barrel  while the August Gold Futures contract rose 0 80  or 10 10 to trade at  1280 20 a troy ounce 
USD ILS was down 0 35  to 3 5466  while EUR ILS rose 0 26  to 4 0018 
The US Dollar Index Futures was down 0 57  at 96 61 ",2017-06-04,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.47-491636,491636
196998,418514,MYL,Israel stocks lower at close of trade  TA 35 down 0 12 ,news,"Investing com   Israel stocks were lower after the close on Thursday  as losses in the Biomed  Technology and Real Estate sectors led shares lower 
At the close in Tel Aviv  the TA 35 declined 0 12  
The best performers of the session on the TA 35 were Mylan NV  TA MYL   which rose 2 26  or 310 points to trade at 14050 at the close  Meanwhile  Perrigo  TA PRGO  added 1 16  or 290 points to end at 25260 and Israel Discount Bank Ltd  TA DSCT  was up 1 05  or 9 5 points to 910 5 in late trade 
The worst performers of the session were  Big  Shopping Centers Ltd  TA BIG   which fell 2 38  or 670 points to trade at 27470 at the close   OPKO Health Inc   TA OPK  declined 2 30  or 52 points to end at 2205 and  Isramco  Negev 2 LP  TA ISRAp  was down 2 23  or 1 3 points to 57 0 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 235 to 158 and 109 ended unchanged 
Shares in Isramco Negev 2 LP  TA ISRAp  fell to 3 years lows  down 2 23  or 1 3 to 57 0  
Crude oil for July delivery was up 0 17  or 0 08 to  45 80 a barrel  Elsewhere in commodities trading  Brent oil for delivery in August fell 0 06  or 0 03 to hit  48 03 a barrel  while the August Gold Futures contract fell 1 09  or 14 08 to trade at  1279 12 a troy ounce 
USD ILS was down 0 32  to 3 5290  while EUR ILS fell 0 60  to 3 9613 
The US Dollar Index Futures was up 0 26  at 96 92 ",2017-06-08,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-35-down-0.12-493374,493374
196999,418515,MYL,ISS recommends voting against ten Mylan board nominees,news," Reuters    Influential proxy firm ISS on Monday urged shareholders of generic drugmaker Mylan  NASDAQ MYL  NV to vote against most of the company s nominees to its board of directors  ahead of a shareholder meeting later this month  Mylan has come under fire for sharply increasing the price of EpiPen and classifying the life saving treatment as a generic rather than a branded product  which led to much smaller rebates to state Medicaid programs  Mylan faces multiple investigations   All incumbent directors should be considered accountable for material failures of risk oversight over a number of years  when warning signs were available to  Mylan  but no actions appear to have been taken   ISS said in a report  citing an erosion in  shareholder value  as a result of the EpiPen controversy  ISS recommended that shareholders vote against ten of Mylan s director nominees including CEO Heather Bresch  President Rajiv Malik and Chairman Robert Coury  The proxy firm  however  backed new director nominee Sjoerd Vollenbregt  
Mylan met with ISS last week and discussed the role of Coury in growing the company  and defended his compensation  which was more than  97 million in 2016 ",2017-06-12,Reuters,https://www.investing.com/news/stock-market-news/iss-recommends-voting-against-ten-mylan-board-nominees-494353,494353
197000,418516,MYL,Israel stocks higher at close of trade  TA 35 up 0 33 ,news,"Investing com   Israel stocks were higher after the close on Tuesday  as gains in the Real Estate  Insurance and Biomed sectors led shares higher 
At the close in Tel Aviv  the TA 35 added 0 33  
The best performers of the session on the TA 35 were  Sodastream International Ltd   TA SODA   which rose 6 57  or 1160 0 points to trade at 18810 0 at the close  Meanwhile   Frutarom  Industries Ltd  TA FRUT  added 2 52  or 580 points to end at 23600 and  Airport City  Ltd  TA ARPT  was up 2 45  or 115 points to 4815 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 4 08  or 570 points to trade at 13400 at the close  Perrigo  TA PRGO  declined 2 91  or 750 points to end at 25000 and  Isramco  Negev 2 LP  TA ISRAp  was down 1 43  or 0 8 points to 55 2 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 246 to 145 and 109 ended unchanged 
Shares in Isramco Negev 2 LP  TA ISRAp  fell to 3 years lows  falling 1 43  or 0 8 to 55 2  
Crude oil for July delivery was down 0 78  or 0 36 to  45 72 a barrel  Elsewhere in commodities trading  Brent oil for delivery in August fell 0 54  or 0 26 to hit  48 03 a barrel  while the August Gold Futures contract fell 0 22  or 2 74 to trade at  1266 16 a troy ounce 
USD ILS was down 0 42  to 3 5304  while EUR ILS fell 0 39  to 3 9565 
The US Dollar Index Futures was down 0 16  at 96 99 ",2017-06-13,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.33-494899,494899
197001,418517,MYL,Adamis wins U S  approval to sell EpiPen rival  shares soar,news,By Bill Berkrot  Reuters    Adamis Pharmaceuticals Corp said on Thursday it received U S  approval for its emergency epinephrine syringes to treat severe allergic reactions that it intends to be a lower cost rival to Mylan  NASDAQ MYL  NV s widely used EpiPen  sending its shares up more than 50 percent  The company said it was looking for a marketing partner and would set a price for the product before its launch sometime in the second half of this year  Adamis said its pre filled epinephrine syringes would be sold under the brand name Symjepi  Mylan has faced severe criticism and congressional and legal investigations after it doubled the cost for a pair of EpiPens to around  600  enraging consumers and putting it in the center of the ongoing debate over the high cost of prescription medicines in the United States  It has since offered its own generic version for about  300 in response to the furor   We plan to position the product as a lower cost alternative   Mark Flather  senior director for investor relations and corporate communications for Adamis  told Reuters   We want to be part of the solution   Epinephrine is the life saving recommended treatment for severe allergic reactions  such as to bee stings  exposure to peanuts or medications  Mylan has for years owned more than 90 percent of the market for emergency epinephrine injectors and its own authorized generic has recently surpassed sales of the branded version   With an anticipated lower cost and attractive design  we believe Symjepi will be a meaningful competitor to EpiPen    Wells Fargo   NYSE WFC  Securities analyst David Maris said in a research note  Other rival products are available  Impax Laboratories Inc s Adrenaclick device is being sold through CVS Health  NYSE CVS  Corp s drugstore chain for about  110 a pair  Privately held Kaleo earlier this year began selling its Auvi Q epinephrine auto injector that it reacquired from Sanofi  PA SASY  SA under an unusual pricing strategy but with little success so far  The company said it would make the product available at no cost to many consumers but charge insurers  4 500  Sanofi in April sued Mylan  accusing it of engaging in illegal practices to squash EpiPen competition when the French drugmaker held the Auvi Q rights  Adamis shares soared 53 3 percent to close at  5 75 on the Nasdaq and further rose to  6 00 in extended trading  Mylan shares closed down 2 4 percent at  36 98 ,2017-06-15,Reuters,"https://www.investing.com/news/stock-market-news/adamis-gets-u.s.-approval-to-sell-epipen-rival,-shares-soar-496021",496021
197007,418523,MYL,Glaxo  GSK  Beats On Q4 Earnings  To Focus On Oncology In  19,opinion,"GlaxoSmithKline plc   NYSE GSK   reported adjusted earnings of 79 cents per American depositary share   ADS   for the fourth quarter of 2018  which beat the Zacks Consensus Estimate of 70 cents  Earnings were up 10  at constant exchange rate   CER   from the year ago figure Shares of Glaxo were up almost 3 1  on Feb 6  However  the stock has lost 1 8  in the past six months against the  s 1 3  rise Quarterly revenues rose 6  at CER to  10 4 billion   8 2 billion   driven by growth in all the three business segments  especially strong performance at the Vaccines segment  The top line beat the Zacks Consensus Estimate of  9 85 billion                                                           Full Year ResultsThe company s adjusted earnings per ADS were  3 18 per share for the full year  up 12  at CER  Full year revenues rose 5  at CER to approximately  41 billion All growth rates mentioned below are on a year over year basis and at CER Quarterly HighlightsSales were up 8  in the United States and 6  in the International markets  Sales in Europe were up 1  year over yearGlaxo reports financial figures under three segments  Pharmaceuticals  Vaccines and Consumer Healthcare The Pharmaceuticals division registered 4  increase in revenues at CER  The upside was driven by HIV drugs  Tivicay and Juluca  and new respiratory disease drugs  Growth in Nucala and the Ellipta portfolio offset the strong decline in sales of Seretide Advair  Sales of Established Pharmaceuticals rose 1  HIV sales increased 6  at CER on the back of 7  and 18  growth in the Europe and International markets  respectively  U S  sales were up 3  at CER  These encouraging numbers were driven by continued sales growth for Triumeq  Tivicay and Juluca  The company continued to hold 27  of the HIV vaccine market share in the United States during the fourth quarter  However  sales of another HIV drug named Epzicom Kivexa tumbled 31  at CER due to severe generic competition Notably  the company s latest product from the HIV portfolio is Juluca  dolutegravir   rilpivirine   the first two drug regimen  once daily  single pill for HIV  The drug was approved in the United States in November 2017  It generated sales of  62 million  a marked improvement from  37 million registered in the third quarter of 2018 Respiratory sales were also up 2  at CER  The sales increase from the Ellipta portfolio and Nucala was partly offset by a fall in sales of older products like Seretide Advair  Sales of new respiratory portfolio grew 34   including  77 million quarterly contribution  up 83 3  sequentially  from the newly launched Trelegy Ellipta  only once daily single inhaler triple therapy for COPD  benefiting from the U S  label expansion in April In the International markets  sales of respiratory drugs increased 10  and 7  in Europe  However  sales in the United States were down 3  as decline in Advair sales offset growth registered by the new products in the category Earlier this month  the FDA  Mylan s   NASDAQ MYL   generic version of Advair   Wixela Inhub   the first Advair generic in the United States  which is expected to be launched by the end of this month  Glaxo expects the generic launch to severely impact the already declining sales of Advair in 2019  Moreover  Glaxo will move Advair to its Established Pharmaceuticals portfolio starting with the first quarter of 2019 Immuno inflammation drugs like Benlysta rose 34  in the quarter under discussion Sales in the Consumer Healthcare segment increased 1  at CER as strong performances in Oral health and Nutrition were partly offset by decline in the Wellness and Skin health category  Although the segment performed well in the United States and International markets  it is facing increased competition and slowing demand in Europe Unfavorable impact of Horlicks and MaxiNutrition divestment along with other smaller brands in the United Kingdom was offset by growth of Transderm Scop in the United States as it benefited from supply constraints faced by its generic competitors In December 2018  the company announced the divestment of renowned brands      in the emerging markets  which is expected to be closed by the end of 2019  In the same month  it announced a  with Pfizer   NYSE PFE   to create the world s largest Consumer Healthcare business  Glaxo expects to eventually spin off the business in the next three years following the closure of the deal in the second half of 2019 Sales from the Vaccines segment were impressive  having increased 18  at CER  primarily driven by higher sales of new shingles vaccine  Shingrix and strong performance of influenza products  However  sales of meningitis vaccines Bexsero and Menveo were down 3  and 37   respectively  Shingrix sales more than doubled to  221 million in the reported quarter driven by market expansion in new patient population The company  however  expects its meningitis portfolio to return to strong growth in 2019 Influenza vaccine  Fluarix grew 69  due to improved European sales and stronger sales in the United States Selling  general and administration  SG A  costs increased 3  year over year to  2 5 billion due to increased commercial activities to support launches  partly offset by cost control initiatives Research and development  R D  expenses were down 1  to  1 billion  reflecting benefits of re prioritization of the R D portfolio  which was partially offset by increased investments to support progress of clinical studies  especially oncology 2019 OutlookGlaxo expects its EPS to decline 5 9  at CER in 2019  including the impact of Advair generic and costs related to the acquisition of TESARO  The guidance assumes closure of joint venture with Pfizer for Consumer Healthcare business and divestment of certain nutrition brands in India Bangladesh in 2019Loss of Advair sales in the United States due to generic launch is expected to result in a slight decline in sales in Glaxo s Pharmaceutical segment in 2019  Novartis   NYSE NVS   and Hikma Pharmaceuticals are also looking to get approval for its Advair generic  A potential approval of their drugs will further erode sales of the branded drug Our TakeWe are encouraged by Glaxo s restructuring initiatives to focus on strengthening its pharmaceutical portfolio  The company boosted its oncology portfolio with the acquisition of  in January and a collaboration agreement with Germany based   announced this month  Following these two transactions  the company will have 16 oncology pipeline candidates including candidates developed in house These transactions along with the restructuring initiatives related to the Consumer Health segment will help the company to get rid of slowing businesses and should help in successful development of its oncology pipeline GlaxoSmithKline plc Price  Consensus and EPS Surprise
    Zacks Rank Glaxo currently carries a Zacks Rank  3  Hold   You can see  Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ",2019-02-06,Zacks Investment Research,https://www.investing.com/analysis/glaxo-gsk-beats-on-q4-earnings-to-focus-on-oncology-in-19-200385245,200385245
197008,418524,MYL,Acorda  ACOR  Q4 Earnings And Revenues Surpass Estimates,opinion,Acorda Therapeutics  Inc    NASDAQ ACOR   announced fourth quarter 2018 earnings per share of 45 cents  significantly beating the Zacks Consensus Estimate of a loss of 60 cents  However  the figure declined from the year ago earnings of 61 cents Acorda generated total revenues of  69 1 million in the fourth quarter  comprehensively outshining the Zacks Consensus Estimate of  41 million  However  sales tumbled a massive 63 3  year over year Shares of Acorda have plunged 38  in the past year  wider than the  decline 18 4  Quarter in DetailMajority of Acorda s net product revenues were drawn from the company s key multiple sclerosis  MS  drug Ampyra  which raked in sales of  64 2 million in the reported quarter  Sales of Ampyra plunged 61 6  year over year and 53 4  sequentially due to completion of generic launches including Mylan s   NASDAQ MYL   authorized generic version Also  on fourth quarter conference call  the company stated that Ampyra sales will see a steady decline in the quarters ahead in 2019 In March 2017  the U S  District Court for the District of Delaware invalidated four patents pertaining to Ampyra on the basis of obviousness  Originally  these patents were set to expire between 2025 and 2027  Last July  the Federal Circuit denied Acorda s plea for a preliminary injunction to avoid at risk launches preceding the Appeals Court decision Last September  the U S  Court of Appeals for the Federal Circuit upheld the District Court s previous ruling by a 2 to 1 vote to invalidate four patents of Ampyra  This paved the way for the entry of a generic product Acorda filed an en banc petition  requesting a review by the entire court regarding the unfavorable ruling for Ampyra  The idea of the application is to request for a session  which will be heard by all the judges of the court  In January 2019  the Federal Circuit denied Acorda s petition for an en banc hearing of the Ampyra patent appeal case Notably  in the quarter under consideration  royalty revenues plummeted 82 6  to  2 8 million from the year ago figure of  16 1 million Acorda s research and development  R D  expenses  excluding share based compensation expenses  were  25 9 million  reflecting a decrease of 21 2  year over year Selling  general and administrative  SG A  expenses  excluding share based compensation expenses  were  33 million  representing a 3 2  year over year dip Acorda had  445 million as cash  cash equivalents and investments as of December 2018 Pipeline UpdatesAcorda s biggest achievement in 2018 was the FDA approval of its Parkinson s disease  PD  drug  Inbrija  levodopa inhalation powder   in late last December  Following this nod  the product became the first and the only legitimate inhaled levodopa for treating OFF periods in patients suffering Parkinson s and receiving a carbidopa   levodopa regimen  Inbrija is expected to be launched during the first quarter of 2019 in the United States  The drug is also under review in the EU with a decision pending by this year end 2019 GuidanceThe company will no longer provide any outlook for Ampyra due to declining revenues  resulting from the entrance of generics The company expects full year R D and SG A expenses  excluding share based compensation  for 2019 in the band of  70  80 million and  200  210 million  respectivelyAcorda Therapeutics  Inc  Price  Consensus and EPS Surprise   Zacks Rank   Other Stocks to ConsiderAcorda currently carries a Zacks Rank  2  Buy   Other top ranked stocks in the healthcare sector include Sunesis Pharmaceuticals  Inc     NASDAQ SNSS    and BioDelivery Sciences International  Inc     NASDAQ BDSI     both sporting a Zacks Rank  1  Strong Buy   You can see  Sunesis  loss per share estimates have been narrowed 14 7  for 2019 over the past 60 days BioDelivery Sciences  loss per share estimates has been narrowed 12  for 2019 over the past 60 days  The stock has skyrocketed 113 8  in the past year Zacks  Top 10 Stocks for 2019In addition to the stocks discussed above  wouldn t you like to know about our 10 finest buy and holds for the year From more than 4 000 companies covered by the Zacks Rank  these 10 were picked by a process that consistently beats the market  Even during 2018 while the market dropped  5 2   our Top 10s were up well into double digits  And during bullish 2012   2017  they soared far above the market s  126 3   reaching  181 9  This year  the portfolio features a player that thrives on volatility  an AI comer  and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs ,2019-02-14,Zacks Investment Research,https://www.investing.com/analysis/acorda-acor-q4-earnings-and-revenues-surpass-estimates-200388884,200388884
197009,418525,MYL,Mylan  MYL  To Report Q4 Earnings  What s In The Offing ,opinion,"Mylan N V    NASDAQ MYL   is scheduled to report fourth quarter 2018 results on Feb 26  after the market closes 
The company s performance has been mixed so far  with earnings missing estimates in two of the last four quarters  Mylan reported average negative earnings surprise of 1 95  over the said time frame  In the last reported quarter  the company s earnings beat estimates by 6 8   Let s see how things are shaping up for this announcement 
Mylan s stock has lost 17 5  in the past six months compared with the  decline of 24 4  

 
Factors to Consider
Along with third quarter results  Mylan reiterated its outlook for 2018  Mylan expects 2018 total revenues of  11 25  12 25 billion  The company anticipates adjusted earnings per share  EPS  around  4 55  4 90 
Mylan proactively discontinued a number of products  while also transferring some to other sites  These have led to a temporary disruption in supply of certain products and reduction in volumes in North America generic sales  This  in turn  might impact sales 
While Mylan has one of the largest product portfolios among all generic pharmaceutical companies  the company has suffered a few setbacks in recent times  Mylan suffered a major setback as rival Teva Pharmaceutical Industries Ltd    NYSE TEVA   won the FDA approval for the first generic version of the former s EpiPen and EpiPen Jr  epinephrine  auto injector for the emergency treatment of allergic reactions  including those that are life threatening  anaphylaxis   in adults and pediatric patients 
The approval of a generic will negatively impact EpiPen sales of Mylan  as the generic will obviously be priced lower  Mylan was earlier under the scanner for high price of the product   We note that the company already has its own authorized generic for the product  Teva has also launched its generic version 
During the earnings call  we expect investors to focus on the performance of EpiPen  newly launched biosimilars and other updates from the company s pipeline 
Mylan received a significant boost when the FDA approved its generic version of GlaxoSmithKline s Advair Diskus   Wixela Inhub   following a few setbacks  Notably  this is the first generic of Advair Diskus approved  which  in turn  will give Mylan an edge over its competitors  Mylan has launched the generic 
The biosimilar business continues to gain traction  Mylan and partner Biocon had earlier obtained FDA approval of Fulphila  a biosimilar of Neulasta  The European Commission  EC  granted marketing authorization to Hulio  a biosimilar of Humira  for all indications  Approval of new biosimilars should boost sales 
In November 2019  Mylan and partner Theravance Biopharma  Inc  obtained FDA approval for Yupelri  revefenacin  inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary disease  COPD   Yupelri  a long acting muscarinic antagonist  LAMA   is the first and only once daily  nebulized bronchodilator approved for the treatment of COPD in the United States 
Earnings Whispers
Our proven model doesn t show that Mylan is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat on earnings  That is not the case here as you will see below 
Earnings ESP  The Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is  1 37   You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Mylan currently carries a Zacks Rank  3  While the rank is favorable  the company s negative ESP makes surprise prediction difficult 
Note that we caution against Sell rated stocks   4 or 5  going into earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks to Consider
Here are few pharma company you may want to consider  as our model shows that it has the right combination of elements to deliver an earnings beat this quarter 
Mallinckrodt   NYSE MNK   has an Earnings ESP of  2 25  and a Zacks Rank  2  The company is scheduled to report results on Feb 26  You can see  
Jazz Pharmaceuticals plc    NASDAQ JAZZ   has an Earnings ESP of  3 55  and a Zacks Rank  3  It is scheduled to release results on Feb 26 
Zacks  Top 10 Stocks for 2019
In addition to the stocks discussed above  would you like to know about our 10 finest buy and holds for the year 
Who wouldn t  Our annual Top 10s have beaten the market with amazing regularity  In 2018  while the market dropped  5 2   the portfolio scored well into double digits overall with individual stocks rising as high as  61 5   And from 2012 2017  while the market boomed  126 3  Zacks  Top 10s reached an even more sensational  181 9  ",2019-02-20,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-to-report-q4-earnings-whats-in-the-offing-200390394,200390394
197010,418526,MYL,Momenta  MNTA  Q4 Loss Narrower Than Expected  Revenues Beat,opinion,"Shares of Momenta Pharmaceuticals Inc    NASDAQ MNTA   gained 8 6  after the company reported better than expected results for the fourth quarter The company reported loss per share of 7 cents in the quarter  excluding restructuring charges   narrower than the Zacks Consensus Estimate of 46 cents and the year ago loss of 18 cents Revenues in the quarter came in at  42 8 million  which declined from  64 6 million in the year ago quarter but beat the Zacks Consensus Estimate of  21 1 million Quarter in DetailMomenta s top line comprises product revenues of  10 8 million earned from Sandoz s sales of Glatopa  a generic version of Copaxone  20 mg   compared with  13 4 million in the year ago quarter due to increasing competition from Mylan s   NASDAQ MYL   entry into the Copaxone market Research and development revenues came in at  32 1 million compared with  51 2 million in the year ago quarter Research and development expenses decreased to  28 7 million from  36 1 million in the year ago quarter  due to decrease in spending on biosimilars program  As a result of its strategic review  results announced in October 2018   Momenta concluded to advance two late stage biosimilar assets   M923  which is its wholly owned proposed biosimilar to AbbVie s   NYSE ABBV   Humira  and M710  which is a proposed biosimilar to Regeneron s Eylea being developed in collaboration with Mylan  The company decided to exit participation in the development of its five other biosimilar programs  including M834  a proposed biosimilar to Orencia General and administrative expenses were  21 5 million  up 36 1  year over year due to increased legal costs and depreciation Pipeline UpdateMomenta entered into a settlement agreement with AbbVie in November 2018  providing worldwide rights to launch M923  Under the terms of the agreements and subject to approval by health regulatory authorities  Momenta may launch M923 worldwide based on agreed to launch dates  including in the United States in November 2023  In August 2018  Mylan initiated a clinical trial in patients with diabetic macular edema to compare safety  efficacy and immunogenicity of M710 with Eylea Momenta s novel auto immune portfolio includes M230  a Selective Immunomodulator of Fc receptors  SIF3   M281  an anti FcRn monoclonal antibody  and M254 Momenta initiated two phase II proof of concept clinical trials on M281  one in generalized myasthenia gravis  gMG  and the other in hemolytic disease of the fetus and newborn  HDFN   with top line results anticipated in 2020 and 2021  respectively   Momenta also plans to initiate a third study of M281 in an additional autoimmune indication in 2019 In January 2019  Momenta announced that the first subject was dosed in the phase I II clinical trial of M254 in immune thrombocytopenia   ITP   The multi part study will first enroll healthy volunteers  and includes single and multiple dose studies  and a randomized cross over study comparing M254 to IVIg  Preliminary clinical data is expected in 2020 The phase I trial on M230 in healthy volunteers to evaluate the safety and tolerability is ongoing  Momenta s partner  CSL expects to complete the phase I study by the end of 2019 2018 ResultsMomenta generated revenues of  75 6 million in 2018  significantly down from  138 8 million in 2017 2019 GuidanceMomenta expects 2019 expenses to be  45  55 million   The company completed a  230 million equity financing in December and ended the year with a cash balance of  449 million Our TakeMomenta s fourth quarter results were better than expected  Last year was a transformational year for Momenta as it undertook a strategic review with the goal to transform the company from its dual focus on novel drugs in biosimilars to a company primarily focused on the discovery and development of novel drugs to treat rare  immune mediated disorders  The company has narrowed its focus on its biosimilars portfolio Earlier  the FDA approval of Glatopa 40 mg relieved Momenta  but competition was stiff as Mylan had already won the FDA s approval for a generic version of Teva Pharmaceuticals    NYSE TEVA   Copaxone 40 mg  thereby limiting gains Hence  Momenta is now focussing on its novel drugs portfolio  We expect investors to focus on further updates from the drug candidates in development as the year progress  Zacks Rank
Momenta currently carries a Zacks Rank  3  Hold   You can see  This Could Be the Fastest Way to Grow Wealth in 2019Research indicates one sector is poised to deliver a crop of the best performing stocks you ll find anywhere in the market  Breaking news in this space frequently creates quick double  and triple digit profit opportunities These companies are changing the world   and owning their stocks could transform your portfolio in 2019 and beyond  Recent trades from this sector have generated  98    119  and  164  gains in as little as 1 month ",2019-02-24,Zacks Investment Research,https://www.investing.com/analysis/momenta-mnta-q4-loss-narrower-than-expected-revenues-beat-200392205,200392205
197011,418527,MYL,Mylan  MYL  Q4 Earnings   Revenues Miss Estimates  Stock Down,opinion,"Shares of Mylan N V   NASDAQ MYL   have declined 9 7  in after market trading  after the company reported lower than expected results for the fourth quarter and issued a tepid 2019 guidance 
Mylan s stock has lost 31 8  in the past six months compared with the  decline of 24 3  

 
Adjusted earnings of  1 30 per share missed the Zacks Consensus Estimate of  1 33 and declined from  1 43 in the year ago quarter 
However  fourth quarter revenues of  3 08 billion missed the Zacks Consensus Estimate of  3 12 billion and declined 4 9  from the prior year quarter 
Quarter in Detail
The company posts results in three segments on a geographic basis  namely North America  Europe and Rest of World 
North America segment s net sales came in at  1 10 billion  down 16   This decline was primarily attributable to lower volumes on existing products due to actions associated with the restructuring and remediation activities at the Morgantown plant  the timing of purchases of products by customers and the impact of the implementation of new accounting standards 
The FDA completed an inspection at Mylan s plant in Morgantown  WV  in 2018 and made observations through a Form 483  Thereafter  Mylan submitted a comprehensive response to the FDA  During the second quarter of 2018  Mylan started a restructuring and remediation program to reduce complexity at the Morgantown manufacturing facility  which led to the discontinuation and transfer of a number of products to other manufacturing sites  a reduction in workforce and extensive remediation activities 
These actions have led to a temporary disruption in supply of certain products  In the fourth quarter  the company received a warning letter related to the previously disclosed observations 
Net sales in the Europe segment were  1 09 billion  up  15 8 million  which was primarily driven by new product sales and higher volumes on existing products 
Rest of World segment s net sales of  851 4 million were up 4   driven by new products 
Adjusted gross margin of 54 6  was slightly down from 55 5  in the year ago quarter 
2018 Results
Earnings per share of  4 58 were up from  4 56 in 2017 but missed the Zacks Consensus Estimate of  4 63  Revenues were  11 43 billion  down 4  from 2017 and missed the Zacks Consensus Estimate of  11 46 billion 
2019 Guidance
Revenues are projected between  11 5 billion and  12 5 billion  with a midpoint of  12 billion that is above the Zacks Consensus Estimate of  11 89 billion 
The company anticipates adjusted EPS around  3 80  4 80  lower than the Zacks Consensus Estimate of  4 99 
Our Take
Mylan s fourth quarter results were disappointing as the company missed on both earnings and sales  While the generic market in large has been experiencing a slowdown  Mylan itself proactively discontinued a number of products along with transferring some to other sites 
These have led to a temporary disruption in supply of certain products and reduced volumes in North America generic sales  including the EpiPen auto injector  We note that rival Teva Pharmaceutical   NYSE TEVA   has already won the FDA approval for the first generic version of Mylan s EpiPen and EpiPen Jr  which  in turn  will impact sales further 
Moreover  slower than expected uptake of generic Copaxone  even after reducing the price by more than 60   adversely impacted sales in North America 
The guidance for 2019 was disappointing as well 
Nevertheless  Mylan received a significant boost when the FDA approved its generic version of GlaxoSmithKline s   NYSE GSK   Advair Diskus   Wixela Inhub   following a few setbacks  Notably  this is the first generic of Advair Diskus approved  which  in turn  will give Mylan an edge over its competitors  Mylan has launched the generic and continues to gain traction with its biosimilar portfolio 
Mylan and partner Biocon obtained the FDA approval for Fulphila  a biosimilar of Neulasta  The company earlier received the FDA approval for a biosimilar version of Roche Holdings    OTC RHHBY   Herceptin 
Zacks Rank
Mylan currently carries a Zacks Rank  3  Hold   You can see  
Is Your Investment Advisor Fumbling Your Financial Future See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-02-26,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-q4-earnings--revenues-miss-estimates-stock-down-200393103,200393103
197012,418528,MYL,Theravance  TBPH  Q4 Loss Narrows  Revenues Beat Estimates,opinion,"Theravance Biopharma  Inc    NASDAQ TBPH   incurred a loss of 92 cents per share in fourth quarter 2018  narrower than the Zacks Consensus Estimate of a loss of  1 12 and the year ago loss of  1 64 
Total revenues in the quarter under review skyrocketed 248 5  year over year to  15 7 million  mainly on the back of an upfront payment received from Johnson   Johnson   NYSE JNJ   in relation to a joint development agreement for Theravance s pan Janus kinase inhibitor  TD 1473  Moreover  the top line surpassed the Zacks Consensus Estimate of  12 3 million 
Quarter in Detail
In November 2018  Theravance completed the sale of its only marketed drug  Vibativ to Cumberland Pharmaceuticals  As a result  the company was not able to generate a full quarter of product sales for the drug 
Vibativ is a once daily dual mechanism antibiotic  approved in the United States  Europe and certain other countries for specifically difficult to treat infections  The drug generated U S  revenues of  2 4 million in the fourth quarter  down 41 5  from the year ago period s figure 
Revenues from collaborations  primarily related to the collaboration with J J for TD 1473  were  10 million compared with  0 39 million in the year earlier quarter  Profit sharing revenues related to Yupelri was  3 3 million in the quarter 
Theravance is collaborating with Mylan   NASDAQ MYL   for the development and commercialization of Yupelri  revefenacin  for the maintenance treatment of adults with chronic obstructive pulmonary disease  COPD   which was approved by the FDA last November  Formal launch activities of Yupelri are currently underway 
Research and development expenses were  52 3 million  up 2 3  from the year ago quarter  primarily due to higher costs to support key programs 
Selling  general   administrative expenses decreased 13 5  to  25 5 million  due to lower expenses regarding share based compensation 
Pipeline and Other Updates
Theravance has a promising pipeline  The company inked a collaboration agreement with Johnson   Johnson s subsidiary  Janssen for developing its JAK inhibitors  TD 1473 and TD 0714  for the treatment of inflammatory intestinal diseases 
In November 2018  Theravance dosed the first patient in a phase II study on its gut selective pan JAK inhibitor  TD 1473 for the treatment of patients with Crohn s disease  The candidate is also being evaluated in phase Ib study for the treatment of ulcerative colitis 
Also  in November 2018  Theravance dosed the first patient in a phase I study on its novel  inhaled  lung selective pan Janus kinase  JAK  inhibitor  TD 8236  The candidate is currently being developed to evaluate its potential for the treatment of various serious respiratory diseases  The company plans to provide biomarker data of TD 8236 in healthy volunteers and asthma patients by mid 2019 
Last month  Theravance dosed the first patient in a phase III study on ampreloxetine  TD 9855  for treating patients with symptomatic neurogenic orthostatic hypotension  nOH  
Notably  Theravance has an economic interest in royalties paid by Glaxo   NYSE GSK   on Trelegy Ellipta s global sales  Trelegy Ellipta  a triple combination therapy of inhaled corticosteroid  ICS  LAMA LABA  fluticasone furoate umeclidinium vilanterol  FF UMEC VI    was approved in September 2017 as a maintenance treatment for COPD patients who are not adequately treated by a combination of ICS and LABA 
Glaxo plans to complete the phase III CAPTAIN study on Trelegy Ellipta for treating asthma patients in the first half of 2019  If data from the study is found to be positive  Glaxo will submit a supplemental new drug application  sNDA  in the second half of this year for Trelegy Ellipta to treat asthma 
In the fourth quarter of 2018  Glaxo recorded sales of  100 million for Trelegy Ellipta  Theravance is eligible to receive 5 5 8 5   tiered  of the product s worldwide net sales 
2019 Outlook
For 2019  Theravance anticipates operating loss  excluding non cash share based compensation  to be  210  230 million 
Zacks Rank
Theravance currently carries a Zacks Rank  2  Buy   You can see  
Is Your Investment Advisor Fumbling Your Financial Future 
See how you can more effectively safeguard your retirement with a new Special Report   4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future  ",2019-02-27,Zacks Investment Research,https://www.investing.com/analysis/theravance-tbph-q4-loss-narrows-revenues-beat-estimates-200393119,200393119
197013,418529,MYL,Israel stocks higher at close of trade  TA 35 up 0 17 ,news,"Investing com   Israel stocks were higher after the close on Thursday  as gains in the Technology  Communication and Biomed sectors led shares higher 
At the close in Tel Aviv  the TA 35 gained 0 17  
The best performers of the session on the TA 35 were  OPKO Health Inc   TA OPK   which rose 4 57  or 110 points to trade at 2515 at the close  Meanwhile  Mylan NV  TA MYL  added 4 57  or 610 points to end at 13950 and  Sodastream International Ltd   TA SODA  was up 2 80  or 530 0 points to 19480 0 in late trade 
The worst performers of the session were  Frutarom   TA FRUT   which fell 2 78  or 610 points to trade at 21320 at the close  Melisron  TA MLSR  declined 1 93  or 400 points to end at 20310 and Harel  TA HARL  was down 1 73  or 35 points to 1988 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 226 to 186 and 89 ended unchanged 
Crude oil for June delivery was up 1 69  or 0 80 to  48 13 a barrel  Elsewhere in commodities trading  Brent oil for delivery in July rose 1 67  or 0 84 to hit  51 06 a barrel  while the June Gold Futures contract rose 0 50  or 6 11 to trade at  1225 01 a troy ounce 
USD ILS was up 0 25  to 3 6124  while EUR ILS rose 0 19  to 3 9251 
The US Dollar Index Futures was unchanged 0 00  at 99 50 ",2017-05-11,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.17-483183,483183
197014,418530,MYL,Israel stocks lower at close of trade  TA 35 down 0 17 ,news,"Investing com   Israel stocks were lower after the close on Tuesday  as losses in the Banking  Oil   Gas and Communication sectors led shares lower 
At the close in Tel Aviv  the TA 35 declined 0 17  
The best performers of the session on the TA 35 were Mylan NV  TA MYL   which rose 2 69  or 370 points to trade at 14110 at the close  Meanwhile  Harel  TA HARL  added 2 41  or 48 points to end at 2041 and Partner  TA PTNR  was up 2 07  or 40 points to 1970 in late trade 
The worst performers of the session were Teva  TA TEVA   which fell 3 36  or 360 points to trade at 10340 at the close   Gazit Globe  Ltd  TA GZT  declined 2 24  or 80 points to end at 3495 and Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ  was down 1 55  or 9 5 points to 605 3 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 290 to 128 and 84 ended unchanged 
Shares in Teva  TA TEVA  fell to 5 year lows  losing 3 36  or 360 to 10340  
Crude oil for July delivery was up 0 12  or 0 06 to  51 19 a barrel  Elsewhere in commodities trading  Brent oil for delivery in July rose 0 15  or 0 08 to hit  53 95 a barrel  while the June Gold Futures contract fell 0 08  or 1 03 to trade at  1260 37 a troy ounce 
USD ILS was up 0 16  to 3 5902  while EUR ILS rose 0 10  to 4 0320 
The US Dollar Index Futures was up 0 02  at 96 90 ",2017-05-23,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-35-down-0.17-487587,487587
197015,418531,MYL,Investment funds urge shareholders to vote down Mylan board  pay,news,NEW YORK  Reuters    The New York City and State pension funds and the California State Teachers  Retirement System are fighting the re election of six board members at drugmaker  Mylan Inc   NASDAQ MYL  and its 2016 executive pay including Chairman Robert Coury s compensation of more than  97 million  The funds  along with Netherlands based pension fund PGGM  said they control 4 3 million shares of the company and are urging shareholders to vote against the company at Mylan s June 22 annual meeting  In a May 30 letter released on Wednesday in a regulatory filing  the funds said Coury s compensation in 2016 totalled  160 million including vesting and other payments  and came despite the company s price hiking scandal around its emergency allergy treatment EpiPen and share decline  The company has been the subject of federal and state investigations and agreed last fall to pay  465 million to settle U S  Justice Department allegations that it overcharged the government for EpiPen  The letter noted the decline in Mylan shares  which now trade for around  40  less than half the  82 that rival Teva Pharmaceuticals had offered to buy the company for in April of 2015   All of the mudslinging back and forth between Mylan and Teva only served to reinforce our concern that Chairman Coury would rather keep his pay and power at Mylan s helm than likely lose those benefits to Teva cost  and position cutting   the investors wrote  Mylan said in a statement that Coury s compensation  was granted and earned over his 15 year tenure as CEO and then Executive Chairman or directly relates to his retirement as an executive in 2016 and transition to Non Executive Chairman   The company said that its compensatin is designed to drive execution against its strategy and is aligned with performance and long term shareholder value  Regarding its overall performance  the company said  despite industry wide headwinds in 2016  including volatility and valuation contraction in the generic and specialty pharmaceutical industry  Mylan delivered strong financial and operational results for the year  and outperformed many of its peers  ,2017-05-31,Reuters,"https://www.investing.com/news/stock-market-news/investment-funds-urge-shareholders-to-vote-down-mylan-board,-pay-490186",490186
197016,418532,MYL,Taxpayers overpaid  1 3B for EpiPen   800M more than Mylan claimed  shares ease 1 ,news,Mylan N V   MYL  1   slips on below average volume on the heels of an announcement from Senator Chuck Grassley s  R Iowa  office that an HHS estimate showed taxpayers overpaid by as much as  1 27B for EpiPen from 2006 through 2016   805M more than the company reported during settlement talks with the Department of Justice  The nature of the overcharges was a misclassification of the product under the Medicaid Drug Rebate Program Senator Grassley has requested a full accounting of the matter for months  The Centers for Medicare and Medicaid Services  CMS  provided records that confirmed that CMS notified Mylan on several occasions that EpiPen was misclassified  but the company took no action  Mylan has repeatedly refused to provide its records of communications with CMS to the Senate Judiciary Committee  A subpoena is the next step  a real possibility Previously  Mylan will be a no show at Senate hearing  Nov  22  2016 Previously  Senator Grassley says Mylan a bit over the top with EpiPen settlement press release  Nov  21  2016 Now read ,2017-05-31,Seeking Alpha,"https://www.investing.com/news/stock-market-news/taxpayers-overpaid-$1.3b-for-epipen,-$800m-more-than-mylan-claimed;-shares-ease-1-490398",490398
197017,418533,MYL,Mylan may have overcharged U S  for EpiPen by  1 27 billion  HHS,news,"By Michael Erman NEW YORK  Reuters    The U S  government may have overpaid drugmaker Mylan  NASDAQ MYL  N V  by as much as  1 27 billion between 2006 and 2016 for its EpiPen emergency allergy treatment  the Department of Health and Human Services said on Wednesday  The amount is nearly three times a proposed settlement that the company announced in October  The analysis on the EpiPen payments  which was conducted by the Department of Health and Human Services  Office of Inspector General  was released by Republican Senator Chuck Grassley   Mylan and the Obama Administration reportedly were close to settling the overpayment for much less than  1 27 billion   Grassley said in a statement   Taxpayers have a right to know what happened here and to be repaid whatever they are owed   Grassley is the chairman of the Senate Judiciary Committee  which launched a probe of EpiPen pricing last year  A Mylan spokesperson said the drugmaker continues to work with the government to finalize the settlement as soon as possible  The company  which was already under fire for steep price increases on the devices  said in October it agreed to settle with the U S  government for  465 million after it was accused of improperly classifying EpiPen with the Medicaid Drug Rebate Program as a generic treatment  Mylan did not admit any wronging  Drugmakers pay a rebate of 13 percent to state Medicaid programs on sales of generics  rather than the minimum rebate of 23 1 percent on branded drugs  
Mylan shares closed down 1 percent  or 38 cents  at  38 98 on the Nasdaq on Wednesday ",2017-05-31,Reuters,https://www.investing.com/news/stock-market-news/mylan-may-have-overcharged-u.s.-for-epipens-by-$1.27-billion:-hhs-490392,490392
197018,418534,MYL,Israel stocks higher at close of trade  TA 35 up 0 13 ,news,"Investing com   Israel stocks were higher after the close on Thursday  as gains in the Oil   Gas  Biomed and Real Estate sectors led shares higher 
At the close in Tel Aviv  the TA 35 gained 0 13  
The best performers of the session on the TA 35 were Perrigo  TA PRGO   which rose 7 10  or 1760 points to trade at 26560 at the close  Meanwhile  Teva Pharmaceutical Industries Ltd  TA TEVA  added 2 27  or 230 points to end at 10380 and Delek Drilling LP  TA DEDRp  was up 2 19  or 32 points to 1490 in late trade 
The worst performers of the session were  OPKO Health Inc   TA OPK   which fell 4 01  or 90 points to trade at 2153 at the close  Tower Semiconductor Ltd  TA TSEM  declined 2 39  or 219 points to end at 8960 and Mylan NV  TA MYL  was down 2 37  or 340 points to 13980 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 293 to 124 and 86 ended unchanged 
Shares in OPKO Health Inc  TA OPK  fell to all time lows  falling 4 01  or 90 to 2153  
Crude oil for July delivery was up 0 68  or 0 33 to  48 65 a barrel  Elsewhere in commodities trading  Brent oil for delivery in August rose 0 39  or 0 20 to hit  50 96 a barrel  while the June Gold Futures contract fell 0 60  or 7 66 to trade at  1264 34 a troy ounce 
USD ILS was up 0 20  to 3 5513  while EUR ILS rose 0 04  to 3 9867 
The US Dollar Index Futures was up 0 12  at 97 03 ",2017-06-01,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.13-490784,490784
197019,418535,MYL,Mylan launches generic Azilect in U S ,news,Mylan N V   NASDAQ MYL  launches its generic version of Teva s  NYSE TEVA  Azilect  rasagiline tablets  for the treatment of Parkinson s disease According to QuintilesIMS Health  the American market is   343M Now read ,2017-06-02,Seeking Alpha,https://www.investing.com/news/stock-market-news/mylan-launches-generic-azilect-in-u.s.-491200,491200
197027,418543,MYL,Acorda  ACOR  Plans To Launch Inbrija In Q1  What To Expect,opinion,On Jan 9  we issued an updated research report on Acorda Therapeutics  Inc    NASDAQ ACOR   Acorda s biggest achievement in 2018 was the FDA approval of its Parkinson s disease  PD  drug  Inbrija  levodopa inhalation powder   in late December 2018  Following this nod  the product became the first and the only approved inhaled levodopa for treating OFF periods in patients suffering Parkinson s and receiving a carbidopa   levodopa regimen  Inbrija is expected to be launched during the first quarter of 2019  The drug is also under review in the EU with a decision expected anytime soon Notably  more than 350 000 people in the United States are enduring OFF periods related to PD  Inbrija will help address the large unmet medical need for those affected with the ailment  Acorda estimates Inbrija s market opportunity to be more than  800 million in the United States Inbrija might face competition from a similar product of small pharma company Sunovion  which might get the FDA approval later this month  However  Acorda is confident that Inbrija will capture the majority market share Shares of Acorda have shed 30 1  value in the past year  wider than the  decline of 20 6  Successful commercialization of Inbrija is critical for long term growth at Acorda  especially as generic competition looms large on its key multiple sclerosis  MS  drug Ampyra  Although most part of Acorda s net product revenues is drawn from Ampyra  the drug s sales still have been declining of late due to close contest from generic launches including Mylan s   NASDAQ MYL   authorized generic version  which was unveiled last September Acorda is still heavily dependent on Ampyra for growth as Inbrija is yet to be launched in the market and contribute to the top line of the company Apart from these two drugs  Acorda has a pipeline of novel neurological therapies addressing a wide range of disorders  The company is evaluating two phase II candidates  namely SYN120 and BTT1023 for the treatment of PD dementia and primary sclerosing cholangitis  respectively Another early stage candidate  CVT 427   an inhaled zolmitriptan   is being evaluated for the treatment of acute migraine  using Acorda s ARCUS drug delivery technology Approval of these candidates will provide long term growth prospects for the company  given the lucrative market that is being targeted Acorda Therapeutics  Inc  Price and Consensus   Zacks Rank   Other Stocks to ConsiderAcorda currently sports a Zacks Rank  1  Strong Buy   Other top ranked stocks to look in the healthcare sector include Vanda Pharmaceuticals Inc    NASDAQ VNDA   and Inovio Pharmaceuticals  Inc    NASDAQ INO    both sporting the same top Zacks Rank of 1 as Acorda  You can see  Vanda s earnings estimates have moved 11 1  north for 2019 over the past 90 days  The stock has skyrocketed 102 1  in a year Inovio s loss per share estimates has been narrowed 2 8  for 2019 in the last 90 days  The stock has gained 8 9  in the past year Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-09,Zacks Investment Research,https://www.investing.com/analysis/acorda-acor-plans-to-launch-inbrija-in-q1-what-to-expect-200374395,200374395
197028,418544,MYL,Mylan  MYL  Jumps  Stock Rises 7 1 ,opinion,Mylan N V    NASDAQ MYL   was a big mover last session  as the company saw its shares rise more than 7  on the day  The move came on solid volume too with far more shares changing hands than in a normal session  This breaks the recent trend of the company  as the stock is now trading above the volatile price range of  27 23 to  29 87 in the past one month time frame The move came after reports that the company s generic version of asthma treatment drug  Advair  obtained U S  Food and Drug Administration  FDA  approval   The company has seen two negative estimate revisions in the past few weeks  while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks  suggesting there may be trouble down the road  So make sure to keep an eye on this stock going forward  to see if this recent move higher can last Mylan currently has a Zacks Rank  3  Hold  while its  is negative Mylan N V  Price   Investors interested in the Medical   Generic Drugs industry may consider Assembly Biosciences  Inc    NASDAQ ASMB    which has a Zacks Rank  1  Strong Buy   You can see t Is MYL going up  Or down  Predict to see what others think  Up or Down Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2019-01-30,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-jumps-stock-rises-71-200381853,200381853
197029,418545,MYL,Israel stocks higher at close of trade  TA 35 up 0 66 ,news,"Investing com   Israel stocks were higher after the close on Wednesday  as gains in the Banking  Real Estate and Communication sectors led shares higher 
At the close in Tel Aviv  the TA 35 rose 0 66  
The best performers of the session on the TA 35 were Cellcom  TA CEL   which rose 3 32  or 119 points to trade at 3700 at the close  Meanwhile   Sodastream International Ltd   TA SODA  added 2 78  or 520 0 points to end at 19200 0 and Partner  TA PTNR  was up 2 60  or 50 points to 1970 in late trade 
The worst performers of the session were Teva  TA TEVA   which fell 2 24  or 260 points to trade at 11360 at the close  Mylan NV  TA MYL  declined 1 17  or 160 points to end at 13540 and  OPKO Health Inc   TA OPK  was down 0 93  or 25 points to 2650 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 216 to 184 and 40 ended unchanged 
Shares in Teva  TA TEVA  fell to 5 year lows  down 2 24  or 260 to 11360  Shares in Sodastream International Ltd  TA SODA  rose to all time highs  rising 2 78  or 520 0 to 19200 0  Shares in OPKO Health Inc  TA OPK  fell to 3 years lows  falling 0 93  or 25 to 2650  
Crude oil for May delivery was down 0 42  or 0 22 to  52 19 a barrel  Elsewhere in commodities trading  Brent oil for delivery in June fell 0 44  or 0 24 to hit  54 65 a barrel  while the June Gold Futures contract fell 0 97  or 12 60 to trade at  1281 50 a troy ounce 
USD ILS was up 0 18  to 3 6713  while EUR ILS unchanged 0 00  to 3 9324 
The US Dollar Index Futures was up 0 24  at 99 65 ",2017-04-19,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.66-475431,475431
197030,418546,MYL,Mylan launches generic version of anti psychotic med Trilafon,news,Mylan N V   MYL  0 5   announces the U S  commercial launch of perphenazine tablets  the generic version of Merck  NYSE MRK  s Trilafon anti psychotic medication that is also approved to control severe nausea and vomiting in adults According to IMS Health  the U S  market is   41M Now read  How To Position Yourself For A Market That Has Lost Its Mojo,2017-04-20,Seeking Alpha,https://www.investing.com/news/stock-market-news/mylan-launches-generic-version-of-anti-psychotic-med-trilafon-475990,475990
197031,418547,MYL,GSK must pay  3 million in generic Paxil suicide lawsuit  U S  jury,news,"By Nate Raymond and Barbara Grzincic  Reuters    GlaxoSmithKline  L GSK  must pay  3 million to a woman who sued the drug company over the death of her husband  a lawyer who committed suicide after taking a generic version of the antidepressant Paxil  a U S  jury said on Thursday  The jury s award followed a trial in federal court in Chicago in a lawsuit over the death of Stewart Dolin  a partner at Reed Smith LLP who jumped in front of an oncoming commuter train in 2010 after taking a generic equivalent of GSK s Paxil  The verdict by the nine member jury in favor of Dolin s wife  Wendy Dolin  was confirmed by GSK  which said in a statement it was disappointed and planned to appeal   GSK maintains that because it did not manufacture or market the medicine ingested by Mr  Dolin  it should not be liable   GSK said   Additionally  the Paxil label provided complete and adequate warnings during the time period relevant to this lawsuit   Brent Wisner  a lawyer for Wendy Dolin  said his client was  very pleased  with the verdict  adding that  justice has been served   Wendy Dolin filed the lawsuit in 2012 against London based GSK and Mylan  NASDAQ MYL   which manufactured paroxetine hydrochloride  the generic version of Paxil her 57 year old husband was taking before his suicide  A federal judge dismissed Mylan from the lawsuit in 2014 but allowed Dolin to proceed against GSK because it controlled the drug s design and label  which applied to both the brand name and generic versions of the drug  The label included a  black box  warning that paroxetine  like all SSRI type antidepressants  can increase the risk of suicidal behavior by users under age 25  At trial  Dolin s lawyers had requested  39 million  They alleged GSK had evidence paroxetine increases the risk of suicide by older users by as much as 670 percent  yet failed to include that on the warning label  In his opening statement on March 14  GSK attorney Andrew Bayman said the label was appropriate and its wording was mandated by the U S  Food and Drug Administration  
The case is Dolin v  GlaxoSmithKline  U S  District Court  Northern District of Illinois  No  12 cv 6403 ",2017-04-20,Reuters,https://www.investing.com/news/stock-market-news/gsk-must-pay-$3-million-in-generic-paxil-suicide-lawsuit:-u.s.-jury-476039,476039
197032,418548,MYL,Israel stocks higher at close of trade  TA 35 up 0 03 ,news,"Investing com   Israel stocks were higher after the close on Tuesday  as gains in the Oil   Gas  Biomed and Technology sectors led shares higher 
At the close in Tel Aviv  the TA 35 rose 0 03  
The best performers of the session on the TA 35 were  OPKO Health Inc   TA OPK   which rose 4 63  or 126 points to trade at 2850 at the close  Meanwhile   ICL  Israel Chemicals Ltd  TA ICL  added 2 42  or 36 points to end at 1524 and Delek Drilling LP  TA DEDRp  was up 2 21  or 28 points to 1295 in late trade 
The worst performers of the session were Teva  TA TEVA   which fell 3 71  or 430 points to trade at 11160 at the close  Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ  declined 2 14  or 13 5 points to end at 616 5 and Mylan NV  TA MYL  was down 1 32  or 180 points to 13460 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 274 to 138 and 36 ended unchanged 
Shares in Teva  TA TEVA  fell to 5 year lows  falling 3 71  or 430 to 11160  Shares in Bezeq Israeli Telecommunication Corp Ltd  TA BEZQ  fell to 52 week lows  falling 2 14  or 13 5 to 616 5  
Crude oil for June delivery was down 0 43  or 0 21 to  49 02 a barrel  Elsewhere in commodities trading  Brent oil for delivery in July fell 0 31  or 0 16 to hit  51 97 a barrel  while the June Gold Futures contract fell 0 74  or 9 42 to trade at  1268 08 a troy ounce 
USD ILS was down 0 13  to 3 6464  while EUR ILS rose 0 40  to 3 9841 
The US Dollar Index Futures was down 0 20  at 98 71 ",2017-04-25,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.03-477168,477168
197033,418549,MYL,GlaxoSmithKline reports Q1 results,news,GlaxoSmithKline  NYSE GSK   Q1 EPS of  0 25Revenue of  7 38B   18 5  Y Y Shares  0 12  PM Press ReleaseNow read  GlaxoSmithKline  Delay In Mylan  NASDAQ MYL  s Advair Generic Is A Helpful Short Term Boost  But It Is Inevitably Coming,2017-04-26,Seeking Alpha,https://www.investing.com/news/stock-market-news/glaxosmithkline-reports-q1-results-477497,477497
197034,418550,MYL,Israel stocks higher at close of trade  TA 35 up 0 56 ,news,"Investing com   Israel stocks were higher after the close on Wednesday  as gains in the Insurance  Technology and Communication sectors led shares higher 
At the close in Tel Aviv  the TA 35 added 0 56  to hit a new 1 month high 
The best performers of the session on the TA 35 were Perrigo  TA PRGO   which rose 9 01  or 2200 points to trade at 26610 at the close  Meanwhile  Mylan NV  TA MYL  added 2 30  or 310 points to end at 13770 and Teva  TA TEVA  was up 1 88  or 210 points to 11370 in late trade 
The worst performers of the session were  Airport City  Ltd  TA ARPT   which fell 2 39  or 119 points to trade at 4860 at the close   Amot Investments  Ltd  TA AMOT  declined 1 53  or 27 points to end at 1735 and Tower Semiconductor Ltd  TA TSEM  was down 1 52  or 123 points to 7990 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 228 to 175 and 99 ended unchanged 
Crude oil for June delivery was up 0 79  or 0 39 to  49 95 a barrel  Elsewhere in commodities trading  Brent oil for delivery in July rose 0 25  or 0 13 to hit  52 70 a barrel  while the June Gold Futures contract fell 0 20  or 2 55 to trade at  1264 65 a troy ounce 
USD ILS was up 0 05  to 3 6412  while EUR ILS fell 0 43  to 3 9599 
The US Dollar Index Futures was up 0 31  at 99 03 ",2017-04-26,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.56-477639,477639
197035,418551,MYL,Israel stocks higher at close of trade  TA 35 up 0 46 ,news,"Investing com   Israel stocks were higher after the close on Thursday  as gains in the Real Estate  Banking and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 35 rose 0 46  
The best performers of the session on the TA 35 were Nice Ltd  TA NICE   which rose 4 73  or 1160 points to trade at 25700 at the close  Meanwhile  Mylan NV  TA MYL  added 2 63  or 350 points to end at 13660 and  Mizrahi Tefahot   TA MZTF  was up 2 25  or 131 points to 5961 in late trade 
The worst performers of the session were  Ormat Technologies   TA ORA   which fell 2 08  or 450 points to trade at 21160 at the close   OPKO Health Inc   TA OPK  declined 1 82  or 50 points to end at 2693 and Partner  TA PTNR  was down 1 59  or 29 points to 1800 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 207 to 203 and 91 ended unchanged 
Crude oil for June delivery was down 2 57  or 1 23 to  46 59 a barrel  Elsewhere in commodities trading  Brent oil for delivery in July fell 2 34  or 1 19 to hit  49 60 a barrel  while the June Gold Futures contract fell 1 39  or 17 30 to trade at  1231 20 a troy ounce 
USD ILS was down 0 07  to 3 6172  while EUR ILS rose 0 49  to 3 9597 
The US Dollar Index Futures was down 0 42  at 98 84 ",2017-05-04,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.46-480225,480225
197036,418552,MYL,Mylan Q1 EPS  0 93 vs  estimate  0 92 ,news,Investing com    NASDAQ Mylan  first quarter earnings per share beat estimates The pharmaceutical reported a 22  rise in adjusted  diluted Q1 EPS to  0 93 v s estimate of  0 92 Revenues were up 24  at  2 72 bn  missing an estimate of  2 84 bn Mylan shares were up 3 26  pre market at  39 25 ,2017-05-10,Investing.com,https://www.investing.com/news/stock-market-news/mylan-q1-eps-$0.93-vs.-estimate-$0.92-482418,482418
197037,418553,MYL,Mylan disagrees with FDA over generic Advair rejection,news,"By Michael Erman and Natalie Grover  Reuters    Generic drug maker Mylan NV  O MYL  said on Wednesday it disagrees with the U S  Food and Drug Administration  which declined to approve Mylan s generic for GlaxoSmithKline Plc s  L GSK  blockbuster Advair in March  Mylan President Rajiv Malik said the FDA was asking it to comply with standards set out in draft guidance the agency issued  but that it believes it is not required to do so  An FDA spokeswoman declined to comment  saying she was prohibited by law from discussing a pending application  Mylan made the comments while reporting first quarter earnings  in which it flagged declining sales for emergency allergy treatment EpiPen but said it will still meet previously announced earnings targets for the year  Malik said the company could not comment further on the length of the delay for approval until it meets with the FDA to discuss their disagreement  but that the FDA had designated it as requiring a  major  amendment to its application  A  major  amendment means a delay of 10 months for an FDA response  Numis analyst Stefan Hamill said in a research note earlier this month about another generic version of Advair from  Hikma Pharmaceuticals   L HIK   It is awaiting an FDA decision by May 10 and analysts on Wednesday said they were now expecting the FDA to also question that application  Mylan shares fell 0 8 percent to  37 73 in afternoon trading  The company backed its full year profit and revenue forecast  and reported a first quarter profit that edged past expectations  helped by demand for products it gained through the acquisition of Swedish drugmaker Meda   Our overall expectations for the global pricing environment are unchanged and we are still predicting mid single digit percentage erosion globally for the year   Malik said  Mylan has come under fire for sharply increasing the price of EpiPen and classifying the life saving treatment as a generic rather than a branded product  which led to much smaller rebates to state Medicaid programs  The company said first quarter sales of EpiPen in North America declined due to increased competition and the launch of its authorized generic  Mylan said net income surged to  66 4 million  or 12 cents per share in the first quarter ended March 31  from  13 9 million  or 3 cents per share  a year earlier  Excluding one time items  Mylan earned 93 cents per share  beating analysts  average estimate by 1 cent  according to Thomson Reuters I B E S  
Revenue rose 24 percent to  2 72 billion  Analysts on average had expected  2 84 billion ",2017-05-10,Reuters,https://www.investing.com/news/stock-market-news/epipen-maker-mylan's-profit-surges-482362,482362
197040,418556,MYL,Mylan  MYL  Down 9 5  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Mylan  NASDAQ MYL   Shares have lost about 9 5  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Mylan due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts  Mylan Beats on Earnings  Misses Revenues in Q3Mylan s adjusted earnings of  1 25 per share beat the Zacks Consensus Estimate of  1 17 and were up from  1 10 in the year ago quarter However  third quarter revenues of  2 86 billion missed the Zacks Consensus Estimate of  2 87 billion and were down 4  from the prior year quarter Quarter in DetailThe company posts results in three segments on a geographic basis  namely North America  Europe and Rest of World North America segment s net sales came in at  1 01 billion  down 14   This decline was primarily due to lower volumes on existing products like the EpiPen Auto Injector  This was partially offset by new product sales  including the recent launch of Fulphila  a biosimilar of Neulasta  The decline in volumes was primarily driven by the timing of purchases of products by customers  divestiture of certain contract manufacturing assets  loss of exclusivity of a product  and actions associated with the restructuring and remediation program at the Morgantown manufacturing facility The FDA completed an inspection at Mylan s plant in Morgantown  West Virginia earlier this year and made observations through a Form 483  Thereafter  Mylan submitted a comprehensive response to the FDA  During the second quarter of 2018  Mylan started a restructuring and remediation program to reduce complexity at the Morgantown manufacturing facility  which led to the discontinuation and transfer of a number of products to other manufacturing sites  a reduction of the workforce and extensive remediation activities  These actions have led to a temporary disruption in supply of certain products Net sales in the Europe segment were  1 04 billion in the quarter  an increase of  0 5 million  which was primarily driven by new product sales and higher  volumes on existing products Rest of World segment s net sales of  773 7 million were up 4   driven by new products Adjusted gross margin of 55  was slightly down from 53  in the year ago quarter 2018 Outlook ReiteratedMylan expects 2018 total revenues of  11 25  12 25 billion  The company anticipates adjusted EPS around  4 55  4 90  
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed an upward trend in fresh estimates 
VGM Scores
Currently  Mylan has an average Growth Score of C  however its Momentum Score is doing a lot better with an A  Following the exact same course  the stock was allocated a grade of A on the value side  putting it in the top 20  for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been trending upward for the stock  and the magnitude of these revisions looks promising  Notably  Mylan has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-12-04,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-down-95-since-last-earnings-report-can-it-rebound-200365337,200365337
197041,418557,MYL,Momenta  MNTA  Down 16 7  Since Last Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Momenta Pharmaceuticals  MNTA   Shares have lost about 16 7  in that time frame  underperforming the S P 500 
Will the recent negative trend continue leading up to its next earnings release  or is Momenta due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important drivers  Momenta Reports Narrower Than Expected Loss in Q3Momenta reported loss per share of 45 cents in the quarter  excluding restructuring charges   narrower than the Zacks Consensus Estimate of 63 cents but wider than the year ago loss of 44 cents Revenues in the quarter came in at  14 9 million  significantly down from  24 1 million in the year ago quarter and missed the Zacks Consensus Estimate by 13 2  Quarter in DetailMomenta s top line comprises product revenues of  13 6 million earned from Sandoz s sales of Glatopa  a generic version of Copaxone  20 mg   compared with  10 9 million in the year ago quarter  The increase in product revenues was primarily due to non recurring deduction of a  5 million contractual amount in 2017  which was offset by lower net sales of Glatopa  driven by Mylan  NASDAQ MYL  N V  s entry into the Copaxone market Research and development revenues came in at  1 3 million compared with  13 2 million in the year ago quarter  The decrease was primarily due to a  10 million milestone achieved in the 2017 period Research and development expenses decreased to  30 7 million from  37 9 million in the year ago quarter due to a decrease in external R D expenses for M923  General and administrative expenses were roughly flat at  20 4 million Pipeline UpdatesAs a result of its strategic review  results announced in October 2018   Momenta plans to advance its two late stage biosimilar assets  M923  which is its wholly owned proposed biosimilar to AbbVie s Humira  and M710  which is its proposed biosimilar to Regeneron s Eylea being developed in collaboration with Mylan  The company is in discussions with its collaboration partner  Mylan  to exit its participation in the development of its five other biosimilar programs  including M834  a proposed biosimilar to Orencia Momenta recently announced that it entered into a settlement with AbbVie Inc  NYSE ABBV    to enable the commercialization of M923  Per the terms of the agreement and subject to approval by health regulatory authorities  Momenta may launch M923 in the United States on Nov 20  2023 and in Europe upon approval by the European Medicines Agency The company intends to submit a biologics license application for M923 to the FDA in the fourth quarter of 2018 and a marketing authorization application in the European Union in the first half of 2019 Momenta is now seeking commercialization partners for M923 In August 2018  Mylan initiated a clinical trial in patients with diabetic macular edema to compare safety  efficacy and immunogenicity of M710 with Eylea Momenta s novel auto immune portfolio includes M230  a Selective Immunomodulator of Fc receptors  SIF3   M281  an anti FcRn monoclonal antibody  and M254 In October 2018  Momenta announced additional data from its phase I study of M281 in healthy volunteers The company announced that it plans to commence two phase II proof of concept clinical trials  one in generalized myasthenia gravis  gMG  and one in hemolytic disease of the fetus and newborn  HDFN   in the fourth quarter of 2018 The company intends to initiate a phase I II proof of concept study in immune thrombocytopenic purpura  ITP  in early 2019  pending regulatory feedback  
How Have Estimates Been Moving Since Then 
Fresh estimates followed a downward path over the past two months 
VGM Scores
At this time  Momenta has a poor Growth Score of F  however its Momentum Score is doing a bit better with a D  Charting a somewhat similar path  the stock was allocated a grade of F on the value side  putting it in the fifth quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of F  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Momenta has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-12-06,Zacks Investment Research,https://www.investing.com/analysis/momenta-mnta-down-167-since-last-earnings-report-can-it-rebound-200366145,200366145
197042,418558,MYL,Teva  TEVA  Stock Poised To Record Big Gains In 2019 ,opinion,"Shares of Teva Pharmaceutical Industries Limited   NYSE TEVA   have picked up pace this year so far after declining sharply in 2017  Though the stock has declined 2 7  this year  it has outperformed its  s decline of 14  
 

 
Last year  Teva s stock declined a massive 54 6   underperforming the industry s decline of 26 3  
Teva is one of the world s largest generic drug makers and carries a Zacks Rank  2  Buy  It appears on track to come up with a good performance in 2019 
You can see  
What s Going in Teva s Favor 
The Israel based generic drug maker has been facing significant challenges  This includes accelerated generic competition for its blockbuster multiple sclerosis drug  Copaxone  new competition for branded products  pricing erosion in the U S  generics business and a massive debt load of approximately  30 billion  
Mylan s   NASDAQ MYL   earlier than expected launch of the first generic version of the 40 mg strength of Copaxone in October last year was a major setback for Teva  In the same month  Mylan also launched the second generic version of the 20 mg formulation of Copaxone  The first generic version of the 20 mg formulation has been marketed by Momenta Pharmaceuticals  Inc    NASDAQ MNTA   and Sandoz   Novartis    NYSE NVS   generic arm   since 2015 
With the entry of the generic version of the 40 mg formulation and the entry of a second generic version of the 20 mg formulation  there has been rapid erosion in sales of Copaxone  Moreover  a second generic version of the 40 mg formulation  Glatopa  was launched by Sandoz in February this year  much earlier than its scheduled launch in April  A couple of other companies are also looking to get approval for their generic versions of the 40 mg formulation and generic competition is expected to increase in 2019 
However  Teva has undertaken some strategic and restructuring initiatives to revive growth 
The company divested some non core assets last year  mainly in the Women s Health business  to cut its significant debt load  It also has a new organizational structure in place  is closing plants  cutting down its generics portfolio  eliminating low value R D projects  and is reducing global workforce to revive growth  Teva is progressing well on these re structuring activities and expects to save almost  3 billion by the end of 2019 from these initiatives  which should boost the company s profits next year 
Its financial position also seems more stable than before as it is regularly paying down debt  Regular payment of debt is lowering its interest expense  which should again pull up its profits 
On the last earnings conference call held in November  Teva slightly raised the lower end of its full year sales guidance  However  it significantly raised its earnings guidance  following solid third quarter results and accelerated cost savings  The company also upped its free cash flow guidance  A guidance raise always suggests management s confidence in the company s potential to do well 
Most importantly  on the last earnings conference call  Teva management confirmedsigns of stabilization in U S  generic drug pricing  The company also said that the rate of sales erosion in the North American Generic business slowed significantly in the third quarter from second quarter levels due to optimization of its generics product portfolio as well as product launches 
Teva gained FDA approval for Truxima  CT P10   its biosimilar to Roche s Rituxan and launched limited doses of its generic version of Mylan s EpiPen and generic version of Lilly s blockbuster products Cialis in September November 2018  Next year  Teva will launch the generic version of lower dose EpiPen Jr  0 15mg  and bring in additional supply of 0 3 mg EpiPen generics  All these new generic biosimilar launches and slowing sales erosion in the generics segment can improve Teva s topline in the Generics segment in 2019 
Its newest drugs  Austedo and Ajovy  could emerge as significant contributors to the branded drugs portfolio in 2019 and thereafter 
Bottom Line
Overall  though Teva s woes like lower Copaxone sales and pricing erosion in the U S  generics business will continue in 2019  revenues from new branded and generic launches  accelerated cost savings and improving business fundamentals should provide top and bottom line support 
Will You Make a Fortune on the Shift to Electric Cars  
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge 
With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research 
It s not the one you think ",2018-12-11,Zacks Investment Research,https://www.investing.com/analysis/teva-teva-stock-poised-to-record-big-gains-in-2019-200367144,200367144
197043,418559,MYL,MYL Vs  SUPN  Which Stock Is The Better Value Option ,opinion,"Investors looking for stocks in the Medical   Generic Drugs sector might want to consider either Mylan  NASDAQ MYL  or Supernus Pharmaceuticals  SUPN   But which of these two stocks presents investors with the better value opportunity right now  Let s take a closer look 
Everyone has their own methods for finding great value opportunities  but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank  The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends  while our Style Scores work to grade companies based on specific traits 
Mylan and Supernus Pharmaceuticals are sporting Zacks Ranks of  2  Buy  and  5  Strong Sell   respectively  right now  The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates  so investors should rest assured that MYL has an improving earnings outlook  But this is just one piece of the puzzle for value investors 
Value investors analyze a variety of traditional  tried and true metrics to help find companies that they believe are undervalued at their current share price levels 
The Style Score Value grade factors in a variety of key fundamental metrics  including the popular P E ratio  P S ratio  earnings yield  cash flow per share  and a number of other key stats that are commonly used by value investors 
MYL currently has a forward P E ratio of 5 69  while SUPN has a forward P E of 15 32  We also note that MYL has a PEG ratio of 0 88  This popular metric is similar to the widely known P E ratio  with the difference being that the PEG ratio also takes into account the company s expected earnings growth rate  SUPN currently has a PEG ratio of 0 90 
Another notable valuation metric for MYL is its P B ratio of 1 24  The P B is a method of comparing a stock s market value to its book value  which is defined as total assets minus total liabilities  By comparison  SUPN has a P B of 4 45 
These are just a few of the metrics contributing to MYL s Value grade of A and SUPN s Value grade of D 
MYL is currently sporting an improving earnings outlook  which makes it stick out in our Zacks Rank model  And  based on the above valuation metrics  we feel that MYL is likely the superior value option right now ",2019-01-09,Zacks Investment Research,https://www.investing.com/analysis/myl-vs-supn-which-stock-is-the-better-value-option-200374413,200374413
197044,418560,MYL,U S  senator launches probe into five top opioid drugmakers,news," Reuters    U S  Democratic Senator Claire McCaskill sought on Tuesday details from the nation s top opioid drugmakers on their sales and marketing practices  as lawmakers step up efforts to tackle the country s deadly opioid crisis  The Missouri senator s investigation comes amid an epidemic of opioid addiction  with 91 Americans dying everyday as a result of overdose  according to the U S  Centers for Disease Control and Prevention   This epidemic is the direct result of a calculated sales and marketing strategy major opioid manufacturers have allegedly pursued over the past 20 years to expand their market share   McCaskill  the top Democrat on the Senate Homeland Security and Governmental Affairs Committee  wrote in a letter to the drugmakers   McCaskill asked Johnson   Johnson  NYSE JNJ   Mylan  NASDAQ MYL  NV  Purdue Pharma  Insys Therapeutics Inc and Depomed Inc for internal estimates of the risk of abuse  addiction and overdose of opioids  The companies are the top five U S  prescription opioid drugmakers by 2015 sales  according to McCaskill s letter  Depomed and Purdue Pharma said they were reviewing the letter and would respond accordingly  Purdue also said its OxyContin painkiller made up just 2 percent of the U S  opioid analgesic prescription market  Johnson   Johnson said it had received the letter and would address the senator s request   We believe that we have acted appropriately  responsibly and in the best interests of patients regarding our opioid pain medications   said Jessica Castles Smith  a spokeswoman for Johnson   Johnson unit Janssen  
Insys and Mylan did not immediately respond to requests for comment ",2017-03-28,Reuters,https://www.investing.com/news/stock-market-news/u.s.-senator-launches-probe-into-five-top-opioid-drugmakers-469407,469407
197045,418561,MYL,Israel stocks lower at close of trade  TA 35 down 0 22 ,news,"Investing com   Israel stocks were lower after the close on Thursday  as losses in the Banking  Insurance and Financials sectors led shares lower 
At the close in Tel Aviv  the TA 35 declined 0 22  
The best performers of the session on the TA 35 were  Airport City  Ltd  TA ARPT   which rose 2 35  or 107 points to trade at 4661 at the close  Meanwhile   Amot Investments  Ltd  TA AMOT  added 1 86  or 32 points to end at 1749 and Alony Hetz Properties and Investments Ltd  TA ALHE  was up 1 70  or 57 points to 3412 in late trade 
The worst performers of the session were Partner  TA PTNR   which fell 3 05  or 60 points to trade at 1905 at the close  Mylan NV  TA MYL  declined 2 66  or 400 points to end at 14640 and Perrigo  TA PRGO  was down 1 73  or 430 points to 24480 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 231 to 173 and 43 ended unchanged 
Crude oil for May delivery was up 1 31  or 0 65 to  50 16 a barrel  Elsewhere in commodities trading  Brent oil for delivery in June rose 0 86  or 0 45 to hit  52 99 a barrel  while the April Gold Futures contract fell 0 45  or 5 70 to trade at  1248 00 a troy ounce 
USD ILS was up 0 11  to 3 6218  while EUR ILS fell 0 18  to 3 8878 
The US Dollar Index Futures was up 0 17  at 99 95 ",2017-03-30,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-35-down-0.22-469977,469977
197046,418562,MYL,Israel stocks lower at close of trade  TA 35 down 0 10 ,news,"Investing com   Israel stocks were lower after the close on Sunday  as losses in the Biomed  Banking and Technology sectors led shares lower 
At the close in Tel Aviv  the TA 35 fell 0 10  
The best performers of the session on the TA 35 were  Sodastream International Ltd   TA SODA   which rose 3 86  or 660 0 points to trade at 17740 0 at the close  Meanwhile  Partner  TA PTNR  added 3 73  or 71 points to end at 1976 and  Airport City  Ltd  TA ARPT  was up 2 55  or 119 points to 4780 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 5 26  or 770 points to trade at 13870 at the close  Teva  TA TEVA  declined 2 52  or 300 points to end at 11610 and Perrigo  TA PRGO  was down 2 25  or 550 points to 23930 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 270 to 139 and 38 ended unchanged 
Shares in Teva  TA TEVA  fell to 5 year lows  down 2 52  or 300 to 11610  Shares in Airport City Ltd  TA ARPT  rose to all time highs  gaining 2 55  or 119 to 4780  Shares in Perrigo  TA PRGO  fell to 5 year lows  down 2 25  or 550 to 23930  
Crude oil for May delivery was up 0 91  or 0 46 to  50 81 a barrel  Elsewhere in commodities trading  Brent oil for delivery in June rose 1 07  or 0 57 to hit  53 70 a barrel  while the April Gold Futures contract rose 0 19  or 2 40 to trade at  1247 40 a troy ounce 
USD ILS was down 0 09  to 3 6289  while EUR ILS fell 0 22  to 3 8679 
The US Dollar Index Futures was down 0 03  at 100 42 ",2017-04-02,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-35-down-0.10-470508,470508
197047,418563,MYL,Israel stocks lower at close of trade  TA 35 down 0 10 ,news,"Investing com   Israel stocks were lower after the close on Monday  as losses in the Communication  Banking and Insurance sectors led shares lower 
At the close in Tel Aviv  the TA 35 lost 0 10  to hit a new 3 months low 
The best performers of the session on the TA 35 were  Strauss Group   TA STRS   which rose 3 09  or 195 points to trade at 6514 at the close  Meanwhile   Frutarom   TA FRUT  added 1 63  or 330 points to end at 20580 and Mylan NV  TA MYL  was up 1 44  or 200 points to 14070 in late trade 
The worst performers of the session were  Israel Corp   TA ILCO   which fell 2 29  or 1550 points to trade at 66130 at the close   ICL  Israel Chemicals Ltd  TA ICL  declined 1 87  or 29 points to end at 1519 and  OPKO Health Inc   TA OPK  was down 1 65  or 48 points to 2864 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 217 to 191 and 31 ended unchanged 
Crude oil for May delivery was down 0 65  or 0 33 to  50 27 a barrel  Elsewhere in commodities trading  Brent oil for delivery in June fell 0 62  or 0 33 to hit  53 20 a barrel  while the June Gold Futures contract rose 0 25  or 3 15 to trade at  1254 35 a troy ounce 
USD ILS was down 0 03  to 3 6277  while EUR ILS fell 0 07  to 3 8651 
The US Dollar Index Futures was up 0 06  at 100 48 ",2017-04-03,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-35-down-0.10-470809,470809
197048,418564,MYL,Mylan hit with new EpiPen lawsuit,news,"Mylan  NASDAQ MYL  has been hit with a new proposed class action lawsuit over the price of its EpiPen allergy treatment  which shot up to more than  600 for a two pack of the device from less than  100 in 2007 
Although other suits have been filed  the case is the first to focus on the role of pharmacy benefit managers and to bring claims under the Racketeer Influenced and Corrupt Organizations Act ",2017-04-04,Seeking Alpha,https://www.investing.com/news/stock-market-news/mylan-hit-with-new-epipen-lawsuit-471087,471087
197049,418565,MYL,Israel stocks lower at close of trade  TA 35 down 0 14 ,news,"Investing com   Israel stocks were lower after the close on Wednesday  as losses in the Communication  Insurance and Oil   Gas sectors led shares lower 
At the close in Tel Aviv  the TA 35 lost 0 14  
The best performers of the session on the TA 35 were Leumi  TA LUMI   which rose 3 77  or 59 points to trade at 1625 at the close  Meanwhile   Israel Corp   TA ILCO  added 2 79  or 1860 points to end at 68460 and  ICL  Israel Chemicals Ltd  TA ICL  was up 2 26  or 35 points to 1585 in late trade 
The worst performers of the session were Cellcom  TA CEL   which fell 4 37  or 164 points to trade at 3591 at the close  Mylan NV  TA MYL  declined 4 12  or 600 points to end at 13970 and Partner  TA PTNR  was down 3 30  or 65 points to 1904 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 221 to 163 and 46 ended unchanged 
Crude oil for May delivery was up 0 07  or 0 04 to  53 44 a barrel  Elsewhere in commodities trading  Brent oil for delivery in June fell 0 07  or 0 04 to hit  56 19 a barrel  while the June Gold Futures contract rose 0 33  or 4 15 to trade at  1278 35 a troy ounce 
USD ILS was down 0 11  to 3 6529  while EUR ILS fell 0 09  to 3 8782 
The US Dollar Index Futures was down 0 16  at 100 47 ",2017-04-12,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-35-down-0.14-473821,473821
197052,418568,MYL,Theravance  TBPH  Beats On Q3 Earnings  Inks Deal For Vibativ,opinion,Theravance Biopharma  Inc    NASDAQ TBPH   incurred third quarter 2018 loss of  1 10 per share  narrower than the Zacks Consensus Estimate of a loss of  1 18 and the year ago loss of  1 27 Total revenues in the quarter under review skyrocketed 200  year over year to  12 8 million  mainly on the back of an upfront payment received from Johnson   Johnson   NYSE JNJ   in relation to a joint development agreement for Theravance s pan Janus kinase inhibitor  TD 1473  Moreover  the top line surpassed the Zacks Consensus Estimate of  10 8 million Shares of Theravance have lost 15 1  year to date  comparing unfavorably with the  decline of 4 9  Quarter in DetailVibativ is a once daily dual mechanism antibiotic approved in the United States  Europe and certain other countries for specifically difficult to treat infections  The drug generated U S  revenues of  3 8 million in the third quarter  down 7 3  from the year ago period s figure  Revenues from collaborations were  8 9 million compared with  0 14 million in the year earlier quarter Research and development expenses were  52 7 million  up 34 1  from the year ago period  primarily due to higher cost regarding employees and share based compensation Selling  general   administrative expenses rose 4 8  to  21 9 million To Divest VibativIn a separate press release  Theravance announced that it has signed an agreement with specialty pharma Cumberland Pharmaceuticals in order to sell its only marketed drug  Vibativ  Per the deal  Cumberland is entitled to pay  25 million to Theravance as well as tiered royalties of up to 20  on the product s future net sales in the United States We believe  the sale is a strategic fit for Theravance as this will help the company solely focus on the upcoming launch of Yupelri  upon potential approval  The transaction is expected to be completed in mid November  subject to customary closing conditions Pipeline and Other UpdatesCurrently  the new drug application  NDA  for Yupelri  revefenacin  is under review for the treatment of adults with chronic obstructive pulmonary disease  COPD   A response from the FDA is expected on Nov 13  2018  Last month  Theravance along with partner Mylan   NASDAQ MYL   announced positive new data from multiple studies of Yupelri on COPD patients  Theravance is preparing for the commercial launch of the drug upon potential approval If approved  Yupelri will be the first once daily nebulized long acting muscarinic antagonist  LAMA  option for COPD patients In February 2018  Theravance entered into a global collaboration agreement with Janssen to jointly develop and commercialize its pan Janus kinase inhibitor  TD 1473  for the treatment of inflammatory intestinal diseases TD 1473 is currently being evaluated in mid stage studies  namely a phase Ib program on TD 1473 for treating patients with moderate to severe ulcerative colitis and a phase IIb III analysis on patients with moderate to severely active ulcerative colitis Theravance is also screening patients in a phase II induction study to evaluate TD 1473 for Crohn s disease  The company expects to start dosing the first patient before the end of this year Another candidate in Theravance s portfolio is TD 9855  currently under inspection for addressing symptomatic neurogenic orthostatic hypotension  nOH   In August  the company announced a positive top line outcome from the phase II investigation on the candidate  Additionally  Theravance expects to initiate a phase III study in late 2018 or early 2019 Both TD 1473 and TD 9855 will soon enter late stage developmental studies Theravance is also prepping up for the first in human study on TD 8236  a novel inhaled JAK inhibitor  evaluated for the treatment of serious respiratory diseases In September 2018  Theravance announced that the Committee for Medicinal Products for Human Use  CHMP  rendered a positive opinion on the label expansion of Glaxo s   NYSE GSK   COPD drug  Trelegy Ellipta  in Europe  Theravance has an economic interest in royalties paid by Glaxo on Trelegy Ellipta s global sales Glaxo is seeking an approval for Trelegy Ellipta to cover a broader patient population  who are not adequately treated by a long acting muscarinic antagonist  LAMA  and a long acting beta2 agonist   LABA    Theravance has an economic interest in the drug and earns royalties on its sales Trelegy Ellipta  a triple combination therapy of inhaled corticosteroid  ICS  LAMA LABA  fluticasone furoate umeclidinium vilanterol  FF UMEC VI    is already approved as a maintenance treatment for COPD patients  who are not adequately treated by a combination of ICS and a LABA In the third quarter of 2018  Glaxo recorded sales of  56 million for Trelegy Ellipta  While Theravance is eligible to receive 5 5 8 5   tiered  of the product s worldwide net sales Presently  Trelegy Ellipta is available across 16 countries with nine more expected over the course of 2019 2018 Outlook ReiteratedTheravance persistently anticipates operating loss excluding non cash share based compensation for 2018 in the range of  180  200 million Theravance Biopharma  Inc  Price  Consensus and EPS Surprise   Zacks RankTheravance Biopharma carries a Zacks Rank  2  Buy   You can see  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-07,Zacks Investment Research,https://www.investing.com/analysis/theravance-tbph-beats-on-q3-earnings-inks-deal-for-vibativ-200357074,200357074
197053,418569,MYL,Momenta  MNTA  Reports Narrower Than Expected Loss In Q3 ,opinion,"Shares of Momenta Pharmaceuticals Inc    NASDAQ MNTA   gained 0 5  after the company reported mixed results for the third quarter  
Momenta s stock has gained 4  in the year so far  against the  decline of 14 3  

 
The company reported loss per share of 45 cents in the quarter  excluding restructuring charges   narrower than the Zacks Consensus Estimate of 63 cents but wider than the year ago loss of 44 cents 
Revenues in the quarter came in at  14 9 million  significantly down from  24 1 million in the year ago quarter and missed the Zacks Consensus Estimate by 13 2  
Quarter in Detail
Momenta s top line comprises product revenues of  13 6 million earned from Sandoz s sales of Glatopa  a generic version of Copaxone  20 mg   compared with  10 9 million in the year ago quarter  The increase in product revenues was primarily due to non recurring deduction of a  5 million contractual amount in 2017  which was offset by lower net sales of Glatopa  driven by Mylan N V  s   NASDAQ MYL   entry into the Copaxone market 
Research and development revenues came in at  1 3 million compared with  13 2 million in the year ago quarter  The decrease was primarily due to a  10 million milestone achieved in the 2017 period 
Research and development expenses decreased to  30 7 million from  37 9 million in the year ago quarter due to a decrease in external R D expenses for M923  General and administrative expenses were roughly flat at  20 4 million 
Pipeline Updates
As a result of its strategic review  results announced in October 2018   Momenta plans to advance its two late stage biosimilar assets  M923  which is its wholly owned proposed biosimilar to AbbVie s   NYSE ABBV   Humira  and M710  which is its proposed biosimilar to Regeneron s Eylea being developed in collaboration with Mylan  The company is in discussions with its collaboration partner  Mylan  to exit its participation in the development of its five other biosimilar programs  including M834  a proposed biosimilar to Orencia 
Momenta recently announced that it entered into a settlement with AbbVie Inc   to enable the commercialization of M923  Per the terms of the agreement and subject to approval by health regulatory authorities  Momenta may launch M923 in the United States on Nov 20  2023 and in Europe upon approval by the European Medicines Agency 
The company intends to submit a biologics license application for M923 to the FDA in the fourth quarter of 2018 and a marketing authorization application in the European Union in the first half of 2019 Momenta is now seeking commercialization partners for M923 
In August 2018  Mylan initiated a clinical trial in patients with diabetic macular edema to compare safety  efficacy and immunogenicity of M710 with Eylea 
Momenta s novel auto immune portfolio includes M230  a Selective Immunomodulator of Fc receptors  SIF3   M281  an anti FcRn monoclonal antibody  and M254 
In October 2018  Momenta announced additional data from its phase I study of M281 in healthy volunteers 
The company announced that it plans to commence two phase II proof of concept clinical trials  one in generalized myasthenia gravis  gMG  and one in hemolytic disease of the fetus and newborn  HDFN   in the fourth quarter of 2018 
The company intends to initiate a phase I II proof of concept study in immune thrombocytopenic purpura  ITP  in early 2019  pending regulatory feedback 
Our Take
Momenta s third quarter results were pretty ho hum with loss coming in narrower than expected  while revenues lagging estimates   While the FDA approval of Glatopa 40 mg should relieve Momenta  competition will limit market share gains for the company as Mylan has already won the FDA s approval for a generic version of Teva Pharmaceuticals    NYSE TEVA   Copaxone 40 mg  The company continues to face fierce competition due to growing pricing pressure from Mylan and Teva 
The completion of the strategic review has narrowed the company s focus on its biosimilar portfolio 
Zacks Rank
Momenta currently carries a Zacks Rank  3  Hold   You can see  
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-11-09,Zacks Investment Research,https://www.investing.com/analysis/momenta-mnta-reports-narrowerthanexpected-loss-in-q3-200357781,200357781
197054,418570,MYL,Mylan Recalls Valsartan Lots  Gets FDA Warning For Facility,opinion,Mylan N V    NASDAQ MYL   announced that it would voluntary recall select lots of blood pressure medicine Valsartan in the United States  The company recalled these due to traces of an impurity  N nitrosodiethylamine  NDEA  contained in the API Valsartan  manufactured by Mylan Laboratories Limited  Mylan stated that it would recall at least 15 lots of medicines containing valsartan distributed in the United States between March 2017 and November 2018 and manufactured by units Mylan Pharmaceuticals and Mylan Laboratories The company also commented on a Warning Letter it received from the FDA on Nov 9  which raised concerns related to its manufacturing facility in Morgantown  WV  The company has implemented a comprehensive restructuring and remediation plan at this facility  Considering the company s ongoing restructuring at this facility  Mylan said there is a temporary disruption in supply of certain products  and it has discontinued some products and transferred others to different facilities  The company stated that these activities are already reflected in its 2018 outlook  and the issues raised in the Warning Letter are being addressed within the context of this plan  Shares of the company fell about 2  following the news  However  the shares of the company have declined 19 8  year to date compared with the  s decline of 9 3   Mylan N V  Price   Zacks Rank   Stocks to ConsiderMylan is a Zacks Rank  3  Hold  stock Some better ranked stocks worth considering are Bristol Myers Squibb Company   NYSE BMY    Johnson and Johnson   NYSE JNJ   and Merck   Co    NYSE MRK    While Bristol Myers sports a Zacks Rank  1  Strong Buy   J J and Merck carry a Zacks Rank  2  Buy   You can see  Bristol Myers  earnings per share estimates have increased from  3 62 to  3 84 for 2018 and from  3 82 to  4 08 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters with average of 11 99  J J s earnings per share estimates have increased from  8 14 to  8 16 for 2018 and from  8 61 to  8 66 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters with average of 1 65   Shares of the company have increased 36  year to date Merck s earnings per share estimates have increased from  4 27 to  4 34 for 2018 and from  4 63 to  4 71 for 2019 over the past 60 days  The company delivered a positive earnings surprise in all the trailing four quarters with average of 3 96   Shares of the company have increased 36  year to date Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2018-11-20,Zacks Investment Research,https://www.investing.com/analysis/mylan-recalls-valsartan-lots-gets-fda-warning-for-facility-200361433,200361433
197055,418571,MYL,3 Reasons Why Glaxo  GSK  Stock Is Up This Year So Far ,opinion,So far this year  GlaxoSmithKline plc s   NYSE GSK   shares have outperformed the   rising 14 4  compared with a 6 7  increase for the industry   Meanwhile  estimates for 2018 and 2019 have risen 1 4  and 1 3   respectively in the past 60 days Its strong quarterly results  successful product launches and positive pipeline and regulatory updates have all contributed to the upside Strong ResultsGlaxo s total revenues rose 4  at constant exchange rate in the first nine months of 2018 led by sales growth in each of its three global businesses   Pharmaceuticals  Vaccines and Consumer Healthcare segments  While adjusted earnings rose 12   operating profit rose 7   supported by aggressive cost savings and operating improvements Following an encouraging performance in the first nine months of the year and higher than expected sales of its shingles vaccine  Shingrix  on the third quarter conference call  Glaxo raised its earnings growth outlook for the full year Also  a delay in launch of generic versions of its top selling product  Advair is benefiting Glaxo s profits Three companies Mylan   NASDAQ MYL    Hikma Pharmaceuticals and Novartis   NYSE NVS    which are trying to bring a generic version of Advair in the market  have received a complete response letter  CRL  from the FDA  While Mylan and Hikma got a CRL last year  Novartis received the same this year  delaying the entry of generics in the U S  marketSuccessful Product LaunchesGlaxo s new products like Nucala  severe eosinophilic asthma   the inhaled Ellipta portfolio  chronic obstructive pulmonary disorder COPD and asthma   Tivicay and Triumeq  HIV  and Menveo  Bexsero  meningitis vaccines  are all doing well and represent significant commercial opportunity In 2017  Glaxo received approvals for three key new drugs  Shingrix vaccine for shingles  which enjoys preferential recommendation from ACIP  Trelegy Ellipta  which provides three medicines in a single inhaler to treat COPD and Juluca  dolutegravir and rilpivirine   the first two drug regimen  once daily  single pill for HIV  All the three products have done well in 2018  particularly Shingrix Juluca has been developed by Glaxo HIV focused company  ViiV Healthcare  in partnership with Johnson   Johnson   NYSE JNJ   In fact  these three products coupled with the buyout of Novartis  stake in the Consumer Healthcare JV have strengthened Glaxo s competitive position  In June 2018  Glaxo bought Novartis  36 5  stake in their consumer health care joint venture for  13 billion   9 2 billion  With the acquisition of Novartis  stake  Glaxo now has 100  ownership of its Consumer Healthcare unit  which includes products such as Sensodyne and Flonase  The deal has strengthened Glaxo s competitive position in the market and was given a heads up by the investor community Pipeline   Regulatory Successes Glaxo has made significant progress with its late stage pipeline  We think Glaxo possesses one of the stronger late stage pipelines in large cap pharma  particularly in HIV therapeutic area HIV is expected to be an important growth driver for Glaxo s Pharma business going forward  It had some positive developments in its HIV pipeline recently   It is progressing well on its two drug regimens in HIV  making regulatory filings in the United States and Europe to get its HIV drug  Tivicay approved as a two drug regimen  2DR  in combination with lamivudine on the back of the positive GEMINI study data  Glaxo anticipates U S  approval in the second quarter of 2019 Glaxo also announced positive data from both the FLAIR and ATLAS studies this year  evaluating cabotegravir plus rilpivirine in a long acting  once monthly HIV formulation  Glaxo believes that this long acting injectable HIV therapy will provide a highly differentiated treatment option for patients seeking a long lasting therapy for HIV  freeing them of the burden of daily oral therapy  It believes the positive data from these studies will allow it to file for approval in the first half of 2019 Meanwhile  key regulatory approvals this year included Juluca in EU and Japan  Shingrix in EU and Japan  an expanded label for Trelegy Ellipta in the United States and EU  which can drive sales of these products Glaxo currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of All                 Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-11-26,Zacks Investment Research,https://www.investing.com/analysis/3-reasons-why-glaxo-gsk-stock-is-up-this-year-so-far-200362709,200362709
197056,418572,MYL,United Therapeutics  UTHR  Up 2  Since Last Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for United Therapeutics  UTHR   Shares have added about 2  in that time frame  outperforming the S P 500 
Will the recent positive trend continue leading up to its next earnings release  or is United Therapeutics due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at the most recent earnings report in order to get a better handle on the important catalysts  United Therapeutics Q3 Earnings   Sales BeatUnited Therapeutics reported adjusted earnings of  3 98 per share for the third quarter of 2018  which beat the Zacks Consensus Estimate of  3 49  Earnings declined 15  year over year  Adjusted earnings excluded the impact of share based compensation expenses  an impairment charge related to investment in a privately held company and some other items  Including these items  reported earnings came in at  2 42 per share  down 61  year over year Revenues for the reported quarter were  412 7 million  beating the Zacks Consensus Estimate of  372 million  Revenues declined 7  year over year The Quarter in DetailUnited Therapeutics markets four products for the treatment of PAH   Remodulin  Tyvaso  Adcirca and Orenitram Adcirca sales were  74 6 million  down 25  year over year as generic competition resulted in lower volumes in the quarter  Adcirca experienced loss of exclusivity in May this year and a generic formulation was launched by Mylan  NASDAQ MYL  in August  A higher allowance for product returns offset a price increase by Lilly and also hurt Adcirca s sales Orenitram sales amounted to  53 8 million in the quarter  up 2  year over year  Remodulin sales were  153 6 million  down 18  year over year due to lower sales in international markets  which offset higher U S  sales  Tyvaso sales totaled  107 8 million  up 21  year over year on price increases and easy comparisons from the year ago quarter Remodulin is also expected to face generic competition this year  which could reduce sales from these products  Remodulin lost exclusivity in June and generics are expected to be launched soon  However  on the call  management sounded confident that branded Remodulin revenues will continue to rise despite generic competition this year  This is due to the company s branded product s established safety profile and supply chain reliability  its patient support services and highly differentiated benefits  Moreover  the settlement agreements with the four generic manufacturers do not cover the right to market the generic formulations of Remodulin in the next generation drug delivery systems Unituxin s  for the treatment of pediatric patients with high risk neuroblastoma  sales of  22 9 million were up 35  year over year on an increase in the number of vials sold and a price increase Research and development  R D  expenses escalated 50  to  92 8 million due to higher costs to support the company s pipeline of cardiopulmonary and cancer drugs and to develop its organ manufacturing projects Selling  general and administrative  SG A  expenses rose 11 1  to  69 4 million 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates 
VGM Scores
At this time  United Therapeutics has a subpar Growth Score of D  though it is lagging a bit on the Momentum Score front with an F  However  the stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of C  If you aren t focused on one strategy  this score is the one you should be interested in 
Outlook
Estimates have been broadly trending downward for the stock  and the magnitude of these revisions looks promising  Notably  United Therapeutics has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-11-29,Zacks Investment Research,https://www.investing.com/analysis/united-therapeutics-uthr-up-2-since-last-earnings-report-can-it-continue-200363983,200363983
197057,418573,MYL,Israel stocks higher at close of trade  TA 35 up 1 54 ,news,"Investing com   Israel stocks were higher after the close on Wednesday  as gains in the Real Estate  Insurance and Banking sectors led shares higher 
At the close in Tel Aviv  the TA 35 gained 1 54  
The best performers of the session on the TA 35 were Mylan NV  TA MYL   which rose 8 15  or 1240 points to trade at 16460 at the close  Meanwhile  Melisron  TA MLSR  added 4 74  or 860 points to end at 18990 and  Ormat Technologies   TA ORA  was up 4 68  or 950 points to 21250 in late trade 
The worst performers of the session were  OPKO Health Inc   TA OPK   which fell 0 67  or 21 points to trade at 3132 at the close  Nice Ltd  TA NICE  declined 0 24  or 60 points to end at 25230 and  Gazit Globe   TA GZT  was down 0 13  or 5 points to 3785 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 283 to 103 and 56 ended unchanged 
Shares in Melisron  TA MLSR  rose to all time highs  up 4 74  or 860 to 18990  
Crude oil for April delivery was down 0 15  or 0 08 to  53 93 a barrel  Elsewhere in commodities trading  Brent oil for delivery in May rose 0 05  or 0 03 to hit  56 54 a barrel  while the April Gold Futures contract fell 0 75  or 9 40 to trade at  1244 50 a troy ounce 
USD ILS was up 0 17  to 3 6517  while EUR ILS fell 0 01  to 3 8551 
The US Dollar Index Futures was up 0 36  at 101 69 ",2017-03-01,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-1.54-463035,463035
197058,418574,MYL,Israel stocks higher at close of trade  TA 35 up 0 02 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Biomed  Real Estate and Banking sectors led shares higher 
At the close in Tel Aviv  the TA 35 gained 0 02  
The best performers of the session on the TA 35 were Alony Hetz Properties and Investments Ltd  TA ALHE   which rose 2 00  or 68 points to trade at 3467 at the close  Meanwhile  Avner Oil Exploration LP  TA AVNRp  added 1 90  or 4 6 points to end at 247 0 and Mylan NV  TA MYL  was up 1 51  or 250 points to 16800 in late trade 
The worst performers of the session were Harel  TA HARL   which fell 3 04  or 61 points to trade at 1944 at the close   Sodastream International Ltd   TA SODA  declined 2 11  or 390 0 points to end at 18080 0 and Perrigo  TA PRGO  was down 1 99  or 540 points to 26660 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 190 to 184 and 70 ended unchanged 
Shares in Perrigo  TA PRGO  fell to 5 year lows  down 1 99  or 540 to 26660  
Crude oil for April delivery was up 1 18  or 0 62 to  53 23 a barrel  Elsewhere in commodities trading  Brent oil for delivery in May rose 1 31  or 0 72 to hit  55 80 a barrel  while the April Gold Futures contract rose 0 13  or 1 60 to trade at  1234 50 a troy ounce 
USD ILS was down 0 04  to 3 6967  while EUR ILS rose 1 09  to 3 9263 
The US Dollar Index Futures was down 0 79  at 101 35 ",2017-03-05,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.02-463876,463876
197059,418575,MYL,Israel stocks higher at close of trade  TA 35 up 0 02 ,news,"Investing com   Israel stocks were higher after the close on Tuesday  as gains in the Banking  Real Estate and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 35 rose 0 02  
The best performers of the session on the TA 35 were  OPKO Health Inc   TA OPK   which rose 3 84  or 106 points to trade at 2863 at the close  Meanwhile  Poalim  TA POLI  added 1 81  or 41 points to end at 2305 and Melisron  TA MLSR  was up 1 66  or 320 points to 19650 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 3 23  or 530 points to trade at 15890 at the close  Teva  TA TEVA  declined 3 08  or 380 points to end at 11970 and Perrigo  TA PRGO  was down 1 88  or 490 points to 25630 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 216 to 164 and 64 ended unchanged 
Shares in Melisron  TA MLSR  rose to all time highs  rising 1 66  or 320 to 19650  Shares in Perrigo  TA PRGO  fell to 5 year lows  down 1 88  or 490 to 25630  
Crude oil for April delivery was up 0 26  or 0 14 to  53 34 a barrel  Elsewhere in commodities trading  Brent oil for delivery in May rose 0 14  or 0 08 to hit  56 09 a barrel  while the April Gold Futures contract fell 0 43  or 5 25 to trade at  1220 25 a troy ounce 
USD ILS was down 0 00  to 3 6777  while EUR ILS fell 0 02  to 3 8913 
The US Dollar Index Futures was up 0 05  at 101 72 ",2017-03-07,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.02-464342,464342
197060,418576,MYL,Israel stocks lower at close of trade  TA 35 down 1 02 ,news,"Investing com   Israel stocks were lower after the close on Sunday  as losses in the Insurance  Banking and Financials sectors led shares lower 
At the close in Tel Aviv  the TA 35 fell 1 02  to hit a new 3 months low 
The best performers of the session on the TA 35 were Alony Hetz Properties and Investments Ltd  TA ALHE   which rose 1 08  or 37 points to trade at 3448 at the close  Meanwhile   Airport City  Ltd  TA ARPT  added 0 73  or 34 points to end at 4699 and Paz Oil  TA PZOL  was up 0 66  or 390 points to 59710 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 2 68  or 410 points to trade at 14890 at the close   Sodastream International Ltd   TA SODA  declined 2 42  or 420 0 points to end at 16910 0 and Perrigo  TA PRGO  was down 2 27  or 570 points to 24510 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 219 to 177 and 33 ended unchanged 
Shares in Perrigo  TA PRGO  fell to 5 year lows  falling 2 27  or 570 to 24510  
Crude oil for May delivery was up 0 84  or 0 40 to  48 10 a barrel  Elsewhere in commodities trading  Brent oil for delivery in June unchanged 0 00  or 0 00 to hit  50 92 a barrel  while the April Gold Futures contract fell 0 34  or 4 20 to trade at  1243 00 a troy ounce 
USD ILS was down 0 48  to 3 6344  while EUR ILS fell 0 35  to 3 9246 
The US Dollar Index Futures was up 0 03  at 99 59 ",2017-03-26,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-35-down-1.02-468890,468890
197061,418577,MYL,Drug Maker s Chart Flashes Lower Prices Ahead,opinion,"Mylan  NASDAQ MYL  is a leading developer of branded and generic drugs  The stock has been slumping since peaking in late January 2018 at  46 72 a share  Since that high pivot  it has fallen by more than 10 points and is now trading at  36 33 a share  The current daily chart pattern is forming a bearish consolidation pattern  which indicates lower share prices ahead 
Support Watch
Traders and investors should now watch for major support around the  34 50 area  This support level is where MYL broke out in October 2017 and should be defended again when retested ",2018-07-17,Nicholas Santiago,https://www.investing.com/analysis/the-mylan-myl-chart-pattern-suggests-lower-ahead-200331397,200331397
197062,418578,MYL,5 Biotech and Pharmaceutical Companies To Watch In 2018,opinion,"1 TEVATeva Pharmaceutical Industries Limited  NYSE TEVA  is a pharmaceutical company that develops  manufactures and distributes generic medicines worldwide  Teva Pharmaceutical was founded in 1901 and is headquartered in Israel  This month TEVA received FDA approval for its generic version of Mylan s EpiPen  an epinephrine auto injector  This is the first generic EpiPen approval and could prove to be very favorable to Teva  as Mylan  NASDAQ MYL  have experienced inconsistent supply of product this year  However  the financial results may be delayed until next year  as there is a ramp up period and sales profits will produce higher 2019 results as it is expected that the Teva product could capture approx  40  of the market share for epinephrine auto injectors  Looking at the daily TEVA chart below  Teva looks to follow the age old adage  buy the rumor  sell the news  in the short term  as it traded higher on the news release and has moved down since  But  if it finds near term support  TEVA could be a good buy opportunity back to the top and beyond  
2 Verastem Inc  NASDAQ VSTM Verastem  Inc  a company established in 2010 in Needham  Mass is a biopharmaceutical company which focuses on developing drugs for the treatment of cancer  The companies lead drug to date is the defactinib  an orally taken combination therapy with immune oncology agents and other anti  cancer compounds  Defactinib is in phase 1b study for treatment of pancreatic cancer  as well as in Phase 1 and 2 clinical trials of the treatment of ovarian cancer  non small cell lung cancer  mesothelioma and pancreatic cancer  Along with other drugs in clinical trials for hematologic  blood  cancers such as Chronic lymphocytic leukemia and small lymphocytic lymphoma and non Hodgkin lymphoma  The company just released 2018 2nd Quarter results with a smaller loss than expected and a solid balance sheet and the stock reacted positively  This is a good Biopharma stock to put on your watch list  Watch for the stock to dip back down to support between  7 50 and  8 00 per share and think about entering if it bounces off support   see chart below  
3 MRKMerck  NYSE MRK  is a major drug manufacturer with a large portfolio of therapeutic and preventive drugs to treat cardiovascular diseases  Type 2 diabetes  asthma  nasal allergy symptoms  chronic hepatitis C  HIV 1 infections  hypertension  arthritis and pain  inflammatory and osteoporosis diseases and cholesterol modifying medicines among others  As the population ages  many of these agents become even more important  The company was founded in 1891 and is headquartered in Kenilworth  New Jersey  While this stock is already up significantly on the year  many analysts feel Merck is well positioned to move much higher as it is a good position to ride the current demographic wave of population aging and as investors look to move from high growth stocks into more defensive growth stocks  Big Pharma is a solid choice  Looking at the chart below  the stock is in a good technical trend and is good to watch for a pull back before entering long   
4 ABBVAbbVie  NYSE ABBV   Inc is a major drug manufacturer with products ranging from treating autoimmune diseases   oral therapies for patients with chronic lymphocytic leukemia   this drug is keeping a friend of mine alive as I write this   This large drug maker has a good portfolio of drugs with a lineup that promises to service the ageing population that is slated to have the adults over the age of 85 double over the next couple of decades and as this population becomes older they also become more dependent on drug therapies  One of AbbVie s most important drugs is Humira a rheumatoid arthritis drug therapy with around  20 Billion in sales this year  Also  they are not just sitting back but are working on new drugs for Rheumatoid arthritis and other long term drug therapies as well  Plus  the stock is offering a nice 3 9  dividend yield which could rise in the future as some of these new drugs come online  The stock has recently been in a sideways move and is a good long term Big Pharma play as some of the new drugs come online and the population ages  Look for the long trade as it bounces off current support   see Chart below  
5 PFEPfizer Inc  NYSE PFE  is a major drug manufacturer that develops and sell drug therapy products worldwide  Pfizer was founded in 1849 and is headquartered in New York City  Among their many drug therapies  they focus on vaccines  oncology  inflammation  and immunology and rare diseases  Common brand names include Lipitor  Lyrica  Celebrex  Viagra  as well as consumer over the counter products such as Advil and Centrum vitamins  These are drugs that are well suited to take advantage of chronic diseases that are more and more important as the general population age increases  Plus  Pfizer is investing over  3 5 Billion in R   D for future growth and has a nice dividend yield of over 3   The stock has found some solid footing over the last couple of months but is still a good longer term hold with good growth potential and a good yield to boot ",2018-08-27,Bill Poulos,https://www.investing.com/analysis/5-biotech-and-pharmaceutical-companies-to-watch-in-2018-200340901,200340901
197063,418579,MYL,Mylan  MYL  Q3 Earnings  Is A Disappointment In The Cards ,opinion,"Mylan N V    NASDAQ MYL   is scheduled to report third quarter 2018 results on Nov  5  after the market closes 
The company s performance has been dismal so far  having missed earnings estimates in three of the last four quarters  The company reported an average negative earnings surprise of 6 12  over the said time frame Mylan N V  Price  Consensus and EPS Surprise
 

   In the last reported quarter  the company missed earnings estimates by 13   Let s see how things are shaping up for this announcement 
Mylan s stock has lost 19 2  in the year so far  against the  growth of 0 8  

 
Factors to Consider This Quarter
Concurrent with second quarter results  Mylan lowered its annual outlook as a result of the change in expected product launches and resizing of product opportunities in the United States  The restructuring in Morgantown also impacted guidance 
Mylan expects 2018 total revenues of  11 25  12 25 billion  down from the previous projection of  11 75  13 25 billion  Mylan anticipates adjusted earnings per share around  4 55  4 90  down from the earlier estimate of  5 20  5 60 
Moreover  Mylan is evaluating strategic alternatives as the generic business in North America continues to experience pricing and competitive pressure 
While Mylan has one of the largest product portfolios among all generic pharmaceutical companies  the company has suffered a few setbacks in recent times  Mylan recently suffered a major setback as rival Teva Pharmaceutical Industries Ltd    NYSE TEVA   won the FDA approval for the first generic version of the former s EpiPen and EpiPen Jr  epinephrine  auto injector for the emergency treatment of allergic reactions  including those that are life threatening  anaphylaxis   in adults and pediatric patients 
The approval of a generic would negatively impact EpiPen sales of Mylan as the generic will obviously be priced lower  Mylan was earlier under the scanner for high price of the product  We note that the company already has its own authorized generic for the same 
The company earlier suffered a setback  when the FDA refused to approve its Abbreviated New Drug Application for Wixela  the generic version of GlaxoSmithKline s   NYSE GSK   asthma drug  Advair Diskus  The company recently stated that it has not received any new information request from the FDA for the same 
Nevertheless  the biosimilar business continues to gain traction 
Mylan and partner Biocon obtained FDA approval of Fulphila  a biosimilar of Neulasta  The news comes as a significant boost for Mylan  given the potential market for Fulphilia  The company also received the FDA approval for Ogivri  a biosimilar version of Herceptin  
The European Medicines Agency s Committee for Medicinal Products for Human Use  CHMP  issued a positive opinion recommending approval of Fulphila and Ogivri  The European Commission  EC  has granted marketing authorization to Hulio  a biosimilar of Humira for all indications 
During the earnings call  we expect investors to focus on the performance of EpiPen  newly launched biosimilars and other updates from its pipeline 
Earnings Whispers
Our proven model doesn t show that Mylan is likely to beat estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  to be able to beat on earnings  That is not the case here as you will see below 
Earnings ESP  The Earnings ESP  which represents the difference between the Most Accurate Estimate and the Zacks Consensus Estimate  is  1 12   You can uncover the best stocks to buy or sell before they re reported with our  
Zacks Rank  Mylan currently carries a Zacks Rank  3  While the rank is favorable  the company s negative ESP makes surprise prediction difficult 
Note that we caution against Sell rated stocks   4 or 5  going into an earnings announcement  especially when the company is seeing negative estimate revisions  They are best avoided 
Stock to Consider
Here is a pharma company you may want to consider  as our model shows that it has the right combination of elements to deliver an earnings beat this quarter 
Pacira Pharmaceuticals   NASDAQ PCRX   has an Earnings ESP of  45 9  and a Zacks Rank  2  The company is scheduled to report results on Nov 1  You can see  
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating revenue  and cures for a variety of deadly diseases are in the pipeline So are big potential profits for early investors  Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it ",2018-10-31,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-q3-earnings-is-a-disappointment-in-the-cards-200352647,200352647
197064,418580,MYL,Mylan  MYL  Surpasses Q3 Earnings Estimates,opinion,"Mylan  NASDAQ MYL  came out with quarterly earnings of  1 25 per share  beating the Zacks Consensus Estimate of  1 17 per share  This compares to earnings of  1 10 per share a year ago  These figures are adjusted for non recurring items 
This quarterly report represents an earnings surprise of 6 84   A quarter ago  it was expected that this generic drugmaker would post earnings of  1 23 per share when it actually produced earnings of  1 07  delivering a surprise of  13 01  
Over the last four quarters  the company has surpassed consensus EPS estimates two times 
Mylan  which belongs to the Zacks Medical   Generic Drugs industry  posted revenues of  2 86 billion for the quarter ended September 2018  missing the Zacks Consensus Estimate by 0 29   This compares to year ago revenues of  2 99 billion  The company has not been able to beat consensus revenue estimates over the last four quarters 
The sustainability of the stock s immediate price movement based on the recently released numbers and future earnings expectations will mostly depend on management s commentary on the earnings call 
Mylan shares have lost about 25 1  since the beginning of the year versus the S P 500 s gain of 1 9  
What s Next for Mylan 
While Mylan has underperformed the market so far this year  the question that comes to investors  minds is  what s next for the stock 
There are no easy answers to this key question  but one reliable measure that can help investors address this is the company s earnings outlook  Not only does this include current consensus earnings expectations for the coming quarter s   but also how these expectations have changed lately 
Empirical research shows a strong correlation between near term stock movements and trends in earnings estimate revisions  Investors can track such revisions by themselves or rely on a tried and tested rating tool like the Zacks Rank  which has an impressive track record of harnessing the power of earnings estimate revisions 
Ahead of this earnings release  the estimate revisions trend for Mylan was mixed  While the magnitude and direction of estimate revisions could change following the company s just released earnings report  the current status translates into a Zacks Rank  3  Hold  for the stock  So  the shares are expected to perform in line with the market in the near future  You can see the complete list of today s Zacks  1 Rank  Strong Buy  stocks here 
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead  The current consensus EPS estimate is  1 38 on  3 12 billion in revenues for the coming quarter and  4 62 on  11 50 billion in revenues for the current fiscal year 
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well  In terms of the Zacks Industry Rank  Medical   Generic Drugs is currently in the bottom 28  of the 250 plus Zacks industries  Our research shows that the top 50  of the Zacks ranked industries outperform the bottom 50  by a factor of more than 2 to 1 ",2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-surpasses-q3-earnings-estimates-200355068,200355068
197065,418581,MYL,Mylan  MYL  Earnings Beat  Revenues Miss Estimates In Q3,opinion,"Shares of Mylan N V   NASDAQ MYL   are up 8 1  in after market trading  after the company beat on earnings in the third quarter  Mylan s stock has lost 25 8  so far this year compared with the industry s decline of 6 6    Adjusted earnings of  1 25 per share beat the Zacks Consensus Estimate of  1 17 and were up from  1 10 in the year ago quarter However  third quarter revenues of  2 86 billion missed the Zacks Consensus Estimate of  2 87 billion and were down 4  from the prior year quarter Quarter in DetailThe company posts results in three segments on a geographic basis  namely North America  Europe and Rest of World North America segment s net sales came in at  1 01 billion  down 14   This decline was primarily due to lower volumes on existing products like the EpiPen Auto Injector  This was partially offset by new product sales  including the recent launch of Fulphila  a biosimilar of Neulasta  The decline in volumes was primarily driven by the timing of purchases of products by customers  divestiture of certain contract manufacturing assets  loss of exclusivity of a product  and actions associated with the restructuring and remediation program at the Morgantown manufacturing facility The FDA completed an inspection at Mylan s plant in Morgantown  West Virginia earlier this year and made observations through a Form 483  Thereafter  Mylan submitted a comprehensive response to the FDA  During the second quarter of 2018  Mylan started a restructuring and remediation program to reduce complexity at the Morgantown manufacturing facility  which led to the discontinuation and transfer of a number of products to other manufacturing sites  a reduction of the workforce and extensive remediation activities  These actions have led to a temporary disruption in supply of certain products Net sales in the Europe segment were  1 04 billion in the quarter  an increase of  0 5 million  which was primarily driven by new product sales and higher  volumes on existing products Rest of World segment s net sales of  773 7 million were up 4   driven by new products Adjusted gross margin of 55  was slightly down from 53  in the year ago quarter 2018 Outlook ReiteratedMylan expects 2018 total revenues of  11 25  12 25 billion  The company anticipates adjusted EPS around  4 55  4 90 Our TakeMylan s third quarter results were mixed as the company s earnings beat estimates but revenues missed the same Mylan proactively discontinued a number of products  while also transferring some to other sites  These have led to a temporary disruption in supply of certain products and reduced volumes in North America generic sales Nevertheless  Mylan continues to gain traction with its biosimilar portfolio  The company has launched nearly 475 new products year to date across its segments  including a record number of complex generics and biosimilars  In August 2018  Mylan completed an agreement with certain subsidiaries of Novartis AG   NYSE NVS   to purchase worldwide rights to their global cystic fibrosis products  consisting of the TOBI Podhaler and TOBI solution  This should further broaden the company s portfolio  Mylan and partner Biocon obtained the FDA approval for Fulphila  The company earlier received the FDA approval for a biosimilar version of Roche Holdings    OTC RHHBY   Herceptin Meanhwile  the company expects an approval of the generic version of GlaxoSmithKline s   NYSE GSK   asthma drug  Advair Diskus  Wixela  The FDA had earlier issued a complete response letter  CRL  for the same  Nevertheless  Mylan is in discussions with the FDA  regarding the progress of its review  Based on our latest update from the agency  the FDA is in the final stage of the labeling review However  these new approvals might not be enough to combat the persistent decline in North America  Zacks Rank
Mylan carries a Zacks Rank  3  Hold   You can see   Today s Stocks from Zacks  Hottest StrategiesIt s hard to believe  even for us at Zacks  But while the market gained  21 9  in 2017  our top stock picking screens have returned  115 0    109 3    104 9    98 6   and  67 1  And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   2017  the composite yearly average gain for these strategies has beaten the market more than 19X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2018-11-05,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-earnings-beat-revenues-miss-estimates-in-q3-200355578,200355578
197066,418582,MYL,Israel stocks higher at close of trade  TA 25 up 0 50 ,news,"Investing com   Israel stocks were higher after the close on Tuesday  as gains in the Banking  Financials and Real Estate sectors led shares higher 
At the close in Tel Aviv  the TA 25 added 0 50  
The best performers of the session on the TA 25 were  Israel Corp   TA ILCO   which rose 2 71  or 1940 points to trade at 73400 at the close  Meanwhile  First  International  Bank of Israel  TA FTIN  added 2 71  or 149 points to end at 5642 and  ICL  Israel Chemicals Ltd  TA ICL  was up 2 55  or 44 points to 1769 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 4 24  or 590 points to trade at 13330 at the close  Bezeq  TA BEZQ  declined 1 49  or 10 0 points to end at 660 0 and  Frutarom   TA FRUT  was down 1 33  or 270 points to 20030 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 226 to 124 and 91 ended unchanged 
Crude oil for March delivery was up 1 12  or 0 59 to  53 34 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March rose 0 85  or 0 47 to hit  55 70 a barrel  while the February Gold contract fell 0 17  or 2 10 to trade at  1213 50 a troy ounce 
USD ILS was down 0 09  to 3 7865  while EUR ILS fell 0 22  to 4 0728 
The US Dollar Index was up 0 14  at 100 09 ",2017-01-24,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.50-455332,455332
197067,418583,MYL,Israel stocks higher at close of trade  TA 25 up 0 53 ,news,"Investing com   Israel stocks were higher after the close on Wednesday  as gains in the Communication  Insurance and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 25 gained 0 53  
The best performers of the session on the TA 25 were First  International  Bank of Israel  TA FTIN   which rose 3 33  or 188 points to trade at 5830 at the close  Meanwhile  Mylan NV  TA MYL  added 2 93  or 390 points to end at 13720 and  Israel Corp   TA ILCO  was up 2 93  or 2150 points to 75550 in late trade 
The worst performers of the session were  OPKO Health Inc   TA OPK   which fell 1 43  or 46 points to trade at 3177 at the close  Perrigo  TA PRGO  declined 0 54  or 150 points to end at 27380 and Avner L  TA AVNRp  was down 0 40  or 1 0 points to 247 0 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 233 to 116 and 91 ended unchanged 
Shares in First International Bank of Israel  TA FTIN  rose to 52 week highs  rising 3 33  or 188 to 5830  Shares in Perrigo  TA PRGO  fell to 5 year lows  losing 0 54  or 150 to 27380  
Crude oil for March delivery was up 0 41  or 0 22 to  53 40 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March rose 0 27  or 0 15 to hit  55 59 a barrel  while the February Gold contract fell 1 18  or 14 25 to trade at  1196 55 a troy ounce 
USD ILS was down 0 25  to 3 7828  while EUR ILS fell 0 13  to 4 0641 
The US Dollar Index was down 0 22  at 100 05 ",2017-01-25,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.53-455606,455606
197068,418584,MYL,Israel stocks higher at close of trade  TA 25 up 0 07 ,news,"Investing com   Israel stocks were higher after the close on Tuesday  as gains in the Insurance  Technology and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 25 rose 0 07  
The best performers of the session on the TA 25 were Mylan NV  TA MYL   which rose 2 78  or 380 points to trade at 14070 at the close  Meanwhile   Strauss Group   TA STRS  added 1 76  or 105 points to end at 6062 and  Elbit Systems   TA ESLT  was up 1 47  or 600 points to 41450 in late trade 
The worst performers of the session were Teva  TA TEVA   which fell 5 30  or 690 points to trade at 12340 at the close   Frutarom   TA FRUT  declined 0 80  or 160 points to end at 19890 and Discount  TA DSCT  was down 0 45  or 3 5 points to 783 0 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 197 to 155 and 89 ended unchanged 
Shares in Elbit Systems  TA ESLT  rose to all time highs  gaining 1 47  or 600 to 41450  
Crude oil for March delivery was up 1 43  or 0 75 to  53 38 a barrel  Elsewhere in commodities trading  Brent oil for delivery in April rose 1 64  or 0 91 to hit  56 23 a barrel  while the April Gold Futures contract rose 1 55  or 18 55 to trade at  1214 55 a troy ounce 
USD ILS was down 0 17  to 3 7679  while EUR ILS rose 0 87  to 4 0718 
The US Dollar Index Futures was down 0 99  at 99 43 ",2017-01-31,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.07-456913,456913
197069,418585,MYL,Israel stocks higher at close of trade  TA 25 up 0 79 ,news,"Investing com   Israel stocks were higher after the close on Wednesday  as gains in the Biomed  Technology and Oil   Gas sectors led shares higher 
At the close in Tel Aviv  the TA 25 rose 0 79  
The best performers of the session on the TA 25 were Teva  TA TEVA   which rose 3 40  or 420 points to trade at 12760 at the close  Meanwhile  Mylan NV  TA MYL  added 3 20  or 450 points to end at 14520 and Perrigo  TA PRGO  was up 2 53  or 710 points to 28730 in late trade 
The worst performers of the session were  ICL  Israel Chemicals Ltd  TA ICL   which fell 1 16  or 20 points to trade at 1710 at the close  First  International  Bank of Israel  TA FTIN  declined 0 86  or 49 points to end at 5616 and  Frutarom   TA FRUT  was down 0 85  or 170 points to 19720 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 252 to 114 and 75 ended unchanged 
Crude oil for March delivery was up 0 91  or 0 48 to  53 29 a barrel  Elsewhere in commodities trading  Brent oil for delivery in April rose 1 08  or 0 60 to hit  56 18 a barrel  while the April Gold Futures contract fell 0 57  or 6 90 to trade at  1204 50 a troy ounce 
USD ILS was up 0 27  to 3 7796  while EUR ILS fell 0 08  to 4 0668 
The US Dollar Index Futures was up 0 28  at 99 81 ",2017-02-01,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.79-457207,457207
197070,418586,MYL,Israel stocks lower at close of trade  TA 25 down 0 35 ,news,"Investing com   Israel stocks were lower after the close on Thursday  as losses in the Biomed  Communication and Technology sectors led shares lower 
At the close in Tel Aviv  the TA 25 fell 0 35  
The best performers of the session on the TA 25 were Perrigo  TA PRGO   which rose 2 09  or 600 points to trade at 29330 at the close  Meanwhile  Mylan NV  TA MYL  added 1 03  or 150 points to end at 14670 and Teva  TA TEVA  was up 0 71  or 90 points to 12850 in late trade 
The worst performers of the session were  Ormat Technologies   TA ORA   which fell 1 82  or 370 points to trade at 19960 at the close  Bezeq  TA BEZQ  declined 1 60  or 10 5 points to end at 645 0 and  OPKO Health Inc   TA OPK  was down 1 59  or 52 points to 3217 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 201 to 152 and 88 ended unchanged 
Shares in Bezeq  TA BEZQ  fell to 52 week lows  losing 1 60  or 10 5 to 645 0  
Crude oil for March delivery was down 0 48  or 0 26 to  53 62 a barrel  Elsewhere in commodities trading  Brent oil for delivery in April fell 0 30  or 0 17 to hit  56 63 a barrel  while the April Gold Futures contract rose 0 88  or 10 65 to trade at  1218 95 a troy ounce 
USD ILS was down 0 55  to 3 7536  while EUR ILS fell 0 15  to 4 0559 
The US Dollar Index Futures was down 0 23  at 99 46 ",2017-02-02,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-25-down-0.35-457488,457488
197071,418587,MYL,Senators question Kaleo   4 500 tag on opioid overdose treatment,news,"By Ankur Banerjee  Reuters    U S  Democrat Senator Claire McCaskill on Thursday asked Kaleo Pharmaceuticals to justify the more than 550 percent surge in the price of its device to treat painkiller overdoses  becoming the second senator to question Evzio s  4 500 price tag  Evzio contains the overdose reversing drug naloxone and can be used in emergencies by people without medical training  Privately held Kaleo has raised the price of a twin pack to  4 500  from  690 in 2014  according to a Kaiser Health News report   The concerns over Evzio s price comes at a time when pharmaceutical companies are facing intense scrutiny over  price gouging   and as lawmakers struggle with the epidemic of opioid abuse  The Centers for Disease Control and Prevention estimates at least 91 Americans succumb every day to opioid overdose  which experts partly blame on unrestricted painkiller prescriptions   At a time when Congress has worked to expand access to naloxone products and to assist state and local communities to equip first responders with this life saving drug  this startling price hike is very concerning   McCaskill said in a letter to Kaleo Chief Executive Spencer Williamson   The letter  which was signed by 30 U S  senators  asked Kaleo for information on Evzio s price structure and why the company chose to adjust prices   We received the letter from the Senators and are in communication with them to ensure all questions are addressed   Williamson told Reuters in an e mailed statement  Democrat Senator Amy Klobuchar sent Kaleo a letter earlier this month  voicing similar concerns  Williamson said that Americans with commercial insurance and a prescription could get Evzio  which was approved in 2014  for no out of pocket cost  or for  360 if they paid cash  He added that people without insurance and with household income under  100 000 could get Evzio for no out of pocket cost  Kaleo s other product is Auvi Q  an emergency allergy auto injector that is a rival to Mylan  NASDAQ MYL  NV s EpiPen  which came under intense criticism last year for its high price  
Kaleo said last month that it would offer Auvi Q at no cost to many consumers  but set a list price   to be used as the benchmark cost to insurance companies   at a whopping  4 500 ",2017-02-09,Reuters,"https://www.investing.com/news/politics-news/senators-question-kaleo'-$4,500-tag-on-opioid-overdose-treatment-459027",459027
197072,418588,MYL,Israel stocks higher at close of trade  TA 35 up 0 57 ,news,"Investing com   Israel stocks were higher after the close on Wednesday  as gains in the Oil   Gas  Insurance and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 35 rose 0 57  to hit a new 1 month high 
The best performers of the session on the TA 35 were  Sodastream International Ltd   TA SODA   which rose 8 90  or 1560 0 points to trade at 19090 0 at the close  Meanwhile  Teva  TA TEVA  added 6 22  or 790 points to end at 13500 and Mylan NV  TA MYL  was up 4 50  or 670 points to 15560 in late trade 
The worst performers of the session were Tower Semiconductor Ltd  TA TSEM   which fell 2 48  or 208 points to trade at 8193 at the close  Alony Hetz  TA ALHE  declined 2 44  or 80 points to end at 3200 and  Israel Corp   TA ILCO  was down 2 43  or 1780 points to 71400 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 241 to 134 and 66 ended unchanged 
Shares in Sodastream International Ltd  TA SODA  rose to all time highs  rising 8 90  or 1560 0 to 19090 0  
Crude oil for March delivery was up 0 36  or 0 19 to  53 39 a barrel  Elsewhere in commodities trading  Brent oil for delivery in April rose 0 32  or 0 18 to hit  56 15 a barrel  while the April Gold Futures contract rose 0 04  or 0 45 to trade at  1225 85 a troy ounce 
USD ILS was up 0 06  to 3 7506  while EUR ILS rose 0 04  to 3 9658 
The US Dollar Index Futures was up 0 13  at 101 33 ",2017-02-15,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-35-up-0.57-460118,460118
197073,418589,MYL,Trump s pick to lead health agency calls EpiPen issue  disturbing ,news,"By Susan Cornwell WASHINGTON  Reuters    U S  President Donald Trump s choice to lead an important health agency said on Thursday that the way pharmaceutical companies classify products as generic or branded needs to be reviewed in order to help hold down government spending  as she cited Mylan  NASDAQ MYL  NV s EpiPen emergency allergy treatment   Seema Verma  Trump s nominee to lead the Centers for Medicare and Medicaid Services  CMS   did not answer questions about whether the U S  government should negotiate with pharmaceutical companies over drug prices   I think what happened with     the EpiPen issue is very disturbing   Verma said at her confirmation hearing before the Senate Finance Committee   The idea that perhaps Medicaid programs  which are struggling to pay for those programs  that they could have potentially received rebates is disturbing to me    Mylan has been criticized for listing EpiPen with Medicaid as a generic product even though it listed it with the Food and Drug Administration as a branded product  The classification led to Mylan s paying significantly smaller rebates to the Medicaid healthcare program for the poor than if EpiPen were classified as branded   I would like to review the processes in place there  in terms of the classifications  in terms of brand and generic  to ensure that type of thing doesn t happen again   Verma said  CMS said last year that it had  expressly advised  Mylan that the drugmaker had improperly classified EpiPen  Mylan said last month that U S  antitrust authorities had launched an investigation into EpiPen  The company said suggestions it took any inappropriate or unlawful actions to prevent generic competition was  without merit   Mylan has also come under fire for raising the price of a two pack of EpiPens to  600 last summer from  100 in 2008  Mylan began selling a generic version of EpiPen for  300 per two pack in December  Verma also said she would produce records of communication between the agency and Mylan  when questioned by Republican Senator Chuck Grassley  A statement from Grassley s office said Mylan had overcharged states and taxpayers by  potentially hundreds of millions of dollars    Democrats were not pleased with Verma s sidestepping a question from Senator Debbie Stabenow about whether she agreed with Trump that the government should negotiate with drug companies over prices of drugs covered by the Medicare healthcare program for the elderly and disabled  
 I don t think that s a simple yes or no answer   Verma said   The goal is to make sure that we re getting affordable prices for our seniors  ",2017-02-16,Reuters,https://www.investing.com/news/politics-news/trump's-pick-to-lead-health-agency-calls-epipen-issue-'disturbing'-460486,460486
197075,418591,MYL,Mylan  MYL  To Get CRL Again For Generic Advair From FDA ,opinion,"Shares of Mylan N V    NASDAQ MYL   are down after the company announced that the FDA will not approve its Abbreviated New Drug Application for the generic version of GlaxoSmithKline s   NYSE GSK   asthma drug  Advair Diskus  yet again 
The agency found minor deficiencies in the application  which will be relayed to the company in a Complete Response Letter  CRL  to be issued on June 27  2018 
The news comes as a disappointment for Mylan  Last year  the FDA had issued a CRL for it  as well  A probable approval would have boosted Mylan s generic portfolio immensely  given the potential market for the same 
The CRL also puts a question mark on Mylan s 2018 guidance and the company is expected to update on the same 
Mylan s stock has gained 4 2  in the last six months compared with the  gain of 3 9  

 
After a challenging 2017  things were looking up for Mylan in 2018 with recent approvals  which are expected to help the company combat the persistent decline in EpiPen sales 
Mylan s biosimilar portfolio got a boost with the recent FDA approval of Fulphila  a biosimilar of Neulasta  The company had earlier won the FDA approval of Ogivri  a biosimilar of Herceptin 
Earlier  Mylan received a major boost with the FDA approval for a generic version of Teva s   NYSE TEVA   Copaxone 40mg  Being one of the first filers  it will also enjoy 180 days of exclusivity  The company has more than 30 submissions planned in 2018 
Hence  the approval of generic Advair would have further propelled the company s broad portfolio of biosimilars and generics 
Meanwhile  Mylan is not the only company whose ANDA has been rejected by the FDA  Earlier in 2018  Swiss pharma giant Novartis    NYSE NVS   generic arm Sandoz also got a CRL from the FDA for its generic version of Advair  Sandoz is in the process of addressing the issues identified in the CRL and it does not expect to launch the generic before 2019 end  Hikma Pharmaceuticals also received a CRL from the FDA in 2017 for its generic version of Advair 
On the other hand  the delay in approval of generic version of Advair bodes well for Glaxo  Concurrent with the first quarter results  Glaxo stated that it expects Advair sales of around  750 million in 2018  assuming a mid year introduction of a substitutable generic competitor to Advair in the United States  
Zacks Rank
Mylan carries a Zacks Rank  3  Hold   You can see  
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia and other conditions 
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-06-14,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-to-get-crl-again-for-generic-advair-from-fda-200325094,200325094
197076,418592,MYL,Company News For Jun 15  2018,opinion,Etsy Inc  s   NASDAQ ETSY   shares jumped 26 3  after the company announced that it now expects 2018 revenue to grow 32  to 34  year over year  up from its previous forecast of an increase of 22  to 24 Royal Caribbean Cruises Ltd    NYSE RCL   soared 5 1  after announcing that it has acquired a 66 7  stake in luxury cruise line Silversea Cruises for  1 billionMylan N V    NASDAQ MYL   shares plummeted 5 2  after the FDA refused to approve its Abbreviated New Drug Application for the generic version of GlaxoSmithKline plc s   NYSE GSK   asthma drug  Advair DiskusShares of Twitter Inc    NYSE TWTR   surged 6 2  after the company revealed the updates of its social networking platform to make it easier for users to find and follow big events and news,2018-06-14,Zacks Investment Research,https://www.investing.com/analysis/company-news-for-jun-15-2018-200325351,200325351
197077,418593,MYL,Mylan Drops After FDA Finds Deficiencies In Its Version of Advair  Watch This Leve,opinion,Shares of the pharmaceutical giant  Mylan NV  NASDAQ MYL   are falling by nearly 5 0 percent to  39 70 a share  The sharp decline in the stock comes after the FDA said that it found minor deficiencies in Mylan s generic version of Advair  Today  the stock is fighting to stay above its important 50 and 200 day moving averages  A close below these key support levels will signal further downside in the stock price  Either way  should the stock decline further from current levels the next major support area would be around the  35 00 area  This is where the stock broke out on early May 2018 and should be defended by the institutional crowd if retested ,2018-06-15,Nicholas Santiago,https://www.investing.com/analysis/mylan-drops-after-fda-finds-deficiencies-in-its-version-of-advair-watch-this-leve-200325121,200325121
197078,418594,MYL,Israel stocks lower at close of trade  TA 25 down 0 74 ,news,"Investing com   Israel stocks were lower after the close on Sunday  as losses in the Biomed  Technology and Insurance sectors led shares lower 
At the close in Tel Aviv  the TA 25 declined 0 74  
The best performers of the session on the TA 25 were  Gazit Globe   TA GZT   which rose 3 56  or 117 points to trade at 3400 at the close  Meanwhile  Mylan NV  TA MYL  added 2 34  or 340 points to end at 14900 and Avner L  TA AVNRp  was up 2 15  or 5 7 points to 271 0 in late trade 
The worst performers of the session were  OPKO Health Inc   TA OPK   which fell 19 50  or 860 points to trade at 3550 at the close  First  International  Bank of Israel  TA FTIN  declined 0 53  or 30 points to end at 5620 and Bezeq  TA BEZQ  was down 0 27  or 2 0 points to 730 0 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 273 to 91 and 81 ended unchanged 
Crude oil for February delivery was up 0 24  or 0 13 to  53 90 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March fell 0 19  or 0 11 to hit  56 74 a barrel  while the February Gold contract fell 0 53  or 6 10 to trade at  1152 00 a troy ounce 
USD ILS was up 0 57  to 3 8650  while EUR ILS rose 0 51  to 4 0560 
The US Dollar Index was down 0 28  at 102 37 ",2017-01-01,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-25-down-0.74-450629,450629
197079,418595,MYL,Israel stocks higher at close of trade  TA 25 up 0 13 ,news,"Investing com   Israel stocks were higher after the close on Tuesday  as gains in the Biomed  Technology and Real Estate sectors led shares higher 
At the close in Tel Aviv  the TA 25 added 0 13  
The best performers of the session on the TA 25 were  OPKO Health Inc   TA OPK   which rose 2 96  or 102 points to trade at 3552 at the close  Meanwhile  Teva  TA TEVA  added 2 27  or 320 points to end at 14390 and Mylan NV  TA MYL  was up 1 88  or 280 points to 15170 in late trade 
The worst performers of the session were  Strauss Group   TA STRS   which fell 2 15  or 133 points to trade at 6062 at the close  Bezeq  TA BEZQ  declined 2 07  or 14 8 points to end at 698 5 and First  International  Bank of Israel  TA FTIN  was down 1 64  or 92 points to 5521 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 220 to 143 and 78 ended unchanged 
Crude oil for February delivery was up 0 82  or 0 44 to  54 16 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March rose 0 84  or 0 48 to hit  57 30 a barrel  while the February Gold contract rose 0 33  or 3 80 to trade at  1155 50 a troy ounce 
USD ILS was up 0 47  to 3 8740  while EUR ILS rose 0 10  to 4 0234 
The US Dollar Index was up 1 02  at 103 41 ",2017-01-03,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.13-450854,450854
197080,418596,MYL,Israel stocks higher at close of trade  TA 25 up 0 24 ,news,"Investing com   Israel stocks were higher after the close on Thursday  as gains in the Banking  Real Estate and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 25 rose 0 24  
The best performers of the session on the TA 25 were  Israel Corp   TA ILCO   which rose 4 15  or 2730 points to trade at 68530 at the close  Meanwhile   ICL  Israel Chemicals Ltd  TA ICL  added 3 86  or 63 points to end at 1695 and Poalim  TA POLI  was up 1 90  or 44 points to 2364 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 1 76  or 270 points to trade at 15030 at the close  Teva  TA TEVA  declined 1 44  or 210 points to end at 14390 and  OPKO Health Inc   TA OPK  was down 1 44  or 51 points to 3496 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 180 to 175 and 86 ended unchanged 
Shares in Poalim  TA POLI  rose to 5 year highs  rising 1 90  or 44 to 2364  
Crude oil for February delivery was up 0 69  or 0 37 to  53 63 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March rose 0 69  or 0 39 to hit  56 85 a barrel  while the February Gold contract rose 1 45  or 16 85 to trade at  1182 15 a troy ounce 
USD ILS was down 0 48  to 3 8436  while EUR ILS rose 0 76  to 4 0756 
The US Dollar Index was down 1 06  at 101 40 ",2017-01-05,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.24-451352,451352
197081,418597,MYL,Israel stocks lower at close of trade  TA 25 down 0 24 ,news,"Investing com   Israel stocks were lower after the close on Tuesday  as losses in the Insurance  Biomed and Financials sectors led shares lower 
At the close in Tel Aviv  the TA 25 declined 0 24  
The best performers of the session on the TA 25 were Mylan NV  TA MYL   which rose 1 15  or 170 points to trade at 14960 at the close  Meanwhile   Azrieli Group   TA AZRG  added 1 14  or 190 points to end at 16900 and  Gazit Globe   TA GZT  was up 0 96  or 34 points to 3574 in late trade 
The worst performers of the session were Teva  TA TEVA   which fell 1 62  or 220 points to trade at 13330 at the close   Frutarom   TA FRUT  declined 1 59  or 330 points to end at 20390 and  ICL  Israel Chemicals Ltd  TA ICL  was down 1 03  or 18 points to 1722 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 198 to 178 and 64 ended unchanged 
Crude oil for February delivery was down 1 40  or 0 73 to  51 23 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March fell 1 60  or 0 88 to hit  54 06 a barrel  while the February Gold contract rose 0 34  or 4 05 to trade at  1188 95 a troy ounce 
USD ILS was up 0 01  to 3 8437  while EUR ILS rose 0 19  to 4 0709 
The US Dollar Index was down 0 21  at 101 71 ",2017-01-10,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-25-down-0.24-452210,452210
197082,418598,MYL,Israel stocks lower at close of trade  TA 25 down 0 59 ,news,"Investing com   Israel stocks were lower after the close on Thursday  as losses in the Biomed  Technology and Oil   Gas sectors led shares lower 
At the close in Tel Aviv  the TA 25 lost 0 59  to hit a new 1 month low 
The best performers of the session on the TA 25 were Nice Ltd  TA NICE   which rose 3 41  or 870 points to trade at 26380 at the close  Meanwhile  First  International  Bank of Israel  TA FTIN  added 1 75  or 96 points to end at 5580 and  Mizrahi Tefahot   TA MZTF  was up 1 64  or 95 points to 5871 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 7 18  or 1080 points to trade at 13960 at the close   OPKO Health Inc   TA OPK  declined 4 14  or 151 points to end at 3493 and Teva  TA TEVA  was down 3 70  or 500 points to 13020 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 205 to 158 and 77 ended unchanged 
Shares in Mizrahi Tefahot  TA MZTF  rose to all time highs  up 1 64  or 95 to 5871  Shares in Teva  TA TEVA  fell to 3 years lows  falling 3 70  or 500 to 13020  
Crude oil for February delivery was up 1 42  or 0 74 to  52 99 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March rose 1 62  or 0 89 to hit  55 99 a barrel  while the February Gold contract rose 0 41  or 4 90 to trade at  1201 50 a troy ounce 
USD ILS was down 0 25  to 3 8245  while EUR ILS rose 0 39  to 4 0736 
The US Dollar Index was down 0 64  at 101 05 ",2017-01-12,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-25-down-0.59-452786,452786
197083,418599,MYL,Mallinckrodt to pay  100 million to settle U S  probe on drug pricing,news,"By Diane Bartz
WASHINGTON  Reuters     Mallinckrodt  Plc  N MNK  has agreed to pay  100 million to settle allegations that a subsidiary broke U S  antitrust law by sharply increasing the price of a multiple sclerosis drug while ensuring that no rival medicine appeared on the market  the Federal Trade Commission said on Wednesday 
Mallinckrodt s share price dropped sharply to just under  43 from above  49 on a report Wednesday  which proved incorrect  that the FTC would sue Mallinckrodt  It spiked above  50 after news of a settlement and closed at  46 53  down 5 8 percent 
In 2001  Questcor bought the rights to Acthar  a type of hormone based drug used to treat infantile spasms as well as multiple sclerosis  Over time  the company raised the price from  40 per vial to more than  34 000  the FTC said  Questcor was acquired by Mallinckrodt in 2014 
Acthar  which is off patent  represented 34 percent of Mallinckrodt s  3 4 billion in net sales for fiscal 2016  the company said in a government filing 
Per patient  Medicare spent more on Acthar than for any other drug in 2015  putting out  504 million for just 3 104 patients  according to the Medicare Drug Spending Dashboard 
Several U S  drug makers have been criticized for sharp increases in drugs  notably Turing Pharmaceuticals  Daraprim and Mylan s  O MYL  EpiPen  The U S  Centers for Medicare and Medicaid Services reported 11 drugs saw price increases of more than 100 percent in 2015 
 This is an egregious case of a monopolist doing a deal to eliminate potential competition and keep its power over pricing  It is abhorrent that lifesaving drugs cost New Yorkers tens of thousands of dollars   said Attorney General Eric Schneiderman in a statement 
Mallinckrodt  an Irish company headquartered in the United Kingdom  said the settlement would not affect its net sales and slammed the FTC s probe 
 We continue to strongly disagree with allegations outlined in the FTC s complaint  believing that key claims are unsupported and even contradicted by scientific data and market facts   a company representative said in a statement 
Questcor also bought the rights to Synacthen in 2013 in order to prevent the development of a rival drug  the FTC said in its complaint  Under the settlement  Mallinckrodt will also license Synacthen rights 
 This is too little  too late  The proper thing would have been to block the  Synacthen  deal in the first place   said David Balto  a veteran of the FTC now in private practice 
The drug s pricing has also come under criticism from lawmakers concerned about abusive increases in drug prices  Senator Amy Klobuchar  a Minnesota Democrat  criticized the sharp price increase as early as 2008 
Klobuchar called the settlement announced on Wednesday  a strong message that companies will not be able to keep the profits they earn by violating antitrust laws  
In addition to the FTC and New York  the settlement also included Alaska  Maryland  Texas and Washington ",2017-01-18,Reuters,https://www.investing.com/news/stock-market-news/mallinckrodt-to-pay-$100-million-to-settle-u.s.-probe-on-drug-pricing-454112,454112
197084,418600,MYL,U S  health agency tells Grassley there is no EpiPen settlement yet,news,"NEW YORK  Reuters    Mylan  NASDAQ MYL  NV has yet to reach a settlement with the U S  Department of Justice over the classification in the Medicaid program of life saving allergy treatment EpiPen  the acting head of a top U S  government health regulatory agency told Senator Charles Grassley in a letter disclosed on Thursday  In the letter  which Grassley released  Andrew Slavitt  who has run the Centers for Medicare   Medicaid Services  said that Mylan had not reached a settlement yet with any potential party regarding the treatment   Mylan said in October that it would pay  465 million to settle questions over whether it underpaid U S  government healthcare programs  
Mylan was not immediately available for comment ",2017-01-19,Reuters,https://www.investing.com/news/stock-market-news/u.s.-health-agency-tells-grassley-there-is-no-epipen-settlement-yet-454437,454437
197087,418603,MYL,Theravance Biopharma  TBPH  Q1 Loss Narrows  Sales Up Y Y,opinion,"Theravance Biopharma   NASDAQ TBPH   reported first quarter 2018 loss of  1 22 per share  narrower than the Zacks Consensus Estimate of a loss of  1 29 and the year ago loss of  1 27 Total revenues in the quarter surged 169 5  year over year to  8 3 million  This upside can mainly be attributed to amortization of the upfront fees related to a global development and commercialization agreement with Janssen  subsidiary of Johnson   Johnson   NYSE JNJ    for TD 1473  Moreover  the top line surpassed the Zacks Consensus Estimate of  5 74 million Theravance shares were up 3 4  on May 8  following the earnings release  However  shares have underperformed the  in a year s time  The stock has lost 12 6  compared with the industry s 2 9  decrease Quarterly DetailsVibativ generated U S  revenues of  3 7 million in the first quarter  up 20 6  from the year ago period  Revenues from collaborations were  4 6 million compared with  37 000 in the year earlier quarter Research and development expenses were  47 8 million  up 21 4  from the year ago period while selling  general   administrative expenses rose 44 6  to  24 7 million  The increase in expenses was due to higher employee related costs and stock based compensation Pipeline and Other UpdatesIn February 2018  Theravance entered into a global collaboration agreement with Janssen to jointly develop and commercialize its pan Janus kinase inhibitor  TD 1473  for the treatment of inflammatory intestinal diseases   A phase II study and a phase IIb III study are likely to be initiated in the second half of 2018 to evaluate TD 1473 in Crohn s disease and ulcerative colitis  respectively In January  Theravance along with partner Mylan   NASDAQ MYL   announced that the new drug application   NDA   for pipeline candidate  revefenacin  TD 4208   has been accepted by the FDA for treatment of adults with chronic obstructive pulmonary disease  A response from the regulatory body is expected on Nov 13  2018  The company is preparing for the commercial launch of the drug upon potential approval The company s collaboration partner Alfasigma for velusetrag  TD 5108  opted in to acquire rights to the candidate  Per the opt in decision  global rights to develop  manufacture and commercialize velusetrag will be transferred to Alfasigma for  10 million upfront fees and future milestone payments and royalties  Theravance has decided not to pursue further development of velusetrag as part of its pipeline strategy 2018 Outlook ReiteratedTheravance continues to expect operating loss  excluding non cash share based compensation  for 2018 in the range of  180  200 million Theravance Biopharma  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Key PickTheravance currently carries a Zacks Rank  3  Hold  A better ranked stock in the health care sector is Ligand Pharmaceuticals Incorporated   NASDAQ LGND    sporting a Zacks Rank  1  Strong Buy   You can see  Ligand s earnings per share estimates moved up from  4 40 to  4 43 and remained stable at  5 32 for 2018 and 2019  respectively  in the last 30 days  The company pulled off a positive earnings surprise in three of the last four quarters with an average beat of 24 88   The company s stock is up 14 9  so far this year The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-05-08,Zacks Investment Research,https://www.investing.com/analysis/theravance-biopharma-tbph-q1-loss-narrows-sales-up-yy-200314807,200314807
197088,418604,MYL,Mylan  MYL  Q1 Earnings Lag On Weak North America Sales,opinion,"Mylan   NASDAQ MYL   reported disappointing results for the first quarter as earnings and sales both missed estimates Mylan N V  Price and Consensus

   Adjusted earnings of 96 cents per share missed the Zacks Consensus Estimate of 99 cents but was up from 93 cents in the year ago quarter 
First quarter revenues of  2 68 billion missed the Zacks Consensus Estimate of  2 78 billion and were down 1  from the prior year period 
Mylan s stock has lost 7 3  in the last six months compared with the  decline of 6 0  

 
Quarter in Detail
The company posts results in three segments on a geographic basis namely North America  Europe and Rest of World 
North America segment s third party net sales came in at  985 3 million  down 19  due to a decrease in the sales of branded products  including EpiPen Auto Injector  the impact of the loss of exclusivity of olmesartan and olmesartan HCTZ and the prior year divestiture of certain contract manufacturing assets 
Sales were adversely impacted due to the implementation of new accounting standards along with lower volumes  and to a lesser extent  pricing  on other existing products partially offset by new product introductions 
Third party net sales from Europe were  1 04 billion  up 16   This was propelled by new product introductions across the region combined with volume expansion which offset the impact of pricing on existing products   Favorable foreign currency translation positively impacted sales by 14  
Rest of World segment s third party net sales of  626 7 million was up 8   driven by new products and increased volume from the anti retroviral franchise and higher sales in the emerging markets 
Adjusted gross margin of 52 9  was down from 53 5  in the year ago quarter 
During the quarter  Mylan repurchased 9 8 million ordinary shares for  432 0 million completing the previously authorized share repurchase program 
2018 Outlook Reiterated
Mylan expects revenues of  11 75  13 25 billion in 2018 while the Zacks Consensus Estimate stands at  12 45 billion  Mylan anticipates adjusted EPS of around  5 20  5 60 in 2018 while the Zacks Consensus Estimate is pegged at  5 35 
Our Take
Mylan s first quarter results were dismal as challenges in North America persist   The generic business in the United States continues to experience pricing pressure  Loss of exclusivity on olmesartan products also impacted sales 
Nevertheless  things are likely to look up in the long run  Mylan has already won an FDA approval for a generic version of Teva Pharmaceuticals    NYSE TEVA   Copaxone 40 mg  Notably  this is the first generic of Copaxone that has been approved  Since Mylan was one of the first applicants to submit a substantially complete ANDA for glatiramer acetate Injection  40 mg mL containing a Paragraph IV certification  the company and other first filers may be eligible for 180 days of generic drug exclusivity  The company also received an FDA approval for a biosimilar version of Roche Holdings    OTC RHHBY   Herceptin 
Although volatility in the U S  market is expected to persist in 2018  yet these approvals should position Mylan better in the year ahead and help combat the decline in EpiPen sales  The company has more than 30 submissions planned in 2018  The launch of generic version of Estrace cream is also underway 
Key anticipated approvals also include a biosimilar version of Neulasta with a target action date in June 2018  The company expects to launch the biosimilar in the second half assuming approval  The EMA has also accepted applications for both the biosimilars  Mylan and partner Momenta   NASDAQ MNTA   will initiate a patient clinical trial of M710   a proposed biosimilar of ophthalmology drug Eylea   in the first half of 2018 
Zacks Rank
Mylan carries a Zacks Rank  3  Hold   You can see  
The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early x ",2018-05-09,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-q1-earnings-lag-on-weak-north-america-sales-200314726,200314726
197089,418605,MYL,Should You Hold Momenta  MNTA  Stock In Your Portfolio ,opinion,"Cambridge  MA based Momenta Pharmaceuticals  Inc    NASDAQ MNTA   is currently facing challenging business conditions It operates in three areas   Complex Generics  Biosimilars and Novel Therapeutics The company markets Glatopa  a generic version of Teva s   NYSE TEVA   multiple sclerosis  MS  drug Copaxone  20 mg   in collaboration with Novartis    NYSE NVS   Sandoz  Glatopa is the first substitutable generic drug approved for the treatment of relapsing forms of multiple sclerosis  RRMS    Offering major relief to investors  the FDA finally approved Sandoz s Abbreviated New Drug Application for Glatopa 40 mg in February 2018  after initial setbacks However  Mylan   NASDAQ MYL   won the FDA s approval for a generic version of Teva Pharmaceuticals Copaxone 40 mg earlier than Momenta  Notably  this is the first generic of Copaxone that has been approved  Since Mylan was one of the first applicants to submit a substantially complete ANDA for glatiramer acetate Injection  40 mg mL  containing a Paragraph IV certification  the company already has an upper hand in the market which shall make it difficult for Momenta to gain market share   While Sandoz is still in the early phases of the launch  Mylan launched its generic equivalents of once daily Copaxone 20 mg mL and three times weekly Copaxone 40 mg mL in October 2017   As a result  the market and contractual profit share revenue of Glatopa 20 mg mL has been reduced by an accelerated conversion of patients from once daily 20 mg mL glatiramer acetate injection to three times weekly 40 mg mL glatiramer acetate injection due to lower pricing in that market  At the end of 2017  Teva s three times weekly Copaxone 40 mg mL and Mylan N V  s three times weekly generic equivalent product accounted for approximately 82  of the overall U S  glatiramer acetate injection market  20 mg mL and 40 mg mL  based on volume prescribed While the progress with the biosimilars pipeline has been encouraging  Momenta suffered another setback when the company and partner Mylan announced that M834  a proposed biosimilar for Orencia  did not meet its primary pharmacokinetic end points in a phase I study to compare the pharmacokinetics  safety and immunogenicity of M834 to Orencia in normal healthy volunteers The Biologics License Application   BLA   for Momenta s M923  a biosimilar version of Humira  is also ready to be filed with the FDA   However  the filing of the BLA is dependent on the outcome of the company s ongoing strategic review We note that given the recent setbacks  Momenta initiated a strategic review of its ongoing operations with the goal of reducing expenditure on its biosimilar portfolio  which should free up additional capital to fully fund its novel autoimmune portfolio  The company does not have the runway to develop the broad portfolio it created barring the revenue stream from Glatopa  without excessive dilution for its investors  Hence  Momenta is exploring a few options and expects to complete this strategic review by the end of the second quarter of 2018 Momenta Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Nevertheless  the autoimmune portfolio holds promises  Momenta s stock has gained 72 1  in the past six months against the  decline of 8 7  Zacks RankMomenta currently carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of All Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-05-22,Zacks Investment Research,https://www.investing.com/analysis/should-you-hold-momenta-mnta-stock-in-your-portfolio-200318735,200318735
197090,418606,MYL,Mylan  MYL  Up 10 2  Since Earnings Report  Can It Continue ,opinion,"It has been about a month since the last earnings report for Mylan N V    NASDAQ MYL    Shares have added about 10 2  in that time frame 
Will the recent positive trend continue leading up to its next earnings release  or is MYL due for a pullback  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts Mylan Q1 Earnings Lag on Weak North America SalesMylan reported disappointing results for the first quarter as earnings and sales both missed estimates Adjusted earnings of  0 96 per share missed the Zacks Consensus Estimate of  0 99 but was up from  0 93 in the year ago quarter First quarter revenues of  2 68 billion missed the Zacks Consensus Estimate of  2 78 billion and were down 1  from the prior year period Quarter in DetailThe company posts results in three segments on a geographic basis namely North America  Europe and Rest of World North America segment s third party net sales came in at  985 3 million  down 19  due to a decrease in the sales of branded products  including EpiPen Auto Injector  the impact of the loss of exclusivity of olmesartan and olmesartan HCTZ and the prior year divestiture of certain contract manufacturing assets Sales were adversely impacted due to the implementation of new accounting standards along with lower volumes  and to a lesser extent  pricing  on other existing products partially offset by new product introductions Third party net sales from Europe were  1 04 billion  up 16   This was propelled by new product introductions across the region combined with volume expansion which offset the impact of pricing on existing products   Favorable foreign currency translation positively impacted sales by 14  Rest of World segment s third party net sales of  626 7 million was up 8   driven by new products and increased volume from the anti retroviral franchise and higher sales in the emerging markets Adjusted gross margin of 52 9  was down from 53 5  in the year ago quarter During the quarter  Mylan repurchased 9 8 million ordinary shares for  432 0 million completing the previously authorized share repurchase program 2018 Outlook ReiteratedMylan expects revenues of  11 75  13 25 billion in 2018 while the Zacks Consensus Estimate stands at  12 45 billion  Mylan anticipates adjusted EPS of around  5 20  5 60 in 2018 while the Zacks Consensus Estimate is pegged at  5 35 
How Have Estimates Been Moving Since Then 
In the past month  investors have witnessed a downward trend in fresh estimates  There has been one revision higher for the current quarter compared to three lower Mylan N V  Price and Consensus
    VGM Scores
At this time  MYL has a nice Growth Score of B  a grade with the same score on the momentum front  The stock was allocated a grade of A on the value side  putting it in the top quintile for this investment strategy 
Overall  the stock has an aggregate VGM Score of A  If you aren t focused on one strategy  this score is the one you should be interested in 
Based on our scores  the stock is more suitable for value investors than those looking for growth and momentum 
Outlook
Estimates have been broadly trending downward for the stock and the magnitude of these revisions indicates a downward shift  Interestingly  MYL has a Zacks Rank  3  Hold   We expect an in line return from the stock in the next few months ",2018-06-07,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-up-102-since-earnings-report-can-it-continue-200323339,200323339
197091,418607,MYL,Israel stocks higher at close of trade  TA 25 up 0 06 ,news,"Investing com   Israel stocks were higher after the close on Thursday  as gains in the Insurance  Communication and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 25 rose 0 06  
The best performers of the session on the TA 25 were Nice Ltd  TA NICE   which rose 2 10  or 530 points to trade at 25780 at the close  Meanwhile   OPKO Health Inc   TA OPK  added 1 78  or 80 points to end at 4575 and Mylan NV  TA MYL  was up 1 53  or 220 points to 14570 in late trade 
The worst performers of the session were Paz Oil  TA PZOL   which fell 3 93  or 2450 points to trade at 59850 at the close   Azrieli Group   TA AZRG  declined 3 10  or 530 points to end at 16540 and  Gazit Globe   TA GZT  was down 2 87  or 100 points to 3390 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 226 to 115 and 101 ended unchanged 
Shares in OPKO Health Inc  TA OPK  rose to 52 week highs  gaining 1 78  or 80 to 4575  
Crude oil for January delivery was down 1 18  or 0 60 to  50 44 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February fell 0 52  or 0 28 to hit  53 62 a barrel  while the February Gold contract fell 3 01  or 35 05 to trade at  1128 65 a troy ounce 
USD ILS was up 0 61  to 3 8517  while EUR ILS fell 0 52  to 4 0121 
The US Dollar Index was up 1 20  at 103 25 ",2016-12-15,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.06-448075,448075
197092,418608,MYL,Mylan launches EpiPen generic at  300 percent two pack,news," Reuters    Mylan  NASDAQ MYL  NV  which has come under fire for its drug pricing  said on Friday it would start selling a generic version of its life saving EpiPen allergy treatment for  300 per two pack  a more than 50 percent discount 
The company has been under investigation by the U S  government  and its chief executive was called before Congress to testify on raising the price of a pair of EpiPens to more than  600 from  100 in 2008 
Mylan  which first announced it would launch the generic version of its allergy auto injector EpiPen for  300 in August  said the authorized generic would be available in pharmacies starting next week 
Mylan s move comes a day after 20 U S  states filed a lawsuit over pricing against generic drugmakers  including Mylan  Teva Pharmaceuticals and four other generic drugmakers 
The U S  Department of Justice on Wednesday filed criminal charges against two generic drug industry executives  alleging that they colluded to fix prices and split up market share 
The cases are part of a broader generic drug pricing probe that is under way at the state and federal level  as well as in the U S  Congress  In 2014  media reports of sharply rising drug prices led to Congressional hearings 
Mylan has been criticized for classifying EpiPen as a generic product  which led to its paying significantly smaller rebates to state Medicaid programs for the poor than if the drug were classified as branded 
The company said in October that it would pay  465 million to settle questions on the impact of the classification on U S  government healthcare costs 
Mylan said earlier this month it expected to cut less than 10 percent of its workforce to integrate its acquisitions 

Mylan s shares were up about 1 percent in early trading on Friday ",2016-12-16,Reuters,https://www.investing.com/news/stock-market-news/mylan-launches-epipen-generic-at-$300-percent-two-pack-448321,448321
197093,418609,MYL,U S  lawmakers press Heritage Pharma on high prices for antibiotic,news,"By Sarah N  Lynch
WASHINGTON  Reuters    Two U S  lawmakers are questioning whether Heritage Pharmaceuticals misled them in response to a 2014 congressional inquiry about the rising price a common antibiotic  after 20 U S  states this week accused the company of price fixing 
In a Dec  16 letter to Heritage seen by Reuters  Maryland Democratic Representative Elijah Cummings and Vermont Independent Senator Bernie Sanders said they feared the company was  disingenuous at best  in October 2014 when it told them it had not seen any significant price increases for its doxycycline hyclate product 
 We are very concerned that you made these assertions to Congress on behalf of Heritage during the exact time period that its executives were engaged in a price fixing scheme to prevent competition from driving down prices of doxycycline hyclate   they wrote 
In response to Friday s letter  the company said it does not make the same version of doxycycline hyclate that the lawmakers asked about in 2014  Heritage makes a delayed release version  not the immediate release version that was the subject of the 2014 inquiry 
Heritage said it explained this to the lawmakers in its 2014 response 
The letter to Heritage comes after criminal and civil charges were filed by the Justice Department and 20 states in connection with an alleged price fixing scheme involving doxycycline hyclate and glyburide  a diabetes drug 
On Wednesday  the Justice Department criminally charged Heritage s former Chief Executive Officer Jeffrey Glazer and former Heritage Vice President of Commercial Operations Jason Malek  accusing them of colluding with other generic manufacturers in schemes that entailed allocating market share and conspiring to raise prices 
The next day  20 states filed a parallel civil lawsuit against Heritage  along with Mylan  NASDAQ MYL  NV  Teva Pharmaceuticals  Mayne Pharma Group  Citron Pharma and Aurobindo Pharma Ltd   saying they colluded to fix prices 
The lawsuit characterized Heritage as the  ringleader   with Glazer and Malek overseeing and running the scheme 
Mylan and Teva have previously denied the states  civil charges 
Sanders and Cummings launched a congressional inquiry into rising generic drug prices on Oct  2  2014  including the price of doxycycline hyclate 
As part of that  they sent a letter to Glazer while he was still CEO of Heritage to inquire about the prices 
Gary Ruckelshaus  who was then Heritage s outside counsel and now serves as vice president and general counsel  responded later that month and said Heritage  has not seen any significant price increases  for the drug ",2016-12-16,Reuters,https://www.investing.com/news/politics-news/u.s.-lawmakers-press-heritage-pharma-on-high-prices-for-antibiotic-448439,448439
197094,418610,MYL,Israel stocks higher at close of trade  TA 25 up 0 30 ,news,"Investing com   Israel stocks were higher after the close on Tuesday  as gains in the Banking  Biomed and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 25 added 0 30  to hit a new 3 months high 
The best performers of the session on the TA 25 were Poalim  TA POLI   which rose 3 33  or 74 points to trade at 2299 at the close  Meanwhile  Leumi  TA LUMI  added 2 99  or 47 points to end at 1620 and  Ormat Technologies   TA ORA  was up 2 16  or 430 points to 20330 in late trade 
The worst performers of the session were  Elbit Systems   TA ESLT   which fell 1 69  or 660 points to trade at 38500 at the close  Mylan NV  TA MYL  declined 1 50  or 220 points to end at 14460 and  Gazit Globe   TA GZT  was down 1 26  or 42 points to 3280 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 193 to 158 and 91 ended unchanged 
Shares in Leumi  TA LUMI  rose to 52 week highs  gaining 2 99  or 47 to 1620  Shares in Ormat Technologies  TA ORA  rose to all time highs  rising 2 16  or 430 to 20330  
Crude oil for February delivery was up 0 92  or 0 49 to  53 55 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February rose 1 42  or 0 78 to hit  55 70 a barrel  while the February Gold contract fell 1 17  or 13 35 to trade at  1129 35 a troy ounce 
USD ILS was down 0 37  to 3 8493  while EUR ILS fell 0 65  to 3 9948 
The US Dollar Index was up 0 34  at 103 42 ",2016-12-20,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.30-448934,448934
197095,418611,MYL,Israel stocks lower at close of trade  TA 25 down 0 36 ,news,"Investing com   Israel stocks were lower after the close on Wednesday  as losses in the Biomed  Insurance and Technology sectors led shares lower 
At the close in Tel Aviv  the TA 25 lost 0 36  
The best performers of the session on the TA 25 were  OPKO Health Inc   TA OPK   which rose 1 33  or 60 points to trade at 4560 at the close  Meanwhile  Discount  TA DSCT  added 1 22  or 9 6 points to end at 793 6 and  Strauss Group   TA STRS  was up 0 93  or 55 points to 5940 in late trade 
The worst performers of the session were  Israel Corp   TA ILCO   which fell 2 51  or 1540 points to trade at 59900 at the close   ICL  Israel Chemicals Ltd  TA ICL  declined 1 52  or 23 points to end at 1493 and Mylan NV  TA MYL  was down 1 45  or 210 points to 14250 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 199 to 151 and 93 ended unchanged 
Crude oil for February delivery was down 0 36  or 0 19 to  53 11 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February fell 0 52  or 0 29 to hit  55 06 a barrel  while the February Gold contract fell 0 10  or 1 10 to trade at  1132 50 a troy ounce 
USD ILS was down 0 38  to 3 8293  while EUR ILS fell 0 03  to 3 9943 
The US Dollar Index was down 0 30  at 102 95 ",2016-12-21,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-25-down-0.36-449208,449208
197096,418612,MYL,Israel stocks higher at close of trade  TA 25 up 0 94 ,news,"Investing com   Israel stocks were higher after the close on Tuesday  as gains in the Biomed  Technology and Communication sectors led shares higher 
At the close in Tel Aviv  the TA 25 rose 0 94  to hit a new 6 months high 
The best performers of the session on the TA 25 were Perrigo  TA PRGO   which rose 2 96  or 950 points to trade at 33080 at the close  Meanwhile  Mylan NV  TA MYL  added 1 88  or 270 points to end at 14640 and First  International  Bank of Israel  TA FTIN  was up 1 62  or 90 points to 5658 in late trade 
The worst performers of the session were Paz Oil  TA PZOL   which fell 0 41  or 230 points to trade at 56250 at the close   Frutarom   TA FRUT  declined 0 35  or 70 points to end at 20090 and  Strauss Group   TA STRS  was down 0 25  or 15 points to 5992 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 235 to 127 and 82 ended unchanged 
Shares in First International Bank of Israel  TA FTIN  rose to 52 week highs  rising 1 62  or 90 to 5658  
Crude oil for February delivery was up 1 26  or 0 67 to  53 69 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March rose 1 13  or 0 63 to hit  56 53 a barrel  while the February Gold contract rose 0 37  or 4 15 to trade at  1137 75 a troy ounce 
USD ILS was up 0 70  to 3 8481  while EUR ILS rose 0 72  to 4 0246 
The US Dollar Index was up 0 09  at 103 04 ",2016-12-27,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.94-450033,450033
197097,418613,MYL,Israel stocks higher at close of trade  TA 25 up 0 23 ,news,"Investing com   Israel stocks were higher after the close on Wednesday  as gains in the Communication  Insurance and Real Estate sectors led shares higher 
At the close in Tel Aviv  the TA 25 gained 0 23  to hit a new 6 months high 
The best performers of the session on the TA 25 were  Israel Corp   TA ILCO   which rose 3 89  or 2390 points to trade at 63820 at the close  Meanwhile   ICL  Israel Chemicals Ltd  TA ICL  added 3 54  or 54 points to end at 1580 and Bezeq  TA BEZQ  was up 2 65  or 19 0 points to 735 0 in late trade 
The worst performers of the session were  OPKO Health Inc   TA OPK   which fell 2 14  or 98 points to trade at 4484 at the close  Perrigo  TA PRGO  declined 1 96  or 650 points to end at 32430 and Mylan NV  TA MYL  was down 1 64  or 240 points to 14400 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 227 to 130 and 87 ended unchanged 
Crude oil for February delivery was up 0 37  or 0 20 to  54 10 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March rose 0 35  or 0 20 to hit  57 03 a barrel  while the February Gold contract rose 0 00  or 0 05 to trade at  1138 85 a troy ounce 
USD ILS was up 0 49  to 3 8564  while EUR ILS fell 0 13  to 4 0084 
The US Dollar Index was up 0 41  at 103 42 ",2016-12-28,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.23-450174,450174
197098,418614,MYL,Israel stocks lower at close of trade  TA 25 down 0 55 ,news,"Investing com   Israel stocks were lower after the close on Thursday  as losses in the Biomed  Technology and Banking sectors led shares lower 
At the close in Tel Aviv  the TA 25 declined 0 55  
The best performers of the session on the TA 25 were  Azrieli Group   TA AZRG   which rose 1 15  or 190 points to trade at 16710 at the close  Meanwhile  Mylan NV  TA MYL  added 1 11  or 160 points to end at 14560 and  Strauss Group   TA STRS  was up 0 91  or 55 points to 6094 in late trade 
The worst performers of the session were  OPKO Health Inc   TA OPK   which fell 1 65  or 74 points to trade at 4410 at the close  Perrigo  TA PRGO  declined 1 54  or 500 points to end at 31930 and Teva  TA TEVA  was down 1 50  or 210 points to 13830 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 222 to 149 and 74 ended unchanged 
Crude oil for February delivery was up 0 24  or 0 13 to  54 19 a barrel  Elsewhere in commodities trading  Brent oil for delivery in March rose 0 56  or 0 32 to hit  57 28 a barrel  while the February Gold contract rose 0 83  or 9 45 to trade at  1150 35 a troy ounce 
USD ILS was down 0 26  to 3 8446  while EUR ILS rose 0 47  to 4 0324 
The US Dollar Index was down 0 52  at 102 70 ",2016-12-29,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-25-down-0.55-450350,450350
197102,418618,MYL,Mylan Inks Deal With Mapi Pharma For Multiple Sclerosis Drug ,opinion,"Mylan N V    NASDAQ MYL   announced that it has inked an agreement with Israel based Mapi Pharma Ltd 
Both companies have teamed up for the development and commercialization of GA Depot  a long acting Glatiramer Acetate product  Mylan also acquired the global marketing rights of the product 
We note that GA Depot is a proposed once monthly injection for the treatment of patients with relapsing remitting multiple sclerosis   MS    or RRMS  Mapi Pharma has completed an open label phase II trial  The company is also preparing to commence phase III trials to support marketing applications  Both companies are preparing to submit an investigational new drug application to the FDA  as well as other global health authorities 
We remind investors that Mylan already has experience in the Glatiramer Acetate market 
In October 2017  Mylan launched the generic version of Teva s   NYSE TEVA   Copaxone 40 mg mL which is indicated for the treatment of patients with relapsing forms of MS  Mylan s partner in Europe  Synthon  also received marketing authorization approval in Europe for Glatiramer Acetate Injection 40 mg mL 
An estimated 2 3 million people on a worldwide basis are living with MS  Nearly 1 million people are living with MS in the United States  RRMS accounts for approximately 85  of initial MS diagnoses   
The deal with Mapi Pharma will further strengthen the company s presence in the MS market 

 
Mylan s stock has gained 9 9  in the last six months  as against the  decline of 10 1  
Mylan has one of the largest product portfolios among all generic pharmaceutical companies   With the acquisition of the Topicals Business  Mylan gained a complementary portfolio of approximately 25 branded and generic topical products  including an active pipeline of approximately 25 products as well as established United States sales and marketing infrastructure targeting dermatologists  The Topicals Business added to Mylan an integrated manufacturing and development platform along with a leading topicals focused contract development and manufacturing organization 
Mylan is also exploring the world of biosimilars  The company formed a partnership with Biocon and also has a collaboration agreement with Momenta Pharmaceuticals   NASDAQ MNTA    The company also received an FDA approval for a biosimilar version of Roche Holdings    OTC RHHBY   Herceptin 
Zacks Rank
Mylan carries a Zacks Rank  3  Hold   You can see   
5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-04-11,Zacks Investment Research,https://www.investing.com/analysis/mylan-inks-deal-with-mapi-pharma-for-multiple-sclerosis-drug-200304844,200304844
197103,418619,MYL,Mylan Stock To Leave Three Painful Years Behind ,opinion,"Three years ago  in mid April 2015  Mylan  NASDAQ MYL  stock was trading in the vicinity of  77 a share following a phenomenal rally from as low as  5 75 in late October 2008  Currently above  40  Mylan is trying to recover from its 61 7  selloff which dragged the share price to  29 39 by August  2017  Will the bulls be able to recover or simply fall into another bearish ambush  Let s see if we can find the answer to this question with the help of the   Our analysis begins with the weekly price chart of Mylan stock below 
This chart shows that the bull market from  5 75 to  76 69 has developed as a five wave  pattern  labeled I II III IV V  The market took the guideline of alternation into account  since wave II looks like an   while wave IV is much sharper  According to the theory  every impulse is followed by a three wave correction in the other direction  Naturally  Mylan s decline to  29 39 looks like a simple A B C zigzag retracement  whose wave C is an expanding   The 61 8   has been breached slightly  but it still managed to help the bulls out and lead Mylan stock to  47 82 in January  2018  Now let s move on to the 4 hour chart of MYL and see if we can trust this recent strength 
The rebound from  29 39 to  47 82 has a five wave structure  as well  Wave 3 is not the longest among waves 1  3 and 5  since wave 5 is extended  but it is still longer than wave 1  so there is no violation of the Wave Principle s rules  If this count is correct  Mylan stock is in another a b c zigzag in wave II  whose wave  c  is still under construction  However  despite all the pain Mylan shareholders had to suffer during the last three months  and the last three years if we consider the bigger picture  the stock s weekly and hourly charts both point up  This means that as long as the bottom at  29 39 holds  this drug manufacturer s future remains bright  at least according to the charts ",2018-04-25,EWM Interactive,https://www.investing.com/analysis/mylan-stock-to-leave-three-painful-years-behind-200308794,200308794
197104,418620,MYL,Israel stocks lower at close of trade  TA 25 down 0 53 ,news,"Investing com   Israel stocks were lower after the close on Thursday  as losses in the Communication  Biomed and Technology sectors led shares lower 
At the close in Tel Aviv  the TA 25 fell 0 53  
The best performers of the session on the TA 25 were  Israel Corp   TA ILCO   which rose 3 16  or 1870 points to trade at 61000 at the close  Meanwhile   ICL  Israel Chemicals Ltd  TA ICL  added 2 65  or 39 points to end at 1509 and Mylan NV  TA MYL  was up 1 81  or 250 points to 14060 in late trade 
The worst performers of the session were Bezeq  TA BEZQ   which fell 2 97  or 21 0 points to trade at 687 0 at the close   Gazit Globe   TA GZT  declined 2 16  or 75 points to end at 3401 and  Ormat Technologies   TA ORA  was down 2 05  or 380 points to 18150 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 191 to 156 and 96 ended unchanged 
Crude oil for January delivery was up 3 78  or 1 87 to  51 31 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February rose 4 03  or 2 09 to hit  53 93 a barrel  while the February Gold contract fell 0 33  or 3 90 to trade at  1170 00 a troy ounce 
USD ILS was up 0 02  to 3 8327  while EUR ILS rose 0 15  to 4 0673 
The US Dollar Index was down 0 31  at 101 31 ",2016-12-01,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-25-down-0.53-444946,444946
197105,418621,MYL,Israel stocks lower at close of trade  TA 25 down 0 37 ,news,"Investing com   Israel stocks were lower after the close on Sunday  as losses in the Biomed  Insurance and Technology sectors led shares lower 
At the close in Tel Aviv  the TA 25 declined 0 37  
The best performers of the session on the TA 25 were  Frutarom   TA FRUT   which rose 2 55  or 520 points to trade at 20920 at the close  Meanwhile   Elbit Systems   TA ESLT  added 1 79  or 680 points to end at 38680 and  Delek Group   TA DLEKG  was up 1 35  or 1110 points to 83110 in late trade 
The worst performers of the session were Teva  TA TEVA   which fell 2 71  or 390 points to trade at 14010 at the close  Mylan NV  TA MYL  declined 2 20  or 310 points to end at 13750 and  Israel Corp   TA ILCO  was down 1 15  or 700 points to 60300 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 182 to 160 and 101 ended unchanged 
Shares in Teva  TA TEVA  fell to 52 week lows  down 2 71  or 390 to 14010  
Crude oil for January delivery was up 1 23  or 0 63 to  51 69 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February rose 0 91  or 0 49 to hit  54 43 a barrel  while the February Gold contract rose 0 82  or 9 60 to trade at  1179 00 a troy ounce 
USD ILS was down 0 32  to 3 8167  while EUR ILS fell 0 25  to 4 0716 
The US Dollar Index was down 0 27  at 100 75 ",2016-12-04,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-25-down-0.37-445476,445476
197106,418622,MYL,Israel stocks lower at close of trade  TA 25 down 0 30 ,news,"Investing com   Israel stocks were lower after the close on Tuesday  as losses in the Communication  Biomed and Real Estate sectors led shares lower 
At the close in Tel Aviv  the TA 25 fell 0 30  
The best performers of the session on the TA 25 were  ICL  Israel Chemicals Ltd  TA ICL   which rose 2 41  or 37 points to trade at 1572 at the close  Meanwhile  Discount  TA DSCT  added 2 03  or 16 0 points to end at 806 0 and  OPKO Health Inc   TA OPK  was up 1 63  or 67 points to 4182 in late trade 
The worst performers of the session were Teva  TA TEVA   which fell 4 91  or 690 points to trade at 13360 at the close  Mylan NV  TA MYL  declined 4 40  or 610 points to end at 13260 and Perrigo  TA PRGO  was down 3 35  or 1100 points to 31780 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 208 to 149 and 86 ended unchanged 
Shares in Teva  TA TEVA  fell to 3 years lows  losing 4 91  or 690 to 13360  Shares in Discount  TA DSCT  rose to 5 year highs  rising 2 03  or 16 0 to 806 0  Shares in Mylan NV  TA MYL  fell to all time lows  down 4 40  or 610 to 13260  
Crude oil for January delivery was down 1 78  or 0 92 to  50 87 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February fell 1 55  or 0 85 to hit  54 09 a barrel  while the February Gold contract fell 0 26  or 3 05 to trade at  1173 45 a troy ounce 
USD ILS was down 0 12  to 3 8064  while EUR ILS fell 0 40  to 4 0862 
The US Dollar Index was up 0 23  at 100 39 ",2016-12-06,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-25-down-0.30-445957,445957
197107,418623,MYL,Israel stocks lower at close of trade  TA 25 down 0 33 ,news,"Investing com   Israel stocks were lower after the close on Wednesday  as losses in the Banking  Financials and Insurance sectors led shares lower 
At the close in Tel Aviv  the TA 25 lost 0 33  
The best performers of the session on the TA 25 were  Ormat Technologies   TA ORA   which rose 1 43  or 260 points to trade at 18480 at the close  Meanwhile   Gazit Globe   TA GZT  added 1 35  or 46 points to end at 3456 and  OPKO Health Inc   TA OPK  was up 1 27  or 53 points to 4235 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 2 94  or 390 points to trade at 12870 at the close  Teva  TA TEVA  declined 1 50  or 200 points to end at 13160 and Poalim  TA POLI  was down 1 16  or 27 points to 2306 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 184 to 170 and 88 ended unchanged 
Shares in Mylan NV  TA MYL  fell to all time lows  losing 2 94  or 390 to 12870  Shares in Teva  TA TEVA  fell to 3 years lows  losing 1 50  or 200 to 13160  
Crude oil for January delivery was down 1 55  or 0 79 to  50 14 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February fell 1 09  or 0 59 to hit  53 34 a barrel  while the February Gold contract rose 0 87  or 10 15 to trade at  1180 25 a troy ounce 
USD ILS was down 0 51  to 3 7964  while EUR ILS fell 0 19  to 4 0865 
The US Dollar Index was down 0 32  at 100 19 ",2016-12-07,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-25-down-0.33-446267,446267
197108,418624,MYL,Israel stocks higher at close of trade  TA 25 up 0 34 ,news,"Investing com   Israel stocks were higher after the close on Thursday  as gains in the Oil   Gas  Communication and Technology sectors led shares higher 
At the close in Tel Aviv  the TA 25 added 0 34  
The best performers of the session on the TA 25 were  Israel Corp   TA ILCO   which rose 3 00  or 1880 points to trade at 64500 at the close  Meanwhile  Teva  TA TEVA  added 2 51  or 330 points to end at 13490 and Mylan NV  TA MYL  was up 2 33  or 300 points to 13170 in late trade 
The worst performers of the session were  OPKO Health Inc   TA OPK   which fell 3 33  or 141 points to trade at 4094 at the close  Perrigo  TA PRGO  declined 1 17  or 370 points to end at 31290 and Paz Oil  TA PZOL  was down 0 69  or 430 points to 62140 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 222 to 140 and 80 ended unchanged 
Crude oil for January delivery was up 1 65  or 0 82 to  50 59 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February rose 1 47  or 0 78 to hit  53 78 a barrel  while the February Gold contract fell 0 42  or 5 00 to trade at  1172 50 a troy ounce 
USD ILS was up 0 25  to 3 8169  while EUR ILS fell 1 01  to 4 0501 
The US Dollar Index was up 0 91  at 101 19 ",2016-12-08,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.34-446555,446555
197109,418625,MYL,Israel stocks higher at close of trade  TA 25 up 1 08 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Technology  Biomed and Oil   Gas sectors led shares higher 
At the close in Tel Aviv  the TA 25 added 1 08  to hit a new 1 month high 
The best performers of the session on the TA 25 were Mylan NV  TA MYL   which rose 6 76  or 890 points to trade at 14060 at the close  Meanwhile  Teva  TA TEVA  added 3 78  or 510 points to end at 14000 and  Ormat Technologies   TA ORA  was up 3 01  or 560 points to 19160 in late trade 
The worst performers of the session were  Azrieli Group   TA AZRG   which fell 0 82  or 140 points to trade at 16960 at the close   Isramco  L  TA ISRAp  declined 0 45  or 0 3 points to end at 65 9 and Discount  TA DSCT  was down 0 40  or 3 2 points to 794 6 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 227 to 130 and 85 ended unchanged 
Shares in Ormat Technologies  TA ORA  rose to all time highs  up 3 01  or 560 to 19160  
Crude oil for January delivery was up 1 28  or 0 65 to  51 49 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February rose 0 87  or 0 47 to hit  54 36 a barrel  while the February Gold contract fell 0 94  or 11 00 to trade at  1161 40 a troy ounce 
USD ILS was up 0 49  to 3 8312  while EUR ILS fell 0 10  to 4 0430 
The US Dollar Index was up 0 48  at 101 60 ",2016-12-11,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-1.08-447040,447040
197110,418626,MYL,Israel stocks higher at close of trade  TA 25 up 0 55 ,news,"Investing com   Israel stocks were higher after the close on Tuesday  as gains in the Insurance  Technology and Real Estate sectors led shares higher 
At the close in Tel Aviv  the TA 25 gained 0 55  to hit a new 3 months high 
The best performers of the session on the TA 25 were Mylan NV  TA MYL   which rose 4 16  or 580 points to trade at 14530 at the close  Meanwhile   OPKO Health Inc   TA OPK  added 2 70  or 117 points to end at 4452 and Teva  TA TEVA  was up 2 58  or 360 points to 14290 in late trade 
The worst performers of the session were  Israel Corp   TA ILCO   which fell 2 57  or 1680 points to trade at 63600 at the close  First  International  Bank of Israel  TA FTIN  declined 1 58  or 86 points to end at 5368 and Discount  TA DSCT  was down 1 52  or 11 9 points to 770 1 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 183 to 163 and 96 ended unchanged 
Crude oil for January delivery was down 0 34  or 0 18 to  52 65 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February fell 0 36  or 0 20 to hit  55 49 a barrel  while the February Gold contract fell 0 63  or 7 35 to trade at  1158 45 a troy ounce 
USD ILS was down 0 69  to 3 8005  while EUR ILS fell 0 67  to 4 0435 
The US Dollar Index was down 0 02  at 100 98 ",2016-12-13,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.55-447463,447463
197115,418631,MYL,Mylan  MYL  Q4 Earnings Surpass Estimates  Revenues Miss,opinion,"Mylan N V    NASDAQ MYL   reported mixed results for fourth quarter 2017 as EpiPen sales declined  Adjusted earnings of  1 43 per share beat the Zacks Consensus Estimate of  1 41 but was down from  1 57 reported in the year ago quarter Mylan N V  Price and Consensus
     
Fourth quarter revenues of  3 24 billion missed the Zacks Consensus Estimate of  3 27 billion and were down 1  from the prior year period  Mylan s stock has lost 10 9  over a year  better than the  decline of 36 1  Quarter in DetailThe company posts results in three segments on a geographic basis namely North America  Europe and Rest of World North America segment s third party net sales came in at  1 30 billion  down 17  on a sales decline of existing products as a result of lower volume and pricing  partially offset by contribution from new products  The generics business in North America experienced higher price erosion than the previous quarters including the impact of the loss of market exclusivity of olmesartan and olmesartan HCTZ  Sales of the EpiPen Auto Injector plunged significantly  a decrease of  131 9 million  due to effect of the launch of authorized generic and higher governmental rebates Third party net sales from Europe were  1 07 billion  up 16   This was propelled by new product introductions across the region combined with volume expansion and pricing on existing products   Favorable foreign currency translation had an impact of 9  within the continent Rest of World segment s third party net sales of  815 7 million was up 12   driven by new products and increased net sales from the anti retroviral franchise and higher sales in the emerging markets plus a favourable foreign currency translation had an impact of 3  Adjusted gross margin contracted to 55 5  from 56 6  in the year ago quarter due to lower gross profit from the sales of existing products in North America including the EpiPen Auto Injector  partially offset by the contributions from new products During 2017  Mylan repurchased approximately 12 4 million shares for approximately  500 2 million under its previously approved share repurchase program  In January 2018  Mylan bought back additional ordinary shares worth 9 8 million for approximately  432 0 million and completed that share buyback program 2017 ResultsRevenues for 2017 came in at  11 91 billion  up 8  from 2016  However  the top line missed the Zacks Consensus Estimate of  11 95 billion  While adjusted EPS of  4 56 was down 7  from 2016 but surpassed the consensus mark of  4 54  2018 OutlookMylan expects revenues of  11 75  13 25 billion in 2018  The Zacks Consensus Estimate of  12 64 billion is well within the guidance provided by the company Mylan anticipates adjusted EPS of around  5 20  5 60 in 2018 while the Zacks Consensus Estimate is pegged at  5 34 Our TakeMylan s fourth quarter results were mixed with the bottom line exceeding expectations but sales lagging the same due to weak EpiPen sales  The generic business in the United States continues to experience pricing pressure We note that Mylan has already won an FDA approval for a generic version of Teva Pharmaceuticals    NYSE TEVA   Copaxone 40 mg  Notably  this is the first generic of Copaxone that has been approved  Since Mylan was one of the first applicants to submit a substantially complete ANDA  abbreviated new drug application  for glatiramer acetate Injection  40 mg mL containing a Paragraph IV certification  the company and other first filers may be eligible for 180 days of generic drug exclusivity  The company also received an FDA approval for a biosimilar version of Roche Holdings    OTC RHHBY   Herceptin Although volatility in the US markets is expected to continue in 2018  yet these regulatory body approvals should position Mylan better in the year ahead and help it combat the decline in EpiPen sales  Meanwhile  the company received a complete response letter from the FDA regarding its ANDA for the generic version of GlaxoSmithKline plc s   NYSE GSK   asthma drug Advair Diskus and is working to address the issues Zacks RankMylan carries a Zacks Rank  3  Hold   You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-02-28,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-q4-earnings-surpass-estimates-revenues-miss-200295336,200295336
197116,418632,MYL,Can New Approvals Help Mylan Stock Turn Around In 2018  ,opinion,"Shares of Mylan N V    NASDAQ MYL   have gained 7 6  in the last three months  as against the  decline of 3 7  

 
Mylan s fourth quarter results were mixed with the bottom line exceeding expectations but the top line lagging the same due to weak EpiPen sales  The generic business in the United States continues to experience pricing pressure 
The year 2017 was challenging for Mylan given the ongoing pricing pressure in the United States and uncertain regulatory environment  Moreover  the company s efforts to get Advair s generic approved faced a jolt when the FDA issued a complete response letter to its abbreviated new drug application  ANDA  for generic Advair Diskus 
However  things are looking up for Mylan in 2018  We note that Mylan got a major boost with the FDA s approval of a generic version of Teva Pharmaceuticals    NYSE TEVA   Copaxone 40 mg  Notably  this is the first generic of Copaxone that has been approved  Since Mylan was one of the first applicants to submit a substantially complete ANDA for glatiramer acetate Injection  40 mg mL containing a Paragraph IV certification  the company and other first filers may be eligible for 180 days of generic drug exclusivity  The company also received an FDA approval for a biosimilar version of Roche Holdings    OTC RHHBY   Herceptin 
Although volatility in the US markets is expected to persist in 2018  yet these  approvals should position Mylan better in the year ahead and help it combat the decline in EpiPen sales  The company has more than 30 submissions planned in 2018  The launch of generic version of Estrace cream is also in the offing 
Meanwhile  key anticipated approvals include a biosimilar version of Neulasta with a target action date in June 2018  The company expects to launch the biosimilar in the second half assuming approval  The EMA has also accepted applications for both the biosimilars 
Meanwhile  Mylan and partner Momenta   NASDAQ MNTA   announced that the companies will initiate a patient clinical trial of M710   a proposed biosimilar of Eylea   in the first half of 2018  The trial will be a randomized  double blind  active control  multi center study in patients with diabetic macular edema to compare the safety  efficacy and immunogenicity of M710 with the reference drug 
We note that Eylea  a vascular endothelial growth factor  VEGF  inhibitor  has been approved for the treatment of neovascular  wet  age related macular degeneration  macular edema  following retinal vein occlusion  diabetic macular edema and diabetic retinopathy in patients with diabetic macular edema 
The company is also looking forward for a tentative approval of generic Restatis with a target action date in July 2018 
Zacks Rank
Mylan carries a Zacks Rank  3  Hold   You can see   
The Hottest Tech Mega Trend of All
Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ",2018-03-09,Zacks Investment Research,https://www.investing.com/analysis/can-new-approvals-help-mylan-stock-turn-around-in-2018-200296756,200296756
197117,418633,MYL,Should Value Investors Pick Mylan  MYL  Stock ,opinion,Value investing is easily one of the most popular ways to find great stocks in any market environment  After all  who wouldn t want to find stocks that are either flying under the radar and are compelling buys  or offer up tantalizing discounts when compared to fair value One way to find these companies is by looking at several key metrics and financial ratios  many of which are crucial in the value stock selection process  Let s put Mylan N V    NASDAQ MYL   stock into this equation and find out if it is a good choice for value oriented investors right now  or if investors subscribing to this methodology should look elsewhere for top picks PE RatioA key metric that value investors always look at is the Price to Earnings Ratio  or PE for short  This shows us how much investors are willing to pay for each dollar of earnings in a given stock  and is easily one of the most popular financial ratios in the world  The best use of the PE ratio is to compare the stock s current PE ratio with  a  where this ratio has been in the past  b  how it compares to the average for the industry sector  and c  how it compares to the market as a whole On this front  Mylan has a trailing twelve months PE ratio of 9 1  as you can see in the chart below This level actually compares pretty favorably with the market at large  as the PE for the S P 500 stands at about 21 3  If we focus on the long term PE trend  Mylan s current PE level puts it below its midpoint over the past five years  with the number having risen rapidly over the past few months Further  the stock s PE is also slightly undervalued than the  s trailing twelve months PE ratio We should also point out that Mylan has a forward PE ratio  price relative to this year s earnings  of just 7 8  so it is fair to say that a slightly more value oriented path may be ahead for Mylan stock in the near term too P S RatioAnother key metric to note is the Price Sales ratio  This approach compares a given stock s price to its total sales  where a lower reading is generally considered better  Some people like this metric more than other value focused ones because it looks at sales  something that is far harder to manipulate with accounting tricks than earnings Right now  Mylan has a P S ratio of about 1 9  This is a bit lower than the S P 500 average  which comes in at 3 4x right now  Also  as we can see in the chart below  this is well below the highs for this stock in particular over the past few years If anything  MYL is in the lower end of its range in the time period from a P S metric  suggesting some level of undervalued trading at least compared to historical norms Broad Value OutlookIn aggregate  Mylan currently has a Value Score of A  putting it into the top 20  of all stocks we cover from this look  This makes Mylan a solid choice for value investors  and some of its other key metrics make this pretty clear too For example  its P CF ratio  another great indicator of value  comes in at 5 3  which is far better than the industry average of 10 6  Clearly  MYL is a solid choice on the value front from multiple angles What About the Stock Overall Though Mylan might be a good choice for value investors  there are plenty of other factors to consider before investing in this name  In particular  it is worth noting that the company has a Growth Score of D and a Momentum Score of D  This gives MYL a Zacks VGM score   or its overarching fundamental grade   of B   You can read more about the Zacks Style Scores  Meanwhile  the company s recent earnings estimates have been mixed at best  The current quarter has seen no estimates go higher in the past sixty days compared to three lower  while the full year estimate has seen five up and three down in the same time period This has had a significant impact on the consensus estimate though as the current quarter consensus estimate has fallen by 8 8  in the past two months  while the full year estimate has inched up by 1 3   You can see the consensus estimate trend and recent price action for the stock in the chart below Mylan N V  Price and Consensus   This somewhat mixed trend is why the stock has just a Zacks Rank  3  Hold  and why we are looking for in line performance from the company in the near term Bottom LineMylan is an inspired choice for value investors  as it is hard to beat its incredible lineup of statistics on this front  However  with a sluggish industry rank  Bottom 27  out of more than 250 industries  and a Zacks Rank  3  it is hard to get too excited about this company overall  In fact  over the past two years  the industry has clearly underperformed the broader market  as you can see below So  value investors might want to wait for estimates  analyst sentiment and broader factors to turn around in this name first  but once that happens  this stock could be a compelling pick The Hottest Tech Mega Trend of All Last year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2018-03-15,Zacks Investment Research,https://www.investing.com/analysis/should-value-investors-pick-mylan-myl-stock-200298680,200298680
197118,418634,MYL,U S  consumers will want Trump  Congress to take on drug prices,news,By Deena Beasley and Toni Clarke LOS ANGELES WASHINGTON  Reuters    Americans  growing alarm over rising prescription drug costs will pressure a new U S  administration and Congress to take action on pharmaceutical pricing  industry executives and healthcare experts say  Drugmaker stocks  battered in recent months  soared this week after Republican presidential candidate Donald Trump s victory  Democratic rival Hillary Clinton had vowed to take on pharmaceutical  price gouging   and some pundits predicted the Democrats would gain control of the Senate  giving her a stronger hand  The Republican sweep of Congress eliminated those fears  while boosting chances for other measures  such as corporate tax reforms that would benefit industry  However  the vote did not change a key dynamic  U S  consumers are paying more of the cost of drugs through higher health insurance deductibles and copayments  making them more sensitive to manufacturer price hikes  Most recently  a sixfold increase in the price of Mylan  NASDAQ MYL  NV s EpiPen stoked outrage for families who rely on the lifesaving allergy shot and prompted investigations by state attorneys general and Congress  If a manufacturer sharply raises the price of a drug   it will be in the headlines  I don t think it matters which party is in office   said Sandra Hunt  principal at PricewaterhouseCooper s health industry practice  Republican lawmakers have taken up drug pricing alongside Democrats  Republicans Senator Charles Grassley of Iowa  chair of the Senate Judiciary Committee  and Representative Jason Chaffetz  chair of the House Committee on Oversight and Government Reform  led inquiries into Mylan s EpiPen pricing   A very strong majority of Republican voters want the Congress to address drug prices   said John Rother  president and CEO of the National Coalition on Health Care  which campaigns for lower prices  An October Kaiser Family Foundation survey showed that 74 percent of respondents said making drugs for chronic conditions affordable should be a top health care priority for the federal government  Among Republican respondents  68 percent put drug prices as a top priority  A poll conducted by the Harvard T H  Chan School of Public Health found that 64 percent of voters   including 78 percent of likely Clinton voters and 48 percent of Trump supporters   believe the federal government should be able to limit pharmaceutical drug price hikes  BIGGER PRIORITY THAN OBAMACARE Trump and Republican leaders have vowed to repeal President Barack Obama s healthcare reform law  known as Obamacare  which has extended medical insurance to more than 20 million Americans  Despite complaints about Obamacare insurance premium increases  just 37 percent of Kaiser poll respondents said that overturning it was a high priority  Chaffetz is  evaluating his next steps  on the drug pricing issue when the next Congress convenes  an aide said  A representative for Grassley said he would press forward with a scheduled Nov  30 hearing into Mylan s EpiPen pricing   The U S  has always been a country that supports innovation     and we hope it will remain the same   said Pascal Soriot  chief executive of AstraZeneca Plc  which sells drugs like cholesterol fighter Crestor   But we also believe we will continue to have to deal with price ressures    Clinton s proposals to curb drug prices included capping consumers  monthly out of pocket costs  In the past  Trump has suggested allowing the government s Medicare health program for seniors to negotiate prices and making it easier to import drugs from countries where they sell for less  A Trump administration also could provide extra funding to the U S  Food and Drug Administration to speed approval of generic drugs  which still tend to cost far less than their brand name equivalents  health policy experts said  Capital Alpha Partners analyst Kim Monk  in a research note on Wednesday  said she expects advisors and Congress to steer Trump toward  more Republican oriented ideas   including pricing drugs based on their relative health benefit and requiring more disclosure of pricing details  Consumer advocate Rother cited the FAIR Drug Pricing Act  introduced in September by Senators John McCain  an Arizona Republican  and Tammy Baldwin  Wisconsin Democrat  as a potential vehicle for federal action  The bill would require manufacturers to explain annual price increases of more than 10 percent   It is a bipartisan bill consistent with traditional Republican health policy based on transparency and competition   Rother said  In California  voters on Tuesday rejected a ballot measure that would have require drugmakers to provide state health plans with discounts similar to those given to the U S  Department of Veterans Affairs  The VA pays the lowest prices in the country   Drugmakers spent more than  106 million on a campaign to defeat the measure   A similar measure will go before Ohio voters  who backed Trump in the election  next November  The coalition behind California s proposition on Wednesday urged legislators to come up with  a more comprehensive solution to lower sky rocketing drug prices  ,2016-11-11,Reuters,"https://www.investing.com/news/politics-news/u.s.-consumers-will-want-trump,-congress-to-take-on-drug-prices-440072",440072
197119,418635,MYL,Israel stocks higher at close of trade  TA 25 up 0 52 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Insurance  Banking and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 25 rose 0 52  
The best performers of the session on the TA 25 were Leumi  TA LUMI   which rose 3 87  or 59 points to trade at 1582 at the close  Meanwhile   Ormat Technologies   TA ORA  added 3 04  or 530 points to end at 17950 and  Elbit Systems   TA ESLT  was up 2 23  or 840 points to 38590 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 3 14  or 470 points to trade at 14490 at the close   Gazit Globe   TA GZT  declined 2 61  or 86 points to end at 3210 and Melisron  TA MLSR  was down 2 02  or 320 points to 15500 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 166 to 162 and 114 ended unchanged 
Shares in Leumi  TA LUMI  rose to 52 week highs  up 3 87  or 59 to 1582  
Crude oil for December delivery was down 3 43  or 1 53 to  43 13 a barrel  Elsewhere in commodities trading  Brent oil for delivery in January fell 2 79  or 1 28 to hit  44 56 a barrel  while the December Gold contract fell 3 10  or 39 25 to trade at  1227 15 a troy ounce 
USD ILS was down 0 07  to 3 8336  while EUR ILS fell 0 29  to 4 1656 
The US Dollar Index was up 0 20  at 98 99 ",2016-11-13,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.52-440252,440252
197120,418636,MYL,Mallinckrodt  12  as short seller Left claims CEO commits fraud,news,Mallinckrodt   NYSE MNK  plunged 12  in today s trade after short seller Andrew Left accused CEO Mark Trudeau of committing securities  fraud  Trudeau has been caught red handed committing securities fraud   exposed by none other than the newly released Medicare drug spending dashboard   according to Citron Research editor Left  who called into question MNK s Acthar Gel sales derived from government sources such as Medicaid and Medicare Leerink analysts say the report attempts to question whether the government should be paying Acthar s average  80K  100K net price per patient per year and calling it to the attention of government figures who have been targeting excessive drug pricing issues  in the type of issue that became a major headache for Mylan  NASDAQ MYL  recently with EpiPen ,2016-11-16,Seeking Alpha,https://www.investing.com/news/stock-market-news/mallinckrodt--12-as-short-seller-left-claims-ceo-commits-fraud-441591,441591
197121,418637,MYL,Israel stocks higher at close of trade  TA 25 up 0 01 ,news,"Investing com   Israel stocks were higher after the close on Thursday  as gains in the Oil   Gas  Financials and Insurance sectors led shares higher 
At the close in Tel Aviv  the TA 25 added 0 01  
The best performers of the session on the TA 25 were  Delek Group   TA DLEKG   which rose 2 67  or 2010 points to trade at 77410 at the close  Meanwhile  Delek Drilling LP  TA DEDRp  added 2 54  or 33 points to end at 1330 and Avner L  TA AVNRp  was up 2 52  or 6 1 points to 248 0 in late trade 
The worst performers of the session were Mylan NV  TA MYL   which fell 2 39  or 350 points to trade at 14320 at the close   Elbit Systems   TA ESLT  declined 1 91  or 770 points to end at 39530 and  Azrieli Group   TA AZRG  was down 1 75  or 280 points to 15750 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 200 to 142 and 101 ended unchanged 
Crude oil for December delivery was up 0 70  or 0 32 to  45 89 a barrel  Elsewhere in commodities trading  Brent oil for delivery in January rose 0 60  or 0 28 to hit  46 91 a barrel  while the December Gold contract rose 0 25  or 3 10 to trade at  1227 00 a troy ounce 
USD ILS was up 0 14  to 3 8584  while EUR ILS fell 0 08  to 4 1165 
The US Dollar Index was up 0 13  at 100 51 ",2016-11-17,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.01-441857,441857
197122,418638,MYL,Israel stocks higher at close of trade  TA 25 up 0 36 ,news,"Investing com   Israel stocks were higher after the close on Sunday  as gains in the Communication  Insurance and Technology sectors led shares higher 
At the close in Tel Aviv  the TA 25 added 0 36  to hit a new 1 month high 
The best performers of the session on the TA 25 were Perrigo  TA PRGO   which rose 2 32  or 770 points to trade at 33900 at the close  Meanwhile   Elbit Systems   TA ESLT  added 1 44  or 570 points to end at 40100 and Teva  TA TEVA  was up 1 08  or 160 points to 14910 in late trade 
The worst performers of the session were  Gazit Globe   TA GZT   which fell 2 68  or 94 points to trade at 3418 at the close  Mylan NV  TA MYL  declined 1 61  or 230 points to end at 14090 and  Azrieli Group   TA AZRG  was down 1 27  or 200 points to 15550 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 203 to 139 and 101 ended unchanged 
Crude oil for January delivery was unchanged 0 00  or 0 00 to  46 36 a barrel  Elsewhere in commodities trading  Brent oil for delivery in January rose 0 69  or 0 32 to hit  46 81 a barrel  while the December Gold contract fell 0 74  or 9 00 to trade at  1207 90 a troy ounce 
USD ILS was up 0 59  to 3 8874  while EUR ILS rose 0 20  to 4 1160 
The US Dollar Index was up 0 41  at 101 41 ",2016-11-20,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-0.36-442566,442566
197123,418639,MYL,Mylan declines Senate committee request to testify about EpiPen,news," Reuters    Mylan NV  O MYL  has declined a U S  Senate committee request to testify about a  465 million pending settlement to resolve charges the company underpaid government healthcare programs by misclassifying its the EpiPen emergency allergy treatment  In a Nov  18 letter to the Senate Judiciary Committee released on Monday  Mylan said the company would not attend since government agencies had also refused to testify  Senator Chuck Grassley  who chairs the committee and had scheduled the hearing for Nov  30  said in a statement on Monday that Mylan was  ducking responsibility   Mylan has come under fire for raising the price of a pair of EpiPens to  600 from  100 in 2008 and listing it with Medicaid as a generic product even though it is listed with the U S  Food and Drug Administration as a branded product  Companies pay smaller rebates to Medicaid for generics  Following months of Congressional scrutiny  Mylan in October announced a settlement with the Justice Department  The settlement has not yet been executed  however   This seems to contradict Mylan s claim that all potential liability claims have been resolved   Grassley said  Officials at the Justice Department and the Centers for Medicare and Medicaid Services  which administers Medicare and Medicaid  have declined to testify at the hearing  Grassley may reschedule the hearing and has the power to issue subpoenas  Jill Gerber  a spokeswoman for Grassley  said in an email  The authority is rarely used and would require a vote or the unanimous consent of the committee  she added   One way or another  I intend to get answers for patients and taxpayers   Grassley said in the statement  Separately  Grassley wrote on Monday to the Securities and Exchange Commission encouraging it to investigate  if it was not already doing so  whether Mylan misled investors when it announced its settlement with the Justice Department  He asked the SEC to let the committee know by Nov  29 whether it was investigating  
The SEC declined to comment  A Mylan spokeswoman did not immediately respond to a request for comment ",2016-11-21,Reuters,https://www.investing.com/news/stock-market-news/mylan-declines-senate-committee-request-to-testify-about-epipen-442818,442818
197124,418640,MYL,U S  Senate panel postpones Mylan hearing,news,WASHINGTON  Reuters    The U S  Senate Judiciary Committee on Monday postponed a hearing planned for next week to discuss Mylan NV s  O MYL  pending  465 million settlement to resolve charges that it underpaid government healthcare programs by misclassifying its EpiPen emergency allergy treatment  Mylan  the Justice Department and the Centers for Medicare and Medicaid Services had all declined to send officials to the Nov  30 hearing  the committee said in a statement    Unfortunately  because of the unconventional refusal by these three entities to attend  we must now consider compelling their participation   committee Chairman Charles Grassley said in the statement   This committee will not stop until our questions are answered and any appropriate actions are taken   Mylan has come under fire for raising the price of a pair of EpiPens to  600 from  100 in 2008 and listing it with Medicaid as a generic product even though it is listed with the U S  Food and Drug Administration as a branded product  Companies pay smaller rebates to Medicaid for generics ,2016-11-23,Reuters,https://www.investing.com/news/stock-market-news/u.s.-senate-panel-postpones-mylan-hearing-443369,443369
197125,418641,MYL,Israel stocks lower at close of trade  TA 25 down 0 07 ,news,"Investing com   Israel stocks were lower after the close on Tuesday  as losses in the Biomed  Technology and Communication sectors led shares lower 
At the close in Tel Aviv  the TA 25 declined 0 07  
The best performers of the session on the TA 25 were  Gazit Globe   TA GZT   which rose 2 52  or 85 points to trade at 3460 at the close  Meanwhile  Discount  TA DSCT  added 1 99  or 15 2 points to end at 779 2 and  Delek Group   TA DLEKG  was up 1 80  or 1390 points to 78630 in late trade 
The worst performers of the session were  OPKO Health Inc   TA OPK   which fell 1 28  or 53 points to trade at 4098 at the close   Frutarom   TA FRUT  declined 1 19  or 250 points to end at 20700 and Mylan NV  TA MYL  was down 1 12  or 160 points to 14070 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 178 to 169 and 96 ended unchanged 
Crude oil for January delivery was down 3 80  or 1 79 to  45 29 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February fell 3 74  or 1 84 to hit  47 37 a barrel  while the December Gold contract fell 0 45  or 5 30 to trade at  1185 50 a troy ounce 
USD ILS was down 0 08  to 3 8372  while EUR ILS fell 0 08  to 4 0739 
The US Dollar Index was up 0 04  at 101 25 ",2016-11-29,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-25-down-0.07-444341,444341
197126,418642,MYL,Israel stocks lower at close of trade  TA 25 down 0 34 ,news,"Investing com   Israel stocks were lower after the close on Wednesday  as losses in the Insurance  Technology and Biomed sectors led shares lower 
At the close in Tel Aviv  the TA 25 lost 0 34  
The best performers of the session on the TA 25 were  Delek Group   TA DLEKG   which rose 3 59  or 2820 points to trade at 81450 at the close  Meanwhile  Delek Drilling LP  TA DEDRp  added 3 03  or 42 points to end at 1427 and  Israel Corp   TA ILCO  was up 3 01  or 1730 points to 59130 in late trade 
The worst performers of the session were Teva  TA TEVA   which fell 2 81  or 410 points to trade at 14200 at the close   OPKO Health Inc   TA OPK  declined 1 85  or 76 points to end at 4022 and Mylan NV  TA MYL  was down 1 85  or 260 points to 13810 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 178 to 178 and 87 ended unchanged 
Shares in Teva  TA TEVA  fell to 52 week lows  losing 2 81  or 410 to 14200  Shares in Delek Drilling LP  TA DEDRp  rose to 52 week highs  gaining 3 03  or 42 to 1427  
Crude oil for January delivery was up 6 96  or 3 15 to  48 38 a barrel  Elsewhere in commodities trading  Brent oil for delivery in February rose 7 40  or 3 50 to hit  50 82 a barrel  while the February Gold contract fell 1 07  or 12 75 to trade at  1178 05 a troy ounce 
USD ILS was up 0 02  to 3 8337  while EUR ILS fell 0 35  to 4 0678 
The US Dollar Index was up 0 49  at 101 47 ",2016-11-30,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-25-down-0.34-444645,444645
197128,418644,MYL,Glaxo  GSK  Earnings And Revenues Surpass Estimates In Q4  ,opinion,GlaxoSmithKline plc   NYSE GSK   reported core earnings of 72 cents per American depositary share in the fourth quarter of 2017  surpassing the Zacks Consensus Estimate of 69 cents  The bottom line was up 11  at constant exchange rate  CER  compared with the year ago figure Glaxo s shares have lost 9 4  in a year s time against the  s 14 1  increase  Quarterly revenues rose 4  at CER to  10 3 billion   7 6 billion   driven by strong segmental performances in Consumer Healthcare  Pharmaceuticals and Vaccines  The top line also outpaced the Zacks Consensus Estimate of  9 9 billion All growth rates mentioned below are on a year over year basis and at CER Quarterly HighlightsSales were up 4  in the United States and 7  in the International markets  On the flip side  sales in Europe were flat year over year Sales of New Pharmaceutical and Vaccine products surged 51   driven by HIV drugs  Tivicay and Triumeq  respiratory drugs  the Ellipta products and Nucala  and the meningitis preventive vaccines  Bexsero and Menveo Glaxo reports financial figures under three segments  Pharmaceuticals  Vaccines and Consumer Healthcare The Pharmaceuticals division registered 3  revenue growth  driven by HIV drugs  Tivicay and Triumeq and respiratory disease drugs  Relvar Breo and Nucala  This upside was but partly offset by the impact of recent divestments and a sales decrease of older respiratory products including Seretide Advair and Established Pharmaceuticals HIV sales increased 17  on the back of 19  and 28  growth in the United States and International sales  respectively  Europe sales were also up 7  year over year  The encouraging numbers were driven by continued market share growth for both Triumeq  sales up 27   and Tivicay  sales up 41    However  sales of another HIV drug Epzicom Kivexa tumbled 61  due to an increased generic competition  particularly affecting the European market Notably  the company s latest product from the HIV portfolio is Juluca  dolutegravir   rilpivirine   the first two drug regimen  once daily  single pill for HIV  It was approved in the United States in November 2017  The drug generated initial sales of  5 million during the quarter  However  this week  Gilead Sciences   NASDAQ GILD   has announced an FDA approval of its triple combination  once daily single tablet regimen  Biktarvy  bictegravir  emtricitabine  tenofovir alafenamide   for HIV 1 infection treatment  This approval might pose competitive threats to Juluca in the coming quarters Respiratory sales were up 2  at CER  In the EU and the International markets  sales increased 4  and 6   respectively  However  in the United States  the metric was flat year over year  The sales improvement was mainly driven by the new respiratory products sales growth  partially offset by the sales decline of older products like Seretide Advair  Flovent and Ventolin Notably  the recently launched respiratory product  Trelegy Ellipta  only once daily single inhaler triple therapy for COPD   has generated initial sales of  2 million in the United States and the EU during the reported quarter The Ellipta products recorded a 53  surge in sales  driven by market share gains with the global roll out continuing  However  this upside was offset by lower sales of Seretide Advair  down 14    Flixotide Flovent and Ventolin sales decreased 12  and 9   respectively Immuno inflammation drugs  including Benlysta  rose 15  in the quarter The new grouping of Established Pharmaceuticals comprises the previous Established Products  Cardiovascular  metabolic and urology  CVMU  and other Pharma products  Established Pharmaceuticals sales declined 5  in the quarter under review Sales in the Consumer Healthcare segment climbed 4   despite a slowdown in market conditions  The power brands  particularly in Pain relief and Oral health categories  saw a sturdy performance in the quarter Sales from the Vaccines segment were impressive  having increased 9  year over year  Geographically  the United States  Europe and the international markets increased 16   2  and 9   respectively  While meningitis vaccines   Bexsero   decreased 5  in the United States  the same increased 15  in the Europe market  While Menveo in the United States posted higher sales  the same was offset by a weak performance of the Established Vaccines due to increasing competitive pressures on Infanrix and Pediarix in the United States and Europe It is important to note that in October 2017  the FDA granted an approval to Glaxo s shingles vaccine  Shingrix  Later in the same month  the U S  Centers for Disease Control and Prevention s Advisory Committee on Immunization Practices voted in favor of three recommendations for the use of Shingrix  The vaccine is preferred over Merck s   NYSE MRK   Zostavax  Owing to this favorable recommendation  Shingrix generated initial sales of  22 million in the United States during the period under discussion 2017 ResultsFull year sales gained 3  year over year to  39 3 billion   30 2 billion   However  the metric marginally missed the Zacks Consensus Estimate of  39 5 billion The 2017 earnings of  2 9 per share were in line with the Zacks Consensus Estimate  The full year bottom line reflects 4  growth compared with the year ago figure  Moreover  reported earnings matched the previously announced guidance for 2017 2018 OutlookThe company stated that EPS growth for 2018 is uncertain due to the timing of the entry of Advair generics in the market  Hence  it issued two sets of guidance for 2018 The company expects 4 7  EPS growth at CER in 2018  if no Advair generics are launched further this year  However  in the probable event of introducing Advair generics in the U S  market by mid 2018  Glaxo anticipates adjusted EPS to be flat to down 3  year over year at CER Three companies Mylan   NASDAQ MYL    Hikma Pharmaceuticals and Novartis which are trying to bring a generic version of Advair in the market received a complete response letter  CRL  from the FDA  While  Mylan and Hikma received CRL last year  Novartis received the same this week delaying the entry of generics in the U S  market Long term GuidanceThe company projects its EPS to witness a CAGR in the mid to high single digit range through 2020 While the Vaccine segment is estimated to register a mid to high single digit growth through 2020 despite competition for pediatric and flu vaccines  the Consumer Healthcare segment is expected to deliver low to mid single digit top line CAGR through 2020 GlaxoSmithKline PLC Price  Consensus and EPS Surprise    Zacks RankGlaxo carries a Zacks Rank  3  Hold   You can see  Will You Make a Fortune on the Shift to Electric Cars  Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research It s not the one you think ,2018-02-07,Zacks Investment Research,https://www.investing.com/analysis/glaxo-gsk-earnings-and-revenues-surpass-estimates-in-q4-200288601,200288601
197129,418645,MYL,Teva Stock Falls As Novartis Brings Another Copaxone Generic,opinion,Shares of Teva Pharmaceutical Industries Limited   NYSE TEVA   were down around 4  on Tuesday  as another generic version of its blockbuster multiple sclerosis injection  Copaxone was launched earlier than expected Sandoz   Novartis    NYSE NVS   generic arm   announced the FDA approval and launch of Glatopa 40 mg ml  its generic version of 40 mg formulation of Copaxone  This will be the second generic version of the 40 mg formulation of Copaxone  The launch came much earlier than expected  Teva  on its fourth quarter conference call held last week  had said that the second generic version of the 40 mg formulation was likely to be launched in April this year The first generic version of Copaxone 40 mg was launched by Mylan   NASDAQ MYL   in October last year  also much earlier than expected  which dealt a major blow to Teva  Also at the same time  Mylan launched the second biosimilar version of the 20 mg formulation  Please note that the first generic version of Copaxone 20 mg has been marketed by Momenta   NASDAQ MNTA   and Sandoz since 2015 With the entry of the generic version of the 40 mg formulation and the entry of a second generic version of the 20 mg formulation  Copaxone sales witnessed rapid erosion Now  with the launch of the second generic version of the 40 mg formulation  sales are expected to decline further In 2017  Copaxone sales totaled  3 8 billion  down almost 10  from 2016 levels  For 2018  Teva estimates Copaxone sales to fall to  1 8 billion as the Copaxone franchise continues to erode  In fact  Teva issued a weak outlook for 2018 wherein it expects sales and profits to decline further this year The Israel based generic drugmaker had a tough 2017 as it faced significant challenges in the form of accelerated generic competition for Copaxone  new competition for branded products  pricing erosion in the U S  generics business  lower than expected contribution from generic launches and a massive debt load of more than  32 billion  Mylan s earlier than expected launch of the first generic version of the 40 mg strength of Copaxone was a major setback for Teva Teva divested some non core assets  mainly in the Women s Health business  to cut its significant debt load  The company also has a new organizational structure in place  is closing plants  cutting down its generics portfolio  eliminating low value R D projects  and aims to cut its global workforce by more than 25  over the next two years as part of a restructuring plan it revealed in December  Though the company expects to save almost  3 billion by the end of 2019from these restructuring initiatives  a clear path to growth is not visible These efforts might not be enough to revive the company s fortunes during this challenging period  especially as it faces erosion of its largest product  Copaxone  Other than that  divestures and pricing pressure in the U S  generic business will continue to hurt the top line in 2018 Teva s shares have slumped 49 7  in the past year compared with the  sdecline of 36 1  Teva carries a Zacks Rank  4  Sell  You can see  Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks  has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-02-13,Zacks Investment Research,https://www.investing.com/analysis/teva-stock-falls-as-novartis-brings-another-copaxone-generic-200290321,200290321
197130,418646,MYL,U S  Senate panel urges FTC to launch antitrust probe of Mylan,news,"By Sarah N  Lynch WASHINGTON  Reuters    The U S  Senate Judiciary Committee urged federal antitrust regulators on Monday to launch a probe into whether EpiPen maker Mylan  NASDAQ MYL  NV broke the law by preventing schools from purchasing competing allergy treatments  
The bipartisan request to the Federal Trade Commission by Senate Judiciary Chairman Charles Grassley and Ranking Member Patrick Leahy comes just a few weeks before the committee is slated to convene a hearing to scrutinize a pending  465 million settlement that Mylan has said will resolve claims it underpaid rebates to state and federal Medicaid programs ",2016-11-07,Reuters,https://www.investing.com/news/stock-market-news/u.s.-senate-panel-urges-ftc-to-launch-antitrust-probe-of-mylan-438504,438504
197131,418647,MYL,Three U S  senators ask Mylan for EpiPen military reimbursements,news," Reuters    Three members of the U S  Senate Judiciary Committee  ahead of a planned hearing late this month  said Mylan  NASDAQ MYL  NV appears to have greatly overcharged the military for its lifesaving allergy treatment EpiPen and asked the pharmaceutical company when it plans to reimburse the Department of Defense  The reimbursement demand came in a letter on Monday to Mylan Chief Executive Heather Bresch  from Senate Judiciary Chairman Charles Grassley  an Iowa Republican  and committee members Richard Blumenthal of Connecticut and Amy Klobuchar of Minnesota  both Democrats   We are alarmed that Mylan may have overcharged our military for this life saving drug   the Senators wrote  They said Mylan for years may have knowingly misclassified EpiPen as a generic product in order to avoid higher rebates the company would have had to pay state and federal Medicaid programs had it been classified as a branded product  The Medicaid rebate for a generic is 13 percent compared with a minimum of 23 1 percent for a branded medicine  Mylan spokeswoman Nina Devlin declined to comment on the letter  or its demands  The drug company has come under fire from consumers and politicians in recent months for raising the U S  list price on a pack of two EpiPen injectors nearly six fold to  600 since 2008  Lawmakers  including Grassley  have called for investigations into Mylan s pricing  helping put the product in the spotlight amid a larger debate over big drug price increases in the United States   Pentagon spending on EpiPen jumped to  57 million over the past year from  9 million in 2008  an increase driven by volume and by hefty price hikes that had a bigger bite on prescriptions filled at retail pharmacies  Reuters reported on Oct  28  citing previously unreported data   The Pentagon gets a government discount on EpiPens dispensed at military treatment facilities and by mail order  But nearly half of its spending was at retail pharmacies where it most recently paid an average of  509 for EpiPen and  528 for EpiPen Jr two packs   three times higher than its discounted rate  according to the data  
The Senate Judiciary Committee is slated to hold a hearing Nov  30 on EpiPen pricing and related matters ",2016-11-07,Reuters,https://www.investing.com/news/stock-market-news/three-u.s.-senators-ask-mylan-for-epipen-military-reimbursements-438512,438512
197132,418648,MYL,Mylan  1 1  late as Senate panel urges FTC to investigate EpiPen practices,news,After a solid day  Mylan  MYL  4 5   is giving some back in the postmarket session   1 1   as the Senate Judiciary Committee calls on the FTC to investigate the drugmaker s business practices for possible anticompetitive behavior  The committee s leadership is responding to news reports saying Mylan engaged in exclusive deals with schools  preventing them from purchasing competitors to the EpiPen auto injector  In a letter to the FTC  committee Chairman Chuck Grassley and Ranking Member Patrick Leahy say  Increasing patient access to safe  effective and affordable medications has long been a shared priority of ours  We also share a strong belief that potential anti competitive actions by drug industry participants must be aggressively investigated because of their impact on competition and drug costs   The committee has scheduled a hearing to look over a reported settlement between the Justice Dept  and Mylan tied to a separate issue  misclassification of EpiPen in the Medicaid Drug Rebate Program  ,2016-11-07,Seeking Alpha,https://www.investing.com/news/stock-market-news/mylan--1.1-late-as-senate-panel-urges-ftc-to-investigate-epipen-practices-438514,438514
197133,418649,MYL,Mylan submits U S  marketing application for Herceptin biosimilar,news,Mylan N V   NASDAQ MYL  submits a Biologics License Application  BLA  to the FDA seeking approval of its biosimilar to Roche s  OTCQX RHHBY  cancer med Herceptin  trastuzumab   This is the company s first BLA filing for a biosimilar in the U S Its trastuzumab biosimilar  co developed with Biocon Ltd   is currently being sold in 11 countries  including India ,2016-11-08,Seeking Alpha,https://www.investing.com/news/stock-market-news/mylan-submits-u.s.-marketing-application-for-herceptin-biosimilar-438703,438703
197134,418650,MYL,Mylan Q3 EPS estimate  1 46 on revenues of  3 14 bn ,news,Investing com   Mylan  NASDAQ MYL  Q3 EPS estimate  1 46  on yoy rise in revenues to  3 14 bn Earnings to reflect  465 mn settlement of EpiPen allergy injector pricing storm Mylan to report earnings on Wednesday after the market closes Political pressure on drug prices clouds share price prospects for Mylan and the sector Hillary Clinton campaigned against the pricing of EpiPen NASDAQ Biotechnology Index down over 26  since the beginning of 2016 ,2016-11-08,Investing.com,https://www.investing.com/news/stock-market-news/mylan-q3-eps-estimate-$1.46-on-revenues-of-$3.14-bn-438693,438693
197135,418651,MYL,Pharmaceuticals buoyed by Trump shock win ,news,Investing com   Pharmaceutical stocks were boosted Wednesday by Donald Trump s surprise presidential win During his campaign  Trump said he would dismantle Obama s healthcare program Sector was sold prior to election result as Clinton was seen increasing controls on drug pricing In the U S    Pfizer   NYSE PFE  was up over 4  in pre market trade as Mylan  NASDAQ MYL  added over 6  European pharmaceuticals stocks were also higher ,2016-11-09,Investing.com,https://www.investing.com/news/stock-market-news/pharmaceuticals-buoyed-by-trump-shock-win-439090,439090
197136,418652,MYL,Israel stocks higher at close of trade  TA 25 up 1 22 ,news,"Investing com   Israel stocks were higher after the close on Wednesday  as gains in the Biomed  Banking and Financials sectors led shares higher 
At the close in Tel Aviv  the TA 25 rose 1 22  
The best performers of the session on the TA 25 were Mylan NV  TA MYL   which rose 7 24  or 1010 points to trade at 14960 at the close  Meanwhile  Teva  TA TEVA  added 4 53  or 670 points to end at 15460 and  Elbit Systems   TA ESLT  was up 2 71  or 1000 points to 37940 in late trade 
The worst performers of the session were  Ormat Technologies   TA ORA   which fell 4 21  or 780 points to trade at 17730 at the close   Gazit Globe   TA GZT  declined 3 92  or 140 points to end at 3430 and Melisron  TA MLSR  was down 2 04  or 340 points to 16360 
Falling stocks outnumbered advancing ones on the Tel Aviv Stock Exchange by 231 to 104 and 109 ended unchanged 
Crude oil for December delivery was down 0 84  or 0 38 to  44 60 a barrel  Elsewhere in commodities trading  Brent oil for delivery in January fell 0 85  or 0 39 to hit  45 65 a barrel  while the December Gold contract rose 1 13  or 14 35 to trade at  1288 85 a troy ounce 
USD ILS was up 0 29  to 3 8162  while EUR ILS fell 0 50  to 4 1783 
The US Dollar Index was up 0 42  at 98 29 ",2016-11-09,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-higher-at-close-of-trade;-ta-25-up-1.22-439205,439205
197137,418653,MYL,Mylan Q3 top line up 13   non GAAP EPS off 4  and shy of consensus  shares down 2  after hours,news,Mylan N V   NASDAQ MYL  Q3 results   M   Total Revenues  3 057 1   13 4    Generics Third Party Net Sales  2 610 8   16 6    Specialty Third Party Net Sales  418 7   4 6   North America  1 098 8   0 8    Europe  842 0   37 6    ROW  670 0   25 0   Net Income   119 8    128 0    Non GAAP Net Income  726 4   1 0    EBITDA  294 7   64 7    Non GAAP EBITDA  1 060 9   7 5    EPS   0 23    127 7    Non GAAP EPS  1 38   3 5    Cash Flow Ops  1 240 5   10 3   Consensus view was non GAAP EPS of  1 46 on revenues of  3 1B No guidance given Shares are off 2  after hours on robust volume ,2016-11-09,Seeking Alpha,https://www.investing.com/news/stock-market-news/mylan-q3-top-line-up-13;-non-gaap-eps-off-4-and-shy-of-consensus;-shares-down-2-after-hours-439361,439361
197140,418656,MYL,This Pharma Play Could See Nice Gains,opinion,"Some stocks have had little to brag about over the past couple of years 
Mylan  NASDAQ MYL  has had a rough go of it the past two years  losing nearly 50  of its value  The question is whether or not a pattern opportunity has formed during the stock s decline  It s possible 

Over the past year  MYL may have been forming a bullish inverse head and shoulders pattern with a test of the neckline and falling resistance taking place at  1   If a breakout happens here  it could attract buyers to this hard hit stock 
Another thing that catches our attention is the large  unfilled gap that took place back in 2015 at the  65 zone  Quite often  gaps end up getting filled  If this gap does fill  MYL will make some nice gains from current levels 
Full Disclosure  Members are long this stock with a tight stop ",2017-12-18,Chris Kimble,https://www.investing.com/analysis/this-pharma-play-could-see-nice-gains-200274083,200274083
197141,418657,MYL,Momenta Reports Positive Top Line Data On Antibody M281,opinion,"Momenta Pharmaceuticals  Inc    NASDAQ MNTA   reported positive top line data on pipeline candidate  M281 from a phase I single ascending dose  SAD  and multiple ascending dose  MAD  study of normal human volunteers 
The phase I randomized  double blind  placebo controlled study evaluated the safety  tolerability  pharmacokinetics and pharmacodynamics of M281 
M281 is a fully human anti neonatal Fc receptor  FcRn  aglycosylated immunoglobulin G  IgG1  monoclonal antibody  engineered to reduce circulating pathogenic IgG antibodies  in excess of that achieved by any current treatments  by completely blocking endogenous IgG recycling via FcRn 
The candidate did not exhibit any adverse event  was well tolerated  and decreased circulating IgG levels up to 89  with a mean reduction of 84  over the 98 day MAD study  In addition  the SAD portion of the study enrolled five cohorts with a total of 34 healthy adult volunteers and showed that a single dose of M281 achieved up to an 80  reduction of circulating IgG antibodies 
We remind investors that Momenta plans to present the top line results at a future conference 
Momenta s novel therapeutics portfolio has three pipeline candidates   M281  M254  and M230 
Meanwhile  the company is also trying hard to bring biosimilars to the market  Last week  Momenta and partner Mylan N V    NASDAQ MYL   announced that the companies will initiate a patient clinical trial of M710   a proposed biosimilar of Regeneron Pharmaceuticals    NASDAQ REGN   Eylea   in the first half of 2018  The commercial opportunity is significant  The company has collaborated with Mylan to develop  manufacture and commercialize six of its current biosimilar candidates 
Momenta and Mylan have entered into an agreement to develop  manufacture and commercialize six of Momenta s biosimilar candidates  including M834  a proposed biosimilar of Orencia 
Concurrent with the third quarter earnings  Momenta announced that M834 did not meet its primary pharmacokinetic end points in a phase I study to compare the pharmacokinetics  safety and immunogenicity of M834 to Orencia in normal healthy volunteers 

 
Momenta s stock have increased 8  in the last twelve months as against the  loss  of 0 2  
Momenta has had a rough ride  of late  The company suffered a setback when Mylan won the FDA approval for a generic version of Teva Pharmaceuticals   NYSE TEVA   Copaxone 40 mg  Notably  this is the first generic of Copaxone that has been approved 
Since Mylan was one of the first applicants to submit a substantially complete ANDA for glatiramer acetate Injection  40 mg mL  containing a Paragraph IV certification  the company and other first filers might be eligible for 180 days of generic drug exclusivity  On the other hand  Momenta s ANDA approval is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA  resulting in a delay of approval 
Zacks Rank
Momenta currently carries a Zacks Rank  3  Hold   You can see  
5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2018-01-08,Zacks Investment Research,https://www.investing.com/analysis/momenta-reports-positive-topline-data-on-antibody-m281-200278534,200278534
197142,418658,MYL,Theravance s NDA For COPD Candidate Gets FDA Acceptance,opinion,Theravance Biopharma  Inc    NASDAQ TBPH   and partner Mylan  NASDAQ MYL  have announced that the new drug application  NDA  for their pipeline candidate  revefenacin  TD 4208   has been accepted by the FDA for treatment of adults with chronic obstructive pulmonary disease  COPD   A response from the regulatory body is expected on Nov 13  2018 Notably  revefenacin is an experimental once daily nebulized long acting muscarinic antagonist  LAMA  therapy for COPD Notably  Theravance and Mylan had entered into a development and commercialization agreement for revefenacin back in February 2015  Under the contractual terms  the companies will co develop revefenacin for COPD and other respiratory diseases  While Theravance will lead the U S  registration development program  Mylan will be responsible for the product s commercial manufacturing Shares of Theravance have underperformed the  in a year s time  The stock has gained 0 2  while the broader industry increased 17 2  We remind investors that Theravance submitted the NDA to the FDA for revefenacin in November 2017 for the aforementioned indication  The NDA submission was supported by positive data from two replicate pivotal phase III efficacy studies and a single 12 month  open label  active comparator safety trial  In October 2016  the company reported positive data from both the phase III trials  The programs met the primary endpoints  demonstrating statistically significant improvements over placebo after 12 weeks of dosing  each comprising 88 mcg of revefenacin once daily and 175 mcg once daily  respectively Significantly  the company initiated a phase IIIb study last March  evaluating revefenacin on patients with low peak inspiratory flow rate  Data from the study is likely to be out by early 2018 Per the company s press release  COPD is the third leading cause for death in the United States  This grim picture suggests that while 15 7 million Americans are diagnosed with the disease  a larger number of patients still remains undiagnosed  An approval will thus be a huge boost to those patients  preferring nebulized therapy but with no access to a nebulized LAMA  Hence  there is a large commercial countrywide opportunity awaiting revefenacin in the COPD area Theravance Biopharma  Inc  Price   Zacks Rank   Key PicksTheravance carries a Zacks Rank  3  Hold   Some better ranked stocks in the health care sector are Exelixis  Inc    NASDAQ EXEL    XOMA Corporation   NASDAQ XOMA   and Sucampo Pharmaceuticals  Inc    NASDAQ SCMP    each carrying a Zacks Rank  2  Buy   You can see  Exelixis  earnings per share estimates have been revised upward from 72 cents to 77 cents for 2018 over the last 60 days  The company pulled off a positive surprise in all the trailing four quarters with an average beat of 572 92   Share price of the company has soared 71 5  in a year s time XOMA s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 over the last 60 days  The company came up with an average beat of 47 92   The stock has skyrocketed 706 4  in the last 12 months Sucampo delivered a positive surprise in three of the last four quarters with an average beat of 15 63   The company s share price has surged 67  in a year Don t Even Think About Buying Bitcoin Until You Read ThisThe most popular cryptocurrency skyrocketed last year  giving some investors the chance to bank 20X returns or even more  Those gains  however  came with serious volatility and risk  Bitcoin sank 25  or more 3 times in 2017 Zacks has just released a new Special Report to help readers capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly ,2018-01-29,Zacks Investment Research,https://www.investing.com/analysis/theravances-nda-for-copd-candidate-gets-fda-acceptance-200285099,200285099
197143,418659,MYL,Exclusive  EpiPen price hikes add millions to Pentagon costs,news,By Caroline Humer and Ruthy Munoz NEW YORK WASHINGTON  Reuters    Mylan  NASDAQ MYL  NV s price hikes on EpiPens have added millions to U S  Department of Defense spending since 2008 as the agency covered more prescriptions for the lifesaving allergy shot at near retail prices  government data provided to Reuters shows  Pentagon spending rose to  57 million over the past year from  9 million in 2008   an increase driven both by volume and by price hikes that had a bigger bite on prescriptions filled at retail pharmacies  according to the previously unreported data  The Pentagon gets a government discount on EpiPens dispensed at military treatment facilities and by mail order  But nearly half of its spending was at retail pharmacies where it most recently paid an average of  509 for EpiPen and  528 for EpiPen Jr two packs   three times higher than its discounted rate  the data shows  That may change  Both the Pentagon and Mylan told Reuters that discussions are underway that could extend the military discount to EpiPens filled at retail pharmacies through the use of rebates  Mylan spokeswoman Nina Devlin declined to comment on the specific Department of Defense spending  She said in an emailed statement that talks were underway to address  any questions or concerns from the agency   She declined to say if any repayment was on the table  A Reuters analysis of the data estimated a difference of about  54 million between what the agency paid for EpiPens at retail pharmacies from 2009 through 2016 and what it would have paid at military clinics  Mylan Chief Executive Officer Heather Bresch has drawn public scrutiny for raising the U S  list price on a pack of two injectors nearly six fold to  600 since 2008  Affordability has become a bigger issue with the increased diagnosis and awareness of food allergies  Families who rely on EpiPens to safeguard their children against possibly fatal allergic reactions often purchase several to carry with them  keep at school and with caregivers  In response to the criticism  Mylan is providing more families with coupons to pay for EpiPens and plans to market a half price version  The drugmaker also agreed to pay  465 million to settle questions over whether the Medicaid program for the poor overpaid because EpiPens were classified as a generic treatment  a category that allows manufacturers to give smaller rebates to government agencies  While Medicaid providers don t take issue with the increased use of EpiPens  they have bristled over the price hikes   The rate of increases in their cost is not justifiable   said Dr  J  Mario Molina  chief executive of Molina Healthcare  which runs Medicaid plans in California and 11 other states  THE FULL PICTURE The impact of Mylan s price hikes on government health programs  such as Medicaid  has been obscured by highly complex pharmaceutical pricing and opaque negotiations  The Centers for Medicare and Medicaid Services  as well as several large state Medicaid programs  have released partial details on their spending  saying full information on rebates is confidential under U S  law  Without such details  it is impossible to discern what price an agency is paying for EpiPen  At Reuters  request  the Defense Department provided the most comprehensive picture of EpiPen spending by a government agency  including fiscal year expenditures since 2008  average price per pack and the number of prescriptions filled by type of dispensing location for all EpiPens obtained by military service members  their families and retirees  The department s spending on EpiPens has increased fivefold since 2008  far outpacing the 130 percent growth in prescriptions  the data shows  Defense spending on the injectors at retail pharmacies   which accounted for 53 500 of 226 000 EpiPen prescriptions for the last fiscal year that ended Sept  30   has grown more than tenfold  to  28 million from  2 4 million in 2008  While EpiPen spending represents a fraction of a percent of the Defense Department s  49 billion annual healthcare budget  the data illustrates the premium it was paying for EpiPens at retail outlets   Lawmakers would not be terribly happy to hear that DoD is paying more at retail   said Brian Bruen  a drug economics researcher at George Washington University s Milken Institute School of Public Health   DISCOUNT BY DEFINITION The Defense Department and Department of Veterans Affairs  typically pay among the lowest drug prices in the country because of discounts mandated by law  as well as rebates negotiated with drugmakers  Bruen said  Indeed  the Pentagon has paid  173 for an EpiPen two pack filled through mail order and  169 at military facilities in fiscal year 2016  A key factor for government discounts is whether a drug is patent protected and has market exclusivity  or it is a generic  made cheaper by competition  The EpiPen  which packages a generic allergy antidote in a patented  easy to use injector  is somewhat of a hybrid   For the Defense Department  pharmaceutical companies pay rebates on brand name drugs dispensed by retail pharmacies  reducing the final cost to the agency s discounted rate  EpiPen s classification as a generic drug prevents it from receiving mandated rebates  Mylan provided documentation it said showed the military had accepted the generic classification for EpiPen in 2008  Under Mylan s settlement with the federal government  Medicaid will classify EpiPen as a branded drug  Devlin said  That will qualify Medicaid for a 23 percent rebate  up from the 13 percent it gets on generics  Any price hikes will be capped at the inflation rate  a protection not afforded generic drug purchases   It was always our intention that the reclassification would benefit all government agencies impacted by the classification  including the VA and Tricare  Defense  programs   Devlin said ,2016-10-28,Reuters,https://www.investing.com/news/stock-market-news/exclusive:-epipen-price-hikes-add-millions-to-pentagon-costs-435486,435486
197144,418660,MYL,EpiPen price adds millions to Pentagon costs,news,Mylan  NASDAQ MYL  s price hikes on EpiPens have added millions to DoD spending since 2008 as the agency covered more prescriptions for the lifesaving allergy shot at near retail prices  government data provided to Reuters shows That may change  Both the Pentagon and Mylan told Reuters that discussions are underway that could extend a military discount to EpiPens filled at retail pharmacies through the use of rebates ,2016-10-28,Seeking Alpha,https://www.investing.com/news/stock-market-news/epipen-price-adds-millions-to-pentagon-costs-435501,435501
197145,418661,MYL,Senator Grassley asks Defense Department to explain EpiPen spending,news," Reuters    U S  Senator Chuck Grassley asked the Department of Defense and the Department of Veterans Affairs on Tuesday to explain spending trends for the EpiPen emergency allergy treatment  The request followed a recent report by Reuters detailing how EpiPen price hikes by manufacturer Mylan  NASDAQ MYL  NV had added millions to U S  Department of Defense spending since 2008 as the agency covered more prescriptions for the lifesaving allergy shot at near retail prices   We know the price increase for EpiPens is hitting individual consumers and Medicare and Medicaid   Grassley  a Republican  said in a statement    We need to determine whether taxpayers overpaid for the EpiPen through the Department of Defense and the VA and whether they deserve a rebate  as they do with Medicaid   Spending that isn t warranted squeezes the health care budget   Mylan agreed last month to pay  465 million to settle questions of whether it underpaid U S  government healthcare programs by misclassifying EpiPen   
The company raised the price for a package of two EpiPens by sixfold to more than  600 over the last decade ",2016-11-01,Reuters,https://www.investing.com/news/politics-news/senator-grassley-asks-defense-department-to-explain-epipen-spending-436653,436653
197146,418662,MYL,West Virginia urges Justice Dept to reject settlement with Mylan,news,"By Sarah N  Lynch WASHINGTON  Reuters    West Virginia Attorney General Patrick Morrisey on Wednesday blasted Mylan  NASDAQ MYL  NV s announced  465 million settlement with the U S  Justice Department over the drugmaker s classification of its lifesaving allergy treatment EpiPen as a generic  saying the amount was  woefully deficient   The department has not acknowledged such a deal almost a month after Mylan announced it  and department spokeswoman Nicole Navas declined to comment on Wednesday  A spokesperson for Mylan did not respond to requests for comment  In a Nov  2 letter to Attorney General Loretta Lynch  Morrisey said there were no reports that such a deal had been finalized  But he urged the department to reject the  465 million figure because it  does not nearly pay for the damage done by Mylan   Mylan has come under fire for hiking the price of EpiPen to more than  600 for a package of two in less than a decade  Mylan s Oct  7 announcement about the settlement came just months after congressional scrutiny into the issue began  For years  the company had classified EpiPen as a generic drug instead of a branded one  resulting in smaller rebates to state and federal Medicaid programs  Morrisey said Mylan should not be allowed to receive a  windfall after flagrantly defrauding the Medicaid Drug Rebate Program   The Medicaid rebate for a generic is 13 percent compared with a minimum 23 1 percent for a branded drug  Morrisey in August started conducting an investigation into the rebates and antitrust concerns as to whether Mylan took steps to block market competition  The probe became public in September after Morrisey filed an action against Mylan for allegedly refusing to comply with a subpoena  Curtis Johnson  a spokesman for his office  confirmed the investigation was still ongoing  The New York Attorney General is also investigating whether Mylan broke antitrust laws in writing contracts to provide EpiPens to school systems  Centers for Medicare and Medicaid Services Acting Administrator Andrew Slavitt revealed in an Oct  5 letter to lawmakers that the centers had on  multiple occasions  provided guidance to the industry and Mylan about the proper classification of drugs  Until Oct  7  the company had not told shareholders about the possible misclassification of the EpiPen or the pending settlement with the Justice Department  That day  Mylan also revealed that the U S  Securities and Exchange Commission had launched an investigation and was seeking copies of its communications with the centers and documents related to the Medicaid rebate program  Senate Judiciary Chairman Charles Grassley  an Iowa Republican  plans to hold a hearing on Nov  30 to scrutinize the terms of the purported settlement  One topic that could also come up at the hearing is the question of how EpiPen price spikes have affected the U S  military s spending  Last week  Reuters reported that nearly half of the Pentagon s spending on EpiPens was at retail pharmacies  which do not give the same government discounts as medical treatment centers  As a result  Pentagon spending on EpiPens rose to  57 million over the past year  from  9 million in 2008  Grassley  as well as Senate Democrats Amy Klobuchar and Richard Blumenthal  have responded by sending letters to the Department of Defense and Department of Veterans Affairs seeking further details to determine whether they might be owed rebates  
On Tuesday  17 U S  Senate Democrats sent a letter to Mylan asking a variety of questions and demanding copies of all of the guidance that Mylan received from the centers about the classification since 2007  when Mylan acquired the company that owned the EpiPen ",2016-11-02,Reuters,https://www.investing.com/news/stock-market-news/west-virginia-urges-justice-department-to-reject-settlement-with-mylan-436934,436934
197151,418667,MYL,Glaxo  Pfizer s ViiV Healthcare Begins HIV Drug Combo Study,opinion,"GlaxoSmithKline   NYSE GSK   along with partner Pfizer  Inc    NYSE PFE   announced that its HIV focused company  ViiV Healthcare  has initiated a phase III program to evaluate combination of long acting  injectable cabotegravir and Johnson   Johnson s   NYSE JNJ   rilpivirine for treating adults with virally suppressed HIV 1 infection 
Shares of GlaxoSmithKline have underperformed the  so far this year  The stock has lost 7 7   comparing unfavorably with the industry s 15 3  rally during the period 

The ATLAS 2M trials comprise the third phase III study undertaken by ViiV Healthcare to investigate a two drug regimen for the treatment of HIV  The phase III program is designed to evaluate non inferior antiviral activity of the combination regimen at 48 weeks when administered every 8 weeks versus every 4 weeks  The study will also evaluate pharmacokinetics  safety and tolerability of the combination therapy  Preliminary data from the study is anticipated in 2019 
Notably  ViiV Healthcare was formed in November 2009 by GlaxoSmithKline and Pfizer  The partners were later joined by Shionogi in October 2012 
We remind investors that another phase III ATLAS study is already evaluating the monthly dosing of the combination regimen in virally suppressed patients  while the FLAIR study is evaluating the combination in the first line setting  Outcomes from the study are expected in 2018 
Notably  last week  GlaxoSmithKline and partner J J   NYSE JNJ   announced the FDA approval for Juluca  a two drug complete regimen of Tivicay rilpivirine and Edurant dolutegravir as a single tablet for treating HIV 1 infection  Most medicines for HIV treatment are made up of three or more antiretroviral drugs  Juluca is the first two drug regimen that reduces the number of medicines HIV patients take without compromising on the efficacy of a conventional three drug regimen 
Meanwhile  several companies are working on developing drugscombination regimens to treat HIV  Gilead s   NASDAQ GILD   bictegravir single table regimen  STR  is under priority review in the United States  The FDA is expected to announce its decision in February next year 
To the uninitiated  Mylan  NASDAQ MYL  has received a tentative approval to treat HIV from the FDA for its combination tablet comprising efavirenz  lamivudine and tenofovir disoproxil fumarate 
With companies increasingly developing drugs to treat this life threatening disease  competition has intensified manifold in the space GlaxoSmithKline PLC Price

   Zacks Rank
GlaxoSmithKline carries a Zacks Rank  3  Hold   You can see  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-11-28,Zacks Investment Research,https://www.investing.com/analysis/glaxo-pfizers-viiv-healthcare-begins-hiv-drug-combo-study-200268903,200268903
197152,418668,MYL,Glaxo Stock Down So Far This Year  Is A Reversal In Store ,opinion,GlaxoSmithKline plc s   NYSE GSK   shares have declined 7 9  this year so far  underperforming the 16 2  increase witnessed by the  The British pharma and consumer giant s stock was on a rising trajectory till the announcement of third quarter results on Oct 25  On the call  Glaxo expressed its interest to purchase Pfizer s   NYSE PFE   consumer healthcare business  which the latter plans to put up for sale  However  Glaxo s interest in buying Pfizer s unit raised investor concerns about the acquirer possibly sacrificing a portion of its dividend payment due to the potential buyout  Shares declined sharply thereafter  Since the earnings release  shares of Glaxo have declined 12 4   Earnings estimates for 2018 also witnessed a decline of 4  in the past 90 days Meanwhile  persistent challenges like stiff competition  genericization  pricing pressure and slowing growth in emerging markets have been hurting sales  Pricing pressure and competitive dynamics are hurting sales in Glaxo s respiratory franchise  particularly the older products  Meanwhile  its top selling product  Advair is also expected to face generic competition in the United States next year  which will further hurt sales  Mylan   NASDAQ MYL   and Hikma Pharmaceuticals are looking to bring generic versions of Advair in the United StaresSales of Advair are already being adversely impacted by pricing and competitive pressure in the United States and generic competition in Europe The slowdown in sales of the Consumer Healthcare segment this year due to a slowdown in global growth of its key consumer categories is also a concern However  not everything is going wrong at Glaxo  Its newer respiratory HIV drugs and vaccines are all doing well and will continue to boost revenues  These new products generated 29  of Glaxo s Pharmaceuticals and Vaccine sales in the first nine months of 2017  Going ahead  Glaxo expects new pharmaceutical and vaccine products including contributions from Shingrix to deliver sales of  6 billion per annum by 2018 Meanwhile  Glaxo has made significant progress with its late stage pipeline  We think Glaxo possesses one of the stronger late stage pipelines in large cap pharma  The company is focused on oncology  immuno inflammation  HIV and respiratory therapeutic areas  By 2020  the company plans to terminate  partner or divest about 30 pre clinical and clinical programs and instead allocate 80  of capital to priority programs in two current areas   Respiratory and HIV infectious   and two potential areas   Oncology and Immuno inflammation Recent back to back approvals of three new products   Trelegy Ellipta  only once daily single inhaler triple therapy for COPD   Shingrix vaccine  prevention of shingles  and Juluca   first dual treatment for HIV     have strengthened Glaxo s competitive position We would like to see if Glaxo s strong pipeline  consistent outperformance of new HIV drugs and vaccines  three new products  and cost cuts can bring it back on track next year Glaxo has a Zacks Rank  3  Hold   You can see Another large cap pharma stock that has declined this year is Merck   Co   Inc    NYSE MRK   due to several notable pipeline setbacks this year The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for regular investors who make the right trades early ,2017-11-29,Zacks Investment Research,https://www.investing.com/analysis/glaxo-stock-down-so-far-this-year-is-a-reversal-in-store-200269474,200269474
197153,418669,MYL,Cancer Space Update  Pfizer s Bavencio Fails In Phase III,opinion,"There was no major news in the cancer space this week  except the failure of Pfizer Inc  s   NYSE PFE   Bavencio in a gastric cancer study  In a setback to Eisai Co   Ltd    OTC ESALY    National Institute of Health and Care Excellence   NICE   did not recommend the approval of its breast cancer drug  Halaven  for use in second line setting in UK Meanwhile  AstraZeneca s   NYSE AZN   filing for label expansion of Tagrisso in first line setting for treating lung cancer was accepted by the European Medicines Agency   EMA    Apart from this  Bristol Myers    NYSE BMY   blockbuster drug  Opdivo  again proved its worth by achieving superior overall survival   OS   in a phase III lung cancer study  Moreover  Celldex Therapeutics  Inc    NASDAQ CLDX   also announced initiation of a phase I study on its new oncology candidate  CDX 1140  in solid tumors Recap of the Week s Most Important StoriesPfizer s Bavencio Fails in Gastric Cancer Study  Pfizer along with its Germany based partner Merck  NYSE MRK  KGaA announced the failure of a phase III study evaluating their key pipeline candidate  Bavencio  avelumab   for the treatment of gastric cancer in third line setting The study   JAVELIN Gastric 300   evaluated Bavencio as a monotherapy in patients with unresectable  recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma and whose disease has progressed following two prior therapeutic regimens  However  another study  JAVELIN Gastric 100  continues to evaluate the drug in first line switch maintenance setting   Read more   Pfizer  Inc  Price
    Eisai s Halaven Suffers Setback in UK  Eisai announced that NICE did not recommend approval for Halaven in UK in second line setting for treating locally advanced or metastatic breast cancer who have received chemotherapy  The approval would have given competitive advantage to the drug  The drug is already approved in the UK in third or later line setting for the same indication Eisai Co  Price
    Bristol Myers  Opdivo Superior in Lung Cancer Study  Bristol Myers  PD 1 immune checkpoint inhibitor  Opdivo  achieved superior OS compared to docetaxel in a phase III study  The study   CheckMate  078   evaluated the drug in previously treated advanced or metastatic non small cell lung cancer  The study  which was conducted mainly in Chinese patients  achieved its primary endpoint of OS earlier than expected  The company s biologics license application  filed on the basis of the positive results from the study  has been accepted by the China Food and Drug Administration Bristol Myers Squibb Company Price
    This week the EMA accepted Mylan s   NASDAQ MYL   marketing authorization applications for a biosimilar of Roche s   OTC RHHBY   breast and gastric cancer drug  Herceptin  and Amgen s neutropenia drug  Neulasta 5 Medical Stocks to Buy NowZacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia  AIDS  muscular dystrophy  hemophilia  and other conditions New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline  Early investors could realize exceptional profits ",2017-11-30,Zacks Investment Research,https://www.investing.com/analysis/cancer-space-update-pfizers-bavencio-fails-in-phase-iii-200269735,200269735
197154,418670,MYL,3 Drug Biotech Stocks In Focus On World AIDS Day,opinion,"Every year  World Aids Day is celebrated on Dec 1 to raise public awareness about Acquired Immuno Deficiency Syndrome  popularly known as AIDS  The day is observed to make people aware about proper cure and prevention of the disease  In this regard  this year  the theme for the day this year is  Right to Health   This day also commemorates those who have died from an AIDS related illness 
World AIDS Day is one of the eight official global public health campaigns marked by the World Health Organization  WHO   According to WHO  globally  about 36 7 million people were suffering from HIV AIDS at the end of 2016  Of the total  2 1 million were children less than 15 years old 
AIDS is a pandemic disease caused due to the infection of Human Immunodeficiency Virus  HIV   The virus weakens the immune system by destroying cells that fight diseases and infections  eventually leading to AIDS  Medicines for the treatment of HIV are called antiretroviral therapy  ART  that slow or put a check on the progression of the virus 
Currently  companies are investigating new medicines to treat  prevent and ultimately cure HIV  Scientists also are exploring new treatment paradigms like two drug regimens  making therapies drugs drugs with improved long term safety profiles and new mechanisms of actions 
Despite improved medical understanding of HIV and significant efforts made by leading government and medical bodies to prevent and treat HIV AIDS  this disease still has limited treatment options  In 2016  1 million people died of AIDS related illnesses  totaling to 35 0 million since the start of the epidemic 
Based on these statistics  it is not surprising that several healthcare companies are investing a significant amount of their R D expenditures on developing treatments and devices for HIV and AIDS 
Stocks to Watch For 
On World AIDS Day  here are some of the key pharma companies in the HIV market that investors can rely on 
GlaxoSmithKline   NYSE GSK   has a long standing commitment to HIV and AIDS  The company had developed the widely used antibiotic amoxycillin around 40 years ago  which was the first medicine approved to treat HIV  The sales of older HIV products   Epzicom and Selzentry   have been declining  However  the newer HIV drugs  Triumeq and Tivicay   are witnessing a consistent increase in sales and gaining market share 
Meanwhile  a significant portion of its R D expenditures are being used toward developing HIV medicines to treat prevent HIV 
Last week  Glaxo and partner Johnson   Johnson announced the FDA approval for Juluca   a combination of Glaxo s Edurant dolutegravir and J J s Tivicay rilpivirine into a single tablet   for the treatment of HIV  Most medicines for HIV treatment are made up of three or more antiretroviral drugs  Juluca is the first two drug regimen to be approved that reduces the number of medicines HIV patients take without compromising on the efficacy of a conventional three drug regimen 
This week ViiV Healthcare  an HIV company majorly owned by Glaxo and Pfizer   NYSE PFE    announced the start of a large late stage African study that will evaluate long acting cabotegravirinjection for the prevention of HIV in sexually active women  If approved  cabotegravir injections will be administered every two months as opposed to presently available oral anti retroviral medication  which needs to be taken every day 
Already  ViiV Healthcare has started conducting a HPTN 083 study on cabotegravirin HIV uninfected men and transgender women who have sex with men  under co funding with National Institute of Allergy and Infectious Diseases  NIAID   Meanwhile  cabotegraviris also being evaluated in three late stage studies as atwo drug regimen withEdurant  with the third study initiation announced earlier this week 
Furthermore  Glaxo is developing two drug regimen ofdolutegravir   lamivudine 
Gilead   NASDAQ GILD   is a dominant player in the HIV market with an impressive portfolio  In fact  Gilead s HIV franchise is a major contributor to sales with approved drugs like Genvoya  Truvada  Atripla  Stribild  Descovy  Odefsey and Complera 
The company was the first to introduce a single tablet regimen  STR  for the treatment of HIV   Atripla  Gilead s other STRs for HIV include Complera Eviplera and Stribild  Its TAF based product  Genvoya  happens to be a bestseller surpassing both Truvada and Atripla since fourth quarter 2016 
Currently  Gilead s bictegravir single table regimen  STR  for HIV treatment is under priority review in the United States  The FDA is expected to announce its decision in February 2018 
The STR is a fixed dose combination of bictegravir  an INSTI  and emtricitabine tenofovir alafenamide  FTC TAF   a dual NRTI backbone  This combination is also under review in the EU 
Another company working towards developing HIV drugs is Johnson and Johnson   NYSE JNJ    The company along with partner Glaxo recently received FDA approval for first two drug regimen  Juluca  as discussed above  Further  the company along with The Bill   Melinda Gates Foundation and National Institutes of Health is conducting an efficacy study for an investigational mosaic HIV 1 preventive vaccine 
The study will evaluate whether the vaccine is safe and is able to reduce the incidence of HIV infection among women in sub Saharan Africa   HIV has a significant unmet need and women and girls account for about 60  of people living with HIV in eastern and southern Africa 
Others
Some other popular marketed HIV drugs are AbbVie s   NYSE ABBV    Kaletra and Merck s   NYSE MRK   Isentress 
Mylan   NASDAQ MYL   also recently received a tentative FDA approval for its combination tablet comprising efavirenz  lamivudine and tenofovir disoproxil fumarate 
Meanwhile  Merck is developing an investigational non nucleoside reverse transcriptase inhibitor  doravirine both as a single entity tablet and in combination  fixed dose tablet  with other antiretroviral agents   lamivudine and tenofovir disoproxil fumarate  TDF   The company plans to file regulatory applications for the same before the end of 2017 
Conclusion
AIDS HIV is a life threatening disease which has limited medical cure  However  there are numerous companies that are developing drugs for the treatment and care for people suffering from HIV and for them who are at risk of becoming infected with HIV  thereby making the space competitive 
While Johnson   Johnson sports a Zacks Rank  1  Strong Buy   both Glaxo and Gilead carry a Zacks Rank  3  Hold   You can see  
Investor Alert  Breakthroughs Pending 
A medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline 
Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ",2017-12-01,Zacks Investment Research,https://www.investing.com/analysis/3-drugbiotech-stocks-in-focus-on-world-aids-day-200270068,200270068
197155,418671,MYL,Mylan Announces IPR Proceedings For Sanofi s Lantus Patents ,opinion,"Mylan N V    NASDAQ MYL   announced that the U S  Patent and Trademark Appeal Board   PTAB   has instituted inter partes review   IPR   proceedings on all claims against two Orange Book listed patents   U S  Patent Nos  7 476 652 and 7 713 930  respectively 
The two patents are owned by Sanofi   NYSE SNY   for Lantus  insulin glargine injection  100 Units mL 
We remind investors that Mylan s 505 b  2  new drug application   NDA   for Insulin Glargine in vial and pen dosage forms is under active review with the FDA 
In October  Sanofi initiated a patent infringement litigation against Mylan s NDA in the United States District Court for the District of New Jersey alleging violation of 18 patents in the suit inclusive of these two Lantus patents 
Lantus and Lantus Solostar are both approved for improving glycemic control in adult patients with diabetes mellitus 
Sanofi s diabetes franchise seems highly weighed on with its key product Lantus facing a tremendous competitive pressure at the payor level as well as from other biosimilars in several European markets besides Japan  Moreover  a biosimilar version of Lantus had hit the markets last December 

 
Meanwhile  shares of Mylan have rallied 4 9  so far this year  outperforming the  s 26 7  decline during the period 
Mylan is a leading generic drug company in terms of both total and new prescriptions  The company s pursuit of first to file opportunities should help it maintain a strong position in the global generics market 
Mylan is also exploring the world of biosimilars  a market with potential to grow to  20 billion by 2020  A partnership with Biocon and collaborations with Momenta Pharmaceuticals  Inc    NASDAQ MNTA   and Mabion have aided the company to develop a portfolio of 16 biosimilar insulin analog generic products 
However  Mylan s performance in 2017 continues to be affected by the ongoing challenges in North America  The third quarter witnessed a fast decline in EpiPen sales  thanks to the launch of an authorized generic as well as the contraction of overall epinephrine auto injector market 
In a major boost  Mylan also received an FDA approval for the generic version of Copaxone 40mg  As one of the first filers  the company will enjoy 180 days of exclusivity  The recent FDA approval for Mylan s biosimilar version of Roche Holdings    OTC RHHBY   Herceptin will also boost the company s biosimilar portfolio 
Zacks Rank 
Mylan carries a Zacks Rank  3  Hold   You can see  
Investor Alert  Breakthroughs PendingA medical advance is now at the flashpoint between theory and realization  Billions of dollars in research have poured into it  Companies are already generating substantial revenue  and even more wondrous products are in the pipeline Cures for a variety of deadly diseases are in sight  and so are big potential profits for early investors  Zacks names 5 stocks to buy now ",2017-12-15,Zacks Investment Research,https://www.investing.com/analysis/mylan-announces-ipr-proceedings-for-sanofis-lantus-patents-200273735,200273735
197156,418672,MYL,Senate Republicans seek probe of Mylan EpiPen oversight,news,"By Brendan Pierson NEW YORK  Reuters    Mylan NV  O MYL  faced new scrutiny over price hikes for its anti allergy EpiPen on Tuesday  with U S  lawmakers calling for a probe of oversight of the company s rebates to government healthcare plans  while West Virginia said it was investigating whether Mylan defrauded its Medicaid department   Mylan is grappling with a growing backlash from U S  consumers  lawmakers and prosecutors over EpiPen prices  which have risen from about  100 in 2007 to more than  600 for a pair of the devices  The EpiPen delivers a dose of epinephrine  an antidote to a severe and potentially deadly allergic reaction to anything from nuts to bee stings  The rising cost has made it difficult for many families to afford EpiPens  prompting a public outcry that has resonated with legislators   Mylan Chief Executive Heather Bresch is to testify about the price hikes on Wednesday before an oversight committee of the House of Representatives  Bresch is the daughter of Senator Joe Manchin  a Democrat from West Virginia  In her prepared testimony  released on Tuesday  Bresch said Mylan was already moving to address concerns about price by expanding discount programs and launching a  300 generic version  She said that  after rebates  fees and costs  the company makes only about  100 per EpiPen pack  and that a majority of consumers pay less than  50 out of pocket for a pack   Ahead of the hearing  Republicans on the Senate Finance Committee said they were concerned that Mylan was allowed to inappropriately classify EpiPen as a generic drug  reducing the potential discounts to the government s Medicaid health program for the poor    We are concerned that the controls in place  if any  are inadequate to ensure that Medicaid is receiving the full amount of rebates afforded to it by law   the Senate Republicans  led by Orrin Hatch of Utah  said in a letter to the U S  Department of Health and Human Services Inspector General   Under current law  branded drugs  and generic drugs available from a single source  are subject to a rebate of at least 23 1 percent of the average manufacturer price for Medicaid  Non innovator drugs are subject to a much lower 13 percent rebate  The Finance Committee Republicans are asking Inspector General Daniel Levinson to examine the federal health agency s oversight of the rebate program   Mylan has said it has complied with all laws and regulations regarding rebates   Also on Tuesday  West Virginia Attorney General Patrick Morrisey said he was investigating the rebates and the possibility that Mylan violated the state s antitrust law when it sued and settled with a would be generic competitor  Mylan spokeswoman Nina Devlin said the company was cooperating with the investigation   EpiPen has also posed a cost burden to the federal Medicare health program for the elderly  according to an analysis from the Kaiser Family Foundation  a health policy research group  Before rebates  EpiPen costs for Medicare Part D shot up more than 1 000 percent between 2007 and 2014  from  7 million to  87 9 million  the report said   Devlin  in an emailed statement  said that from 2010 to 2015  rebates to Medicare Part D plans were up 440 percent  which would reduce the increase stated by the Kaiser Family report  She said that any analysis that does not take those specific rebates into account is fundamentally flawed  
While rebates to Medicare  which are not disclosed by the program  would have offset the cost to a degree  it was still far higher than a 164 percent increase in EpiPen prescriptions to Medicare patients  the Kaiser Family report said ",2016-09-20,Reuters,https://www.investing.com/news/stock-market-news/senate-republicans-seek-probe-of-mylan-epipen-oversight-427425,427425
197157,418673,MYL,Lawmakers blast Mylan CEO over  sickening  EpiPen price hikes,news,"By Toni Clarke WASHINGTON  Reuters    U S  lawmakers on Wednesday blasted Mylan  NASDAQ MYL  NV Chief Executive Heather Bresch for sharply increasing prices for the EpiPen emergency allergy treatment at a congressional hearing in which Republicans and Democrats questioned the reasons behind rising U S  drug costs  The House Committee on Oversight and Government Reform called Bresch to testify in the wake of public outrage over EpiPen  whose list price has risen to  600 for a pair of the devices compared with  100 in 2007  Lawmakers in turn described the actions as  sickening    disgusting  and showing  blatant disrespect  for American families who can no longer afford the life saving device for children susceptible to severe allergic reactions   At several points  they cut off Bresch s efforts to explain the intricacies of U S  pharmaceutical pricing  including how health insurers and other payers take a percentage of treatment sales   Several lawmakers noted EpiPen s growing profits over the same period as well as Bresch s annual salary  which has increased from around  2 5 million to more than  18 million  They also faulted the U S  Food and Drug Administration for moving too slowly to allow competing products to reach the market  U S  Representative Elijah Cummings  ranking Democrat on the committee  said Mylan  jacked up  the price of the product  to get filthy rich at the expense of our constituents   He questioned whether Mylan would change course in any way following the backlash over its pricing   After Mylan takes our punches they ll fly back to their mansions in their private jets and laugh all the way to the bank   Cummings said  Bresch defended the price hikes  saying that after rebates  marketing costs and other expenses  Mylan earns about  100 for a pair of EpiPens  She emphasized that the company plans a half price version of the device  that it provides them free to many schools and said that Mylan s generic medications combined have saved the U S  healthcare system  180 billion in costs over a decade   Our concern was absolutely that anyone who needs an EpiPen has one   Bresch told the hearing  Mylan will also soon seek approval for a new formulation that extends the shelf life of EpiPen from 18 months to at least 24 months  cutting down replacement costs  Bresch said   GROWING SCRUTINY  The EpiPen is an automatic injector  delivering a dose of the generic medicine epinephrine through a quick jab in the thigh  It commands over 90 percent of the market  with no competition expected until next year at the earliest    I am a very conservative  pro business Republican  but I am really sickened by what I     heard here today   Representative John J  Duncan Jr  of Tennessee said at Wednesday s hearing  The EpiPen price increases ignited a national controversy in August following complaints by families  Congressional lawmakers have called on federal agencies to investigate Mylan s business practices   Several U S  states are probing the impact of the price increases on government healthcare programs such as Medicaid  The pricing furor has hurt company shares  bringing them to a historically low valuation  At the hearing  Committee Chairman Jason Chaffetz of Utah questioned why Mylan could now afford to offer a generic version of EpiPen for about  300    Suddenly  feeling the heat  Mylan has offered a generic version and cut the price in half  so that does beg the question what was happening with that other  300   Holding up an EpiPen  he said   the actual juice that s in here that you need costs about a dollar    In 2015  EpiPen accounted for  1 billion of Mylan s overall sales of  9 45 billion and about 20 percent of company profit  Critics say EpiPen would remain profitable at a lower price   A recent analysis by the consumer watchdog Public Citizen found that an EpiPen two pack costs  69 in the United Kingdom   181 81 in Canada and  210 21 in Germany  Lawmakers are trying to determine whether Mylan made more money on EpiPen than warranted from state Medicaid programs by having it classified as a generic product  resulting in much smaller rebates to the government health plans   The FDA classifies EpiPen as branded but the Centers for Medicare and Medicaid Services deems it a generic for the purposes of Medicaid s drug rebate program  Participating companies pay 13 percent in rebates on generic drugs versus 23 percent on branded products  Mylan has said it complied with all laws and regulations regarding rebates  
EpiPen has also increased the cost burden to the Medicare program for the elderly  according to an analysis from the Kaiser Family Foundation  a health policy research group  Before rebates  EpiPen costs for Medicare Part D increased more than 1 000 percent between 2007 and 2014  from  7 million to  87 9 million  the report said ",2016-09-21,Reuters,https://www.investing.com/news/stock-market-news/u.s.-lawmakers-grill-mylan-ceo-over-epipen-steep-price-increases-427674,427674
197158,418674,MYL,Parent bloggers question role in Mylan s EpiPen schools push,news,"By Dave McKinney CHICAGO  Reuters    When Mylan  NASDAQ MYL  NV recruited food allergy bloggers to learn about its campaign to get allergic shock antidotes into schools  many were eager to join the maker of the EpiPens they carry in purses and stash in book bags to protect their children against potentially lethal attacks  The bloggers  more than a dozen mothers of children with serious allergies  embraced the effort Mylan outlined in a series of  summits  it held for them beginning in 2013  They wrote impassioned posts on blogs shared with tens of thousands of followers on social media  Their personal testimony helped persuade a number of state lawmakers to pass bills to get schools to stock epinephrine injectors  such as the EpiPen  according to legislators and others familiar with the lobbying effort  During the same period  the company was marking up its EpiPen to more than  600 per twin pack  six times the 2007 price  creating a burden for many of the bloggers  followers  other parents of children whose lives are threatened by bee stings and peanuts  At least four of the bloggers told Reuters they believe Mylan took advantage of their goodwill  Some have joined public criticism of those price hikes   I personally believe that Mylan held the summits to gain blogger trust and then used those bloggers to spread word about their initiatives  They raised prices while those initiatives gained traction   Ruth LovettSmith  a former food allergy blogger from Massachusetts who attended three summits  said in an email  Mylan spokeswoman Lauren Kashtan declined to comment on the criticism  But in an email  she said the company regretted that it had not anticipated  the potential financial issues for the growing minority of patients  whose EpiPens are not covered by insurance or a patient assistance program  Mylan now offers coupons to more families to cover out of pocket costs and said it would soon release a half price EpiPen  Kashtan also said the blogger summits served a worthy purpose   Mylan aimed to provide access to information  resources and expertise about anaphylaxis and life threatening allergies   said Kashtan  who represented the company at four summits   We are proud to have brought together such a passionate and dedicated group of advocates   Chief executive Heather Bresch was blasted Wednesday at a hearing before U S  lawmakers who  along with prosecutors in several states  are investigating the price hikes  EpiPen sales exceed  1 billion a year and command more than 90 percent of the market  STEAKS AND BLOG POLISHING The effort to get epinephrine injectors into schools is a point of pride for Mylan  which has credited its alliances with advocates for its success   We have collaborated with government officials  leading advocacy organizations  parents  caregivers and healthcare professionals to successfully champion legislation and policies   Mylan said in a 2015 report on its social responsibility efforts  LovettSmith  whose son has nut allergies  went to her first Mylan blogger summit in January 2013 at a boutique midtown Manhattan hotel overlooking the Empire State Building  It was the first of at least four summits  each involving about 15 bloggers  some of whom attended more than one event  They wrote about being treated to three course dinners featuring pan seared yellow fin tuna or marinated grilled hanger steak  At a 2014 summit at the company s Canonsburg  Pa   headquarters  Mylan brought an outside communications consultant to help the women polish their blogs  advocate to policymakers  practice on camera television interviews and speak at public events  participants told Reuters  Homa Woodrum  a lawyer in Las Vegas whose 8 year old daughter relies on EpiPens for nut and oat allergies  attended that summit  But she skipped an invitation to a May 2015 event at California s Disneyland  uncomfortable with the shift in venue to a resort   It starts to seem a little like you re being buttered up   Woodrum said  Bloggers who attended summits testified on behalf of schools  bills in Nevada  Maine and Michigan  according to interviews and legislative records  In all  48 states adopted laws requiring or enabling schools to stock epinephrine injectors  In many cases  Mylan subsequently donated EpiPens to schools  Stanley Short  a Democratic representative who co sponsored the Maine bill  credited a blogger with alerting him to the issue  The woman  who attended the Disneyland summit  brought her son to a legislative hearing  where he demonstrated how he would press an EpiPen into his thigh to stop an allergic reaction  Mylan s lobbyist attended the hearing  but the boy s show and tell  sealed the deal   Short said   With me and most of the legislators  it s that first hand experience of a mother talking about her child and a child talking about what they go through personally that did it   MIXED REACTIONS Bloggers who went to Disneyland told Reuters pricing was not on the drugmaker s agenda  By then  some were aware of the hikes and brought them up  Mylan talked about the role of other parties  including insurers  in determining what consumers pay  they said  Blogger Kelly Rudnicki s food allergy advocacy led to work as a paid Mylan spokeswoman  But  she said in an email  she quit last month because of the pricing controversy  She said she believes Mylan should apologize and cut its prices on EpiPens  and Bresch should step down  Rudnicki  whose 14 year old son has severe food allergies  said the bloggers supported Mylan because they believed it  had our back and manufactured a device that we couldn t live without   Mylan declined to discuss Rudnicki s criticism  The company confirmed she resigned  adding it had thanked her for her work  Some bloggers like Caroline Moassessi  a food allergy activist from Reno  Nev   take a more nuanced view  She attended three summits and testified in Nevada to allow schools and other public venues to stock epinephrine  She also has felt the full effect of price hikes  As a small business owner  she paid  3 000 in 2015 for EpiPens for her son and daughter  Each child carries two pens at all times and keeps two more at school  Moassessi also carries two injectors  While Moassessi would rather pay less  she said she recognizes that Mylan is in business to make a profit  
 I know they re a business trying to make as much as they can  like Ford  Chevy  Macy s   she said   I m not naive about that  whatsoever  ",2016-09-23,Reuters,https://www.investing.com/news/stock-market-news/parent-bloggers-question-role-in-mylans-epipen-schools-push-428072,428072
197159,418675,MYL,Mylan reiterates profit on EpiPen two pack in U S ,news," Reuters    Under fire generic drugmaker Mylan NV  O MYL  reiterated it makes a net profit of  104  after taxes  for a pair of its EpiPen emergency allergy treatment sold in the United States  the company said in a filing on Monday  The unexpected filing comes after the Wall Street Journal reported earlier in the day that the company substantially reduced its calculation of EpiPen profits by applying the statutory U S  tax rate of 37 5 percent during a congressional hearing on Wednesday  U S  lawmakers at the hearing lambasted Mylan Chief Executive Heather Bresch for sharply increasing prices for the treatment to  600 for a pair from  100 in 2007  
 Without the tax related reduction  Mylan s profits on the EpiPen two pack would be closer to  160  or 60 percent higher than the figure the company gave Congress   the WSJ report said ",2016-09-26,Reuters,https://www.investing.com/news/stock-market-news/mylan-reiterates-profit-on-epipen-two-pack-in-u.s.-428541,428541
197160,418676,MYL,U S  agency told Mylan that EpiPen was misclassified,news,"By Diane Bartz WASHINGTON  Reuters    A U S  federal health agency said on Wednesday it had  expressly advised  Mylan NV  O MYL  that the drugmaker had improperly classified its EpiPen emergency allergy treatment in a way that allowed it to pay lower rebates to state health programs  The disclosure comes as U S  lawmakers and prosecutors are investigating Mylan over steep price hikes for the EpiPen device which have rendered the drug unaffordable for a growing number of families  A least one state has launched an investigation into whether Mylan failed to pay proper rebates to the Medicaid program for the poor  The Centers for Medicare and Medicaid Services  or CMS  said in a statement it had  on multiple occasions  provided guidance to the industry and Mylan on the proper classification of drugs and has expressly advised Mylan that their classification of EpiPen for purposes of the Medicaid Drug Rebate program was incorrect   CMS  part of the U S  Department of Health and Human Services  declined to say what action it took to push for the misclassification to be corrected or when it spoke to Mylan  Mylan classified EpiPen with the Medicaid Drug Rebate Program as a generic treatment  which provides a rebate of 13 percent to state Medicaid programs  rather than as a branded drug  which pays a minimum rebate of 23 1 percent   Mylan has said it complied with CMS rules  The company did not immediately respond to requests for comment on the CMS statement  Mylan has been heavily criticized for sharply raising the price of EpiPen devices  which are carried by people with life threatening allergies  Mylan acquired the product in 2007 and has raised the list price for a pair of EpiPens to  600 from about  100 in 2008  Earlier on Wednesday  U S  Senators Richard Blumenthal  Charles Grassley and Amy Klobuchar asked the U S  Department of Justice to investigate a possible misclassification  
 The facts     suggest that Mylan may have knowingly misclassified EpiPens  potentially in violation of the False Claims Act and other statutes   the lawmakers said in a letter to Attorney General Loretta Lynch  The False Claims Act is used to pursue companies that defraud the federal government ",2016-09-28,Reuters,https://www.investing.com/news/politics-news/senators-ask-justice-department-to-consider-probe-of-epipen-medicaid-classification-429096,429096
197161,418677,MYL,Clinton expected to hit Wells Fargo in speech on  bad corporate actors ,news,"By Amanda Becker WHITE PLAINS  N Y   Reuters    U S  presidential candidate Hillary Clinton on Monday will unveil a plan to make it easier for consumers to take legal action against  bad corporate actors   citing  Wells Fargo    Co and Mylan Pharmaceuticals  according to a campaign official   While campaigning in Ohio  the Democratic nominee will explain how she would  if elected on Nov  8  curb the prevalence of contractual clauses that require consumers  employees and other individuals to resolve legal disputes in private arbitration proceedings instead of in courts  her campaign said  Mandatory arbitration clauses sometimes require that claims be pursued on an individual basis instead of on behalf of a class of similarly situated individuals  Consumer advocates say this makes it prohibitively expensive to take legal action  Clinton will call on the U S  Congress to give agencies such as the Federal Trade Commission  the Federal Communications Commission and the Department of Labor the authority to restrict the use of arbitration clauses in consumer  employment and antitrust agreements  according to a preliminary plan reviewed by Reuters   Clinton will also discuss how she believes that the Consumer Financial Protection Bureau and other agencies already have the authority to curb the use of such clauses under the 2010 Dodd Frank Act  The planning document said she would urge the Securities and Exchange Commission to exercise its authority to make related rules authorized by the financial reform law  Wells Fargo  N WFC  is expected to be in the crosshairs when Clinton discusses how she would curb mandatory arbitration clauses   For years  the bank s employees opened as many as 2 million checking  savings and credit card accounts without the customers  permission in order to meet sales quotas  Wells Fargo reached a  190 million settlement with federal regulators earlier this month   When Wells Fargo chief John Stumpf testified before Congress recently about the unauthorized accounts  he said he did not expect the bank to waive a clause signed by its customers in order to open their authorized accounts  The clause said they would arbitrate disputes instead of suing Wells Fargo in court   Democratic lawmakers in Congress  including Senator Elizabeth Warren of Massachusetts  have called on Wells Fargo to toss out the mandatory arbitration clause and allow customers to sue   
Clinton is also expected to criticize Mylan  O MYL  for sharply raising without justification the price of EpiPens  which deliver life saving drugs to those with allergies  The criticism will be part of a larger push to curb excessive market concentration and encourage competition that benefits consumers  her campaign said ",2016-10-03,Reuters,https://www.investing.com/news/stock-market-news/clinton-expected-to-hit-wells-fargo-in-speech-on-'bad-corporate-actors'-429902,429902
197162,418678,MYL,U S  government health plans spent over  1 billion on EpiPens over five years,news,"By Bill Berkrot  Reuters    U S  government health plans spent more than  1 billion on Mylan  NASDAQ MYL  NV s EpiPen emergency allergic reaction treatment between 2011 and 2015  according to figures released by the Centers for Medicare and Medicaid Services on Wednesday  Mylan is under scrutiny for raising prices on the lifesaving EpiPen sixfold in less than a decade  making the devices unaffordable for a growing number of families  U S  lawmakers and prosecutors are also investigating what impact Mylan s EpiPen pricing has had on government funded health programs  CMS  in response to a request from U S  Senator Amy Klobuchar of Minnesota  said in a letter that the Medicaid plan for the poor spent  797 million on EpiPen in the five year period  including rebates provided by Mylan  or  960 million before rebates  Costs for the Medicare Part D program for the elderly was nearly  335 million  a figure that does not reflect rebates  Klobuchar and other lawmakers contend that Mylan underpaid rebates to state Medicaid programs by misclassifying EpiPen as a generic instead of a branded drug  The Medicaid rebate for a generic is 13 percent compared with a minimum 23 1 percent for a branded drug  CMS said it could not determine how much the government is owed for EpiPens  but reiterated its view that Mylan had misclassified the product   CMS has  on multiple occasions  provided guidance to the industry and Mylan on the proper classification of drugs and has expressly told Mylan that the product is incorrectly classified   the agency said  Mylan has said it complied with CMS rules  On Wednesday  it noted that the classification of EpiPen for Medicaid rebates had been made in 1997  a decade before it acquired the product   New CMS rules that took effect this year allow companies to clarify any classification issues for a product like EpiPen  with companies asked to submit their requests by April 1  2017    It would be premature to comment further on this issue until the CMS process has concluded   Mylan said  Klobuchar in a statement called for  clear answers on how deep this misclassification goes  how much it has cost taxpayers across the country  how many other drugs may be misclassified  and how we get that money back  Mylan Chief Executive Heather Bresch was blasted by lawmakers during a congressional hearing last month for raising the list price for a pair of EpiPens to more than  600 this year  It cost about  100 in 2007  when Mylan acquired the product  Mylan has said the list price does not reflect its true earnings on EpiPen once its discounts to payers  development costs and other expenses are taken into account  
It has sought to address the criticism by offering discounts more widely to consumers and plans to make available a generic version for about  300 ",2016-10-05,Reuters,https://www.investing.com/news/stock-market-news/u.s.-government-health-plans-spent-over-$1-billion-on-epipens-over-five-years-430623,430623
197163,418679,MYL,Mylan to pay  465 million over EpiPen Medicaid rebate dispute,news,"By Deena Beasley  Reuters    Mylan NV  O MYL  on Friday said it will pay  465 million to settle questions of whether it underpaid U S  government healthcare programs by misclassifying its EpiPen emergency allergy treatment  which has come under intense scrutiny after a series of drastic price increases  Mylan has been lambasted by consumers and lawmakers for raising prices on the lifesaving EpiPen sixfold to over  600 for a package of two in less than a decade  making the devices unaffordable for a growing number of families  Lawmakers were trying to determine whether Mylan made more money on EpiPen than warranted from state Medicaid programs by having it classified as a generic product  resulting in much smaller rebates to the government health plans  Mylan Chief Executive Heather Bresch was grilled by the House Committee on Oversight and Government Reform for the price increase and they were skeptical of her profit analysis of the product  The Centers for Medicare and Medicaid Services  in response to a request from U S  Senator Amy Klobuchar of Minnesota  said this week that the Medicaid plan for the poor spent  797 million on EpiPen between 2011 and 2015  including rebates provided by Mylan  or  960 million before rebates  Lawmakers have contended that Mylan underpaid Medicaid rebates by misclassifying EpiPen as a generic instead of a branded drug  The Medicaid rebate for a generic is 13 percent compared with a minimum 23 1 percent for a branded drug   I am glad the Department of Justice pursued this so quickly   Klobuchar said in a statement   If other drugs are misclassified  and surely EpiPen isn t the only one     the taxpayers need to get their money back   Mylan said in a regulatory filing on Friday that EpiPen will be classified as a branded drug as of April 1  2017  Bresch told lawmakers this week that Mylan plans to launch a  300 generic version of EpiPen as soon as possible this year  Mylan also lowered its 2016 earnings outlook  but the drugmaker affirmed its 2018 forecast and its shares rose 11 percent to  39 90 after hours   Kudos to management for fast action   AB Bernstein analyst Ronny Gal said in a video message to investors   This was one of the major risks everyone was focusing on     now it is essentially off the table   Mylan said it will record a pretax charge of about  465 million in the quarter ended Sept  30  The company  which will make the payment to the Department of Justice and other government agencies  said the settlement does not include any finding of wrongdoing  Mylan  citing changes to the EpiPen consumer discount program and upcoming launch of a generic version  said it now expects full year 2016 adjusted earnings per share of  4 70 to  4 90  down from  4 85 to  5 15  
Mylan said it  remains committed  to its target of at least  6 00 in adjusted earnings per share in 2018 ",2016-10-07,Reuters,https://www.investing.com/news/stock-market-news/mylan-agrees-to-$465-million-settlement-over-epipen-classification-431102,431102
197164,418680,MYL,Wall St up as Clinton seen debate winner  U S  crude above  50 ,news,Investing com   U S  stocks were higher early Monday as Clinton seen winner of presidential debate  The DJI was up 0 77  at 11 00 ET  while the S P 500 added 0 77   The tech heavy Nasdaq composite was up 0 83   The Treasury market was closed for the Columbus Day holiday  U S  crude moved back above  50 after upbeat remarks by Saudi energy minister Putin on OPEC deal  Mylan  NASDAQ MYL  added 9 77  to  39 45 after agreeing to pay  465 mn to settle EpiPen rebate dispute ,2016-10-10,Investing.com,https://www.investing.com/news/stock-market-news/wall-st-up-as-clinton-seen-debate-winner;-u.s.-crude-above-$50-431436,431436
197167,418683,MYL,Theravance  TBPH  Submits NDA For COPD Candidate Revefenacin,opinion,"Theravance Biopharma  Inc    NASDAQ TBPH   and partner Mylan   NASDAQ MYL   announced that the new drug application for the combined entity s key pipeline candidate  revefenacin  TD 4208   has been submitted to the FDA for treatment of adults with chronic obstructive pulmonary disease   COPD   
Notably  revefenacin is an experimental once daily nebulized long acting muscarinic antagonist   LAMA   to treat COPD 
We remind investors that Theravance and Mylan entered into a development and commercialization agreement for revefenacin in February 2015  Under the terms of the agreement  the companies will codevelop revefenacin for COPD and other respiratory diseases  While Theravance will lead the U S  registration development program  Mylan will be responsible for the product s commercial manufacture 
Shares of Theravance have underperformed the  so far this year  The stock has lost 11 3  while the broader industry has remained flat during the period 

 
The NDA submission was supported by positive data from two replicate pivotal phase III efficacy studies and a single 12 month  open label  active comparator safety trial  In October 2016  the company reported positive data from both the phase III studies  The programs met their primary endpoints demonstrating statistically significant improvements over placebo after 12 weeks of dosing for each of the doses of revefenacin comprising 88 mcg once daily and 175 mcg once daily  respectively 
Earlier in July  the company had announced positive data from the 12 month safety study  Findings from the study demonstrated that both the doses of revefenacin were generally well tolerated with low rates of adverse events and serious adverse events  respectively 
Significantly  the company initiated a phase IIIb study  evaluating revefenacin on patients with low peak inspiratory flow rate in March 2017  Data from the study is expected in early 2018 
Per the company s press release  COPD is the third leading cause for death in the United States  The grim picture suggests that while 12 7 million Americans are diagnosed with the disease  almost an equal number of patients remain undiagnosed  An approval will be a huge boost as patients who prefer nebulized therapy  have no access to a nebulized LAMA  Hence  there is a large commercial countrywide opportunity for revefenacin in the COPD area Theravance Biopharma  Inc  Price

   Zacks Rank   Key Picks
Theravance carries a Zacks Rank  3  Hold   A few better ranked stocks in the health care sector include Ligand Pharmaceuticals Inc    NASDAQ LGND   and Achillion Pharmaceuticals  Inc    NASDAQ ACHN    both carrying a Zacks Rank  2  Buy   You can see  
Ligand s earnings per share estimates have moved up from  3 68 to  3 70 for 2018 over the last 30 days  The company delivered positive earnings surprises in two of the trailing four quarters with an average beat of 8 22   Share price of the company has surged 40 5  year to date 
Achillion s loss per share estimates have narrowed from 65 cents to 63 cents for 2017 and from 74 cents to 67 cents for 2018 over the last 30 days  The company came up with positive earnings surprises in two of the trailing four quarters with an average beat of 4 51  
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7   and  90 2  respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-11-14,Zacks Investment Research,https://www.investing.com/analysis/theravance-tbph-submits-nda-for-copd-candidate-revefenacin-200265126,200265126
197168,418684,MYL,Theravance Shares Rise On Approval Of Glaxo s COPD Therapy,opinion,"Theravance Biopharma  Inc  s   NASDAQ TBPH   shares rose almost 6 5  on Thursday following the approval of GlaxoSmithKline plc s   NYSE GSK   chronic obstructive pulmonary disease   COPD   therapy  Trelegy Ellipta in Europe  Investors cheered the approval as Theravance has an economic interest on the royalties that Glaxo will pay to its partner Innoviva  Inc    NASDAQ INVA   on global sales of Trelegy Ellipta 
We note that Innoviva spun off its biopharmaceutical operations in June 2014 into a subsidiary called Theravance Biopharma  As part of the spin off agreement between the two entities  Theravance is eligible to receive 85  of any future payments paid by Glaxo in connection with GSK Partnered Respiratory Programs 
Moreover  Glaxo is expected to pay Innoviva royalties in the range of 6 5  to 10  on global sales of Trelegy Elipta  Theravance will receive cash flows  which amount to approximately 5 5  to 8 5  of worldwide net sales of the drug 
However  Theravance s shares are down 9 4  so far this year  underperforming the  s decline of 0 4  

Trelegy Ellipta  a triple combination therapy  was granted marketing authorization in the EU as maintenance therapy for treatment of patients with COPD on Nov 16  It was approved in the United States in September this year  The product is expected to bring in blockbuster sales 
Meanwhile  earlier this week  Theravance submitted a new drug application to the FDA for its COPD candidate  revefenacin  which has been developed in partnership with Mylan   NASDAQ MYL    Revefenacin is nebulized long acting muscarinic antagonist   LAMA    An approval will be a huge boost as patients who prefer nebulized therapy have no access to a nebulized LAMA 
Theravance has a Zacks Rank  3  Hold   You can see  Theravance Biopharma  Inc  Price
 

   Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-11-17,Zacks Investment Research,https://www.investing.com/analysis/theravance-shares-rise-on-approval-of-glaxos-copd-therapy-200266378,200266378
197169,418685,MYL,U S  lawmakers question Mylan s Medicaid EpiPen rebates,news,By Deena Beasley  Reuters    Two key U S  congressional committee members on Friday called for an investigation into whether Mylan  NASDAQ MYL  NV  under fire for raising the price of its EpiPen device  overcharged the government s low income healthcare program for the allergy treatment  In a letter to the secretary of the Department of Health and Human Services  Senator Ron Wyden and Representative Frank Pallone  both Democrats  seek clarification of whether EpiPen was classified as a generic   non innovator  drug  or a brand name drug by the Medicaid program  Under current law  branded drugs  and generic drugs available from a single source  are required to pay a rebate amount of at least 23 1 percent of the average manufacturer price  Generic drugs are subject to a much lower 13 percent rebate  Mylan  in an emailed statement  said it has complied with all laws and regulations regarding Medicaid rebates  and intends to file with regulators  by next April as required under new guidelines  for EpiPen to be classified as a  non innovator  product  The device jabs a dose of the drug epinephrine into the thigh to counter dangerous allergic reactions such as to peanuts  food allergies and bee stings   Mylan  whose tax address is in the Netherlands but which has corporate headquarters in Canonsburg  Pennsylvania  has raised the U S  price of EpiPen from less than  100 when it acquired the product in 2007 to more than  600  Amid an outcry by parents  consumer groups and U S  politicians  the company said on Monday it will soon launch the first generic version of the device for  300  half the list price of its branded product   Wyden  ranking member of the Senate Finance Committee  and Pallone  ranking member of the House Energy   Commerce Committee  said in the letter on Friday   It has recently come to our attention that Mylan has classified EpiPen as a generic drug  under the Medicaid rebate program  even though it is considered a new drug by the Food and Drug Administration  Shares of Mylan  which fell 4 7 percent to close at  39 97 on Friday  have dropped 19 percent since mid August ,2016-09-02,Reuters,https://www.investing.com/news/stock-market-news/u.s.-lawmakers-question-mylan's-medicaid-epipen-rebates-424043,424043
197170,418686,MYL,New York to probe Mylan EpiPen contracts for schools,news,"WASHINGTON  Reuters    New York has opened a probe into whether Mylan Pharmaceuticals  O MYL  broke antitrust law in writing contracts to provide EpiPens to some schools systems  state Attorney General Eric Schneiderman said in a statement on Tuesday  A person briefed on the matter said the New York attorney general s office has subpoenaed documents from Mylan over the EpiPen program   There had been allegations that schools which had used Mylan s EpiPen4Schools program  which gives many schools the devices for free  were contractually barred from buying products from Mylan competitors for a year  Senators Richard Blumenthal and Amy Klobuchar asked the Federal Trade Commission on Tuesday to investigate the allegation  
Mylan did not immediately respond to a request for comment ",2016-09-06,Reuters,https://www.investing.com/news/stock-market-news/new-york-to-probe-mylan-epipen-contracts-for-schools-424558,424558
197171,418687,MYL,Allergan vows limited price hikes  says  outliers  deter research,news,"By Ransdell Pierson  Reuters    The chief executive officer of Allergan  NYSE AGN pa  Plc said his company would limit annual price increases on its prescription drugs  and that  outlier  drugmakers that have imposed huge price increases on their products were scaring off venture capital investors  Allergan  the maker of such products as Botox  plans to raise prices no more than once a year and keep price hikes to no more than low to mid single digit percentages  slightly above the current annual rate of inflation  CEO Brent Saunders said on Tuesday   Price increases taken by Allergan so far this year reflect that range  and will be the pattern for price increases next year and beyond  Saunders said in an interview   Allergan is committed to being a good citizen in self policing and being disciplined about price increases   Saunders said   And I hope others in the industry follow   Without mentioning names  Saunders said several drugmakers that have come under fire from patients  consumer groups and politicians for huge price increases  had been  reprehensible  and were choking off investment in start up companies doing cutting edge drug research   My biggest fear  every time there s another headline or more regulator negativity  is that venture capital needed for innovation could move out of the sector   Saunders said  adding the amount of venture capital backing for early stage drugmakers was slowing   If the bottom of the ecosystem  which is so important for early drug discovery  begins to evaporate  innovation will start to go away   he said   It has started   Saunders outlined his price restraint vow in a blog earlier on Tuesday   Allergan s biggest products are Botox  used to treat wrinkles and medical conditions such as migraine headaches  and Restasis to treat dry eye  Although a significant portion of Botox sales are for uninsured cosmetic conditions that patients pay out of pocket  Saunders said Allergan would attempt to limit price increases for all uses of the brand  Allergan shares closed 1 3 percent higher at  239 12 on the New York Stock Exchange on Tuesday  amid a moderate advance for the Arca Pharmaceutical Index of large U S  and European drugmakers  QUESTIONS CLINTON PROPOSALS Democratic presidential nominee Hillary Clinton has cited Turing Pharmaceuticals LLC s 5 000 percent price increase for AIDS drug Daraprim and Mylan  NASDAQ MYL  NV s repeated steep price increases on its EpiPen device for severe allergy sufferers as  troubling  examples of price hikes that have attracted bipartisan congressional scrutiny  Valeant Pharmaceuticals International Inc has also drawn criticism for hefty increases on two heart drugs and other medicines  Clinton said on Friday that if elected president in November  she would create an oversight panel to protect U S  consumers from large price hikes on long available innovative drugs  a proposal that Saunders described as  impractical     I d like to stop outliers too  but implementing that would be hard to do   Saunders said   In a free market  who says what would fall under the panel s purview  and what the price should be   
Clinton also called for emergency government imports of generics when there is insufficient market competition  Saunders said such imported drugs  lacking strict U S  regulatory review and made under different manufacturing conditions  could have safety issues ",2016-09-06,Reuters,"https://www.investing.com/news/stock-market-news/allergan-vows-limited-price-hikes,-says-'outliers'-deter-research-424547",424547
197172,418688,MYL,Senate investigations panel to probe Mylan s EpiPen pricing,news,"WASHINGTON  Reuters    The U S  Senate s permanent subcommittee on investigations will probe Mylan  NASDAQ MYL  Pharmaceuticals  pricing of the allergy auto injector EpiPen  according to a press release issued on Wednesday  The release described the probe as a  preliminary inquiry   Mylan has been criticized   including by Democratic presidential candidate Hillary Clinton   for sharply raising the price of EpiPens  which are carried by people with life threatening allergies  Mylan raised the price from about  100 in 2008 to about  600 currently  It has offered some discounts but this has done little to allay concerns   Our review of this matter will be robust  thorough  and bipartisan  Parents and school districts in Ohio  Missouri and across the country need affordable access to this life saving drug  and we share their concern over Mylan s sustained price increases   Senators Rob Portman  the Republican chair of the subcommittee  and Claire McCaskill  the top Democrat  said in a statement  
Mylan did not immediately respond to a request for comment ",2016-09-07,Reuters,https://www.investing.com/news/stock-market-news/senate-investigations-panel-to-probe-mylan's-epipen-pricing-424817,424817
197173,418689,MYL,Mylan CEO to testify before House panel over EpiPen pricing,news,"WASHINGTON  Reuters    Mylan  NASDAQ MYL  NL Chief Executive Officer Heather Bresch will appear at a Sept  21 congressional hearing over price increases for its EpiPen emergency allergy treatment  the U S  House of Representatives Oversight Committee said in a statement on Wednesday  Mylan has been widely criticized  including by U S  Democratic presidential candidate Hillary Clinton  for sharply raising the price of EpiPens  which are carried by people with life threatening allergies  Mylan  which acquired the product in 2007  recently raised the list price for a pair of EpiPen auto injectors to  600  The price has been rising from a cost of about  100 in 2008   Mylan spokeswoman Nina Devlin confirmed that Bresch will attend the hearing   Heather is very good at being able to give an answer without offering much information   said Evercore ISI analyst Umer Raffat  adding that he will be watching for any other issues that might be raised by the Committee   A probe into EpiPen pricing by a U S  Senate subcommittee was announced on Sept  7  Bresch is the daughter of U S  Senator Joe Manchin  a Democrat from West Virginia  The House panel co chairmen  Republican Representative Jason Chaffetz and Democratic Representative Elijah Cummings  noted there is      justified outrage from families and schools across the country struggling to afford the high cost of EpiPens   The committee planned to look at how to spur competition in the EpiPen market and speed approval by the Food and Drug Administration  FDA  of generic alternatives  according to the statement  In response to the furor  Mylan last month said it would sell its own generic version of EpiPen for  300  Teva Pharmaceutical Industries  which for years has been working on developing a generic alternative to EpiPen  said last week that it hopes to gain U S  approval by late 2017 or early 20018  EpiPen  which has annual sales of about  1 billion  delivers a potentially life saving dose of epinephrine by injection into the thigh to counter dangerous allergic reactions  including to peanuts and bee stings  Mylan owns 94 percent of the market for such auto injected devices  
The committee said it also planned to call as a witness Dr Doug Throckmorton  the FDA s deputy director at the Center for Drug Evaluation and Research ",2016-09-14,Reuters,https://www.investing.com/news/stock-market-news/mylan-ceo-to-testify-before-house-panel-over-epipen-pricing-426130,426130
197174,418690,MYL,California governor signs epinephrine bill  blasts Mylan,news,"By Dan Levine SAN FRANCISCO  Reuters    California Governor Jerry Brown on Friday signed a bill to allow businesses across the state to carry epinephrine auto injectors  but sharply admonished drugmaker Mylan  NASDAQ MYL  NL over its recent price increases  Mylan has been widely criticized  including by U S  Democratic presidential candidate Hillary Clinton  for raising the price of EpiPens  which are carried by people with life threatening allergies  The company  which acquired the product in 2007  recently raised the list price for a pair of EpiPen auto injectors to  600  The price has been rising from a cost of about  100 in 2008  A probe into EpiPen pricing by a U S  Senate subcommittee was announced on Sept  7  Brown s decision on Friday highlights the predicament facing allergy advocates  who strongly support epinephrine access legislation but have criticized Mylan s pricing   Over two dozen U S  states have passed laws similar to California s authorizing businesses to stock epinephrine  according to advocacy group Food Allergy Research   Education   Brown said he was signing the bill because EpiPens save lives  but that he strongly objected to Mylan s pricing   State government cannot stop unconscionable price increases  but it can shed light on such rapacious corporate behavior   Brown said in a statement  A Mylan representative could not immediately be reached for comment  EpiPen  which has annual sales of about  1 billion  delivers a potentially life saving dose of epinephrine by injection into the thigh to counter dangerous allergic reactions  including to peanuts and bee stings  Mylan owns 94 percent of the market for such auto injected devices   
In response to the furor over pricing  Mylan last month said it would sell its own generic version of EpiPen for  300 ",2016-09-16,Reuters,"https://www.investing.com/news/politics-news/california-governor-signs-epinephrine-bill,-blasts-mylan-426753",426753
197175,418691,MYL,Mylan shares languish at low valuation as EpiPen hearing nears,news,"By Lewis Krauskopf NEW YORK  Reuters    Shares of Mylan  NASDAQ MYL  NV are trading at historically low valuations as the company s chief executive officer is set to face a congressional grilling on Wednesday over the price of its EpiPen emergency allergy treatment   The stock is trading at 7 5 times estimated earnings for the next 12 months  holding near its lowest in at least 30 years and well below its five year average of 11 times  according to Thomson Reuters Datastream  Since late August  when the EpiPen price increases came into the spotlight  Mylan shares have fallen about 15 percent  For the year  they are off about 23 percent  against a nearly 4 percent decline for the NYSE Arca Pharmaceutical index  a broad gauge of large and small drugmakers  A test for the shares looms on Wednesday  when Mylan CEO Heather Bresch testifies before the U S  House of Representatives Oversight Committee over price increases of EpiPen  an auto injector of allergy medicine   The hearing will come the day after West Virginia disclosed an investigation into whether Mylan violated antitrust laws or defrauded the state s Medicaid program  A probe into EpiPen pricing by a U S  Senate subcommittee was also announced on Sept  7  The stock  is just not working because of the overhang from all the headline stuff on EpiPen   said Guggenheim Securities analyst Louise Chen  who rates the shares  neutral   One concern among analysts is how fallout over EpiPen pricing will affect Mylan s roughly  1 billion in annual sales of the device   Mylan said last month that it would introduce the first generic version of EpiPen for  300  half the price of the branded product  as it tries to quell the backlash  Further competition looms from Teva Pharmaceutical Industries  NYSE TEVA   which hopes to start selling an EpiPen like device by 2018  Chen also said investors were unsure of the benefits from Mylan s recently completed  7 billion acquisition of Swedish drugmaker Meda  which some had deemed expensive   Deutsche Bank   DE DBKGn  analyst Gregg Gilbert stuck to his  buy  rating on Mylan stock earlier this month  noting its valuation   
But in a research note  Gilbert cautioned   Investors will have little patience if execution falters on the base business and or the newly acquired Meda business  ",2016-09-20,Reuters,https://www.investing.com/news/stock-market-news/mylan-shares-languish-at-low-valuation-as-epipen-hearing-nears-427380,427380
197181,418697,MYL,Sucampo  SCMP  Beats On Q3 Earnings   Revenues  Ups  17 View,opinion,"Sucampo Pharmaceuticals  Inc    NASDAQ SCMP   reported adjusted earnings of 27 cents per share in the third quarter of 2017  beating the Zacks Consensus Estimate of 25 cents  However  reported earnings were down 10  from the year ago figure of 30 cents Total revenue came in at  61 3 million  up 6  from the year ago quarter  and surpassed the Zacks Consensus Estimate of  57 44 million  driven by higher Amitiza sales in the United States and Japan  Sucampo has a license  commercialization and supply agreement with Mylan N V    NASDAQ MYL   for marketing Amitiza in Japan Sucampo s share price has decreased 29 2  year to date  while the  lost 0 9  The Quarter in DetailProduct sales were  35 8 million  up 14  year over year  Product royalty revenues were  23 million  up 11  year over year Sales of Amitiza as reported by Takeda Pharmaceutical for royalty calculation purposes  in the United States were  115 2 million  up 6  due to strong marketing and selling  as well as growth in branded market  Takeda holds the global marketing rights for Amitiza outside Japan and China and pays royalties to Sucampo  As reported by Mylan  Amitizia sales increased 18  to  20 5 million in Japan  Unit volume increased 35  The company s operational expense  R D and S GA  increased 4  from the year ago period to  22 6 million due to inclusion of research   development expense related to Vtesse DevelopmentsIn July 2017  the company filed a supplemental new drug application  sNDA  with the FDA for label expansion of Amitizia to include pediatric patients  10 17 year of age  suffering from functional constipation  The sNDA was granted priority review with a decision expected on Jan 28  2018 Moreover  during the quarter  the FDA granted Fast Track status to CPP 1X sulindac  which is being developed for adults with familial adenomatous polyposis 2017 Guidance RaisedSucampo raised its guidance for full year 2017  The company now expects total revenue in the range of  250 million to  255 million  previously  220 million to  230 million   The Zacks Consensus Estimate for 2017 is  228 5 million The company increased its adjusted net income guidance to the range of  63 million to  68 million  previously  56 million to  66 million  and adjusted earnings in the range of  1 10 to  1 15  previously  1 00 to  1 10  Sucampo Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank   Key PicksSucampo carries a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the pharma sector includes Agenus Inc    NASDAQ AGEN   and Exelixis  Inc    NASDAQ EXEL    Both the stocks carry a Zacks Rank  2  Buy   You can see  Agenus  loss estimates remained stable at  1 17 for 2017 and narrowed from  1 40 to  1 36 for 2018 over the last 30 days  The company delivered a positive earnings surprise in three of the four trailing quarters with an average beat of 4 27  Exelixis  earnings per share estimates remained stable at 26 cents for 2017 and increased from 63 cents to 64 cents for 2018 over the last 30 days  The company delivered positive earnings surprises in all the four trailing quarters with an average beat of 543 59   The company s shares are up 62 5  so far this year Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-11-01,Zacks Investment Research,https://www.investing.com/analysis/sucampo-scmp-beats-on-q3-earnings--revenues-ups-17-view-200257956,200257956
197182,418698,MYL,Momenta s  MNTA  Biosimilar Study Fails  Q3 Loss Narrows ,opinion,"Shares of Momenta Pharmaceuticals Inc    NASDAQ MNTA   were down 12 6  after the company reported disappointing results from a phase I study on M834  which it was conducting with partner Mylan N V    NASDAQ MYL   for the proposed biosimilar of Orencia 
The company also reported a loss of 44 cents per share in the third quarter  narrower than the Zacks Consensus Estimate of 46 cents  The reported loss was  however  wider than the year ago loss of 26 cents Mylan N V  Price and EPS Surprise
 

   Revenues in the quarter came in at  24 1 million and topped the Zacks Consensus Estimate of loss of  23 2 million  However  revenues were down 17 3  from the year ago quarter  
Momenta s stock has decreased 15 1  year to date compared with the  rally of 4 1  

 
Quarter in Detail
Momenta s top line comprises product revenues of  10 9 million earned from Sandoz s sales of Glatopa  a generic version of Copaxone  20 mg   compared with  23 4 million in the year ago quarter  The 53  decrease was primarily due to higher sales deductions  inventory price adjustments owing to Mylan s entry into the Copaxone market along with a deduction of  0 2 million for reimbursing the company s share of Glatopa related legal expenses to Sandoz 
Collaborative research and development revenues came in at  13 2 million  up from  5 8 million in the year ago quarter  The increase was due to a  10 million commercial milestone payment earned in connection with Glatopa 20mg mL  However  the upside in sales was partially offset by less revenues due to the termination of the Baxalta Collaboration Agreement  effective Dec 31  2016 
While  research and development expenses were up to  37 9 million from  31 6 million  general and administrative expenses increased 31  to  20 7 million 
Outlook Updated
Momenta now expects operating expenses  excluding stock based compensation and net of collaborative revenues  in the range of  200  210 million  compared with the previous guidance of  210  230 million in 2017  The guidance also includes approximately  50 million of capital expenditure on M923  Operating expenses in third quarter 2017 are projected around  43  53 million 
Momenta expect to generate revenues of  45 million from Mylan as upfront payment on a quarterly basis 
Pipeline Update
Sandoz s abbreviated New Drug Application  ANDA  for the 40 mg thrice weekly formulation of Copaxone  Glatopa 40mg  was under the FDA review  However  Momenta suffered a setback with the FDA issuing a warning letter to Pfizer Inc    NYSE PFE   in February 2017  which is Sandoz s contracted fill finish manufacturing partner for Glatopa 
Pfizer has submitted a comprehensive response to the observations cited in the warning letter  The ANDA approval is now contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued to Pfizer 
Meanwhile  Momenta continues to progress with its other pipeline candidates  Currently  Momenta s M923  a biosimilar version of AbbVie  Inc   Humira  is being evaluated in a phase III study in patients suffering from moderate to severe chronic plaque psoriasis  Moving ahead  the company plans to submit the candidate for approval to regulatory bodies 
However  Momenta announced that M834 did not meet its primary pharmacokinetic end points in a phase I study to compare the pharmacokinetics  safety and immunogenicity of M834 to Orencia in normal healthy volunteers  Hence  Momenta and partner Mylan will evaluate the next course of action 
Furthermore  Momenta s novel autoimmune portfolio includes  M230  a Selective Immunomodulator of Fc receptors  SIF3  and M281  an anti FcRn monoclonal antibody  Momenta successfully completed a phase I single ascending dose study in healthy volunteers for M281  The multiple ascending dose portion of the study was initiated in January 2017 and completed in August 2017  Top line data is expected in fourth quarter 2017 
Our Take
Momenta s third quarter results were overshadowed by the disappointing results from a phase I study on the proposed biosimilar verison of Orencia  
Momenta has already suffered a blow  We note that Mylan has already won FDA approval for a generic version of Teva Pharmaceuticals   NYSE TEVA   Copaxone 40 mg  Notably  this is the first generic of Copaxone that has been approved 
Since Mylan was one of the first applicants to submit a substantially complete ANDA for glatiramer acetate Injection  40 mg mL  containing a Paragraph IV certification  the company and other first filers may be eligible for 180 days of generic drug exclusivity  On the other hand  Momenta s ANDA approval for Glatopa is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA  resulting in a delay of approval 
Zacks Rank
Momenta currently carries a Zacks Rank  3  Hold   You can see  
More Stock News  Tech Opportunity Worth  386 Billion in 2017
From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future 
Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-11-02,Zacks Investment Research,https://www.investing.com/analysis/momentas-mnta-biosimilar-study-fails-q3-loss-narrows-200257998,200257998
197183,418699,MYL,Will Regeneron Pharma  REGN  Disappoint In Q3 Earnings ,opinion,"Regeneron Pharmaceuticals  Inc    NASDAQ REGN   is scheduled to release third quarter 2017 results on Nov 8  before the opening bell Last quarter  Regeneron Pharma beat earnings expectations by 30 3   The company s performance has been mixed so far  In the last four quarters  it surpassed earnings estimates on two occasions and missed in two  Overall  the company has recorded an average positive earnings surprise of 10 1   Let s see how things are shaping up for this quarter   Regeneron s stock has lost 2 3  year to date compared to the  s decline of 1 2  Factors Influencing This QuarterRegeneron Pharma s key growth driver  Eylea  is likely to continue to contribute to the company s top line growth   Based on a strong first half  the company raised its sales guidance for Eylea   In 2017  Regeneron Pharma expects Eylea net sales to grow around 10   earlier guidance  growth in single digits  in the United States  The Zacks Consensus Estimate for the drug s sales  worldwide basis  is currently  1 4 billion for the quarter We note that Regeneron Pharma has a global development and commercialization agreement with Bayer  DE BAYGN  AG   OTC BAYRY   outside the United States for Eylea  Product revenues from ex U S  Eylea sales are recorded by Bayer Meanwhile  Regeneron Pharma is working on expanding Eylea label into additional indications  While a phase III study  PANORAMA  is evaluating Eylea for the treatment of moderately severe to severe non proliferative diabetic retinopathy in patients without DME  another phase III study  in Japan  is evaluating it for neovascular glaucoma Apart from Eylea  investors will remain focused on the uptake of new drugs   Kevzara and Dupixent  Kevzara  sarilumab   an anti interleukin  IL  6 receptor monoclonal antibody was approved in Canada for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response to or intolerance to one or more biologic or non biologic Disease Modifying Anti Rheumatic Drugs and was approved by the FDA in May 2017  The FDA also approved Dupixent  dupilumab  Injection for the treatment of adults with moderate to severe atopic dermatitis  AD    The initial uptake of the drug is encouraging  The drug was approved in Europe also  The company is also evaluating the drug for treating asthma in adults  LIBERTY ASTHMA QUEST study    A phase III study of Dupixent in pediatric patients  6 11 years of age  with uncontrolled persistent asthma was initiated in second quarter 2017 Hence  focus will be on the company s performance  particularly Eylea and Dupixient uptake during the third quarter earnings call  Investors are also expected to await updates on the company s pipeline Meanwhile  Regeneron Pharma and partner Sanofi   NYSE SNY   are allowed to continue to sell their PCSK9 inhibitor  Praluent  in the United States by the Court of Appeals for the Federal Circuit following a favorable ruling  This bodes well and we expect the management to throw more light on the upside if any  However  sales of the drug have failed to impress so far Earnings WhispersOur proven model does not conclusively show that Regeneron Pharma is likely to beat earnings estimates this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  However  that is not the case here  as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  1 6   This is because both the Most Accurate estimate is  3 99 while the Zacks Consensus Estimate is  3 93  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Regeneron Pharma currently carries a Zacks Rank  4  Sell   Note that  we caution against stocks with a Zacks Rank  4 or 5  Strong Sell  before going into the earnings announcement  especially when the company is seeing negative estimate revisions Regeneron Pharmaceuticals  Inc  Price and EPS Surprise
    Stock That Warrants a LookHere is a health care stock that you may want to consider instead  as our model shows that it has the right combination of elements to post an earnings beat this quarter Mylan N V    NASDAQ MYL   has an Earnings ESP of  3 6  and currently carries a Zacks Rank  2  The company is expected to release third quarter results on Nov 6   You can see  Looking for Stocks with Skyrocketing Upside 
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana 
Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-11-02,Zacks Investment Research,https://www.investing.com/analysis/will-regeneron-pharma-regn-disappoint-in-q3-earnings-200258169,200258169
197184,418700,MYL,Mylan shares jump after pledge to cut cost of its EpiPen injectors ,news,Investing com   Mylan  NASDAQ MYL  shares jumped Thursday after pledge to cut cost of EpiPen injectors Mylan shares were up 3 48  at  44 65 in heavy pre active trade Mylan under heavy political pressure to cut EpiPen cost after six fold rise in several years Pharmaceutical firm to offer  savings card  to cover up to  300 of EpiPen Pak 2 cost This will effectively cut cost of anti allergy injector by 50  ,2016-08-25,Investing.com,https://www.investing.com/news/stock-market-news/mylan-shares-jump-after-pledge-to-cut-cost-of-its-epipen-injectors-422300,422300
197185,418701,MYL,Wall St opens lower ahead of key Yellen speech ,news,Investing com   U S  stocks opened lower early Thursday ahead of Fed chair Yellen s speech Friday Investors opted for caution despite upbeat jobless claims and durable goods orders data Fed member Esther George said it was time to raise U S  rates gradually The DJI was down 0 16  at 09 45 ET  while the S P 500 fell 0 14  The tech heavy Nasdaq composite declined 0 25  Mylan  NASDAQ MYL  rose 4  after succumbing to political pressure to offer discounts on its EpiPen allergy treatment ,2016-08-25,Investing.com,https://www.investing.com/news/stock-market-news/wall-st-opens-lower-ahead-of-key-yellen-speech-422342,422342
197186,418702,MYL,Mylan to launch generic EpiPen auto injector ,news,Investing com   Mylan  NASDAQ MYL  said Monday it will launch generic EpiPen injector Two pack anti allergy injection pack priced at  300  50  discount to Mylan list price Mylan last week introduced  savings cards  to reduce cost of EpiPen brand by 50  That move came after heavy political pressure to make EpiPen cheaper Mylan s shares were up 1 16  in pre market trade at 06 45 ET ,2016-08-29,Investing.com,https://www.investing.com/news/stock-market-news/mylan-to-launch-generic-epipen-auto-injector-422852,422852
197187,418703,MYL,Adamis Pharma down over 11  as Mylan to launch generic EpiPen version ,news,Investing com   Adamis sharply lower Monday after rival Mylan  NASDAQ MYL  to launch cheaper version of treatment  Adamis was down 11 41  at 10 00 ET on turnover of 1 8 mn shares Adamis shares rose 25 3  Friday on bets Adamis anti allergy treatment could rival EpiPen  FDA in June rejected approval of Adamis treatment  Firm still working for approval Mylan Monday said its generic version of EpiPen would be half the price of branded product Myland was under heavy political pressure to lower the cost of its treatment ,2016-08-29,Investing.com,https://www.investing.com/news/stock-market-news/adamis-pharma-down-over-11-as-mylan-to-launch-generic-epipen-version-422879,422879
197188,418704,MYL,House Committee requests EpiPen documents from Mylan,news," Reuters    U S  representatives Jason Chaffetz and Elijah Cummings of the House Committee on Oversight and Government Reform sent a letter to Mylan  NASDAQ MYL  NV Chief Executive Heather Bresch on Monday asking for documents and communications related to the fast increasing price of allergy auto injector EpiPens  Mylan said earlier it would launch the first generic version of EpiPen for  300  half the price of the branded product  in the drugmaker s second step in less than a week to counter a backlash over the product s steep price  
Chaffetz and Cummings  the committee s chairman and ranking member respectively  requested documents related to Mylan s revenue from sales of EpiPens since 2007  manufacturing costs and the amount the company receives from federal health care programs ",2016-08-29,Reuters,https://www.investing.com/news/politics-news/house-committee-requests-epipen-documents-from-mylan-422943,422943
197189,418705,MYL,EpiPen maker Mylan hires banks for debut euro bond,news,"By Michael Turner LONDON  IFR    Mylan has hired banks for a euro denominated multi tranche debut euro bond  a day after the under fire drugmaker announced it would launch a generic version of its EpiPen allergy injection at half the price   The company has mandated  Deutsche Bank   DE DBKGn    Citigroup   NYSE C   ING and JP Morgan to host a series of investor meetings in Europe from September 7 9  The company has been under pressure from US lawmakers and presidential candidate Hillary Clinton for increasing the price of a two cartridge EpiPen set from around US 100 in 2008 to US 600 today   That s outrageous   Clinton said in a statement on her website   It s just the latest troubling example of a company taking advantage of its consumers   Mylan bosses have sought to deflect some of the criticism by announcing on Monday the impending release of a generic version of the drug  which will be sold at US 300  nL3N1BA37U  The Reg S benchmark transaction will be issued by Mylan NV and guaranteed by  Mylan Inc   NASDAQ MYL   While this will be Mylan NV s first foray into the euro bond market  the issuer has US 11 43bn of debt outstanding  almost all in US dollars  according to Thomson Reuters data   
Mylan is rated Baa3 by Moody s and BBB  by S P and Fitch  all with stable outlooks ",2016-08-30,Reuters,https://www.investing.com/news/stock-market-news/epipen-maker-mylan-hires-banks-for-debut-euro-bond-423106,423106
197190,418706,MYL,Senators press Mylan on  exorbitantly expensive  EpiPen,news,By Diane Bartz WASHINGTON  Reuters    Democrat Elizabeth Warren and 19 other U S  senators voiced concern to the chief executive of Mylan NV  O MYL  about the high cost of its EpiPen on Tuesday  calling the device used in the case of life threatening allergies  exorbitantly expensive   Mylan has been under fire for steadily raising the price of the device from about  100 in 2008 to about  600 currently  In a letter to Mylan CEO Heather Bresch  the daughter of Senator Joe Manchin of West Virginia  the lawmakers asked the company to spell out the company s programs to provide some people with lower cost EpiPens  Such discount programs are often an  industry tactic to keep costs high through a complex shell game   the letter said   Insurance companies  the government and employers still bear the burden of these excessive prices  In turn  those costs are eventually passed on to consumers in the form of higher premiums   the senators wrote  Mylan said this week it would launch the first generic version of its allergy auto injector EpiPen for  300  half the price of the branded product  the drugmaker s second step in less than a week to counter the backlash over the product s steep price  It also reduced the out of pocket costs of EpiPen for some patients last week  EpiPen has a 94 percent market share for auto injector devices  which jab a dose of the drug epinephrine into the thigh to counter dangerous allergic reactions such as to peanuts  other foods and bee stings  Asked about the letter  Mylan spokeswoman Lauren Kashtan said in an email statement   We have acknowledged receipt of letters from congressional offices and intend to respond to them   Mylan has defended EpiPen s high price  saying it spent hundreds of millions of dollars to improve the product since acquiring it in 2007  It has also said it recoups less than half the list price for EpiPens  In their letter  the lawmakers asked Mylan how much insurers paid for the EpiPen in 2009 and how much they pay now  They also asked how many EpiPens Mylan provided to low income  uninsured consumers and how many schools purchased EpiPens versus how many received them for free  In addition to Warren  other signatories included Senators Patrick Leahy of Vermont  the top Democrat on the Judiciary Committee  Barbara Boxer  a California Democrat  Dick Durbin  an Illinois Democrat  Jack Reed and Sheldon Whitehouse  both Democrats from Rhode Island and Sherrod Brown  an Ohio Democrat ,2016-08-30,Reuters,https://www.investing.com/news/politics-news/senators-press-mylan-on-'exorbitantly-expensive'-epipen-423237,423237
197191,418707,MYL,Clinton offers plan to curb  unjustified  price hikes on life saving drugs,news,"By Amanda Becker and Ransdell Pierson WASHINGTON NEW YORK  Reuters    Hillary Clinton said on Friday that if elected to the White House she would create an oversight panel to protect U S  consumers from large price hikes on long available  lifesaving drugs and to import alternative treatments if necessary  adding to her pledges to rein in overall drug prices  Clinton  the Democratic presidential candidate  would seek to give the panel an  aggressive new set of enforcement tools   including the ability to levy fines and impose penalties on manufacturers when there has been an  unjustified  outlier price increase  on a long available or generic drug  her campaign said   Over the past year  we ve seen far too many examples of drug companies raising prices excessively for long standing  life saving treatments with little or no new innovation or R D   Clinton said in a statement  If Clinton defeats Republican rival Donald Trump in the Nov  8 election  she would need the support of the U S  Congress to implement key measures of her proposal  which follows a broader plan to rein in drug prices that she announced a year ago  Even though her latest plan would likely affect a small number of companies  it could be difficult to get Republican lawmakers on board  Morningstar analyst Damien Conover said  adding that a  Republican Congress would push back hard on this   Clinton s campaign cited Turing Pharmaceuticals LLC s raising the price of its AIDS drug Daraprim  pyrimethamine  and Mylan  NASDAQ MYL  NV s repeated steep price increases on EpiPen for severe allergy sufferers as  troubling  examples of price hikes that have attracted bipartisan congressional scrutiny  Conover said Clinton s plan to address unjustified price hikes is less of a concern to the drug industry than her pledge last year to reduce drug prices overall  Drugmakers have said that lowering or limiting drug prices would hamper their ability to invest in research and lead to fewer new therapies  The ARCA Pharmaceutical Index of large U S  and European drugmakers rose 0 30 percent on Friday  in line with gains for the broad stock market  Shares of Mylan fell 4 6 percent to  40 00 on the Nasdaq  The Nasdaq biotech index slipped 0 40 percent  The decline was slight compared to the more than 4 7 percent drop in the index seen on Sept  21  2015  when Clinton blasted  price gouging  in the specialty drug market on Twitter  responding to reports that Turing had acquired Daraprim  an older antibiotic  and then hiked its price by 5 000 percent   Soon afterward  Clinton presented a general plan to lower prescription drug costs  including allowing Medicare to negotiate drug prices and demand higher rebates for prescription drugs   Her plan would also include caps on monthly and annual out of pocket costs for patients with chronic or serious health conditions  It aims to prohibit manufacturers from paying generic drugmakers to delay launching their cheaper products  and would eliminate corporate writeoffs for direct to consumer pharmaceutical advertising  A  BOLD IDEA  Dr  Peter Bach  the director of a nonpartisan health policy research group at New York s Memorial Sloan Kettering Cancer Center  said Clinton s announcement on Friday was a  flag  for drug manufacturers that her administration would notice and respond to steep price hikes   It s a response to the broader industry phenomenon of generating added profits by raising the price of drugs for which there is no competition   Bach said  saying the campaign was focusing on a  sub category  of manufacturers that had not invested heavily in developing a drug  Bach said he was contacted by the Clinton campaign about his work on drug pricing but had not advised the campaign in a formal capacity  The oversight panel would be made up of representatives from existing public health and consumer protection agencies who convene to examine the scope of a drug price increase  the manufacturer s production cost and the treatment s relative value to patients and public health  Clinton s campaign said  Terry Haines  head of political analysis for Evercore ISI  said Clinton s proposed panel had little hope of getting through Congress   But Clinton  if elected  might be able to achieve price reform via changes to Medicare s prescription drug benefit  known as Medicare Part D  if she works with Congress to reform the Affordable Care Act  popularly known as Obamacare  Haines said  In that event  Haines said shares of pharmaceutical and biotech companies could come  under sustained headline risk in 2017 as ACA reforms are discussed    In cases where a price hike determined to be unjustified is accompanied by insufficient market competition  Clinton s administration would intervene to purchase alternative drugs from comparably regulated markets or assist manufacturers in bringing the product to market in the United States  Dr  Aaron Kesselheim  an associate professor at Harvard Medical School  called it a  bold idea  to get the federal government  involved in helping stabilizing some of these generic drug markets   Until recently  there was a lengthy wait for generic drug approval by the U S  Food and Drug Administration  Although the wait time has shortened  there is often not enough consistent demand for manufacturers to enter the U S  market  Kesselheim said   Having the government get involved as a long term purchaser of these products creates a stockpile to stabilize the market   he said  
Kesselheim has testified before Congress about high cost generic and long available drugs and spoke to Clinton s campaign about his research as it developed its proposals ",2016-09-02,Reuters,https://www.investing.com/news/stock-market-news/clinton-offers-plan-to-curb-'unjustified'-price-hikes-on-life-saving-drugs-423918,423918
197198,418714,MYL,3 Stocks To Watch Today  MYL  HFC  MRO,opinion,"Long Mylan  NASDAQ MYL 

Long HollyFrontier Corporation  NYSE HFC 

Short Marathon Oil  NYSE MRO ",2017-10-29,Ryan Mallory,https://www.investing.com/analysis/swing-trade-myl-hfc-mro-200221637,200221637
197199,418715,MYL,Is A Turnaround In Store For Teva  TEVA  In Q3 Earnings ,opinion,Teva Pharmaceutical Industries Ltd    NYSE TEVA   will be reporting third quarter 2017 earnings on Nov 2  before the market opens  Last quarter  the company delivered a negative earnings surprise of 8 11  This generic drug maker s shares have lost 63 3  so far this year  while the witnessed a decrease of 28 7  Teva s earnings have surpassed expectations in only one of the last four quarters  met the same in one and missed expectations in the remaining two  resulting in an average negative surprise of 1 66  Let s see how things are shaping up for this announcement Factors to ConsiderA challenging environment in the U S  generics business and continued deterioration in Venezuela have been hurting Teva s sales The U S  generics industry is facing significant competitive and pricing pressure  which have been affecting the company s generic revenues  An increase in FDA generic drug approvals and ongoing customer consolidation are resulting in additional competitive pressure in the industry The challenges in the U S  generics market are expected to hurt sales in the third quarter as well  In fact  at the Q2 conference call  management had said that the drug price erosion will accelerate in the second half of this year  Meanwhile  delay in the launch of some new generic drugs and increased competition for some others are also expected to hurt segment sales Meanwhile  in the Specialty segment  loss of exclusivity of key drugs like Copaxone  Azilect and Nuvigil will hurt sales  Sales of blockbuster multiple sclerosis  MS  treatment Copaxone are likely to erode due to lower volumes of the 20 mg formulation  which is facing generic competition  Glatopa  a generic version of Copaxone 20 mg  has been on the market since June 2015 In fact  earlier this month  in a major blow to Teva  Mylan   NASDAQ MYL   launched its generic version of the 40 mg formulation  much earlier than expected  Mylan also launched a second generic version of Copaxone 20 mg formulation  once daily  Though these generic launches will not hurt Teva s third quarter sales and profits  Teva estimates that it will have a negative impact of at least 25 cents per share on fourth quarter earnings Meanwhile  low margin Anda distribution business and low margins in the Generic Medicines segment may hurt gross margins in the quarter Also  last month  Teva announced the appointment of K re Schultz as president and chief executive officer  CEO   thus ending its more than six month long search for a permanent CEO  Schultz is likely to address Teva s first conference call  We expect him to discuss his strategies to help the company regain lost ground Earnings WhispersOur proven model does not conclusively show that Teva is likely to beat on earnings this quarter  This is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  Its Earnings ESP is  2 64  as the Most Accurate estimate stands at  1 03 per share while the Zacks Consensus Estimate is pegged higher at  1 06 per share  You can uncover the best stocks to buy or sell before they re reported with our  Zacks Rank  Teva has a Zacks Rank  5  Strong Sell   We caution against stocks with a Zacks Rank  4  Sell  or  5 going into an earnings announcement  especially when the company is seeing negative estimate revisions Stocks to ConsiderSome stocks in the biotech pharma sector that have a positive Earnings ESP and a favorable Zacks Rank are Agenus Inc    NASDAQ AGEN    scheduled to release results on Nov 7  has an Earnings ESP of   8 11  and a Zacks Rank  2  You can see  Clovis Oncology  Inc    NASDAQ CLVS    scheduled to release results on Nov 1  has an Earnings ESP of  2 01  and a Zacks Rank  2 Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ,2017-10-29,Zacks Investment Research,https://www.investing.com/analysis/is-a-turnaround-in-store-for-teva-teva-in-q3-earnings-200257097,200257097
197200,418716,MYL,Senators introduce bill aimed at getting generic drugs to market,news,"By Diane Bartz WASHINGTON  Reuters    Four U S  senators   two Democrats and two Republicans   introduced a bill on Tuesday aimed at preventing big pharmaceutical companies from using safety rules to prevent generic drugs from coming to market  Senators Charles Grassley  chair of the Judiciary Committee  and Patrick Leahy  the top Democrat  are sponsors of the bill along with Senators Mike Lee and Amy Klobuchar  the chair of the antitrust subcommittee and top Democrat  respectively  The Food and Drug Administration  which ensures the safety of the country s food and drug supply  has a risk evaluation and mitigation strategy program  called REMS  which is designed to ensure that the riskiest drugs are dispensed safely  But there have been complaints that the program has been misused by brand name drug companies to prevent generic manufacturers from getting the drug samples needed to market cheaper versions  Generic companies also complain their drugs are not allowed to share a safety protocol  making it difficult to come to market  The bill would allow a generic manufacturer who faces either of these situations to file a lawsuit to force access to a sample or force negotiations for a safety protocol   Balancing the cost of developing lifesaving medications with the need to make available affordable prescription drugs to consumers has always been a difficult task  It s a consistent topic at my town meetings   Grassley said in a statement   Unfortunately  we re seeing some brand name drug companies engage in anti competitive tactics that delay entry of lower cost generic drugs into the market  This bill takes important steps to ensure that our laws are not frustrated   There is a similar bill in the House of Representatives which addresses the same issue but uses a different strategy  For example  it requires the generic company seeking a REMS drug to get FDA authorization to obtain the sample  In one of the REMS disputes which is public  Mylan  NASDAQ MYL  Pharmaceuticals filed a lawsuit in 2014 against  Celgene Corp   NASDAQ CELG   accusing it of using REMS to prevent generic copies of Thalomid and Revlimid to market  The Senate Judiciary Committee s antitrust panel will hold a hearing on its bill on June 21  The Pharmaceutical Research and Manufacturers of America  or PhRMA  which counts major drugmakers among its members  said it had no immediate comment  The Generic Pharmaceutical Association was pleased to see the bill introduced  
 It is worth noting and recognizing recent efforts by representatives in the branded industry to highlight the valuable role generic medicines play in driving healthcare system savings   said Chip Davis  GPhA s president   Continued use of these anticompetitive practices by certain manufacturers drives the exact opposite outcome  ",2016-06-14,Reuters,https://www.investing.com/news/politics-news/senators-introduce-bill-aimed-at-getting-generic-drugs-to-market-408423,408423
197201,418717,MYL,Roche CEO  sleeps better  as risk to drugmaker s growth recedes,news,"By John Miller and Ben Hirschler LONDON  Reuters    Roche  S ROG  is increasingly confident it will continue to lift sales and profit even as cut rate copies of the Swiss drugmaker s older cancer medicines start to grab business next year  its chief executive said on Wednesday  Big wins for three new drugs in recent months have helped to offset what Roche s Severin Schwan acknowledges as a serious threat from so called biosimilars   In terms of growth  I am now at the point where I sleep much better   Schwan told Reuters on a visit to London  In February the company won U S  Food and Drug Administration  FDA  breakthrough status for new multiple sclerosis drug Ocrevus   That was followed in May by U S  approval of immuno oncology drug Tecentriq for bladder cancer  with an expected sign off for lung cancer waiting in the wings  Then came a surprise early announcement that Roche s blood cancer drug Gazyva worked better than an older drug  Together  these developments have boosted Schwan s optimism that Roche can more than replace income lost as rivals such as  Novartis   S NOVN  and Mylan  O MYL  begin selling biosimilar copies of older Roche drugs in the second half of 2017  REDUCED RISK  I would have been much more cautious 12 or 18 months ago  but the situation has been substantially de risked since then   Schwan said  Roche has said that sales will increase by a low to mid single digit percentage this year  with profit outpacing revenue growth  but it has not given any longer term forecasts  Prospects could be enhanced further by positive outcomes in trials testing other potential blockbuster drugs  including ACE910  for haemophilia  and lampalizumab  for sight loss  Roche is also awaiting results of the Aphinity trial that pairs Perjeta with Herceptin in breast cancer patients and could triple the commercial opportunity for Perjeta   People are very optimistic about it    actually  so are we   Schwan said   Roche s three established cancer blockbusters Rituxan  Herceptin and Avastin  which account for annual sales of nearly 20 billion Swiss francs   21 billion   all face biosimilar competition by the end of the decade   All are antibody drugs that have proved to be huge commercial hits  which is why companies such as Novartis and Mylan are seeking to copy them  The first biosimilar antibody to come to market    a copy of arthritis drug Remicade that is now on sale in Europe    has gained market share faster than expected  knocking sales of the original product from Merck  N MRK  by more than 40 percent in two years  DISCOUNT CONCERNS  Discounting could cut even deeper  however  Novartis CEO Joe Jimenez has forecast price cuts as high as 75 percent on copied products  Despite such projections  Schwan still thinks discounts are likely to be between 30 percent and 60 percent    It has not changed our view   he said of the Remicade experience  On the acquisitions front  Roche will continue to make smaller deals to add early stage drugs to its portfolio  Schwan said  but his view that the biotech market remains overpriced means that larger transactions are unlikely    It is still overvalued   he said  adding that recent corrections have not brought valuations back to fundamental levels  Other companies may need to go on a buying spree to fill depleted pipelines  but Schwan rates the chances of Roche doing a big deal as  very low    Uncertainty over biosimilars has cast a cloud over 48 year old Schwan s eight years at the helm  but he intends to stick around for a while yet if the board plays along  His time at the top is lengthy by the standards of the Swiss group s peers but hardly an anomaly at Roche  which has had only seven chief executives in 120 years   
 It s not up to me to decide how long I can do this job  but the one thing you see at Roche is very long tenures at the top   he said ",2016-06-22,Reuters,https://www.investing.com/news/stock-market-news/roche-ceo-'sleeps-better'-as-risk-to-drugmaker's-growth-recedes-409967,409967
197202,418718,MYL,Israel stocks lower at close of trade  TA 25 down 0 04 ,news,"Investing com   Israel stocks were lower after the close on Thursday  as losses in the Communication  Oil   Gas and Real Estate sectors led shares lower 
At the close in Tel Aviv  the TA 25 declined 0 04  
The best performers of the session on the TA 25 were Mylan NV  TA MYL   which rose 1 46  or 260 00 points to trade at 18050 00 at the close  Meanwhile  Teva  TA TEVA  added 1 09  or 230 points to end at 21270 and First  International  Bank of Israel  TA FTIN  was up 0 95  or 46 points to 4888 in late trade 
The worst performers of the session were Bezeq  TA BEZQ   which fell 1 09  or 8 4 points to trade at 762 0 at the close  Poalim  TA POLI  declined 0 85  or 17 points to end at 1988 and  Ormat Technologies   TA ORA  was down 0 75  or 130 points to 17100 
Rising stocks outnumbered declining ones on the Tel Aviv Stock Exchange by 166 to 161 and 111 ended unchanged 
Crude oil for September delivery was down 0 50  or 0 23 to  45 52 a barrel  Elsewhere in commodities trading  Brent oil for delivery in September fell 0 30  or 0 14 to hit  47 03 a barrel  while the August Gold contract rose 0 24  or 3 20 to trade at  1322 50 a troy ounce 
USD ILS was down 0 22  to 3 8478  while EUR ILS fell 0 45  to 4 2299 
The US Dollar Index was unchanged 0 00  at 97 16 ",2016-07-21,Investing.com,https://www.investing.com/news/stock-market-news/israel-stocks-lower-at-close-of-trade;-ta-25-down-0.04-415790,415790
197203,418719,MYL,U S  lawmakers press Mylan on EpiPen price increases,news,"WASHINGTON  Reuters    Two senior lawmakers on the U S  Senate s Judiciary Committee on Monday pushed for information regarding sharp price increases for EpiPens  drug filled injectable devices used by people to counter potentially deadly allergic reactions 
Senator Chuck Grassley  chairman of the Senate Judiciary Committee  wrote Mylan  NASDAQ MYL  Chief Executive Heather Bresch on Monday to ask how Mylan determined the price of EpiPens and what changes had been made to the product to account for the higher price 
The top Democrat on the committee s antitrust subcommittee  Senator Amy Klobuchar  urged the Federal Trade Commission on Monday to investigate the prices  citing news reports showing that the price of a pack of two EpiPens had gone from  100 in 2008 to  500 this year  Mylan acquired the product in 2007 
 Although the antitrust laws do not prohibit price gouging  regardless of how unseemly it may be  they do prohibit the use of unreasonable restraints of trade to facilitate or protect a price increase   wrote Klobuchar  a Minnesota Democrat who said her daughter relies on an EpiPen 
 The FTC should investigate whether Mylan Pharmaceuticals engaged in activity  such as using incentives or exclusionary contracts with insurers  distributors  or pharmacies  to deny an alternative product access to the market  
An EpiPen injects a pre measured dose of epinephrine  adrenaline  that people use if they are having a dangerous allergic reaction 
The FTC did not say whether an investigation was under way   The commission takes seriously its obligation to take action where pharmaceutical companies have violated the antitrust laws   a spokesman said 
Mylan did not immediately comment on the letters but noted in an email that nearly 80 percent of people with commercial insurance who use a savings card can get the medicine for free 
 With changes in the healthcare insurance landscape  an increasing number of people and families are enrolled in high deductible health plans  and deductible amounts continue to rise  This shift has presented new challenges for consumers  and they are bearing more of the cost   Mylan also said 
The FTC opened a probe into Turing Pharmaceuticals for possible antitrust violations in connection with the company s decision to sharply raise the price of a life saving drug  Turing had raised the price of Daraprim to  750 a tablet from  13 50 ",2016-08-22,Reuters,https://www.investing.com/news/politics-news/u.s.-lawmakers-press-mylan-on-epipen-price-increases-421722,421722
197204,418720,MYL,Drug price hikes can damage company reputations  White House,news,WASHINGTON  Reuters    The White House on Wednesday said pharmaceutical firms risked damaging their reputations with big price hikes  but it sidestepped commenting directly on Mylan  NASDAQ MYL  NV s decision to raise the price of its severe allergy treatment drug EpiPen   I m obviously not going to make specific comments to specifically second guess the pricing strategy     of one private enterprise   White House spokesman Josh Earnest said at a news briefing   I will observe  however  that pharmaceutical companies that often try to portray themselves as the inventors of life saving medication often do real damage to their reputation by being greedy and jacking up prices   he said ,2016-08-24,Reuters,https://www.investing.com/news/politics-news/drug-price-hikes-can-damage-company-reputations:-white-house-422147,422147
197209,418725,MYL,Stock Market Is On A Rampage,opinion,"This stock market is on a rampage  The VIX is hammered into single digits  and the SPY  NYSE SPY  not only has been sailing higher for the past 20 months  it has even escaped its intermediate term channel  The bulls are  without a doubt  running wild 

For those of you with a little contrarian blood left pumping in your veins  you might consider shorting Mylan  NASDAQ MYL   now that the stock has surged following FDA approval of one of its drugs  We re banging right up against a trendline as well as overhead supply 

As for the small caps     the bane of my existence for the past five weeks     it has ripped over 12  higher since eclipse day  although it s showing just a touch of weakness right now  My goodness  a red bar     someone call the authorities ",2017-10-05,Tim Knight,https://www.investing.com/analysis/escape-velocity-200217068,200217068
197214,418730,MYL,Mylan CFO John Sheehan announces intentions to retire in April,news,"Investing com     Mylan Inc   O MYL  chief financial officer John Sheehan announced on Friday that he will retire from the company  effective April 1  
Sheehan  who joined the third largest pharmaceutical company in the U S  in 2010  has led the company s global finance  financial planning and analysis  treasury  investor relations and tax functions over the last six years  Mylan will immediately begin a search for Sheehan s successor  the company said Friday  
 John has served with distinction as Mylan s CFO for the past six years  contributing significantly to Mylan s success during this time and helping to ensure that we delivered consistently strong financial performance   Mylan executive chairman Robert Coury said in a statement   Importantly  John has demonstrated all of the qualities that make Mylan so special  dedication to our mission  passionate leadership and an unwavering commitment to doing what is right  I am extremely grateful to John for his service to Mylan and for helping to position the company so well for the future  
Before coming to Mylan  Sheehan spent two and a half years at Delphi Automotive  LLP in Detroit  where he oversaw all aspects of the company s global financing operations as its chief financial officer  Sheehan also spearheaded a comprehensive restructuring plan at the major automotive supplier and spent time as the company s chief accounting officer and controller  Sheehan  a former partner at KPMG  received a bachelor s degree in accounting from St  Bonaventure University   
 I am very grateful for the opportunity to have served as CFO of Mylan during such an exciting period of growth and expansion for the company   Sheehan said   This has been the most professionally rewarding experience of my career and I am very proud of all that Mylan has accomplished  I am confident that the talented and dedicated team here will continue to drive strong growth and shareholder value going forward  and I look forward to handing the reins over to my successor  
After months of intense speculation  Mylan failed in its  26 billion hostile takeover bid of Dublin based  Perrigo Co   N PRGO  in early November  Mylan must wait until at least November before it makes its next attempt to acquire the biotech company  
Shares in Mylan inched up 0 08 or 0 16  to 49 50 in after hours trading ",2016-01-08,Investing.com,https://www.investing.com/news/stock-market-news/mylan-cfo-john-sheehan-announces-intentions-to-retire-in-april-379338,379338
197218,418734,MYL,S P 500 Futures   ES Up Side Stop Run And New All Time Highs ,opinion,"Yesterday  the S P 500 futures  ESU17 CME  started the day with another narrow  low volume Globex session  On the 8 30 CT futures open the ES trade 2474 25  and then down ticked to an early low of 2472 50  just below the vwap  At 10 11 40 I put this out 

TRADINGDATA2   driley  The ES and NQ have been back and filling  There are a lot of buy stops in the ES above 2478 up to 2483  2485  

At 11 04 the ES shot straight up to 2483 00  After a few downticks the ES rallie up to 2485 25  taking out the the stops I posted  and then the next move was up to 2488 50  The Russell 2000  RTYU17 CME  had been outperforming all day also  it was up  0 85   while the ES was up  0 40   and the NQ was up 0 50  
After the 2488 50 high  the ES get hit by a few small sell programs  pushing the future back down under the vwap to 2477 75 around at around 12 40 
After some sideways price action and three failed attempts to hold above the vwap  the ES started selling off late in the day when the MiM started showing small for sale  At 2 30 CT the ES traded 2470 50 as the MiM was showing  160 million for sale  After the 2470 50 low  the ES up ticked  and then made another new low at at 2468 50  exactly 20 handles off the high  The ES then made another new low at 2467 50  and traded up to 2472 25  as the MiM  flipped  to  125 million to buy  The actual NYSE MOC ended up buy  500 million 
In the end it was a case of running the buy stops early and the sell stops late  The algos had a field day 
August September Weakness Could be a Positive for the Market
From Stock Trader s Almanac 
Over the last 30 years  1987 to 2016  August and September combined have been the worst two consecutive months of the year for DJIA  S P 500 and NASDAQ  August ranks dead last while September has been second worst  This one two combo has resulted in average losses of 0 2  by NASDAQ to 1 8  by DJIA  S P 500 average decline has been 1 3   As recently as 2015 the period was hit with a sizable pullback  In many years  this weakness proved to have been a great buying opportunity 
In the following table  August September performance by DJIA  S P 500 and NASDAQ has been ranked from strongest to weakest with subsequent fourth performance  In years when August and September combined for a net loss  fourth quarter average performance more than doubled for DJIA and S P 500 while the frequency of fourth quarter gains also improved  Of the 14 down August September periods suffered by S P 500  just one subsequent fourth quarter was also down  2008 

Our  currently has the Almanac Investor Stock and ETF Portfolios in a defensive posture with a mixture of long  short and defensive positions along with some cash  Well chosen defensive positions in healthcare  utilities and bonds have ensured the portfolios have not fallen significantly behind the major indexes during their grind modestly higher the past few months while still being well aligned to survive any potentially weakness lurking ahead  Our Seasonal MACD Buy Signal will confirm when it is safe to be more aggressive sometime after October 1  well ahead of any fourth quarter or year end rally 
While You Were Sleeping

Overnight  stocks traded lower across the board  as tension continues to build with North Korea  As of 6 45am CT  the last print in the S P 500 futures is 2463 00  down  9 75 handles  with 250k contracts traded 
In Asia  7 out of 11 markets closed lower  Shanghai  0 19    and in Europe 11 out of 12 markets are trading lower this morning  FTSE  0 81   
Today s economic calendar includes MBA Mortgage Applications  7 00 AM ET   Productivity and Costs  8 30 AM ET   Wholesale Trade  10 00 AM ET   EIA Petroleum Status Report  10 30 AM ET   Chicago Fed s Charles Evans Speaks  1 00 PM ET   and a 10 Year Note Auction  1 00 PM ET  
Earnings  Mylan  NASDAQ MYL   Office Depot  Scripps Networks  Starwood Property Trust  Sun Life  Tribune  Twenty First Century Fox  US Foods 
Time For A Pull Back
Our View  One of the things the markets have done is overlook a lot of the geopolitical risk  but how long can that go on  The North Korea headline may have had something to do with the late weakness  but how much is hard to say  After running all the stops I have been talking about  and the 2488 50 high  I think a short term top could be in  Mondays total volume was only 580 000  and yesterday s was 1 35 million  that s a big increase 
So  in a world of  what goes up must come down   we want to see how the markets act  but our view is to sell the rallies  2488 50 could be it for now 
PitBull  CLU osc 0 16 turns up on a close above 50 15  ESU osc 4 14 turns down on a close below 2469 46  VIX osc 3  1 turns down on a close below 10 05 


In Asia 7 out of 11 markets closed lower  Shanghai Comp  0 19   Hang Seng  0 35   Nikkei  1 29 
In Europe 11 out of 12 markets are trading lower  CAC  1 68   DAX  1 26   FTSE  0 81 
Fair Value  S P  2 55  NASDAQ  1 70  Dow  38 70
Total Volume  1 3mil ESU  and 860 SPU traded in the pit",2017-08-10,Danny Riley,https://www.investing.com/analysis/sp-500-futures-es-up-side-stop-run-and-new-alltime-highs-200206426,200206426
197219,418735,MYL,Falling Earnings Estimates Signal Weakness Ahead For Mylan  MYL ,opinion,Similar to wise buying decisions  exiting certain underperformers at the right time helps maximize portfolio returns  Selling off losers can be difficult  but if both the share price and estimates are falling  it could be time to get rid of the security before more losses hit your portfolio One such stock that you may want to consider dropping is Mylan N V    NASDAQ MYL    which has witnessed a significant price decline in the past four weeks  and it has seen negative earnings estimate revisions for the current quarter and the current year  A Zacks Rank  5  Strong Sell  further confirms weakness in MYL A key reason for this move has been the negative trend in earnings estimate revisions  For the full year  we have seen six estimates moving down in the past 30 days  compared with no upward revisions  This trend has caused the consensus estimate to trend lower  going from  5 24 a share a month ago to its current level of  4 56 Also  for the current quarter  Mylan has seen five downward estimate revisions versus no revisions in the opposite direction  dragging the consensus estimate down to  1 20 a share from  1 45 over the past 30 days   The stock also has seen some pretty dismal trading lately  as the share price has dropped 23 5  in the past month Mylan N V  Price and Consensus    So it may not be a good decision to keep this stock in your portfolio anymore  at least if you don t have a long time horizon to wait If you are still interested in the Health Care sector  you may instead consider a better ranked stock   Gilead Sciences  Inc    NASDAQ GILD    The stock currently holds a Zacks Rank  2  Buy  and may be a better selection at this time  You can see  The Hottest Tech Mega Trend of AllLast year  it generated  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for regular investors who make the right trades early ,2017-08-16,Zacks Investment Research,https://www.investing.com/analysis/falling-earnings-estimates-signal-weakness-ahead-for-mylan-myl-200207573,200207573
197220,418736,MYL,Why Did Mylan  MYL  Stock Surge Today ,opinion,"Shares of much maligned drugmaker Mylan NV   NASDAQ MYL   climbed on Thursday after the U S  Justice Department announced that it officially reached a settlement with the company regarding its EpiPen lawsuit 
The U S  Justice Department  that Mylan will have to pay  465 million in settlement fees to Medicaid programs in all 50 states to end the nearly year long lawsuit that accused the pharmaceutical company of knowingly misclassifying its EpiPen product as a generic in order to avoid Medicaid rebate payments 
According to the lawsuit  Mylan knowingly bypassed the Medicaid Drug Rebate Program  which was put in place to prevent drug makers from price gouging brand name  single source drugs  The law forces pharmaceutical companies that have complete control over a drug to pay much higher rebate prices  Generic drugs that come from more than one manufacturer pay much lower rebate fees 
The lawsuit states that Mylan simply classified its EpiPen product  which injects epinephrine to help treat emergency allergic reactions  as a generic when there weren t FDA approved drugs equivalent to EpiPen 
The real kicker is that the lawsuit contended that Mylan upped the price of its EpiPen product by roughly 400  from 2010 to 2016  charging as much as  600 for the treatment 
Mylan previously confirmed that the company had reached a settlement with the Justice Department nearly 10 months ago  but the U S  Attorney s Office in Massachusetts did not make it official until Thursday 
 Mylan misclassified its brand name drug  EpiPen  to profit at the expense of the Medicaid program   U S  Attorney William D  Weinreb said in a statement   We will continue to root out fraud and abuse to protect the integrity of Medicaid and ensure a level playing field for pharmaceutical companies  
The pharmaceutical company was also forced into a five year corporate integrity agreement that will see Mylan under much heavier scrutiny  However  the EpiPen maker did not confess any wrongdoing as part of the settlement 
 As we said when we announced the settlement last year  bringing closure to this matter is the right course of action for Mylan and our stakeholders to allow us to move forward   Mylan CEO Heather Bresch said in a statement   Over the course of the last year  we have taken significant steps to enhance access to epinephrine auto injectors  including bringing a solution to the fast changing healthcare landscape in the U S  by launching an authorized generic version at less than half the wholesale acquisition cost of the brand and meaningfully expanding our patient access programs  
Members of both parties of Congress have said that the  465 million  and lenient 
Shares of Mylan rose as much as 2  on Thursday morning but the stock still sits only slightly above its 52 week low at  30 95 a share  Mylan is currently a Zacks Rank  5  Strong Sell   but it seems that at least some investors and the company are relieved to have this lawsuit officially behind them  
One Simple Trading IdeaSince 1988  the Zacks system has more than doubled the S P 500 with an average gain of  25  per year  With compounding  rebalancing  and exclusive of fees  it can turn thousands into millions of dollars 
This proven stock picking system is grounded on a single big idea that can be fortune shaping and life changing  You can apply it to your portfolio starting today ",2017-08-17,Zacks Investment Research,https://www.investing.com/analysis/why-did-mylan-myl-stock-surge-today-200207957,200207957
197221,418737,MYL,Mylan Finalizes Settlement Agreement With DOJ For  465M,opinion,"Mylan N V    NASDAQ MYL   recently announced that its subsidiaries  Mylan Inc  and Mylan Specialty L P   have signed an agreement with the U S  Department of Justice  DOJ  and two other relators  The agreement finalizes the Medicaid drug rebate settlement worth  465 million  announced in Oct 2017   
The settlement resolves claims which relates to the classification of EpiPen Auto Injector and EpiPen Jr Auto Injector for purposes of the Medicaid Drug Rebate Program 
DOJ wanted to ascertain whether EpiPen products were properly classified with the Centers for Medicare and Medicaid Services as a non innovator drug under the applicable definition in the Medicaid Rebate statute  The drugs were subjected to the formula which is used to calculate rebates to Medicaid for such drugs 
We note that Mylan has been under immense pressure since Aug 2016 when the company came under the spotlight for price increase of EpiPen since its acquisition of the drug in 2007  drawing immense criticism from lawmakers  consumers and the common people alike  Further  Mylan made it to the headlines for wrongly classifying EpiPen as a generic product in the Medicaid Drug Rebate Program  The misclassification implied that Mylan has been vastly underpaying rebates to Medicaid for the drug for a long time than it would have if the drug was classified as a branded one 
EpiPen Auto Injector was classified as a non innovator drug with CMS before Mylan acquired the product in 2007 based on longstanding written guidance from the federal government 
Nevertheless  the settlement provides for resolution of all potential Medicaid rebate liability claims by the federal government  as well as potential claims by certain hospitals and other covered entities that participate in the 340B Drug Pricing Program  Moreover  Mylan will reclassify EpiPen Auto Injector for purposes of the Medicaid Drug Rebate Program and pay the rebate applicable to innovator products  effective Apr 1 

Mylan s stock has fallen 16 7  year to date compared with the  decline of 14 9  
Mylan s second quarter results were dismal as the company missed on both earnings and sales estimates due to challenges in North America  The cut in annual guidance was also disappointing  Ongoing challenges in the U S  and uncertain regulatory environment in the region has led the company to defer all major launches in the U S  from the 2017 guidance to 2018 including generic version of GlaxoSmithKline Inc    NYSE GSK   asthma drug Advair Diskusand generic Copaxone 
Meanwhile  Mylan s Biologics License Application for proposed biosimilar version of Roche Holdings   OTC RHHBY   Herceptin is currently under review by FDA  The anticipated FDA goal date set under the Biosimilar User Fee Act is Sep3  We expect investor focus on the same 
Zacks Rank
Mylan currently carries a Zacks Rank  5  Strong Sell  
A better ranked stock in the health care sector is Gilead Sciences  Inc    NASDAQ GILD   which carriesa Zacks Rank  2  Buy   You can see  
Gilead s earnings per share estimates increased from  7 92 to  8 53 for 2017  over the last 30 days following strong results in the second quarter  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 8 18  
4 Surprising Tech Stocks to Keep an Eye On 
Tech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without  More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really takes off ",2017-08-18,Zacks Investment Research,https://www.investing.com/analysis/mylan-finalizes-settlement-agreement-with-doj-for-465m-200208228,200208228
197222,418738,MYL,Why Have Mylan s  MYL  Shares Lost 19 4  So Far This Year  ,opinion,"Shares of Mylan N V    NASDAQ MYL   have lost almost 19 4  in the year so far thereby underperforming the 4 5  increase registered by the  during this period  Here we analyze the factors that led to the underperformance 

Mylan  a global pharmaceutical company has a well established generics business and is known for specialty pharmaceuticals products 
We note that Mylan has been under immense pressure since August 2016 when the company faced severe criticism from lawmakers  consumers and the common people alike for price increase of EpiPen since its acquisition of the drug in 2007  Further  Mylan made it to the headlines for wrongly classifying EpiPen as a generic product in the Medicaid Drug Rebate Program  The misclassification implied that Mylan has been vastly underpaying rebates to Medicaid for the drug for a long time than it would have if the drug was classified as a branded one 
The company recently signed an agreement with the U S  Department of Justice and two other relators which finalizes the Medicaid drug rebate settlement worth  465 million  announced in Oct 2016 
Sales from EpiPen continue to decline due to increased competition and the impact of the launch of the authorized generic  Adamis Pharmaceuticals   NASDAQ ADMP   recently received FDA nod for Symjepi  a generic version of EpiPen  EpiPen will represent less than 5  of global revenues and less than 10  of sales in North America in 2017 
The company s efforts to get the generic version of GlaxoSmithKline plc s   NYSE GSK   asthma drug Advair Diskus suffered a blow when the FDA issued a complete response letter to its ANDA for the generic version  Although the company did not mention the contents of the CRL such setbacks are likely to weigh on shares 
Moreover  the FDA recently accepted Novartis AG   NYSE NVS   Sandoz s ANDA for Advair  A potential approval will give Sandoz the edge over Mylan  Moreover  the company believes that approval delays will persist in 2017 thereby impacting business further  The company believes that increased competition resulting from FDA s focus on accelerating the approvals of third  fourth or fifth generics will impact sales 
Meanwhile  Mylan s second quarter results were dismal as the company missed on both earnings and sales estimates due to challenges in North America  The cut in annual guidance was also disappointing  Mylan now expects revenues of  11 5  12 5 billion in 2017  down from the earlier projection of  12 25  13 75 billion 
The company now projects earnings per share in the range of  4 30  4 70  down from the previous projected range of  5 15  5 55  The guidance was lowered due to expected delays in the timing of certain key new product launches 
2017 will be challenging for the company due to volatility and uncertainty in the world s largest pharmaceutical market   the U S  due to pressure from both accelerated new approvals on the company s existing generic products and continued consolidation of the customer base  Contributions from new product launches in the U S  were one of the lowest in the second quarter  The company also saw increased competition for its existing generic products  as FDA approves more generics through accelerated approvals 
Zacks Rank
Mylan currently carries a Zacks Rank  5  Strong Sell   You can see  
4 Surprising Tech Stocks to Keep an Eye OnTech stocks have been a major force behind the market s record highs  but picking the best ones to buy can be tough  There s a simple way to invest in the success of the entire sector  Zacks has just released a Special Report revealing one thing tech companies literally cannot function without 
More importantly  it reveals 4 top stocks set to skyrocket on increasing demand for these devices  I encourage you to get the report now   before the next wave of innovations really take off ",2017-08-23,Zacks Investment Research,https://www.investing.com/analysis/why-have-mylans-myl-shares-lost-194-so-far-this-year-200209116,200209116
197223,418739,MYL,India s Biocon May Seek US Listing,news,"By   

BANGALORE  India    Biocon Ltd   Asia s largest insulin maker  could seek a listing on a stock exchange in the United States for better access to the world s biggest pharmaceuticals market  but the option will have to wait for now  Chairman Kiran Mazumdar Shaw told reporters in Bangalore Tuesday 
A U S  listing  will always help     but it can happen after two years or three years  said Mazumdar Shaw  who recently raised 5 5 billion rupees  about  83 million  by taking Syngene  a contract research services unit  public in Mumbai 
Currently  the company is more focused on getting regulatory approvals for its various products in the U S  and Europe  Mazumdar Shaw said  She was speaking at the inauguration of a new plant to assemble disposable insulin pens  at the company s Bangalore facility 
Biocon  which began in Mazumdar Shaw s garage in Bangalore in 1978  now sells biotech drugs to treat breast cancer and psoriasis  in addition to insulin  which the company also sells in the U S   in partnership with Mylan  NASDAQ MYL  Pharmaceuticals 
The disposable pen was designed by U S  firm Becton Dickinson and will be sold under the brand name Basalog One  Biocon can assemble 10 million of them in a year at the new factory  with the ability to increase that capacity four fold  according to Mazumdar Shaw ",2015-09-15,International Business Times,https://www.investing.com/news/stock-market-news/india's-biocon-may-seek-us-listing-361606,361606
197224,418740,MYL,Mylan May Lose  26B Perrigo Takeover Deal  Reports,news,"By   

Generic drug maker Mylan  O MYL  NV may lose its protracted hostile takeover bid for peer Perrigo Company Plc   N PRGO  as only a minority of Perrigo s shareholders reportedly tendered their stock into Mylan s  26 billion takeover proposal by late Thursday night 
Around 40 percent of Perrigo s ordinary shares had been tendered with 10 hours left    significantly short of Mylan s acceptance threshold of 50 percent  reports said  quoting sources close to the matter 
While shares could still be tendered  many large investors would have done so by now if they wanted to accept the offer  the sources added 
If the deal does not secure the support  it would represent a major win for Perrigo chief executive Joseph Papa  who has long maintained that Mylan has resorted to  inappropriate tactics to push its inadequate offer   and on Tuesday urged investors against taking up the offer 
Perrigo  which makes over the counter medicines  reported better than expected third quarter profit last month and announced a  2 billion share buyback and job cuts meant to appease investors ahead of the Mylan vote 
Mylan  which initially made a bid for Perrigo in April  went hostile in September  with both companies trading barbs about the perceived value of the deal and shareholder interests  Mylan contends that the Perrigo board s inaction over the deal was a  reckless gamble  while Perrigo has criticized Mylan s corporate governance  which it said lacks transparency  Mylan has also drawn accusations of insider dealing earlier in the year 
Mergers and consolidation deals worth  532 billion have been announced in the healthcare industry so far this year    a jump of 60 percent from 2014  the Wall Street Journal said  citing a report from data provider Dealogic ",2015-11-13,International Business Times,https://www.investing.com/news/stock-market-news/mylan-may-lose-$26b-perrigo-takeover-deal:-reports-371134,371134
197230,418746,MYL,Is A Surprise Coming For Mylan  MYL  This Earnings Season ,opinion,Investors are always looking for stocks that are poised to beat at earnings season and Mylan N V    NASDAQ MYL   may be one such company  The firm has earnings coming up pretty soon  and events are shaping up quite nicely for their report That is because Mylan is seeing favorable earnings estimate revision activity as of late  which is generally a precursor to an earnings beat  After all  analysts raising estimates right before earnings with the most up to date information possible is a pretty good indicator of some favorable trends underneath the surface for MYL in this report In fact  the Most Accurate Estimate for the current quarter is currently at  1 21 per share for MYL  compared to a broader Zacks Consensus Estimate of  1 19 per share  This suggests that analysts have very recently bumped up their estimates for MYL  giving the stock a Zacks Earnings ESP of  1 68  heading into earnings season Mylan N V  Price and EPS Surprise      Why is this Important A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises  and outperforming the market  Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank  3  Hold  or better show a positive surprise nearly 70  of the time  and have returned over 28  on average in annual returns  see more   Given that MYL has a Zacks Rank  3 and an ESP in positive territory  investors might want to consider this stock ahead of earnings  You can see  Clearly  recent earnings estimate revisions suggest that good things are ahead for Mylan  and that a beat might be in the cards for the upcoming report Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-08-08,Zacks Investment Research,https://www.investing.com/analysis/is-a-surprise-coming-for-mylan-myl-this-earnings-season-200205995,200205995
197231,418747,MYL,Mylan  MYL  Misses On Q2 Earnings   Sales  Lowers View ,opinion,"Mylan N V    NASDAQ MYL   reported disappointing second quarter 2017 results wherein both earnings and sales missed estimates  The company also lowered its guidance  Shares are trading down due to dismal results 

Mylan s stock fell 16 7  year to date compared with the  decline of 14 9  
The company reported earnings of  1 10 per share  which missed the Zacks Consensus Estimate of  1 18 and was down from  1 16 reported in the year ago quarter 
Second quarter revenues of  2 96 billion missed the Zacks Consensus Estimate of  3 00 billion  Nevertheless  the top line recorded 15 7  year over year growth on the back of acquisitions Mylan N V  Price and EPS Surprise
 

   Quarter in Detail
The company report results in three segments on a geographic basis   North America  Europe and Rest of World 
North America segment third party net sales came in at  1 28 billion  down 9  due to a decline in sales of existing products as a result of lower volume and pricing which more than offset the acquisitions of Meda AB and the non sterile  topicals focused business of Renaissance Acquisition Holdings  LLC  Sales of the EpiPen Auto Injector declined in the current quarter due to increased competition and the impact of the authorized generic launch  Generics products experienced price erosion in the mid single digits 
Third party net sales from Europe were  954 3 million  up 59  propelled by the acquisition of Meda which was partially offset by lower volume on existing products  Unfavorable foreign currency translation had an impact of 3  within Europe 
Rest of World segment third party net sales of  692 6 million was up 29  fueled by the Meda acquisition  Moreover  net sales from existing products increased due to higher sales from the anti retroviral franchise while sales from new products and higher volumes on existing products more than offset lower pricing  Foreign currency translation had a favorable impact of 2  
Adjusted gross margin declined to 54  from 56  in the year ago quarter due to lower gross profit from the sales of existing products in North America  including the EpiPen Auto Injector  partially offset by the contributions from the acquired businesses 
2017 Outlook Lowered
Mylan now expects revenues of  11 5  12 5 billion in 2017  down from the earlier projection of  12 25  13 75 billion in 2017  The company now projects earnings in the range of  4 30  4 70  down from the previous projected range of  5 15  5 55  The guidance was lowered as a result of expected delays in the timing of certain key new product launches 
Ongoing challenges in the U S  and uncertain regulatory environment in the region has led the company to defer all major launches in the U S  from the 2017 guidance to 2018 including generic Advair and generic Copaxone  Pricing in generics is expected to decline in mid single digits globally  with high single digit erosion expected in North America 
Our Take
Mylan s second quarter results were dismal as the company missed on both earnings and sales estimates due to challenges in North America  Pricing continues to impact results and the company projects mid single digit price erosion globally  The decrease in guidance was also disappointing  The company recently suffered a few setbacks 
Mylan received a complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of GlaxoSmithKline plc s   NYSE GSK   asthma drug Advair Diskus 
On a positive note  the FDA Oncologic Drugs Advisory Committee recently unanimously recommended approval of Mylan s biosimilar version of Roche Holding  SIX ROG  AG s   OTC RHHBY   breast cancer drug Herceptin 
Zacks Rank   Key Pick
Mylan currently carries a Zacks Rank  4  Sell  
A better ranked stock in the health care sector is Gilead Sciences  Inc    NASDAQ GILD   which carriesa Zacks Rank  2  Buy   You can see  
Gilead s earnings per share estimates increased from  7 92 to  8 53 for 2017  over the last 30 days following strong results in the second quarter  The company delivered positive earnings surprises in three of the trailing four quarters  with an average beat of 8 18  
More Stock News  Tech Opportunity Worth  386 Billion in 2017
From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future 
Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-08-09,Zacks Investment Research,https://www.investing.com/analysis/mylan-myl-misses-on-q2-earnings--sales-lowers-view-200206325,200206325
197232,418748,MYL,Economic Calendar And Watch List 8 9 2017,opinion,"Morning Notes

US Futures are down this morning along with European shares with escalating tensions between the US and North Korea  This comes after the SPY  NYSE SPY  hit record highs during yesterday s session and sold off sharply into late trading  Asian stocks settled mostly lower 


Technicals



The SPY opened just above the ascending resistance trendline during Tuesday s session and posted record highs before drifting back lower to close back below this significant trendline  Support will lie at the low of Tuesday s range at  246 83  followed by  246 64   246 37  the 20 EMA at  246 32  then  246 13  the short term pivot point at  245 70  continued with  244 67  the 50 SMA at  244 40  and  244 31  Further support lies at  243 76  then gap entry at  243 30 and gap fill at  242 55  Resistance will lie at the record high of Tuesday s range at  248 91 


Small Cap Watch List

 Please refer to the momentum scanners displayed live in the chat room for potential plays at the market open  


  Others On Watch  


Economic Calendar

0830 Productivity and Costs

1030 EIA Weekly Petroleum Status Report

1300 Fed Pres  Evans Speaks


Notable Earnings Before Open Mylan N V   NASDAQ MYL    EPS Est   1 19

Weibo Corp  NASDAQ WB    EPS Est   0 31

The Childrens Place Retail Stores  NASDAQ PLCE    EPS Est   0 74

Notable Earnings After Close

Twenty First Century Fox Inc  NASDAQ FOX    EPS Est   0 34

Jack In The Box Inc  NASDAQ JACK    EPS Est   1 06",2017-08-09,Warrior Trading,https://www.investing.com/analysis/economic-calendar--watch-list-892017-200206220,200206220
197233,418749,MYL,U S  consumer groups oppose Teva bid for generic drug rival Mylan,news,"WASHINGTON  Reuters    A proposed merger of the two largest U S  generic drug makers drew fire on Tuesday from Consumers Union and seven other groups  who asked antitrust enforcers to stop Teva Pharmaceutical Industries  ARCA TEVA  Ltd s  TA TEVA  proposal to purchase Mylan NV  O MYL   saying it would lead to higher prices and more drug shortages  At this point  there is no deal  Mylan has been rebuffing Teva s takeover bids  including one in April for  40 billion  Meanwhile  Mylan has pressed on with a  34 billion hostile bid for  Perrigo Co  Plc  N PRGO   But the groups remain concerned  In their letter to Federal Trade Commission Chairwoman Edith Ramirez  the groups urged the FTC to look at more than just overlapping drugs made by both companies  to determine if a merger of drug makers is legal  The two companies  the letter said  would make 25 percent of all generic drugs   We believe you will conclude that the merger would substantially lessen competition in violation of the antitrust laws  and should be blocked   they said in the letter  Even without the deal  the groups said that more than half of retail generic drugs saw their prices go up between July 2013 and July 2014   In the last decade  there has been significant consolidation among generic drug manufacturers  This increased consolidation has already led to higher prices and to generic drug shortages   the groups wrote in a letter  The groups also said that Teva and Mylan  between them  make 12 of the 70 drugs that the Food and Drug Administration says are in short supply    Along with exacerbating the current drug shortages of these medications  a merger between the two largest generic manufacturers would likely eliminate more manufacturing facilities  leading to reduced production and creating other shortages of generic and specialty drugs   the letter said   Teva said in a statement that it was confident it could arrange sufficient asset sales to make the deal acceptable to antitrust enforcers   Teva remains deeply committed to consummating a transaction with Mylan that offers an unparalleled opportunity for greater access to much needed medicines   a company spokesperson said   Consumer groups signing the letter were  Consumers Union   
Consumer Federation of America  US Public Interest Research Group  Public Citizen  Consumer Action  Consumer Watchdog  Community Catalyst  and the National Center for Health Research ",2015-07-14,Reuters,https://www.investing.com/news/stock-market-news/u.s.-consumer-groups-oppose-teva-bid-for-generic-drug-rival-mylan-351165,351165
197237,418753,MYL,Adamis Gets FDA Nod For Generic Version Of Mylan s EpiPen ,opinion,Shares of Adamis Pharmaceuticals Corporation   NASDAQ ADMP   soared more than 50  on Thursday after the FDA approved the company s Epinephrine injection  USP  1 1000  0 3 mg Pre filled single dose syringe   PFS  which is the generic version of Mylan N V  s   NASDAQ MYL   EpiPen  the best selling but high cost treatment for life threatening allergies  Shares of Adamis were up on the news while the news was a blow for the shares of Mylan which went down about 2 38  Adamis Pharmaceuticals  share price shows that the company has outperformed the Zacks classified  industry year to date  The stock has surged 99 7  compared with the industry s gain of 16 8  The FDA approved the trade name Symjepi for the pre filled syringe which will treat allergic reactions  Symjepi provides two single dose syringes  It is  expected to hit the market in the second half of 2017 Symjepi will be available at lower cost and will be available in smaller size when compared with EpiPen  EpiPen has been facing concerns over pricing in the past  Mylan has been under immense pressure since Aug 2016 when the company came under the spotlight for price increase of EpiPen since its acquisition of the drug in 2007  drawing immense flak from lawmakers  consumers and the common people alike As a result of the increased prices of EpiPen  Mylan launched the first authorized generic for EpiPen Auto Injector in Dec 2016 at a wholesale acquisition cost  WAC  of  300 per epinephrine injection USP two pack  which is more than 50  lower than the WAC of EpiPen 2 Pak Auto Injectors Another leading drug store chain CVS Health Corp    NYSE CVS   announced in January this year that that it is now selling a cheaper alternative to EpiPen  The authorized generic treatment is called Adrenaclick  and is made by Impax Laboratories Inc    NASDAQ IPXL    and is priced at  109 99 for a two pack Coming back to the release  Adamis is in discussions with potential partners in order to facilitate access of the PFS to a broader patient group Zacks RankAdamis currently carries a Zacks Rank 3  Hold   You can see  Adamis Pharmaceuticals Corporation Price and Consensus    3 Top Picks to Ride the Hottest Tech TrendZacks just released a Special Report to guide you through a space that has already begun to transform our entire economy    Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce  the world s first trillionaires   but that should still leave plenty of money for those who make the right trades early ,2017-06-15,Zacks Investment Research,https://www.investing.com/analysis/adamis-gets-fda-nod-for-generic-version-of-mylan's-epipen-200195706,200195706
197238,418754,MYL,Novartis  NVS  Biosimilar Of MabThera Approved In The EU,opinion,"Novartis AG   NYSE NVS   announced that its generic arm  Sandoz  has received European Commission  EC  approval for Rixathon  a biosimilar version of Roche s   OTC RHHBY   MabThera in Europe 
The biosimilar version has been approved for all the indications of the branded drug  Rixathon is approved for non Hodgkin s lymphoma  follicular lymphoma and diffuse large B cell lymphoma  and chronic lymphocytic leukemia  as well as immunological diseases such as rheumatoid arthritis  granulomatosis with polyangiitis  and microscopic polyangiitis 
We note that Sandoz is a global leader in biosimilars  With the approval of Rixathon  Sandoz now has four biosimilar drugs approved in Europe along with a deep pipeline  Sandoz plans to obtain the approval for four more biosimilars of major oncology and immunology biologics by 2020 
Last month  the European Medicines Agency  EMA  accepted the company s Marketing Authorization Applications for biosimilar versions of Humira  adalimumab  and Remicade  infliximab  for review  The generic unit had generated  10 1 billion sales in 2016 
Last week  the FDA accepted Sandoz s Abbreviated New Drug Application  ANDA  for a generic version of GlaxoSmithKline s   NYSE GSK   asthma drug  Advair Diskus 
We remind investors that Sandoz gaining additional expertise in the development of orally inhaled medicines through its 2010 acquisition of Oriel Therapeutics  Inc  Upon approval  the generic drug will treat asthma in patients aged four years and older  as well as provide maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease  COPD  
Earlier in 2017  Mylan   NASDAQ MYL   received a complete response letter from the FDA regarding its ANDA for Advair Diskus 
Hence  we expect investors to remain focused on Sandoz s ANDA approval  A potential approval will give Sandoz the edge over Mylan and boost its portfolio 

Novartis has outperformed the Zacks classified industry in the last six months  The stock has rallied 12 6  compared with the  industry s gain of 11 4  
Going forward  we expect that the approval of new drugs and label expansion of existing ones will bode well for Novartis  However  the company faces stiff generic competition for key drugs like Gleevec 
Zacks Rank
Novartis currently carries a Zacks Rank  3  Hold  
You can see  
Looking for Stocks with Skyrocketing Upside  
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana  Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ",2017-06-19,Zacks Investment Research,https://www.investing.com/analysis/novartis-(nvs)-biosimilar-of-mabthera-approved-in-the-eu-200196103,200196103
197239,418755,MYL,Sucampo  SCMP  Remains Focused On Amitza Label Expansion ,opinion,"We issued an updated report on Sucampo Pharmaceuticals  Inc    NASDAQ SCMP   on July 4 
Rockville  MD based Sucampo Pharmaceuticals is a global biopharmaceutical company which currently has one marketed product  Amitiza  in its portfolio   Amitiza is approved for chronic idiopathic constipation  CIC  in adults  irritable bowel syndrome with constipation  IBS C  among adult women and opioid induced constipation  OIC  in patients with chronic non cancer pain 
Sucampo has a license  commercialization and supply agreement with Mylan   NASDAQ MYL   for marketing Amitiza in Japan  where it is approved for chronic constipation  CC   except constipation caused by organic diseases  Japanese pharma company Takeda  which holds global marketing rights for Amitiza outside Japan and China  continues to work on launching Amitiza in new markets  The company s collaborations with firms like Takeda and Mylan for the commercialization of Amitiza is a big positive 
A look at Sucampo s share price movement reveals that the company has underperformed the Zacks classified  industry year to date  The stock is down 21 1  against the industry s gain of 6 2  

Sucampo is working on expanding Amitiza s label  Sucampo is developing the sprinkle formulation of Amitiza in adults and pediatric patients The company plans to make regulatory filings for both adult and pediatric patients in the U S  in the second half of 2017  This will further boost the revenues of the company once approved 
This global pharmaceutical company is also focusing on acquisitions  The company s acquisition of Japanese company  R Tech added Rescula to Sucampo s marketed drug list  Through this acquisition  Sucampo boosted its pipeline across diverse therapeutic areas like gastroenterology  ophthalmology  autoimmune and inflammatory diseases  and oncology 
Meanwhile  with the acquisition of Vtesse in Apr 2017  Sucampo added a late stage program in Niemann Pick Disease type C1 to its pipeline  Moreover  Sucampo entered into an option and collaboration agreement with Cancer Prevention Pharmaceuticals in Jan 2016  whereby it gained the sole option to acquire an exclusive license to commercialize the late stage CPP 1X sulindac combination product in North America for the treatment of FAP in a phase III study  The study is expected to be complete in 2018  potential approval in 2019  
Nevertheless  Sucampo s dependence on Amitiza for growth is concerning  Also  some companies are trying to market and sell generic version of Amitiza  Any decline in Amitiza s sales will adversely impact the top line Sucampo Pharmaceuticals  Inc  Price and Consensus
 

   Zacks Rank   Stocks to Consider
Sucampo currently carries a Zacks Rank  3  Hold   Better ranked stocks in health care sector include Enzo Biochem  Inc    NYSE ENZ   and Sanofi   NYSE SNY    While Enzo Biochem sports a Zacks Rank  1  Strong Buy   Sanofi holds a Zacks Rank  2  Buy   You can see  
Enzo Biochem s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018 over the last 30 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 55 83   The share price of the company has increased 61 1  year to date 
Sanofi s earnings per share estimates increased from  3 08 to  3 18 for 2017 and from  3 26 to  3 30 for 2018 over last 30 days  The company pulled off positive earnings surprises in three of the trailing four quarters  with an average beat of 5 10   The share price of the company has increased 18 2  year to date 
Today s Stocks from Zacks  Hottest Strategies
It s hard to believe  even for us at Zacks  But while the market gained  18 8  from 2016   Q1 2017  our top stock picking screens have returned  157 0    128 0    97 8    94 7  and  90 2   respectively 
And this outperformance has not just been a recent phenomenon  Over the years it has been remarkably consistent  From 2000   Q1 2017  the composite yearly average gain for these strategies has beaten the market more than 11X over  Maybe even more remarkable is the fact that we re willing to share their latest stocks with you without cost or obligation ",2017-07-05,Zacks Investment Research,https://www.investing.com/analysis/sucampo-(scmp)-remains-focused-on-amitza-label-expansion-200199328,200199328
197240,418756,MYL,What Lies In Store For Glaxo  GSK  This Earnings Season ,opinion,"GlaxoSmithKline plc   NYSE GSK   is scheduled to report second quarter 2017 results on Jul 26 before market opens  Last quarter  the company delivered in line earnings Glaxo s shares are up 10 1  this year so far  underperforming the 11 9  increase witnessed by the Zacks classified  industry Glaxo s performance has been pretty good so far  with the company s earnings beating expectations thrice in the four trailing quarters while meeting estimates in the remaining quarter  Overall  the company has delivered an average positive earnings surprise of 12 28  Let s see how things are shaping up for this quarter Factors to ConsiderAll of its business segments   Pharmaceuticals  Vaccines and Consumer Healthcare   are expected to do well in the to be reported quarter Glaxo s Pharmaceuticals segment is expected to be driven by strong sales of new HIV products  Tivicay and Triumeq  Sales of newly launched respiratory drugs  the Ellipta products and Nucala are expected to offset the declines in Seretide  Advair and Avodart  Many of Glaxo s key drugs like Lovaza and Avodart are facing declining sales due to generic competition  Importantly  pricing dynamics and competitive pressure are hurting sales of its top selling drug Advair in the US while generic competition is hurting Advair sales in Europe At the first quarter call  the company had mentioned a lot of uncertainty surrounding the timing of Advair generic launch  However  Mylan N V  s   NASDAQ MYL   efforts to bring a generic version for Advair in the market suffered a blow as the FDA issued a complete response letter to its abbreviated new drug application  ANDA  in Apr 2017  thereby delaying the entry of the generic  Hikma Pharmaceuticals  generic version of Advair was also denied approval by the FDA in May 2017  A generic version of Advair is therefore not likely to be approved this year The Vaccines segment will continue to benefit from the uptake of meningitis vaccines  Bexsero and Menveo  acquired from Novartis  Importantly  growth of the Consumer Healthcare segment has slowed down  At the first quarter conference call  management had mentioned that the impact of general sales tax and continued slowdown in the nutrition category in India  challenging economic conditions in some other international markets and the Nigerian beverage business divestment are expected to hurt Consumer Healthcare segment sales this year  These factors might impact second quarter results However  cost savings from restructuring and continued efficiencies are likely to boost operating profits Earnings WhispersOur proven model does not conclusively show that Glaxo is likely to beat on earnings this quarter  This is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  Its Earnings ESP is  1 45  as the Most Accurate estimate stands at 68 cents while the Zacks Consensus Estimate is pegged higher at 69 cents  You can uncover the best stocks to buy or sell before they re reported with our Zacks Rank  Glaxo s Zacks Rank  2 increases the predictive power of ESP  However  we need to have a positive ESP to be confident about an earnings beat We caution against Sell rated stocks  Zacks Rank  4 or 5  going into the earnings announcement  especially when the company is seeing negative estimate revisions GlaxoSmithKline PLC Price and EPS Surprise
    Stock to Consider
A couple of stocks in the large cap pharmaceuticals sector that also have a positive Earnings ESP and a favorable Zacks Rank are Novo Nordisk  CO NOVOb  A S   NYSE NVO    scheduled to release results on Aug 9  has an Earnings ESP of  7 14  and a Zacks Rank  2  You can see  Pfizer  Inc    NYSE PFE   has an Earnings ESP of  1 54  and a Zacks Rank  3  The company is scheduled to release results on Aug 1 3 Top Picks to Ride the Hottest Tech Trend    Zacks just released a Special Report to guide you through a space that has already begun to transform our entire economy    Last year  it was generating  8 billion in global revenues  By 2020  it s predicted to blast through the roof to  47 billion  Famed investor Mark Cuban says it will produce   the world s first trillionaires    but that should still leave plenty of money for those who make the right trades early ",2017-07-19,Zacks Investment Research,https://www.investing.com/analysis/what-lies-in-store-for-glaxo-(gsk)-this-earnings-season-200202467,200202467
197241,418757,MYL,GlaxoSmithKline  GSK  Beats On Q2 Earnings  Lowers Guidance,opinion,"GlaxoSmithKline plc s   NYSE GSK   reported core earnings of 70 cents per American depositary share in the second quarter of 2017  which beat the Zacks Consensus Estimate of 68 cents by almost 3  
Earnings were however down 2  year over year at constant exchange rates  CER   driven by a negative impact of settlement of intercompany transaction during the quarter 
So far this year  Glaxo s shares have gained 5 6   comparing unfavorably with the  s increase of 10 7  

Quarterly revenues were up 3  at CER to  9 42 billion   7 3 billion  on the back of strong performances by all the business segments  However  revenue marginally missed the Zacks Consensus Estimate of  9 52 billion 
All growth rates mentioned below are on a year on year basis and at CER 
Quarterly Highlights
Sales were up 5  in the U S  and 1  in International markets  Also  sales in Europe registered a growth rate of 2  
Sales of New Pharmaceutical and Vaccine products were up 47  driven by HIV drugs  Tivicay and Triumeq  respiratory drugs  the Ellipta products and Nucala  vaccines to prevent meningitis  and drugs like Bexsero and Menveo 
Glaxo reports results under three segments  Pharmaceuticals  Vaccines and Consumer Healthcare The Pharmaceuticals division registered revenue growth of 3  driven by HIV drugs  Tivicay and Triumeq  and respiratory disease drugs  Relvar Breo and Nucala  This was partly offset by the impact of recent divestments on Established Pharmaceuticals 
HIV sales were up 17  on 24  growth in the U S  and 27  in International sales  Europe sales were however flat year over year  The encouraging numbers came on the back of continued market share growth for both Triumeq  sales up 44   and Tivicay  sales up 37    However  sales of another HIV drug Epzicom Kivexa tumbled 63  due to an increased generic competition  particularly affecting the European market 
Respiratory sales increased 4  on the back of 7  growth in both the U S  and 5  in the international markets  In Europe  however  respiratory sales slid 2  as the portfolio continued to transition to newer products including Relvar Breo Ellipta 
Sales of new respiratory products like Relvar Breo Ellipta  Anoro Ellipta  Arnuity Ellipta and Nucala offset the decline in Seretide Advair sales  down 14    Flixotide Flovent and Ventolin sales decreased 1  and 8  respectively 
The Ellipta products recorded a 73  surge in sales  driven by market share gains with the global roll out continuing 
Immuno inflammation drugs  which include Benlysta  rose 9  in the quarter 
The new grouping of Established Pharmaceuticals includes the previous Established Products  Cardiovascular  metabolic and urology  CVMU  and other Pharma products  Established Pharmaceuticals sales were down 7  in the quarter 
However  sales were flat in the Consumer Healthcare segment due to a slowdown in market conditions  Sales were hurt by the disposal of the Nigeria beverages business in 2016  challenging conditions in some emerging markets  particularly India  and a weaker allergy performance in the U S  However  the power brands  particularly in Pain relief and Oral health categories saw a strong performance in the quarter 
Sales from the Vaccines segment were up 5   Geographically  the U S  was up 12   Europe was up 10  whereas international markets were down 5   Sales benefited from a continued uptake of meningitis vaccines  Bexsero globally and Menveo in the international markets  The segment also experienced a strong performance of the Established Vaccines  driven by higher demand for Boostrix and Hepatitis vaccines  particularly 
OutlookThe company expects to face a generic competition for Advair in the U S  which will affect the top line  However  there is uncertainty regarding the timing of launch of a generic version of the drug  With no generic version of Advair expected to be launched in 2017  the company expects core 2017 earnings growth of 3 5  at CER  lower than 5 7   projected previously 
Additionally  during the second quarter  the company decided to invest in a Priority Review Voucher to accelerate the FDA s review for its two drug regimen in HIV  This investment decision along with other accelerated launch cost  related with the HIV drugs  led to the lowered profit guidance 
We remind investors that Mylan s   NASDAQ MYL   efforts to bring a generic version for Advair in the market suffered a blow as the FDA issued a complete response letter to its abbreviated new drug application  ANDA  for Advair in April  thereby delaying the entry of the generic  Hikma Pharmaceuticals PLC s generic version of Advair was also denied an approval by the FDA in May 2017  A generic version of Advair is therefore not likely to be approved of this year 
Glaxo expects an approval for Shingrix in the U S  and Europe  besides Closed Triple in the fourth quarter of 2017  Hence  these products should generate a significant sales figure only in 2018 
Long Term Outlook
Glaxo expects its adjusted EPS growth through 2020 to be in the range of mid to high single digits  During the period  the company plans to stop development of pre clinical and clinical programmes and instead  shift the pipeline focus to Respiratory and HIV infectious diseases  therapeutic areas  where the company already enjoys a strong presence  Also  the company will make R D investments in two potentially fast growing therapeutic areas   Oncology and Immuno inflammation  Its cost reduction initiatives would lead additional  1 billion annual cost savings by 2020 GlaxoSmithKline PLC Price  Consensus and EPS Surprise

   Zacks Rank   Key Picks
Glaxo currently carries a Zacks Rank  3  Hold   Some better ranked stock in the healthcare sector includes Enzo Biochem  Inc    NYSE ENZ   and Exelixis  Inc    NASDAQ EXEL    Each of these stock sports a Zacks Rank  1  Strong Buy   You can see  
Exelixis s earnings per share estimates inched up from 53 cents to 55 cents for 2018  over the last 30 days  The company has delivered positive earnings surprises in all the trailing four quarters with an average beat of 512 11   Exelixis s shares have soared 87 9  so far this year 
Enzo Biochem s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018  over the last 60 days  The company delivered positive earnings surprises in all the trailing four quarters  with an average beat of 55 83   The share price of the company has increased 62 7  year to date 
More Stock News  Tech Opportunity Worth  386 Billion in 2017
From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future 
Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity   Most importantly  it reveals 4 stocks with massive profit potential ",2017-07-26,Zacks Investment Research,"https://www.investing.com/analysis/glaxosmithkline-(gsk)-beats-on-q2-earnings,-lowers-guidance-200204024",200204024
197242,418758,MYL,Mylan  Guidance Concerns Grow As Drug Approvals Are Delayed,opinion,"Mylan  NASDAQ MYL  has drifted down by about 14  since early March as  concerns have grown over that time  Concerns have specifically centered around risk to 2017 and 2018 guidance due to approval delays in the company s new product pipeline  Additionally  the company s core business  generics and Epipens  have had new developments that have raised concerns over their outlooks as well 

2017 and 2018 guidance could move lower
The company has given 2017 guidance of  5 15    5 55  with  850 million revenue from global new product launches  Management noted that the list of drugs that will contribute to the  850 million is long  but did not break out expected contributions by drug  As a result  it s unclear how much revenue management expected from drugs that are currently still pending approval  i e  Copaxone and Advair   If the company is not able to get approval for some of these bigger drugs  the company could potentially miss its  850 million contribution from new products  which could thereby put management s  5 15    5 55 guidance in jeopardy  As a result  investors have grown more concerned that management could potentially lower their 2017 guidance when they report 2Q on August 9th  which could push consensus estimates down further  Consensus estimates for 2017 currently are already below the bottom end of management s guidance at  5 10 
Beyond 2017  the company has also given guidance for 2018 EPS of  6 00  However  with 2017 guidance in danger  one wonders if the company can achieve its 2018 target  Should 2017 EPS move down to   5  the company would need to grow EPS by 20   to achieve its  6 EPS target in 2018  which would likely require an accretive acquisition  At 3 7x net debt EBITDA  this may be difficult to do  Consensus estimates are already  0 30 below the  6 target  but could move lower if the company moves its 2018 guidance lower 

New products  Copaxone  Advair delays
With that in mind  let s zoom into what s happened with Copaxone and Advair   the two drugs that investors believed would make up a large chunk of the new product revenues  but have had issues receiving FDA approval 
Mylan received a non approval for Advair back in late March  Management gave further details on its 1Q conference call  noting that the company disagreed on several points raised by the FDA  and have submitted their response to those points  The FDA has not asked for additional clinical endpoint or device related studies  Instead  the FDA has asked the company to relate its existing study results to newly issued industry draft guidance  In terms of next steps  the company is now waiting to have a face to face meeting with the FDA to address some of the issues  but cannot give further guidance on timing until that meeting happens  As of mid June  the company has still not had that meeting  but management is hopeful that they can give a more detailed update by their 2Q call 
What does this mean for Advair and for the stock  Most investors  and management  had expected the Advair generic to be approved this year and to contribute to revenue  And given that the drug was expected to be the first generic to market for the  4 2 billion Advair branded drug  investors had big expectations for the generic  As we begin to enter the 2H of 2018 and still do not have clarity on the timing of the drug  investors are beginning to lower those expectations  Several analysts have noted that they no longer expect the drug to contribute to revenue in 2017 
What about Copaxone  The drug has a long history of delays  but investors began to see the light at the end of the tunnel when management noted on its 1Q conference call that they had an upcoming action date for both the 20mg and 40mg in June  However  in mid June  management disclosed that the company had received a request for additional information on the 20mg application  Investors are again beginning to lower expectations for the drug given that we re now in August and have not received an update on the drug 
There are a few things to consider as it relates to company s new drug guidance  First  the company has noted that there is a long list of drugs that are expected to contribute to that  850 million guidance  and the company has already received 20 drug approvals year to date  Second  management s guidance of  850 million likely includes a risk adjustment to both the Copaxone and Advair generics  and therefore it is possible that management did not expect a significant contribution from those drugs  As a result  there is a possibility that the delays for the two drugs does not hurt the company s guidance as much as investors believe  However  it s clear that the Advair  or Wixela Inhub  and Copaxone generics are key to the company s plans in the U S   as shown by the company s Investor Day slides below 

Core business  generic pricing environment  Epipen competitor
Investor concerns are also growing for Mylan s generic portfolio  Management has noted that they expect to see mid single digit price erosion among their generics  This runs counter to other generic manufacturers that have experienced pressure in recent quarters and expect double digit price erosion for the year  For example  Novartis s  NYSE NVS  generic division Sandoz reported a global pricing decline of 8  and US generics sales down 15   Much of these dire expectations are driven by consolidating retail wholesale buyer groups and the fact that as much as 1 4 to 1 3 of US generic prescriptions may be up for bidding in the remainder of 2017  Investors fear that Mylan may need to lower guidance further in the midst of a weakening generic pricing environment 
Other threats to the company s products have emerged as well  In mid June  Adamis Pharma  NASDAQ ADMP  announced FDA approval of its Symjepi product  which is expected to be a low cost competitor to the Epipen 
In regards to the generic pricing environment  Mylan would note that the company has advantages in the generic market that others do not   including greater scale and support that provides differentiation and more insulation from the broader pricing issues 
In regards to the Epipen competitor  it s important to note that the Epipen is becoming a smaller portion of its overall revenues and that investors are not as focused on the product as they were in the past  Analysts now only model  5  of MYL sales from the Epipen  and expect that to continue to shrink in the coming years 
However  these issues in totality do raise the risk that the company could see further pressure in other areas of its guidance as well 
Bull case rests on early approval  biosimilar pipeline
While there has been a steady wave of negative news in recent months  expectations may have lowered sufficiently enough to where the risk reward is potentially attractive  As noted above  many analysts are not holding out hope for a 2017 approval for either the Advair or Copaxone generic  There is still a chance that the drugs get approval this year in 2017 though  and either approval would be a surprise and send the stock higher 
Additionally  the company s biosimilar pipeline shows promise  The Trastuzumab biosimilar  in particular  recently received a unanimous recommendation from the FDA s ODAC panel for approval  With a BsUFA goal date on September 3rd  there is a high chance that the drug gets approved  With the branded Trastuzumab generating  7 billion in 2016 US sales  Mylan s biosimilar could generate a sizable amount of revenue when the patent expires in 2019  In total  Mylan has 16 biosimilars that target  88 billion in branded drug sales ",2017-08-03,The Non-Consensus,https://www.investing.com/analysis/mylan-guidance-concerns-grow-as-drug-approvals-are-delayed-200204928,200204928
197243,418759,MYL,Momenta  MNTA  Q2 Loss In Line With Estimates  Sales Beat,opinion,"Momenta Pharmaceuticals Inc    NASDAQ MNTA   reported a loss of 50 cents per share in the second quarter of 2017  in line with the Zacks Consensus Estimate  The reported loss was  however  wider than the year ago loss of 31 cents Momenta Pharmaceuticals  Inc  Price and EPS Surprise

   Revenues in the quarter improved 10 8  to  23 6 million and topped the Zacks Consensus Estimate of  22 9 million 
Momenta s stock has rallied 6 3  year to date compared with the  rally of 9 9  

 
Quarter in Detail
Momenta s top line comprises product revenues of  19 1 million earned from Sandoz s sales of Glatopa  a generic version of Copaxone  20 mg   compared with  20 7 million in the year ago quarter  The decrease was primarily due to lower sales deductions in the second quarter of 2016  as well as legal reimbursement in the second quarter of 2017 
Collaborative research and development revenues came in at  4 4 million  down from  5 8 million in the year ago quarter  The decline in revenues was mainly due to the termination of the Baxalta Collaboration Agreement  effective Dec 31  2016 
While  research and development expenses were up to  39 1 million from  33 2 million  general and administrative expenses increased 52  to  22 6 million 
Outlook Updated
Momenta now expects operating expenses  excluding stock based compensation and net of collaborative revenues  in the range of  210  230 million  compared with the previous guidance of  200  240 million in 2017  The guidance also includes approximately  55 million of capital expenditure on M923  Operating expenses in the third quarter of 2017 are projected around  50  60 million 
Momenta expect to generate revenues of  45 million from Mylan N V    NASDAQ MYL   as upfront payment on a quarterly basis  In Jul 2017  Momenta earned a  10 million milestone payment from Sandoz as Glatopa 20 mg continues to be the sole FDA approved generic of Copaxone 20 mg 
Pipeline Update
Sandoz s abbreviated New Drug Application  ANDA  for the 40 mg thrice weekly formulation of Copaxone  Glatopa 40mg  was under the FDA review  However  Momenta suffered a setback with the FDA issuing a warning letter to Pfizer Inc    NYSE PFE   in Feb 2017  which is Sandoz s contracted fill finish manufacturing partner for Glatopa 
Pfizer has submitted a comprehensive response to the observations cited in the warning letter  The ANDA approval is now contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued to Pfizer 
Meanwhile  Momenta continues to progress with its other pipeline candidates  Currently  Momenta s M923  a biosimilar version of AbbVie  Inc    NYSE ABBV   Humira  is being evaluated in a phase III study in patients suffering from moderate to severe chronic plaque psoriasis  Moving ahead  the company plans to submit the candidate for approval to regulatory bodies in the fourth quarter of 2017  Also  it expects first commercial launch of M923 to be as early as the 2020 timeframe 
The company completed enrolment in the phase I study on M834  a biosimilar version of Orencia  abatacept  in Apr 2017 under its collaboration with Mylan  Top line data from the study are expected in the second half of 2017 
Furthermore  Momenta s novel autoimmune portfolio includes  M230  a Selective Immunomodulator of Fc receptors  SIF3  and M281  an anti FcRn monoclonal antibody  In Jan 2017  the company entered into a research collaboration and license agreement with CSL for M230 and potential future Fc multimer programs  The candidate is expected to enter clinic in 2017 
Momenta successfully completed a phase I single ascending dose study in healthy volunteers for M281  The multiple ascending dose portion of the study was initiated in Jan 2017  expected to be completed in Aug 2017  and data from the single and multiple ascending dose portions of the study are projected in the second half of 2017 
Our Take
Momenta s loss per share came in line with estimates in the second quarter of 2017 while sales beat estimates  The ANDA approval for Glatopa is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA  resulting in a delay of approval  We expect the warning letter will remain a drag on the company s shares till the issue is solved 
Nevertheless  sales of Glatopa 20mg continue to do well  Glatopa 20mg has captured approximately 40  of the market in the U S  In addition  a potential approval of M923 will boost investor confidence 
Zacks Rank
Momenta currently carries a Zacks Rank  3  Hold   You can see  
More Stock News  Tech Opportunity Worth  386 Billion in 2017
From driverless cars to artificial intelligence  we ve seen an unsurpassed growth of high tech products in recent months  Yesterday s science fiction is becoming today s reality  Despite all the innovation  there is a single component no tech company can survive without  Demand for this critical device will reach  387 billion this year alone  and it s likely to grow even faster in the future 
Zacks has released a brand new Special Report to help you take advantage of this exciting investment opportunity  Most importantly  it reveals 4 stocks with massive profit potential ",2017-08-03,Zacks Investment Research,https://www.investing.com/analysis/momenta-mnta-q2-loss-in-line-with-estimates-sales-beat-200205190,200205190
197244,418760,MYL,Teva Poised To Raise Stake In Mylan  Sources,news,"By   

Teva Pharmaceutical Industries  ARCA TEVA  Ltd is looking to buy more shares in Mylan  NASDAQ MYL  NV  positioning itself for a possible legal challenge to the generics drugmaker that has spurned its takeover bid  people familiar with the matter said 
The strategy is a sign of Teva s commitment to its  40 billion   26 billion  bid for Mylan  as the latter presses on with its own  34 billion hostile bid for over the counter drug company Perrigo Company Plc 
Teva last week disclosed a 1 8 percent stake in Mylan  which blasted the move as breaching U S  antitrust laws because of the stake s size  U S antitrust laws bar companies from acquiring stakes worth more than  76 3 million in rivals without first obtaining regulatory approval  Teva s stake in Mylan far exceeds that threshold 
The dispute boils down to where Mylan  which is incorporated in the Netherlands  has its  principal  offices  Mylan argues these are located within the United States for the purposes of the U S  Federal Trade Commission  thereby affording it antitrust protection  even as it lists its principal executives offices in Britain in filings with the U S  Securities and Exchange Commission 
Despite this issue  Teva may increase its stake in Mylan to around 4 6 percent  the people said  Such a stake would allow Teva to have standing in Dutch court to potentially challenge Mylan  which has so far refused to engage with its Israeli rival  the people added 
Teva may seek to reach this ownership threshold ahead of Mylan s record date  or the date in which a shareholder must officially own shares to be entitled to vote on the tender offer for Perrigo  they said  This would raise pressure on Mylan s management ahead of the vote  the people added 
A tender offer for Mylan is likely to come after Teva raises its stake  the people said 
The sources asked not to be identified because Teva s deliberations are not public  Representatives for Teva and Mylan declined to comment 
Mylan  which makes the EpiPen product for severe allergies  can take advantage of Dutch provisions that would make a hostile takeover difficult because of its incorporation in the Netherlands 
Hedge fund Paulson   Co LP in April raised its stake in Mylan to around 4 6 percent  including derivatives  to put pressure on Mylan management to pursue a tie up with Teva  The hedge fund has been privately encouraging Mylan s board to consider Teva s takeover proposal  people previously told Reuters ",2015-06-03,International Business Times,https://www.investing.com/news/stock-market-news/teva-poised-to-raise-stake-in-mylan:-sources-344770,344770
197245,418761,MYL,Teva raises its stake in acquisition target Mylan,news,"By Olivia Oran  Reuters    Teva Pharmaceutical  ARCA TEVA  Industries Ltd  TA TEVA  has increased its stake in Mylan NV  O MYL  to nearly 2 2 percent as it presses on with an unsolicited bid for its generic drug making rival  a regulatory filing showed on Friday  The strategy is another sign of Teva s commitment to its  40 billion takeover proposal for Mylan  as the latter continues to pursue its own hostile bid for over the counter drug company Perrigo Company PLC  N PRGO   Teva had accumulated around 10 5 million shares in Mylan as of June 4  according to the filing  Teva last week disclosed a 1 8 percent stake in Mylan  which on Monday said in a letter addressed to Teva Chief Executive Officer Erez Vigodman that the move breached antitrust laws because of the stake s size   U S  antitrust laws bar companies from acquiring stakes worth more than  76 3 million in rivals without first obtaining regulatory approval  Teva s stake exceeds this amount  Companies found guilty of FTC violations could face multimillion dollar fines for every day in the market they purchase shares   Mylan  which is incorporated in the Netherlands  argues that it is entitled to antitrust protection because its principal offices are located within the United States for U S  Federal Trade Commission purposes  even as it lists its principal executives offices in Britain in filings with the U S  Securities and Exchange Commission  The Federal Trade Commission has refused to comment on whether it is investigating Teva in connection to its stake building in Mylan   Following Mylan s letter  Teva did not purchase shares in Mylan from June 1 to June 3  It resumed buying on June 4   Teva is looking to increase its stake in Mylan to around 4 6 percent  Reuters previously reported  A stake of this size would allow Teva to have standing in Dutch court to potentially challenge Mylan  which so far has refused to engage in tie up talks   
Teva has not yet submitted a formal offer to buy Mylan but will likely do so after it completes accumulating shares  Reuters reported ",2015-06-05,Reuters,https://www.investing.com/news/stock-market-news/teva-raises-its-stake-in-acquisition-target-mylan-345288,345288
197246,418762,MYL,Teva bosses issue riposte to Mylan  praise takeover plan,news,By Toby Sterling AMSTERDAM  Reuters    Executives at Israeli drugmaker Teva  TA TEVA  sent an open letter to takeover target Mylan  O MYL  on Monday  saying they remain committed to a deal and reiterated that Teva s  40 billion takeover proposal would benefit shareholders of both firms  In the letter  addressed to Mylan executive founder Robert Coury  Teva CEO Erez Vigodman and Chairman Yitzhak Peterburg repeated that a combination would add value to both companies  The letter said Mylan had made  made grossly incorrect statements to mislead your stockholders and other stakeholders about us   Mylan responded later on Monday  saying Teva s statements continue to leave it and its stakeholders with  great uncertainty  regarding the Israeli drugmaker s intentions  In a letter addressed to Vigodman  Coury asked for  straightforward  answers to two questions     The first is whether Teva was planning a legally binding exchange offer for Mylan  The second is whether any such offer would contain a  hell or high water provision  under which Teva would agree to whatever the U S  Federal Trade Commission requires to clear the transaction  The letters are the latest in a series of unusually combative communications between the two companies  Teva began an unsolicited pursuit of Mylan NV in April but has yet to make a formal offer as it awaits antitrust approval in the United States  Coury has since sent two open letters criticising Teva as a poor fit for Mylan  most recently on June 1  Spurning Teva s advances  Mylan has begun pursuing its own unsolicited  32 7 billion bid for Perrigo of Ireland  Coury has previously said that Teva  has engaged in a pattern of making noncommittal  unclear  inaccurate and non specific statements to shareholders     regarding its intentions with respect to Mylan   Teva has built a 2 2 percent stake in Mylan ahead of making a formal offer  Mylan has its operational headquarters in Canonsburg  Pennsylvania  but is incorporated in the Netherlands ,2015-06-08,Reuters,"https://www.investing.com/news/stock-market-news/teva-bosses-issue-riposte-to-mylan,-praise-takeover-plan-345634",345634
197249,418765,MYL,Theravance Mylan Presents Phase III Data On COPD Candidate,opinion,Theravance Biopharma  Inc    NASDAQ TBPH    along with its partner Mylan   NASDAQ MYL    recently announced the presentation of additional efficacy and safety data from two pivotal phase III studies evaluating its key late stage pipeline candidate  revefenacin  TD 4208   The presentation was made at the American Thoracic Society  ATS  International Conference Revefenacin is an experimental once daily nebulized long acting muscarinic antagonist  which is being developed for the treatment of chronic obstructive pulmonary disease  COPD  We remind investors that Theravance and Mylan entered into development and commercialization agreement for revefenacin in Feb 2015  Under the terms of the agreement  the companies will co develop revefenacin for COPD and other respiratory diseases  While Theravance will lead the U S  registration development program  Mylan will be responsible for the commercial manufacture of the product  Theravance is entitled to receive up to  220 million in development and sales milestone payments  Theravance is also eligible for a profit sharing arrangement with Mylan on U S  sales and double digit royalties on ex U S  sales Shares of Theravance have significantly outperformed the Zacks classified  industry so far this year  The stock has gained 14 6  during the period  while the broader industry has witnessed an increase of 7 2  Coming back to the latest news  the company reported positive top line data from two similar three month phase III studies in Oct 2016  Data from the two studies were announced in two separate presentations at the 2017 ATS meeting  While the first presentation was focused on efficacy outcomes  the second presentation featured safety and tolerability data  Data from the first presentation demonstrated statistically significant and clinically meaningful improvements compared to placebo The studies were conducted in more than 1 250 patients with moderate to very severe COPD  Moreover  data from a single 12 month safety study evaluating the candidate is expected in mid 2017  Positive data from the safety study would allow Theravance to file a new drug application for revefenacin in the U S  by the end of 2017 Meanwhile  the company initiated a phase IIIb study evaluating revefenacin in patients with low peak inspiratory flow rate in Mar 2017  Data from the study is expected in early 2018 Per the company s press release  COPD is the third leading cause of death in the U S  This is mainly because 12 7 million Americans are diagnosed with the disease  while an almost an equal number of patients remain undiagnosed  An approval will be a huge boost as there is large commercial opportunity for revefenacin in the COPD area Theravance Biopharma  Inc  Price   Zacks Rank   Key PicksTheravance currently carries a Zacks Rank  4  Sell   Some better ranked stocks in healthcare sector are VIVUS  Inc    NASDAQ VVUS   and Regeneron Pharmaceuticals  Inc    NASDAQ REGN    Each of these stocks sports a Zacks Rank  1  Strong Buy   You can see  VIVUS s loss per share estimates narrowed from 50 cents to 39 cents for 2017 in the last 30 days  The company delivered positive earnings surprises in all the four trailing quarters with an average beat of 233 69  Regeneron s earnings per share estimates increased from  10 16 to  10 52 for 2017 and from  10 90 to  12 10  over the last 30 days  The company posted positive earnings surprises in two of the four trailing quarters with an average beat of 0 45  Looking for Stocks with Skyrocketing Upside Zacks has just released a Special Report on the booming investment opportunities of legal marijuana Ignited by new referendums and legislation  this industry is expected to blast from an already robust  6 7 billion to  20 2 billion in 2021  Early investors stand to make a killing  but you have to be ready to act and know just where to look ,2017-05-23,Zacks Investment Research,https://www.investing.com/analysis/theravance-mylan-presents-phase-iii-data-on-copd-candidate-200191141,200191141
197250,418766,MYL,Wall Street s two major indexes drop  oil falls ,news,"By Sinead Carew NEW YORK  Reuters    Major U S  stock indexes lost ground on lackluster earnings reports on Tuesday  while oil fell on concerns about U S  crude stockpiles and Saudi Arabia s announcement that it ended its military campaign in Yemen  European and other markets moved higher  and currency trading was choppy  The Nasdaq composite index was the brightest spot in U S  stock markets  It gained 0 4 percent  helped by a  40 billion biotechnology acquisition proposal   But many investors held back as they waited for more quarterly reports and 2015 forecasts  said Kim Forrest  senior equity research analyst at Fort Pitt Capital Group in Pittsburgh    There s no clear trend   said Forrest   We haven t seen much change in forecasts for the remainder of the year   Teva Pharmaceutical Industries  ARCA TEVA  Ltd  made an unsolicited bid to buy smaller rival Mylan  NASDAQ MYL  NV  sending the Nasdaq Biotechnology index up 1 8 percent   The Dow Jones industrial average fell 85 34 points  or 0 47 percent  to 17 949 59  the S P 500 lost 3 11 points  or 0 15 percent  to 2 097 29 and the Nasdaq Composite added 19 50 points  or 0 39 percent  to 5 014 10  Oil prices fell on the Saudi news and anticipation of a weekly build in U S  crude stockpiles  A preliminary Reuters survey showed that U S  crude inventories likely rose by 2 4 million barrels last week  Positioning ahead of the expiry of the front month contract in U S  crude also accounted for a lot of the activity  traders and analysts said  Brent crude settled down 2 16 percent to  62 08 per barrel but was still up 13 percent from the start of the month  U S  crude contracts for May  which expire on Tuesday  settled down 1 99 percent at  55 26  but were still up about 16 percent so far this month  The dollar was mixed against major currencies  The euro gained slightly after euro zone finance ministers moved away from fixing a deadline for Greek fiscal reforms  The euro had pared its gains later in the day after falling earlier against the dollar on a report that European Central Bank staff had proposed to increase the insurance it would demand in return for emergency funding to Greek banks   The dollar was last up 0 4 percent against the yen at 119 65 yen  The dollar index was up 0 04 percent  U S  Treasuries prices fell  adding to the prior day s losses  as some traders pared bullish bets tied to soft domestic data and concerns on whether Greece would hammer out a deal with its creditors before it runs out cash  
 There s not a lot of conviction in either direction for the market   said Justin Lederer  Treasury strategist at Cantor Fitzgerald in New York ",2015-04-21,Reuters,"https://www.investing.com/news/stock-market-news/asian-stocks-steady-after-china-stimulus,-euro-hurt-by-greek-woes-338055",338055
197251,418767,MYL,Teva s turnaround CEO sets sights on  40 billion mega deal,news,"By Tova Cohen and Steven Scheer TEL AVIV  Reuters    Israeli turnaround specialist Erez Vigodman  the chief executive of Teva Pharmaceutical Industries  N TEVA   is looking to pull off the ultimate transformation  with the biggest deal in Israel s corporate history  His unsolicited  40 billion offer for smaller generic drug rival  Mylan Inc   O MYL  is Vigodman s attempt to turn Teva into a global drug powerhouse with a  100 billion market valuation  a far cry from its start as a small wholesale drug business in Jerusalem more than a century ago  Despite having no pharmaceutical experience  Vigodman  55  was hired by Teva in February last year after he had turned around MA Industries  an Israeli agro chemicals group  A certified public accountant and graduate of the program of management development at Harvard s business school  he was tasked with cutting costs and improving profits in the face of rising competition   He is a change agent with an impressive strategic mindset and a proven ability to execute restructuring programs   Teva board member Amir Elstein has said of Vigodman  At MA Industries  today called Adama  Vigodman restored profitability and invested in growth areas  In 2010 he tried to buy U S  based Albaugh for  1 billion but when analysts and investors criticized the high price  Vigodman pulled the offer  Instead  in 2011 he orchestrated a reverse merger with China National Chemical Corp  giving MA access to China  Prior to that  during his tenure as CEO of Strauss Group from 2001 2009  sales at Israel s second largest food company more than doubled  Benny Landa  an industrialist who led an investor bid last year to shake up Teva s board  has called Vigodman  a strategic thinker with excellent managerial skills     a straight shooter whom the Street will learn to trust   At Teva  after slashing debt by  2 billion  selling some plants and shutting others  the company s stock price has soared and this February Vigodman said Teva was ready to return to making acquisitions  Last month he announced the  3 5 billion purchase of U S  firm Auspex  NASDAQ ASPX  Pharmaceuticals  Teva  TA TEVA   Israel s biggest company  has grown through a series of large acquisitions over the past two decades  reaching annual sales of  20 billion  but its bid for Mylan is of a scale unprecedented in Israel s corporate history   equal to 15 percent of the high tech country s economy  It is an audacious bid from a company facing generic competition for its biggest money maker  the multiple sclerosis drug Copaxone  whose patent expires this year  Analysts have talked of the need for Vigodman to find a new growth engine through a  transformational  deal and some had picked Pennsylvania based Mylan as Teva s best option  Vigodman now has a battle on his hands  He may need to significantly sweeten the offer and needs to win over Mylan s shareholders to clinch a deal  Mylan s Executive Chairman Robert Coury has said the combination of Teva and Mylan was  without sound industrial logic or cultural fit   Landa has also questioned the logic  
 I understand the short term attractiveness of being a  100 billion company and saving costs  but I don t get it strategically   Landa said ",2015-04-22,Reuters,https://www.investing.com/news/stock-market-news/teva's-turnaround-ceo-sets-sights-on-$40-billion-mega-deal-338353,338353
197252,418768,MYL,Mylan says Teva offer too low and stock  unacceptable ,news," Reuters    Mylan NV  O MYL  rejected Teva Pharmaceutical Industries  ARCA TEVA  Ltd s  TA TEVA  unsolicited  40 billion takeover offer on Monday  saying it was too low and calling Teva stock an  unacceptable  currency  Teva  the world s biggest maker of generic drugs  last week offered  82 per share in cash and stock for smaller rival Mylan  Mylan  which is pursuing its own takeover of  Perrigo Co  Plc  N PRGO   had been expected to reject the offer after having indicated that such a combination would not be a good fit  In response to the Mylan rejection  Teva said it was standing by its cash and stock offer   Mylan shares fell 3 48 percent to  73 44 on Nasdaq  and Teva fell 2 3 percent to  62 91 on the New York Stock Exchange   High Risk Currency  Mylan Executive Chairman Rob Coury said in a lengthy letter to Teva released on Monday that Mylan would not consider any discussions unless  the starting point  was  significantly in excess of  100 per share   Wall Street analysts had said Mylan might be looking for  90 to  95 per share and an increased cash component  Coury said in the letter  which described Teva s culture as  dysfunctional   that Teva s stock was an unacceptable currency because it had underperformed its peers  including Mylan  over the last three years   The Mylan board has no interest in considering an expression of interest that    requires Mylan shareholders to accept what we believe is low quality and high risk currency in the form of Teva shares   it said   In addition  it said its customers and partners had voiced concerns about Teva and did not support the possible combination  Mylan said it remained committed to its  31 billion offer for Perrigo  which has been rejected  Mylan plans to take the offer directly to Perrigo shareholders in what is set to be one of the most high profile hostile takeover attempts of the year  Mylan s pursuit of Perrigo  a major producer of over the counter drugs  is widely seen as an attempt to fend off Teva  
 While we are disappointed that Mylan has formally rejected our proposal  the Teva board and management team are fully committed to completing the combination of Teva and Mylan   Teva CEO Erez Vigodman said in a statement ",2015-04-27,Reuters,https://www.investing.com/news/stock-market-news/mylan-says-teva-offer-too-low-and-stock-'unacceptable'-339105,339105
197255,418771,MYL,Sucampo  SCMP  Down 7 6  Since Earnings Report  Can It Rebound ,opinion,"It has been about a month since the last earnings report for Sucampo Pharmaceuticals  Inc    NASDAQ SCMP    Shares have lost about 7 6  in that time frame  underperforming the market 
Will the recent negative trend continue leading up to the stock s next earnings release  or is it due for a breakout  Before we dive into how investors and analysts have reacted as of late  let s take a quick look at its most recent earnings report in order to get a better handle on the important catalysts Sucampo Beats Q4 Earnings  2017 View ReaffirmedSucampo reported adjusted earnings of  0 68 per share in the fourth quarter of 2016  beating the Zacks Consensus Estimate of  0 49 by 38 8   Reported earnings were also up by 58 1  from the year ago figure of  0 48 Total revenue came in at  73 million  up 32  from the year ago quarter  and surpassed the Zacks Consensus Estimate of  64 million  driven by the receipt of a milestone payment from  Mylan  NASDAQ MYL  of  10 0 million in the reported quarter as well as higher Amitiza sales in both North America and Japan  Sucampo has a license  commercialization and supply agreement with Mylan for marketing Amitiza in Japan The Quarter in DetailProduct sales were  42 3 million  up 42 8  year over year  and product royalty revenue was  26 3 million  up 14 5  year over year Sales of Amitiza Sucampo s marketed product  as reported by Takeda Pharmaceutical for royalty calculation purposes  in the U S  were  114 2 million  up 11   Takeda holds the global marketing rights for Amitiza outside Japan and China and pays royalties to Sucampo  Total prescriptions for the product in the U S  were  down 2  Adjusted EBITDA were  42 8 million up 54  year over year In Mar 2017  Sucampo received a Paragraph IV certification notice letter for an Abbreviated New Drug Application  ANDA  submitted to the FDA by Amneal Pharmaceuticals requesting approval to market a generic version of the 8 mcg and 24 mcg Amitiza soft gelatin capsule products Meanwhile  the company has entered into a settlement and license agreement with generic drug maker  Dr  Reddy s which is also looking to gain FDA approval for its generic version of Amitiza 2016 ResultsFor 2016  earnings came in at  1 51 per share compared with earnings of 96 cents per share in 2015  Results also beat the Zacks Consensus Estimate of  1 22 Revenues in 2016 came in at  230 1 million  up 50  year over year and surpassed the Zacks Consensus Estimate of  221 98 million DevelopmentsIn Dec 2016  the company initiated the clinical development of a sprinkle formulation of Amitiza  Top line results are expected in the first quarter of 2017 The company also plans to initiate a randomized  bioequivalence study comparing sprinkle and capsule formulations of Amitiza in adult chronic idiopathic constipation  CIC  patients  A supplemental new drug application  sNDA  for approval of the sprinkle formulation for adults is expected to be submitted in the second half of 2017 During the quarter the company also announced that Andrew Smith  the Chief Financial Officer  will be leaving Sucampo to move back to Europe   H Peter Pfreundschuh  will become Sucampo s new Chief Financial Officer  effective March 2017 2017 Guidance ReaffirmedSucampo reaffirmed its guidance for the full year 2017  The company expects total revenue in the range of  220 0 million to  230 0 million  The Zacks Consensus Estimate for 2017 is  227 28 million The company expects adjusted net income in the range of   80 0 million to  90 0 million  and adjusted earnings in the range  of  1 35 to  1 50 The company forecasts adjusted EBITDA of  145 0 million to  155 0 million  Adjusted EBITDA guidance excludes stock option related costs of  6 0 million
How Have Estimates Been Moving Since Then 
Following the release  investors have witnessed a downward trend in fresh estimates  There has been one revision lower for the current quarter  In the past month  the consensus estimate has shifted lower by 18 4  due to these changes Sucampo Pharmaceuticals  Inc  Price and Consensus
    VGM Scores
At this time  Sucampo s stock has a poor Growth Score of  F   a grade with the same score on the momentum front  However  the stock was allocated also a grade of  C  on the value side  putting it in the middle 20  for this investment strategy 
Overall  the stocks has an aggregate VGM Score of  F   If you aren t focused on one strategy  this score is the one you should be interested in 
Zacks  style scores indicate that the company s stock is suitable solely for value investors 
Outlook
Estimates have been broadly trending downward for the stock  The magnitude of this revision also indicates a downward shift  The stock has a Zacks Rank  5  Strong Sell   We are looking for a below average return from the stock in the next few months ",2017-04-10,Zacks Investment Research,https://www.investing.com/analysis/sucampo-(scmp)-down-7.6-since-earnings-report:-can-it-rebound-200181919,200181919
197256,418772,MYL,Pharma Stock Roundup  Merck Gets CRL For Label Expansion Effort  Roche Cancer Drug Tops ,opinion,"It was a relatively slow week with key highlights including a complete response letter  CRL  for Merck s   NYSE MRK   label expansion efforts for its diabetes drugs and positive data on Roche s   OTC RHHBY   lung cancer treatment Recap of the Week s Most Important StoriesRoche Cancer Drug Tops Pfizer Drug in Study  Roche s cancer drug  Alecensa  once again topped Pfizer s   NYSE PFE   Xalkori in a study conducted in patients with ALK positive non small cell lung cancer  NSCLC   Results from the late stage head to head study showed that patients on Alecensa lived significantly longer without their disease progressing compared to those on Xalkori  Roche intends to submit this data to regulatory authorities  Alecensa has Breakthrough Therapy Designation  BTD  for the treatment of people with advanced ALK positive NSCLC who have not received prior treatment with an ALK inhibitor  Alecensa is currently approved for use in ALK positive NSCLC patients whose disease has progressed after being on Xalkori or who are intolerant to the drug  Label expansion into the first line indication would expand the patient population and Alecensa s sales potential immensely  Read more    Roche is a Zacks Rank  1  Strong Buy  stock  You can see  Merck Diabetes Drug Label Expansion Effort Fails  Merck failed in its efforts to get TECOS  Trial Evaluating Cardiovascular Outcomes with Sitagliptin  study data added to the labels of its diabetes drugs   Januvia  Janumet and Janumet XR  With death from cardiovascular disease being significantly higher in adults with diabetes compared to those without diabetes  the addition of positive cardiovascular outcomes data would have helped drive sales of these drugs  Last year  the FDA had added cardiovascular data to the label of Lilly and Boehringer Ingelheim s diabetes drug Jardiance   Read more    Bristol Myers Apexigen in Clinical Trial Collaboration  Bristol Myers   NYSE BMY   is collaborating with clinical stage biopharma company Apexigen for the evaluation of Apexigen s APX005M in combination with Bristol Myers  PD 1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors  The combination will be studied in second line metastatic NSCLC patients who have failed prior chemotherapy and metastatic melanoma patients who have failed prior immuno oncology therapy  Read more    Year to date  Bristol Myers has underperformed the Zacks categorized  industry with the company s shares declining 9 4  compared to the industry gain of 5 6  FDA Warning Letter for Mylan Facility in India  Mylan   NASDAQ MYL   got a warning letter from the FDA for one of its drug manufacturing facilities located in India  The letter mentioned significant violations of current good manufacturing practice  CGMP  regulations for finished pharmaceuticals  This is not the first time that Mylan has received a warning letter from the agency for its manufacturing facilities  Read more    Performance
The NYSE ARCA Pharmaceutical Index dipped slightly  0 11   over the last five trading sessions  Among major pharma stocks  Lilly was up 0 7  while AstraZeneca   NYSE AZN   was down 1 1   Over the last six months  Lilly gained 7 1  while AstraZeneca was down 2 1  
What s Next in the Pharma World First quarter earnings season is round the corner with industry bellwether Johnson   Johnson   NYSE JNJ   expected to report results on Apr 18 Zacks  Best Private Investment IdeasWhile we are happy to share many articles like this on the website  our best recommendations and most in depth research are not available to the public  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time  Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors ",2017-04-13,Zacks Investment Research,"https://www.investing.com/analysis/pharma-stock-roundup:-merck-gets-crl-for-label-expansion-effort,-roche-cancer-drug-tops-200182717",200182717
197257,418773,MYL,Glaxo  GSK  Reports In Line Q1 Earnings  Reiterates View,opinion,"GlaxoSmithKline plc s   NYSE GSK   first quarter results came roughly in line with expectations  Glaxo reported first quarter 2017 core earnings of 62 cents per American Depositary Share  ADS   in line with the Zacks Consensus Estimate  Earnings were up 9  year over year at constant exchange rates  CER  
Quarterly revenues were up 5  at CER to  9 2 billion   7 4 billion  on the back of strong performance at all the business segments and beat the Zacks Consensus Estimate of  9 1 billion 
All growth rates mentioned below are on a year on year basis and at CER 

Glaxo s share price increased 5 2  this year compared to the 5 9  gain witnessed by the Zacks classified  industry 
Quarterly Highlights
Glaxo reports results under three segments  Pharmaceuticals  Vaccines and Consumer Healthcare  Pharmaceuticals were up 4  while Consumer Healthcare up 2   Vaccines segment was up 16  
The Pharmaceuticals division registered revenues growth of 4  driven by strong growth of new products  particularly by Triumeq  Tivicay and Relvar Breo Ellipta which was partly offset by the impact of divestments  Respiratory sales were up 5  driven by the Ellipta portfolio and Nucala while HIV sales grew 35  on the back of a continued increase in market share for Triumeq and Tivicay  Sales of Established Pharmaceuticals declined 6  due to recent divestments 
Vaccines sales increased 16  driven by strong performance from Meningitis vaccines and higher demand for Established Vaccines along with the phasing of shipments in Emerging Markets  The segment also experienced strong performance of the Established Vaccines driven by higher demand in Emerging Markets  including the benefit of the acceleration of a number of shipments  particularly Synflorix 
However  growth slowed in the Consumer Healthcare segment primarily due to the disposal of the Nigeria beverages business  challenging conditions in international markets and a delayed start to the allergy season  On a positive note  strong performances from power brands  particularly in Oral health and the Cold   flu resulted in 2  growth 
Sales of New Pharmaceutical and Vaccine products in the quarter grew 52  and accounted for roughly 27  of Pharmaceuticals and Vaccines turnover in the quarter 
Outlook
Assuming that the generic version of Advair will not be introduced in the markets in 2017  the company expects core earnings per share to grow around 5 7  accounting for a 15 20  decline in Advair sales in the U S  in 2017  Assuming generic competition for Advair in the U S  in mid 2017  the company expects Advair sales of  1 billion in the U S  while core earnings per share are projected to be flat or decline slightly GlaxoSmithKline PLC Price and EPS Surprise
 

   Our Take
Glaxo first quarter earnings came roughly in line with expectations  Although sales of new products  Tivicay and Triumeq  Relvar Breo  Anoro  Incruse  and Nucala  and Bexsero and Menveo  will boost the top line  the potential entry for generics for Advair will impact performance 
We remind investors that Mylan s   NASDAQ MYL   efforts to bring a generic verison for Advair in the market suffered a blow as the FDA issued a complete response letter to its abbreviated new drug application  ANDA  for Advair  There are other companies too who are developing the generic for Advair  Hikma Pharmaceuticals PLC has also submitted its ANDA for its generic version of Advair to the FDA  A decision is expected on May 10 
Growth has slowed in a number of emerging markets  particularly India  Moreover  the HIV portfolio has its own set of challenges given the generics for Epzicom Kivexa in most markets across the U S  and Europe  Nevertheless  continued increase in market shares for Triumeq and Tivicay should combat this decline 
The company is currently focusing on near term launches in respiratory  HIV and Vaccines franchises and will throw more light on its business priorities in the second quarter call scheduled in Jul 2017  Hence  we expect investors to keep an eye for data read outs and approval of new drugs vaccines  regulatory decision on shingles vaccine Shingrix expected in fourth quarter 2017  given Glaxo s deep pipeline 
Zacks Rank   Key Picks
Glaxo currently carries a Zacks Rank  3  Hold  
A couple of better ranked stocks in the health care sector include Grifols  S A    NASDAQ GRFS   and Infinity Pharmaceuticals  Inc    NASDAQ INFI    Both Grifols and Infinity sport a Zacks Rank  1  Strong Buy   You can see  
Grifols  earnings estimates increased 10 6  for 2017 over the last 60 days  The company s shares have appreciated 31 4  so far this year 
Shares of Infinity have gained 58 5  this year so far  while the company s loss estimates for 2017 narrowed almost 6  in the past 60 days 
You can see the complete list of today s Zacks  1 Rank stocks here The Best   Worst of ZacksToday you are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  From 1988 through 2015 this list has averaged a stellar gain of  25  per year  Plus  you may download 220 Zacks Rank  5  Strong Sells   Even though this list holds many stocks that seem to be solid  it has historically performed 6X worse than the market ",2017-04-27,Zacks Investment Research,"https://www.investing.com/analysis/glaxo-(gsk)-reports-in-line-q1-earnings,-reiterates-view-200185747",200185747
197258,418774,MYL,Momenta  MNTA  Q1 Loss Narrower Than Expected  Sales Beat,opinion,"Momenta Pharmaceuticals Inc    NASDAQ MNTA   reported loss of 46 cents per share in the first quarter of 2017 which was narrower than the Zacks Consensus Estimate loss of  1 09  In fact  the company posted a loss of 35 cents in the year ago quarter as well 
But revenues in the quarter surged 34 1  to  26 6 million and topped the Zacks Consensus Estimate of  22 million 
Shares of Momenta have underperformed the Zacks categorized  industry in year to date  The stock rallied 4 6  compared with the industry s gain of 5 4  

Quarter in Detail
Momenta s top line comprises product revenues of  23 4 million earned from Sandoz s sales of Glatopa  a generic version of Copaxone  20 mg   compared with  14 8 million in the year ago quarter  The increase was on the back of increased number of Glatopa 20 mg units sold 
Collaborative research and development revenues came in at  3 2 million  down from  5 1 million in the year ago quarter   The decline in revenues was mainly due to the termination of the Baxalta Collaboration Agreement  effective Dec 31  2016 
While  research and development expenses were up 25 5  to  36 1 million  general and administrative expenses increased 47 7  to  23 1 million 
Outlook
Momenta reiterated its guidance for operating expenses for 2017  The company expects operating expenses  excluding stock based compensation and net of collaborative revenues  in the range of  200  240 million in 2017  The guidance also includes approximately  55 million of capital expenditure on M923 slated for 2017  Operating expenses in the second quarter of 2017 are projected around  50  60 million 
Collaboration revenues  under its agreement with Mylan   NASDAQ MYL   are anticipated to be  1 8 million per quarter  Moreover  the company anticipates to recognize the  50 million upfront payment from CSL as revenues in the second half of 2017 
Pipeline Update
Sandoz s abbreviated New Drug Application  ANDA  for the 40 mg thrice weekly formulation of Copaxone  Glatopa 40mg  was under the FDA review  However  Momenta suffered a setback with the FDA issuing a warning letter to Pfizer   NYSE PFE    which is Sandoz s contracted fill finish manufacturing partner for Glatopa 
In fact  the ANDA approval is now contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued to Pfizer  Pfizer submitted a comprehensive response to the observations cited in the warning letterMeanwhile  Momenta continues to progress with its other pipeline candidates  In fact  under its collaboration with Mylan in Apr 2017  the company completed enrolment in the phase I study on M834  a biosimilar version of Orencia  abatacept   Top line data from the study are expected in the second half of 2017 
Again  in Dec 2016  the company inked an early termination of the collaboration agreement with Shire plc   NASDAQ SHPG    to develop and commercialize M923  a biosimilar version of Humira  adalimumab   In lieu  the company received a one time asset return payment of  51 2 million from Shire in Jan 2017 
Currently  Momenta s M923 is being evaluated in a phase III study  It announced positive results from a phase III study on M923 in patients suffering from moderate to severe chronic plaque psoriasis  Moving ahead  the company plans to submit the candidate for approval to regulatory bodies by mid 2017  Also  it expects first commercial launch of M923 to be as early as the 2020 timeframe 
Furthermore  Momenta s novel autoimmune portfolio includes two recombinant molecules  M230  a Selective Immunomodulator of Fc receptors  SIF3  and M281  an anti FcRn monoclonal antibody  In Jan 2017  the company entered into a research collaboration and license agreement with CSL for M230 and potential future Fc multimer programs  The candidate is expected to enter clinic in 2017 
In fact  this company successfully completed a phase I single ascending dose study in healthy volunteers for M281  The multiple ascending dose portion of the study was initiated in Jan 2017 and data from the single and multiple ascending dose portions of the study are projected in the second half of 2017 
M254 is a tetra Fc sialylated immunoglobulin with consistent enhanced anti inflammatory activity  The company continues to progress the M254 program and expects to initiate an investigational new drug  IND  enabling toxicology study in 2017 and is anticipated to enter a clinical study in 2018 
Our Take
The company posted narrower than expected loss and sales beat estimates in the first quarter of 2017  The ANDA approval for Glatopa is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA  resulting in a delay of approval  Notably  the warning letter will remain a drag on the company s shares till the issue is solved 
However  sales of Glatopa 20mg continue to do well  In addition  a potential submission of M923 for approval in mid 2017 will boost investor confidence  Further  Momenta may collaborate with some other company for the future development and commercialization of the drug Momenta Pharmaceuticals  Inc  Price  Consensus and EPS Surprise
    Zacks Rank
Momenta currently carries a Zacks Rank  3  Hold   You can see  
Will You Make a Fortune on the Shift to Electric Cars 
Here s another stock idea to consider  Much like petroleum 150 years ago  lithium power may soon shake the world  creating millionaires and reshaping geo politics  Soon electric vehicles  EVs  may be cheaper than gas guzzlers  Some are already reaching 265 miles on a single charge  With battery prices plummeting and charging stations set to multiply  one company stands out as the  1 stock to buy according to Zacks research  It s not the one you think ",2017-05-02,Zacks Investment Research,"https://www.investing.com/analysis/momenta-(mnta)-q1-loss-narrower-than-expected,-sales-beat-200186865",200186865
197259,418775,MYL,Wall St  ticks up on M A but energy weighs as crude drops,news,"By Tanya Agrawal NEW YORK  Reuters    U S  stocks rose on Wednesday on merger activity in the healthcare sector even as energy stocks sold off after a large buildup in crude stockpiles sent oil futures reeling  Traders are keeping an eye out for the release of minutes from the Federal Open Market Committee s March policy meeting  in which the Fed downgraded its economic growth and inflation projections while leaving the door open to raising rates in the near future  The minutes are due at 2 p m  EDT  Mylan shares  O MYL  jumped 14 4 percent to  68 15  boosting the Nasdaq and the S P healthcare sector   on news it offered to buy Perrigo  N PRGO  for about  29 billion in cash and stock  Perrigo shares jumped 21 7 percent to  200 50  Biotech and pharmaceuticals have seen more than  60 billion in deals so far this year  the highest volume since 2009  Brent crude  slid 4 5 percent and U S  crude  lost 5 6 percent after data from the U S  Energy Information Administration showed the largest weekly build in oil inventories since March 2001   Expect to see a lot more consolidation in the energy sector   said Brian Amidei  managing director and partner at HighTower Advisors in California  referring to the state of smaller players after the sharp decline in oil prices in the past year  Energy stocks  which had been supported by Royal Dutch Shell s  L RDSa   70 billion bid for rival BG Group  L BG   fell sharply after the EIA data  At 12 49 p m  EDT the Dow Jones industrial average  DJI  rose 38 67 points  or 0 22 percent  to 17 914 09  the S P 500  SPX  gained 5 93 points  or 0 29 percent  to 2 082 26  and the Nasdaq Composite  IXIC  added 37 49 points  or 0 76 percent  to 4 947 72  New York Fed President William Dudley said a June rate hike remains on the table  reiterating the Fed mantra that any tightening is data dependent  As the reporting season gains momentum  first quarter S P 500 earnings are projected to show a decline of 2 8 percent from a year earlier  which would be the worst comparatives since the third quarter of 2009  Advancing issues outnumbered declining ones on the NYSE by 1 762 to 1 176  for a 1 50 to 1 ratio on the upside  on the Nasdaq  1 680 issues rose and 946 fell  for a 1 78 to 1 ratio favoring advancers  
The benchmark S P 500 index was posting 11 new 52 week highs and no new lows  the Nasdaq Composite was recording 60 new highs and 21 new lows ",2015-04-08,Reuters,https://www.investing.com/news/stock-market-news/futures-flat-ahead-of-fed-minutes;-m-amp;a-eyed-336092,336092
197265,418781,MYL,Consort Medical  Pipeline And Margin Momentum ,opinion,"Consort Medical s  LON CSRT  H117 interims evidenced underlying earnings growth  ongoing margin expansion and increased diversity in the business and customer base  At Bespak significant contract wins and recent and potential near term launches support longer term growth  Increased capacity utilisation and the serialisation opportunity could drive Aesica operating margin towards the double digit target  M A could supplement Consort s existing product  competency or geographic capabilities  Nevertheless  organic growth is supported by a growing pipeline  with 16 disclosed Bespak projects and an  Innovation funnel  of 11 early stage development feasibility projects 

Bespak  Pipeline and business development delivery
Bespak revenue growth   4 3  to  58 9m  was supported by solid and diversifying product and service revenues  c 25  is non respiratory   EBIT margin was  60bp to 20 7   The Syrina VapourSoft master development agreement and UCB Cimzia autoinjector  INJ570  approval should add impetus to the injectables franchise  In respiratory  the launch of VAL100  AstraZeneca  and potential DEV610  Mylan  NASDAQ MYL   approval could generate meaningful revenues and diversify customer dependency 
To read the entire report Please click on the pdf File Below",2016-12-20,Edison,https://www.investing.com/analysis/consort-medical---pipeline-and-margin-momentum-200170285,200170285
197266,418782,MYL,Stocks Close Lower For Final Session Of 2016,opinion,"U S  stocks closed the final trading session of 2016 lower as complacency lingered and volume and data were light ahead of the New Year holiday weekend  Treasuries were higher and the U S  dollar  gold and crude oil prices ticked lower  In light economic news  a read on some regional manufacturing activity missed expectations 
The Dow Jones Industrial Average  DJIA  decreased 57 points  0 3   to 19 763  the S P 500 Index lost 10 points  0 5   to 2 239 and the Nasdaq Composite declined 49 points  0 9   to 5 383  In moderately light volume  783 million shares were traded on the NYSE and 1 5 billion shares changed hands on the Nasdaq  WTI crude oil ticked  0 05 lower to  53 72 per barrel and wholesale gasoline was  0 01 lower at  1 67 per gallon  Elsewhere  the Bloomberg gold spot price shed  5 73 to  1 152 40 per ounce  and the Dollar Index a comparison of the U S  dollar to six major world currencies was 0 4  lower at 102 30  Markets were lower for the week  as the DJIA declined 0 9   the S P 500 Index lost 1 1  and the Nasdaq Composite decreased 1 5  
Mylan NV  NASDAQ MYL  38  announced the launch of a generic version of Dow member Johnson   Johnson  NYSE JNJ  s  JNJ  115  drug  Concerta  aimed at treating Attention Deficit Hyperactivity Disorder  ADHD   MYL traded higher and JNJ was little changed 
Cabelas Inc  NYSE CAB    CAB  59  dropped after the company received a  second request  from the Federal Trade Commission  FTC  for additional information in regard to its proposed merger with Bass Pro Shops 
Regional manufacturing activity slips
The Chicago Purchasing Managers Index    declined more than expected but remained in expansion territory  above 50   decreasing to 54 6 in December from 57 6 in November  and versus the Bloomberg expectation of a dip to 56 8  Growth in  new orders and production both decelerated  while inventories and employment both signaled contraction 
Treasuries were higher  with the yield on the 2 year note dipping 2 basis points  bps  to 1 20   the yield on the 10 year note declining 3 bps to 2 44  and the 30 year bond rate slipping 1 bp to 3 07  
Bond yields have rallied this year in the wake of upbeat economic data  which has accompanied high expectations for fiscal stimulus  tax reform and regulatory rollbacks following the surprise November Presidential election  Also  the rally in rates was bolstered in early December as the Fed s highly expected 25 bp increase to its target for the fed funds rate included a forecast for more rate hikes in 2017 than it had previously projected  
Please note  All U S  markets will be closed on Monday in observance of the New Year holiday 
Europe modestly higher and Asia mixed to close out 2016 European equities finished slightly higher  amid lingering complacency to close out 2016  which saw mixed performance in the region as U K  markets stood out with a sharp rally  though Italian stocks fell noticeably on exacerbated banking sector concerns  Financials led to the upside  as the banking sector got a reprieve  with Italian lender Banca Monte dei Paschi di Siena SpA  OTC BMDPD   BMDPD  7  announcing plans to issue about  15 8 billion of debt to bolster is capital position  The report comes as the company is expected to receive government support after it approved a bank bailout decree that will allow it to increase its public borrowing by 20 billion euros to help fund bank bailouts  Stocks shrugged off flared up geopolitical concerns as the U S  announced new sanctions against Russia  as well as the expulsion of 35 diplomats  due to allegations that the country interfered with the November elections  Russia announced today that it will not retaliate by expelling American diplomats  The euro and British pound traded higher versus the U S  dollar  while bond yields in the region gained ground 
Stocks in Asia finished mixed in the final trading session of 2016  which has seen divergent performance  while volume continued to be subdued ahead of the New Year holiday  with markets in South Korea closed today  Japanese equities declined despite the yen giving back some of yesterday s advance  Stocks trading in mainland China and Hong Kong advanced on the heels of yesterday s upbeat November trade data  Chinese stocks rebounded from recent weakness that has come courtesy of festering currency liquidity concerns in the wake of the U S  dollar s recent jump  uncertainty following government crackdowns notably on the real estate and insurance sectors and lingering uneasiness regarding trade relations with the U S  
Australian securities fell  with financials seeing pressure  Indian equities rallied  along with other emerging markets  continuing to pare recent weakness that has been fostered by earnings and economic concerns  along with government reform uncertainty and monetary policy divergence  
Stocks limp to 2016 finish line 
U S  stocks finished lower on the holiday shortened final week of 2016  with the markets complacent amid a lack of catalysts and data light ahead of the New Year  The U S  dollar and Treasury yields pulled back from 2016 rallies  while crude oil prices added to a year to date surge  The global markets assessed the wild swings in 2016  with the Fed raising rates in the wake of some signs the economy is gaining steam  while showing some resiliency in the face of heightened political uncertainty in Europe  notably a short lived negative reaction to the U K  s vote to leave the European Union  known as Brexit  All major U S  indexes rallied sharply on the year  bolstered by the surprise November election  which saw Donald Trump win the Presidency and the Republicans gain control of Congress  On the year  most major sectors jumped  led by energy issues on crude oil s surge and financials in the wake of the upward charge in interest rates  but real estate stocks dipped and healthcare issues saw red 
The New Year will begin with another shortened week  but the  will be robust  with the ISM Manufacturing and non Manufacturing Indexes being joined by the Fed s minutes from its December meeting where it raised rates and offered a forecast for a faster pace of hikes in 2017 than it had previously estimated  Other reports include the trade balance  factory orders and Markit s reads on manufacturing and services sector activity  However  the headlining release will likely be Friday s December nonfarm payroll report 
A compelling support for 2017 is investor flows into U S  based funds  helping to keep the bull market alive  The populist trend seen globally last year may not continue and investors should focus on market reactions in the face of political  shocks  and on the improving global manufacturing picture  
International reports due out next week include  Australia trade balance  China manufacturing and services data  India preliminary 1Q GDP estimate  Eurozone Markit s business activity reports  CPI estimate  economic confidence and retail sales  Germany factory orders  U K  Markit s business activity reports ",2017-01-01,Marvin Clark,https://www.investing.com/analysis/stocks-close-lower-for-final-session-of-2016-200171156,200171156
197268,418784,MYL,Trump Vows To Slash Drug Prices  Sends Biotech Stocks Lower,opinion,"The post election biotech honeymoon is over  Shares of the iShares Nasdaq Biotechnology ETF  are down more than 3 6  in morning trading Wednesday following a new warning from President elect Donald Trump that he will indeed be targeting high drug prices 
Immediately following the election  IBB soared more than 9  as investors assumed that Trump would be much less likely to crack down on exorbitant drug price hikes than Hillary Clinton  After all  Clinton had put drug prices at the forefront of her campaign  while Trump is typically an outspoken supporter of deregulation 
In an interview with   which recently named him its  Person of the Year   the president elect promised to lower the cost of costly medications and suggested that investors may have misread his intentions 
 I m going to bring down drug price   Trump told Time   I don t like what has happened with drug prices  
Trump s warning was  as usual  concise and vague  but the message clearly resonated with biotech investors  Companies with existing price scandals  such as Mylan   NASDAQ MYL    felt the brunt of the sell off today  while ETFs like IBB and the SPDR S P Biotech  MX XBI  ETF  highlighted the range of the trading 
Interestingly enough  Trump s has previously promised to roll back FDA regulations to make things easier for companies to do business  It looks like Trump s FDA promises could be more focused on food and farming regulations now  as a move to bring drug costs down would imply some sort of intervention in the pharmaceuticals industry 
Stocks that Aren t in the News  Yet 
You are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street  They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015 with a stellar average gain of  26  per year ",2016-12-07,Zacks Investment Research,"https://www.investing.com/analysis/trump-vows-to-slash-drug-prices,-sends-biotech-stocks-lower-200168776",200168776
197275,418791,MYL,Your Two Minute Earnings Preview For Mylan  MYL  Stock ,opinion,"This quick video takes a look at Mylan  NASDAQ MYL  ahead of its earnings report  The pharma company has been under pressure for much of 2016 while a bottom 33  industry rank isn t helping matters either 
Even more troubling than the weak industry rank is the rank for MYL stock  Shares of Mylan are now in  sell  territory  while the VGM score for the stock is just a  C   Additionally  the stock has a negative earnings ESP  which can be a harbinger of a miss in earnings season 
However  investors should note that while estimates are definitely trending lower  MYL does have a history of beating earnings expectations  The company has missed just twice in the past five years  so history is definitely on Mylan s side  though it could be a case where the outlook and the sector perception weigh on the shares more than anything MYLAN NV Price  Consensus and EPS Surprise   
Mylan reports on November 9th after the bell  and we are looking for earnings of  1 50 per share  Make sure to watch the video for a quick guide to MYL heading into the report  but if you want to learn more about trading in earnings season  check out our Zacks Live Trader below for additional information 
Confidential from ZacksWould you like to access Zacks  2 best trades that are not available to the public  Zacks Executive VP  Steve Reitmeister knows which of our experts has the hottest hand and when key trades are about to be triggered  Today he is prepared to pass the Best of Our Best along to you ",2016-11-08,Zacks Investment Research,https://www.investing.com/analysis/your-two-minute-earnings-preview-for-mylan-(myl)-stock-200163545,200163545
197276,418792,MYL,3 Things To Watch When Mylan Reports Earnings On Wednesday,opinion,"by Clement Thibault
Mylan  NASDAQ MYL   the global manufacturer and distributor of generic  branded generic and specialty pharmaceuticals will release its Q3 2016 earnings report on Wednesday  November 9  after the market close 

1  Earnings and Revenue
Mylan is expected to report earnings of  1 46 on  3 14 billion in revenue  The company s revenues are anticipated to continue to rise  with growth of 16  expected this quarter  Mylan s earnings have also been moving up  although growth in this area has been widely inconsistent over the past year because of rising expenses  varying between more than 20  to the low single digits  This time around  earnings are expected to grow by a meager 2  

2  EpiPen Controversy
Pricing issues have weighed heavily on the pharmaceuticals sector  particularly since the Martin Shkreli Turing Pharmaceuticals scandal in September 2015  when news broke that Shkreli  then Turing s CEO  had hiked the price of a drug used to treat AIDs by over 5400   The latest focus of this growing storm is Mylan  which came under fire in August because of the price of its life saving EpiPen a decades old  auto injector used by millions of people to combat anaphylaxis brought on by such common things as food allergies and insect bites which it had inherited as part of a larger purchase of medicinal lines from Merck KGaA  DE MRK  in 2007 
The Turing scandal goes a long way toward explaining why this whole thing blew up so badly for Mylan this past summer  After MYL acquired the EpiPen  they set out to market the product to parents whose children suffered from a broad variety of allergies and were at risk for anaphylactic shock  Mylan s efforts surpassed their expectations for the EpiPen which isn t even one of their core products  The marketing campaign helped drive the EpiPen price from  100 in 2009  for a two pack of injectors  to over  600 today for the same two pack an increase of more than 500   To reduce the criticism and calm angry consumers  MYL has decided to launch a generic EpiPen of its own  which will be priced at  300 for a two pack  While this may appease angry consumers  it will certainly hurt Mylan s specialty segment profit margins 
As if the summertime controversy wasn t enough  in early October word went out that Mylan had reached a settlement with US authorities over the misclassification of the EpiPen in the Medicaid Drug Rebate Program  The company was found to have labeled the device as a  non innovator  or generic drug  allowing the company to pay lower rebates to the US government on purchases of the drug  The  465 million settlement  which Mylan has agreed to pay  is expected to show up in the company s report this quarter 
Both issues likely won t fade away any time soon as they go deeper than controversies and settlements  Pharmaceutical companies  Mylan included  have become the eye of a political storm surrounding drug pricing  affordability and pharmaceutical company practices  Hillary Clinton has called on Mylan to reduce the price of its device yet further and has recommended a Federal  response team  monitor drug price hikes going forward  The idea of governmen controls on the price of drugs is a nightmare scenario for big and small pharma as well as investors who follow and buy the sector  Indeed  the current political environment is one of the leading reasons why the NASDAQ Biotechnology Index is down over 26  since the beginning of 2016 

3  Generic Drugs
Mylan s core business  generics  involves recreating drugs whose patents have expired  generating competitive offerings and driving prices down  Mylan s generics business is actually performing well  growing at a 10  rate over last year  a noteworthy accomplishment considering that generics represent 85  of Mylan s business  This rate of growth is expected to continue over the next few years  and would be great news for the price of Mylan s stock   if the company were not to become embroiled in another scandal 
Unfortunately  last Thursday  a report was released that a Federal inquiry into drug price fixing has found more meaningful evidence than previously thought that the practice is widespread and ongoing  The report named Mylan and Teva  NYSE TEVA  along with nine other pharmaceutical companies  and led to a sharp  8  drop in the stock s price when the news broke 
Conclusion
Mylan s ongoing and multiple legal issues should be a serious concern for investors  Indeed  the stock is now down to  35  less than half of its high of  76 in April 2015  Still  along with the EpiPen it has a number of successful lines including Simvastatin  a cholesterol reducer  and Omeprazole which is used to treat digestive issues  Nevertheless  the presidential election  coupled with several calls by US senators to intervene in the pharma industry and a price fixing scandal are probably more than many investors are willing to take on at this point 
If one was to ignore all of the above and focus on the numbers  Mylan would be a solid company in which to invest  Revenue has been up every quarter since 2010  the company has a reasonable 22 P E ratio  cash flow of  2 billion TTM from operations  current liabilities of  3 7 billion but on  6 billion in current assets   and that s not counting the fresh  6 billion it just raised from a bond offering 
However  right now Mylan is simply plagued by too many legal issues to be a solid buy  First  watch the elections since the results will undoubtedly affect not just Mylan  but the entire healthcare sector  But do keep an eye on Mylan  With its solid fundamentals it could be a good risk reward play should its share price drop further  We like the company for the longer term and believe there will come a period of reduced uncertainty paired with a good entry point  But that period is not now ",2016-11-08,Clement Thibault/Investing.com ,https://www.investing.com/analysis/3-things-to-watch-when-mylan-reports-earnings-on-wednesday-200163125,200163125
197277,418793,MYL,Theravance  TBPH  Posts Narrower than Expected Q3 Loss,opinion,"Theravance Biopharma  Inc    NASDAQ TBPH   reported third quarter 2016 loss of 73 cents per share  much narrower than both the Zacks Consensus Estimate of a loss of 95 cents and the year ago loss of  1 40 Total revenue in the quarter surged 78 3  year over year to  19 1 million on the back of higher collaboration revenues and beat the Zacks Consensus Estimate of  16 4 million 
Quarterly Details
Theravance s sole marketed product  Vibativ  generated U S  revenues of  3 9 million in the third quarter of 2016  up 68 7  from the year ago period  However  the figure tanked 27 2  sequentially due to seasonality and trends in surgical admissions 
Revenues from collaborations soared approximately 81  to  15 2 million  This was due to the recognition of upfront payment of  15 million from Takeda Pharmaceutical Company Limited   OTC TKPYY   under a commercialization agreement for TD 8954 
Research and development expenses were  32 million  up 5 2  from the year ago period mainly due costs associated with the advancement of the company s priority programs 
Selling  general   administrative expenses  on the other hand  declined 11 2  to  20 3 million mainly due to lower costs associated with share based compensation expense and timing of other expenses 
2016 Outlook
Theravance expects operating loss  excluding share based compensation  of approximately  140 million in 2016 
Pipeline Update
Theravance has made significant progress with its pipeline  In Oct 2016  Theravance and Mylan N V    NASDAQ MYL   announced positive top line data from two replicate three month phase III studies evaluating revefenacin  TD 4208  for the treatment of chronic obstructive pulmonary disease  COPD  
Data showed that the studies met primary efficacy endpoints  demonstrating statistically significant and clinically meaningful improvements over placebo in trough lung function after 12 weeks of dosing for both the 88 mcg once daily and 175 mcg once daily of revefenacin  Both the doses of the candidate were found to be generally well tolerated in the studies 
In addition to the two efficacy studies  the phase III program includes an ongoing 12 month  open label  active comparator safety study  which is expected to be complete in 2017  Positive data from the safety study would allow Theravance to file a new drug application for revefenacin in the U S  by the end of 2017 
We note that Theravance has partnered with Mylan for the development and commercialization of nebulized revefenacin products for the treatment of COPD and other respiratory diseases 
Theravance is working on expanding Vibativ s label  The company is evaluating Vibativ in a phase III study for the treatment of primary bacteremia with the study expected to be complete in 2018  Moreover  the TOUR registry program is on track and is generating useful data across a range of difficult to treat infections 
With a number of updates expected on the pipeline front over the upcoming quarters  we expect investor focus to remain on pipeline updates by the company 
THERAVANCE BIO Price  Consensus and EPS Surprise
    Zacks Rank   a Stock to Consider
Theravance is a Zacks Rank  3  Hold  stock  A better ranked stock in the health care sector is Infinity Pharmaceuticals  Inc    NASDAQ INFI    sporting a Zacks Rank  1  Strong Buy   You can see  
Infinity s loss estimates narrowed from  3 84 to  3 79 for 2016 over the last 60 days  The company has posted a positive surprise in all of the four trailing quarters with an average beat of 67 62  
Zacks  Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website  how would you like to follow all Zacks  private buys and sells in real time 
Our experts cover all kinds of trades  from value to momentum       from stocks under  10 to ETF and option moves       from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises  You can even look inside exclusive portfolios that are normally closed to new investors  Starting today  for the next month  you can have unrestricted access ",2016-11-08,Zacks Investment Research,https://www.investing.com/analysis/theravance-(tbph)-posts-narrower-than-expected-q3-loss-200163698,200163698
197278,418794,MYL,Opening Bell  Trump Victory Stuns Markets,opinion,"by Eli Wright
It s official  Donald J  Trump has won the White House and Republicans have retained control of both the Senate and Congress  Markets were stunned this morning as the Republican candidate s come from behind victory became clear 
In Asia  the Nikkei took a nose dive  closing down 5 36  at 16 251 54  the Hang Seng fell 2 29  to 22 388  and the Shanghai Composite dipped 0 62  to 3 128 45 
In Europe  the FTSE 100 opened at 6 702  down 2   currently it s trading at 6 818 down just 0 37   the DAX began the day down 3   trading now at 10 351  a decline of 1 25   the Stoxx 50 was also down 3  at the open  but is now trading at 2 973  down by 1 62  
US markets remained cautiously optimistic yesterday and closed up  on the expectation that by this morning Hillary Clinton would be the 45th president elect  However  overnight  the election picture changed drastically and futures markets went into a tailspin  quickly dropping 5  at which point trading was briefly suspended  However  after Trump declared victory  futures began moving up  but remain down  S P 500 futures are currently trading at 2 095 25  down 1 88   the Dow is at 17 960  down 1 78  while the NASDAQ is at 4 697 25  down 2 2  

Looking at the S P monthly chart  above  despite clear upward movement  the Doji bearish reversal  along with indicators such as the MACD and RSI are currently showing a bearish divergence  indicating a possible  additional 10 15  downside  The market could potentially reach 1 730 1 830  where there is once again a strong demand threshold 
Forex
The US Dollar Index remains within its two year range  However  over the short term  the dollar is tanking against the euro and safe haven currencies such as the yen and Swiss franc  Additionally  with the economic uncertainty of Trump s presidency factored in  chances of a December Fed rate hike are dropping  they currently stand at 61 8   
The Mexican peso has been moving lower for almost four years now  but the prospect of a Trump presidency has accelerated the trend 

The Mexican peso sank to an all time  record low  falling more than 13   before paring losses  It is currently down 8 24  to  0 0501  Mexico s central bank has scheduled an emergency conference with the country s finance ministry later today  and may decide to raise interest rates in an attempt to stabilize the currency 
Commodities
Risk appetite  which has been wavering over the past weeks was quashed again this morning  and gold is up 2 54   trading at  1306 65 and likely heading higher 

The yellow metal s monthly chart indicates it could hit a probable zone of  1 390  1 420  possibly breaking above resistance from there  Silver has also gained  up 2 38  to  18 793 
Oil is holding at  45  while Brent is up 0 4   to  46 20  the EIA Crude Oil Inventories weekly report will be released later today 
Natural gas futures fell yesterday to their lowest levels since August  as a warmer than expected start to winter deepened concerns of a possible supply glut  Currently  prices are down 0 08  to  2 631 
Stocks
Global stocks went into a tailspin as the morning progressed  It remains to be seen how heavily US markets will sell the news 
Companies reporting later today include 
Generic pharmaceuticals maker Mylan  NASDAQ MYL  reports Q3 earnings after the close  It s forecast to show EPS of  1 51  a YoY gain of approximately 5   Revenue is expected to increase yet again  it s been up every quarter since 2010  However  the real question is how significantly the recent EpiPen price gouging controversy  and ongoing price fixing investigation will continue to affect the stock 
Restaurant chain Shake Shack  NYSE SHAK  also reports Q3 results after the close  Expected EPS of  0 15 with revenues anticipated to rise by 2  this quarter  The company has beaten estimates in each of the last four quarters  SHAK has an annual average sales volume of around  5 million per restaurant  higher than any other fast food chain  but Q2 same store sales growth  SSSG  was only 4 5   less than the expected 4 9   and a 61  decline from the 11 7  SSSG in Q2 2015  
Media giant Viacom  NASDAQ VIAB  reported Q4 earnings this morning  beating EPS expectations of  0 65 to come in at  0 69  Revenues disappointed  however coming in at  3 23B  below the  3 49B expected ",2016-11-09,Investing.com,https://www.investing.com/analysis/opening-bell:-200163613,200163613
197279,418795,MYL,Mylan  MYL  Misses Q3 Earnings  Reiterates 2016 EPS Forecast,opinion,"Mylan NV   NASDAQ MYL   just released its third quarter fiscal 2016 financial results  posting earnings of  1 38 per share and revenues of  3 06 billion  MYL is a  4  Sell   and is up 0 21  to  39 00 per share in after hours trading shortly after its earnings report was released 
Missed earnings estimates  The company reported earnings of  1 38 cents per share  missing the Zacks Consensus Estimate of  1 50 per share and falling 3 5  year over year  This number excludes  1 61 from non recurring items 
Missed revenue estimates  The company saw revenue figures of  3 06 billion  lagging behind our consensus estimate of  3 230 billion but rising 13 4  year over year 
Mylan reported that its Generics segment third party brought in net sales of  2 61 billion  up 17   or 16  on an adjusted basis  compared to the prior year period  Specialty segment third party net sales came in at  418 7 million  down 4  year over year 
Looking ahead  Mylan  remains committed  to its recently updated full year 2016 adjusted EPS guidance of  4 70 to  4 90 per share  and to its 2018 adjusted EPS target of  6 00 per share 
Mylan CEO Heather Bresch commented   Our third quarter results were consistent with the full year guidance we provided a few weeks ago  During the quarter  we reported strong performance across our European and Rest of World regions  as well as solid performance across our North American region In our Specialty segment  while EpiPen  Auto Injector scripts grew quarter over quarter  volumes were down due to the lack of wholesaler purchases in the quarter in anticipation of our upcoming generic launch  
Here s a graph that looks at Mylan s price  consensus  and EPS surprise MYLAN NV Price  Consensus and EPS Surprise   Mylan NV is a pharmaceutical company  The company develops  licenses  manufactures  markets and distributes generic and specialty pharmaceuticals  It operates primarily in the United States  Canada  Europe  the Middle East  Africa  India  Australia  Japan and New Zealand  Mylan NV  formerly known as Mylan Inc   is based in Canonsburg  Pennsylvania 
Stocks that Aren t in the News Yet
You are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street  They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015  with a stellar average gain of  26  per year ",2016-11-09,Zacks Investment Research,"https://www.investing.com/analysis/mylan-(myl)-misses-q3-earnings,-reiterates-2016-eps-forecast-200163747",200163747
197288,418804,MYL,Mylan  MYL  To Report Q3 Earnings  Stock Likely To Disappoint,opinion,Mylan N V    NASDAQ MYL   is scheduled to report third quarter 2016 results on Nov 9  after the market closes  The company s performance has been decent so far  having beaten earnings estimates in three of the trailing four quarters  Overall  it has delivered an average positive surprise of 0 86  Last quarter  the company recorded a positive earnings surprise of 0 87   Let s see how things are shaping up for this announcement Factors to Consider This QuarterMylan was in the news through the entire third quarter for the massive price hike of its severe allergy treatment  EpiPen  in the recent years  for which it drew flak from lawmakers  consumers and the common people alike  Reeling under pressure  Mylan tried to mitigate the issue by offering a savings card for up to  300  expanding the eligibility of its patient assistance program and announcing the upcoming launch of a generic EpiPen at a discount of over 50  on the branded product s price The company again made it to the headlines when several lawmakers questioned Medicaid rebates for EpiPen  The Centers for Medicare   Medicaid Services found that Mylan had misclassified EpiPen as a non innovator multiple source drug or a generic drug in the Medicaid Drug Rebate Program  This means that the company has been vastly underpaying rebates to Medicaid for the drug for a long time  This led to millions of dollars in overpayment for the drug by states and the federal government under the Medicaid Drug Rebate Program Finally  last month  Mylan agreed to pay  465 million to the U S  Department of Justice and other government agencies to settle the issues regarding the classification EpiPen for purposes of the Medicaid Drug Rebate Program  The company expects to take a third quarter 2016 pre tax charge of approximately  465 million to reflect this settlement Concurrent to the announcement of the settlement  Mylan lowered its 2016 earnings outlook  The company now expects earnings in the range of  4 70  4 90 per share  marking a significant reduction from the previous guidance of  4 85  5 15 The company attributes the lowered earnings guidance largely to the changes in EpiPen access programs and the upcoming launch of generic EpiPen  Mylan also stated said that it expects to see a considerable impact of this guidance in the third quarter of 2016 Meanwhile  Mylan s Generics segment has been performing well over the last few quarters and should continue the momentum this quarter as well  Moreover  the company has seen quite a few generic launches over the past few quarters and this one was no exception  Newly launched products should perform well and aid the top line  while acquisitions contribute meaningfully  thereby driving segmental growth In the to be reported quarter  in Aug 2016   Mylan acquired Swedish drug maker Meda in a deal worth  9 9 billion Notably  Mylan s Specialty segment  of which EpiPen is the most significant product  is expected to take a hit On the third quarter call  investor focus will be on the company s performance as well as on the EpiPen pricing controversy given that lawmakers continue to question the company s pricing policy  and political  public and media focus is on the issue Earnings WhispersOur proven model does not conclusively show that Mylan is likely to beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to likely post an earnings beat  That is not the case here  as you will see below Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is  1 99   Please check our  that enables you find stocks that are expected to come out with earnings surprises Zacks Rank  Mylan currently has a Zacks Rank  4  Sell   As it is  we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions MYLAN NV Price and EPS Surprise    Stocks that Warrant a LookHere are some health care stocks that you may want to consider instead  as our model shows that these have the right combination of elements to post an earnings beat this quarter ARIAD Pharmaceuticals Inc    NASDAQ ARIA   is scheduled to report third quarter results on Nov 7  It has an Earnings ESP of  5 26  and a Zacks Rank  2  You can see  The Earnings ESP for Aquinox Pharmaceuticals Inc    NASDAQ AQXP   is  3 33  and it carries a Zacks Rank  3  The company is expected to release third quarter results on Nov 8 Synergy Pharmaceuticals  Inc    NASDAQ SGYP   is expected to report third quarter results on Nov 14  It has an Earnings ESP of  18 18  and a Zacks Rank  3 Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-11-02,Zacks Investment Research,https://www.investing.com/analysis/mylan-(myl)-to-report-q3-earnings:-stock-likely-to-disappoint-200162580,200162580
197289,418805,MYL,Endo International  Surviving Despite Collusion Charges,opinion,"Thursday was not a good day for generic drug companies  On that day   broke the news that the U S  Department of Justice was investigating multiple generic pharmaceutical companies on charges of price collusion  These news are particularly problematic given how pharmaceutical companies have been under severe attack from the public for buying the rights to cheap generic drugs and massively jacking up the price in order to make a profit  Several companies such as Teva Pharma Industries Ltd  NYSE TEVA   Impax Laboratories Inc  NASDAQ IPXL   and Mylan  NASDAQ MYL  Pharmaceuticals saw a massive single day drop due to the news 
Investors should be naturally leery of investing in any of these companies  but Endo International PLC  NASDAQ ENDP  is at particular risk  Endo took a massive hit alongside everyone else as it lost 19 5 percent of its value  and the company has issues even before it will have to deal with the inevitable storm of political outrage  fines  and additional regulations better than its competitors 
The company s ongoing discussion to sell Paladin Labs to relieve its massive debt load is concerning  as is its stock performance over the past year and the intense competition it faces  Investors should look to sell their holdings in Endo and avoid the temptation to buy on the dip  The Collusion Charge
The collusion charge is what caused Endo s stock to collapse and is the biggest problem in the short to medium term  As the aforementioned Bloomberg report noted  the Justice Department s investigation targets two dozen companies and drugs and has sent subpoenas to these companies  While some companies like Teva indicated their willingness to cooperate  Endo did not comment 
The fact that  high level executives  could be charged and fined would be enough to give any company jitters under normal circumstances  and these are much worse than normal circumstances  The Democratic Party has made political hay for the past year by targeting pharmaceuticals who they argue unfairly jack up prices which hurt the ordinary consumer 
If Hillary Clinton is elected president as seems likely  she has vowed to regulate real estate  as well as pharmaceutical prices to prevent them from doing the sorts of actions which have attracted media attention  These regulations would likely limit the ability of smaller pharmaceutical firms like Endo to grow  and has investors concerned  Even if Trump prevails  his populist mindset means that he would need little persuading to go after corporations oppressing the white working class that are the core of his support 
Regardless of political victors  Big Pharma will likely have few friends in Washington in the coming months  Endo s Problems
The collusion charge is problematic  but if that was Endo s only problem  I would recommend buying and taking advantage of this price fall  But Endo has more concerns than angry politicians 
The first is Endo s debt load   recently reported that Endo has discussed selling Paladin Labs Inc  to specialty pharmaceutical company Knight Therapeutics Inc  TO GUD   The deal would be explicitly made so that Endo could  pay down some of its  8 billion in debt   even though it would be selling Paladin at a significant loss compared to the price it originally paid 
This debt load happened because Endo went on a major acquisition spree before 2016  acquiring Paladin in addition to issuing  5 billion in debt as part of an  8 billion purchase of   Yet despite these acquisitions  Endo has not been able to increase its revenue enough to make these acquisitions worthwhile  In May  Endo had to slash its year end estimates for revenue and earnings per share by 11 and 23 percent respectively  These changes caused the stock to fall by 40 percent  and Endo s current value is only 25 percent of its peak back at the beginning of this year  Too many problems
There is always a temptation to go against the grain and try to buy low when a stock falls like Endo s has  but investors should be leery of the company and of the pharmaceutical industry in general  While pharmaceuticals will always be in high demand  they are also the target of politicians intent on further regulating the industry  The latest charges of collusion are a perfect opportunity for them  which will hurt the industry s ability to innovate and grow  But even if there were no legal issues  Endo itself has concerns which should unnerve any investor  The company is facing tough competition  has failed to increase revenue enough to compensate for its high debt loads  and has watched its stock fall off a cliff as a result  Investors may be potentially interested if Endo s value falls to  10 to  12  but the safer bet is to just stay away from the company and sell any holdings  Things are almost certainly going to go worse for Endo and pharmaceutics before they get better ",2016-11-05,Alex Newman,https://www.investing.com/analysis/endo-international:-surviving-despite-collusion-charges-200162946,200162946
197290,418806,MYL,The Best Options Trade For Mylan  MYL  Earnings ,opinion,"On Wednesday  November 9th  Mylan  MYL  will release its third quarter earnings results after the bell  The company is a Zacks Rank 4  Sell   and have a Value  Growth  and Momentum score of C 
Dave will look at Mylan s past earnings  take a look at what is currently going on with the company  and give us his thoughts on their upcoming earnings announcement 
Furthermore  Dave will uncover some potential options trades for investors looking to make a play on Mylan ahead of earnings 
Mylan in Focus
Mylan NV is a pharmaceutical company  The company develops  licenses  manufactures  markets and distributes generic and specialty pharmaceuticals  It operates primarily in the United States  Canada  Europe  the Middle East  Africa  India  Australia  Japan and New Zealand  Mylan NV  formerly known as Mylan Inc  NASDAQ MYL    is based in Canonsburg  Pennsylvania 
Mylan is expected to  according to the Zacks Consensus Estimate  Last quarter they beat earnings expectations by 0 87  at  1 16 per share  beating estimates of  1 15 a share MYLAN NV Price  Consensus and EPS Surprise   
Mylan is trading around  36 a share  and they are near their 52 week low of  33 60  A major reason for Mylan is trading near their 52 week low is because of recent controversy over their price hike on the EpiPen  Furthermore  Mylan has experienced further controversy with lawmakers questioning their Medicaid rebates for EpiPen  We have a full   and their average EPS surprise is 0 86  
Bottom Line
How should investors play Mylan ahead of their earnings report  For insights on the best options trades  make sure you are subscribe to Live Trader to see Dave Bartosiak at 1 30 pm this afternoon 
Confidential from ZacksWould you like to access Zacks  2 best trades that are not available to the public  Zacks Executive VP  Steve Reitmeister knows which of our experts has the hottest hand and when key trades are about to be triggered  Today he is prepared to pass the Best of Our Best along to you ",2016-11-07,Zacks Investment Research,https://www.investing.com/analysis/the-best-options-trade-for-mylan-(myl)-earnings-200163224,200163224
197297,418813,MYL,Momenta  MNTA  Q3 Loss Narrower Than Expected  Sales Up,opinion,"Momenta Pharmaceuticals Inc    NASDAQ MNTA   reported a loss of 26 cents per share in the third quarter of 2016  narrower than both the Zacks Consensus Estimate of a loss of 29 cents and the year ago loss of 44 cents Moreover  revenues in the quarter surged 110 9  to  29 1 million and beat the Zacks Consensus Estimate of  26 6 million Quarter in DetailMomenta s top line comprised product revenues of  23 3 million earned from Novartis AG   NYSE NVS   Sandoz s sales of Glatopa  a generic version of Copaxone  20 mg  Note that Sandoz s abbreviated New Drug Application  ANDA  for the 40 mg thrice weekly formulation of Copaxone is currently under FDA review  A tentative approval is expected in the upcoming months Collaborative research and development revenues came in at  5 8 million  up 13 7  primarily driven by revenues recognized from the amortization of an upfront payment under the collaboration agreement with Mylan N V    NASDAQ MYL   While research and development expenses were down 0 3  to  31 6 million  general and administrative expenses increased 26 4  to  15 6 million OutlookMomenta expects operating expenses  excluding stock based compensation and net of collaborative revenues  in the range of  40  45 million for the fourth quarter of 2016 Collaboration revenues  under its agreement with Mylan are anticipated to be  1 8 million per quarter Pipeline UpdateMomenta continues to progress with its pipeline candidates  Under its collaboration with Mylan  the company initiated a phase I study on M834  a biosimilar version of Orencia  abatacept   Top line data from the study are expected by the end of 2017 In the third quarter  Momenta regained global development and commercialization rights to M923  a biosimilar version of Humira  adalimumab   M923 is currently being evaluated in a phase III study  Top line results from the study should be out by late 2016  with the first regulatory submission for marketing approval planned for mid 2017 MOMENTA PHARMA Price  Consensus and EPS Surprise
    Our TakeMomenta reported encouraging results for the third quarter of 2016  wherein loss was narrower than expectations and revenues beat estimates We note that Glatopa sales have rebounded since the third quarter of 2015 as inventories were worked through  However  Teva has already switched approximately 75  of once daily Copaxone 20 mg patients to thrice weekly Copaxone 40 mg  Nevertheless  we are encouraged by the company s progress with the biosimilars in its pipeline Zacks Rank   Key PicksMomenta carries a Zacks Rank  2  Buy   Infinity Pharmaceuticals  Inc    NASDAQ INFI   is another favorably placed stock in the healthcare sector  sporting a Zacks Rank  1  Strong Buy   You can see  Infinity s loss estimates narrowed from  3 84 to  3 79 for 2016 but remained unchanged for 2017 over the last 60 days  The company has posted a positive surprise in all of the four trailing quarters with an average beat of 67 62  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-11-02,Zacks Investment Research,"https://www.investing.com/analysis/momenta-(mnta)-q3-loss-narrower-than-expected,-sales-up-200162588",200162588
197299,418815,MYL,Mylan  MYL  Stock Gains On  465 Million Settlement Over EpiPens,opinion,"On Monday  shares of controversy ridden pharmaceutical company Mylan NV    NASDAQ MYL    are gaining  up over 8 5  in morning trading after the drug maker  in order to settle charges that Mylan overcharged the U S  government for its anti allergy EpiPen Auto Injector 
MYL stock was up as much as 13  in premarket trading 
Mylan struck the deal last Friday after the market closed to pay the U S  Department of Justice  as well as other agencies  over whether or not its EpiPen should be classified as a generic or brand name drug under the Medicaid Drug Rebate program 
Mylan CEO Heather Bresch commented   This agreement is another important step in Mylan s efforts to move forward and bring resolution to all EpiPen Auto Injector related matters Entering into this settlement is the right course of action at this time for the Company  its stakeholders and the Medicaid program   
Since August  Mylan has been facing intense backlash after it was revealed that the price of EpiPen increased over 400  over the past several years  a standard two pack of the allergy medication now costs nearly  600 
The pharmaceutical company also announced a new full year earnings forecast  Mylan now expects earnings per share of  4 70  4 90  much lower than its previous guidance of  4 85  5 15 per share 
Currently  MYL is a Zacks Rank  3  Hold   and has lost over 33  year to date 
For more information on Mylan s ongoing saga  check out Episode  13 of the Zacks Friday Finish Line podcast 

Stocks that Aren t in the News Yet
You are invited to download the full  up to the minute list of 220 Zacks Rank  1  Strong Buys  free of charge  Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street  They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015  with a stellar average gain of  26  per year ",2016-10-10,Zacks Investment Research,https://www.investing.com/analysis/mylan-(myl)-stock-gains-on-$465-million-settlement-over-epipens-200158037,200158037
197300,418816,MYL,Company News For October 11  2016,opinion,"     Shares of Twitter Inc     tanked 11 5  after a Bloomberg report said that the social media company won t attract any takeover bids
	     Shares of Mylan  NASDAQ MYL  NV    soared 8 2  after the company decided to pay  465 million in order to settle charges that Mylan overcharged the U S  government for its anti allergy EpiPen Auto Injector
	     Shares of Merck  NYSE MRK    Co   Inc     advanced 1 8  after the company announced positive results for a rival lung cancer drug
	     Dover Corp s    shares dropped 7 7  after the company expects its earnings per share for this year to be  3 00 to  3 05  down from its previous forecast of  3 35 to  3 45",2016-10-10,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-october-11,-2016-200158171",200158171
197301,418817,MYL,Mylan Up On EpiPen Medicaid Settlement  Cuts 2016 Outlook,opinion,"Mylan N V  s   NASDAQ MYL   shares gained 8 2  after the company announced that it has agreed to pay  465 million to resolve the disputes regarding the classification of its severe allergy treatment  EpiPen  The decision came after several lawmakers criticized the classification of the drug as well as the rebate obligations under the Medicaid drug rebate program  Mylan has reached a settlement with the U S  Department of Justice and other government agencies in this regard  Overall  the company s shares are up 6 6  since the announcement 
The proposed settlement offers to resolve all potential rebate liability claims by federal and state governments on whether EpiPen should have been classified as an innovator drug or branded drug for the purpose of Centers for Medicaid and Medicare Services  CMS   and therefore subject to a higher rebate formula 
The CMS found that Mylan had misclassified EpiPen as a non innovator drug or a generic drug  This implied that Mylan has been vastly underpaying rebates to Medicaid for the drug for a long time  Apparently  instead of the 23 1  rebate for a branded drug  Mylan has been paying the much lower generic rebate of 13  
Mylan said in its press release that the settlement did not imply any admission of wrongdoing on the part of the company or any of its affiliated entities or personnel  EpiPen has been classified with CMS as a non innovator drug since before Mylan acquired the product in 2007 based on longstanding written guidance from the federal government 
Mylan intends to continue to work with the government to finalize the settlement and will enter into a corporate integrity agreement with the Office of Inspector General of the Department of Health and Human Services 
Mylan expects to take a third quarter 2016 pre tax charge of approximately  465 million to reflect this settlement 
MYLAN NV Price
    Cuts 2016 Earnings Outlook
Concurrent to the announcement of settlement  Mylan lowered 2016 earnings outlook  The company now expects earnings in the range of  4 70  4 90 per share  This is significantly lower than the previously guided range of  4 85  5 15 per share 
The company attributes the cut in the earnings guidance largely to the previously announced changes in EpiPen access programs and the upcoming launch of generic EpiPen  Mylan said that it expects to see considerable impact of this guidance in the third quarter of 2016 
Meanwhile  Mylan is targeting earnings of at least  6 00 per share in 2018 
The company will report third quarter 2016 results on Nov 9  after the market closes 
We note that Mylan has been under immense pressure ever since the company came under scrutiny of several lawmakers for the massive price hike of EpiPen 
Zacks Rank   Key Picks
Mylan currently carries a Zacks Rank  4  Sell   Some better ranked stocks in the health care sector include Incyte Corporation   NASDAQ INCY    Geron Corporation   NASDAQ GERN   and VIVUS Inc    NASDAQ VVUS    While Incyte and Geron sport a Zacks Rank  1  Strong Buy   VIVUS carries a Zacks Rank  2  Buy   You can see  
Incyte s earnings estimates for 2016 and 2017 were up a respective 29 5  and 11 5  over the last 60 days  The company has beaten estimates thrice in the last four quarters with an average surprise of 335 16  
Geron has recorded an average positive surprise of 20 78  over the trailing four quarters 
VIVUS has recorded an average positive surprise of 39 88  over the trailing four quarters  Share price of the company gained 4 7  year to date 
Confidential from Zacks
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-10-11,Zacks Investment Research,"https://www.investing.com/analysis/mylan-up-on-epipen-medicaid-settlement,-cuts-2016-outlook-200158398",200158398
197302,418818,MYL,The Zacks Analyst Blog Highlights  Alibaba  Time Warner  Halliburton  Mylan And Wells Fargo,opinion,"For Immediate Release

Chicago  IL   October 13  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Alibaba  NYSE BABA   NYSE    Time Warner  NYSE    Halliburton  NYSE HAL   NYSE    Mylan  NASDAQ MYL   NASDAQ     andWells Fargo  NYSE WFC   NYSE     

Today  Zacks is promoting its   Buy   stock recommendations    

Here are highlights from Wednesday s Analyst Blog  

New Research Reports for Alibaba  Halliburton and Time Warner

Today s Research Daily features new research reports on 16 major stocks  including Alibaba  NYSE      Time Warner  NYSE     and Halliburton  NYSE      These 16 reports have been hand picked from the roughly 80 research reports issued by our analyst team today  You can see 

Shares of Strong Buy rated Alibaba have been strong performers this year  they are up more than 29  year to date   with analysts steadily raising estimates for this year and next  Driving this momentum is the steadily improving outlook for China and Alibaba s dominant position in that market  The Zacks analyst likes the company s dominance in the fast growing mobile commerce market in China  its continued efforts to develop new products  international growth opportunities and strong financial position  Alibaba Group s fiscal first quarter results exceeded the Zacks Consensus Estimate  The solid growth in Alibaba s China retail and mobile business as well as strength across most of the core operating metrics aided the results  You can  

Shares of Buy rated Time Warner have handily outperformed the broader market as well as the media space  the stock is up more than 21  year to date  on greater appreciation for the company s proactive strategic initiatives in response to the evolving media landscape  These include investments in digital platforms like the Hulu stake  HBO GO   HBO NOW  the Flixter purchase and the device agnostic UltraViolet digital movie technology  In a way  Time Warner has shown its willingness and ability to explore every possible avenue to monetize its substantial content  The fact that it has an impressive track record of earnings surprises and operating and capital efficiencies further add to the Time Warner story   You can  

Halliburton  s shares have gained a phenomenal 37  year to date  The analyst likes the Buy rated stock s leading position in the North American oilfield services market  with particular emphasis on the unconventional shale plays  HAL has held up well amid the rig count carnage that has hit activity levels and pricing  This can be attributed to aggressive expense management  In fact  HAL is trying to use the challenges prevailing in the industry to its advantage  mainly by offering low cost solutions that will aid producers in churning out more by investing less   You can  

Other noteworthy reports we are featuring today include Mylan  NASDAQ      and Wells Fargo  NYSE     

Today s Private Buys   Sells from Zacks Research
	While we share the above news with the public  our sensitive recommendations are hidden from everyone but selected members  Would you like to peek behind the curtain and view them  Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum       from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors      

You can find all of today s stock research reports   

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   











Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact
	Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-10-12,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-alibaba,-time-warner,-halliburton,-mylan-and-wells-fargo-200158601",200158601
197305,418821,MYL,Mylan  MYL  CEO s Testimony Underestimated EpiPen Profits,opinion,"Last week  Mylan s   NASDAQ MYL    testified before lawmakers and elected government officials regarding a recent price increase on its lifesaving product that treats severe allergic reactions   The product is   and since there are no direct competitors in the market  Mylan has had full discretion over how much it charges for the injection pen   A pair of pens went for about  100 in 2008  and since then  the price has ballooned to  600 
What exacerbates the problem is the fact that many pens expire after a year  so people with severe allergy problems are forced to pay for new pens every year  although insurance plans can help in making the drug affordable    With this  it is not too surprising to see why  practices 
Today  it has been revealed that the company s CEO underestimated the amount of profit which the company makes per two pen pack   Mrs  Bresch stated that Mylan makes roughly  100 in profit  but that number applies the 37 5  statutory tax rate  a percentage which Mylan didn t actually pay   Mylan s overall effective tax rate was 4 2  and 7 4  in 2014 and 2015 respectively  
The committee that Heather testified in front of did not believe in Mylan s reported profitability from EpiPens last week  and they were right to have doubts   Without including the statutory tax rate  Mylan s profit on two packs comes out to about  160   This is 60  more profit than the figure that Mylan gave to congress   Mylan is a Zacks Rank  3  Hold  and its stock fell by about 2  today 
The Zacks Rank is a truly marvelous trading tool   Our ranking system has beaten the S P 500  yielding an average return of 25  per year for the last 29 years   Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ",2016-09-26,Zacks Investment Research,https://www.investing.com/analysis/mylan-(myl)-ceo's-testimony-underestimated-epipen-profits-200155620,200155620
197306,418822,MYL,Stocks And Crude  We re In A Holding Pattern,opinion,"It s becoming increasingly difficult to wax poetic about a market that s doing absolutely nothing  Just look at what has happened over the past ten weeks on the ES    no net change 

Sure  it has had its ups and downs  but the market is  on the whole  trendless 
The big news is Wednesday s crude oil breakout based on the OPEC deal  to be put into action in November  evidently   I m intrigued by ZeroHedge s deeper look at this deal  since it appears to be a lot more smoke and mirrors than a meaningful suppression of supply  All the same  the market liked what it heard and presently the price bar is resting daintily on its trendline  which now appears to be assuming the role of support 

It dawned on me that the charts for Mylan  NASDAQ MYL   of Epi pen fame  and Wells Fargo  NYSE WFC   of creating bogus accounts fame  seemed a little similar  so I laid them on top of one another  Sure enough  in spite of being in utterly different industries  the charts are quite similar  We can think of this as the Reputation Being Destroyed Forever pattern  sort of like Volkswagen  DE VOWG p  ",2016-09-29,Tim Knight,https://www.investing.com/analysis/holding-pattern-200156236,200156236
197307,418823,MYL,So Quiet You Can Hear An Epipen Drop,opinion,It seems we ve entered an age in which price gouging and outrageous executive compensation  embraced like they used to be  Mylan Inc  NASDAQ MYL  stock is headed for major support failure  red line  ,2016-10-02,Tim Knight,https://www.investing.com/analysis/so-quiet-you-can-hear-an-epipen-drop-200156554,200156554
197309,418825,MYL,The Zacks Analyst Blog Highlights  Powershares Dynamic Pharmaceuticals ETF  SPDR S P Pharmaceuticals ETF  IShares U S  Pharmaceuticals And Market Vectors Pharmaceutical,opinion,"For Immediate Release 

Chicago  IL   September 12  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Powershares Dynamic Pharmaceuticals ETF     SPDR S P Pharmaceuticals ETF     iShares U S  Pharmaceuticals    and Market Vectors Pharmaceutical     

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Friday s Analyst Blog  

Would a Clinton Presidency Spell Doom for Pharma ETFs 

The pharma sector remains in the limelight thanks to the ongoing drug pricing controversy  Over the past one year  both pharma and biotech stocks have been under immense pressure due to the pricing controversy  While the high price of drugs has always been a matter of concern  political and media focus on this issue has increased significantly since last September following Democratic Presidential candidate Hillary Clinton s  price gouging  tweet 
	The situation has heated up in recent times given the price hikes taken by Mylan  NASDAQ MYL  for its life saving combination product EpiPen  Clinton announced a health care plan that will address the excessive price hikes of treatments that have been available for years and also reaffirmed her earlier broader plan  announced last September  with the aim to lower drug prices for all Americans   Read   
	With drug costs remaining a concern and lawmakers focusing on the need to control drug prices and make prescription drugs affordable  drug companies may find it a bit difficult to justify their high prices by citing the years and funds that go into bringing new treatments to market and the need to invest in R D to bring additional treatments to market 
	On a positive note  Allergan s CEO Brent Saunders said in a blog post that the company will not engage in price gouging actions or predatory pricing and will limit price increases M As to Continue  
	With Pfizer  NYSE PFE  recently announcing that it will be acquiring oncology focused Medivation for approximately  14 billion  expectations are that M A activities will pick up pace in the latter half of the year  Meanwhile  small bolt on acquisitions  in licensing activities and collaborations for the development of pipeline candidates are expected to continue 
	Several pharma companies are focusing on in licensing mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time  Small biotech companies are open to such deals    most of them find it challenging to raise cash  thereby making it difficult to survive and continue with the development of promising pipeline candidates  Therefore  it makes sense to seek deals with pharma companies sitting on huge piles of cash   Read   
	Therapeutic areas attracting a lot of interest include central nervous system disorders  hepatitis C virus  HCV  and immunology inflammation  Another highly lucrative area is immuno oncology  Major players in this field include Bristol Myers  AstraZeneca  Merck  NYSE MRK  and Roche 
	Another trend being witnessed is the divestment of non core business segments  Companies like Pfizer  UCB  Novartis  Glaxo and AstraZeneca have all been a part of this trend  The monetization of non core assets allows these companies to focus on their areas of expertise New Products Should Gain Traction
	Highly awaited new products that gained approval last year should contribute significantly to revenues  While 45 drugs were approved by the FDA last year  so far in 2016  the FDA has approved 16 drugs   Read    
	Biosimilars are also a focus area  Pfizer s acquisition of Hospira gives it a strong position in the biosimilars market  Companies like Novartis are involved in the development of biosimilars as well   in fact  Novartis  Sandoz was the first company to launch a biosimilar in the U S Pharma ETFs in Focus
	Highlighted below are some pharma ETFs   ETFs present a low cost and convenient way to get a diversified exposure to the sector Powershares Dynamic Pharmaceuticals ETF    
	PJP  launched in Jun 2005 by Invesco PowerShares  tracks the Dynamic Pharmaceuticals Intellidex Index  The fund covers health care stocks  The top 3 holdings include Allergan  NYSE AGN pa  plc  Merck   Co  Inc  and Johnson   Johnson  NYSE JNJ   5 04  each   The total assets of the fund as of Sep 7  2016 were  1 101 3 million representing 23 holdings  The fund s expense ratio is 0 56  while dividend yield is 4 32   The trading volume is roughly 66 769 shares per day SPDR S P Pharmaceuticals ETF    
	XPH  launched in Jun 2006  tracks the S P Pharmaceuticals Select Industry Index  This ETF primarily covers pharma stocks  99 7   with the top 3 holdings being Mallinckrodt  NYSE MNK  plc  5 73    Endo International plc  5 68    and Merck   Co   Inc   5 09   
	Total assets as of Sep 6  2016 were  509 7 million representing 36 holdings  The fund s expense ratio is 0 35  and dividend yield is 0 54   The trading volume is roughly 190 063 shares per day iShares U S  Pharmaceuticals    
	IHE  launched in May 2006  seeks investment results that correspond generally to the price and yield performance of the Dow Jones U S  Select Pharmaceuticals Index  The fund mainly consists of pharma companies  87 2    Biotech companies account for about 12 7  of the fund 
	The top 3 holdings of this fund are Johnson   Johnson  10 16    Merck   Co  Inc   8 47   and Pfizer  8 43    The total assets of the fund as of Sep 7  2016 were  599 4 million representing 37 holdings  The fund s expense ratio is 0 44  with the dividend yield being 0 99   The trading volume is roughly 15 010 shares per day Market Vectors Pharmaceutical    
	PPH was launched in Dec 2011 and tracks the Market Vectors U S  Listed Pharmaceutical 25 Index  While the expense ratio is 0 35   dividend yield is 2 38   The trading volume is roughly 27 771 shares per day Conclusion
	While pricing pressure remains a headwind  cost cutting  downsizing and new products should support growth  Increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector Want key ETF info delivered straight to your inbox 
	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2016-09-11,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-powershares-dynamic-pharmaceuticals-etf,-spdr-s-p-pharmaceuticals-etf,-ishares-u.s.-pharmaceuticals-and-market-vectors-pharmaceutical-200153050",200153050
197310,418826,MYL,4 Biotech Stocks To Buy As Election Fever Rises,opinion,"Despite recent events  Hillary Cinton maintains her lead over Trump and remains widely anticipated to win the race to the White House  Positions of both candidates on a variety of issues have been discussed with great detail  For instance  Clinton has continued to emphasize that the pharma industry and biotech companies in particular require greater regulation 
As a result of this stance and other issues  biotech stocks suffered losses throughout the year  However  the sector s stocks enjoyed a rare day of gains on Monday  the strongest in months  This underlines the fact that the sector may continue to enjoy gains and enjoys strong long term potential  Adding select stocks from the sector to your portfolio could still make for a smart choice 
Clinton Protests Price Hikes
Rising drug prices first raised Clinton s ire in Sep 2015  Her  price gouging  tweet led to a major sell off thereby cutting short the phenomenal run of health care stocks  particularly in the biotech sector  While Clinton expressed concerns over the entire industry s pricing practices  the tweet was primarily in response to Turing raising the price of Daraprim from  13 50 to  750 per pill in a single shot 
Matters have not been helped by Clinton s recent tweet on a similar issue  Toward the end of August  a couple of U S  senators raised questions about Mylan N V    NASDAQ MYL   over pricing epinephrine auto injector EpiPen  Making matter worse  Clinton posted a tweet  saying  EpiPens can be the difference between life and death  There s no justification for these price hikes    Read   
Sector Still Sports Strengths
Primarily due to price related concerns  the iShares Nasdaq Biotechnology  IBB  was down 20  year to date at the beginning of Feb 2016  Even now the sector remains in the red and has lost around 15  since the start of the year  However  the biotech sector remains a good option for investors who are looking for investment opportunities which have little relationship with the direction the economy is taking  
Additionally  most of the sector s losses came toward the beginning of the year  Now  stocks from this industry can only perform better  Though drug pricing will continue to be an important issue  other developments will also make their impact felt  Biosimilars are likely to gain prominence and provide the industry with a new avenue of growth 
Further  as valuations become more attractive the rest of the year could also witness the announcement of several mergers and acquisitions  Products which received approval last year are also likely to substantially add to revenues  
Our Choices
Despite the year s reverses  biotech stocks continue to have inherent strengths  The worst could be over for the sector and it may now be poised to make a turnaround 
This is why it makes sense to pick biotech stocks at this point  We have narrowed down our search to the following stocks based on a good Zacks Rank and other relevant metrics 
ANI Pharmaceuticals  Inc    NASDAQ ANIP   is involved in developing  manufacturing and marketing generic and branded pharma products in the U S 
ANI Pharmaceuticals has a Zacks Rank  1  Strong Buy  The company has expected earnings growth of 55 5  for the current year  It has a P E  F1  of 16 79 
Cambrex Corp    NYSE CBM   is a provider of a variety of products utilized in the development and commercialization of new and generic drugs across the world 
Cambrex has a Zacks Rank  1  The company has expected earnings growth of 39 8  for the current year  The forward price to earnings  P E  ratio for the current financial year  F1  is 18 50 
PDL BioPharma   NASDAQ PDLI   is a biopharmaceutical company focused on the research  development and commercialization of novel therapies for inflammation and autoimmune diseases  acute cardiac conditions and cancer 
PDL BioPharma s earnings estimate for the current year has improved by 20 4  over the last 30 days  The forward price to earnings  P E  ratio for the current financial year  F1  is 4 57  The stock has a Zacks Rank  2  Buy    You can see  
Innoviva  Inc    NASDAQ INVA   is focused on the development  commercialization and financial management of bio pharmaceuticals 
Innoviva has a Zacks Rank  2  The company has expected earnings growth of more than 100  for the current year  The forward price to earnings  P E  ratio for the current financial year  F1  is 19 47 
Zacks  Best Investment Ideas for Long Term Profit
Today you can gain access to long term trades with double and triple digit profit potential rarely available to the public  Starting now  you can look inside our stocks under  10  home run and value stock portfolios  plus more  Want a peek at this private information ",2016-09-13,Zacks Investment Research,https://www.investing.com/analysis/4-biotech-stocks-to-buy-as-election-fever-rises-200153342,200153342
197311,418827,MYL,The Zacks Analyst Blog Highlights  Mylan  ANI Pharmaceuticals  Cambrex  PDL BioPharma And Innoviva,opinion,"For Immediate Release 

Chicago  IL   September 14  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Mylan  NASDAQ MYL  N V      ANI Pharmaceuticals  Inc      Cambrex Corp      PDL BioPharma    and Innoviva  Inc      

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Tuesday s Analyst Blog  

4 Biotech Stocks to Buy as Election Fever Rises

Despite recent events  Hillary Clinton maintains her lead over Trump and remains widely anticipated to win the race to the White House  Positions of both candidates on a variety of issues have been discussed with great detail  For instance  Clinton has continued to emphasize that the pharma industry and biotech companies in particular require greater regulation 

As a result of this stance and other issues  biotech stocks suffered losses throughout the year  However  the sector s stocks enjoyed a rare day of gains on Monday  the strongest in months  This underlines the fact that the sector may continue to enjoy gains and enjoys strong long term potential  Adding select stocks from the sector to your portfolio could still make for a smart choice 

Clinton Protests Price Hikes

Rising drug prices first raised Clinton s ire in Sep 2015  Her  price gouging  tweet led to a major sell off thereby cutting short the phenomenal run of health care stocks  particularly in the biotech sector  While Clinton expressed concerns over the entire industry s pricing practices  the tweet was primarily in response to Turing raising the price of Daraprim from  13 50 to  750 per pill in a single shot 

Matters have not been helped by Clinton s recent tweet on a similar issue  Toward the end of August  a couple of U S  senators raised questions about Mylan N V     over pricing epinephrine auto injector EpiPen  Making matter worse  Clinton posted a tweet  saying  EpiPens can be the difference between life and death  There s no justification for these price hikes    Read    

Sector Still Sports Strengths

Primarily due to price related concerns  the iShares Nasdaq Biotechnology  IBB  was down 20  year to date at the beginning of Feb 2016  Even now the sector remains in the red and has lost around 15  since the start of the year  However  the biotech sector remains a good option for investors who are looking for investment opportunities which have little relationship with the direction the economy is taking 

Additionally  most of the sector s losses came toward the beginning of the year  Now  stocks from this industry can only perform better  Though drug pricing will continue to be an important issue  other developments will also make their impact felt  Biosimilars are likely to gain prominence and provide the industry with a new avenue of growth 

Further  as valuations become more attractive the rest of the year could also witness the announcement of several mergers and acquisitions  Products which received approval last year are also likely to substantially add to revenues 

Our Choices

Despite the year s reverses  biotech stocks continue to have inherent strengths  The worst could be over for the sector and it may now be poised to make a turnaround 

This is why it makes sense to pick biotech stocks at this point  We have narrowed down our search to the following stocks based on a good Zacks Rank and other relevant metrics 

ANI Pharmaceuticals  Inc      is involved in developing  manufacturing and marketing generic and branded pharma products in the U S 

ANI Pharmaceuticals has a Zacks Rank  1  Strong Buy  The company has expected earnings growth of 55 5  for the current year  It has a P E  F1  of 16 79 

Cambrex Corp      is a provider of a variety of products utilized in the development and commercialization of new and generic drugs across the world 

Cambrex has a Zacks Rank  1  The company has expected earnings growth of 39 8  for the current year  The forward price to earnings  P E  ratio for the current financial year  F1  is 18 50 

PDL BioPharma     is a biopharmaceutical company focused on the research  development and commercialization of novel therapies for inflammation and autoimmune diseases  acute cardiac conditions and cancer 

PDL BioPharma s earnings estimate for the current year has improved by 20 4  over the last 30 days  The forward price to earnings  P E  ratio for the current financial year  F1  is 4 57  The stock has a Zacks Rank  2  Buy   You can see   

Innoviva  Inc      is focused on the development  commercialization and financial management of bio pharmaceuticals 

Innoviva has a Zacks Rank  2  The company has expected earnings growth of more than 100  for the current year  The forward price to earnings  P E  ratio for the current financial year  F1  is 19 47 

Zacks  Best Investment Ideas for Long Term Profit

Today you can gain access to long term trades with double and triple digit profit potential rarely available to the public  Starting now  you can look inside our stocks under  10  home run and value stock portfolios  plus more  Want a peek at this private information  

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact
	Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-09-13,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-mylan,-ani-pharmaceuticals,-cambrex,-pdl-biopharma-and-innoviva-200153526",200153526
197312,418828,MYL,Inside The Recent Surge In Biotech ETFs,opinion,"The biotech space gained the much needed strength on September 12 with every ETF being in the green  Positive news ushered into the sector on Monday  giving several stocks and funds a solid lift  Notably  biotech stocks are caught in a web of issues this year including overvaluation concerns and the likely negative impact of the presidential election in the U S  
Investors should note that with the presidential candidate  policymakers  the media and the general public raising questions over high drug pricing lately  biotech stocks and the related ETFs haven fallen out of investor favor  read    
Hillary Clinton   the Democratic presidential candidate   is among those who have been vocal about the steep pricing on life saving drugs for long  read    
However  braving such issues  biotech stocks and ETFs registered solid gains on September 12  Below we highlight the drivers in detail 
Surge in Deals 
The sector has always been at the epicenter of mergers and acquisitions  Horizon Pharma PLC   NASDAQ HZNP    announced that it will acquire Raptor Pharmaceutical Corp   NASDAQ RPTP   for about  800 million  Following the announcement  Horizon Pharma added over 9 4  and Raptor Pharmaceutical surged over 20 5  on September 12 
Shares of Perrigo Company Plc   NYSE PRGO   spiked about 7 4  on September 12 as activist investor Starboard Value LP revealed a 4 6  stake in the drug company  Starboard also added that it sees   to fair value  for Perrigo shares at the current level and  substantial opportunities  in it 
If this was not enough  Gilead Sciences Inc    NASDAQ GILD   disclosed that it intends to pursue a host of  rather than a huge one  All these news acted as a cornerstone for the entire biotech space 
Successful Clinical Trial 
Shares of Foamix Pharmaceuticals Ltd    NASDAQ FOMX   shot up over 15 7  on September 12 after the company announced  that a drug designed to  rosacea had shown strong results in a Phase 2 clinical trial  
Dovish Fed Comments 
Though the broader market went into a tailspin on September 9  dovish comments by Fed Governor  on the policy tightening issue on September 12  triggered a relief rally to start this week  With chances of a September hike slumping to   as per changes in Fed funds futures  high growth  high beta sectors like biotech had reasons to rejoice 
Trump s Chances of Winning Growing 
Lately  chances of Republican candidate Donald Trump s winning the presidential election are rising  The  daily presidential tracking poll results indicated on Monday that Donald Trump  48 7   is leading Hillary Clinton  45 8   by close to 3 percentage points in the seven day polling period ending September 11 
However   Real Clear Politics  poll results showed that Clinton  45 9   beat Trump  42 9   by 3 percentage points on September 12  2016  Whatever the case  Donald Trump s steadfastness in the presidential election race  for biotech stocks  given Clinton s constant move against the price gouging issue in the pharmaceutical space  read    
Surging ETFs in Focus
Below we highlight five ETFs that scooped up strong gains on September 12 
ALPS Medical Breakthroughs ETF   SI SBIO    Up 3 94 
PowerShares Dynamic Biotechnology   Genome Portfolio ETF    Up 3 81 
SPDR S P Biotech ETF    Up 3 61 
iShares Nasdaq Biotechnology ETF    Up 3 04 
First Trust NYSE Arca Biotechnology Index Fund   LON FBT     Up 2 92 
Want key ETF info delivered straight to your inbox  
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2016-09-14,Zacks Investment Research,https://www.investing.com/analysis/inside-the-recent-surge-in-biotech-etfs-200153574,200153574
197313,418829,MYL,Forget Novavax  Buy These 4 Biotech Stocks Instead,opinion,"Shares of Novavax  Inc    NASDAQ NVAX   plunged around 82  in pre market trading on Friday after the biopharmaceutical company announced a day before that its key vaccine candidate unexpectedly failed to meet the primary endpoint in a phase III trial 
What Went Wrong at Novavax
Top line data presented from the Resolve trial evaluating its RSV F vaccine for preventing lower respiratory tract disease in 11 856 older adults  60 years of age and older  failed to meet the pre specified primary or the secondary efficacy objectives  The primary objective of the randomized  placebo controlled Resolve trial was to demonstrate efficacy in preventing moderate severe RSV associated lower respiratory tract disease while the secondary objective was to show efficacy in reducing the incidence of all symptomatic respiratory disease due to RSV  RSV ARD   Though the vaccine was well tolerated in the trial  it failed to demonstrate vaccine efficacy 
Chief Gregory Glenn said that an initial analysis did not show any issues with the  trial execution  data collection  data integrity  or drug product quality  that can be blamed for the unfavorable outcome 
Also top line results presented from another phase II rollover trial of the vaccine candidate showed absence of efficacy of a single immunization  However  the data did suggest improved vaccine efficacy from the second year of dosing 
Novavax is a clinical stage company and has no marketed products at present  There are currently no approved vaccines to fight RSV  Novavax s vaccine  if approved  can bring in huge revenues for the company  Therefore  the failure of this key pipeline candidate in late stage trials is a huge setback for the stock  Novavax has a Zacks Rank  4  Sell  NOVAVAX INC Price
 

   The Broader Sector Picture
It has been a pretty rough year for the healthcare sector  A changing competitive scenario and media and political focus on the high prices of drugs have made things difficult for the pharma biotech sector since the past one year 
Democratic presidential candidate  Hillary Clinton has pledged to find ways to institute reforms to curb rising drug prices and thereby lower prescription drug costs for all Americans  The situation worsened when Mylan N V    NASDAQ MYL   increased the price of its life saving combination product EpiPen  This month  Clinton  in a statement on her website  announced measures to curb  unjustified  price hikes of lifesaving treatments  especially the ones that have been in the market for long 
However  the sector s fundamentals remain strong   strong pipelines  innovative treatments  impressive results  growing demand for drugs especially for rare to treat diseases  an aging population and increased health care spending should support growth 
Healthcare merger and acquisition activity is also gaining strength  This week  Bayer  DE BAYGN  AG   OTC BAYRY   announced that it will be acquiring Monsanto Company   NYSE MON   for  66 billion while Horizon Pharma plc   NASDAQ HZNP   announced its intention of buy Raptor Pharmaceuticals Corp    NASDAQ RPTP   
In August  Pfizer  Inc    NYSE PFE   announced that it intends to buy oncology focused Medivation  Inc    NASDAQ MDVN   for approximately  14 billion  This was preceded by the buyout of Anacor in Jun 2016 and Hospira in Sep 2015  In Jun 2016  Shire plc   NYSE S   acquired Baxalta to further strengthen its rare disease portfolio  Aegerion Pharmaceuticals   NASDAQ AEGR   and QLT Inc    NASDAQ QLTI   entered into a definitive merger agreement in Jun 2016 to form a new company  Novelion Therapeutics Inc 
Merger and acquisitions are expected to increase in the back half of the year  Meanwhile  small bolt on acquisitions  in licensing activities and collaborations for the development of pipeline candidates are expected to continue 
4 Stocks to Buy
Given the strong fundamentals  biotech companies with new therapies or interesting pipeline candidates promise bountiful opportunities for investors  These stocks are well positioned in today s market environment and could see considerable upside riding on the aforementioned trends 
We have narrowed down the list of choices by focusing on stocks with a favorable Zacks Rank  1  Strong Buy  or  2  Buy  and a  of  A  or  B 
PDL BioPharma  Inc    NASDAQ PDLI  
Nevada based  PDL BioPharma manages a portfolio of patents and royalty assets in the United States and Europe  The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases  It has a Zacks Rank  2 and a VGM score of  B  
The stock has also witnessed positive estimate revisions in the past 30 days 
Its 2016 earnings estimate rose 20  while that for 2017 is up a massive 200  over the past 30 days 
Vanda Pharmaceuticals  Inc    NASDAQ VNDA  
This Washington based biopharmaceutical company is focused on developing products for central nervous system disorders  Its estimated loss for 2016 narrowed down over the past 30 days while for 2017  estimates switched from a loss of 3 cents to earnings of 16 cents over the same time frame  It has a VGM score of  B  and a Zacks Rank  2  You can see the 
Exelixis  Inc    NASDAQ EXEL   
Exelixis is a biopharmaceutical company focused on developing and commercializing small molecule therapies for the treatment of cancer  It has a Zacks Rank  2 and a VGM score of  B   Its loss per share estimate for both 2016 and 2017 has narrowed down over the past 30 days 
Neogenomics Inc  
This clinical laboratory specializes in cancer genetics diagnostic testing  It has a Zacks Rank  2 and a VGM score of  A  
Now See Our Private Investment Ideas
While the above ideas are being shared with the public  other trades are hidden from everyone but selected members  Would you like to peek behind the curtain and view them 
Starting today  for the next month  you can follow all Zacks  private buys and sells in real time from value to momentum        from stocks under  10 to ETF and option moves       from insider trades to companies that are about to report positive earnings surprises  we ve called them with 80   accuracy   You can even look inside portfolios so exclusive that they are normally closed to new investors ",2016-09-16,Zacks Investment Research,"https://www.investing.com/analysis/forget-novavax,-buy-these-4-biotech-stocks-instead-200154035",200154035
197314,418830,MYL,Mylan CEO s Mother Pushed Schools To Buy EpiPens,opinion,"Gayle Manchin  former First Lady of West Virginia and mother of embattled Mylan   NASDAQ MYL   CEO Heather Bresch  may have used her position as head of the National Association of State Boards of Education to encourage states to require schools to buy EpiPens  according to a new report from  
Manchin took over this role in 2012  the same year her daughter was made CEO of Mylan  and eleven states soon followed her direction by drafting laws that required epinephrine auto injectors in schools  By 2013  most states recommended schools stock this allergy medication after the so called federal  EpiPen Law  helped fund those that did 
The news surrounding Manchin is the latest in a series of controversies surrounding Mylan and its  on EpiPens over the last several years  The company is the center of congressional investigations related to the popular allergy treatment  and it also faces an  in New York related to its EpiPens4Schools program 
According to the USA Today report  Mylan s relationship with the National Association of State Boards of Education appears to have begun in October 2012  when the company sponsored several health presentations at the association s annual conference 
Just two months later  the association announced its  epinephrine policy intiative   which was designed to help state boards of education develop health policies that included access to auto injectors 
While Manchin s organization never specifically mentioned Mylan when it recommended epinephrine auto injectors  it didn t really have to  As critics have pointed out  Mylan is basically the only maker of these allergy treatments in the world 
It s not difficult to see the connection here  and this latest detail will only add more drama to the ongoing Mylan controversy ",2016-09-20,Zacks Investment Research,https://www.investing.com/analysis/mylan-ceo's-mother-pushed-schools-to-buy-epipens-200154594,200154594
197315,418831,MYL,Here s What Pissed Off Congressmen Said To Mylan s CEO ,opinion,"Mylan   NASDAQ MYL   CEO Heather Bresch responded to questions from the House Oversight Committee Wednesday as Congress continues its probe into the company s price hikes on EpiPens  Despite their usual partisan gridlock  members of Congress united to absolutely grill Bresch over the scandal 
Unconvincing Talk
Bresch attempted to explain to the House committee that Mylan made less than  100 on a standard two pack of EpiPens  which retails for nearly  609  but the representatives didn t buy her logic  especially when she refused to admit that her company raised the price of the medication in an attempt to make more money 
Ms  Bresch was also seemingly unprepared for many of the committee s questions  the embattled chief executive didn t come with the information about the company s revenue and patient assistance programs that Congress previously requested 
The Roast of Heather Bresch 
Both Republicans and Democrats took Bresch s appearance in Congress as an opportunity to skewer her and her company for their pricing strategy that saw the cost of EpiPens increase by over 400  in just a few years 
 I am a very conservative and pro business Republican  but I am sickened by what I ve heard   said Rep  John Duncan  a Republican from Tennessee 
Tammy Duckworth  a Democrat from Illinois  questioned Bresch about the company s EpiPen4Schools program  which is currently the subject of an  in New York  Duckworth questioned Mylan s decision to make schools sign non compete agreements  calling the practice  an unfair monopoly  
Duckworth also mentioned that schools were unaware that the president of the National Association of State Boards of Education  which pushed state governments to mandate that schools keep EpiPens in stock  was actually Bresch s own mother  also read    
Democratic Rep  Elijah Cummings of Maryland likened Mylan s conduct to that of Martin Shkreli and Turing Pharmaceuticals 
 After the hearing  you know what he called us  Imbeciles  You know why he said that  Because he knew he would go back and do the same thing  So he took his punches he rope a doped us  Even worse  he took the Fifth   Cumming said in reference to Shkreli s congressional testimony earlier this year 
Another visibly upset lawmaker was Jason Chaffetz  a Republican from Utah  Chaffetz seemed baffled when Bresch attempted to argue that Mylan doesn t actually make that much profit on the drug 
 That doesn t make any sense   Chaffetz said   This is why we don t believe you  
Rep  Eleanor Norton  a Democratic delegate from Washington D C   also called Bresch s personal income into question 
 What have you done to earn this 671  increase    she asked  referencing Bresch s salary increase and stock gains since taking over as Mylan chief 
Bottom Line
Wednesday s hearing was the second time this week that Congress put its partisan rivalry on hold to gang up on a corporate CEO  On Tuesday  a Senate committee roasted Wells Fargo   NYSE WFC   CEO John Strumpf for his role in the company s fraudulent account s scandal  also read    
With this year s rather contentious election continuing to heat up  I don t expect Congress to be getting along much longer ",2016-09-22,Zacks Investment Research,https://www.investing.com/analysis/here's-what-pissed-off-congressmen-said-to-mylan's-ceo-200155058,200155058
197318,418834,MYL,Mylan s EpiPen Misclassified  Rebates Underpaid  Stock Down,opinion,Mylan N V    NASDAQ MYL   continues to take a hit  with shares currently down 4 7   as a new issue drew the attention of lawmakers  A couple of U S  congressional committee members have raised questions regarding Mylan s payments to Medicaid for its severe allergy treatment  EpiPen EpiPen Misclassified as a GenericIn a letter to the secretary of the Department of Health and Human Services dated Sep 2  2016  Senate Finance Committee Ranking Member Ron Wyden  and House Energy and Commerce Committee Ranking Member Frank Pallone  have sought further details regarding EpiPen s classification and rebate obligations under the Medicaid drug rebate program  following revelations that Medicaid may have been grossly overpaying for EpiPen over nearly two decades due to a misclassification by Mylan The letter noted that while EpiPen was considered a branded drug in the new drug application to the FDA  it has been classified as a generic drug  also known as non innovator multiple source drug  in the Medicaid program since at least 1997  This implies that Mylan has been vastly underpaying rebates owed to Medicaid for EpiPen for a long time  Apparently  instead of the 23 1  rebate for a branded drug  Mylan has been paying the much lower generic rebate of 13  However  in an e mail  Mylan said that the company has complied with all laws and regulations regarding the Medicaid rebate classification of EpiPen Note that on Sep 1  U S  Senator Amy Klobuchar had issued a statement related to the drug category misclassification of EpiPen  According to the letter  the Centers for Medicare   Medicaid Services  CMS  found that Mylan had misclassified EpiPen as a generic drug  leading to overpayment for the drug by the state and federal governments under the Medicaid drug rebate program  The Minnesota Department of Human Services has estimated that this misclassification will cost the state more than  4 million dollars this year alone In a letter dated Aug 31  U S  Senators Amy Klobuchar  Chuck Grassley and Richard Blumenthal asked the CMS to provide information on the impact of Mylan s price hike on government prescription drug costs Meanwhile  Senator Klobuchar has asked for an immediate and comprehensive nationwide investigation by the CMS into overpayments throughout the U S MYLAN NV Price     Developments So FarMylan  shares are crashed almost 18  ever since the company came under scrutiny of several U S  senators for the massive price hike of EpiPen in recent years  Democratic Presidential candidate Hillary Clinton had even posted a tweet saying  EpiPens can be the difference between life and death  There s no justification for these price hikes   asking the company to lower costs immediately Mylan acquired EpiPen in 2007  following which it has hiked the price of a pack of two from  100 to the present level of approximately  600 Amid harsh criticism from parents  consumers and lawmakers alike  Mylan tried to mitigate the situation by offering a savings card for up to  300  expanding the eligibility of its patient assistance program and announcing the upcoming launch of a generic EpiPen at a discount of over 50  on the branded product s price Meanwhile  on Sep 2  Hillary Clinton unveiled a plan to protect consumers from  unjustified price hikes  of prescription drugs  including EpiPen  If elected  she proposes to create a dedicated group charged with protecting consumers from unreasonable price hikes and holding companies accountable  among other issues Horizon Pharma plc s   NASDAQ HZNP   shares have also declined 4 2   As per sources  the company could face a tough situation if Hillary Clinton s proposal is realized  Other companies like Endo International plc   NASDAQ ENDP   could also be at risk Mylan is currently a Zacks Rank  3  Hold  stock  ANI Pharmaceuticals  Inc    NASDAQ ANIP   is a better ranked stock in the health care sector  sporting a Zacks Rank  1  Strong Buy  Confidential from ZacksBeyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ,2016-09-04,Zacks Investment Research,"https://www.investing.com/analysis/mylan's-epipen-misclassified,-rebates-underpaid;-stock-down-200151805",200151805
197319,418835,MYL,Burlington Stores  Movado Group  Mylan  Allergan And Valeant Highlighted As Zacks Bull And Bear Of The Day ,opinion,"For Immediate Release

	Chicago  IL   September 07  2016    highlights Burlington Stores  Inc     as the Bull of the Day and  Movado Group  Inc     as the Bear of the Day  In addition  Zacks Equity Research provides analysis on   Mylan  NASDAQ MYL  NV     Allergan Inc  NYSE AGN pa        and Valeant    

	Here is a synopsis of all five stocks 

  

Burlington Stores  Inc     is a rare retailer that not only beat on the earnings estimate but raised full year guidance  This  is expected to grow earnings by the double digits both this year and next 

	Burlington Stores is a off price retailer with 570 stores in 45 states and Puerto Rico  It is more than just the old Burlington Coats stores  however 

	It sells women s ready to wear apparel  menswear  youth apparel  baby  beauty  footwear  accessories  as well as coats 

Big Beat in the Second Quarter

	On Aug 25  Burlington reported fiscal 2016 second quarter results and blew by the Zacks Consensus by 9 cents as the off price model remained hot  Earnings were  0 39 compared to the Zacks Consensus of  0 30 

	It has an excellent track record of beating 

	Burlington hasn t missed since it went IPO in 2013 

	Net sales rose 9 7  to  1 26 billion  Comparable store sales jumped 5 4  while gross margin rose 40 basis points to 39 6  

	Merchandise inventories stayed in check  falling to  745 million versus  802 3 million last year as comparable store inventory fell 7  

Raised Full Year Guidance

	Burlington is a rare retailer to also raise full year guidance based on strong trends it sees heading into the fall season 

	It expects net sales to rise in the range of 7 8  to 8 3  with comparable store sales to trend between 3 6  to 4 1  

	It will also open 25 net new stores 

	The analysts liked what they heard as they raised their estimates to match the company s raised guidance 

	The fiscal 2016 Zacks Consensus Estimate jumped to  2 97 from  2 79 just 60 days ago  Earnings are now expected to rise 29  

	The analysts are also bullish on fiscal 2017  The Zacks Consensus Estimate jumped to  3 47 from  3 26 over the prior 2 months  That s another 17  earnings growth 

 

Movado Group  Inc     continues to struggle in a depressed luxury retail environment  This Zacks Rank  5  Strong Sell  recently cut its full year guidance for the second time this year 

	Movado Group makes watches in its Switzerland manufacturing facilities under the brands Movado  Ebel  Concord  ESQ Movado  Coach  Tommy Hilfiger  Hugo Boss  Juicy Couture  Lacoste and Ferrari  NYSE RACE   It also operates about 38 Movado retail stores globally 

Earnings Miss and Sales Fall

	On Aug 25  Movado reported fiscal second quarter 2017 results and missed on the Zacks Consensus Estimate by 4 cents  Earnings were  0 27 versus the consensus of  0 31 

	It was the first earnings miss in the last 5 quarters 

	Net sales fell 12  to  128 1 million from  145 6 million in the year ago quarter  On a constant dollar basis  they fell 11 2  

	The company called it a  challenging retail and economic environment  

Cutting Full Year Guidance Again

	Given the market conditions in both the fashion watch market and in luxury retail  in general  it s not surprising that Movado cut its full year guidance for the second time this year 

	It cut its full year EPS guidance last quarter by 30 cents 

	Net sales for the year are now expected to be in the range of  550 million to  560 million 

	However  it is optimistic about the upcoming holiday season  including increasing its television advertising to support Movado in the United States 

	The analysts aren t optimistic  however 

	Fiscal 2017 earnings estimates were cut in the last 30 days  The Zacks Consensus Estimate has fallen to  1 41 from  1 61 just 90 days ago  Earnings are expected to decline 31  in fiscal 2017  The company made  2 06 last year 

	Estimates are trending lower for fiscal 2018 as well  The fiscal 2018 Zacks Consensus has fallen to  1 54 from  1 73 over the last 30 days 

Additional content 

Pharma Roundup  Mylan s Antitrust Probe  Allergan Limits Drug Price Hikes

	On Tuesday  New York Attorney General Eric Schneiderman opened an investigation into Mylan NV    that focuses on the drugmaker s contracts with local school districts to purchase its EpiPens 

	In a statement  Schneiderman said  No child s life should be put at risk because a parent  school or health care provider cannot afford a simple  life saving device because of a drug maker s anticompetitive practices  

	According to      the probe will be broad  but one of the main focus points is whether or not its EpiPens4School program  which offered a significant discount on the drug  locked schools into anti competitive contracts 

	Last month  the pharma leader drew widespread criticism after it was discovered that the company increased the price of EpiPens over 400  over the last several years  To put that in perspective  the drug cost  57 a shot when Mylan acquired it in 2007  and now  a two pack of EpiPens costs more than  600 

	Shortly afterwards  Mylan  it would take several steps to make the lifesaving allergy treatment more affordable to patients 

Allergan CEO Pledges Limit on Drug Price Increase

	Also on Tuesday  healthcare giant Allergan Inc  s    CEO Brett Saunders has offered a promise to limit price hikes on the drugs it sells  writing in a  that  I understand the public outcry and add my voice to the condemnation of these behaviors  

	Saunders argues that there is a  long standing unwritten social contract  between patients  physicians  policy makers  and the greater public  and  Those who have taken aggressive or predatory price increases have violated this social contract  

	While not explicitly naming names  it s pretty clear he is referring to Martin Shkreli and Turing Pharmaceuticals  Valeant      and Mylan s recent EpiPen controversy 

	Allergan s pricing pledge is significant  as it opposes the common practice taken by fellow biotech and pharmaceutical companies  raising drug prices two to three times every year  This usually means that drug costs can significantly exceed the annual inflation rate 

	 For our industry to remain a vibrant and important part of the healthcare ecosystem  Allergan commits to this social contract and I encourage others to formulate their own self policing actions   Saunders continues 

	Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days  



About the Bull and Bear of the Day

	Every day  the analysts at Zacks Equity Research select two stocks that are likely to outperform  Bull  or underperform  Bear  the markets over the next 3 6 months 

About the Analyst Blog

	Updated throughout every trading day  the  provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets 

About Zacks Equity Research

	Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

	Continuous analyst coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

	Zacks  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Media Contact

	Zacks Investment Research

	800 767 3771 ext  9339





	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-09-06,Zacks Investment Research,"https://www.investing.com/analysis/burlington-stores,-movado-group,-mylan,-allergan-and-valeant-highlighted-as-zacks-bull-and-bear-of-the-day-200152240",200152240
197320,418836,MYL,Will A Clinton Presidency Spell Doom For Pharma ETFs ,opinion,"The pharma sectorremains in the limelight thanks to the ongoing drug pricing controversy  Over the past one year  both pharma and biotech stocks have been under immense pressure due to the pricing controversy  While the high price of drugs has always been a matter of concern  political and media focus on this issue has increased significantly since last September following Democratic Presidential candidate Hillary Clinton s  price gouging  tweet 

	The situation has heated up in recent times given the price hikes taken by Mylan  NASDAQ MYL  for its life saving combination product EpiPen  Clinton announced a health care plan that will address the excessive price hikes of treatments that have been available for years and also reaffirmed her earlier broader plan  announced last September  with the aim to lower drug prices for all Americans   Read   

	With drug costs remaining a concern and lawmakers focusing on the need to control drug prices and make prescription drugs affordable  drug companies may find it a bit difficult to justify their high prices by citing the years and funds that go into bringing new treatments to market and the need to invest in R D to bring additional treatments to market 

	On a positive note  Allergan s CEO Brent Saunders said in a blog post that the company will not engage in price gouging actions or predatory pricing and will limit price increases 
M As to Continue  

	With Pfizer  NYSE PFE  recently announcing that it will be acquiring oncology focused Medivation for approximately  14 billion  expectations are that M A activities will pick up pace in the latter half of the year  Meanwhile  small bolt on acquisitions  in licensing activities and collaborations for the development of pipeline candidates are expected to continue 

	Several pharma companies are focusing on in licensing mid to late stage pipeline candidates that look promising  instead of developing a product from scratch  which involves a lot of funds and time  Small biotech companies are open to such deals    most of them find it challenging to raise cash  thereby making it difficult to survive and continue with the development of promising pipeline candidates  Therefore  it makes sense to seek deals with pharma companies sitting on huge piles of cash   Read   

	Therapeutic areas attracting a lot of interest include central nervous system disorders  hepatitis C virus  HCV  and immunology inflammation  Another highly lucrative area is immuno oncology  Major players in this field include Bristol Myers  AstraZeneca  Merck  NYSE MRK  and Roche 

	Another trend being witnessed is the divestment of non core business segments  Companies like Pfizer  UCB  Novartis  Glaxo and AstraZeneca have all been a part of this trend  The monetization of non core assets allows these companies to focus on their areas of expertise 
New Products Should Gain Traction

	Highly awaited new products that gained approval last year should contribute significantly to revenues  While 45 drugs were approved by the FDA last year  so far in 2016  the FDA has approved 16 drugs   Read   

	Biosimilars are also a focus area  Pfizer s acquisition of Hospira gives it a strong position in the biosimilars market  Companies like Novartis are involved in the development of biosimilars as well   in fact  Novartis  Sandoz was the first company to launch a biosimilar in the U S  
Pharma ETFs in Focus

	Highlighted below are some pharma ETFs   ETFs present a low cost and convenient way to get a diversified exposure to the sector 
Powershares Dynamic Pharmaceuticals ETF   

	PJP  launched in Jun 2005 by Invesco PowerShares  tracks the Dynamic Pharmaceuticals Intellidex Index  The fund covers health care stocks  The top 3 holdings include Allergan  NYSE AGN pa  plc  Merck   Co  Inc  and Johnson   Johnson  NYSE JNJ   5 04  each   The total assets of the fund as of Sep 7  2016 were  1 101 3 million representing 23 holdings  The fund s expense ratio is 0 56  while dividend yield is 4 32   The trading volume is roughly 66 769 shares per day 
SPDR S P Pharmaceuticals ETF   

	XPH  launched in Jun 2006  tracks the S P Pharmaceuticals Select Industry Index  This ETF primarily covers pharma stocks  99 7   with the top 3 holdings being Mallinckrodt  NYSE MNK  plc  5 73    Endo International plc  5 68    and Merck   Co   Inc   5 09   

	Total assets as of Sep 6  2016 were  509 7 million representing 36 holdings  The fund s expense ratio is 0 35  and dividend yield is 0 54   The trading volume is roughly 190 063 shares per day 
iShares U S  Pharmaceuticals   

	IHE  launched in May 2006  seeks investment results that correspond generally to the price and yield performance of the Dow Jones U S  Select Pharmaceuticals Index  The fund mainly consists of pharma companies  87 2    Biotech companies account for about 12 7  of the fund 

	The top 3 holdings of this fund are Johnson   Johnson  10 16    Merck   Co  Inc   8 47   and Pfizer  8 43    The total assets of the fund as of Sep 7  2016 were  599 4 million representing 37 holdings  The fund s expense ratio is 0 44  with the dividend yield being 0 99   The trading volume is roughly 15 010 shares per day 
Market Vectors Pharmaceutical   

	PPH was launched in Dec 2011 and tracks the Market Vectors U S  Listed Pharmaceutical 25 Index  While the expense ratio is 0 35   dividend yield is 2 38   The trading volume is roughly 27 771 shares per day 
Conclusion

	While pricing pressure remains a headwind  cost cutting  downsizing and new products should support growth  Increased pipeline visibility and appropriate utilization of cash should increase confidence in the sector 
Want key ETF info delivered straight to your inbox 

	Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2016-09-09,Zacks Investment Research,https://www.investing.com/analysis/will-a-clinton-presidency-spell-doom-for-pharma-etfs-200152803,200152803
197321,418837,MYL,Mylan Promises  300 Generic EpiPen,opinion,"In a continuation of its response to widespread criticism  pharmaceutical company Mylan NV   NASDAQ MYL   announced Monday that it will launch a generic version of the EpiPen at a 50  discount to the standard version of its popular allergy medication 
The unexpected move comes just days after Mylan announced that it will take several steps to make EpiPens more affordable after a number of healthcare reform advocates  including Democratic presidential nominee Hillary Clinton  directed criticism towards the company last week 
Clinton and others used the EpiPen as an example of the oftentimes absurd pricing strategies that have become commonplace in today s pharmaceutical industry  Over the past several years  Mylan has raised the price of a standard two pack of EpiPens by more than 400   and the life saving medication now has a sticker price of  608 
Mylan said it plans to launch its generic version of the EpiPen within the next several weeks  The non branded version will cost  300 per two pack 
Last Thursday  Mylan announced that it will provide an instant savings card worth  300 to any patient that currently pays full price for the EpiPen out of pocket  This would represent savings of about 50   or about the same as the generic price  for patients without insurance or for those with high deductible plans 
Mylan also announced that it is doubling the eligibility for patient assistance to 400  of the federal poverty level  This means that a family of four making up to  97 200 would be eligible to pay effectively nothing for an EpiPen 
Mylan did not announce what  if any  discounts it will offer for the generic version of the drug  and it s still unclear why patients would choose to use the branded version if the generic version is the exact same medication  as Mylan claims 
In a  announcing the new generic EpiPen  Mylan CEO Heather Bresch detailed the effectiveness of generic alternatives and claimed that the  complexity and opaqueness of today s branded pharmaceutical supply chain  led the company to bypass the brand system and offer an alternative 
 Generic drugs have a long  proven track record of delivering significant savings to both patients and the overall healthcare system   Bresch said    The launch of a generic EpiPen   which follows the steps we took last week on the brand to immediately reduce patients  out of pocket costs  will offer a long term solution to further reduce costs and ease the burden and complexity of the process on the patient  
While Mylan s recent efforts to respond to criticism may reek like a desperate PR move to some investors  they might just be exactly what the company needed to do  and if these new options make EpiPens more accessible to the patients that need them  it could be a win win ",2016-08-29,Zacks Investment Research,https://www.investing.com/analysis/mylan-promises-$300-generic-epipen-200150623,200150623
197322,418838,MYL,Company News For August 30  2016,opinion,"     Shares of Mylan  NASDAQ MYL  NV    gained 0 4  after the drug maker said that it would launch a cheaper generic version of its allergy treatment EpiPen
	     Shares of Herbalife  NYSE HLF  Ltd     soared 4 5  after its largest shareholder  Carl Icahn purchased around 2 million additional shares of the company
	     Shares of Caesars Entertainment Corp    tanked 15 7  after a court ruled that the company will have to face about  11 billion in claims from bondholders
	     Core Mark Holding Company  Inc  s    shares nosedived 14 2  after the company reported the expiration of its supply agreement with 1 100 Circle K stores",2016-08-29,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-august-30,-2016-200150798",200150798
197323,418839,MYL,It Looks Like A Hike,opinion,"Jackson Hole 2016 has come and gone and Fed members seem determined to raise rates at least once before year end  Based on the comments and conversations  the markets quickly adjusted to factoring in one hike in the September to December time frame 
But without sure signs of accelerating jobs or other economic growth  it is uncertain if there will be further rate hikes after the token one to come this year  So  we will all go back to closely watching the economic and corporate datapoints while keeping the corner of our eye on any Breaking News headlines 
Speaking of Breaking News headlines  The script from the EpiPen Mylan  NASDAQ MYL  saga could rival Michael Clayton  It was unfortunate timing for those investors who were riding the Healthcare subway last week when Hillary s tweet released a box of crickets and worms into the sector  And  just when biotech and drug CEOs were looking forward to a year away from the Congressional hot seat  But the good news is that the new Watergate Hotel is open and it looks great  Just ask for the Mylan group rate 
While the Fed speak last week sparked the U S  dollar and short term interest rates  it is uncertain if equity and risk investors are spooked  While the markets did sell off on Friday  trading remains very thin with the end of summer holidays still impacting  In looking at the numbers from last week  what does seem more certain is that investors continue to shift into more traditionally higher risk investments  Into Cyclicals like Technology and Banks and out of defensive income proxies  Into Junk and Emerging Market fixed income and out of Treasuries  Into EM Equities and out of domestic and developed Equities  The U S  dollar could be a thorn for a shift into these riskier investments  but if the markets become convinced that the Fed is one and done until 2017  then the Dollar could take a back seat as investments move into these newer areas of risk 
So unless the economy or global financial markets completely fall apart  we are getting a Fed Funds rate increase before year end 
 In light of the continued solid performance of the labor market and our outlook for economic activity and inflation  I believe the case for an increase in the federal funds rate has strengthened in recent months   Ms  Yellen said in remarks delivered here Friday 
The remarks left the door open for a Fed rate increase at its Sept  20 21 policy meeting  but the chairwoman hedged her comments in ways that give the central bank an out if economic data disappoint in the next few weeks 
Most important  the Fed s decision appears to hinge on whether the Labor Department s Sept  2 jobs report shows steady gains in hiring  Job gains have averaged 190 000 a month over the past three months 
 Our decisions always depend on the degree to which incoming data continues to confirm the  Fed s  outlook   she said  If the Fed doesn t move in September  it has two more meetings this year  one in November just before U S  elections and another in December  Her comments suggest she expects a move at one of these meetings if the central bank doesn t raise rates in September 
And Fischer doubled down on what Yellen said 
 I think what the Chair said today was consistent with answering yes to both of your questions  but these are not things we know until we see the data  
 I think the evidence is the economy has strengthened  the big numbers are better than they have been for some time  
 In looking back at the timing of the 2015 Fed Funds rate hike  here is a chart of the Two Year Yield 
While it did snap higher on Friday  will it need to have a follow through move like in Nov Dec 2015 before we get the next hike 

The markets pushed September s Fed Funds rate hike probability to 42  on Friday 

Looking at the week s returns shows several interesting moves 
  Natural Gas    Crude Oil   Italy Spain   Europe   EFA   EEM   U S  Dollar  1    Banks   XLF which leads all XL Sectors   Semis   Nasdaq100   Junk Bonds   Risk Free U S  Treasuries   Small Caps   Large Caps   Utes  Staples  REITs lag as high dividend payers see further selling   EpiPen takes down Healthcare and Biotech   XRT  2  on a difficult week for Retailer earnings  save Best Buy   Tiffany s    Oil  Precious Metals and any stock touching either was the worst place to be  blame the Fed   US   

Sectors assets holding their trends the best 

Sectors which continue to give their investors butterflies 

Tough for the equity income proxies to outperform when everyone owns them 
Two of the most crowded sectors right now are consumer staples and utilities  according to analysis by Vadim Zlotnikov  a co head of multi asset solutions and chief market strategist at AllianceBernstein LP  Such stocks have been popular this year because their regular dividend payouts make them attractive as income bearing substitutes for bonds  Utilities are the second best performing sector of the S P 500 so far in 2016  rising 15  
Mr  Zlotnikov s analysis ranks North American traded utilities stocks in the 94th percentile in terms of how  crowded  they are as of mid August compared with the past 18 years  Consumer staples companies are in the 99th percentile  Energy stocks  which are up nearly as much as utilities so far this year in the S P 500  are in the 9th percentile 
Overwhelmingly popular  or  crowded   trades in recent years have tended to provide some outperformance on the way up  but lose all those gains and more in the subsequent drawdowns  according to the analysis 

As U S  Trust shows below  it is the Cyclical groups which have put up some of the best performance since February 

As the Energy sector tries to stabilize this year  here is a good look at its importance to the S P 500 

The recent outperformance in U S  Small Caps is giving the team at Leuthold a valuable Very Long Term Momentum BUY signal 
 LeutholdGroup   SmallCap positive  VLT  Momentum issued a  RUT BUY  While it s a short history  since 1979 only one signal failed 

If you need a new Short strategy  try developing one that shorts those companies cutting dividends and stock repos which are heavily owned by the indexes 
Mr  Damodaran  who likes to be provocative  says with rates this low  traditional valuation metrics are distorted  Instead  the inability of companies to keep paying off their investors will cause the next downturn   This is the weakest link in this market   Mr  Damodaran said in an interview   We know cash flows will go down  What we don t know is what the market is pricing in  
Meanwhile  S P 500 companies have logged four consecutive quarters of shrinking profits and tepid sales  That could force companies to buy less of their own stock and would take away a pillar of support for this market 
With earnings growth expected to be tepid in the coming quarters  maintaining dividends and repurchasing stock will only become more difficult  That trend might have already started  By one estimate  the value of stock buyback announcements in the second quarter slowed to its lowest level in four years 

Economic data worth highlighting last week was New Home Sales which crushed it 
Existing home sales posted a less impressive number but this is likely impacted by the low inventory and rising prices of the existing base 

ISI Group has the inventory chart that you were just thinking about 

Rising restaurant wages  employee healthcare costs   real estate rents making eating at home much cheaper than eating out 

 Remember back when Men had higher salaries than Women  
A soon to be future question given this chart 

Cable and satellite companies might be forced to develop an  always on screensaver  of the Barry White music library 

Disclaimer  The information presented here is for informational purposes only  and this document is not to be construed as an offer to sell  or the solicitation of an offer to buy  securities  Some investments are not suitable for all investors  and there can be no assurance that any investment strategy will be successful  The hyperlinks included in this message provide direct access to other Internet resources  including Web sites  While we believe this information to be from reliable sources  361 Capital is not responsible for the accuracy or content of information contained in these sites  Although we make every effort to ensure these links are accurate  up to date and relevant  we cannot take responsibility for pages maintained by external providers  The views expressed by these external providers on their own Web pages or on external sites they link to are not necessarily those of 361 Capital ",2016-08-30,Blaine Rollins,https://www.investing.com/analysis/it-looks-like-a-hike-200150687,200150687
197324,418840,MYL,U S  Stocks Outdo Global Markets,opinion,"U S  equities bucked the global trend to finish solidly in the green  showing some resiliency in the face of the continued pressure on crude oil prices  as well as weakness overseas on increased Fed rate hike expectations  Favorable economic data likely lent some support  despite the global markets treading cautiously ahead of Friday s key August nonfarm payroll report  Treasuries and gold were higher  while the U S  dollar was flat 
The Dow Jones Industrial Average  DJIA  rose 108 points  0 6   to 18 504  the S P 500 Index gained 11 points  0 5   to 2 180  and the Nasdaq Composite increased 13 points  0 3   to 5 232  In light volume  647 million shares were traded on the NYSE and 1 4 billion shares changed hands on the Nasdaq  WTI crude oil lost  0 66 to  46 98 per barrel  wholesale gasoline declined  0 03 to  1 40 per gallon and the Bloomberg gold spot price increased  2 35 to  1 323 53 per ounce  Elsewhere  the Dollar Index a comparison of the U S  dollar to six major world currencies was unchanged at 95 58 
Mylan NV  NASDAQ MYL  43  announced that it will launch the first generic EpiPen Auto Injector at a list price of  300 for a two pack carton  representing a discount of more than 50  to its branded EpiPen  The drug maker came under scrutiny last week for its pricing of its branded EpiPen shots at  600  which it said today that it will continue to sell  Shares were higher 
Personal income and spending rise as expected Personal income    was 0 4  higher month over month  m m  in July  matching the Bloomberg forecast and compared to June s upwardly revised 0 3  increase  Personal spending came in 0 3  higher m m last month the fourth straight monthly gain in line with expectations and versus June s favorably revised 0 5  rise  The July savings rate as a percentage of disposable income was 5 7   The PCE Deflator came in flat  as expected  Compared to last year  the deflator was 0 8  higher  matching estimates  Excluding food and energy  the PCE Core Index ticked 0 1  higher m m  in line with expectations  and the index was up 1 6  y y  above estimates of a 1 5  rise 
The Dallas Fed Manufacturing Index fell to  6 2 for August from July s unrevised  1 3 level with economists forecasting a decrease to  3 9  A reading below zero denotes contraction in manufacturing activity 
Treasuries finished higher  as the yield on the 2 Year note declined 4 basis points  bps  to 0 81   while the yields on the 10 Year note and the 30 Year bond dropped 7 bps to 1 57  and 2 22   respectively 
On the heels of last week s comments from Federal Reserve Chairwoman Janet Yellen and Vice Chair Stanley Fischer that suggested a September rate hike remains a possibility  this Friday s August nonfarm payroll report is poised to be a key focus for the global markets  The report will also be preceded by key reads on Manufacturing Purchasing Managers Indexes  PMIs  from ISM and Markit  the trade balance  Consumer Confidence  and August vehicle sales  Tomorrow will bring the Consumer Confidence Index  which economists expect to fall slightly to a level of 97 0 for August from July s 97 3  and the S P CoreLogic Case Shiller Home Price Index  forecasted to show prices in the 20 city composite rose 5 12  y y in June  but ticked 0 1  lower m m on a seasonally adjusted basis    
Europe lower on oil and Fed rate hike uneasiness  Asia mixed
European equities traded to the downside  amid lighter than usual volume as the U K  markets were closed for a holiday  Fed rate hike expectations got a boost from Friday s comments from Federal Reserve Chairwoman Janet Yellen  which was followed by Fed Vice Chair Stanley Fischer s remarks that suggested rate hikes next month and in December could be possibilities  The euro and British pound finished lower versus the U S  dollar  while bond yields in the region mostly dipped  Amid the elevated Fed rate hike expectations  utilities led to the downside  along with oil and gas issues  which saw pressure as crude oil prices declined on supply concerns and a stronger U S  dollar  Political uncertainty lingered in the region as Spain s Prime Minister Rajoy is set to face a confidence vote tomorrow  per Bloomberg   
Stocks in Asia finished mixed on the heels of Friday s comments from the Fed s Yellen and Fischer that kept the possibility of a September rate hike in play  Mainland Chinese equities finished flat and those traded in Hong Kong declined  while the nation reported a year over year  y y  acceleration in July industrial profits  Australian securities dropped amid weakness in basic materials and oil   gas stocks  while South Korean listings also declined  However  India s markets advanced  and stocks in Japan rallied as the yen weakened amid a rise in the U S  dollar on the aforementioned Fed comments  as well as Bank of Japan Governor Kuroda s reiterated pledge to deploy further stimulus measures if needed 
A host of economic reports from Japan will dominate tomorrow s international economic calendar  including labor data  personal income and consumption  retail sales and trade figures  From across the pond will come Germany s Import Price Index  housing prices from the U K   CPI from Spain  retail sales from Italy  and confidence gauges from the Eurozone ",2016-08-31,Marvin Clark,https://www.investing.com/analysis/u.s.-stocks-outdo-global-markets-200150944,200150944
197325,418841,MYL,Mylan Stock  Can It Survive The Epipen Blues ,opinion,"Mylan Inc   NASDAQ MYL 
On August 10th  the CEO of Mylan  Heather Bresch  assured that reliance on the Epipen was starting to ware down  This was the day the CEO was talking about earnings on the conference call  The CEO tried to downplay the whole necessity of the Epipen  Maybe it was to take attention away from it  and rightly so  That is because one week later after many analysts and investors had a chance to analyze the numbers  what they revealed was quite shocking 
What exactly was so shocking to where the Mylan issue has become such a huge dilemma in the news lately  Well how about the fact that from 2008 to now  the Epipen has risen in price by 400   That would make it hard for a standard adult to be able to afford the cost of having to use an Epipen  Even if you factor in the possibility about insurance companies that doesn t help either  That s because most insurers don t even cover the cost of the Epipen anymore  You can see now why this problems has blown up greatly in the media 
It got so bad that one week later  Senator Chuck Grassley who is the Chairman of the U S  Senate Judiciary Committee Chairman  asked the CEO of Mylan why is the price hiked by so much  This was a question in which the CEO could not respond to clearly  After all  Mylan acquired the Epipen drug in 2007  The Epipen is responsible for helping people at the time of an allergic reaction  Many think of an allergic reaction as being small  but there are times where an allergic reaction can be severe and life threatening  If that is the case  then the allergic reaction can lead to death 
That s where the problem lies  because this treatment is not a product that is just wanted  It is a necessity for patients to avoid death  Yet Mylan has increased the price by 400  from 2007  The main question is why  It is not a newly developed drug  and the company doesn t need to be reimbursed for development costs  Patients had been forced to drive to Canada to get the Epipen at 1 3 the total U S  cost 
With such a huge backlash from the medical community  the senate and many others Mylan had to quickly get into a reactive position  It has been forced to squelch criticism by doing something drastic  This drastic measure was announced on Monday  where the pharmaceutical drug maker would launch a generic Epipen with a 50  discount  While a nice gesture on Mylan s part  a 50  discount to a drug that has already risen by 400  is nothing  This move is an attempt to squash the harsh criticism  but I don t believe it will work 
That s not all its doing to alleviate pressure on itself  It is also stating that it will offer a  300 instant savings cards to patients that have to pay the full price for the drug out of pocket  As noted before all these gestures are nice  but in the end Mylan is still stopping short of performing one function that would end all the criticism  That function would be to outright cut the price of the drug  The company refuses to take this route when it know full well that it is the right thing to do 
It is not right that Mylan is putting profits in front of patients  lives  Mylan s CEO Bresch continues to blame the broken healthcare system for the reason of the cost being so high  That s far from the truth  because if the company wants to they can cut the price in half or more tomorrow if it wanted to  But analysts wrote that Mylan would receive a big cut per prescription sold  and that would lead to lower revenue  Again  it all comes back to money on why Mylan won t cut the cost of the Epipen  Mylan s stock should continue to feel pressure from this as long as it refrains from cutting the cost of its Epipen treatment ",2016-08-31,Joshua Rodriguez,https://www.investing.com/analysis/mylan-(myl)-stock:-can-it-survive-the-epipen-blues-200150948,200150948
197326,418842,MYL,Mylan  MYL  Gets Positive Copaxone USPTO Ruling Yet Again,opinion,"In a favorable development for Mylan N V    NASDAQ MYL    the U S  Patent and Trademark Office  PTO  once again ruled in favor of the company in its inter partes review  IPR  proceeding  According to the company s recent announcement  the PTO found that the U S  Patent No  8 969 302 that covers Teva Pharmaceuticals Industries Ltd  s   NYSE TEVA   multiple sclerosis drug  Copaxone  40 mg mL   is unpatentable 
We note that this is the third patent related to Copaxone  40 mg mL  to be found unpatentable in the last week  On Aug 24  the PTO s Patent Trial and Appeal Board  PTAB  found Teva s first two patents   U S  Patent Nos  8 232 250 and 8 399 413   unpatentable in Mylan s IPR challenge of these patents 
Mylan had also filed a petition against a fourth Copaxone  40 mg mL  patent  U S  Patent No  9 155 776  However  on Aug 15  the PTAB found the company s petition against this patent ineligible for post grant review due to procedural reasons  Given the favorable rulings in the IPR against the  302   250 and  413 patents  the company will continue to challenge the  776 patent In fact  Mylan believes that it is one of the first companies to have filed a substantially complete abbreviated new drug application  which contains a paragraph IV certification for the 40 mg mL thrice weekly formulation of Copaxone  This makes the company eligible for 180 days of marketing exclusivity in the U S   subject to FDA approval As per IMS Health data  Copaxone  40 mg mL  generated annual sales of approximately  3 3 billion in the U S  as of Jun 30  2016  The latest favorable ruling also raises optimism  If everything goes well  the FDA approval of a generic version of Copaxone  40 mg mL  will be a huge positive for Mylan and boost the performance of the company s generics business MYLAN NV Price
    However  Mylan has been making it to the headlines for all wrong reasons in recent times  Of late  the company faced extensive criticism from all over  including U S  senators and Democratic Presidential candidate Hillary Clinton  for over pricing its epinephrine auto injector  EpiPen 
Reeling under pressure from the issue  earlier this week  the company announced that it will launch the first generic to EpiPen at a list price of  300 per generic EpiPen two pack carton  This represents a discount of more than 50  to the list price  of the branded medicine  Mylan expects to launch the generic version in several weeks  pending completion of labeling revisions 
The company also announced that both the augmented patient assistance program and the  300 savings card that were announced late last week will remain in place for the branded product Mylan is currently a Zacks Rank  3  Hold  stock  A couple of better ranked stocks in the health care sector are ANI Pharmaceuticals  Inc    NASDAQ ANIP   and Geron Corporation   NASDAQ GERN    Both the stocks sport a Zacks Rank  1  Strong Buy  
Confidential from Zacks 
Beyond this Analyst Blog  would you like to see Zacks  best recommendations that are not available to the public  Our Executive VP  Steve Reitmeister  knows when key trades are about to be triggered and which of our experts has the hottest hand ",2016-09-01,Zacks Investment Research,https://www.investing.com/analysis/mylan-(myl)-gets-positive-copaxone-uspto-ruling-yet-again-200151572,200151572
197327,418843,MYL,Healthcare Back In The Spotlight ,opinion,"Although all sectors of the market are sensitive to government policy  healthcare is particularly so  One of the bellwether healthcare indices that we watch is the NASDAQ Biotechnology Index  As the election season was getting underway in earnest earlier this year  it was an open question in our mind whether political noise about drug pricing would continue to put pressure on biotech  Since the candidates had both expressed concerns about drug pricing  perhaps they would focus on areas of greater disagreement and the industry would get less negative publicity  With several of our favorite biotech names approaching attractive price levels and with healthy growth still visible for them  we watched the political environment carefully  While the S P 500 rallied from stumbles earlier in the year  biotech continued to perform anemically 

It is safe to say that the verdict is in  the political pressure is not coming off healthcare  In recent weeks  we ve had a new dose of public outrage about drug pricing  this time focusing on the EpiPen injector manufactured by Mylan  NASDAQ MYL   NASDAQ  MYL   General uncertainty has risen as Aetna  NYSE AET   NYSE  AET  has announced its withdrawal from 11 of the 15 Affordable Care Act  ACA  markets where it had operated    with some analysts calling this withdrawal a  death knell  for the ACA in its current form  As we know  markets do not like uncertainty  With events underway that could require a significant reshaping of the U S  healthcare system yet again  no matter which candidate wins  this is probably a cautionary signal for investors no matter how attractive valuations may begin to look 
Still  we advise readers to work on their shortlist of attractive companies    based on events and fundamentals  We believe that although the long term landscape will include greater pressure on pricing  the regulatory environment will not quickly become one in which the U S  stops being the engine of global pharma and biotech discovery  Fear of price controls is here  actual price controls are far off  As the market begins to discount this reality  perhaps after the dust has settled from the election  many pharma and biotech stocks with good pipelines and strong management teams may present excellent buying opportunities 
We would like to draw readers  attention to one area specifically  biosimilars  We ve covered these drugs in the past    generic versions of the complex new biologic drugs that have provided so many of the last decade s transformative new therapies    Biologics  are large molecules  in contrast to small molecule chemical drugs  and can be extremely challenging to discover and manufacture   The regulatory landscape for these drugs is still being determined  Currently  biologics enjoy a 12 year period of exclusivity for their inventors  one key plank of Hillary Clinton s healthcare platform is the reduction of this period to seven years  which would open opportunities for companies that have the technical know how to produce biosimilars  A Clinton victory is therefore likely to be seen as a bane for many big biotechs  whose future revenues largely depend on the success of the new biologics in their pipelines  On the other hand  it could be a boon for such companies as Coherus Biosciences  NASDAQ  CHRS   Momenta Therapeutics  NASDAQ  MNTA   and AbbVie  NYSE  ABBV    CHRS and MNTA are a small biotechs specializing in biosimilars  ABBV is a large company with extensive experience in producing biologics which has invested heavily in developing biosimilars to challenge its rivals  
Investment implications   Healthcare isn t catching a break  Campaign rhetoric and negative newsflow continue to put pressure on the sector  as the prospect of further shake ups looms and presidential candidates rattle their sabers about drug pricing  Some healthcare stocks  particularly biotechs  have begun to approach attractive valuations  but we believe it s not time to pull the trigger yet  Investors should work on their buy list for the time when the market shrugs off its political anxieties and recognizes that price control fears have been premature  We think investors should look particularly at the biosimilar space as the regulatory environment around it takes shape  as well as focusing on proven biotech innovators with good pipelines and seasoned management ",2016-09-02,Tim Shirata,https://www.investing.com/analysis/healthcare-back-in-the-spotlight-200151468,200151468
197340,418856,MYL,Biotech ETFs In Focus After Mylan s EpiPen Controversy,opinion,"It seems  from what Mylan NV   NASDAQ MYL   did on August 25  that finally the move against the  price gouging  by pharmaceutical companies won the battle to some extent  This is because Mylan NV indicated that it will reduce the cost of its EpiPen emergency allergy medication by about  amid heightened political pressure that was building up on the drug s steep price 
In particular  the drug company said that it would offer a  300  savings card  discount to patients purchasing a two pack of EpiPens  which actually have a retail price of around  
Why Mylan Offers Discounts 
The move came after the company faced intense scrutiny over the pricing of its popular allergy medication  The Democratic presidential candidate Hillary Clinton especially  for the  exorbitant  price hike on EpiPen 
As per    a shot of epinephrine can literally be the difference between life and death  and  over the last several years  Mylan Pharmaceuticals has increased the price of EpiPens by more than 400   They re now charging up to  600 for a two EpiPen set that must be replaced every 12 18 months  This both increases out of pocket costs for families and first responders  and contributes to higher premiums for all Americans and their employers  read    
Clinton has been vocal against drug price gouging since last September  Her tweet at that time had come on the heels  price hike  in about two months  of a drug called Daraprim  used to treat malaria and toxoplasmosis  This gigantic leap in pricing action was taken by a privately held biotech company Turing Pharmaceuticals  read    
Apart from Clinton   were investigating EpiPen s price rises and demanded explanation from the drug maker for this hike  Various   experts and patients were also into the move against the  out of control  price increases of EpiPens 
How Important EpiPen is for Mylan  
Mylan bought the auto injectors in 2007  when the life saving drug generated  200 million in revenues annually  From there  EpiPen s revenues reached over  1 billion in annual sales and make up  40  of Mylan total sales  While sales volume does matter  price hikes played an important role in this staggering revenue 
How Mylan Move is Being Viewed Now  
Even after a 50  discount  the step is viewed as  a  more than a real remedy  by some  Though Clinton sees Mylan s effort positively  she also believes that  discounts for selected customers without lowering the overall price of EpiPens are insufficient   This is particularly true since Mylan has not altered the list price  This seems just a small act to stop the storm raging on Mylan  Notably  this discount will not hold good for people without  or for those with government insurance programs 
How Did Biotech ETFs React  
Mylan shares lost about 12 4  in the last tumultuous five days  as of August 25  2016   when protests against EpiPen s price hikes were intense  On Thursday  MYL shares were down about 0 7  
Most of the biotech ETFs were in the red on Thursday  Biotech ETFs that have sizable weight in Mylan were hammered  VanEck Vectors Generic Drugs ETF  puts 7 04  weight in Mylan and lost about 3 2  on August 25  read    
iShares Nasdaq Biotechnology    which has 3 84  exposure to Mylan  shed about 1 2  on the day  Another biotech ETF SPDR S P Biotech ETF  was down about 1 1  
The price gouging issue has been throttling the biotech space for long  We believe that this blazing issue will be a talking point over the coming days especially given the looming election and will continue to put biotech ETFs in focus  read    
Want key ETF info delivered straight to your inbox  
Zacks  free Fund Newsletter will brief you on top news and analysis  as well as top performing ETFs  each week ",2016-08-25,Zacks Investment Research,https://www.investing.com/analysis/biotech-etfs-in-focus-after-mylan's-epipen-controversy-200150227,200150227
197341,418857,MYL,Here s How Drug Companies Justify Massive Price Hikes,opinion,"Prescription drug pricing remains firmly in the national spotlight this week after Democratic presidential nominee Hillary Clinton and other healthcare reform advocates called out Mylan  NASDAQ MYL  NV   for increasing the price of its popular EpiPen allergy medication by more than 400  over the past several years 
After a U S  Senator whose daughter relies on EpiPens called on the Senate Judiciary Committee to investigate Mylan  Clinton took to social media to unveil her new plan to combat drug price hikes and demand that Mylan reduce the cost of EpiPens immediately 
In response  Mylan and CEO Heather Bresch unveiled a new plan Thursday that would help make EpiPens more affordable for some customers  The drugmaker will offer a savings card to patients who pay for the treatment out of pocket  and it will double the size of its patient assistance program  also read    
Not Good Enough 
Despite this announcement  Bresch and the company received widespread criticism for what many consider to be a rather weak justification for the price hike in the first place  In an interview with   Bresch said  No one s more frustrated than me  and placed the blame on a healthcare system that lacks transparency 
 This system needs to be fixed  No one knows what anything costs   Bresch said 
Bresch argues that the  608 price tag for a two pack of EpiPens  which has been cited by critics throughout the week  is a list price that results from the number of hands that the drug must touch before reaching the patient  and the company never intended for patients to be paying that list price 
According to Bresch  Mylan only nets  274 in sales for a pack of EpiPens  or  137 per pen  She would also note that Mylan s costs include  manufacturing the product  distributing the product  enhancing the product  investing  
Mylan s new discount program wasn t enough to convince Hillary Clinton  as campaign spokesperson Tyrone Gayle said that  Discounts for selected customers without lowering the overall price of EpiPens are insufficient  because the excessive price will likely be passed on through higher insurance premiums  
Many were quick to agree with this criticism  citing the inefficiency of discount programs and questioning the legitimacy of Bresch s explanation for the price hike  Nevertheless  as we look further at the growing trend of massive price increases in the prescription drug market  we find that Bresch s answers becoming standard among industry executives 
Who s to Blame  
As Bresch pointed out  pharmaceutical companies are faced with extremely high costs associated with the production and distribution of drugs  The research and development process for new medications is costly and can take several years  Drugmakers also assume a certain level of risk while working on new treatments that could fail tests and never see the light of day 
This was the primary justification used by pharma bad boy Martin Shkreli after he received significant backlash from his own price hike scandal  Last year  Turing Pharmaceuticals and then CEO Shkreli grabbed headlines after the company bought 62 year old toxoplasmosis drug known as Daraprim and immediately increased its price from  13 50 to  750 per pill 
When asked why such an extreme price increase was necessary  Shkeli claimed that the drug was not profitable at that price and pointed to the benefits patients could receive from a better funded company 
 This is a disease where there hasn t been one pharmaceutical company focused on it for 70 years  We re now a company that is dedicated to the treatment and cure of toxoplasmosis  And with these new profits we can spend all of that upside on these patients who sorely need a new drug  in my opinion   he told  
In a way  Shkreli has a point here  and it definitely extends to other older drugs  Price increases in older drugs can go towards funding the development of a newer  more effective version of the treatment  or they can come as a result of the supply chain drying up over time 
Other than the common research and development argument  drugmakers tend to take the other route that Mylan and Bresch also used  many executives will argue that list prices are less relevant because companies offer extensive discounts to insurers  hospitals  and under covered patients 
As the Clinton campaign pointed out  these discounts are oftentimes paid for by other people in the chain and can result in higher premiums for everyone 
Bottom Line
With the number of U S  politicians targeting drug companies  it s pretty obvious that this issue has taken a political turn  and that does makes sense  At the end of the day  this is an inherently political issue and it challenges everyone s fundamental beliefs about regulation and the free market 
What is clear to see  however  is that prescription drugs tend to cost more in the U S  than in other developed nations  The reason for this depends on who you ask  but pharmaceutical executives have certainly fine tuned their justifications for price hikes over recent years 
For more coverage on this week s price hike scandal  check out this week s episode of the Zacks Friday Finish Line podcast  The drama involving Hillary Clinton and Mylan was the first segment this week ",2016-08-26,Zacks Investment Research,https://www.investing.com/analysis/here's-how-drug-companies-justify-massive-price-hikes-200150344,200150344
197342,418858,MYL,Mylan Digs A Deeper Hole,opinion,"DOW   33   18 448
SPX   2   2172
NAS   5   5212
10 Y    02   1 58 
OIL    61   47 38
GOLD   2 20   1322 60

The number of Americans who applied for unemployment benefits last week fell by 1 000 to 261 000 and remained near post recession lows  Claims fell below the key 300 000 threshold in early 2015 and have remained there for 77 straight weeks  the longest streak since 1970 
Orders for durable or long lasting goods made in the U S  surged 4 4  in July to mark the biggest gain since last fall  Higher demand for passenger jets led the way as expected  The Pentagon also put in a bunch of new orders  Stripping out the volatile transportation sector  orders rose a smaller 1 5   Still  that matches the biggest increase of the year 
Kansas City Fed President Esther George said Thursday she thought it was time to raise interest rates  George  who is a voting member of the Fed s policy committee this year  said she didn t know if anything would cause her to change her mind at the Fed s meeting next month  But she indicated that decision making remains data dependent  George has a hawkish track record  Still  she joins Dallas Fed President Robert Kaplan  FOMC Vice Chair Stanley Fischer and New York Fed President William Dudley on the list of Fed officials calling for rate hikes 
Fed chair Janet Yellen delivers a speech at Jackson Hole tomorrow  she is expected to address possible rate hikes  Fed Funds futures are currently predicting only a 53  chance of a rate hike in calendar year 2016  which  of course is only a bit higher than coin flip  So  given the current overbought condition and the complacency seen in many indicators  the bears tell us that stocks are now  set up  for disappointment if Ms  Yellen s speech takes on a more hawkish tone than expected tomorrow 
Central bankers sit down with their critics  In what is a first for the high profile policy conference at Jackson Hole  Wyoming  eight central bankers  including William Dudley  president of the New York Fed  will meet with 120 activists from the Fed Up Campaign  which wants to see change at the Federal Reserve 
Mylan  NASDAQ MYL  is responding to backlash over price increases for its EpiPen emergency allergy treatment by promising to reduce the costs that some patients pay  though the drug maker stopped short of saying it would roll back prices or limit future increases  EpiPen is a lifesaving treatment for millions whose allergies can send them into severe shock  including many schoolchildren who are advised to keep an injector handy at all times  The price has increased 548  since 2007  After widespread criticism recently  Mylan will  double eligibility  for its EpiPen patient assistance program to 400  of the poverty level  saying that a family of four making  97 200 would now pay nothing out of pocket for a prescription 
What the discount does change is how much people with commercial insurance and a high deductible pay  If you were at on the hook for about  600 before  that will now be cut to about  300  For people without insurance  however  the card won t apply  they d fall under a separate patient assistance program  It also won t apply to people under government insurance programs such as Medicare or Medicaid 
Mylan CEO Heather Bresch  who happens to be the daughter of US Senator Joe Manchin  was making the rounds of TV business interviews today  trying to explain that there was nothing she could do about the price increases  she claimed the health care system is broken  she claimed she can t lower the price because there are many layers  or middlemen  each taking a cut along the supply chain  even if Mylan cut the price  it wouldn t result in lower prices for consumers  Well  she s partially correct   the health care system is broken  The rest is pure hogwash 
The cost of a two pack of EpiPens   shots of epinephrine that relieve symptoms from severe allergies that restrict breathing and can cause death   has risen from  103 50 in 2009 to  608 61 today  despite no changes in the chemical formula  Two vials of the proper dosage of epinephrine and manual syringes would cost only  20  some put the cost of the dosage in each EpiPen at as little as  1 
In 2012  the company behind the EpiPen settled a lawsuit by agreeing to allow a generic competitor into the market in 2015  potentially cutting into a big part of its business  Mylan had already been steadily increasing the price of EpiPen  an injector containing a drug that can save people from life threatening allergy attacks  After the settlement  it started to raise the price even faster  The increasing price hikes reek of a greedy last grab for profits and an attempt to subvert the court s ruling 
Bresch can lower the price  just as easily as she raised the price  or for that matter  even easier than the corporate  inversion  merger with Abbott Labs that moved Mylan s headquarters to the Netherlands last year  so the company could dodge US taxes 
Brazil s Senate has started the impeachment trial of suspended President Dilma Rousseff for violating budget laws  with the chances strong that she will be removed from office  Brazilian markets have rallied lately over the prospect of the Vice President Michel Temer permanently taking over from the Rouseff  although Temer was recently found guilty of violating campaign finance limits  a case that could make him ineligible to run for office for eight years 
Colombia s government and the Marxist rebel group the Revolutionary Armed Forces of Colombia  FARC  have reached a peace deal after 52 years of war that has killed over 220 000 people  In return for giving up its arms  FARC members will be allowed to reintegrate into civilian life and stand for elections  The agreement will be put to a referendum in October  when it is expected to pass 
As one war ends   Turkey has launched its first major ground assault into Syria since the country s civil war began  sending in tanks and special forces backed by U S  airstrikes to help Syrian rebels retake a border town from ISIS  The assault marks a dramatic escalation of Turkey s role in Syria s war  but there is more to the move than just fighting ISIS in Syria  Turkey is also aiming to contain expansion by Syria s Kurds  who are also backed by the United States and have used the fight against ISIS and the chaos of the civil war to seize nearly the entire stretch of the border with Turkey in northern Syria 
Phoenix based ON Semiconductor has won antitrust approval to buy Fairchild Semiconductor International  ON will sell its Ignition IGBT business to Chicago based manufacturer Littelfuse  ON Semi and its rivals  power management circuits are used in everything from aircraft to home appliances and automobiles to computers  The deal was valued at about  2 4 billion  The FTC  in a statement  said that without the sale the merged company would have controlled more than 60 percent of the market for insulated gate bipolar transistors  or IGBTs   a type of semiconductor used in automotive internal combustion engines  ignition systems  That likely would have driven up prices and curbed innovation 
HP Inc   the hardware business of the former Hewlett Packard Co  reported higher than expected quarterly revenue and profit as demand recovered for its notebooks  However  HP forecast current quarter profit below analysts  estimates  reflecting weak sales of its printers as companies cut costs across industries 
Sears Holdings is in really bad shape as its earnings report shows  The struggling owner of Sears and Kmart reported a staggering second quarter loss of  2 03 a share  Same store sales at discounter Kmart fell 3 3   representing the seventh straight quarterly decline  Same store sales at discounter Sears fell 7   representing the eighth straight quarterly decline  And Sears is running out of money to stay afloat  Cash and equivalents declined to  276 million from  1 8 billion a year ago 
The ride hailing giant Uber Technologies is not a public company  but every three months  dozens of shareholders get on a conference call to hear the latest details on its business performance  Uber s losses in the first half of 2016 totaled at least  1 27 billion  For a private business to raise as much capital as Uber is unprecedented  It is also tough to find a tech company that can lose this much money this fast 
The first driverless taxi began work today in a limited public trial on the streets of Singapore  Developer nuTonomy invited a select group of people to download their app and ride for free in its  robo taxi  in a western Singapore hi tech business district  hoping to get feedback ahead of a planned full launch of the service in 2018  The trial rides took place in a Mitsubishi i MiEv electric vehicle  with an engineer sitting behind the steering wheel to monitor the system and take control if necessary 
Over 300 Airbnb hosts have opened up their homes for free to people wracked by earthquakes  floods and fires in central Italy  Louisiana and California  Homes in central Italy  hit by a 6 2 magnitude earthquake Aug  23  are on free offer on the website s urgent accommodation page between Aug  23 and Sept  11  Airbnb accommodation could serve as an alternative to temporary relief camps for the 1 000 residents  whose homes were destroyed  Accommodation is also available to those affected by floods in Louisiana and prolonged wildfires threatening two Californian counties ",2016-08-26,Marvin Clark,https://www.investing.com/analysis/mylan-digs-a-deeper-hole-200150221,200150221
197343,418859,MYL,The Zacks Analyst Blog Highlights  Mylan  Teva Pharmaceutical  Lannett Company  BioSpecifics Technologies And USANA Health Sciences,opinion,"For Immediate Release 

Chicago  IL   August 29  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include  Mylan  NASDAQ MYL  N V      Teva Pharmaceutical Industries  NYSE TEVA  Ltd       Lannett Company  Inc      BioSpecifics Technologies Corp     and USANA Health Sciences Inc      

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Friday s Analyst Blog  

Forget Mylan  Buy These 3 Drug Stocks Instead

The healthcare sector has once again grabbed the spotlight due to exorbitant drug pricing  Generic drug maker  Mylan N V  s     shares crashed almost 12  after the company drew flak for over pricing epinephrine auto injector  EpiPen  which is approved for the treatment of severe allergic reactions 

Earlier this week  a couple of U S  senators raised questions about the company s massive price hike of EpiPen  While one of the senators asked for details of the massive price hike of the product in the recent years among other issues  another urged the Federal Trade Commission to investigate into the company for a likely antitrust violation regarding the issue 

Mylan had acquired EpiPen from Merck  NYSE MRK  KGaA in 2007  following which the product s cost has skyrocketed over 400   As per news reports  Mylan has hiked the price of a pack of two EpiPens from  100 in 2008 to the present level of  500  with some customers reportedly paying  600 or more 

Making matter worse  Democratic Presidential candidate Hillary Clinton even posted a tweet  saying  EpiPens can be the difference between life and death  There s no justification for these price hikes   Reeling under pressure from the issue  the company yesterday announced plans to improve access to EpiPen by expanding the existing programs for patients who are bearing the high expenses  Under this plan  Mylan will double the eligibility for its patient assistance program  which will slash out of pocket costs for uninsured and under insured patients and families 

Similar Controversies Faced by Peers

But Mylan is not the first company to come under scanner for overpricing drugs  While exorbitant drug prices and the lack of affordability of prescription drugs have always been there  price hiking suddenly came to the forefront late last year  Privately held Turing Pharmaceuticals raised the price of Daraprim from  13 50 to  750 per pill in a single shot  thereby attracting public attention as well as criticism  The company had acquired the U S  rights to Daraprim from Impax Laboratories Inc  in Aug 2015 

The price increase didn t go down well with Hillary Clinton then either  whose  price gouging  tweet led to a major sell off in the healthcare sector  cutting short the phenomenal run of health care stocks  particularly in the biotech sector 

What s to Happen Next

It has been widely believed that lack of competition allowed Mylan to raise the price of EpiPen  Auvi Q has been off the markets since last October  while Teva Pharmaceutical Industries Ltd     failed to even receive an approval for its generic version of EpiPen earlier this year  On the bright side for Teva  the controversies surrounding Mylan could now push regulatory agencies to expedite the approval of generic versions of the drug 

Medical Sector Price Index



Against this backdrop  Mylan currently has a Zacks Rank  3  Hold   Here  we have picked three stocks using our   Not only do these stocks have a solid VGM score   V  for Value   G  for Growth and  M  for Momentum  of  B   but they also have a favorable Zacks Rank  1  Strong Buy  or  2  Buy  

The VGM score rates each stock on their combined weighted styles  helping to identify those with the most attractive value  best growth  and most promising momentum  across the board  

Philadelphia  PA based Lannett Company  Inc     develops  manufactures  packages  markets  and distributes solid oral and extended release  tablets and capsules   topical  nasal  and oral solution finished dosage forms of drugs  which target a wide range of therapeutic areas 

The company is also pursuing partnerships  research contracts and internal expansion for the development and production of other dosage forms including ophthalmic  nasal  patch  foam  buccal  sublingual  soft gel  injectable and oral dosages  This Zacks Rank  1 stock has seen its current year earnings per share  EPS  estimate move 11 64  higher over the past 60 days 

Wilbur Street Lynbrook  NY based BioSpecifics Technologies Corp      is a biopharmaceutical company that develops injectable collagenase clostridium histolyticum for multiple indications  Injectable collagenase is marketed as Xiaflex in the U S  for the treatment of Dupuytren s contracture and Peyronie s disease by its partner  Endo International  This Zacks Rank  2 stock s current year EPS estimate has moved up by 9 29  over the past 60 days 

Headquartered in Salt Lake City  UT  USANA Health Sciences Inc      is focused on the development and manufacture of high quality  science based nutritional and personal care products that are distributed internationally through a network marketing system  This Zacks Rank  2 stock has seen its current year EPS estimate move up by 4 92  higher over the past 60 days 

Bottom Line

Regardless of macroeconomic events  drug pricing will remain in focus among policymakers  the media and the public  But instead of focusing on finding someone to take all the blame  emphasis should be on striking a balance between innovation and affordability  With all eyes on the healthcare sector  companies will now become increasingly cautious about drug price hikes  While Mylan attempts to recover from the recent setback  investors could consider these top ranked drug stocks  which also have a superb Style Score 

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days   

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact
	Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-08-28,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-mylan,-teva-pharmaceutical,-lannett-company,-biospecifics-technologies-and-usana-health-sciences-200150589",200150589
197352,418868,MYL,Did Hillary Clinton s Tweet Cause The Sell Off In Mylan  MYL  Stock ,opinion,"Shares of pharmaceutical giant Mylan Inc    NASDAQ MYL   fell over 5 5  in afternoon trading Wednesday as the company faces increased scrutiny over the pricing of its popular EpiPen allergy medication  Interestingly enough  the sell off in Mylan stock seems to be caused by a tweet sent out by Democratic presidential nominee Hillary Clinton 
At about 2 p m  EST  Clinton tweeted the following EpiPens can be the difference between life and death  There s no justification for these price hikes    H  Hillary Clinton   HillaryClinton  With her account s signature   H  marking to signify the message was coming from Clinton herself  the tweet linked to an expansive Facebook  NASDAQ FB  post wherein the former First Lady attacked Mylan and its recent price hikes on the EpiPen 
 Over the last several years  Mylan Pharmaceuticals has increased the price of EpiPens by more than 400   They re now charging up to  600 for a two EpiPen set that must be replaced every 12 18 months  This both increases out of pocket costs for families and first responders  and contributes to higher premiums for all Americans and their employers   Clinton wrote 
The current frontrunner in what is becoming an increasingly polarizing presidential race would go on to describe Mylan s behavior as  outrageous  and introduced her plan to address  exorbitant  drug price hikes  Clinton said her plan would require drug companies to explain significant price hikes and prove that additional costs are linked to better patient benefits and value  With that  she called on Mylan to immediately reduce the price of EpiPens 
Although today s announcement was the first detailed plan to combat the issue  prescription drug reform has been on Clinton s platform for quite a while  In fact  this isn t even the first time one of her tweets caused a sell off 
Back in September of 2015  Clinton tweeted about price gouging in the specialty drug market  which sent biotech ETFS such as  and   LON FBT   tumbling  also read    
As the presidential race continues to heat up  investors should be on the lookout for other policy initiatives that could have a serious effect on the markets ",2016-08-24,Zacks Investment Research,https://www.investing.com/analysis/did-hillary-clinton's-tweet-cause-the-sell-off-in-mylan-(myl)-stock-200149857,200149857
197353,418869,MYL,Mylan  MYL  Listens To Critics  Will Make EpiPen More Affordable,opinion,"In response to widespread criticism  pharmaceutical company Mylan NV   NASDAQ MYL   announced Thursday that it will take several steps to make its popular EpiPen allergy treatment more affordable for some patients 
Mylan found itself in the crosshairs of many healthcare reform advocates this week  including Democratic presidential nominee Hillary Clinton  who used the EpiPen as an example of the aggressive pricing strategies that have become commonplace in today s pharmaceutical industry 
As Clinton pointed out  Wednesday  Mylan has increased the price of EpiPens more than 400  over the past several years  A standard two pack of the allergy medication now costs nearly  600 
In a   the drugmaker said it will provide an instant savings card worth  300 to any patient that currently pays full price for the drug out of pocket  This would represent savings of about 50  for patients without insurance or for those with high deductible plans 
Mylan also announced that it is doubling the eligibility for patient assistance to 400  of the federal poverty level  This means that a family of four making up to  97 200 would be eligible to pay effectively nothing for an EpiPen 
 We responded this morning  first and foremost  ensuring that everybody that needs an EpiPen has an EpiPen   Mylan CEO Heather Bresch told    As a mother I can assure you that the last thing we could ever want is no one to have their EpiPen due to price  
The company also announced that it will continue to offer its EpiPen4Schools program  which provides free epinephrine injectors to schools across the country  and it is opening a pathway for customers to purchase EpiPens directly from Mylan in the hopes of reducing costs 
The impact of today s decision on Mylan s earnings and revenue is still unknown  but the company definitely won an important public relations battle  As drug manufacturers continue to see increased scrutiny  patients could be the big winners if price cuts become a trend ",2016-08-25,Zacks Investment Research,"https://www.investing.com/analysis/mylan-(myl)-listens-to-critics,-will-make-epipen-more-affordable-200150095",200150095
197354,418870,MYL,Market Update   25 08 2016,opinion,"Currencies
EUR USD   even though the data out of the US wasn t good  the USD strengthened and we saw the pair extend the drop until late afternoon  when it started to correct slightly upwards  We have more data out of Eurozone and the US today  but as mentioned already a few times  tomorrow will be the main event  even though there won t be important data out of Eurozone tomorrow 
USD JPY   is still trading in an ever tighter range as we can expect a breakout of the pattern tomorrow  due to the important day Friday promises to be  We will start today with some US data  and then overnight we will have Japanese inflation data  to be followed tomorrow by the US GDP and afterwards the speech by FED Chair Yellen  
GBP USD    while the USD strengthened yesterday across the board  the major exception was against the GBP  It was trading lower in the morning  but as has been the case in recent days  in the course of the morning there is a turnaround and we see the pair move higher again  This morning we once more see a drop  so it will be interesting to see if we see the same thing happening again 
USD ZAR   moved sharply up as the inflation data out of South Africa was weaker than expected  as well as a strengthening of the USD  However  the main reason we moved up was the fact that is was reported that the South African Finance Minister could be rearrested again 
Indices
S P 500   saw the largest loss since the beginning of the month  as the USD strengthened  and also oil dropped further  In case Yellen s comments tomorrow will be interpreted as hawkish  we can expect the S P to drop further as that would bring a rate hike closer  At the moment the nearest support can be found around the 2167 level 

Commodities
Gold   moved sharply down yesterday and broke below the support whish was in place in recent weeks around the 1332 level and reached the lowest level since the last FOMC statement  Tomorrow we are expected to see a lot more volatility with the GDP data out of the US and the much anticipated speech by Yellen at the Jackson Hole Symposium  The big question is if she reiterates what several senior FED members have said in recent days  or if she strikes a different tone 
Oil   dropped after the inventories confirmed the API data that there was an increase in the inventories  albeit not as large as the API figure  Nonetheless  production dropped slightly compared to the previous week  which saw a large increase in production  Gasoline inventories also increased  while a decrease was expected  All of this contributed to a decline of the oil price  and in addition the USD also strengthened a bit 
Regarding the OPEC meeting next month  one other issue we have to take into consideration  besides the ones mentioned earlier this week  is that it was mainly Saudi Arabia which was against cutting production or freezing production in order to gain market share  With Saudi production at record levels  it remains to be seen how much more it can produce  so from that perspective a freeze makes sense  but that could move oil higher  which in turn would bring back US producers  When that happens  it is likely that this would hurt not only the oil price again  but also the Saudi market share  From that point of view  the best course of action from the Saudi perspective would be to not agree to an official production freeze  but rather a de facto production freeze 

Stocks
Teva   dropped sharply after Mylan  NASDAQ MYL  successfully fought Teva s patents on one of its flagship drugs   Copaxone  The fight is about the new dose for the drug  and so far Teva has lost 2 of the 4 rulings  although it has already said it would fight these ",2016-08-25,AvaTrade,https://www.investing.com/analysis/market-update--25-08-2016-200149925,200149925
197355,418871,MYL,US Markets  Jackson Hole Begins Today,opinion,"The Jackson Hole Symposium begins today with market participants curious to see if any indication on a September or even December hike in rates is on the cards  Will the momentum remain with the Bulls 
The Bears were happy to see the NASDAQ  S P 500 and DJ 30 all close down yesterday  when intraday trading on the NASDAQ had it on route to a consecutive nine day gain  The reason for this was a very powerful Tweet by presidential candidate Hillary Clinton saying that there was no justification for the high prices being charged for EpiPens by health care company Mylan  NASDAQ MYL  
This has us questioning if it really was the Tweet that did this or simply a lack of news in the market 
With some chief economists calling the Fed Symposium in Jackson Hole the most important event taking place all summer  the world s economists and investors will be watching this small ski resort in Wyoming with bated breath 
With the most powerful central banker in the world  Fed Chair Janet Yellen going to speak on Friday  the markets are unnervingly quiet  Is this the quiet before the storm 
Some analysts are expecting her to air on the hawkish side in her speech relating to Septembers meeting  We can see why this may be the case  but we aren t agreeing with them entirely 
If her past speeches are anything to go by  Chair Yellen never wants to take anything off the table  She may suggest that the employment and inflation targets have been hit  which could be seen as a signal to hike interest rates  but she has done this in the past without taking any action
Yellen knows that higher interest rates could seriously jeopardize what little growth the US economy actually has  And moving too early could be detrimental to the economy ",2016-08-25,AvaTrade,https://www.investing.com/analysis/us-markets:-jackson-hole-begins-today-200149949,200149949
197364,418880,MYL,Is A Surprise In Store For Inovio  INO  This Earnings Season ,opinion,"Inovio Pharmaceuticals  Inc    NASDAQ INO   is scheduled to report second quarter 2016 results on Aug 8  before the opening bell  In the trailing four quarters  Inovio s performance has been mixed with the company recording an average positive surprise of 180 15   While the company surpassed estimates on two occasions  it missed expectations in the other two 
In the last reported quarter  Inovio had posted a positive surprise of 52 17   Let s see how things are shaping up for this announcement 
Factors at Play
Inovio  a development stage biopharmaceutical company  is focused on the development of active DNA immunotherapies and vaccine treatments targeting various cancer forms and infectious diseases  VGX 3100 is the most advanced candidate in the company s pipeline  Following the successful end of phase II meetings both with the FDA and the European Medicines Agency  the company plans to commence a pivotal phase III study on the candidate for the treatment of HPV 16 18 related high grade cervical dysplasia  CIN 2 3  this year 
Apart from VGX 3100  Inovio has several other candidates in its pipeline in early  to mid stage development  Inovio along with its partner GeneOne Life Science gained approval for the initiation of a phase I study evaluating the Zika vaccine  GLS 5700  in Jun 2016  The first patient was dosed in the study late last month 
Meanwhile  in late Apr 2016  the company acquired all of Bioject Medical Technologies Inc  s assets  including the needle free jet injection technology  devices  and intellectual property for  5 5 million in cash and stock in a bid to further boost its needle free electroporation technology 
Inovio has collaborations with several companies and institutes for the development of its pipeline candidates  And with no approved product in its portfolio  Inovio depends largely on collaborations  grants and other payments for revenues as well as for the development of its pipeline candidates  Therefore  the top line at the company varies on a quarterly basis depending on the timing of such events 
Investor focus should remain on pipeline updates as a lot of pipeline related events are lined up along with the company s plans related to the development of its Ebola and Zika vaccines 
What Our Model Indicates
Our proven model does not conclusively show that Inovio is likely to beat estimates this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  for this to happen  That is not the case here as you will see below 
Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00  since the Most Accurate estimate is in line with the Zacks Consensus Estimate of a loss of 26 cents per share 
Zacks Rank  Inovio currently carries a Zacks Rank  3  Inovio s Zacks Rank  3 when combined with an ESP of 0 00  makes surprise prediction uncertain 
Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions INOVIO PHARMAC Price and EPS Surprise   Stocks That Warrant a Look
Here are some health care stocks that you may want to consider as our model shows that they have the right combination of elements to post an earnings beat this quarter 
The Earnings ESP for Acceleron Pharma  Inc    NASDAQ XLRN   is  7 41  and it carries a Zacks Rank  3  The company is scheduled to report second quarter results on Aug 4 
Mylan N V    NASDAQ MYL   has an Earnings ESP of  1 75  and carries a Zacks Rank  2  It is scheduled to report second quarter results on Aug 9 
The Earnings ESP for Impax Laboratories Inc    NASDAQ IPXL   is  3 03  and it carries a Zacks Rank  2  The company is also scheduled to report second quarter release results on Aug 9 ",2016-08-03,Zacks Investment Research,https://www.investing.com/analysis/is-a-surprise-in-store-for-inovio-(ino)-this-earnings-season-200145911,200145911
197365,418881,MYL,Catalyst  CPRX  Q2 Earnings  Can The Stock Pull A Surprise ,opinion,"Catalyst Pharmaceuticals  Inc    NASDAQ CPRX   is scheduled to report second quarter 2016 results on Aug 9 
Catalyst has maintained an impressive track record so far  The company reported narrower than expected losses in two of the last four quarters  with a positive average surprise of 7 1   Let s see how things are shaping up for this announcement 
Factors Influencing This Quarter
Given that Catalyst does not have any revenue generating products in its portfolio yet  investor focus will remain on pipeline and regulatory updates  At present  Catalyst has three candidates under development   Firdapse  CPP 115 and CPP 109 
In Jun 2016  Catalyst reached an agreement with the FDA for a confirmatory phase III study protocol on lead candidate Firdapse for the symptomatic treatment of Lambert Eaton myasthenic syndrome  LEMS   The company was handed a  refusal to file  letter from the FDA in Feb 2016 in connection with its New Drug Application  NDA  for the product 
The agency had determined that the company s NDA was insufficient after a preliminary review  As part of the clinical protocol for the confirmatory study  the company plans to initiate a small  single center study on Firdapse in the second half of 2016 
Catalyst is also evaluating Firdapse for the treatment of certain types of congenital myasthenic syndromes  CMS  and a specific form of myasthenia gravis  The company has initiated an investigator sponsored phase II III study on Firdapse for the symptomatic treatment of MuSK antibody positive myasthenia gravis  MuSK MG  in Feb 2016 and top line results from this study are expected in 2017 
Apart from Firdapse  the company is looking to develop CPP 115 for the treatment of epilepsy  initially infantile spasms   and other selected neurological indications such as complex partial seizures and Tourette s disorder  Catalyst is also working on a generic version of Sabril  vigabatrin   which is marketed by Lundbeck  for the treatment of infantile spasms and complex partial seizures 
Consequently  its R D spending is expected to go up in 2016 due to clinical development efforts on Firdapse in the pediatric CMS population and MuSK MG 
 CATALYST PHARMA Price and Consensus
   What Our Model Indicates
Our proven model does not conclusively show that Catalyst is likely to beat expectations this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy    2  Buy  or  3  Hold  to be able to beat estimates  That is not the case here  as you will see below 
Zacks ESP  The Earnings ESP  which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate  is 0 00   since both the Most Accurate estimate and the Zacks Consensus Estimate stand a loss of 8 cents 
Zacks Rank  Catalyst carries a Zacks Rank  3  Though this increases the predictive power of ESP  the company s ESP of 0 00  makes surprise prediction difficult 
Note  we caution against stocks with a Zacks Rank  4 or  5  Sell rated stocks  going into an earnings announcement  especially when the company is seeing negative estimate revisions 
Stocks That Warrant a Look
Here are some health care stocks that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter 
Mylan  Inc    NASDAQ MYL   has an Earnings ESP of  1 75  and a Zacks Rank  2  The company is expected to release second quarter results on Aug 9 
Impax Laboratories Inc    NASDAQ IPXL   has an Earnings ESP of  3 03  and a Zacks Rank  2  The company is expected to release second quarter results on Aug 9 
Ironwood Pharmaceuticals   NASDAQ IRWD   has an Earnings ESP of  13 33  and a Zacks Rank  2  The company is expected to report earnings on Aug 4 ",2016-08-03,Zacks Investment Research,https://www.investing.com/analysis/catalyst-(cprx)-q2-earnings:-can-the-stock-pull-a-surprise-200145906,200145906
197366,418882,MYL,Monster Worldwide  MWW  Q2 Earnings  What s In Store ,opinion,Monster Worldwide  Inc    NYSE MWW   is set to report second quarter 2016 results on Aug 9  It delivered a positive earnings surprise of 25 00  in the last quarter  It has a positive four quarter average earnings surprise of 16 04  Let s see how things are shaping up for this announcement Factors to ConsiderIn the last quarter  though Monster Worldwide surpassed earnings estimates  its sales missed the same  Revenues were also down significantly year over year  Even the guidance for the second quarter was lower than expected The company has been seeing weakness in its transactions business in key regions like North America and Canada  We expect that going ahead  given an uncertain macroeconomic outlook  employers might continue to remain conservative with their hiring budget  Further  competition has intensified over the last few years in the online employment market  Many recruiters are already using alternative social media sites such as LinkedIn   NYSE LNKD    Though Monster is now working to build its social media presence  the headwinds will likely remain in the near term Nonetheless  there can be some respite in the form of re branding and cost cutting initiatives that are expected to boost its growth over the long term  In June  the company acquired a mobile based job search startup  Jobr which has a  Tinder like  approach to its platform  This will enable Monster to attract new users  especially the younger generation  which is more inclined toward mobile applications compared to the web This apart  the company will also benefit from its collaborations with companies like kununu and Crelate Inc For the second quarter  the company expects non GAAP earnings per share from continuing operations in the range of breakeven to 4 cents  excluding  2 million to  3 million of stock based compensation and  1 3 million of non cash debt discount amortization pertaining to the convertible debt MONSTER WWD INC Price and EPS Surprise   Earnings WhispersOur proven model does not conclusively show that Monster Worldwide is likely to beat earnings this quarter  This is because a stock needs to have both a positive and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here  as you will see below Zacks ESP  Monster Worldwide has an Earnings ESP of 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 2 cents Zacks Rank  Monster Worldwide s Zacks Rank  3 when combined with a 0 00  ESP makes surprise prediction difficult We caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revisions momentum Stocks to ConsiderHere are some stocks that  as per our model  have the right combination of elements to post an earnings beat this quarter Impax Laboratories   NASDAQ IPXL   has an Earnings ESP of  3 03  and a Zacks Rank  2 Mylan  Inc    NASDAQ MYL   has an Earnings ESP of  1 75  and a Zacks Rank  2 Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days ,2016-08-04,Zacks Investment Research,https://www.investing.com/analysis/monster-worldwide-(mww)-q2-earnings:-what's-in-store-200146352,200146352
197367,418883,MYL,Tessera  TSRA  Surpasses Q2 Earnings   Revenue Estimates,opinion,"Following the earnings release on Aug 2  Tessera Technologies Inc  s   NASDAQ TSRA   shares have slumped 2 4  to close Aug 4 at  31 32  The company reported better than expected results for the second quarter of 2016 
The leading chip packaging and interconnect solutions provider beat the Zacks Consensus Estimate on both the top and bottom lines 
Adjusted earnings of 55 cents per share surpassed the Zacks Consensus Estimate by 7 8  or 4 cents  Revenues of  67 million beat the consensus mark of  65 million by 3 1  
Revenues
Tessera s revenues came ahead of its own guidance range of  64  66 million  Revenues were up 11 7  sequentially and 4 4  year over year  The strength versus a year ago was on account of the increase in recurring revenues  which went from  63 2 million to  66 7 million  Episodic revenues  however  were down from  1 million to  0 3 million   
Margins
Owing to the high percentage of licensing revenues  Tessera usually generates very strong gross margins  Accordingly  Tessera s second quarter gross margin was 99 92   up 7 basis points from 99 85  reported in the previous quarter 
Tessera s quarterly operating expenses were  26 8 million  down 3 4  from  27 7 million last quarter and up 18 9  from the year ago tally of  22 5 million  Operating expenses comprise year over year increase of  1 8 million in litigation expense   1 4 million in amortization expense  and  2 4 million in research and development 
Litigation expenses of  5 3 million were up from  3 5 million in the second quarter of 2015 due to increased case activity 
Net Income
Net income was  27 5 million or earnings of 55 cents a share  compared with  22 1 million or earnings of 43 cents in the prior quarter and  29 million or earnings of 55 cents last year  Earnings increased 27 4  sequentially and 2  year over year  On a GAAP basis  net income was  23 5 million or earnings of 48 cents compared with  18 1 million or earnings of 36 cents in the prior quarter and  26 1 million or earnings of 49 cents in second quarter 2015 
Balance Sheet and Cash Flow
At quarter end  current assets were worth  397 5 million  down  4 7 million sequentially  Cash  cash equivalents and short term investments as of Jun 30  2016 were  371 8 million  up  8 3 million from the Mar 31  2016 level  The company had no debt 
Share Repurchase   Dividend
Tessera spent  9 8 million on cash dividends and  25 2 million to repurchase 0 8 million shares in the reported quarter  Further  management declared a cash dividend of 20 cents per share for the second quarter  payable on Sep 12  2016 to stockholders on record as on Aug 22 
Guidance
For the third quarter  Tessera expects revenues in a range of  61 million  63 million  GAAP earnings per share are expected between 39 cents and 41 cents  and non GAAP earnings per share within 51 53 cents  Currently  the Zacks Consensus Estimate is pegged at 46 cents TESSERA TEC INC Price  Consensus and EPS Surprise
   Our Take
Tessera posted better than expected second quarter results with both the top line and the bottom line outperforming the respective Zacks Consensus Estimates 
Tessera continues to witness improvement with FotoNation imaging group that recorded second highest ever quarterly revenues this quarter  The company stayed aggressive on the capital allocation front with a combination of dividends and share buybacks 
Tessera has intensified its Invensas  FotoNation and IP licensing efforts and is currently working with a number of semiconductor manufacturers and OSATs to enhance its portfolio of advanced packaging and interconnect technologies that encompass ZiBond  Direct Bond Interface  DBI  bonding technologies and BVA 
The company has also made good progress with its Greenfield licensing efforts and is in advanced stage of negotiations with two of its potential Greenfield customers 
Tessera s premium imaging technology continues to see strong interest thereby indicating that the business will grow significantly in the mobile and adjacent markets 
The company is making good progress on the SOC front and its IPU architecture is creating interest among several Asia based SOC providers  thereby opening up opportunities in China 
Tessera is also making good progress on the automotive front and continues to create advanced and intelligent automotive application solutions 
Overall  the company s internal R D efforts  Invensas  FotoNation and IP licensing initiatives and prospects in the automotive market remain bright spots and are expected to drive growth going forward 
Tessera shares carry a Zacks Rank  4  Sell   Better ranked stocks include Impax Laboratories   NASDAQ IPXL    Mylan  Inc    NASDAQ MYL   and MeetMe  Inc    NASDAQ MEET   each carryinga Zacks Rank  2  Buy  ",2016-08-05,Zacks Investment Research,https://www.investing.com/analysis/tessera-(tsra)-surpasses-q2-earnings---revenue-estimates-200146449,200146449
197368,418884,MYL,Can TransDigm  TDG  Spring A Surprise In Q3 Earnings ,opinion,TransDigm Group Incorporated   NYSE TDG   is set to report third quarter fiscal 2016 results  after the closing bell on Aug 9 Last quarter  the company posted a positive earnings surprise of 12 4   TransDigm has managed to beat earnings estimates twice in the trailing four quarters  resulting in an average positive surprise of 10 8  Factors to ConsiderTransDigm designs  produces and supplies highly engineered proprietary aerospace components and certain systems subsystems  In fact  about 90  of its sales are generated by proprietary products  that is  products for which the company owns the intellectual property  This translates into consistent and sustained revenue generation capacity through all phases of the aerospace cycle  We believe that the company s fiscal third quarter results are expected to benefit from its robust proprietary sales Also  we believe that stable aftermarkets  which have historically produced higher gross margins  will be one of the major profit churners this earnings season  The company s commercial transport industry has also been gaining traction over the past few months which is expected to boost third quarter results This apart  the company has been consistently strengthening its highly engineered proprietary aerospace business with strategic acquisitions  During the second quarter of 2016  TransDigm posted a 28 7  year over year increase in top line  as its accretive acquisitions contributed to sales and organic revenue growth  In this regard  we believe that the recently completed Breeze Eastern Corporation buyout is likely to boost sales of proprietary aerospace components  thereby supplementing top line performance during the third quarter Despite these positives  the company s financials have been hurt by weak revenues from business jets and helicopters  This will likely dampen the third quarter results as well  In addition  escalating debts and the consequent rise in interest expenses may weigh on the company s financials Also  softness in global macroeconomic conditions is impacting air travel  adding to the company s woes  Reduction in number of flight hours of customers can also thwart the company s growth momentum TRANSDIGM GROUP Price and EPS Surprise   Earnings WhispersOur proven model does not conclusively show that TransDigm Group will beat earnings this quarter  That is because a stock needs to have both a positive  and a Zacks Rank  1  Strong Buy   2  Buy  or 3  Hold  for this to happen  That is not the case here as you will see below Zacks ESP  Earnings ESP for the company is currently 0 00   This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at  2 80 Zacks Rank  TransDigm Group s Zacks Rank  3  when combined with 0 00  ESP  makes surprise prediction difficult Note that we caution against stocks with a Zacks Rank  4 or 5  Sell rated stocks  going into the earnings announcement  especially when the company is seeing negative estimate revision Stocks That Warrant a LookHere are some companies that you may want to consider  as our model shows that these have the right combination of elements to post an earnings beat this quarter Incyte Corporation   NASDAQ INCY   has an Earnings ESP of  300 00  and carries a Zacks Rank  2  It will be reporting second quarter results on Aug 9 Alamos Gold  Inc    TO AGI   has an Earnings ESP of  100 0  and a Zacks Rank  2  It will report second quarter results on Aug 10 Mylan N V    NASDAQ MYL   has an Earnings ESP of  1 75  and a Zacks Rank  3  The company is scheduled to report second quarter results on Aug 9 ,2016-08-05,Zacks Investment Research,https://www.investing.com/analysis/can-transdigm-(tdg)-spring-a-surprise-in-q3-earnings-200146383,200146383
197369,418885,MYL,Drug Stocks To Watch For Earnings On Aug 9  MYL  INCY   More,opinion,"The Q2 earnings season is almost approaching its end with 87 7   as of Aug 5  of the S P 500 members having already reported results  The Retail sector is the only one at this point that has a substantial number of reports still to come 
But how has this particular earnings season turned out to be  Though the  pace has  improved  with companies reporting better results  still the quarter is on its way to be the fifth in a row to record an earnings decline for the S P 500 index  So far  of the 433 S P 500 companies that have reported as of Aug 5  70 7  breezed past earnings expectations while 52 7  exceeded revenue estimates 
Results in the Technology and Medical sectors have been remarkably better than anticipated  These two sectors have also recorded the highest proportion of positive surprises 
Particularly  our Q2 scorecard for the Medical sector shows that 86 5  have reported results with a blended beat of 77 8   the percentage of companies that have beaten both earnings per share as well as revenue estimates  with the sector posting 6 5  earnings growth on revenue growth of 9 9  
Per our  report  Medical is one of the eight sectors expected to record earnings growth in Q2 
Among drug stocks lined up to report on Aug 9  let s take a look at three such companies 
What to Expect from these Drug Stocks 
Generic drug maker  Mylan N V  s   NASDAQ MYL   performance has been impressive with the company beating earnings estimates in three of the last four quarters with an average positive surprise of 1 79   Mylan currently carries a Zacks Rank  3  Hold   Though the stock s Zacks Rank  3 increases the predictive power of the ESP  it also has an  of  1 74   making a surprise prediction difficult this quarter  The company is scheduled to release Q2 results on Aug 9 MYLAN NV Price and EPS Surprise   The company s business segments   Generics and Specialty   should continue to perform well in Q2  While the Generics segment should benefit from new product launches  the Specialty segment should benefit from higher volumes of EpiPen  Late last week  Mylan announced the completion of the acquisition of the Swedish drug maker  Meda  read more    
Oncology focused Incyte Corporation   NASDAQ INCY   is a biopharmaceutical company with a pretty good track record having surpassed expectations in three of the last four quarters with an average positive surprise of 101 83   Headquartered in Wilmington  DE  Incyte has a favorable Zacks Rank  2  Buy   but an ESP of 0 00  makes a surprise prediction uncertain this quarter  The company s only approved product  Jakafi  should continue to drive top line growth in this quarter as well  Meanwhile  Incyte has a broad pipeline including both targeted and immune therapies  Update on the pipeline front will be another area of focus along with the performance of Jakafi  The company is scheduled to release Q2 results on Aug 9 INCYTE CORP Price and EPS Surprise   Copenhagen  Denmark based Genmab A S  is a biotechnology company focused on the development of differentiated antibody therapeutics for the treatment of cancer  The company has two approved antibodies in its portfolio   Arzerra  for the treatment of certain chronic lymphocytic leukemia indications  and Darzalex  for the treatment of heavily pre treated or double refractory multiple myeloma   Genmab has a licensing agreement with Johnson   Johnson   NYSE JNJ   s Janssen Biotech for Darzalex and Novartis AG   NYSE NVS   for Arzerra  Genmab also has a broad pipeline GENMAB A S Price and EPS Surprise   Last quarter  Genmab reported a positive earnings surprise of 88   Genmab currently has a Zacks Rank  4  Sell  and an ESP of 0 00   As it is  we caution against Sell rated stocks   4 or  5  going into an earnings announcement  The company is expected to release Q2 results on Aug 9 ",2016-08-07,Zacks Investment Research,"https://www.investing.com/analysis/drug-stocks-to-watch-for-earnings-on-aug-9:-myl,-incy---more-200146669",200146669
197370,418886,MYL,Company News For August 10  2016,opinion,"  Shares of Mylan  NASDAQ MYL  N V     increased 2 9  after announcing second quarter adjusted earnings per share of  1 16  beating the Zacks Consensus Estimate by a cent


	  News Corporation s    shares gained 3 7  after declaring fiscal fourth quarter revenues of  2 226 million  outpacing the Zacks Consensus Estimate of  2 040 million


	  Shares of AerCap Holdings N V     advanced 1 2  after reporting second quarter adjusted earnings per share of  1 53  higher than the Zacks Consensus Estimate of  1 43


	  Cheniere Energy  Inc s    shares decreased 1 8  after posting second quarter adjusted loss of  0 68 per share  wider than the Zacks Consensus Estimate of  0 49 decline",2016-08-09,Zacks Investment Research,"https://www.investing.com/analysis/company-news-for-august-10,-2016-200147172",200147172
197377,418893,MYL,The Zacks Analyst Blog Highlights  Manulife Financial  Mylan  Huntsman  Air Lease And Bofi Holding,opinion,"For Immediate Release 

Chicago  IL   July 18  2016   Zacks com announces the list of stocks featured in the Analyst Blog  Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets  Stocks recently featured in the blog include Manulife Financial Corporation     Mylan  NASDAQ MYL  N V      Huntsman Corporation     Air Lease Corporation    and Bofi Holding  Inc     

Today  Zacks is promoting its   Buy   stock recommendations   

Here are highlights from Friday s Analyst Blog  

These Stocks Still Trading Cheap in This Market

The Dow Jones Industrial Average  DJI  hit a 52 week high yesterday  closing at  18 506 41 while the Standard   Poor s 500  which was rising of late  closed the last trading session at  2 163 75  a little lower than its last 52 week high of  2 168 99 
	Since the beginning of 2016  markets were plagued by a number of macroeconomic factors that caused widespread volatility  Fortunes  however  turned around recently  with an improvement in job numbers  rebounding oil prices  negligible impact of Brexit on the U S  market and low volatility in the markets  as indicated by the CBOE Volatility Index  VIX   In fact  so far this year  the DJI and the S P 500 have improved a respective 6 2  and 5 9  Investment Strategy  Go for Value
	Finding the right stocks to invest in is always a challenge  It is more so with an uncertain second quarter earnings season around the corner  At this juncture  knowing the right investment strategy is no mean feat  We believe it is time to let go of your fascination for popular stocks and instead focus on the ones that are trading below their fair value  Investing in cheap stocks is probably the best option right now  seeing that they are both safe and profitable 
	This is known as value investing  and since the emphasis is on cheap stocks with steady growth and solid price momentum  the strategy offers compelling prospects Why Value Investing
	Investors usually have a negative impression about cheap stocks  However  they are not always a bad idea  Sometimes  stocks trade lower than their fair value because of temporary negative factors  In fact  stocks that have a low price earnings or P Es ratio  an impressive outlook  a decent dividend payment history and high returns are a worthy choice for value investors  These stocks are usually a darling for risk averse investors who can t afford to buy high priced stocks during phases of high volatility Picking Such Stocks
	It s never easy to find stocks that offer great value but are trading cheap at the moment  Here  we have used our latest  to zero in on six stocks with healthy prospects that would be sensible picks for value investors 
	Our Value Style Score highlights all valuation metrics and represents them as one score that warns investors against  value traps  and helps them to find stocks that are actually trading cheap 
	A Zacks Rank indicating  Strong Buy  or even  Buy   Zacks Rank  1 or  2  translates into an upward trend in the stock s earnings estimates 
	Thus  stocks with a Value Style Score of  A   when combined with a Zacks Rank  1 or  2  offer the best opportunities in the value investing space 
	Each of these six stocks has both a favorable Zacks Rank and Value Score  We have also considered the P E   an important metric used for recognizing value stocks  All of these stocks have P E less than 10 Our PicksManulife Financial Corporation   
	Headquartered in Toronto  Canada  Manulife Financial is one of the three leading life insurers operating in the Canadian market  The company also has a rapidly growing footprint across the U S  and several Asian countries  Manulife s deep penetration in the Asian market and a growing asset management business are expected to drive long term earnings growth  It also holds a significant market in Canada and the Standard Life  LON SL  Overseas Holdings takeover broadened its share in the region 
	Manulife has a Zacks Rank  2 and a Value Style Score of  A   The stock has a P E ratio of 9 48  The company s expected 3 5 year EPS growth rate is 10  Mylan N V    
	Mylan N V  is a global pharmaceutical company with a well established generics business as well as a presence in specialty pharmaceuticals  The company s business model includes the development  manufacturing and marketing of branded and generic drugs as well as active pharmaceutical ingredients  APIs  in North America  Europe and Rest of World  Notably  Mylan has one of the world s largest API operations 
	This Zacks Rank  2 stock currently has a Value Style Score of  A   Its P E ratio is 9 2  The expected 3 5 year EPS growth rate of the company is 10 4  Huntsman Corporation   
	Huntsman Corporation is one of the world s largest global manufacturers of differentiated and commodity chemical products for a variety of industrial and consumer applications 
	Presently  Huntsman Corporation sports a Zacks Rank  1 and has a Value Style Score of  A   The stock has a P E ratio of 8 62  The company s expected 3 5 year EPS growth rate is 7 75  Air Lease Corporation   
	Air Lease Corporation is an aircraft leasing company  principally engaged in purchasing commercial aircraft and leasing them to airlines around the world  The company provides leasing services in Asia  the Pacific Rim  Latin America  Middle East and eastern Europe 
	Currently  Air Lease Corporation sports a Zacks Rank  1 and has a Value Style Score of  A   The stock has a P E ratio of 8 49  The expected 3 5 year EPS growth rate of the company is 8 91  Bofi Holding  Inc     
	Bofi Holding is the holding company for Bank of Internet USA   a consumer focused  nationwide savings bank operating primarily through the Internet from a single location in San Diego  CA  The company offers an array of consumer banking services  focusing primarily on gathering retail deposits over the Internet  and originating and purchasing multi family and single family loans for investment 
	Bofi Holding currently has a Zacks Rank  2 and has a Value Style Score of  A   The stock has a P E ratio of 7 96  Its expected 3 5 year EPS growth rate is 10  

Want the latest recommendations from Zacks Investment Research  Today  you can download 7 Best Stocks for the Next 30 Days   

Today  Zacks is promoting its   Buy   stock recommendations   

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long term 

Continuous coverage is provided for a universe of 1 150 publicly traded stocks  Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance  Recommendations and target prices are six month time horizons 

Zacks  Profit from the Pros  e mail newsletter provides highlights of the latest analysis from Zacks Equity Research   

About Zacks 

Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

Follow us on Twitter  

Join us on Facebook  

Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

Media Contact
	Zacks Investment Research

800 767 3771 ext  9339





Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-07-17,Zacks Investment Research,"https://www.investing.com/analysis/the-zacks-analyst-blog-highlights:-manulife-financial,-mylan,-huntsman,-air-lease-and-bofi-holding-200142463",200142463
197378,418894,MYL,Zacks com Featured Highlights  Korea Electric Power  Third Point Reinsurance  Mylan N V  And Gray Television,opinion,"For Immediate Release

	Chicago  IL   July 28  2016   Stocks in this week s article include   Korea Electric Power Corp      Third Point Reinsurance Ltd      Mylan  NASDAQ MYL  N V       and Gray Television  Inc     

Screen of the Week of Zacks Investment Research 

4 Buy Rated Stocks with High Earnings Yield

	Earnings yield is a useful ratio for investors who have exposure to both stocks and bonds  This ratio gains an upper hand on the more commonly used P E ratio as it facilitates comparison of stocks with fixed income securities  Interestingly  it is simply the inverse of the P E ratio 

	Earnings yield is calculated as  Annual Earnings per Share Market Price  x 100  If other factors are constant while comparing stocks  the one with a higher earnings yield has the potential to provide comparatively greater returns 

	Earnings yield can also be used to compare the performance of a market index with the 10 year Treasury yield  For instance  when the yield of the market index is more than the 10 year Treasury yield  stocks can be considered as undervalued than bonds  In this situation  investing in the stock market would be a better option for a value investor 

	However  bearing in mind the risk free nature of T bills  it would be a good idea to add a risk premium to the Treasury yield while comparing it with the earnings yield of a stock or the stock market 

The Winning Strategy

	We have set Earnings Yield greater than 10  as our primary screening criterion  but it alone cannot be used for selecting stocks that have the potential to generate solid returns  So  we have added the following parameters to the screen 

Estimated EPS growth for the next 12 months greater than or equal to the S P 500  This metric compares the 12 month forward EPS Estimate with the 12 month Actual EPS 

Average Daily Volume  20 Day  greater than or equal to 100 000    High trading volume implies that a stock has adequate liquidity 

Current Price greater than or equal to  5 00 

Buy Rated Stocks    Stocks with a Zacks Rank  1  Strong Buy  or 2  Buy  generally outperform their peers in any type of market environment 

	Here are four of the seven stocks that made it through the screen 

Korea Electric Power Corp       is an integrated electric utility engaged in the generation  transmission  distribution of electricity and development of electric power resources in South Korea  This Zacks Rank  2 stock has an expected EPS growth rate of 25  for the next 3 5 years 

Third Point Reinsurance Ltd       is a property and casualty reinsurance company based in Bermuda  The company carries a Zacks Rank  1  Its expected EPS growth rate for 3 5 years is 15  

Mylan N V       is a global pharmaceutical company with a well established generics business as well as a presence in specialty pharmaceuticals  The company carries a Zacks Rank  2 and its expected EPS growth rate for the next 3 5 years is 10 41  

Gray Television  Inc       is a communications company headquartered in Atlanta  GA  and currently operates 15 CBS affiliated television stations  seven NBC affiliated television stations  seven ABC affiliated television stations and four daily newspapers  This Zacks Rank  2 company has an expected EPS growth rate of 6 5  for the next 3 5 years 

	You can get the rest of the stocks on this list by signing up now for a 2 week free trial to the Research Wizard stock picking and backtesting software  You can also create your own strategies and test them first before making investments 

	The Research Wizard is a great place to begin  It s easy to use  Everything is in plain language  And it s very intuitive  Start your Research Wizard trial today  And the next time you read an economic report  open up the Research Wizard  plug your finds in  and see what gems come out 

  

Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  

Disclosure  Performance information for Zacks  portfolios and strategies are available at    

Zacks Restaurant Recommendations    In addition to dining at these special places  you can feast on their stock shares  A Zacks Special Report spotlights 5 recent IPOs to watch plus 2 stocks that offer immediate promise in a booming sector  

	Sign up now for your free trial today and start picking better stocks immediately  And with the backtesting feature  you can test your ideas to see how you can improve your trading in both up markets and down markets  Don t wait for the market to get better before you decide to do better  Start learning how to be a better trader today  Disclosure  Officers  directors and or employees of Zacks Investment Research may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material  An affiliated investment advisory firm may own or have sold short securities and or hold long and or short positions in options that are mentioned in this material 

About Screen of the Week 

	Zacks com created the first and best screening system on the web earning the distinction as the   1 site for screening stocks  by Money Magazine  But powerful screening tools is just the start  That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use  Each week  Zacks Profit from the Pros free email newsletter shares a new screening strategy  Learn more about it here 

About Zacks 

	Zacks com is a property of Zacks Investment Research  Inc   which was formed in 1978  The later formation of the Zacks Rank  a proprietary stock picking system  continues to outperform the market by nearly a 3 to 1 margin  The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter  Profit from the Pros  In short  it s your steady flow of Profitable ideas GUARANTEED to be worth your time   

	Follow us on Twitter  

	Join us on Facebook  

	Zacks Investment Research is under common control with affiliated entities  including a broker dealer and an investment adviser   which may engage in transactions involving the foregoing securities for the clients of such affiliates 

	Contact  Jim Giaquinto
	Company  Zacks com
	Phone  312 265 9268
	Email  

	Visit  

	Zacks com provides investment resources and informs you of these resources  which you may choose to use in making your own investment decisions  Zacks is providing information on this resource to you subject to the Zacks  Terms and Conditions of Service  disclaimer    

Past performance is no guarantee of future results  Inherent in any investment is the potential for loss   This material is being provided for informational purposes only and nothing herein constitutes investment  legal  accounting or tax advice  or a recommendation to buy  sell or hold a security  No recommendation or advice is being given as to whether any investment is suitable for a particular investor  It should not be assumed that any investments in securities  companies  sectors or markets identified and described were or will be profitable  All information is current as of the date of herein and is subject to change without notice  Any views or opinions expressed may not reflect those of the firm as a whole  Zacks Investment Research does not engage in investment banking  market making or asset management activities of any securities  These returns are from hypothetical portfolios consisting of stocks with Zacks Rank   1 that were rebalanced monthly with zero transaction costs  These are not the returns of actual portfolios of stocks  The S P 500 is an unmanaged index  Visit  for information about the performance numbers displayed in this press release ",2016-07-27,Zacks Investment Research,"https://www.investing.com/analysis/zacks.com-featured-highlights:-korea-electric-power,-third-point-reinsurance,-mylan-n.v.-and-gray-television-200144711",200144711
197390,418906,MYL,Mylan Beats On Q1 Earnings  Revenues Lag  2016 View Intact,opinion,"Mylan N V  s   NASDAQ MYL   first quarter 2016 earnings  excluding special items  of 76 cents per share beat the Zacks Consensus Estimate by a penny  Also  reported earnings escalated 9  from the year ago quarter  driven by higher revenues Revenues grew 17  to  2 19 billion  but fell short of the Zacks Consensus Estimate of  2 26 billion  The top line recorded year over year growth on the back of solid revenue growth at the Generics segment 
Quarter in Details
Generics third party net sales  derived from sales in North America  Europe and Rest of World  soared 17  to  1 93 billion  Segmental third party net sales climbed 8  to  919 7 million in North America  While new product launches aided revenues  factors offsetting this increase were lower sales on existing products 
Third party net sales from the European market increased 45  to  587 7 million  The increase was mainly due to incremental net sales derived from established products as well as new products  However  higher volumes on existing products  primarily in France  were offset by lower pricing throughout Europe due to government imposed pricing reductions and competitive market conditions 
Third party net sales from Rest of World increased 10  to  420 8 million  Segmental performance was driven mainly by incremental net sales from established products and from certain female healthcare businesses acquired from Famy Care Limited  and to a lesser extent from new product launches across the region  Higher volumes in Japan and Australia also contributed to the increase  This was partially offset by lower pricing throughout the region and a decrease in third party net sales volumes from the anti retroviral franchise 
Beginning from the first quarter of 2016  the company reclassified sales from its Brazilian operation from the Rest of World region to the North America region  The amount reclassified for the three months ended Mar 31  2015  was about  10 2 million 
Third party net sales at the Specialty segment increased 17  to  247 9 million  Specialty segment sales benefited from higher volumes of EpiPen Auto Injector and higher sales of Perforomist Inhalation Solution 
Adjusted gross margin during the first quarter of 2016 expanded to 54  from 53  in the year ago quarter on the back of contribution from established products as well as new product launches  partially offset by decreased margins on existing products in North America 
2016 Outlook Maintained
Mylan reiterated its outlook for 2016  The company continues to expect earnings in the range of  4 85 to  5 15 per share  the midpoint of which represents a year over year increase of 16   while total revenues are expected in the range of  10 5 billion to  11 5 billion  the midpoint of which again represents a year over year increase of 16    The Zacks Consensus Estimate for earnings is  4 90 per share on revenues of  10 6 billion 
Meanwhile  Mylan is set to acquire Meda  a leading international specialty pharmaceutical company  in a deal worth  9 9 billion  The transaction is expected to be completed by the end of the third quarter of 2016 
Our Take
Mylan s first quarter results were mixed with the company beating on the bottom line while missing top line estimates  Nevertheless  we are encouraged by double digit growth both at the Generics and Specialty segments  We are also positive on the Meda deal  We expect investor focus to remain on updates from the transaction  going forward 
Mylan is a Zacks Rank  3  Hold  stock  Some better ranked stocks in the health care sector include Aegerion Pharmaceuticals  Inc    NASDAQ AEGR    Gilead Sciences Inc    NASDAQ GILD   and ANI Pharmaceuticals  Inc    NASDAQ ANIP    All three stocks sport a Zacks Rank  1  Strong Buy  ",2016-05-02,Zacks Investment Research,"https://www.investing.com/analysis/mylan-beats-on-q1-earnings,-revenues-lag,-2016-view-intact-200127669",200127669
197391,418907,MYL,Key Healthcare Earnings For May 3  CVS  MYL  PFE,opinion,"As   more and more companies are starting to post their earnings results  On Tuesday  three big names in the healthcare industry reported their quarterly earnings before the bell  Let s take a look 
CVS Health Corp    NYSE CVS  
The pharmacy company  adjusted first quarter earnings per share of  1 18  beating the Zacks Consensus Estimate by 2 cents and increasing 3 5  year over year  Net revenues were up 18 9  year over year to  43 2 billion  surpassing our consensus estimate of  42 9 billion  Thanks to balanced growth  CVS reiterated its full year 2016 guidance 
Mylan N V    NASDAQ MYL  
Mylan  a pharmaceutical company   per share of  0 76  excluding special items   beating the Zacks Consensus Estimate by a penny and increasing 9  from the year ago quarter  Revenues increased 17  to  2 19 billion  but lagged behind the Zacks Consensus Estimate of  2 26 billion  the top line saw year over year growth thanks to solid revenue growth in its Generics segment 
Pfizer  Inc    NYSE PFE  
One of the biggest names in the pharmaceutical sector  Pfizer  first quarter earnings per share of  0 67  beating the Zacks Consensus Estimate of  0 55  Revenues of  13 005 billion also came in well above expectations  beating our consensus estimate of  11 971 billion  As a result of strong results  Pfizer now expects to earn  2 38  2 48 per share on revenues of  51 billion  53 billion for 2016 
Check out Q1 earnings  scorecard by sector so far ",2016-05-03,Zacks Investment Research,"https://www.investing.com/analysis/key-healthcare-earnings-for-may-3:-cvs,-myl,-pfe-200127612",200127612
197392,418908,MYL,Mylan  MYL  Beats On Q1 Earnings  Misses On Revenues,opinion,"Mylan N V    NASDAQ MYL   is one of the largest generics and specialty pharmaceutical companies in the globe  The company s product portfolio encompasses various therapeutic areas including cardiovascular  central nervous system  anti infective  gastrointestinal  endocrine and metabolic  and respiratory drugs 
Mylan continued to launch generic drugs in the first quarter of 2016  Meanwhile  the company is set to acquire Meda  a leading international specialty pharmaceutical company  in a deal worth  9 9 billion  The transaction is expected to be completed by the end of the third quarter of 2016  Investor focus will be on updates from the Meda deal 
Mylan s performance has been decent with the company beating earnings estimates on two occasions  while posting in line results in one  Overall  the company has delivered an average positive surprise of 1 46  
Currently  Mylan has a Zacks Rank  3  Hold   but that could definitely change following the company s earnings report which was just released  We have highlighted some of the key stats from this just revealed announcement below 
Earnings  Mylan beat on first quarter 2016 earnings by a penny  The company reported EPS of 76 cents while our consensus called for EPS of 75 cents 
Revenues  Revenues  however  fell short of expectations  Mylan posted revenues of  2 19 billion  compared to our consensus estimate of  2 26 billion 
Key Stats  Both Generics and Specialty segment performed well in the first quarter of 2016  Mylan reiterated its outlook for 2016  The company continues to expect earnings in the range of  4 85 to  5 15 per share while total revenues are expected in the range of  10 5 billion to  11 5 billion  The Zacks Consensus Estimate for earnings currently stands at  4 90 per share on revenues of  10 6 billion 
Check back later for our full write up on this Mylan earnings report later ",2016-05-03,Zacks Investment Research,"https://www.investing.com/analysis/mylan-(myl)-beats-on-q1-earnings,-misses-on-revenues-200127577",200127577
197393,418909,MYL,Momenta  MNTA  Reports Narrower than Expected Q1 Loss,opinion,"Momenta Pharmaceuticals Inc    NASDAQ MNTA   reported a loss of 35 cents per share in the first quarter of 2016  narrower than both the Zacks Consensus Estimate of a loss of 38 cents and the year ago loss of 40 cents 

Revenues surged 131 8  to  19 9 million but fell short of the Zacks Consensus Estimate of  27 million 
The Quarter in Detail
Total revenue comprised product revenues of  14 8 million  and research and development revenues of  5 1 million  The company earned product revenues solely from Sandoz s sales of Glatopa  a generic version of Copaxone 20 mg   Since its launch in Jun 2015  Momenta has recognized  58 2 million in product revenues from Sandoz s sales of the drug 
We note that Sandoz s Abbreviated New Drug Application  ANDA  for the 40 mg thrice weekly formulation of Copaxone is currently under FDA review  The companies expect a tentative approval later in 2016 
The company did not earn any revenue from enoxaparin as no contractual profit was earned on Sandoz s net sales of the drug in the quarter due to a change in collaboration economics from a royalty payment to a 50  profit share  reduced unit sales due to a lower market share  and continued competitive pricing 
Research and development expenses were  28 7 million  up 26 4   reflecting higher expenses related to biosimilar and novel autoimmune drug programs  personnel related expenses  and expenses related to the necuparanib study 
General and administrative expenses were  15 6 million  up 98 3  due to higher personnel related expenses 
2016 Outlook
Momenta expects operating expenses  excluding stock based compensation and net of collaborative revenues  in the range of  40 million to  45 million for each of the remaining quarters of 2016  lower than the earlier estimate of  45  55 million 
Pipeline Update
Momenta  in collaboration with Baxalta Inc    NYSE BXLT    initiated a pivotal study on a biosimilar version of Humira  M923  for chronic plaque psoriasis  Enrolment in the study was completed in Apr 2016  with data expected in the second half of 2016 or early 2017  The first regulatory submission is expected in 2017 and the first commercial launch in 2018 
Moreover  Momenta inked an exclusive global collaboration agreement with Mylan N V    NASDAQ MYL   in Jan 2016 to develop  manufacture and commercialize six of its current biosimilar candidates  including M834  a biosimilar version of Orencia  The companies received regulatory clearance in Feb 2016 and expect to initiate a clinical trial on M834 in the second half of 2016  Under the agreement  Momenta received an upfront payment of  45 0 million from Mylan in the reported quarter and expects to receive another  60 million in contingent payments later this year 
Meanwhile  enrollment is ongoing in the phase II trial on necuparanib  in combination with Abraxane plus Gemzar versus Abraxane plus Gemzar alone  in pancreatic cancer following the institution of a protocol amendment in Dec 2015  with data expected in the second half of 2017  Data from the phase I study on the candidate are expected to be published or presented at a medical conference in June 
On the other hand  the company s three novel autoimmune candidates are still in preclinical development  with one of them  M281  expected to enter the clinical stage in 2016  The company has received regulatory clearance to initiate a phase I dosing study on M281 in the forthcoming weeks 
Our Take
Momenta reported mixed results for the first quarter of 2016  with the company posting a narrower than expected loss but revenues missing expectations  On the earnings call  management stated that Glatopa has now captured nearly 35  of the once daily Copaxone 20 mg market  up from 30  at 2015 end 
We note that Glatopa sales have rebounded since the third quarter of 2015 as inventories were worked through  However  Teva has already switched approximately 75  of once daily Copaxone 20 mg patients to thrice weekly Copaxone 40 mg  Nevertheless  we are encouraged by the company s progress with biosimilars in its pipeline 
Momenta currently carries a Zacks Rank  3  Hold   Shire plc   NASDAQ SHPG   is a better ranked stock in the healthcare sector  with a Zacks Rank  2  Buy  ",2016-05-04,Zacks Investment Research,https://www.investing.com/analysis/momenta-(mnta)-reports-narrower-than-expected-q1-loss-200128025,200128025
197403,418919,MYL,Deal Making Mood Helped Equities Move Higher,opinion,"In an interesting development  I read this week that the Controller for the City of New York is upset at the fees their pension fund is paying because of a lack of performance  As someone who experienced the nonsense of this entity  my only thought is they made their bed  now they have to sleep in it  For a little more context  the fund is a monster  some  150 billion  and many large investors get contracts from it to manage different aspects of the porfolio  equities  bonds  real estate  private equity  hedge funds  infrastructure  etc  I was invited and did the obligatory work of submitting my information  Not a response or an email acknowledging my existence  thanks so much  The reality is for any fund less than a billion bucks  you are not on their radar  Still  performance is what matters in the investment world and their fund has not outperformed the indexes  which bothers the head honchos  I am sure it upsets the pension holders as well  Hard to think the fellows at Goldman  Morgan Stanley  NYSE MS   and Blackstone give a rip  though 


Finally  in the market this week  the deal making mood helped equities move higher  With Shell  LONDON RDSa  s agreed upon acquisition of BG Group  LONDON BG   Mylan  NASDAQ MYL  buying Perrigo  and GE announcing they would sell their financing operations to fund a large  50 billion buyback  spirits have turned optimistic  I would imagine that may change at some point  much like the tides of fortune in the great city of New York 


Disclaimer  Y H   C Investments  Yale Bock  and the family of Yale Bock own positions in securities mentioned in the blog post  Investing in stocks can lead to the complete loss of your capital  As always  on any company mentioned here  past performance is not a guarantee of future returns  Investing involves risk of losses on invested capital  One should research any investment and make sure it is suitable with your objectives  risk tolerance  risk profile liquidity considerations  tax situation  and anything else pertinent to your financial situation  Also  the CFA credential in no way implies investment returns will be superior for any charter holder ",2015-04-12,Yale Bock,https://www.investing.com/analysis/the-cradle-of-capitalism-welcomes-a-vegas-kid-248065,248065
197404,418920,MYL,Mixed Ratings On Teva Pharmaceuticals Following Merge With Auspex,opinion,"By Sarah RodenOn March 30  Teva Pharma Industries Ltd  ARCA TEVA  announced they will be acquiring Auspex Pharma  NASDAQ ASPX  in an all cash transaction valued at  3 2 billion  or  101 per Auspex share  Teva stated that Auspex s portfolio of movement disorder treatments will help bolster their core nervous system franchise Teva is the world s largest producer of generic drugs and looks forward to adding SD 809  Auspex s leading pipeline drug  to their portfolio  SD 809 will be used to treat involuntary movement disorders such as Huntington s disease and Tourette Syndrome  SD 809 is expected to be launched commercially in 2016 
Teva CEO Erex Vigodman commented   One of our key priorities for 2015 is to support Teva s mid to long term growth and create value for our shareholders with business development opportunities that are closely aligned with our core therapeutic areas  This transaction represents a first major step with regards to that commitment and we expect to continue this focus in the future  
The acquisition comes after rumors that Teva was in talks to acquire Mylan  NASDAQ MYL  N V   another generic drug maker  These rumors were quickly dispelled but showcased investors  eagerness for a merger 
In other news  Teva s ProAir RespiClick inhaler received FDA approval on April 1  The inhaler is expected to be available in the U S  in the second quarter of 2015 On April 8  analyst  of Standpoint Research downgraded Teva from a Buy to a Hold with an unchanged price target of  78  Moas said he added Teva to his portfolio when  the market collapsed on October 14 15 and broke below 1900   Since then  the market  crossed 2000 and went from fairly valued to overvalued   Now  Moas commented that Teva is  fairly valued  but downgraded the stock  given the recent absolute  35 percent  and relative  2500 bps vs the S P  move since mid October  following the all time high 
Ronnie Moas has a 75  overall success rate recommending stocks with a  9 5  average return per recommendation Separately on April 7  analyst  of Barclay s reiterated his Overweight rating on Teva and raised his price target from  70 to  75  Tsao anticipates  consolidation in the generic marketplace  especially given Teva s stating its willingness to accelerate the process through a  transformative  acquisition   The analyst raised his price target because  Teva offers evidence EPS growth through capital deployment  evidenced by last week s acquisition of ASPX  Douglas Tsao has an 89  overall success rate recommending stocks with a  33 5  average return per rating On average  the top analyst consensus for Teva on TipRanks is Hold Sarah Roden writes about stock market news  She can be reached at Sarah tipranks com ",2015-04-12,Sarah Roden,https://www.investing.com/analysis/mixed-ratings-on-teva-pharmaceuticals-following-merge-with-auspex-pharma-248080,248080
197405,418921,MYL,Bonus Trade Idea  Perrigo Jumps Higher,opinion,"Here is your Bonus Idea with links to the full Top Ten 
Perrigo  N PRGO  stock jumped higher in April when it was announced that Mylan  O MYL  was bidding for the company  This was not a friendly bid  and it has played out in a sue and countersue way ever since 
The chart shows the stock price popping on the initial news and then a Adam and Eve consolidation that failed to launch it higher  Instead  the stock fell back with the Healthcare sell off in late September  ending below the pre bid price  It has been basing there in a ascending triangle for 2 weeks  tightening against 162 as former support becomes resistance 
A break of the resistance to the upside would target a move to 174  A break to the downside  though  would look for a Measured Move lower to 130  The momentum indicators are more positive than negative  supporting the upside  The RSI is rising out of an oversold condition  while the MACD has crossed up 
There is a harmonic pattern in the price action as well  It is a bullish Bat harmonic  also known as a Cypher  This completed at the Potential Reversal Zone at 155 and triggered with the reversal candle the next day  This pattern calls for a retracement of 38 2  of the pattern or a move higher to 173 28 
There is resistance above 162 at 168 60 and 172 75 before 176 20 and 180  Support below stands at 152 and 147 50  Short interest is low at 1 7   and the company is expected to report earnings next November 3rd 
The options chains show an upward bias for this week s October Expiration  There is large open interest at 170 on the Call side and 165 and 170 on the Put side  Moving to the November Expiration  there is larger open interest on the Call side as well and above at the 190 and 200 Strikes  The 160 Strike is largest open interest on the Put side 
Perrigo
Trade Idea 1  Buy the stock on a move over 162 with a stop at 158 50  A simple stock purchase 
Trade Idea 2  Buy the October 160 170 Call Spread  offered at  3 40 late Friday   A defined risk way to participate 
Trade Idea 3  Buy the October 160 170 Call Spread and sell the October 155 Put   2 50   Capping return and adding leverage to the trade with a risk of owning the stock under 155 Friday 
Trade Idea 4  Buy the November 160 175 Call Spread   8 00  and sell the November 150 Put   3 40   Giving the upside more time in the levered trade with further downward protection 
Trade Idea 5  Sell the stock short on a move under 155 with a stop at 160  A straight downside trade 
Trade Idea 6  Buy the November 155 Put   8 20    Using defined risk to follow the stock lower 
After reviewing over 1 000 charts  I have found some good setups for the week  These were selected and should be viewed in the context of the broad Market Macro picture reviewed Friday which  heading into October Options Expiration week  sees the equity markets looking stronger  but they have not sent the all clear signal yet 
Elsewhere  look for gold to continue its short term uptrend  while crude oil does the same but might encounter resistance  The US dollar index has a short term bias lower for the week in the broad consolidation  while US Treasuries are biased lower short term as well  The Shanghai Composite looks to continue in consolidation  while Emerging Markets are biased to the upside 
Volatility looks to return to more normal levels  relieving the downward bias on the equity index ETFs N SPY  N IWM and O QQQ  Their charts all show strength continuing into next week  but with the SPY the strongest followed by the QQQ and then the IWM on the longer term look  Use this information as you prepare for the coming week and trad em well 
The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  Please see my Disclaimer page for my full disclaimer ",2015-10-12,Gregory W. Harmon,"https://www.investing.com/analysis/top-trade-ideas-for-the-week-october-12,-2015:-bonus-idea-267850",267850
197418,418934,MYL,Mylan Laboratories  Good Quarterly Earnings  New M A Deal,opinion,Investors have been pleased with Mylan Laboratories  MYL  quarterly earnings and a new deal on the M A front and pushed MYL shares to new highs  The former resistance at 29 25 has turned into support now  Interesting that a horizontal count from the February congestion pattern points to 32   the same area where the price target from the December January consolidation resides  It makes the 32 32 25 area more significant Before MYL earnings I had a long strangle with Mar 29 calls and Mar 27 puts  Today I sold puts and left with naked calls Sold to close MYL Mar13 27 Put 10 contracts at  0 05Disclaimer  I express only my personal opinion on the market and do not provide any trading or financial advice  see  on my site  ,2013-03-01,Igor Rakhmanov,"https://www.investing.com/analysis/mylan-laboratories:-good-quarterly-earnings,-new-m-a-deal-157220",157220
197419,418935,MYL,Pharma Buyout Continues  Will Mylan Inc Be Next  ,opinion,"The Pharma buyout bonanza continued Monday with the Covidien deal Sunday night  and it has many wondering which stock might be the next target  Some have speculated that Mylan Inc  NASDAQ MYL   could be it  That would be a coup for technical traders as the chart suggests it may be ready to run higher  Take a look 

Since the beginning of March Mylan has been pulling back from the all time high at 57 50  But the longer term support resistance zone between 45 50 and 46 50 has given it support  halting the fall 3 times  Each bounce ended at a lower high  creating a descending triangle pattern as price tightened around the S R zone  That was until Friday last week  On Friday it broke above that descending resistance and continued higher Monday  The target on the break of the triangle is to 61 50  I purposely drew this conservatively  Some would have been interested in a break over the faint blue line a more aggressive take on the triangle  For those that are still skeptical a jump over resistance at 52 will seal the deal with a higher high 

Disclaimer  The information in this blog post represents my own opinions and does not contain a recommendation for any particular security or investment  I or my affiliates may hold positions or other interests in securities mentioned in the Blog  please see my  page for my full disclaimer ",2014-06-17,Gregory W. Harmon,"https://www.investing.com/analysis/pharma-buyout-continues,-will-mylan-inc-be-next-216292",216292
197433,418949,MYL,MYL  Upside Triangle Breakout,opinion,Looking for long candidates satisfying my requirements in the Healthcare sector I have paid attention to Mylan Laboratories  MYL    the generic drug producer This is the medium term 0 25x3 60 min chart  MYL is in the strong medium term uptrend since July  The fact  that the price has overshot the 25 75 target from the June low and not wasting any time reached to new highs  underscores the underlying strength  Not far from the 29 25 target from the horizontal count from the May   June bottom the price moved sideways forming a consolidation pattern  During this consolidation the price printed higher lows indicating the increasing demand and thus forming an Upside Triangle pattern  green lines   Today the price broke out of this Triangle to the upside generating a strong Triple Top buy signal  lime box  To estimate the upside potential of this breakout we have to switch to the 1 box reversal chart The horizontal count from this Upside Triangle points to 32 25  I bought March calls on the breakout today Bought to open MYL Mar13 28 Call 10 contracts at  1 28  Disclosure  I express only my personal opinion on the market and do not provide any trading or financial advice  see  on my site  ,2013-02-02,Igor Rakhmanov,https://www.investing.com/analysis/myl:-upside-triangle-breakout-153435,153435
197434,418950,MYL,Trading Journal  Mylan Labs Is Still In Range,opinion,After the Upside Triangle  green  breakout Mylan Laboratories  MYL  moved sideways in a tight range about two weeks  In the middle of February MYL tried to break out to the upside from this range but failed  Today s market sell off caused the downside breakout from this range in MYL shares and again MYL returned back in the range at the close  It seems that traders and investors are waiting for the MYL quarterly earnings  Feb 27  before the next directional move  I don t see reasons to hold my long calls on MYL any further in conditions of indecisiveness and increasing volatility Sold to close MYL Mar13 28 Call 10 contracts at  1 12Disclaimer  I express only my personal opinion on the market and do not provide any trading or financial advice  see  on my site  ,2013-02-23,Igor Rakhmanov,https://www.investing.com/analysis/trading-journal:-mylan-labs-is-still-in-range-156402,156402
